FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Rando, A
   de la Torre, M
   Martinez-Muriana, A
   Zaragoza, P
   Musaro, A
   Hernandez, S
   Navarro, X
   Toivonen, JM
   Osta, R
AF Rando, Amaya
   de la Torre, Miriam
   Martinez-Muriana, Anna
   Zaragoza, Pilar
   Musaro, Antonio
   Hernandez, Sara
   Navarro, Xavier
   Toivonen, Janne M.
   Osta, Rosario
TI Chemotherapeutic agent 5-fluorouracil increases survival of SOD1 mouse
   model of ALS
SO PLOS ONE
LA English
DT Article
ID AMYOTROPHIC-LATERAL-SCLEROSIS; GENE-EXPRESSION; STEM-CELLS; MICE;
   PROLIFERATION; LEVEL
AB Amyotrophic lateral sclerosis (ALS) is a lethal motor neuron disease with no cure. Currently there are only two ALS drugs approved by the FDA, both with a limited therapeutic effect. In the search for drug candidates for ALS, we studied the effect of known stem cell mobilizing agents (treatment) and antimetabolite 5-fluorouracil (5-FU) (anti-treatment) in SOD1G93A model of ALS. Surprisingly, we found that anti-cancer drug 5-FU increases lifespan, delays the disease onset and improves motor performance in ALS mice. Although we were not able to demonstrate the mechanistic basis of the beneficial 5-FU action in ALS mice, our findings suggest that 5-FU or similar drugs are possible drug candidates for the treatment of motor neuron diseases through drug repurposing.
C1 [Rando, Amaya; de la Torre, Miriam; Zaragoza, Pilar; Toivonen, Janne M.; Osta, Rosario] Univ Zaragoza, Fac Vet, Dept Anat Embriol & Genet Anim, LAGENBIO, Zaragoza, Spain.
   [Rando, Amaya; de la Torre, Miriam; Zaragoza, Pilar; Toivonen, Janne M.; Osta, Rosario] Univ Zaragoza CITA, Inst Agroalimentario Aragon IA2, Zaragoza, Spain.
   [Rando, Amaya; de la Torre, Miriam; Zaragoza, Pilar; Toivonen, Janne M.; Osta, Rosario] CIBA, Inst Invest Sanitaria Aragon, Zaragoza, Spain.
   [Martinez-Muriana, Anna; Navarro, Xavier] Univ Autonoma Barcelona, Inst Neurosci, Bellaterra, Spain.
   [Martinez-Muriana, Anna; Navarro, Xavier] Univ Autonoma Barcelona, Dept Cell Biol Physiol & Immunol, Bellaterra, Spain.
   [Martinez-Muriana, Anna; Navarro, Xavier] Ctr Invest Biomed Red Enfermedades Neurodegenerat, Bellaterra, Spain.
   [Musaro, Antonio] Sapienza Univ Rome, Ist Pasteur Italia, Fdn Cenci Bolognetti, DAHFMO Unit Histol & Med Embryol, Rome, Italy.
   [Musaro, Antonio] Ist Italiano Tecnol, Ctr Life Nano Sci Sapienza, Rome, Italy.
   [Hernandez, Sara] Univ Lleida IRBLLEIDA, Fac Med, Grp Patol Neuromuscular Expt, Dept Med Expt, Lleida, Catalonia, Spain.
RP Toivonen, JM; Osta, R (reprint author), Univ Zaragoza, Fac Vet, Dept Anat Embriol & Genet Anim, LAGENBIO, Zaragoza, Spain.; Toivonen, JM; Osta, R (reprint author), Univ Zaragoza CITA, Inst Agroalimentario Aragon IA2, Zaragoza, Spain.; Toivonen, JM; Osta, R (reprint author), CIBA, Inst Invest Sanitaria Aragon, Zaragoza, Spain.
EM toivonen@unizar.es; osta@unizar.es
RI Hernandez, Sara/N-4017-2014; Musaro, Antonio/P-2953-2019; Osta,
   Rosario/R-5410-2019; Toivonen, Janne/E-5691-2011
OI Hernandez, Sara/0000-0002-6451-724X; Musaro,
   Antonio/0000-0002-2944-9739; Toivonen, Janne/0000-0002-7243-1737
FU Instituto de Salud Carlos III; Fondo Europeo de Desarrollo Regional
   (FEDER) from the European Union [PI14/00947, PI17/00949]; Asociacion
   Adelante de La Roda, Plataforma Afectados por la ELA, Asociacion Juntos
   Venceremos ELA, AVPA Zaragoza; Instituto de Salud Carlos III of Spain
   [RD12/0019/0011, RD16/0011/0035, CB06/05/1105]; Fondazione Roma; Agenzia
   Spaziale Italiana
FX This work was funded by Instituto de Salud Carlos III and Fondo Europeo
   de Desarrollo Regional (FEDER) from the European Union (Grants
   PI14/00947 and PI17/00949), Asociacion Adelante de La Roda, Plataforma
   Afectados por la ELA, Asociacion Juntos Venceremos ELA, AVPA Zaragoza
   (RO), TERCEL (RD12/0019/0011 and RD16/0011/0035) and CIBERNED
   (CB06/05/1105) funds from the Instituto de Salud Carlos III of Spain
   (XN), and Fondazione Roma and Agenzia Spaziale Italiana (AM). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Airey D, 2014, AMYOTROPHIC LATERAL, V14, P1
   Amante DJ, 2010, AMYOTROPH LATERAL SC, V11, P520, DOI 10.3109/17482968.2010.491867
   Beerman I, 2013, CELL STEM CELL, V12, P413, DOI 10.1016/j.stem.2013.01.017
   Bucchia M, 2015, CLIN THER, V37, P668, DOI 10.1016/j.clinthera.2014.12.020
   Calabrese EJ, 2008, BRIT J CLIN PHARMACO, V66, P594, DOI 10.1111/j.1365-2125.2008.03243.x
   Calvo AC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032632
   CHENAILLE PJ, 1990, BLOOD, V76, P508
   Dobrowolny G, 2011, SKELET MUSCLE, V1, DOI 10.1186/2044-5040-1-3
   Fischer LR, 2004, EXP NEUROL, V185, P232, DOI 10.1016/j.expneurol.2003.10.004
   Ghoshal K, 1997, BIOCHEM PHARMACOL, V53, P1569, DOI 10.1016/S0006-2952(97)00040-3
   Grad LI, 2014, P NATL ACAD SCI USA, V111, P3620, DOI 10.1073/pnas.1312245111
   Grad LI, 2011, P NATL ACAD SCI USA, V108, P16398, DOI 10.1073/pnas.1102645108
   GURNEY ME, 1994, NEW ENGL J MED, V331, P1721, DOI 10.1056/NEJM199412223312516
   Halter B, 2010, FREE RADICAL BIO MED, V48, P915, DOI 10.1016/j.freeradbiomed.2010.01.014
   Hardiman O, 2017, NAT REV DIS PRIMERS, V3, DOI [10.1038/nrdp.2017.71, 10.1038/nrdp.2017.85]
   Henriques A, 2011, MOL THER, V19, P284, DOI 10.1038/mt.2010.271
   Leitner M, GUIDELINES PRECLINIC
   Levin J, 2001, BLOOD, V98, P1019, DOI 10.1182/blood.V98.4.1019
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc.1074
   Mancuso R, 2012, NEUROTHERAPEUTICS, V9, P814, DOI 10.1007/s13311-012-0140-y
   Manzano R, 2011, BIOCHEM BIOPH RES CO, V407, P758, DOI 10.1016/j.bbrc.2011.03.096
   Manzano R, 2011, NEURODEGENER DIS, V8, P386, DOI 10.1159/000324159
   Mojardin L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078172
   Moreno-Igoa M, 2010, J MOL MED, V88, P297, DOI 10.1007/s00109-009-0556-y
   Numazawa S, 2011, BASIC CLIN PHARMACOL, V108, P40, DOI 10.1111/j.1742-7843.2010.00621.x
   Olivan S, 2014, EXP ANIM
   Parakh S, 2013, OXID MED CELL LONGEV, DOI 10.1155/2013/408681
   Petrov D, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00068
   Pitzer C, 2008, BRAIN, V131, P3335, DOI 10.1093/brain/awn243
   Pokrishevsky E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184384
   Pokrishevsky E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035050
   Pollari E, 2014, FRONT CELL NEUROSCI, V8, DOI [10.3389/fncel.2014.00131, 10.3389/fnce1.2014.00131]
   Pollari E, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-74
   QUESNIAUX VFJ, 1993, BLOOD, V81, P1497
   Randall TD, 1997, BLOOD, V89, P3596
   Rando A, 2017, NEURODEGENER DIS, V17, P1, DOI 10.1159/000446113
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Udelnow A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020143
NR 39
TC 1
Z9 1
U1 2
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 14
PY 2019
VL 14
IS 1
AR e0210752
DI 10.1371/journal.pone.0210752
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA HH5ZP
UT WOS:000455808000045
PM 30640943
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Biswal, MR
   Justis, BD
   Han, PY
   Li, H
   Gierhart, D
   Dorey, CK
   Lewin, AS
AF Biswal, Manas R.
   Justis, Bradley D.
   Han, Pingyang
   Li, Hong
   Gierhart, Dennis
   Dorey, Cheryl K.
   Lewin, Alfred S.
TI Daily zeaxanthin supplementation prevents atrophy of the retinal pigment
   epithelium (RPE) in a mouse model of mitochondrial oxidative stress
SO PLOS ONE
LA English
DT Article
ID MACULAR DEGENERATION; GEOGRAPHIC ATROPHY; CHOROIDAL NEOVASCULARIZATION;
   BETA-CAROTENE; RAT MODEL; HUMAN EYE; AGE; LUTEIN; CELLS; ACCUMULATION
AB Oxidative damage is implicated in the pathogenesis of age-related macular degeneration (AMD). The dry form of AMD (geographic atrophy) is characterized by loss of RPE, photoreceptors, and macular pigments. The cumulative effects of oxidative stress impact mitochondrial function in RPE. In Sod2(flox/flox)VMD2-cre mice, the RPE specific deletion of Sod2, the gene for mitochondrial manganese superoxide dismutase (MnSOD), leads to elevated oxidative stress in retina and RPE, and causes changes in the RPE and underlying Bruch's membrane that share some features of AMD. This study tested the hypothesis that zeaxanthin supplementation would reduce oxidative stress and preserve RPE structure and function in these mice. Zeaxanthin in retina/RPE/choroid and liver was quantified by LC/MS, retinal function and structure were evaluated by electroretinogram (ERG) and spectral domain optical coherence tomography (SD-OCT), and antioxidant gene expression was measured by RT-PCR. After one month of supplementation, zeaxanthin levels were 5-fold higher in the retina/RPE/choroid and 12-fold higher in liver than in unsupplemented control mice. After four months of supplementation, amplitudes of the ERG a-wave (function of rod photoreceptors) and b-wave (function of the inner retina) were not different in supplemented and control mice. In contrast, the c-wave amplitude (a measure of RPE function) was 28% higher in supplemented mice than in control mice. Higher RPE/choroid expression of antioxidant genes (Cat, Gstm1, Hmox1, Nqo1) and scaffolding protein Sqstm1 were found in supplemented mice than in unsupplemented controls. Reduced nitrotyrosine content in the RPE/choroid was demonstrated by ELISA. Preliminary assessment of retinal ultrastructure indicated that supplementation supported better preservation of RPE structure with more compact basal infoldings and intact mitochondria. We conclude that daily zeaxanthin supplementation protected RPE cells from mitochondrial oxidative stress associated with deficiency in the MnSOD and thereby improved RPE function early in the disease course.
C1 [Biswal, Manas R.; Justis, Bradley D.; Han, Pingyang; Li, Hong; Lewin, Alfred S.] Univ Florida, Coll Med, Dept Mol Genet & Microbiol, Gainesville, FL 32611 USA.
   [Biswal, Manas R.; Lewin, Alfred S.] Univ Florida, Ctr Vis Res, Gainesville, FL 32611 USA.
   [Biswal, Manas R.] Univ S Florida, Coll Pharm, Tampa, FL 33620 USA.
   [Gierhart, Dennis] ZeaVision, Chesterfield, MO USA.
   [Dorey, Cheryl K.] Virginia Tech Carilion Sch Med, Roanoke, VA USA.
   [Lewin, Alfred S.] Univ Florida, Coll Med, Dept Ophthalmol, Gainesville, FL 32610 USA.
RP Biswal, MR (reprint author), Univ Florida, Coll Med, Dept Mol Genet & Microbiol, Gainesville, FL 32611 USA.; Biswal, MR (reprint author), Univ Florida, Ctr Vis Res, Gainesville, FL 32611 USA.; Biswal, MR (reprint author), Univ S Florida, Coll Pharm, Tampa, FL 33620 USA.
EM biswal@ufl.edu
OI Lewin, Alfred/0000-0002-4192-9727
FU National Eye Institute (NEI) [R01EY020825, R01EY026268, 1K99EY027013];
   NEI core grant [P30 EY02172]; ZeaVision LLC; Bright Focus Foundation;
   Shaler Richardson Professorship endowment
FX This research was supported by grants from the National Eye Institute
   (NEI) (R01EY020825 [ASL]; R01EY026268 [ASL]; 1K99EY027013 [MRB]), an NEI
   core grant to the University of Florida (P30 EY02172 [ASL]), a pilot
   grant from ZeaVision LLC (MRB), a grant from Bright Focus Foundation
   (ASL & MRB) and the Shaler Richardson Professorship endowment (ASL).
   None of the funding organization had any role in the design, data
   collection, analysis or preparation of the manuscript for publication.
   The funder provided support in the form of salaries for authors [MRB,
   ASL, HL, PH] and resources for research, but did not have any additional
   role in the study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR [Anonymous], 2016, AG REL MAC DEG FACTS
   Armstrong D, 1998, Angiogenesis, V2, P93, DOI 10.1023/A:1009010628371
   Baba T, 2010, AM J PATHOL, V176, P3085, DOI 10.2353/ajpath.2010.090989
   Bernstein PS, 1998, INVEST OPHTH VIS SCI, V39, P2003
   Bernstein PS, 2001, EXP EYE RES, V72, P215, DOI 10.1006/exer.2000.0954
   Bhosale P, 2004, J BIOL CHEM, V279, P49447, DOI 10.1074/jbc.M405334200
   Bian QN, 2012, FREE RADICAL BIO MED, V53, P1298, DOI 10.1016/j.freeradbiomed.2012.06.024
   Biswal MR, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21272
   Biswal MR, 2015, EXP EYE RES, V140, P94, DOI 10.1016/j.exer.2015.07.022
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Ding JD, 2015, AM J PATHOL, V185, P29, DOI 10.1016/j.ajpath.2014.08.026
   Ebrahem Q, 2006, P NATL ACAD SCI USA, V103, P13480, DOI 10.1073/pnas.0601552103
   Guo JH, 2016, CHEM RES TOXICOL, V29, P2125, DOI 10.1021/acs.chemrestox.6b00233
   Indo HP, 2015, J CLIN BIOCHEM NUTR, V56, P1, DOI 10.3164/jcbn.14-42
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Le YZ, 2008, INVEST OPHTH VIS SCI, V49, P1248, DOI 10.1167/iovs.07-1105
   Leung IYF, 2004, INVEST OPHTH VIS SCI, V45, P3244, DOI 10.1167/iovs.02-1233
   Li BX, 2017, EXP EYE RES, V159, P123, DOI 10.1016/j.exer.2017.02.016
   Li BX, 2014, P NATL ACAD SCI USA, V111, P10173, DOI 10.1073/pnas.1402526111
   Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292
   Mao HY, 2014, INVEST OPHTH VIS SCI, V55, P4613, DOI 10.1167/iovs.14-14633
   Murdaugh LS, 2010, EXP EYE RES, V90, P564, DOI 10.1016/j.exer.2010.01.014
   Olchawa MM, 2017, FREE RADICAL RES, V51, P799, DOI 10.1080/10715762.2017.1380307
   Olk R Joseph, 2015, Int J Retina Vitreous, V1, P22, DOI 10.1186/s40942-015-0019-2
   Orhan C, 2016, J OCUL PHARMACOL TH, V32, P631, DOI 10.1089/jop.2015.0154
   Pinto LH, 2007, DOC OPHTHALMOL, V115, P127, DOI 10.1007/s10633-007-9064-y
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Rex TS, 2004, HUM GENE THER, V15, P960, DOI 10.1089/hum.2004.15.960
   Rosen R, 2015, BIOMED RES INT, DOI 10.1155/2015/687386
   Rudd LP, 2011, CHEM-BIOL INTERACT, V194, P113, DOI 10.1016/j.cbi.2011.08.012
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225
   Sanz MM, 2007, NEUROSCIENCE, V145, P1120, DOI 10.1016/j.neuroscience.2006.12.034
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Sommerburg O, 1999, CURR EYE RES, V19, P491, DOI 10.1076/ceyr.19.6.491.5276
   Sommerburg Olaf, 2000, Biofactors, V11, P3
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Tao RD, 2014, ANTIOXID REDOX SIGN, V20, P1646, DOI 10.1089/ars.2013.5482
   Thomson LR, 2002, INVEST OPHTH VIS SCI, V43, P3538
   Thomson LR, 2002, EXP EYE RES, V75, P529, DOI 10.1006/exer.2002.2050
   Toyoda Y, 2002, INVEST OPHTH VIS SCI, V43, P1210
   Veerappan M, 2016, OPHTHALMOLOGY, V123, P2554, DOI 10.1016/j.ophtha.2016.08.047
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Zhou JL, 2005, EXP EYE RES, V80, P567, DOI 10.1016/j.exer.2004.11.009
   Zou X, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.190
NR 51
TC 2
Z9 2
U1 1
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 28
PY 2018
VL 13
IS 9
AR e0203816
DI 10.1371/journal.pone.0203816
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GV3OT
UT WOS:000446005500010
PM 30265681
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Fan, X
   Li, N
   Wang, XS
   Zhang, JY
   Xu, MY
   Liu, XT
   Wang, BN
AF Fan, Xin
   Li, Ning
   Wang, Xiaoshuang
   Zhang, Jingyu
   Xu, Meiyi
   Liu, Xueting
   Wang, Beinan
TI Protective immune mechanisms of Yifei Tongluo, a Chinese herb
   formulation, in the treatment of mycobacterial infection
SO PLOS ONE
LA English
DT Article
ID HOST-DIRECTED THERAPIES; INFLAMMATORY RESPONSE; T-CELLS; TUBERCULOSIS;
   BCG; LUNG; OPPORTUNITIES; MACROPHAGES; ACTIVATION; CHALLENGES
AB Yifei Tongluo (YFTL) is a traditional Chinese medicine (TCM) formulation which has been shown clinical efficacy in treatment of patients with multidrug-resistant tuberculosis in China. However, the underlying mechanisms of the effects of YFTL are lacking. This study investigated the effects of YFTL on immune regulation with a mouse lung infection model with Bacille Calmette-Guerin (BCG). We found that compared with untreated mice, the lung mycobacterial load in YFTL-treated mice was significantly reduced, accompanied by alleviated pulmonary inflammation with reduction of pro-inflammatory cytokines and increase of prostaglandin E2 (PGE2). Flow cytometry analyses showed that Th1 cells were significantly higher in the lungs of YFTL-treated mice at early infection time. The results suggest that YFTL-treatment down-regulates pulmonary inflammation, which facilitates a rapid infiltration of Thl cells into the lungs. Moreover, the Th1 cells in the lungs were resolved faster at later time concomitant with increased the regulatory T cells (Tregs). The reduction of mycobacterial burden associated with improved tissue pathology, faster Th1 cell trafficking, and accelerated resolution of Th1 cells in the lungs of YFTL-treated mice indicates that YFTL improves mycobacterial clearance by maintaining lung homeostasis and dynamically regulating T cells in the lung parenchyma, and suggests that YFTL can be used as host-directed therapies that target immune responses to mycobacterial infection.
C1 [Fan, Xin; Li, Ning; Wang, Xiaoshuang; Zhang, Jingyu; Xu, Meiyi; Liu, Xueting; Wang, Beinan] Chinese Acad Sci, Inst Microbiol, CAS Key Lab Pathogen Microbiol & Immunol, Beijing, Peoples R China.
   [Xu, Meiyi; Wang, Beinan] Univ Chinese Acad Sci, Beijing, Peoples R China.
RP Wang, BN (reprint author), Chinese Acad Sci, Inst Microbiol, CAS Key Lab Pathogen Microbiol & Immunol, Beijing, Peoples R China.; Wang, BN (reprint author), Univ Chinese Acad Sci, Beijing, Peoples R China.
EM wangbn@im.ac.cn
OI Wang, Beinan/0000-0002-9260-7197
FU National Major Science and Technology Project [2013ZX10005004-005];
   National Natural Science Foundation of China [31370928, 31400760]
FX This work was supported by funding from the National Major Science and
   Technology Project Grant (2013ZX10005004-005), the National Natural
   Science Foundation of China Grant (31370928) and Grant (31400760) for
   Young Scholars. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.;
   This work was supported by funding from the National Major Science and
   Technology Project Grant (2013ZX10005004-005), the National Natural
   Science Foundation of China Grant (31370928) and Grant (31400760) for
   Young Scholars.
CR Altaf M, 2010, TUBERCULOSIS, V90, P333, DOI 10.1016/j.tube.2010.09.002
   Anderson KG, 2014, NAT PROTOC, V9, P209, DOI 10.1038/nprot.2014.005
   Ansari AW, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00312
   Brighenti S, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.TBTB2-0006-2016
   Cao YG, 2009, FUND CLIN PHARMACOL, V23, P457, DOI 10.1111/j.1472-8206.2009.00696.x
   Chavez-Galan L, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00999
   Chen K, 2013, ANNU REV IMMUNOL, V31, P605, DOI 10.1146/annurev-immunol-032712-100019
   Chen MJ, 2008, J EXP MED, V205, P2791, DOI 10.1084/jem.20080767
   Desvignes L, 2009, IMMUNITY, V31, P974, DOI 10.1016/j.immuni.2009.10.007
   Dick T, 1998, FEMS MICROBIOL LETT, V163, P159, DOI 10.1016/S0378-1097(98)00166-9
   Divangahi M, 2013, ADV EXP MED BIOL, V783, P103, DOI 10.1007/978-1-4614-6111-1_6
   Dovedi SJ, 2005, J UROLOGY, V174, P332, DOI 10.1097/01.ju.0000161589.85869
   Erb KJ, 1999, EUR CYTOKINE NETW, V10, P147
   Etna MP, 2014, SEMIN IMMUNOL, V26, P543, DOI 10.1016/j.smim.2014.09.011
   Fan X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107638
   Feng WJ, 2012, J NEW CHIN MED, V44, P22
   Feng WJ, 2014, J HUNAN U CHIN MED, V34, P46
   Friedland JS, 2014, NEW ENGL J MED, V371, P1354, DOI 10.1056/NEJMcibr1408663
   Gopal R, 2012, EUR J IMMUNOL, V42, P364, DOI 10.1002/eji.201141569
   Haoues M, 2012, Arch Inst Pasteur Tunis, V89, P3
   Jaron B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002833
   Jeevan A, 2007, CLIN EXP IMMUNOL, V149, P387, DOI 10.1111/j.1365-2249.2007.03425.x
   Kalinski P, 2012, J IMMUNOL, V188, P21, DOI 10.4049/jimmunol.1101029
   Larson RP, 2013, ADV EXP MED BIOL, V783, P165, DOI 10.1007/978-1-4614-6111-1_9
   Lyadova IV, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010469
   Machelart A, 2017, DRUG DISCOV TODAY, V22, P1250, DOI 10.1016/j.drudis.2017.05.005
   Mayer-Barber KD, 2014, NATURE, V511, P99, DOI 10.1038/nature13489
   Mayer-Barber KD, 2015, COLD SPRING HARB PER, V5, P12
   Moliva Juan I, 2017, Front Immunol, V8, P407, DOI 10.3389/fimmu.2017.00407
   Orme IM, 2015, NAT IMMUNOL, V16, P57, DOI 10.1038/ni.3048
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Sachan M, 2016, CURR PHARM DESIGN, V22, P2599, DOI 10.2174/1381612822666160128150636
   Sakai S, 2014, J IMMUNOL, V192, P2965, DOI 10.4049/jimmunol.1400019
   Sasindran SJ, 2011, FRONT MICROBIOL, V2, DOI 10.3389/fmicb.2011.00002
   Shehzad A, 2013, BRAZ J INFECT DIS, V17, P74, DOI 10.1016/j.bjid.2012.10.009
   Tobin DM, 2012, CELL, V148, P434, DOI 10.1016/j.cell.2011.12.023
   Tobin DM, 2015, COLD SPRING HARB PER, V5
   Tomioka H, 2017, AM J CHINESE MED, V45, P1597, DOI 10.1142/S0192415X17500860
   Tripathi RP, 2012, CURR MED CHEM, V19, P488
   Wang XS, 2017, J INFECT DIS, V215, P644, DOI 10.1093/infdis/jiw598
   Wang YJ, 2016, J ETHNOPHARMACOL, V194, P72, DOI 10.1016/j.jep.2016.08.046
   Winslow GM, 2008, IMMUNOL REV, V225, P284, DOI 10.1111/j.1600-065X.2008.00693.x
   World Health Organization, GLOBAL TUBERCULOSIS
   YOSHIDA A, 1995, J IMMUNOL, V155, P2057
NR 44
TC 1
Z9 1
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 11
PY 2018
VL 13
IS 9
AR e0203678
DI 10.1371/journal.pone.0203678
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GT2UM
UT WOS:000444355500037
PM 30204794
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Budriesi, R
   Vivarelli, F
   Canistro, D
   Aldini, R
   Marquillas, CB
   Corazza, I
   Fato, R
   Cirillo, S
   Bergamini, C
   D'Errico, A
   Bolchi, C
   Cevenini, M
   Degiovanni, A
   Frosini, M
   Camarda, L
   Chiarini, A
   Micucci, M
AF Budriesi, Roberta
   Vivarelli, Fabio
   Canistro, Donatella
   Aldini, Rita
   Marquillas, Clara Babot
   Corazza, Ivan
   Fato, Romana
   Cirillo, Silvia
   Bergamini, Christian
   D'Errico, Antonia
   Bolchi, Cristiano
   Cevenini, Monica
   Degiovanni, Alessio
   Frosini, Maria
   Camarda, Luca
   Chiarini, Alberto
   Micucci, Matteo
TI Liver and intestinal protective effects of Castanea sativa Mill. bark
   extract in high-fat diet rats
SO PLOS ONE
LA English
DT Article
ID ELLAGIC ACID; INCREASED EXPRESSION; CYTOCHROME-P450 2E1; OXIDATIVE
   STRESS; NITRIC-OXIDE; GUINEA-PIG; OBESITY; CELLS; ANTIOXIDANT;
   STEATOHEPATITIS
AB The effects of Castanea sativa Mill. have been studied in high fat diet (HFD) overweight rats. Natural Extract of Chestnut bark (Castanea sativa Mill.) (ENC (R)), rich in ellagitannins, has been studied in 120 male Sprague-Dawley rats, divided in four groups. Two groups were controls: regular (RD) and HDF diet. Two groups received ENC (R) (20 mg/kg/day): RD + ENC (R) and HFD + ENC (R). At baseline and at 7, 14 and 21 days, weight gain, serum lipids, plasma cytokines, liver histology, microsomial enzymes and oxidation, intestinal oxidative stress and contractility were studied. HFD increased body weight, increased pro-inflammatory cytokines, induced hepatocytes microvescicular steatosis, altered microsomial, increased liver and intestinal oxidative stress, deranged intestinal contractility. In HFD-fed rats, ENC (R) exerted antiadipose and antioxidative activities and normalized intestinal contractility, suggesting a potential approach to overweight management associated diseases.
C1 [Budriesi, Roberta; Vivarelli, Fabio; Canistro, Donatella; Aldini, Rita; Marquillas, Clara Babot; Fato, Romana; Cirillo, Silvia; Bergamini, Christian; Camarda, Luca; Chiarini, Alberto; Micucci, Matteo] Alma Mater Studiorum Univ Bologna, Dept Pharm & Biotechnol, Bologna, Italy.
   [Corazza, Ivan] Alma Mater Studiorum Univ Bologna, S Orsola Hosp, Dept Specialist Expt & Diagnost Med, Bologna, Italy.
   [D'Errico, Antonia; Degiovanni, Alessio] Alma Mater Studiorum Univ Bologna, F Addari Inst Oncol & Transplant Pathol, Dept Specialist, Diagnost & Expt Med Dept, Bologna, Italy.
   [Bolchi, Cristiano] Univ Milan, Dept Pharmaceut Sci Pietro Pratesi, Milan, Italy.
   [Cevenini, Monica] Alma Mater Studiorum Univ Bologna, Dept Surg & Med Sci, Bologna, Italy.
   [Frosini, Maria] Univ Siena, Dept Life Sci, Siena, Italy.
   [Chiarini, Alberto] GVM Care & Res, Lugo, Ravenna, Italy.
RP Canistro, D; Micucci, M (reprint author), Alma Mater Studiorum Univ Bologna, Dept Pharm & Biotechnol, Bologna, Italy.
EM donatella.canistro@unibo.it; matteo.micucci2@unibo.it
RI ; bolchi, cristiano/G-5239-2015
OI Corazza, Ivan/0000-0003-2078-1978; CANISTRO,
   DONATELLA/0000-0002-6378-1698; Vivarelli, Fabio/0000-0002-8734-0985;
   Cirillo, Silvia/0000-0003-1533-6247; bolchi,
   cristiano/0000-0002-6726-9501
FU Alma Mater Studiorum-University of Bologna (Italy)
FX This work was supported by Alma Mater Studiorum-University of Bologna
   (Italy) in the form of research financial support awarded to RB, as an
   Associate Professor of the University of Bologna. GVM Care & Research
   provided support in the form of cultural contributions for AC. The
   specific role of this author is articulated in the 'author
   contributions' section. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.; The authors received no specific funding for this work and
   are grateful to Alma Mater Studiorum-University of Bologna (Italy) by
   research financial support (RFO-University of Bologna). The authors
   thank "GVM Care & Research" for cultural contribution and declare that
   it did not have any additional role in the study design, data collection
   and analysis, decision to publish, or preparation of the manuscript. The
   specific roles of these authors are articulated in the 'author
   contributions' section.
CR Abdelmegeed MA, 2012, J HEPATOL, V57, P860, DOI 10.1016/j.jhep.2012.05.019
   Abidov M, 2010, DIABETES OBES METAB, V12, P72, DOI 10.1111/j.1463-1326.2009.01132.x
   Alexopoulos N, 2014, ATHEROSCLEROSIS, V233, P104, DOI 10.1016/j.atherosclerosis.2013.12.023
   ARUNLAKSHANA O, 1959, BRIT J PHARM CHEMOTH, V14, P48, DOI 10.1111/j.1476-5381.1959.tb00928.x
   Asayama K, 2001, FREE RADICAL RES, V34, P337, DOI 10.1080/10715760100300291
   Aubert J, 2011, CLIN RES HEPATOL GAS, V35, P630, DOI 10.1016/j.clinre.2011.04.015
   Basile A, 2000, FITOTERAPIA, V71, pS110, DOI 10.1016/S0367-326X(00)00185-4
   Bhattarai Y, 2016, AM J PHYSIOL-GASTR L, V311, pG210, DOI 10.1152/ajpgi.00085.2016
   Bowles DK, 2004, J APPL PHYSIOL, V96, P2240, DOI 10.1152/japplphysiol.01229.2003
   Braunersreuther V, 2012, WORLD J GASTROENTERO, V18, P727, DOI 10.3748/wjg.v18.i8.727
   Brizi C, 2016, J CELL BIOCHEM, V117, P510, DOI 10.1002/jcb.25302
   Budriesi R, 2010, J MED FOOD, V13, P1104, DOI 10.1089/jmf.2009.0210
   Calliste CA, 2005, J AGR FOOD CHEM, V53, P282, DOI 10.1021/jf049341c
   Canistro D, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02317-8
   Chiarini A, 2013, OXID MED CELL LONGEV, DOI 10.1155/2013/471790
   Christou DD, 2012, AM J PHYSIOL-HEART C, V303, pH743, DOI 10.1152/ajpheart.00394.2012
   Cimino F, 2013, GENES NUTR, V8, P391, DOI 10.1007/s12263-012-0324-4
   Dinkova-Kostova AT, 2012, TRENDS MOL MED, V18, P337, DOI 10.1016/j.molmed.2012.04.003
   El-Assal O, 2004, CELL MOL IMMUNOL, V1, P205
   Frankic T, 2011, J SCI FOOD AGR, V91, P1432, DOI 10.1002/jsfa.4328
   Girish C, 2008, FUND CLIN PHARMACOL, V22, P623, DOI 10.1111/j.1472-8206.2008.00618.x
   Guh DP, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-88
   Huang DW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010254
   Ip E, 2003, HEPATOLOGY, V38, P123, DOI 10.1053/jhep.2003.50307
   Jennings LJ, 1999, AM J PHYSL 1, V277
   Jensen MK, 2013, CIRCULATION, V127, DOI 10.1161/01.cir.0000437739.71477.ee
   Kang I, 2016, ADV NUTR, V7, P961, DOI 10.3945/an.116.012575
   Lei F, 2007, INT J OBESITY, V31, P1023, DOI 10.1038/sj.ijo.0803502
   Lemmers A, 2009, HEPATOLOGY, V49, P646, DOI 10.1002/hep.22680
   Li ZP, 2015, ANAEROBE, V34, P164, DOI 10.1016/j.anaerobe.2015.05.012
   Marchesini G, 2003, HEPATOLOGY, V37, P917, DOI 10.1053/jhep.2003.50161
   Matsuda M, 2014, REV ENDOCR METAB DIS, V15, P1, DOI 10.1007/s11154-013-9271-7
   McGrath JC, 2010, BRIT J PHARMACOL, V160, P1573, DOI 10.1111/j.1476-5381.2010.00873.x
   Melega S, 2013, MUTAT RES-GEN TOX EN, V751, P45, DOI 10.1016/j.mrgentox.2012.10.013
   Micucci M, 2017, J MED FOOD, V20, P592, DOI 10.1089/jmf.2016.0154
   Micucci M, 2014, J MED FOOD, V17, P795, DOI 10.1089/jmf.2013.0090
   Micucci M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080925
   Phan MAT, 2018, CRIT REV FOOD SCI, V58, P1310, DOI 10.1080/10408398.2016.1254595
   Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683
   Motulsky H., 2004, FITTING MODELS BIOL
   Nguyen JCD, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00375
   Okla M, 2015, J NUTR BIOCHEM, V26, P82, DOI 10.1016/j.jnutbio.2014.09.010
   Osabe M, 2008, DRUG METAB DISPOS, V36, P294, DOI 10.1124/dmd.107.017731
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Santini A, 2017, EUR J PHARM SCI, V96, P53, DOI 10.1016/j.ejps.2016.09.003
   Santulli C, 2017, J CELL BIOCHEM, V118, P839, DOI 10.1002/jcb.25760
   Sharma K, 2014, KIDNEY INT SUPPL, V4, P113, DOI 10.1038/kisup.2014.21
   Soory Mena, 2009, Infectious Disorders - Drug Targets, V9, P400
   Stepanova M, 2010, OBES SURG, V20, P640, DOI 10.1007/s11695-010-0078-2
   Sun X, 2014, PHYSIOL BEHAV, V136, P63, DOI 10.1016/j.physbeh.2014.04.017
   Sur Genel, 2014, Maedica (Buchar), V9, P15
   Tallarida RJ, 1987, MANUAL PHARM CALCULA, Vx
   Tomankova V, 2017, BIOMED PAP, V161, P144, DOI 10.5507/bp.2017.026
   Vivarelli F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150913
   Younossi ZM, 2005, HEPATOLOGY, V42, P665, DOI 10.1002/hep.20838
   Yun JW, 2010, PHYTOCHEMISTRY, V71, P1625, DOI 10.1016/j.phytochem.2010.07.011
NR 56
TC 0
Z9 0
U1 2
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 6
PY 2018
VL 13
IS 8
AR e0201540
DI 10.1371/journal.pone.0201540
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GP3UO
UT WOS:000440780000010
PM 30080863
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Wang, Y
   Eans, SO
   Stacy, HM
   Narayanapillai, SC
   Sharma, A
   Fujioka, N
   Haddad, L
   McLaughlin, J
   Avery, BA
   Xing, CG
AF Wang, Yi
   Eans, Shainnel O.
   Stacy, Heather M.
   Narayanapillai, Sreekanth C.
   Sharma, Abhisheak
   Fujioka, Naomi
   Haddad, Linda
   McLaughlin, Jay
   Avery, Bonnie A.
   Xing, Chengguo
TI A stable isotope dilution tandem mass spectrometry method of major
   kavalactones and its applications
SO PLOS ONE
LA English
DT Article
ID KAVA PIPER-METHYSTICUM;
   4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE-INDUCED LUNG
   TUMORIGENESIS; A/J MICE; LABORATORY-ANIMALS; QUALITY-CONTROL; DRY
   EXTRACTS; HERBAL DRUG; CHROMATOGRAPHY; DIHYDROMETHYSTICIN; IONIZATION
AB Kava is regaining its popularity with detailed characterizations warranted. We developed an ultraperformance liquid chromatography high-resolution tandem mass spectrometry (UPLC-MS/MS) method for major kavalactones (kavain, dihydrokavain, methysticin, dihydromethysticin and desmethoxyyangonin) with excellent selectivity and specificity. The method has been validated for different matrices following the Food and Drug Administration guidance of analytical procedures and methods validation. The scope of this method has been demonstrated by quantifying these kavalactones in two kava products, characterizing their tissue distribution and pharmacokinetics in mice, and detecting their presence in human urines and plasmas upon kava intake. As expected, the abundances of these kavalactones differed significantly in kava products. All of them exhibited a large volume of distribution with extensive tissue affinity and adequate mean residence time (MRT) in mice. This method also successfully quantified these kavalactones in human body fluids upon kava consumption at the recommended human dose. This UPLC-MS/MS method therefore can be used to characterize kava products and its pharmacokinetics in animals and in humans.
C1 [Wang, Yi; Narayanapillai, Sreekanth C.; Xing, Chengguo] Univ Florida, Dept Med Chem, Gainesville, FL 32611 USA.
   [Eans, Shainnel O.; Stacy, Heather M.; McLaughlin, Jay] Univ Florida, Dept Pharmacodynam, Gainesville, FL 32610 USA.
   [Narayanapillai, Sreekanth C.; Xing, Chengguo] Univ Minnesota, Dept Med Chem, Minneapolis, MN 55455 USA.
   [Sharma, Abhisheak; Avery, Bonnie A.] Univ Florida, Dept Pharmaceut, Gainesville, FL USA.
   [Fujioka, Naomi] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN USA.
   [Haddad, Linda] Univ Florida, Dept Family Community & Hlth Syst Sci, Gainesville, FL USA.
RP Xing, CG (reprint author), Univ Florida, Dept Med Chem, Gainesville, FL 32611 USA.; Xing, CG (reprint author), Univ Minnesota, Dept Med Chem, Minneapolis, MN 55455 USA.
EM chengguoxing@cop.ufl.edu
RI Sharma, Abhisheak/V-8401-2017; Sharma, Abhisheak/H-9327-2019
OI Sharma, Abhisheak/0000-0003-0553-4039; 
FU National Institute of Health [R01CA193278]; Masonic Cancer Center
   University of Minnesota; University of Florida College of Pharmacy and
   Department of Medicinal Chemistry; COP PROSPER Award
FX Funding was partially provided by the National Institute of Health
   R01CA193278 (CX), Masonic Cancer Center University of Minnesota (NF and
   CX), the Start-up fund from University of Florida College of Pharmacy
   and Department of Medicinal Chemistry (JPM and CX), and the COP PROSPER
   Award (CX). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Anke J, 2004, J ETHNOPHARMACOL, V93, P153, DOI 10.1016/j.jep.2004.04.009
   [Anonymous], 2005, VAL AN PROC TEXT MET
   Baum SS, 1998, PROG NEURO-PSYCHOPH, V22, P1105, DOI 10.1016/S0278-5846(98)00062-1
   Bilia AR, 2002, J AGR FOOD CHEM, V50, P5016, DOI 10.1021/jf020049j
   Bobeldijk I, 2005, J CHROMATOGR A, V1067, P107, DOI 10.1016/j.chroma.2005.01.013
   Clouatre DL, 2004, TOXICOL LETT, V150, P85, DOI 10.1016/j.toxlet.2003.07.005
   Dams R, 2003, J AM SOC MASS SPECTR, V14, P1290, DOI 10.1016/S1044-0305(03)00574-9
   DAVIES B, 1993, PHARMACEUT RES, V10, P1093, DOI 10.1023/A:1018943613122
   Fan H, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009419
   Feltenstein MW, 2003, PHYTOTHER RES, V17, P210, DOI 10.1002/ptr.1107
   Food Administration D, 2001, FED REGISTER, V66, P28526
   Gaub M, 2004, J PHARMACEUT BIOMED, V36, P859, DOI 10.1016/j.jpba.2004.06.030
   Geier FP, 2004, PHYTOTHER RES, V18, P297, DOI 10.1002/ptr.1422
   Guo JS, 2015, ANAL CHEM, V87, P5872, DOI 10.1021/acs.analchem.5b01129
   He XG, 1997, PLANTA MED, V63, P70, DOI 10.1055/s-2006-957608
   JAMIESON DD, 1990, CLIN EXP PHARMACOL P, V17, P495, DOI 10.1111/j.1440-1681.1990.tb01349.x
   KELEDJIAN J, 1988, J PHARM SCI, V77, P1003, DOI 10.1002/jps.2600771203
   King R, 2000, J AM SOC MASS SPECTR, V11, P942, DOI 10.1016/S1044-0305(00)00163-X
   Kuchta K, 2015, PLANTA MED, V81, P1647, DOI 10.1055/s-0035-1558295
   Lasme P, 2008, J AGR FOOD CHEM, V56, P4976, DOI 10.1021/jf800439g
   Lebot V, 2014, FOOD CHEM, V151, P554, DOI 10.1016/j.foodchem.2013.11.120
   Lechtenberg M, 1999, J CHROMATOGR A, V848, P457, DOI 10.1016/S0021-9673(99)00425-2
   LEHMANN E, 1989, PHARMACOPSYCHIATRY, V22, P258, DOI 10.1055/s-2007-1014611
   Leitzman P, 2014, CANCER PREV RES, V7, P86, DOI 10.1158/1940-6207.CAPR-13-0301
   Martin AC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111572
   Mathews JM, 2005, DRUG METAB DISPOS, V33, P1555, DOI 10.1124/dmd.105.004317
   Mathews JM, 2002, DRUG METAB DISPOS, V30, P1153, DOI 10.1124/dmd.30.11.1153
   Murauer A, 2017, PLANTA MED, V83, P1053, DOI 10.1055/s-0043-100632
   Narayanapillai SC, 2016, DRUG METAB DISPOS, V44, P422, DOI 10.1124/dmd.115.068387
   Narayanapillai SC, 2014, CHEM RES TOXICOL, V27, P1871, DOI 10.1021/tx5003194
   Narayanapillai SC, 2014, CARCINOGENESIS, V35, P2365, DOI 10.1093/carcin/bgu149
   Pittler MH, 2003, COCHRANE DB SYST REV, V1
   RASMUSSEN AK, 1979, XENOBIOTICA, V9, P1
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Russmann S, 2003, EUR J GASTROEN HEPAT, V15, P1033, DOI [10.1097/00042737-200309000-00015, 10.1097/01.meg.0000085464.12407.7b]
   Savage KM, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0986-5
   Shaik AA, 2012, ARKIVOC, P137
   Shaik AA, 2009, BIOORG MED CHEM LETT, V19, P5732, DOI 10.1016/j.bmcl.2009.08.003
   Shao Y, 1998, J CHROMATOGR A, V825, P1, DOI 10.1016/S0021-9673(98)00699-2
   Smith KK, 2001, PSYCHOPHARMACOLOGY, V155, P86, DOI 10.1007/s002130100686
   Stevinson C, 2002, DRUG SAFETY, V25, P251, DOI 10.2165/00002018-200225040-00003
   Stokvis E, 2005, RAPID COMMUN MASS SP, V19, P401, DOI 10.1002/rcm.1790
   Tarbah F, 2003, J CHROMATOGR B, V789, P115, DOI 10.1016/S1570-0232(03)00046-1
   Tarbah F, 2013, ANN TOXICOL ANAL, V25, P109
   Teschke R, 2013, PHYTOTHER RES, V27, P472, DOI 10.1002/ptr.4729
   Turner PV, 2011, J AM ASSOC LAB ANIM, V50, P600
   Wang Y, 2017, CHEM RES TOXICOL, V30, P705, DOI 10.1021/acs.chemrestox.6b00426
   WHO, 2016, KAV REV SAF TRAD REC, V1, P1
   WHO (World Health Organization), 2007, ASS RISK HEP KAV PRO
NR 49
TC 1
Z9 1
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 24
PY 2018
VL 13
IS 5
AR e0197940
DI 10.1371/journal.pone.0197940
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GH0HY
UT WOS:000433084300101
PM 29795658
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU de Araujo, AA
   Pereira, ADBF
   de Medeiros, CACX
   Brito, GAD
   Leitao, RFD
   Araujo, LD
   Guedes, PMM
   Hiyari, S
   Pirih, FQ
   de Araujo, RF
AF de Araujo, Aurigena Antunes
   Barbosa Freitas Pereira, Aline de Sousa
   Carvalho Xavier de Medeiros, Caroline Addison
   de Castro Brito, Gerly Anne
   de Carvalho Leitao, Renata Ferreira
   Araujo, Lorena de Souza
   Matta Guedes, Paulo Marcos
   Hiyari, Sarah
   Pirih, Flavia Q.
   de Araujo Junior, Raimundo Fernandes
TI Effects of metformin on inflammation, oxidative stress, and bone loss in
   a rat model of periodontitis
SO PLOS ONE
LA English
DT Article
ID ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; ENDOTHELIAL-CELLS; DISEASE;
   INVOLVEMENT; PATHOGENESIS; OSTEOBLASTS; SUPEROXIDE; RESORPTION; RADICALS
AB Aim
   To evaluate the effects of metformin (Met) on inflammation, oxidative stress, and bone loss in a rat model of ligature-induced periodontitis.
   Materials & methods
   Male albino Wistar rats were divided randomly into five groups of twenty-one rats each, and given the following treatments for 10 days: (1) no ligature + water, (2) ligature + water, (3) ligature + 50 mg/kg Met, (4) ligature + 100 mg/kg Met, and (5) ligature + 200 mg/kg Met. Water or Met was administered orally. Maxillae were fixed and scanned using Micro-computed Tomography (mu CT) to quantitate linear and bone volume/tissue volume (BV/TV) volumetric bone loss. Histopathological characteristics were assessed through immunohistochemical staining for MMP-9, COX-2, the RANKL/RANK/OPG pathway, SOD-1, and GPx-1. Additionally, confocal microscopy was used to analyze osteocalcin fluorescence. UV-VIS analysis was used to examine the levels of malondialdehyde, glutathione, IL-1 beta and TNF-alpha from gingival tissues. Quantitative RT-PCR reaction was used to gene expression of AMPK, NF-kappa B (p65), and Hmgb1 from gingival tissues. Significance among groups were analysed using a one-way ANOVA. A p-value of p<0.05 indicated a significant difference.
   Results
   Treatment with 50 mg/kg Met significantly reduced concentrations of malondialdehyde, IL-1 beta, and TNF-alpha (p < 0.05). Additionally, weak staining was observed for COX-2, MMP-9, RANK, RANKL, SOD-1, and GPx-1 after 50 mg/kg Met. OPG and Osteocalcin showed strong staining in the same group. Radiographically, linear measurements showed a statistically significant reduction in bone loss after 50 mg/kg Met compared to the ligature and Met 200 mg/kg groups. The same pattern was observed volumetrically in BV/TV and decreased osteoclast number (p<0.05). RT-PCR showed increased AMPK expression and decreased expression of NF-kappa B (p65) and HMGB1 after 50 mg/kg Met.
   Conclusions
   Metformin, at a concentration of 50 mg/kg, decreases the inflammatory response, oxidative stress and bone loss in ligature-induced periodontitis in rats.
C1 [de Araujo, Aurigena Antunes] Univ Fed Rio Grande do Norte, Dept Biophys & Pharmacol, Post Grad Program Pharmaceut Sci, Post Grad Program Publ Hlth, Natal, RN, Brazil.
   [Barbosa Freitas Pereira, Aline de Sousa] Univ Fed Rio Grande do Norte, Post Grad Program Publ Hlth, Natal, RN, Brazil.
   [Carvalho Xavier de Medeiros, Caroline Addison] Univ Fed Rio Grande do Norte, Post Grad Program RENORBIO, Dept Biophys & Pharmacol, Post Grad Program Biol Sci, Natal, RN, Brazil.
   [de Castro Brito, Gerly Anne; de Carvalho Leitao, Renata Ferreira] Univ Fed Ceara, Dept Morphol, Post Grad Program Morphol, Fortaleza, Ceara, Brazil.
   [Araujo, Lorena de Souza] Univ Fed Rio Grande do Norte, Post Grad Program Publ Hlth, Natal, RN, Brazil.
   [Matta Guedes, Paulo Marcos] Univ Fed Rio Grande do Norte, Dept Microbiol & Parasitol, Post Grad Program Parasitary Biol, Post Guaduat Biol Sci, Natal, RN, Brazil.
   [Hiyari, Sarah; Pirih, Flavia Q.] Univ Calif Los Angeles, Sch Dent, Sect Periodont, Los Angeles, CA 90024 USA.
   [de Araujo Junior, Raimundo Fernandes] Univ Fed Rio Grande do Norte, Dept Morphol, Post Grad Program Funct & Struct Biol, Post Grad Program Hlth Sci,Dept Morphol, Natal, RN, Brazil.
RP de Araujo, AA (reprint author), Univ Fed Rio Grande do Norte, Dept Biophys & Pharmacol, Post Grad Program Pharmaceut Sci, Post Grad Program Publ Hlth, Natal, RN, Brazil.
EM aurigena@ufrnet.br
RI Guedes, Paulo/Y-2546-2018; Brito, Gerly/C-8597-2013
OI Brito, Gerly/0000-0002-8214-4379; Araujo, Aurigena/0000-0001-9264-4695
FU CNPq [401838/2016-1]
FX This work was funded by CNPq, 401838/2016-1.
CR Akalin FA, 2005, J CLIN PERIODONTOL, V32, P238, DOI 10.1111/j.1600-051X.2005.00669.x
   Al-Khabbaz AK, 2014, ORAL HLTH PREV DENT, V12, P77, DOI 10.3290/j.ohpd.a31223
   Asehnoune K, 2004, J IMMUNOL, V172, P2522, DOI 10.4049/jimmunol.172.4.2522
   Biju T., 2014, J DENT RES, V25, P613, DOI DOI 10.4103/0970-9290.147105
   Cekici A, 2014, PERIODONTOL 2000, V64, P57, DOI 10.1111/prd.12002
   Chapple IL., 1996, CLIN MOL PATHOL, V49, pM247, DOI DOI 10.1136/MP.49.5.M247
   Chomczynski P, 2006, NAT PROTOC, V1, P581, DOI 10.1038/nprot.2006.83
   Costa CM, 2006, J BRAS PATOL MED LAB, V42, P345, DOI DOI 10.1590/S1676-24442006000100011)
   Demmer RT, 2012, DIABETES CARE, V35, P2036, DOI 10.2337/dc11-2453
   EMERIT J, 1982, SEM HOP PARIS, V58, P2670
   Esfahanian N, 2012, MOL MED REP, V5, P1068, DOI 10.3892/mmr.2012.753
   Guma M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140452
   Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x
   Hattori Y, 2006, HYPERTENSION, V47, P1183, DOI 10.1161/01.HYP.0000221429.94591.72
   Hawley SA, 2002, DIABETES, V51, P2420, DOI 10.2337/diabetes.51.8.2420
   Henderson B, 2003, ANNU REV MICROBIOL, V57, P29, DOI 10.1146/annurev.micro.57.030502.090908
   Jang WG, 2011, BONE, V48, P885, DOI 10.1016/j.bone.2010.12.003
   Kantarci A, 2003, J PERIODONTOL, V74, P66, DOI 10.1902/jop.2003.74.1.66
   Kasai T, 2009, J CELL PHYSIOL, V221, P740, DOI 10.1002/jcp.21917
   Katsuragi Hiroaki, 2003, Odontology, V91, P13, DOI 10.1007/s10266-003-0022-1
   KENDALL C, 1983, J IMMUNOL METHODS, V56, P329, DOI 10.1016/S0022-1759(83)80022-2
   KEY LL, 1994, BONE, V15, P431, DOI 10.1016/8756-3282(94)90821-4
   Kondo A, 2013, INT J MOL MED, V31, P1457, DOI 10.3892/ijmm.2013.1349
   Lee YS, 2010, BONE, V47, P926, DOI 10.1016/j.bone.2010.08.001
   Leitao RFC, 2005, J PERIODONTOL, V76, P956, DOI 10.1902/jop.2005.76.6.956
   List JF, 2009, DIABETES CARE, V32, P650, DOI 10.2337/dc08-1863
   Mayer ML, 2013, J IMMUNOL, V190, P1227, DOI 10.4049/jimmunol.1201404
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   REDL H, 1993, BRIT MED BULL, V49, P556, DOI 10.1093/oxfordjournals.bmb.a072630
   SAFIEHGARABEDIAN B, 1995, BRIT J PHARMACOL, V115, P1265, DOI 10.1111/j.1476-5381.1995.tb15035.x
   Salt IP, 2012, EXPERT OPIN INV DRUG, V21, P1155, DOI 10.1517/13543784.2012.696609
   SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x
   Shah M, 2010, BONE, V47, P309, DOI 10.1016/j.bone.2010.04.596
   Siddique YH, 2012, DOSE-RESPONSE, V10, P1, DOI 10.2203/dose-response.10-002.Siddique
   Tokuda H, 2012, J MOL ENDOCRINOL, V49, P47, DOI 10.1530/JME-11-0165
   Zhou Z, 2008, J BONE MINER RES, V23, P1084, DOI [10.1359/jbmr.080234, 10.1359/JBMR.080234]
NR 36
TC 5
Z9 5
U1 1
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 28
PY 2017
VL 12
IS 8
AR e0183506
DI 10.1371/journal.pone.0183506
PG 21
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FE8EO
UT WOS:000408438600029
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Ding, SB
   Jiang, JJ
   Zhang, GF
   Bu, YJ
   Zhang, GH
   Zhao, XM
AF Ding, Shibin
   Jiang, Jinjin
   Zhang, Guofu
   Bu, Yongjun
   Zhang, Guanghui
   Zhao, Xiangmei
TI Resveratrol and caloric restriction prevent hepatic steatosis by
   regulating SIRT1-autophagy pathway and alleviating endoplasmic reticulum
   stress in high-fat diet-fed rats
SO PLOS ONE
LA English
DT Article
ID ER STRESS; GLUCOSE-HOMEOSTASIS; AUTOPHAGY; LIVER; SIRT1; EXPRESSION;
   DISEASE; MICE; SUPPLEMENTATION; INFLAMMATION
AB Background
   Studies have demonstrated that resveratrol ( a natural polyphenol) and caloric restriction activate Sirtuin-1 (SIRT1) and induce autophagy. Furthermore, autophagy is induced by the SIRT1-FoxO signaling pathway and was recently shown to be a critical protective mechanism against non-alcoholic fatty liver disease (NAFLD) development. We aimed to compare the effects of resveratrol and caloric restriction on hepatic lipid metabolism and elucidate the mechanism by which resveratrol supplementation and caloric restriction alleviate hepatosteatosis by examining the molecular interplay between SIRT1 and autophagy.
   Methods and results
   Eight-week-old male Wistar rats (40) were divided into four groups: the STD group, which was fed a standard chow diet; the HFD group, which was fed a high-fat diet; HFD-RES group, which was fed a high-fat diet plus resveratrol (200 mg/kg. bw); and the HFD-CR group, which was fed a high-fat diet in portions containing 70% of the mean intake of the HFD group rats. The groups were maintained for 18 weeks. Metabolic parameters, Oil Red O and hematoxylin-eosin staining of the liver, and the mRNA and protein expression of SIRT1, autophagy markers and endoplasmic reticulum(ER) stress-associated genes in the liver were assessed after the 18-week treatment. We found that resveratrol (200 mg/kg bw) and caloric restriction (30%) partially prevented hepatic steatosis and hepatocyte ballooning, increased the expression of SIRT1 and autophagy markers while decreasing ER stress markers in the liver and alleviated lipid metabolism disorder. Moreover, caloric restriction provided superior protection against HFD-induced hepatic fatty accumulation compared with resveratrol and the effects were associated with decreased total energy intake and body weight.
   Conclusion
   We conclude that the SIRT1-autophagy pathway and decreased ER stress are universally required for the protective effects of moderate caloric restriction (30%) and resveratrol (a pharmacological SIRT1 activator) supplementation against HFD-induced hepatic steatosis.
C1 [Ding, Shibin; Zhang, Guofu; Bu, Yongjun; Zhang, Guanghui; Zhao, Xiangmei] Xinxiang Med Univ, Dept Nutr & Food Hyg, Sch Publ Hlth, Xinxiang, Henan, Peoples R China.
   [Ding, Shibin] Xinxiang Med Univ, Henan Collaborat Innovat Ctr Mol Diag & Lab Med, Xinxiang, Henan, Peoples R China.
   [Jiang, Jinjin] Capital Med Univ, Sch Publ Hlth, Beijing, Peoples R China.
RP Ding, SB (reprint author), Xinxiang Med Univ, Dept Nutr & Food Hyg, Sch Publ Hlth, Xinxiang, Henan, Peoples R China.; Ding, SB (reprint author), Xinxiang Med Univ, Henan Collaborat Innovat Ctr Mol Diag & Lab Med, Xinxiang, Henan, Peoples R China.
EM dingshibin@163.com
FU Key Scientific Research Project of Universities in Henan Province
   [16A330002]; Scientific Research Fund of Xinxiang Medical University
   [2014QN107]
FX This work was supported by the Key Scientific Research Project of
   Universities in Henan Province (16A330002) and Scientific Research Fund
   of Xinxiang Medical University (2014QN107).
CR Abd El-Haleim EA, 2016, WORLD J GASTROENTERO, V22, P2931, DOI 10.3748/wjg.v22.i10.2931
   Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354
   Beaudeux JL, 2010, CURR OPIN CLIN NUTR, V13, P729, DOI 10.1097/MCO.0b013e32833ef291
   Catta-Preta M, 2011, VIRCHOWS ARCH, V459, P477, DOI 10.1007/s00428-011-1147-1
   Chen Q, 2012, LIPIDS HEALTH DIS, V11, DOI 10.1186/1476-511X-11-56
   Colak Y, 2011, MED SCI MONITOR, V17, pHY5, DOI 10.12659/MSM.881749
   Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635
   Cui MX, 2013, J DIABETES RES, DOI 10.1155/2013/852754
   Day C P, 2005, Gastroenterology, V129, P375, DOI 10.1053/j.gastro.2005.05.041
   Ding SB, 2014, J ENDOCRINOL, V221, P167, DOI 10.1530/JOE-13-0386
   Ezquerro S, 2016, SCI REP-UK, V6, DOI 10.1038/srep39942
   Farrell GC, 2006, HEPATOLOGY, V43, pS99, DOI 10.1002/hep.20973
   Fischer-Posovszky P, 2010, AM J CLIN NUTR, V92, P5, DOI 10.3945/ajcn.2009.28435
   Gonzalez-Rodriguez A, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.162
   Heeboll S, 2016, J GASTROEN HEPATOL, V31, P668, DOI 10.1111/jgh.13151
   Heeboll S, 2015, PHARMACOL RES, V95-96, P34, DOI 10.1016/j.phrs.2015.03.005
   Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960
   Ji GY, 2015, LIPIDS HEALTH DIS, V14, DOI 10.1186/s12944-015-0139-6
   Jove M, 2014, AGING CELL, V13, P828, DOI 10.1111/acel.12241
   Kessoku T, 2016, SCI REP-UK, V6, DOI 10.1038/srep22251
   Kim KE, 2016, SCI REP-UK, V6, DOI 10.1038/srep30111
   Kruse R, 2015, DIABETOLOGIA, V58, P2087, DOI 10.1007/s00125-015-3654-0
   la Porte C, 2010, CLIN PHARMACOKINET, V49, P449, DOI 10.2165/11531820-000000000-00000
   Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013
   Loison C, 2002, BRIT J NUTR, V87, P199, DOI [10.1079/BJNBJN2002521, 10.1079/BJN2002521]
   Mansur AP, 2017, INT J CARDIOL, V227, P788, DOI 10.1016/j.ijcard.2016.10.058
   Marino G, 2014, AUTOPHAGY, V10, P1879, DOI 10.4161/auto.36413
   Morselli E, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.8
   Nemoto S, 2004, SCIENCE, V306, P2105, DOI 10.1126/science.1101731
   Ozcan U, 2006, SCIENCE, V313, P1137, DOI 10.1126/science.1128294
   Andrade JMO, 2014, NUTRITION, V30, P915, DOI 10.1016/j.nut.2013.11.016
   Pan QR, 2015, NUTR RES, V35, P576, DOI 10.1016/j.nutres.2015.05.006
   Pfluger PT, 2008, P NATL ACAD SCI USA, V105, P9793, DOI 10.1073/pnas.0802917105
   Poulsen MM, 2013, DIABETES, V62, P1186, DOI 10.2337/db12-0975
   Poulsen MM, 2013, ANN NY ACAD SCI, V1290, P74, DOI 10.1111/nyas.12141
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Rodriguez A, 2012, DIABETOLOGIA, V55, P3038, DOI 10.1007/s00125-012-2671-5
   Singh R, 2009, NATURE, V458, P1131, DOI 10.1038/nature07976
   Tauriainen E, 2011, J NUTR METAB, DOI 10.1155/2011/525094
   Tian YL, 2016, MOL CELL BIOCHEM, V422, P75, DOI 10.1007/s11010-016-2807-x
   Tsutsumi A, 2011, BIOCHEM BIOPH RES CO, V404, P339, DOI 10.1016/j.bbrc.2010.11.120
   Ueno T, 2017, NAT REV GASTRO HEPAT, V14, P170, DOI 10.1038/nrgastro.2016.185
   Xu JQ, 2017, NUTRIENTS, V9, DOI 10.3390/nu9030271
   Yang L, 2010, CELL METAB, V11, P467, DOI 10.1016/j.cmet.2010.04.005
   Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814
   Yki-Jarvinen H, 2014, LANCET DIABETES ENDO, V2, P901, DOI 10.1016/S2213-8587(14)70032-4
   Zhang Q, 2015, INT J BIOL SCI, V11, P559, DOI 10.7150/ijbs.10690
   Zhang XQ, 2014, WORLD J GASTROENTERO, V20, P1768, DOI 10.3748/wjg.v20.i7.1768
   Zhang Y, 2015, MOL NUTR FOOD RES, V59, P1443, DOI 10.1002/mnfr.201500016
NR 49
TC 20
Z9 20
U1 2
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 17
PY 2017
VL 12
IS 8
AR e0183541
DI 10.1371/journal.pone.0183541
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FD9QG
UT WOS:000407856600150
PM 28817690
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Na, ES
   de Jesus-Cortes, H
   Martinez-Rivera, A
   Kabir, ZD
   Wang, JQ
   Ramesh, V
   Onder, Y
   Rajadhyaksha, AM
   Monteggia, LM
   Pieper, AA
AF Na, Elisa S.
   de Jesus-Cortes, Hector
   Martinez-Rivera, Arlene
   Kabir, Zeeba D.
   Wang, Jieqi
   Ramesh, Vijayashree
   Onder, Yasemin
   Rajadhyaksha, Anjali M.
   Monteggia, Lisa M.
   Pieper, Andrew A.
TI D-cycloserine improves synaptic transmission in an animal mode of Rett
   syndrome
SO PLOS ONE
LA English
DT Article
ID OBSESSIVE-COMPULSIVE DISORDER; FEAR-POTENTIATED STARTLE; SOCIAL ANXIETY
   DISORDER; CPG-BINDING PROTEIN-2; MOUSE MODEL; NEUROTROPHIC FACTOR;
   HIPPOCAMPAL-NEURONS; EXPOSURE THERAPY; CONDITIONED FEAR; MECP2
   OVEREXPRESSION
AB Rett syndrome (RTT), a leading cause of intellectual disability in girls, is predominantly caused by mutations in the X-linked gene MECP2. Disruption of Mecp2 in mice recapitulates major features of RTT, including neurobehavioral abnormalities, which can be reversed by re-expression of normal Mecp2. Thus, there is reason to believe that RTT could be amenable to therapeutic intervention throughout the lifespan of patients after the onset of symptoms. A common feature underlying neuropsychiatric disorders, including RTT, is altered synaptic function in the brain. Here, we show that Mecp2(tm1.1Jae/y) mice display lower presynaptic function as assessed by paired pulse ratio, as well as decreased long term potentiation (LTP) at hippocampal Schaffer-collateral-CA1 synapses. Treatment of Mecp2(tm1.1Jae/y) mice with D-cycloserine (DCS), an FDA-approved analog of the amino acid D-alanine with antibiotic and glycinergic activity, corrected the presynaptic but not LTP deficit without affecting deficient hippocampal BDNF levels. DCS treatment did, however, partially restore lower BDNF levels in the brain stem and striatum. Thus, treatment with DCS may mitigate the severity of some of the neurobehavioral symptoms experienced by patients with Rett syndrome.
C1 [Na, Elisa S.] Texas Womans Univ, Dept Psychol & Philosophy, Denton, TX 76204 USA.
   [de Jesus-Cortes, Hector] MIT, Picower Inst Learning & Memory, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
   [Martinez-Rivera, Arlene; Kabir, Zeeba D.; Rajadhyaksha, Anjali M.] Cornell Univ, Weill Cornell Med, Dept Pediat, Div Pediat Neurol, New York, NY USA.
   [Martinez-Rivera, Arlene; Kabir, Zeeba D.; Rajadhyaksha, Anjali M.; Pieper, Andrew A.] Cornell Univ, Weill Cornell Med, Weill Cornell Autism Res Program, New York, NY 10021 USA.
   [Wang, Jieqi; Pieper, Andrew A.] Univ Iowa, Dept Psychiat, Carver Coll Med, Iowa City, IA 52242 USA.
   [Ramesh, Vijayashree; Onder, Yasemin; Monteggia, Lisa M.] UT Southwestern Med Ctr, Dept Neurosci, Dallas, TX 75390 USA.
   [Rajadhyaksha, Anjali M.] Cornell Univ, Weill Cornell Med, Feil Family Brain & Mind Res Inst, New York, NY 10021 USA.
   [Pieper, Andrew A.] Univ Iowa, Dept Neurol, Carver Coll Med, Iowa City, IA 52242 USA.
   [Pieper, Andrew A.] Univ Iowa, Dept Free Radical & Radiat Biol, Carver Coll Med, Iowa City, IA 52242 USA.
   [Pieper, Andrew A.] Univ Iowa, Dept Vet Affairs, Carver Coll Med, Iowa City, IA 52242 USA.
   [Pieper, Andrew A.] Univ Iowa, Pappajohn Biomed Inst, Carver Coll Med, Iowa City, IA 52242 USA.
RP Rajadhyaksha, AM (reprint author), Cornell Univ, Weill Cornell Med, Dept Pediat, Div Pediat Neurol, New York, NY USA.; Rajadhyaksha, AM; Pieper, AA (reprint author), Cornell Univ, Weill Cornell Med, Weill Cornell Autism Res Program, New York, NY 10021 USA.; Pieper, AA (reprint author), Univ Iowa, Dept Psychiat, Carver Coll Med, Iowa City, IA 52242 USA.; Monteggia, LM (reprint author), UT Southwestern Med Ctr, Dept Neurosci, Dallas, TX 75390 USA.; Rajadhyaksha, AM (reprint author), Cornell Univ, Weill Cornell Med, Feil Family Brain & Mind Res Inst, New York, NY 10021 USA.; Pieper, AA (reprint author), Univ Iowa, Dept Neurol, Carver Coll Med, Iowa City, IA 52242 USA.; Pieper, AA (reprint author), Univ Iowa, Dept Free Radical & Radiat Biol, Carver Coll Med, Iowa City, IA 52242 USA.; Pieper, AA (reprint author), Univ Iowa, Dept Vet Affairs, Carver Coll Med, Iowa City, IA 52242 USA.; Pieper, AA (reprint author), Univ Iowa, Pappajohn Biomed Inst, Carver Coll Med, Iowa City, IA 52242 USA.
EM amr2011@med.cornell.edu; lisa.monteggia@utsouthwestern.edu;
   andrewapieper@uiowa.edu
RI Pieper, Andrew/R-5552-2016
FU Rett Syndrome Research Trust; Weill Cornell Autism Research Program; The
   Hartwell Foundation; NIMH [MH081060]
FX This work was supported by research funds from the Rett Syndrome
   Research Trust to AAP, Weill Cornell Autism Research Program funding to
   AMR, funding from The Hartwell Foundation to AAP and AMR, and NIMH grant
   MH081060 to LMM.
CR Akirav I, 2007, NEUROPSYCHOPHARMACOL, V32, P542, DOI 10.1038/sj.npp.1301050
   Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810
   Asaka Y, 2006, NEUROBIOL DIS, V21, P217, DOI 10.1016/j.nbd.2005.07.005
   ASTHANA JC, 1990, ARCH DIS CHILD, V65, P1133, DOI 10.1136/adc.65.10.1133
   Baker JD, 1996, BEHAV NEUROSCI, V110, P618, DOI 10.1037/0735-7044.110.3.618
   Baker KD, 2012, LEARN MEMORY, V19, P461, DOI 10.1101/lm.026674.112
   Balkowiec A, 2002, J NEUROSCI, V22, P10399
   Berger-Sweeney J, 2011, NEUROBIOL LEARN MEM, V96, P637, DOI 10.1016/j.nlm.2011.05.006
   Bertotto ME, 2006, NEUROSCIENCE, V142, P979, DOI 10.1016/j.neuroscience.2006.07.013
   Blue ME, 1999, ANN NEUROL, V45, P541, DOI 10.1002/1531-8249(199904)45:4<541::AID-ANA21>3.0.CO;2-2
   Blue ME, 1999, EXP NEUROL, V156, P345, DOI 10.1006/exnr.1999.7030
   BOJE KM, 1993, BRAIN RES, V603, P207, DOI 10.1016/0006-8993(93)91239-O
   Buchovecky CM, 2013, NAT GENET, V45, P1013, DOI 10.1038/ng.2714
   Chang QA, 2006, NEURON, V49, P341, DOI 10.1016/j.neuron.2005.12.027
   Chen RZ, 2001, NAT GENET, V27, P327, DOI 10.1038/85906
   Chen WG, 2003, SCIENCE, V302, P885, DOI 10.1126/science.1086446
   Deogracias R, 2012, P NATL ACAD SCI USA, V109, P14230, DOI 10.1073/pnas.1206093109
   FALLS WA, 1992, J NEUROSCI, V12, P854
   Fernandez F, 2007, NAT NEUROSCI, V10, P411, DOI 10.1038/nn1860
   Gemelli T, 2006, BIOL PSYCHIAT, V59, P468, DOI 10.1016/j.biopsych.2005.07.025
   Gibson JR, 2008, J NEUROPHYSIOL, V100, P2615, DOI 10.1152/jn.90752.2008
   Guastella AJ, 2008, BIOL PSYCHIAT, V63, P544, DOI 10.1016/j.biopsych.2007.11.011
   Guy J, 2007, SCIENCE, V315, P1143, DOI 10.1126/science.1138389
   HAGBERG B, 1983, ANN NEUROL, V14, P471, DOI 10.1002/ana.410140412
   HAGBERG B, 1986, AM J MED GENET, V24, P47
   HAMBERGER A, 1992, NEUROPEDIATRICS, V23, P212, DOI 10.1055/s-2008-1071344
   Hempstead B L, 2014, Handb Exp Pharmacol, V220, P17, DOI 10.1007/978-3-642-45106-5_2
   Hofmann SG, 2006, ARCH GEN PSYCHIAT, V63, P298, DOI 10.1001/archpsyc.63.3.298
   Hofmann SG, 2006, CNS DRUG REV, V12, P208, DOI 10.1111/j.1527-3458.2006.00208.x
   Hofmann SG, 2013, BIOL MOOD ANXIETY DI, V3, DOI 10.1186/2045-5380-3-11
   Jin SX, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011732
   Katz D M, 2014, Handb Exp Pharmacol, V220, P481, DOI 10.1007/978-3-642-45106-5_18
   Katz DM, 2012, DIS MODEL MECH, V5, P733, DOI 10.1242/dmm.011007
   Katz DM, 2009, RESP PHYSIOL NEUROBI, V168, P101, DOI 10.1016/j.resp.2009.04.017
   Kline DD, 2010, J NEUROSCI, V30, P5303, DOI 10.1523/JNEUROSCI.5503-09.2010
   Kron M, 2014, DIS MODEL MECH, V7, P1047, DOI 10.1242/dmm.016030
   Kushner MG, 2007, BIOL PSYCHIAT, V62, P835, DOI 10.1016/j.biopsych.2006.12.020
   LAMBERT MP, 1972, J BACTERIOL, V110, P978
   Lappalainen R, 1996, PEDIATR NEUROL, V15, P445
   Ledgerwood L, 2004, BEHAV NEUROSCI, V118, P505, DOI 10.1037/0735-7044.118.3.505
   Ledgerwood L, 2003, BEHAV NEUROSCI, V117, P341, DOI 10.1037/0735-7044.117.2.341
   Ledgerwood L, 2005, BIOL PSYCHIAT, V57, P841, DOI 10.1016/j.biopsych.2005.01.023
   Li W, 2014, NEUROPHARMACOLOGY, V76, P737, DOI 10.1016/j.neuropharm.2013.03.024
   Mahgoub M, 2016, NAT NEUROSCI, V19, P1506, DOI 10.1038/nn.4395
   Martinowich K, 2003, SCIENCE, V302, P890, DOI 10.1126/science.1090842
   Massa SM, 2010, J CLIN INVEST, V120, P1774, DOI 10.1172/JCI41356
   Moretti P, 2006, J NEUROSCI, V26, P319, DOI 10.1523/JNEUROSCI.2623-05.2006
   Myers KM, 2011, NEUROPSYCHOPHARMACOL, V36, P274, DOI 10.1038/npp.2010.88
   Myers KM, 2002, NEURON, V36, P567, DOI 10.1016/S0896-6273(02)01064-4
   Na ES, 2014, NEUROPSYCHOPHARMACOL, V39, P1946, DOI 10.1038/npp.2014.43
   Na ES, 2013, NEUROPSYCHOPHARMACOL, V38, P212, DOI 10.1038/npp.2012.116
   Na ES, 2012, J NEUROSCI, V32, P3109, DOI 10.1523/JNEUROSCI.6000-11.2012
   Naidu S, 1997, EUR CHILD ADOLES PSY, V6, P14
   Nelson ED, 2006, CURR BIOL, V16, P710, DOI 10.1016/j.cub.2006.02.062
   Neul Jeffrey Lorenz, 2012, Dialogues Clin Neurosci, V14, P253
   Otto MW, 2010, BIOL PSYCHIAT, V67, P365, DOI 10.1016/j.biopsych.2009.07.036
   Prosser GA, 2013, FEBS J, V280, P1150, DOI 10.1111/febs.12108
   QUARTERMAIN D, 1994, EUR J PHARMACOL, V257, P7, DOI 10.1016/0014-2999(94)90687-4
   Ramirez JM, 2013, RESP PHYSIOL NEUROBI, V189, P280, DOI 10.1016/j.resp.2013.06.022
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Ren J, 2012, J NEUROSCI, V32, P17230, DOI 10.1523/JNEUROSCI.2951-12.2012
   Ressler KJ, 2004, ARCH GEN PSYCHIAT, V61, P1136, DOI 10.1001/archpsyc.61.11.1136
   Roux JC, 2008, NEUROSCI LETT, V447, P82, DOI 10.1016/j.neulet.2008.09.045
   Sampaio TB, 2017, EUR J PHARMACOL, V795, P28, DOI 10.1016/j.ejphar.2016.11.054
   Schmid DA, 2012, J NEUROSCI, V32, P1803, DOI 10.1523/JNEUROSCI.0865-11.2012
   Sheinin A, 2001, NEUROPHARMACOLOGY, V41, P151, DOI 10.1016/S0028-3908(01)00073-9
   Silvestri AJ, 2008, PHYSIOL BEHAV, V93, P274, DOI 10.1016/j.physbeh.2007.08.020
   Sotres-Bayon F, 2007, NEUROPSYCHOPHARMACOL, V32, P1929, DOI 10.1038/sj.npp.1301316
   Sotres-Bayon F, 2009, CEREB CORTEX, V19, P474, DOI 10.1093/cercor/bhn099
   Stettner GM, 2007, J PHYSL, V579, P803
   Tabuchi K, 2007, SCIENCE, V318, P71, DOI 10.1126/science.1146221
   Takasu MA, 2002, SCIENCE, V295, P491, DOI 10.1126/science.1065983
   Voituron N, 2009, RESP PHYSIOL NEUROBI, V168, P109, DOI 10.1016/j.resp.2009.05.013
   Walker DL, 2002, J NEUROSCI, V22, P2343, DOI 10.1523/JNEUROSCI.22-06-02343.2002
   Wang JQ, 2015, NATURE, V521, pE1, DOI 10.1038/nature14444
   Weng SM, 2011, NEUROSCIENCE, V180, P314, DOI 10.1016/j.neuroscience.2011.01.061
   Wilhelm S, 2008, AM J PSYCHIAT, V165, P335, DOI 10.1176/appi.ajp.2007.07050776
   Yaka R, 2003, J BIOL CHEM, V278, P9630, DOI 10.1074/jbc.M209141200
   Yaka R, 2007, FASEB J, V21, P2033, DOI 10.1096/fj.06-7856com
   Yamamoto S, 2008, NEUROPSYCHOPHARMACOL, V33, P2108, DOI 10.1038/sj.npp.1301605
   Yashiro K, 2008, NEUROPHARMACOLOGY, V55, P1081, DOI 10.1016/j.neuropharm.2008.07.046
   Yu H, 2009, J NEUROSCI, V29, P4056, DOI 10.1523/JNEUROSCI.5539-08.2009
   ZAFRA F, 1991, P NATL ACAD SCI USA, V88, P10037, DOI 10.1073/pnas.88.22.10037
   ZAFRA F, 1992, J NEUROSCI, V12, P4793
NR 84
TC 1
Z9 1
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 16
PY 2017
VL 12
IS 8
AR e0183026
DI 10.1371/journal.pone.0183026
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FD6XW
UT WOS:000407672200052
PM 28813484
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Uchihara, Y
   Ueda, F
   Tago, K
   Nakazawa, Y
   Ohe, T
   Mashino, T
   Yokota, S
   Kasahara, T
   Tamura, H
   Funakoshi-Tago, M
AF Uchihara, Yuki
   Ueda, Fumihito
   Tago, Kenji
   Nakazawa, Yosuke
   Ohe, Tomoyuki
   Mashino, Tadahiko
   Yokota, Shigenobu
   Kasahara, Tadashi
   Tamura, Hiroomi
   Funakoshi-Tago, Megumi
TI Alpha-tocopherol attenuates the anti-tumor activity of crizotinib
   against cells transformed by NPM-ALK
SO PLOS ONE
LA English
DT Article
ID ANAPLASTIC LYMPHOMA KINASE; RECEPTOR TYROSINE KINASE; HEPATOCYTE
   GROWTH-FACTOR; VITAMIN-E; LUNG-CANCER; C-MET; PROTEIN; FUSION;
   APOPTOSIS; GENERATION
AB Anaplastic large cell lymphomas (ALCL) are mainly characterized by harboring the fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK). The ALK inhibitor, crizotinib specifically induced apoptosis in Ba/F3 cells expressing NPM-ALK by inhibiting the activation of NPM-ALK and its downstream molecule, signal transducer and activator of transcription factor 3 (STAT3). We found that a-tocopherol, a major component of vitamin E, attenuated the effects of crizotinib independently of its anti-oxidant properties. Although alpha-tocopherol suppressed the inhibitory effects of crizotinib on the signaling axis including NPM-ALK and STAT3, it had no influence on the intake of crizotinib into cells. Crizotinib also directly inhibited the kinase activity of NPM-ALK; however, this inhibitory effect was not altered by the co-treatment with a-tocopherol. Whereas the nuclear localization of NPM-ALK was disappeared by the treatment with crizotinib, the co-treatment with a-tocopherol swept the effect of crizotinib and caused the localization of NPM-ALK in nucleus. The administration of a-tocopherol attenuated the anti-tumor activity of crizotinib against NPM-ALKprovoked tumorigenesis in vivo. Furthermore, the a-tocopherol-induced inhibition of crizotinib-caused apoptosis was also observed in NPM-ALK-positive cells derived from ALCL patients, namely, SUDHL-1 and Ki-JK. Collectively, these results not only revealed the novel mechanism underlying crizotinib-induced apoptosis in NPM-ALK-positive cells, but also suggest that the anti-tumor effects of crizotinib are attenuated when it is taken in combination with vitamin E.
C1 [Uchihara, Yuki; Ueda, Fumihito; Nakazawa, Yosuke; Yokota, Shigenobu; Tamura, Hiroomi; Funakoshi-Tago, Megumi] Keio Univ, Div Hyg Chem, Fac Pharm, Minato Ku, Tokyo, Japan.
   [Tago, Kenji] Jichi Med Univ, Div Struct Biochem, Dept Biochem, Shimotsuke Shi, Tochigiken, Japan.
   [Ohe, Tomoyuki; Mashino, Tadahiko] Keio Univ, Div Med Chem & Bioorgan Chem, Fac Pharm, Minato Ku, Tokyo, Japan.
   [Kasahara, Tadashi] Int Univ Hlth & Welf, Grad Sch, Minato Ku, Tokyo, Japan.
RP Funakoshi-Tago, M (reprint author), Keio Univ, Div Hyg Chem, Fac Pharm, Minato Ku, Tokyo, Japan.
EM tago-mg@pha.keio.ac.jp
FU NOVARTIS foundation
FX We had a monetary support from NOVARTIS foundation for our current
   project. For this support, we would like to describe that NOVARTIS
   foundation had no control to alter our adherence to PLOS ONE policies on
   sharing data and materials.
CR Abe M, 2009, INT IMMUNOPHARMACOL, V9, P870, DOI 10.1016/j.intimp.2009.03.011
   Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312
   BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9
   Ceccon M, 2016, ONCOGENE, V35, P3854, DOI 10.1038/onc.2015.456
   Chiarle R, 2005, NAT MED, V11, P623, DOI 10.1038/nm1249
   Christensen JG, 2007, MOL CANCER THER, V6, P3314, DOI 10.1158/1535-7163.MCT-07-0365
   Desjobert C, 2011, BLOOD, V117, P6627, DOI 10.1182/blood-2010-09-301994
   EPSTEIN AL, 1974, CANCER-AM CANCER SOC, V34, P1851, DOI 10.1002/1097-0142(197412)34:6<1851::AID-CNCR2820340602>3.0.CO;2-4
   Ford ES, 2005, ANN INTERN MED, V143, P116, DOI 10.7326/0003-4819-143-2-200507190-00010
   Freedman JE, 1996, CIRCULATION, V94, P2434, DOI 10.1161/01.CIR.94.10.2434
   Fujita K, 2012, NAT MED, V18, P589, DOI 10.1038/nm.2659
   Gainor JF, 2016, TRANSL LUNG CANCER R, V5, P343, DOI 10.21037/tlcr.2016.03.05
   Gambacorti-Passerini C, 2011, NEW ENGL J MED, V364, P775, DOI 10.1056/NEJMc1013224
   Hallberg B, 2013, NAT REV CANCER, V13, P685, DOI 10.1038/nrc3580
   Heun M, 1997, SCIENCE, V278, P1312, DOI 10.1126/science.278.5341.1312
   Hosomi A, 1997, FEBS LETT, V409, P105, DOI 10.1016/S0014-5793(97)00499-7
   Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849
   Mano H, 2012, CANCER DISCOV, V2, P495, DOI 10.1158/2159-8290.CD-12-0009
   Marzec M, 2007, ONCOGENE, V26, P813, DOI 10.1038/sj.onc.1209843
   Mason DY, 1998, CANCER RES, V58, P1057
   Medeiros LJ, 2007, AM J CLIN PATHOL, V127, P707, DOI 10.1309/R2Q9CCUVTLRYC3H
   Megiorni F, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0228-4
   NAS. Selenium, 2000, DIET REF INT VIT C V, P284
   Nishizawa C, 2009, FREE RADICAL RES, V43, P1240, DOI [10.3109/10715760903273849, 10.3109/13814780903260764]
   Palmer RH, 2009, BIOCHEM J, V420, P345, DOI 10.1042/BJ20090387
   PARRISH DB, 1980, CRC CR REV FOOD SCI, V13, P161, DOI 10.1080/10408398009527288
   Peeters P, 1997, BLOOD, V90, P2535
   Pons E, 1998, LEUKEMIA RES, V22, P797, DOI 10.1016/S0145-2126(98)00071-X
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Roskoski R, 2013, EXPERT OPIN DRUG DIS, V8, P1165, DOI 10.1517/17460441.2013.813015
   Sahu Arvind, 2013, South Asian J Cancer, V2, P91, DOI 10.4103/2278-330X.110506
   SHIMAKAGE M, 1993, INTERVIROLOGY, V36, P215, DOI 10.1159/000150340
   Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945
   Song ZL, 2015, ACTA PHARM SIN B, V5, P34, DOI 10.1016/j.apsb.2014.12.007
   Tartari CJ, 2008, J BIOL CHEM, V283, P3743, DOI 10.1074/jbc.M706067200
   Tasinato A, 1995, P NATL ACAD SCI USA, V92, P12190, DOI 10.1073/pnas.92.26.12190
   Usatyuk PV, 2014, J BIOL CHEM, V289, P13476, DOI 10.1074/jbc.M113.527556
NR 37
TC 4
Z9 4
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 14
PY 2017
VL 12
IS 8
AR e0183003
DI 10.1371/journal.pone.0183003
PG 22
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FD5CP
UT WOS:000407548800045
PM 28806414
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Phie, J
   Krishna, SM
   Moxon, JV
   Omer, SM
   Kinobe, R
   Golledge, J
AF Phie, James
   Krishna, Smriti M.
   Moxon, Joseph V.
   Omer, Safraz M.
   Kinobe, Robert
   Golledge, Jonathan
TI Flavonols reduce aortic atherosclerosis lesion area in apolipoprotein E
   deficient mice: A systematic review and meta-analysis
SO PLOS ONE
LA English
DT Review
ID E-KNOCKOUT MICE; ENZYMATICALLY MODIFIED ISOQUERCITRIN;
   LOW-DENSITY-LIPOPROTEIN; DISEASE RISK-FACTORS; HIGH-FAT DIET;
   CARDIOVASCULAR-DISEASE; ATTENUATE ATHEROSCLEROSIS; ENDOTHELIAL
   DYSFUNCTION; ISOFLAVAN GLABRIDIN; QUERCETIN
AB Diets rich in flavonoids have been reported to have beneficial effects in the primary prevention of cardiovascular events. There are limited data, however, on the cardiovascular benefits of purified flavonoids. The aim of this systematic review and meta-analysis was to examine the reported effects of isolated flavonoids on aortic atherosclerosis in a mouse model. Medline, Pubmed, Science direct and Web of Science were searched to identify studies which examined the effect of isolated flavonoids on aortic atherosclerosis in apolipoprotein E deficient mice. A meta-analysis was performed to determine the overall effect of the flavonoids, and sub-analyses were performed to compare the effects of the flavonols and flavan-3-ols. Eleven studies, which examined a total of 208 mice receiving a flavonoid and 126 control mice, were included. Overall the flavonoids significantly reduced aortic atherosclerosis (SMD 1.10, 95% CI 0.69, 1.51). Of the 18 flavonoid interventions examined 12 were flavonols and 3 were flavan-3-ols. Sub-analyses suggested that the flavonols (SMD 1.31, 95% CI 0.66, 1.91) but not the flavan-3-ols (SMD 0.33, 95% CI -0.19, 0.85) significantly decreased atherosclerosis area. Of the eleven studies, only one examined histological markers of atherosclerosis plaque stability. Most studies did not report blinding of outcome assessors or reproducibility of the primary outcome, and did not justify the sample size used and flavonoid dose administered. Based on the included studies, the flavonols appear to be the most effective flavonoids for reducing aortic atherosclerotic lesion area in apolipoprotein E deficient mice.
C1 [Phie, James; Krishna, Smriti M.; Moxon, Joseph V.; Omer, Safraz M.; Golledge, Jonathan] James Cook Univ, Vasc Biol Unit, Queensland Res Ctr Peripheral Vasc Dis, Sch Med & Dent, Townsville, Qld, Australia.
   [Kinobe, Robert] James Cook Univ, Coll Publ Hlth Med & Vet Sci, Townsville, Qld, Australia.
   [Golledge, Jonathan] Townsville Hosp, Dept Vasc & Endovasc Surg, Townsville, Qld, Australia.
RP Golledge, J (reprint author), James Cook Univ, Vasc Biol Unit, Queensland Res Ctr Peripheral Vasc Dis, Sch Med & Dent, Townsville, Qld, Australia.; Golledge, J (reprint author), Townsville Hosp, Dept Vasc & Endovasc Surg, Townsville, Qld, Australia.
EM jonathan.golledge@jcu.edu.au
RI golledge, jonathan/I-2371-2013
FU National Health and Medical Research Council (NHMRC); Queensland
   Government; Townsville Hospital Private Practice Trust; National Health
   and Medical Research Council, Australia; Australian Postgraduate Award;
   James Cook University College of Medicine and Dentistry Scholarship
FX This work was supported by grants from the National Health and Medical
   Research Council (NHMRC), the Queensland Government and the Townsville
   Hospital Private Practice Trust. Jonathan Golledge holds a Practitioner
   Fellowship from the National Health and Medical Research Council,
   Australia and a Senior Clinical Research Fellowship from the Queensland
   Government. JP is supported by the Australian Postgraduate Award and the
   James Cook University College of Medicine and Dentistry Scholarship. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR [Anonymous], 2015, CARDIOVASCULAR DIS
   Auclair Sylvain, 2009, Atherosclerosis, V204, pe21, DOI 10.1016/j.atherosclerosis.2008.12.007
   Belinky PA, 1998, ATHEROSCLEROSIS, V137, P49, DOI 10.1016/S0021-9150(97)00251-7
   Blankenberg S, 2003, CIRCULATION, V107, P1579, DOI 10.1161/01.CIR.0000058700.41738.12
   Chanet A, 2012, J NUTR BIOCHEM, V23, P469, DOI 10.1016/j.jnutbio.2011.02.001
   Cherubini A, 2005, CURR PHARM DESIGN, V11, P2017, DOI 10.2174/1381612054065783
   Chyu KY, 2004, CIRCULATION, V109, P2448, DOI 10.1161/01.CIR.0000128034.70732.C2
   Cook NC, 1996, J NUTR BIOCHEM, V7, P66, DOI 10.1016/0955-2863(95)00168-9
   Corti R, 2001, CIRCULATION, V104, P249
   de Pascual-Teresa S, 2010, INT J MOL SCI, V11, P1679, DOI 10.3390/ijms11041679
   Dower JI, 2015, J NUTR, V145, P1459, DOI 10.3945/jn.115.211888
   Estruch R, 2013, NEW ENGL J MED, V368, P1279, DOI 10.1056/NEJMoa1200303
   Farnier M, 1998, AM J CARDIOL, V82, p3J, DOI 10.1016/S0002-9149(98)00423-8
   Fuhrman B, 1997, AM J CLIN NUTR, V66, P267
   HANASAKI Y, 1994, FREE RADICAL BIO MED, V16, P845, DOI 10.1016/0891-5849(94)90202-X
   Harnly JM, 2006, J AGR FOOD CHEM, V54, P9966, DOI 10.1021/jf061478a
   Hayek T, 1997, ARTERIOSCL THROM VAS, V17, P2744, DOI 10.1161/01.ATV.17.11.2744
   Hooper L, 2008, AM J CLIN NUTR, V88, P38
   Jeon SM, 2014, J MED FOOD, V17, P310, DOI 10.1089/jmf.2013.2885
   Katcher HI, 2008, AM J CLIN NUTR, V87, P79
   KEYS A, 1986, AM J EPIDEMIOL, V124, P903, DOI 10.1093/oxfordjournals.aje.a114480
   King A, 1999, J AM DIET ASSOC, V99, P213, DOI 10.1016/S0002-8223(99)00051-6
   Krettek A, 2004, AM J PATHOL, V165, P1571, DOI 10.1016/S0002-9440(10)63414-1
   Lai MY, 2003, J PHARM PHARMACOL, V55, P205, DOI 10.1211/002235702522
   Law MR, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1665
   Liao PP, 2014, EUR J PHARMACOL, V740, P488, DOI 10.1016/j.ejphar.2014.06.039
   Lin WQ, 2017, MOL NUTR FOOD RES, V61, DOI 10.1002/mnfr.201600031
   Loke WM, 2010, ARTERIOSCL THROM VAS, V30, P749, DOI 10.1161/ATVBAHA.109.199687
   Luo Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120259
   Makino T, 2009, BIOL PHARM BULL, V32, P2034, DOI 10.1248/bpb.32.2034
   Meir KS, 2004, ARTERIOSCL THROM VAS, V24, P1006, DOI 10.1161/01.ATV.0000128849.12617.f4
   Motoyama K, 2009, NUTRITION, V25, P421, DOI 10.1016/j.nut.2008.08.013
   NAKASHIMA Y, 1994, ARTERIOSCLER THROMB, V14, P133, DOI 10.1161/01.ATV.14.1.133
   Omer SM, 2016, HEART, V102, P69, DOI 10.1136/heartjnl-2015-308322
   Qin M, 2015, VASC PHARMACOL, V70, P23, DOI 10.1016/j.vph.2015.03.002
   Ramirez-Tortosa MC, 1999, J NUTR, V129, P2177
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Rosenblat M, 1999, J BIOL CHEM, V274, P13790, DOI 10.1074/jbc.274.20.13790
   Schierwagen R, 2015, SCI REP-UK, V5, DOI 10.1038/srep12931
   Scholten SD, 2015, OPEN ACCESS J SPORTS, V6, P229, DOI 10.2147/OAJSM.S83159
   Schomig A, 1996, NEW ENGL J MED, V334, P1084, DOI 10.1056/NEJM199604253341702
   Shen Y, 2013, FREE RADICAL BIO MED, V65, P908, DOI 10.1016/j.freeradbiomed.2013.08.185
   Sun GB, 2013, TOXICOL APPL PHARM, V271, P114, DOI 10.1016/j.taap.2013.04.015
   Tokede OA, 2011, EUR J CLIN NUTR, V65, P879, DOI 10.1038/ejcn.2011.64
   Vincent-Baudry S, 2005, AM J CLIN NUTR, V82, P964
   Wang B, 2016, J GERIATR CARDIOL, V13, P846, DOI 10.11909/j.issn.1671-5411.2016.10.013
   Wu BJ, 2006, J EXP MED, V203, P1117, DOI 10.1084/jem.20052321
   Xiao HB, 2011, TOXICOL APPL PHARM, V257, P405, DOI 10.1016/j.taap.2011.09.024
   Xiao L, 2017, FOOD CHEM TOXICOL, V105, P22, DOI 10.1016/j.fct.2017.03.048
   Zeng P, 2015, OXID MED CELL LONGEV, DOI 10.1155/2015/379538
NR 50
TC 3
Z9 3
U1 1
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 25
PY 2017
VL 12
IS 7
AR e0181832
DI 10.1371/journal.pone.0181832
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FB8DV
UT WOS:000406370000058
PM 28742839
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Breedt, E
   Lacerda, L
   Essop, MF
AF Breedt, Emilene
   Lacerda, Lydia
   Essop, M. Faadiel
TI Trimetazidine therapy for diabetic mouse hearts subjected to ex vivo
   acute heart failure
SO PLOS ONE
LA English
DT Article
ID CARDIOVASCULAR-DISEASE PREVENTION; CARDIAC ENERGY-METABOLISM;
   EVIDENCE-BASED GUIDELINES; FATTY-ACID OXIDATION; SUB-SAHARAN AFRICA;
   SEX-DIFFERENCES; CLINICAL CHARACTERISTICS; CARBOHYDRATE-METABOLISM;
   VENTRICULAR-FUNCTION; GLUCOSE-OXIDATION
AB Acute heart failure (AHF) is the most common primary diagnosis for hospitalized heart diseases in Africa. As increased fatty acid beta-oxidation (FAO) during heart failure triggers detrimental effects on the myocardium, we hypothesized that trimetazidine (TMZ) (partial FAO inhibitor) offers cardioprotection under normal and obese-related diabetic conditions. Hearts were isolated from 12-14-week-old obese male and female diabetic (db/db) mice versus lean non-diabetic littermates (db/+) controls. The Langendorff retrograde isolated heart perfusion system was employed to establish an ex vivo AHF model: a) Stabilization phase-Krebs Henseleit buffer (10 mM glucose) at 100 mmHg (25 min); b) Critical Acute Heart Failure (CAHF) phase-(1.2 mM palmitic acid, 2.5 mM glucose) at 20 mmHg (25 min); and c) Recovery Acute Heart Failure phase (RAHF)-(1.2 mM palmitic acid, 10 mM glucose) at 100 mmHg (25 min). Treated groups received 5 mu M TMZ in the perfusate during either the CAHF or RAHF stage for the full duration of each respective phase. Both lean and obese males benefited from TMZ treatment administered during the RAHF phase. Sex differences were observed only in lean groups where the phases of the estrous cycle influenced therapy; only the lean follicular female group responded to TMZ treatment during the CAHF phase. Lean luteal females rather displayed an inherent cardioprotection (without treatments) that was lost with obesity. However, TMZ treatment initiated during RAHF was beneficial for obese luteal females. TMZ treatment triggered significant recovery for male and obese female hearts when administered during RAHF. There were no differences between lean and obese male hearts, while lean females displayed a functional recovery advantage over lean males. Thus TMZ emerges as a worthy therapeutic target to consider for AHF treatment in normal and obese-diabetic individuals (for both sexes), but only when administered during the recovery phase and not during the very acute stages.
C1 [Breedt, Emilene; Lacerda, Lydia; Essop, M. Faadiel] Stellenbosch Univ, Dept Physiol Sci, Cardiometab Res Grp, Stellenbosch, South Africa.
RP Essop, MF (reprint author), Stellenbosch Univ, Dept Physiol Sci, Cardiometab Res Grp, Stellenbosch, South Africa.
EM mfessop@sun.ac.za
OI Essop, Faadiel/0000-0002-8434-4294
FU National Research Foundation (ZA) [96300]; Stellenbosch University
FX This study was supported by the National Research Foundation (ZA) 96300
   and Stellenbosch University.
CR Aasum E, 1997, CARDIOVASC RES, V33, P370, DOI 10.1016/S0008-6363(96)00203-9
   Adams KF, 2005, AM HEART J, V149, P209, DOI 10.1016/j.ahj.2004.08.005
   Atella V, 2009, ATHEROSCLEROSIS SUPP, V10, P3, DOI 10.1016/S1567-5688(09)70003-0
   Barbagallo M, 2001, HYPERTENSION, V37, P142, DOI 10.1161/01.HYP.37.1.142
   Barre J, 2003, BIOPHARM DRUG DISPOS, V24, P159, DOI 10.1002/bdd.350
   Bates SH, 2003, NATURE, V421, P856, DOI 10.1038/nature01388
   Bigos KL, 2009, GENDER MED, V6, P522, DOI 10.1016/j.genm.2009.12.004
   Bucci M, 2012, CARDIOVASC THER, V30, P333, DOI 10.1111/j.1755-5922.2011.00275.x
   Bueno H, 1993, JAMA-J AM MED ASSOC, V303, P2141, DOI DOI 10.1001/JAMA.2010.748
   Caligioni CS, 2009, CURRENT PROTOCOLS NE, pA
   Campbell SE, 2001, AM J PHYSIOL-ENDOC M, V281, pE803
   Cano Climaco, 2003, Am J Ther, V10, P444, DOI 10.1097/00045391-200311000-00011
   Damasceno A, 2007, J AM COLL CARDIOL, V50, P1688, DOI 10.1016/j.jacc.2007.07.030
   Daniels LB, 2006, AM HEART J, V151, P999, DOI 10.1016/j.ahj.2005.10.011
   Deshpande G, 2014, CARDIOVASC RES, V103, DOI 10.1093/cvr/cvu098.179
   Deshpande GP, 2010, CARDIOVASC DRUG THER, V24, P459, DOI 10.1007/s10557-010-6258-4
   Dubey RK, 1998, HYPERTENSION, V31, P522, DOI 10.1161/01.HYP.31.1.522
   Fang J, 2008, J AM COLL CARDIOL, V52, P428, DOI 10.1016/j.jacc.2008.03.061
   Fang YH, 2012, J MOL MED, V90, P31, DOI 10.1007/s00109-011-0804-9
   Felker GM, 2010, CIRC-HEART FAIL, V3, P314, DOI 10.1161/CIRCHEARTFAILURE.109.893222
   Filippatos G, 2007, HEART FAIL REV, V12, P87, DOI 10.1007/s10741-007-9008-3
   Folmes Clifford D L, 2005, Curr Atheroscler Rep, V7, P63, DOI 10.1007/s11883-005-0077-2
   Fragasso G, 2006, EUR HEART J, V27, P942, DOI 10.1093/eurheartj/ehi816
   Gao DF, 2011, HEART, V97, P278, DOI 10.1136/hrt.2010.208751
   Gheorghiade M, 2006, JAMA-J AM MED ASSOC, V296, P2217, DOI 10.1001/jama.296.18.2217
   Go AS, 2013, CIRCULATION, V127, pE6, DOI 10.1161/CIR.0b013e31828124ad
   HEALY B, 1991, NEW ENGL J MED, V325, P274, DOI 10.1056/NEJM199107253250408
   Hummel A, 2015, DTSCH ARZTEBL INT, V112, P298, DOI 10.3238/arztebl.2015.0298
   Ikizler M, 2006, ARCH MED RES, V37, P700, DOI 10.1016/j.arcmed.2006.01.008
   Iozzo P, 2010, NUTR METAB CARDIOVAS, V20, P147, DOI 10.1016/j.numecd.2009.08.011
   Jackson PJ, 1996, XENOBIOTICA, V26, P221, DOI 10.3109/00498259609046702
   JOHNSON LM, 1979, BIOL REPROD, V20, P552, DOI 10.1095/biolreprod20.3.552
   Kantor PF, 2000, CIRC RES, V86, P580, DOI 10.1161/01.RES.86.5.580
   Konhilas JP, 2007, CIRCULATION, V116, P2747, DOI 10.1161/CIRCULATIONAHA.106.672006
   Konhilas JP, 2010, BIOMED RES INT
   Laribi S, 2012, MED EMERG, V10, P25
   Li YJ, 2010, ACTA PHARMACOL SIN, V31, P560, DOI 10.1038/aps.2010.31
   Liu ZL, 2016, METABOLISM, V65, P122, DOI 10.1016/j.metabol.2015.10.022
   Lopaschuk GD, 2010, PHYSIOL REV, V90, P207, DOI 10.1152/physrev.00015.2009
   Lopaschuk GD, 1997, MOL CELL BIOCHEM, V172, P137, DOI 10.1023/A:1006875823561
   Lopaschuk GD, 2003, CIRC RES, V93, pE33, DOI 10.1161/01.RES.0000086964.07404.A5
   Lopaschuk GD, 2001, CORONARY ARTERY DIS, V12, pS8
   Lopatin YM, 2016, INT J CARDIOL, V203, P909, DOI 10.1016/j.ijcard.2015.11.060
   MacDonald JK, 2014, AM J PHYSIOL-HEART C, V306, pH938, DOI 10.1152/ajpheart.00730.2013
   MARCONDES F. K., 2002, Braz. J. Biol., V62, P609, DOI 10.1590/S1519-69842002000400008
   Mather KJ, 2000, J CLIN ENDOCR METAB, V85, P4644, DOI 10.1210/jc.85.12.4644
   Mebazaa A, 2015, EUR J HEART FAIL, V17, P544, DOI 10.1002/ejhf.289
   Metra M, 2010, INT J CARDIOL, V144, P175, DOI 10.1016/j.ijcard.2010.04.003
   Moldovanova I, 2008, HYPERTENSION, V51, P1203, DOI 10.1161/HYPERTENSIONAHA.107.107433
   Monti LD, 2006, AM J PHYSIOL-ENDOC M, V290, pE54, DOI 10.1152/ajpendo.00083.2005
   Mosca L, 2004, ARTERIOSCL THROM VAS, V24, pE29, DOI 10.1161/01.ATV.0000114834.85476.81
   Mosca L, 2007, J AM COLL CARDIOL, V49, P1230, DOI 10.1016/j.jacc.2007.02.020
   Nieminen MS, 2008, EUR J HEART FAIL, V10, P140, DOI 10.1016/j.ejheart.2007.12.012
   Nieminen MS, 2006, EUR HEART J, V27, P2725, DOI 10.1093/eurheartj/ehl193
   Nilsson SE, 2009, GENDER MED, V6, P433, DOI 10.1016/j.genm.2009.09.011
   OCHS HR, 1981, PHARMACOLOGY, V23, P24, DOI 10.1159/000137524
   Odening KE, 2012, HEART RHYTHM, V9, P823, DOI 10.1016/j.hrthm.2012.01.009
   Ogah OS, 2015, CLIN RES CARDIOL, V104, P481, DOI 10.1007/s00392-015-0810-y
   Opie Lionel H., 2010, Transactions of the Royal Society of South Africa, V65, P185, DOI 10.1080/0035919X.2010.537886
   Pang YF, 2015, AM J PHYSIOL-ENDOC M, V308, pE899, DOI 10.1152/ajpendo.00527.2014
   Parissis J, 2015, INT J CARDIOL, V180, P46, DOI 10.1016/j.ijcard.2014.11.123
   Parks RJ, 2013, PFLUG ARCH EUR J PHY, V465, P747, DOI 10.1007/s00424-013-1233-0
   Ponikowski P, 2016, EUR HEART J, V37, P2129, DOI 10.1093/eurheartj/ehw128
   Prior JC, 2014, J RESTORATIVE MED, V3, P85
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Robertson S, 2010, DIABETES, V59, P782, DOI 10.2337/db09-1556
   Sabbah HM, 2005, HEART FAIL REV, V10, P281, DOI 10.1007/s10741-005-7541-5
   Salerno A, 2015, ACTA DIABETOL, V52, P753, DOI 10.1007/s00592-014-0695-7
   Simon N, 1997, BRIT J CLIN PHARMACO, V44, P591, DOI 10.1046/j.1365-2125.1997.t01-1-00628.x
   Simoncini T, 2004, ENDOCRINOLOGY, V145, P5745, DOI 10.1210/en.2004-0510
   Sliwa K, 2008, LANCET, V371, P915, DOI 10.1016/S0140-6736(08)60417-1
   Sliwa K, 2013, HEART, V99, P1317, DOI 10.1136/heartjnl-2013-303592
   Soldin OP, 2009, CLIN PHARMACOKINET, V48, P143, DOI 10.2165/00003088-200948030-00001
   Soldin OP, 2011, BIOMED RES INT
   Stanley William C, 2002, Heart Fail Rev, V7, P115, DOI 10.1023/A:1015320423577
   Tsuchihashi-Makaya M, 2011, INT J CARDIOL, V150, P338, DOI 10.1016/j.ijcard.2011.03.042
   Tuunanen H, 2006, CIRCULATION, V114, P2130, DOI 10.1161/CIRCULATIONAHA.106.645184
   Ussher JR, 2014, CAN J CARDIOL, V30, P940, DOI 10.1016/j.cjca.2014.04.023
   Voors AA, 2012, EUR J HEART FAIL, V14, P955, DOI 10.1093/eurjhf/hfs122
   WHITTEN WK, 1958, J ENDOCRINOL, V17, P307, DOI 10.1677/joe.0.0170307
   Wittnich C, 2013, PFLUG ARCH EUR J PHY, V465, P719, DOI 10.1007/s00424-013-1232-1
   Wood GA, 2007, REPRODUCTION, V133, P1035, DOI 10.1530/REP-06-0302
NR 82
TC 1
Z9 1
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 20
PY 2017
VL 12
IS 6
AR e0179509
DI 10.1371/journal.pone.0179509
PG 27
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EY5UN
UT WOS:000404046100031
PM 28632748
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Lin, KT
   Sun, SP
   Wu, JI
   Wang, LH
AF Lin, Kai-Ti
   Sun, Shu-Pin
   Wu, Jui-I
   Wang, Lu-Hai
TI Low-dose glucocorticoids suppresses ovarian tumor growth and metastasis
   in an immunocompetent syngeneic mouse model
SO PLOS ONE
LA English
DT Article
ID CANCER-CELLS; KAPPA-B; PACLITAXEL; RECEPTOR; IL-18; MICROENVIRONMENT;
   TUMORIGENICITY; INFLAMMASOMES; MICRORNA-708; CHEMOTHERAPY
AB Ovarian cancer has the highest mortality rate among gynecologic malignancies. Despite chemotherapy and surgical debulking options, ovarian cancer recurs and disseminates frequently with a poor prognosis. We previously reported a novel role of glucocorticoids (GCs) in metastatic ovarian cancer by upregulating microRNA-708. In this study, we used an immunocompetent syngeneic mouse model and further evaluated the effect and optimal dosages of GCs in treating metastatic ovarian cancer. The treatment of C57BL/6-derived ovarian cancer ID-8 cells with a synthetic GC, dexamethasone (DEX), induced the expression of microRNA-708, leading to decreased cell migration and invasion through targeting Rap1B. Administration of DEX at a low dose, as low as 5 mu g/kg body weight, inhibited the primary tumor size and abdominal metastasis in mice bearing ID-8 cell-derived ovarian tumors. In the treated primary tumors, microRNA-708 was upregulated, whereas some proinflammatory cytokines, namely interleukin (IL)-1 beta and IL-18, were downregulated. The number of tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment were reduced. Overall, our study shows that low-dose GCs can suppress ovarian cancer progression and metastasis likely through not only the upregulation of the metastasis suppressor microRNA-708, but also the modulation of TAMs and MDSCs in the tumor microenvironment.
C1 [Lin, Kai-Ti; Sun, Shu-Pin; Wu, Jui-I; Wang, Lu-Hai] Natl Hlth Res Inst, Inst Mol & Genom Med, Zhunan, Miaoli County, Taiwan.
   [Wu, Jui-I] Natl Cent Univ, Dept Life Sci, Taoyuan, Taiwan.
   [Wang, Lu-Hai] China Med Univ, Grad Inst Integrated Med, Taichung, Taiwan.
RP Wang, LH (reprint author), Natl Hlth Res Inst, Inst Mol & Genom Med, Zhunan, Miaoli County, Taiwan.; Wang, LH (reprint author), China Med Univ, Grad Inst Integrated Med, Taichung, Taiwan.
EM luhaiwang@mail.cmu.edu.tw
RI LIN, KAI-TI/B-3840-2016
OI LIN, KAI-TI/0000-0001-8656-5755
FU National Research Health Institutes [105A1-MGPP11-014]; Ministry of
   Science and Technology, Taiwan [MOST-104-2320-B-400-011-MY3,
   MOST-105-2321-B-400 -012 -MY3]
FX This study was supported by 105A1-MGPP11-014 from National Research
   Health Institutes, MOST-104-2320-B-400-011-MY3 and MOST-105-2321-B-400
   -012 -MY3 from the Ministry of Science and Technology, Taiwan. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Agarwal R, 2003, NAT REV CANCER, V3, P502, DOI 10.1038/nrc1123
   Arend WP, 2008, IMMUNOL REV, V223, P20, DOI 10.1111/j.1600-065X.2008.00624.x
   Boettner B, 2009, CURR OPIN CELL BIOL, V21, P684, DOI 10.1016/j.ceb.2009.06.004
   Clark AR, 2012, PHARMACOL THERAPEUT, V134, P54, DOI 10.1016/j.pharmthera.2011.12.004
   Cui TX, 2013, IMMUNITY, V39, P611, DOI 10.1016/j.immuni.2013.08.025
   De Bosscher K, 2003, ENDOCR REV, V24, P488, DOI 10.1210/er.2002-0006
   De Oliveira GS, 2014, ANESTH ANALG, V118, P1213, DOI 10.1213/ANE.0b013e3182a5d656
   Gennari A, 1996, ANN ONCOL, V7, P978
   George JA, 2005, CANCER RES, V65, P10381, DOI 10.1158/0008-5472.CAN-05-1822
   Greenaway J, 2008, GYNECOL ONCOL, V108, P385, DOI 10.1016/j.ygyno.2007.10.035
   Greenaway J, 2009, MOL CANCER THER, V8, P64, DOI 10.1158/1535-7163.MCT-08-0864
   Hagemann T, 2005, J IMMUNOL, V175, P1197, DOI 10.4049/jimmunol.175.2.1197
   Hou WJ, 2013, EUR REV MED PHARMACO, V17, P2902
   Kadmiel M, 2013, TRENDS PHARMACOL SCI, V34, P518, DOI 10.1016/j.tips.2013.07.003
   Karst AM, 2010, J ONCOL, V2010, DOI DOI 10.1155/2010/932371
   Liberman AC, 2007, CYTOKINE GROWTH F R, V18, P45, DOI 10.1016/j.cytogfr.2007.01.005
   Lim HX, 2014, J IMMUNOL, V193, P5453, DOI 10.4049/jimmunol.1401282
   Lin KT, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6917
   Lin KT, 2016, STEROIDS
   Luo ZY, 2016, CANCER LETT, V377, P174, DOI 10.1016/j.canlet.2016.04.038
   Marigo I, 2008, IMMUNOL REV, V222, P162, DOI 10.1111/j.1600-065X.2008.00602.x
   Matsuo K, 2010, GYNECOL ONCOL, V116, P61, DOI 10.1016/j.ygyno.2009.09.018
   Munstedt K, 2004, CANCER, V101, P1696, DOI 10.1002/cncr.20534
   Musrap N, 2012, MOL CANCER RES, V10, P1254, DOI 10.1158/1541-7786.MCR-12-0353
   Orengo AM, 2011, INT J CANCER, V129, P1116, DOI 10.1002/ijc.25757
   Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Roby KF, 2008, ADV EXP MED BIOL, V622, P169
   Roby KF, 2000, CARCINOGENESIS, V21, P585, DOI 10.1093/carcin/21.4.585
   Ryu S, 2013, CANCER CELL, V23, P63, DOI 10.1016/j.ccr.2012.11.019
   Sachdev P, 2002, J BIOL CHEM, V277, P17638, DOI 10.1074/jbc.M111575200
   Saini S, 2012, CANCER RES, V72, P3618, DOI 10.1158/0008-5472.CAN-12-0540
   Saini S, 2011, CANCER RES, V71, P6208, DOI 10.1158/0008-5472.CAN-11-0073
   Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Sui MH, 2006, INT J CANCER, V119, P712, DOI 10.1002/ijc.21743
   Terme M, 2011, CANCER RES, V71, P5393, DOI 10.1158/0008-5472.CAN-11-0993
   WALSH D, 1992, CLEV CLIN J MED, V59, P505, DOI 10.3949/ccjm.59.5.505
   Zhang CW, 2006, INT J ONCOL, V28, P551
   Zhang L, 2002, AM J PATHOL, V161, P2295, DOI 10.1016/S0002-9440(10)64505-1
   Zitvogel L, 2012, NAT IMMUNOL, V13, P343, DOI 10.1038/ni.2224
NR 41
TC 3
Z9 3
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 7
PY 2017
VL 12
IS 6
AR e0178937
DI 10.1371/journal.pone.0178937
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EX0AO
UT WOS:000402880700060
PM 28591224
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Rafacho, BPM
   dos Santos, PP
   Goncalves, AD
   Fernandes, AAH
   Okoshi, K
   Chiuso-Minicucci, F
   Azevedo, PS
   Zornoff, LAM
   Minicucci, MF
   Wang, XD
   de Paiva, SAR
AF Murino Rafacho, Bruna Paola
   dos Santos, Priscila Portugal
   Goncalves, Andrea de Freitas
   Henrique Fernandes, Ana Angelica
   Okoshi, Katashi
   Chiuso-Minicucci, Fernanda
   Azevedo, Paula S.
   Mamede Zornoff, Leonardo Antonio
   Minicucci, Marcos Ferreira
   Wang, Xiang-Dong
   Rupp de Paiva, Sergio Alberto
TI Rosemary supplementation (Rosmarinus oficinallis L.) attenuates cardiac
   remodeling after myocardial infarction in rats
SO PLOS ONE
LA English
DT Article
ID OXIDATIVE STRESS; HEART-FAILURE; CARDIOVASCULAR-DISEASE; DIASTOLIC
   DYSFUNCTION; CLINICAL-IMPLICATIONS; ANTIOXIDANT; OFFICINALIS; ACID;
   SIZE; ASSOCIATION
AB Background
   Myocardial infarction (MI) is one of the leading causes of morbidity and mortality worldwide. Dietary intervention on adverse cardiac remodeling after MI has significant clinical relevance. Rosemary leaves are a natural product with antioxidant/anti-inflammatory properties, but its effect on morphology and ventricular function after MI is unknown.
   Methods and results
   To determine the effect of the dietary supplementation of rosemary leaves on cardiac remodeling after MI, male Wistar rats were divided into 6 groups after sham procedure or experimental induced MI: 1) Sham group fed standard chow (SR0, n = 23); 2) Sham group fed standard chow supplemented with 0.02% rosemary (R002) (SR002, n = 23); 3) Sham group fed standard chow supplemented with 0.2% rosemary (R02) (SR02, n = 22); 4) group submitted to MI and fed standard chow (IR0, n = 13); 5) group submitted to MI and fed standard chow supplemented with R002 (IR002, n = 8); and 6) group submitted to MI and fed standard chow supplemented with R02 (IR02, n = 9). After 3 months of the treatment, systolic pressure evaluation, echocardiography and euthanasia were performed. Left ventricular samples were evaluated for: fibrosis, cytokine levels, apoptosis, energy metabolism enzymes, and oxidative stress. Rosemary dietary supplementation attenuated cardiac remodeling by improving energy metabolism and decreasing oxidative stress. Rosemary supplementation of 0.02% improved diastolic function and reduced hypertrophy after MI. Regarding rosemary dose, 0.02% and 0.2% for rats are equivalent to 11 mg and 110 mg for humans, respectively.
   Conclusion
   Our findings support further investigations of the rosemary use as adjuvant therapy in adverse cardiac remodeling.
C1 [Murino Rafacho, Bruna Paola; dos Santos, Priscila Portugal; Goncalves, Andrea de Freitas; Okoshi, Katashi; Chiuso-Minicucci, Fernanda; Azevedo, Paula S.; Mamede Zornoff, Leonardo Antonio; Minicucci, Marcos Ferreira; Rupp de Paiva, Sergio Alberto] UNESP, Internal Med Dept, Botucatu Med Sch, Botucatu, SP, Brazil.
   [Henrique Fernandes, Ana Angelica] UNESP, Dept Biochem, Botucatu Biosci Inst, Botucatu, SP, Brazil.
   [Chiuso-Minicucci, Fernanda] UNESP, Dept Microbiol & Immunol, Botucatu Biosci Inst, Botucatu, SP, Brazil.
   [Wang, Xiang-Dong] Tufts Univ, Nutr & Canc Biol Lab, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA.
RP Rafacho, BPM (reprint author), UNESP, Internal Med Dept, Botucatu Med Sch, Botucatu, SP, Brazil.
EM bpmrafacho@alunos.fmb.unesp.br
RI Paiva, Sergio AR/A-5101-2008; Okoshi, Katashi/A-3955-2011; Zornoff,
   Leonardo/A-5612-2008; Minicucci, Fernanda/A-9220-2015; Fernandes, Ana
   Angelica/D-5291-2012; Azevedo, Paula Schmidt/S-1597-2019; Minicucci,
   Marcos F/A-9094-2008
OI Paiva, Sergio AR/0000-0003-4412-1990; Okoshi,
   Katashi/0000-0001-8980-8839; Zornoff, Leonardo/0000-0002-9831-8820;
   Minicucci, Fernanda/0000-0002-4155-6414; Azevedo, Paula
   Schmidt/0000-0002-5843-6232; Minicucci, Marcos F/0000-0002-5980-4367
FU National Council of Technological and Scientific Development [CNPq
   140262/2011-3]; Sao Paulo Research Foundation [FAPESP 2011/08956-0,
   2011/15059-5]
FX This work was funded by National Council of Technological and Scientific
   Development (CNPq 140262/2011-3) and Sao Paulo Research Foundation
   (FAPESP 2011/08956-0 and 2011/15059-5), Brazil. The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR [Anonymous], 2011, GUIDE CARE USE LAB A
   Assalin HB, 2013, CIRC-HEART FAIL, V6, P809, DOI 10.1161/CIRCHEARTFAILURE.112.000298
   Baba K, 2013, J BIOL CHEM, V288, P18393, DOI 10.1074/jbc.M112.438762
   Bai NS, 2010, J AGR FOOD CHEM, V58, P5363, DOI 10.1021/jf100332w
   Botsoglou N, 2010, FOOD CHEM TOXICOL, V48, P944, DOI 10.1016/j.fct.2010.01.004
   Burneiko RCM, 2006, FOOD CHEM TOXICOL, V44, P1167, DOI 10.1016/j.fct.2006.01.004
   Buttros JB, 2009, PHARMACOLOGY, V84, P29, DOI 10.1159/000222245
   Cheung S, 2007, ONCOL REP, V17, P1525
   Chohan M, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-578
   Cohn JN, 2000, J AM COLL CARDIOL, V35, P569, DOI 10.1016/S0735-1097(99)00630-0
   Csonka C, 2010, J PHARMACOL TOX MET, V61, P163, DOI 10.1016/j.vascn.2010.02.014
   Eilat-Adar S, 2013, NUTRIENTS, V5, P3646, DOI 10.3390/nu5093646
   Ewing JF, 1995, ANAL BIOCHEM, V232, P243, DOI 10.1006/abio.1995.0014
   Forman HJ, 2014, FREE RADICAL BIO MED, V66, P24, DOI 10.1016/j.freeradbiomed.2013.05.045
   Genena AK, 2008, CIENCIA TECNOL ALIME, V28, P463, DOI 10.1590/S0101-20612008000200030
   Gilbert B, 2003, CURR MED CHEM, V10, P13, DOI 10.2174/0929867033368583
   Goncalves AF, 2015, CELL PHYSIOL BIOCHEM, V35, P259, DOI 10.1159/000369693
   HARAGUCHI H, 1995, PLANTA MED, V61, P333, DOI 10.1055/s-2006-958094
   Hori M, 2009, CARDIOVASC RES, V81, P457, DOI 10.1093/cvr/cvn335
   Idikio HA, 2011, CARDIOL RES PRACT, V2011
   Jeong EM, 2015, CIRC J, V79, P470, DOI 10.1253/circj.CJ-15-0064
   Karthik D, 2011, J CARDIOVASC PHARM, V58, P514, DOI 10.1097/FJC.0b013e31822c265d
   Lang RM, 2005, J AM SOC ECHOCARDIOG, V18, P1440, DOI 10.1016/j.echo.2005.10.005
   Lian KC, 2010, TOXICOL APPL PHARM, V245, P21, DOI 10.1016/j.taap.2010.01.003
   Liu QF, 2016, J AGR FOOD CHEM, V64, P6716, DOI 10.1021/acs.jafc.6b03001
   Liu TT, 2014, LIFE SCI, V101, P27, DOI 10.1016/j.lfs.2014.02.004
   Lustosa BB, 2016, INT J CARDIOL, V225, P147, DOI 10.1016/j.ijcard.2016.09.092
   Madamanchi NR, 2013, FREE RADICAL BIO MED, V61, P473, DOI 10.1016/j.freeradbiomed.2013.04.001
   Minicucci MF, 2014, ARQ BRAS CARDIOL, V102, P549, DOI 10.5935/abc.20140051
   Minicucci MF, 2011, INT J CARDIOL, V151, P242, DOI 10.1016/j.ijcard.2011.06.068
   Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI 10.1161/CIR.0000000000000152
   Mozaffarian D, 2011, CIRCULATION, V123, P2870, DOI 10.1161/CIRCULATIONAHA.110.968735
   NEELY JR, 1974, ANNU REV PHYSIOL, V36, P413, DOI 10.1146/annurev.ph.36.030174.002213
   Paiva SAR, 2005, J NUTR, V135, P2109
   Paiva SAR, 2003, AM J PHYSIOL-HEART C, V284, P2242
   Peng CH, 2007, BIOSCI BIOTECH BIOCH, V71, P2223, DOI 10.1271/bbb.70199
   Perez-Fons L, 2010, J AGR FOOD CHEM, V58, P161, DOI 10.1021/jf9026487
   Pfeffer JM, 2000, CARDIOVASC DRUG THER, V14, P579, DOI 10.1023/A:1007890126061
   PFEFFER MA, 1979, CIRC RES, V44, P503, DOI 10.1161/01.RES.44.4.503
   Polegato BF, 2016, ARQ BRAS CARDIOL, V106, P105, DOI 10.5935/abc.20160015
   Posadas SJ, 2009, EXP GERONTOL, V44, P383, DOI 10.1016/j.exger.2009.02.015
   Punithavathi VR, 2010, LIFE SCI, V86, P178, DOI 10.1016/j.lfs.2009.11.021
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Retelny VS, 2008, NUTR CLIN PRACT, V23, P468, DOI 10.1177/0884533608323425
   Ristow M, 2014, DOSE-RESPONSE, V12, P288, DOI 10.2203/dose-response.13-035.Ristow
   Rustin P, 2002, EUR J HUM GENET, V10, P289, DOI 10.1038/sj.ejhg.5200793
   Sadzuka Y, 1997, TOXICOL LETT, V92, P1, DOI 10.1016/S0378-4274(97)00028-3
   Sahu BD, 2014, MOL CELL BIOCHEM, V394, P163, DOI 10.1007/s11010-014-2092-5
   Saks V, 2006, J PHYSIOL-LONDON, V577, P769, DOI 10.1113/jphysiol.2006.120584
   Santos PP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113739
   Scheckel KA, 2008, J NUTR, V138, P2098, DOI 10.3945/jn.108.090431
   SPADARO J, 1980, ARCH PATHOL LAB MED, V104, P179
   Stanley WC, 2005, PHYSIOL REV, V85, P1093, DOI 10.1152/physrev.00006.2004
   Sun DD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033491
   Sun GB, 2012, TOXICOL APPL PHARM, V265, P229, DOI 10.1016/j.taap.2012.10.002
   Sun Y, 2009, CARDIOVASC RES, V81, P482, DOI 10.1093/cvr/cvn333
   Tamaki Y, 2010, PLANTA MED, V76, P683, DOI 10.1055/s-0029-1240622
   van Deel ED, 2008, FREE RADICAL BIO MED, V44, P1305, DOI 10.1016/j.freeradbiomed.2007.12.007
   WEBER KT, 1994, J MOL CELL CARDIOL, V26, P279, DOI 10.1006/jmcc.1994.1036
   WOLFE CL, 1993, CIRCULATION, V87, P881, DOI 10.1161/01.CIR.87.3.881
   Zhou S, 2014, OXID MED CELL LONGEV, V2014, DOI DOI 10.1155/2014/260429
   Zhu YZ, 2004, NAT PROD REP, V21, P478, DOI 10.1039/b304821g
   Zornoff LAM, 2006, NUTRITION, V22, P146, DOI 10.1016/j.nut.2005.05.008
   Zornoff LAM, 2009, ARQ BRAS CARDIOL, V93, P434, DOI 10.1590/S0066-782X2009001000018
   Zornoff LAM, 2009, ARQ BRAS CARDIOL, V92, P157, DOI 10.1590/S0066-782X2009000200013
NR 65
TC 5
Z9 5
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 11
PY 2017
VL 12
IS 5
AR e0177521
DI 10.1371/journal.pone.0177521
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EU8UP
UT WOS:000401314300128
PM 28494028
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Navarro, G
   Martinez-Pinilla, E
   Sanchez-Melgar, A
   Ortiz, R
   Noe, V
   Martins, M
   Ciudad, C
   Franco, R
AF Navarro, Gemma
   Martinez-Pinilla, Eva
   Sanchez-Melgar, Alejandro
   Ortiz, Raquel
   Noe, Veronique
   Martins, Mairena
   Ciudad, Carlos
   Franco, Rafael
TI A genomics approach identifies selective effects of trans-resveratrol in
   cerebral cortex neuron and glia gene expression
SO PLOS ONE
LA English
DT Article
ID INTERACTION NETWORKS; ALZHEIMERS-DISEASE; A-BETA; CELLS; MODEL;
   TOCOPHEROL; RECEPTORS; ADENOSINE; INCREASES; PROTEINS
AB The mode of action of trans-resveratrol, a promising lead compound for the development of neuroprotective drugs, is unknown. Data from a functional genomics study were retrieved with the aim to find differentially expressed genes that may be involved in the benefits provided by trans-resveratrol. Genes that showed a significantly different expression (p< 0.05, cut-off of a two-fold change) in mice fed with a control diet or a control diet containing transresveratrol were different in cortex, heart and skeletal muscle. In neocortex, we identified 4 up-regulated (Strap, Pkp4, Rab2a, Cpne3) and 22 down-regulated (Actn1, Arf3, Atp6v01, Atp1a3, Atp1b2, Cacng7, Crtc1, Dbn1, Dnm1, Epn1, Gfap, Hap, Mark41, Rab5b, Nrxn2, Ogt, Palm, Ptprn2, Ptprs, Syn2, Timp2, Vamp2) genes upon trans-resveratrol consumption. Network analysis of gene products provided evidence of plakophilin 4 up-regulation as a triggering factor for down-regulation of events related to synaptic vesicle transport and neurotransmitter release via underexpression of dynamin1 and Vamp2 (synaptobrevin 2) as node-gene drivers. Analysis by RT-qPCR of some of the selected genes in a glioma cell line showed that dynamin 1 mRNA was down-regulated even in acute trans-resveratrol treatments. Taken all together, these results give insight on the glial-neuronal networks involved in the neuroprotective role of trans-resveratrol.
C1 [Navarro, Gemma; Franco, Rafael] Inst Salud Carlos III, CIBERNED, Ctr Invest Biomed Red Enfermedades Neurodegenerat, Madrid, Spain.
   [Navarro, Gemma; Franco, Rafael] Univ Barcelona IBUB, Inst Biomed, Barcelona, Spain.
   [Navarro, Gemma; Ortiz, Raquel; Franco, Rafael] Univ Barcelona, Fac Biol, Dept Biochem & Mol Biomed, Barcelona, Spain.
   [Martinez-Pinilla, Eva] Univ Oviedo, Inst Neurociencias Principado Asturias INEUROPA, Dept Morfol & Biol Celular, Fac Med, Asturias, Spain.
   [Sanchez-Melgar, Alejandro; Martins, Mairena] Univ Castilla La Mancha, Fac Ciencias & Tecnol Quim, Dept Quim Inorgan Organ & Bioquim, CRIB, Ciudad Real, Spain.
   [Sanchez-Melgar, Alejandro; Martins, Mairena] Univ Castilla La Mancha, Fac Med, Dept Quim Inorgan Organ & Bioquim, CRIB, Ciudad Real, Spain.
   [Noe, Veronique; Ciudad, Carlos] Univ Barcelona, Dept Biochem & Physiol, Sch Pharm, Barcelona, Spain.
   [Noe, Veronique; Ciudad, Carlos] Univ Barcelona IN2UB, Inst Nanotechnol, Barcelona, Spain.
RP Martinez-Pinilla, E (reprint author), Univ Oviedo, Inst Neurociencias Principado Asturias INEUROPA, Dept Morfol & Biol Celular, Fac Med, Asturias, Spain.
EM martinezpinillaeva@gmail.com
RI Martinez-Pinilla, Eva/C-7907-2013; Lopez, Mairena Martin/H-9788-2015;
   Ciudad, Carlos/D-7917-2014
OI Martinez-Pinilla, Eva/0000-0002-0572-0926; Lopez, Mairena
   Martin/0000-0002-6843-3449; Ciudad, Carlos/0000-0002-7855-392X; Navarro
   Brugal, Gemma/0000-0003-4654-0873; Noe, Veronica/0000-0001-7937-8038
FU Plan Nacional de Investigacion Cientifica" (Spanish Ministry of
   "Economia e Innovacion") [SAF2014-51825-R]; Junta de Comunidades de
   Castilla-La Mancha, Spain [PEII-2014-030-P, PRE-8002/2014]
FX This work was partially supported by SAF2014-51825-R from Plan Nacional
   de Investigacion Cientifica" (Spanish Ministry of "Economia e
   Innovacion") and by grant PEII-2014-030-P from Junta de Comunidades de
   Castilla-La Mancha, Spain. ASM was awarded a fellowship (PRE-8002/2014)
   from Junta de Comunidades de Castilla-La Mancha, Spain.r In Memoriam:
   Prof. Adela Mazo, she was a brilliant Chemistry student and, later, a
   stunning colleague. This work was partially supported by SAF2014-51825-R
   from Plan Nacional de Investigacion Cientifica" (Spanish Ministry of
   "Economia e Innovacion") and by grant PEII-2014-030-P from Junta de
   Comunidades de Castilla-La Mancha, Spain. ASM was awarded a fellowship
   (PRE-8002/2014) from Junta de Comunidades de Castilla-La Mancha, Spain.
CR Castillo CA, 2007, NEUROCHEM RES, V32, P1056, DOI 10.1007/s11064-006-9273-x
   Arendt T, 2000, NEUROBIOL AGING, V21, P783, DOI 10.1016/S0197-4580(00)00216-5
   Awasaki T, 2004, CURR BIOL, V14, P668, DOI 10.1016/j.cub.2004.04.001
   Barger JL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002264
   Barth RF, 2009, J NEURO-ONCOL, V94, P299, DOI 10.1007/s11060-009-9875-7
   BENDA P, 1968, SCIENCE, V161, P370, DOI 10.1126/science.161.3839.370
   Bito H, 2003, CELL CALCIUM, V34, P425, DOI 10.1016/S0143-4160(03)00140-4
   Borroto-Escuela DO, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0183
   BOWRY VW, 1993, J AM CHEM SOC, V115, P6029, DOI 10.1021/ja00067a019
   Creutz CE, 1998, J BIOL CHEM, V273, P1393, DOI 10.1074/jbc.273.3.1393
   Cuzzola VF, 2011, CNS NEUROL DISORD-DR, V10, P849, DOI 10.2174/187152711798072310
   dos Santos AQ, 2006, ARCH BIOCHEM BIOPHYS, V453, P161, DOI 10.1016/j.abb.2006.06.025
   Dresen I. M. Gana, 2003, Current Pharmaceutical Biotechnology, V4, P417, DOI 10.2174/1389201033377436
   ELFERINK LA, 1989, J BIOL CHEM, V264, P11061
   Ferretta A, 2014, BBA-MOL BASIS DIS, V1842, P902, DOI 10.1016/j.bbadis.2014.02.010
   Franco R, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00146
   Giust D, 2014, J BIOMED NANOTECHNOL, V10, P1610, DOI 10.1166/jbn.2014.1845
   Hebbar S, 2004, J NEUROBIOL, V60, P499, DOI 10.1002/neu.20031
   HOCHBERG Y, 1990, STAT MED, V9, P811, DOI 10.1002/sim.4780090710
   Hu L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017668
   Jin F, 2008, EUR J PHARMACOL, V600, P78, DOI 10.1016/j.ejphar.2008.10.005
   Karagiannis TC, 2012, PATHOBIOL AGING AGE, P2
   Karuppagounder SS, 2009, NEUROCHEM INT, V54, P111, DOI 10.1016/j.neuint.2008.10.008
   Keil R, 2013, BIOL CHEM, V394, P1005, DOI 10.1515/hsz-2013-0114
   Khan MM, 2010, BRAIN RES, V1328, P139, DOI 10.1016/j.brainres.2010.02.031
   Kim GH, 2015, EXP NEUROBIOL, V24, P325, DOI 10.5607/en.2015.24.4.325
   Kitamoto T, 2002, J NEUROGENET, V16, P205, DOI 10.1080/01677060290209740
   Kontush A, 1996, J LIPID RES, V37, P1436
   Ladiwala ARA, 2010, J BIOL CHEM, V285, P24228, DOI 10.1074/jbc.M110.133108
   Levitan IB, 2015, NEURON CELL MOL BIOL
   Liu DX, 2014, PROG NEURO-PSYCHOPH, V49, P21, DOI 10.1016/j.pnpbp.2013.10.017
   Lu KT, 2008, J AGR FOOD CHEM, V56, P6910, DOI 10.1021/jf8007212
   Lu XF, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-46
   Marambaud P, 2005, J BIOL CHEM, V280, P37377, DOI 10.1074/jbc.M508246200
   Michels G, 2006, TOXICOLOGY, V225, P173, DOI 10.1016/j.tox.2006.05.014
   Nolze A, 2013, RNA, V19, P1483, DOI 10.1261/rna.037945.112
   Perez-Jimenez J, 2011, AM J CLIN NUTR, V93, P1220, DOI 10.3945/ajcn.110.007096
   Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313
   Prince M, 2015, ALZHEIMERS DIS INT, V2015, P84, DOI [DOI 10.1111/J.0963-7214.2004.00293.X, 10.1111/j.0963-7214.2004.00293.x]
   Quincozes-Santos A, 2014, TOXICOL IN VITRO, V28, P544, DOI 10.1016/j.tiv.2013.12.021
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Rege SD, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00218
   Romeu Antoni, 2014, BMC Res Notes, V7, P188, DOI 10.1186/1756-0500-7-188
   Sakai H, 2013, J PHYSIOL-LONDON, V591, P5851, DOI 10.1113/jphysiol.2013.263558
   Salmina AB, 2009, J ALZHEIMERS DIS, V16, P485, DOI 10.3233/JAD-2009-0988
   Savaskan E, 2003, GERONTOLOGY, V49, P380, DOI 10.1159/000073766
   Shen G, 2008, IN VITRO CELL DEV-AN, V44, P280, DOI 10.1007/s11626-008-9115-z
   SONTAG JM, 1994, J BIOL CHEM, V269, P4547
   Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003
   Szklarczyk D, 2011, NUCLEIC ACIDS RES, V39, pD561, DOI 10.1093/nar/gkq973
   Takaoka M., 1939, J CHEM SOC JAPAN, V60, P1090, DOI [DOI 10.1246/NIKKASHI1921.60.1090, 10.1246/nikkashi1921.60.1090]
   Thomsen R, 2011, GLIA, V59, P1782, DOI 10.1002/glia.21223
   Tomsig JL, 2002, CELL MOL LIFE SCI, V59, P1467, DOI 10.1007/s00018-002-8522-7
   Turner RS, 2015, NEUROLOGY, V85, P1383, DOI 10.1212/WNL.0000000000002035
   Verkhratsky A, 2007, GLIAL NEUROBIOLOGY
   Villaflores OB, 2012, TAIWAN J OBSTET GYNE, V51, P515, DOI 10.1016/j.tjog.2012.09.005
   Wang J, 2006, FASEB J, V20, P2313, DOI 10.1096/fj.06-6281com
   WASHBOURNE P, 1995, BIOCHEM J, V305, P721, DOI 10.1042/bj3050721
   Winkle CC, 2016, JOVE-J VIS EXP, DOI 10.3791/53743
   Zhang F, 2010, EUR J PHARMACOL, V636, P1, DOI 10.1016/j.ejphar.2010.03.043
NR 60
TC 3
Z9 3
U1 1
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 25
PY 2017
VL 12
IS 4
AR e0176067
DI 10.1371/journal.pone.0176067
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA ET5FE
UT WOS:000400308800023
PM 28441400
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Pereira, SR
   Pereira, R
   Figueiredo, I
   Freitas, V
   Dinis, TCP
   Almeida, LM
AF Pereira, Sonia R.
   Pereira, Rita
   Figueiredo, Isabel
   Freitas, Victor
   Dinis, Teresa C. P.
   Almeida, Leonor M.
TI Comparison of anti-inflammatory activities of an anthocyanin-rich
   fraction from Portuguese blueberries (Vaccinium corymbosum L.) and
   5-aminosalicylic acid in a TNBS-induced colitis rat model
SO PLOS ONE
LA English
DT Article
ID NF-KAPPA-B; OXIDATIVE STRESS; NUCLEAR TRANSLOCATION; COLONIC
   INFLAMMATION; DIETARY POLYPHENOLS; ENDOTHELIAL-CELLS; CROHNS-DISEASE;
   EXPRESSION; EXTRACTS; CYCLOOXYGENASE-2
AB Despite the actual therapeutic approaches for inflammatory bowel disease (IBD), efficient and secure alternative options remain a research focus. In this context, anthocyanins seem promising natural anti-inflammatory agents, but their action mechanisms and efficacy as compared with established drugs still require more clarification. The main aim of this study was to compare the anti-inflammatory action of a chemically characterized anthocyanin-rich fraction (ARF), obtained from Portuguese blueberries (Vaccinium corymbosum L.), with that of 5-aminosalicylic acid (5-ASA), a first-line drug in IBD, in a 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis rat model. Such fraction showed a high content and great molecular diversity of anthocyanins, with malvidin-3-galactoside and petunidin-3-arabinoside in the highest concentrations. After daily administration by intragastric infusion for 8 days, ARF, at a molar anthocyanin concentration about 30 times lower than 5-ASA, showed a higher effectiveness in counteracting the intestinal inflammation, as assessed by i) body weight variation and colon damage score, ii) reduction in leukocyte infiltration, iii) increase in antioxidant defenses and iv) by downregulation of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) in colon tissue homogenates. The strong inhibition of COX-2 expression seems to be a crucial anti-inflammatory mechanism common to both ARF and 5-ASA, but the additional higher abilities of anthocyanins to downregulate iNOS and to decrease leukocytes infiltration and to increase antioxidant defenses in colon may account for the much higher anti-inflammatory action of anthocyanins. These data may contribute to the development of a promising natural approach in IBD management.
C1 [Pereira, Sonia R.; Pereira, Rita; Figueiredo, Isabel; Dinis, Teresa C. P.; Almeida, Leonor M.] CNC Ctr Neurosci & Cell Biol, Coimbra, Portugal.
   [Pereira, Sonia R.; Pereira, Rita; Dinis, Teresa C. P.; Almeida, Leonor M.] Univ Coimbra, Fac Pharm, Coimbra, Portugal.
   [Freitas, Victor] Univ Porto, Fac Sci, Dept Chem & Biochem, Oporto, Portugal.
RP Almeida, LM (reprint author), CNC Ctr Neurosci & Cell Biol, Coimbra, Portugal.; Almeida, LM (reprint author), Univ Coimbra, Fac Pharm, Coimbra, Portugal.
EM malmeida@ci.uc.pt
OI Freitas, Victor/0000-0003-0586-2278; Almeida, Leonor
   Martins/0000-0002-7769-4712; Pereira, Sonia/0000-0001-7061-3169
FU FCT (Fundagao para a Ciencia e a Tecnologia) [PTDC/SAU-OSM/102907/2008,
   UID/NEU/04539/2013]; FEDER/COMPETE (Fundo Europeu de Desenvolvimento
   Regional, Portugal, through Programa Operacional Factoresde
   Competitividade); FCT [SFRH/BD/89758/2012]
FX This work was supported by the grants PTDC/SAU-OSM/102907/2008 and
   UID/NEU/04539/2013, funded by FCT (Fundagao para a Ciencia e a
   Tecnologia) and FEDER/COMPETE (Fundo Europeu de Desenvolvimento
   Regional, Portugal, through Programa Operacional Factoresde
   Competitividade). Sonia Pereira is a recipient of the grant
   SFRH/BD/89758/2012 from FCT. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Algieri F, 2013, J ETHNOPHARMACOL, V146, P750, DOI 10.1016/j.jep.2013.01.041
   Ancha HR, 2008, EXP BIOL MED, V233, P1301, DOI 10.3181/0805-RM-140
   Rosillo MA, 2012, PHARMACOL RES, V66, P235, DOI 10.1016/j.phrs.2012.05.006
   Atreya I, 2008, J INTERN MED, V263, P591, DOI 10.1111/j.1365-2796.2008.01953.x
   BELL CJ, 1995, AM J PHYSIOL-GASTR L, V268, pG622
   BESSEY OA, 1946, J BIOL CHEM, V164, P321
   Bhattacharyya A, 2014, PHYSIOL REV, V94, P329, DOI 10.1152/physrev.00040.2012
   Bunea A, 2013, PHYTOCHEMISTRY, V95, P436, DOI 10.1016/j.phytochem.2013.06.018
   Chen YL, 2016, OXID MED CELL LONGEV, DOI 10.1155/2016/4196572
   Chun KS, 2004, BIOCHEM PHARMACOL, V68, P1089, DOI 10.1016/j.bcp.2004.05.031
   Circu ML, 2012, SEMIN CELL DEV BIOL, V23, P729, DOI 10.1016/j.semcdb.2012.03.014
   Dahan S, 2007, IMMUNOL REV, V215, P243, DOI 10.1111/j.1600-065X.2006.00484.x
   de Medina FS, 2004, BIOCHEM PHARMACOL, V68, P2317, DOI 10.1016/j.bcp.2004.07.045
   DINIS TCP, 1994, ARCH BIOCHEM BIOPHYS, V315, P161, DOI 10.1006/abbi.1994.1485
   Esposito D, 2014, J AGR FOOD CHEM, V62, P7022, DOI 10.1021/jf4051599
   Faria A, 2005, J AGR FOOD CHEM, V53, P6896, DOI 10.1021/jf0511300
   Farzaei MH, 2015, CURR PHARM BIOTECHNO, V16, P196, DOI 10.2174/1389201016666150118131704
   George S, 2005, J AGR FOOD CHEM, V53, P1370, DOI 10.1021/jf048396b
   Giusti MM, 2001, CURRENT PROTOCOLS FO, P1, DOI DOI 10.1002/0471142913.FAF0102S00
   GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6
   He JA, 2010, ANNU REV FOOD SCI T, V1, P163, DOI 10.1146/annurev.food.080708.100754
   Kahle K, 2006, MOL NUTR FOOD RES, V50, P418, DOI 10.1002/mnfr.200500211
   Lalles JP, 2014, NUTR REV, V72, P82, DOI 10.1111/nure.12082
   Lee SG, 2014, J NUTR BIOCHEM, V25, P404, DOI 10.1016/j.jnutbio.2013.12.001
   Li L, 2014, SCI REP-UK, V4, DOI 10.1038/srep06234
   Lichtenstein GR, 2009, AM J GASTROENTEROL, V104, P465, DOI 10.1038/ajg.2008.168
   Liu LN, 2015, PLANTA MED, V81, P705, DOI 10.1055/s-0035-1545945
   Loddo I, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00551
   Maor I, 2008, DIGEST DIS SCI, V53, P2208, DOI 10.1007/s10620-007-0141-6
   McGhie TK, 2007, MOL NUTR FOOD RES, V51, P702, DOI 10.1002/mnfr.200700092
   Miyoshi J, 2012, ANTICANCER RES, V32, P1193
   Nieto N, 2000, DIGEST DIS SCI, V45, P1820, DOI 10.1023/A:1005565708038
   OSZMIANSKI J, 1988, AM J ENOL VITICULT, V39, P259
   Paixao J, 2012, CHEM-BIOL INTERACT, V199, P192, DOI 10.1016/j.cbi.2012.08.013
   Paixao J, 2011, APOPTOSIS, V16, P976, DOI 10.1007/s10495-011-0632-y
   Rahman I, 2006, NAT PROTOC, V1, P3159, DOI 10.1038/nprot.2006.378
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Rodriguez-saona L. E., 2001, CURRENT PROTOCOLS FO, VF1, P1, DOI DOI 10.1002/0471142913.FAF0101S00
   Romier B, 2009, NUTR REV, V67, P363, DOI 10.1111/j.1753-4887.2009.00210.x
   Sanchez-Fidalgo S, 2010, EUR J PHARMACOL, V633, P78, DOI 10.1016/j.ejphar.2010.01.025
   Scalzo J, 2013, FOOD CHEM, V139, P44, DOI 10.1016/j.foodchem.2013.01.091
   Schreiber S, 2002, GUT, V51, P379, DOI 10.1136/gut.51.3.379
   Serra D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109048
   Serra D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073001
   Siddiqui A, 2006, DIGEST DIS SCI, V51, P698, DOI 10.1007/s10620-006-3194-z
   Singer II, 1998, GASTROENTEROLOGY, V115, P297, DOI 10.1016/S0016-5085(98)70196-9
   Sodagari HR, 2015, EXPERT REV GASTROENT, P1
   Stucchi AF, 2000, AM J PHYSIOL-GASTR L, V279, pG1298
   Wu LH, 2011, EVID-BASED COMPL ALT, P1, DOI 10.1093/ecam/neq040
   Yi WG, 2006, J AGR FOOD CHEM, V54, P5651, DOI 10.1021/jf0531959
   Youdim KA, 2002, J NUTR BIOCHEM, V13, P282, DOI 10.1016/S0955-2863(01)00221-2
NR 51
TC 7
Z9 7
U1 2
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 22
PY 2017
VL 12
IS 3
AR e0174116
DI 10.1371/journal.pone.0174116
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA ER8SZ
UT WOS:000399094700055
PM 28329021
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Hori, D
   Dunkerly-Eyring, B
   Nomura, Y
   Biswas, D
   Steppan, J
   Henao-Mejia, J
   Adachi, H
   Santhanam, L
   Berkowitz, DE
   Steenbergen, C
   Flavell, RA
   Das, S
AF Hori, Daijiro
   Dunkerly-Eyring, Brittany
   Nomura, Yohei
   Biswas, Debjit
   Steppan, Jochen
   Henao-Mejia, Jorge
   Adachi, Hideo
   Santhanam, Lakshmi
   Berkowitz, Dan E.
   Steenbergen, Charles
   Flavell, Richard A.
   Das, Samarjit
TI miR-181b regulates vascular stiffness age dependently in part by
   regulating TGF-beta signaling
SO PLOS ONE
LA English
DT Article
ID NITRIC-OXIDE SYNTHASE; SMOOTH-MUSCLE-CELLS; E-DEFICIENT MICE;
   NF-KAPPA-B; AORTIC STIFFNESS; TISSUE TRANSGLUTAMINASE; ENDOTHELIAL
   FUNCTION; TRABECULAR MESHWORK; MARFAN-SYNDROME; ANGIOTENSIN-II
AB Background Endothelial dysfunction and arterial stiffening play major roles in cardiovascular diseases. The critical role for the miR-181 family in vascular inflammation has been documented. Here we tested whether the miR-181 family can influence the pathogenesis of hypertension and vascular stiffening.
   Methods and results qPCR data showed a significant decrease in miR-181b expression in the aorta of the older mice. Eight miR-181a1/b1(-/-) mice and wild types (C57BL6J: WT) were followed weekly for pulse wave velocity (PWV) and blood pressure measurements. After 20 weeks, the mice were tested for endothelial function and aortic modulus. There was a progressive increase in PWV and higher systolic blood pressure in miR-181a1/b1(-/-) mice compared with WTs. At 21 weeks, aortic modulus was significantly greater in the miR-181a1/b1(-/-) group, and serum TGF-beta was found to be elevated at this time. A luciferase reporter assay confirmed miR181b targets TGF-beta i (TGF-beta induced) in the aortic VSMCs. In contrast, wire myography revealed unaltered endothelial function along with higher nitric oxide production in the miR181a1/ b1(-/-) group. Cultured VECs and VSMCs from the mouse aorta showed more secreted TGF-beta in VSMCs of the miR-181a1/b1(-/-) group; whereas, no change was observed from VECs. Circulating levels of angiotensin II were similar in both groups. Treatment with losartan (0.6 g/L) prevented the increase in PWV, blood pressure, and vascular stiffness in miR181a1/ b1(-/-) mice. Immunohistochemistry and western blot for p-SMAD2/3 validated the inhibitory effect of losartan on TGF-beta signaling in miR-181a1/b1(-/-) mice.
   Conclusions Decreased miR-181b with aging plays a critical role in ECM remodeling by removing the brake on the TGF-beta, pSMAD2/3 pathway.
C1 [Hori, Daijiro; Nomura, Yohei] Johns Hopkins Sch Med, Dept Surg, Baltimore, MD USA.
   [Hori, Daijiro; Nomura, Yohei; Steppan, Jochen; Santhanam, Lakshmi; Berkowitz, Dan E.] Johns Hopkins Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD USA.
   [Hori, Daijiro; Adachi, Hideo] Jichi Med Univ, Saitama Med Ctr, Dept Cardiovasc Surg, Saitama, Japan.
   [Dunkerly-Eyring, Brittany; Biswas, Debjit; Steenbergen, Charles; Das, Samarjit] Johns Hopkins Univ, Dept Cardiovasc Pathol, Ross Res Bldg, Baltimore, MD 21218 USA.
   [Henao-Mejia, Jorge; Flavell, Richard A.] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT USA.
RP Das, S (reprint author), Johns Hopkins Univ, Dept Cardiovasc Pathol, Ross Res Bldg, Baltimore, MD 21218 USA.
EM sdas11@jhmi.edu
FU NIH [HL39752, HL124213, 14SDG18890049]; Japan Heart Foundation / Bayer
   Yakuhin Research Grant Abroad
FX This work was supported by grants from the NIH, HL39752 (CS) and NIH,
   HL124213 (DEB); AHA, 14SDG18890049 (SD); Japan Heart Foundation / Bayer
   Yakuhin Research Grant Abroad (DH). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Agrotis A, 1996, CLIN EXP PHARMACOL P, V23, P363, DOI 10.1111/j.1440-1681.1996.tb02742.x
   Belmadani S, 2008, AM J PHYSIOL-HEART C, V295, pH69, DOI 10.1152/ajpheart.00341.2008
   Busnadiego O, 2013, MOL CELL BIOL, V33, P2388, DOI 10.1128/MCB.00036-13
   Carrella S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144129
   Chatterjee S, 2014, CIRCULATION, V129, P2403, DOI 10.1161/CIRCULATIONAHA.113.007559
   Chen CA, 2008, J BIOL CHEM, V283, P27038, DOI 10.1074/jbc.M802269200
   Crosas-Molist E, 2015, ARTERIOSCL THROM VAS, V35, P960, DOI 10.1161/ATVBAHA.114.304412
   das Neves VJ, 2014, WORLD J CARDIOL, V6, P713, DOI 10.4330/wjc.v6.i8.713
   Das S, 2017, J AM HEART IN PRESS
   Das S, 2012, CIRC RES, V110, P1596, DOI 10.1161/CIRCRESAHA.112.267732
   Diop-Frimpong B, 2011, P NATL ACAD SCI USA, V108, P2909, DOI 10.1073/pnas.1018892108
   Fleenor BS, 2010, J PHYSIOL-LONDON, V588, P3971, DOI 10.1113/jphysiol.2010.194753
   Fok H, 2015, CURR HYPERTENS REP, V17, DOI 10.1007/s11906-015-0569-6
   Franklin SS, 1997, CIRCULATION, V96, P308
   Gao YZ, 2014, AM J PHYSIOL-HEART C, V307, pH1252, DOI 10.1152/ajpheart.00392.2014
   Grumbach IM, 2005, J MOL CELL CARDIOL, V39, P595, DOI 10.1016/j.yjmcc.2005.06.012
   Guo XM, 2014, AM J PHYSIOL-HEART C, V307, pH880, DOI 10.1152/ajpheart.00265.2014
   Habashi JP, 2006, SCIENCE, V312, P117, DOI 10.1126/science.1124287
   Heger J, 2011, J CELL PHYSIOL, V226, P2683, DOI 10.1002/jcp.22619
   Henao-Mejia J, 2013, IMMUNITY, V38, P984, DOI 10.1016/j.immuni.2013.02.021
   Ji JF, 2009, HEPATOLOGY, V50, P472, DOI 10.1002/hep.22989
   Jung SM, 2013, AM J PHYSIOL-HEART C, V305, pH803, DOI 10.1152/ajpheart.00103.2013
   Kobayashi M, 2005, J ATHEROSCLER THROMB, V12, P138, DOI 10.5551/jat.12.138
   Kothapalli D, 2012, CELL REP, V2, P1259, DOI 10.1016/j.celrep.2012.09.018
   Lacolley P, 2009, AM J PHYSIOL-HEART C, V297, pH1567, DOI 10.1152/ajpheart.00622.2009
   Lavoie P, 2005, J HYPERTENS, V23, P1895, DOI 10.1097/01.hjh.0000182521.44440.c5
   Lee KS, 2014, BIOCHEM BIOPH RES CO, V448, P101, DOI 10.1016/j.bbrc.2014.04.079
   Lin CH, 2014, EXP GERONTOL, V58, P174, DOI 10.1016/j.exger.2014.07.017
   Lin JB, 2016, FASEB J, V30, P3216, DOI 10.1096/fj.201500163R
   Ling SK, 2013, J MOL CELL CARDIOL, V65, P127, DOI 10.1016/j.yjmcc.2013.10.003
   Mestdagh P, 2014, NAT METHODS, V11, P809, DOI [10.1038/NMETH.3014, 10.1038/nmeth.3014]
   Neel JC, 2013, CELL SIGNAL, V25, P1556, DOI 10.1016/j.cellsig.2013.03.013
   Nichols WW, 2005, AM J HYPERTENS, V18, p3S, DOI 10.1016/j.amjhyper.2004.10.009
   Pandey D, 2015, J MOL CELLULAR CARDI
   Peiro C, 1997, BRIT J PHARMACOL, V121, P1438, DOI 10.1038/sj.bjp.0701261
   Rahimi K, 2015, CIRC RES, V116, P925, DOI 10.1161/CIRCRESAHA.116.304723
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Reddy AK, 2003, AM J PHYSIOL-HEART C, V285, pH1464, DOI 10.1152/ajpheart.00004.2003
   Remus EW, 2013, ATHEROSCLEROSIS, V228, P168, DOI 10.1016/j.atherosclerosis.2013.01.037
   Saura M, 2002, CIRC RES, V91, P806, DOI 10.1161/01.RES.0000040397.23817.E5
   Sethi A, 2011, INVEST OPHTH VIS SCI, V52, P5240, DOI 10.1167/iovs.11-7287
   Sikka G, 2013, ATHEROSCLEROSIS, V231, P91, DOI 10.1016/j.atherosclerosis.2013.08.026
   Spinale FG, 2013, CIRC RES, V113, P725, DOI 10.1161/CIRCRESAHA.113.300309
   Srinivasan H, 2015, CANADIAN J PHYSL PHA, P1
   Steppan J, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.113.000599
   Sullivan JC, 2006, CIRC RES, V98, P717, DOI 10.1161/01.RES.0000217594.97174.c2
   Sun XH, 2016, CIRC RES, V118, P810, DOI 10.1161/CIRCRESAHA.115.308166
   Sun XH, 2014, TRENDS CARDIOVAS MED, V24, P105, DOI 10.1016/j.tcm.2013.09.002
   Sun XH, 2014, CIRC RES, V114, P32, DOI 10.1161/CIRCRESAHA.113.302089
   Sun XH, 2012, J CLIN INVEST, V122, P1973, DOI 10.1172/JCI61495
   Urbich C, 2008, CARDIOVASC RES, V79, P581, DOI 10.1093/cvr/cvn156
   Wang B, 2010, ONCOGENE, V29, P1787, DOI 10.1038/onc.2009.468
   Wang MY, 2006, ARTERIOSCL THROM VAS, V26, P1503, DOI 10.1161/01.ATV.0000225777.58488.f2
   Wang Y, 2011, ONCOGENE, V30, P1470, DOI 10.1038/onc.2010.531
   Wang YX, 2000, AM J PHYSIOL-HEART C, V278, pH428
   Welge-Lussen U, 2000, INVEST OPHTH VIS SCI, V41, P2229
   Wilkinson IB, 2001, HYPERTENSION, V38, P1461, DOI 10.1161/hy1201.097723
   Williams Adam, 2013, Cold Spring Harb Symp Quant Biol, V78, P223, DOI 10.1101/sqb.2013.78.020024
   Wu J, 2014, CIRC RES, V114, P616, DOI 10.1161/CIRCRESAHA.114.302157
   Yang RH, 2011, AM J PHYSIOL-HEART C, V300, pH1467, DOI 10.1152/ajpheart.00604.2009
   Zhu GS, 2015, HYPERTENSION, V65, P385, DOI 10.1161/HYPERTENSIONAHA.114.04285
NR 61
TC 11
Z9 11
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 21
PY 2017
VL 12
IS 3
AR e0174108
DI 10.1371/journal.pone.0174108
PG 20
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA ER8RG
UT WOS:000399089000062
PM 28323879
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU den Hartigh, LJ
   Wang, SR
   Goodspeed, L
   Wietecha, T
   Houston, B
   Omer, M
   Ogimoto, K
   Subramanian, S
   Gowda, GAN
   O'Brien, KD
   Kaiyala, KJ
   Morton, GJ
   Chait, A
AF den Hartigh, Laura J.
   Wang, Shari
   Goodspeed, Leela
   Wietecha, Tomasz
   Houston, Barbara
   Omer, Mohamed
   Ogimoto, Kayoko
   Subramanian, Savitha
   Gowda, G. A. Nagana
   O'Brien, Kevin D.
   Kaiyala, Karl J.
   Morton, Gregory J.
   Chait, Alan
TI Metabolically distinct weight loss by 10,12 CLA and caloric restriction
   highlight the importance of subcutaneous white adipose tissue for
   glucose homeostasis in mice
SO PLOS ONE
LA English
DT Article
ID CONJUGATED LINOLEIC-ACID; RECEPTOR-DEFICIENT MICE; ENERGY-EXPENDITURE;
   INSULIN-RESISTANCE; BODY-COMPOSITION; RISK MARKERS; OBESE HUMANS;
   SUPPLEMENTATION; TRANS-10; FAT
AB Background
   Widely used as a weight loss supplement, trans-10, cis-12 conjugated linoleic acid (10,12 CLA) promotes fat loss in obese mice and humans, but has also been associated with insulin resistance.
   Objective
   We therefore sought to directly compare weight loss by 10,12 CLA versus caloric restriction (CR, 15-25%), an acceptable healthy method of weight loss, to determine how 10,12 CLA-mediated weight loss fails to improve glucose metabolism.
   Methods
   Obese mice with characteristics of human metabolic syndrome were either supplemented with 10,12 CLA or subjected to CR to promote weight loss. Metabolic endpoints such as energy expenditure, glucose and insulin tolerance testing, and trunk fat distribution were measured.
   Results
   By design, 10,12 CLA and CR caused equivalent weight loss, with greater fat loss by 10,12 CLA accompanied by increased energy expenditure, reduced respiratory quotient, increased fat oxidation, accumulation of alternatively activated macrophages, and browning of subcutaneous white adipose tissue (WAT). Moreover, 10,12 CLA-supplemented mice better defended their body temperature against a cold challenge. However, 10,12 CLA concurrently induced the detrimental loss of subcutaneous WAT without reducing visceral WAT, promoted reduced plasma and WAT adipokine levels, worsened hepatic steatosis, and failed to improve glucose metabolism. Obese mice undergoing CR were protected from subcutaneous-specific fat loss, had improved hepatic steatosis, and subsequently showed the expected improvements in WAT adipokines, glucose metabolism and WAT inflammation.
   Conclusions
   These results suggest that 10,12 CLA mediates the preferential loss of subcutaneous fat that likely contributes to hepatic steatosis and maintained insulin resistance, despite significant weight loss and WAT browning in mice. Collectively, we have shown that weight loss due to 10,12 CLA supplementation or CR results in dramatically different metabolic phenotypes, with the latter promoting a healthier form of weight loss.
C1 [den Hartigh, Laura J.; Wang, Shari; Goodspeed, Leela; Houston, Barbara; Omer, Mohamed; Ogimoto, Kayoko; Subramanian, Savitha; Morton, Gregory J.; Chait, Alan] Univ Washington, Dept Med, Metab, Seattle, WA 98105 USA.
   [Wietecha, Tomasz; O'Brien, Kevin D.] Univ Washington, Dept Med, Cardiol, Seattle, WA USA.
   [Gowda, G. A. Nagana] Univ Washington, Dept Anesthesiol & Pain Med, Northwest Metabol Res Ctr, Seattle, WA 98195 USA.
   [Kaiyala, Karl J.] Univ Washington, Dept Oral Hlth Sci, Seattle, WA 98195 USA.
RP den Hartigh, LJ (reprint author), Univ Washington, Dept Med, Metab, Seattle, WA 98105 USA.
EM lauradh@u.washington.edu
FU NIH National Center for Complimentary and Integrative Health [K01
   AT007177]; NIH National Institute of Diabetes and Digestive and Kidney
   Diseases (NIDDK) [P30 DK035816, P30 DK017047, U24 DK097153, P30
   DK089503]; NIH National Heart, Lung, and Blood Institute [T32 HL007312];
   University of Washington Nutrition Obesity Research Center; NIH Common
   Funds Project; Nutrition Obesity Research Center; University of Michigan
FX This work was supported by funding from the NIH National Center for
   Complimentary and Integrative Health (K01 AT007177), NIH National
   Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
   (University of Washington Nutrition Obesity Research Center Pilot and
   Feasibility Award: P30 DK035816; University of Washington Diabetes
   Research Center Pilot and Feasibility Award: P30 DK017047; University of
   Michigan Pilot and Feasibility Award: U24 DK097153; and University of
   Michigan Nutrition Obesity Research Center: P30 DK089503), and NIH
   National Heart, Lung, and Blood Institute (T32 HL007312).; The following
   core facilities of the University of Washington Nutrition Obesity
   Research Center supported this work: Energy Balance and Glucose
   Metabolism Core, Metabolomics sub core, and Atherosclerosis subcore.
   Jarrell Nelson from the Energy Balance and Glucose Metabolism Core
   contributed significant work to calorimetry analyses. The authors also
   utilized Metabolomics Core Services supported by the NIH Common Funds
   Project and the Nutrition Obesity Research Center, both from the
   University of Michigan, with particular contribution of expertise from
   Arun Das.
CR Abdgawad M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032439
   Aprile M, 2014, PPAR RES, DOI 10.1155/2014/537865
   Bahceci M, 2007, J ENDOCRINOL INVEST, V30, P210, DOI 10.1007/BF03347427
   Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992
   Blanchard PG, 2016, ACTA PHYSL OXF
   Blanck HM, 2007, J AM DIET ASSOC, V107, P441, DOI 10.1016/j.jada.2006.12.009
   Blankson H, 2000, J NUTR, V130, P2943
   BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
   Bostrom P, 2012, NATURE, V481, P463, DOI 10.1038/nature10777
   Cai DM, 2012, BIOCHEM BIOPH RES CO, V422, P621, DOI 10.1016/j.bbrc.2012.05.038
   Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003
   Close RN, 2007, AM J CLIN NUTR, V86, P797
   den Hartigh LJ, 2013, J LIPID RES, V54, P2964, DOI 10.1194/jlr.M035188
   Dong J, 2016, INT J OBESITY, V40, P434, DOI 10.1038/ijo.2015.200
   Evans M, 2002, J NUTR, V132, P450
   Fisher FM, 2002, HORM METAB RES, V34, P650, DOI 10.1055/s-2002-38246
   Flegal KM, 2012, JAMA-J AM MED ASSOC, V307, P491, DOI 10.1001/jama.2012.39
   FOLCH J, 1957, J BIOL CHEM, V226, P497
   Fox CS, 2007, CIRCULATION, V116, P39, DOI 10.1161/CIRCULATIONAHA.106.675355
   Gonzalez-Plaza J J, 2015, SURG OBES RELAT DIS
   Gwang-woong G, 2013, J MICROBIOL BIOTECHN, V23, P1569, DOI 10.4014/jmb.1308.08008
   Hamilton M, 2015, LIPIDS HEALTH DIS, V14, DOI 10.1186/s12944-015-0122-2
   Hamm JK, 1999, ANN NY ACAD SCI, V892, P134, DOI 10.1111/j.1749-6632.1999.tb07792.x
   Harvie M, 2013, BRIT J NUTR, V110, P1534, DOI 10.1017/S0007114513000792
   Hegele RA, 2002, DIABETES, V51, P3586, DOI 10.2337/diabetes.51.12.3586
   Jablonski KA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145342
   Jones JG, 2016, DIABETOLOGIA, V59, P1098, DOI 10.1007/s00125-016-3940-5
   Kaiyala KJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119391
   Kaiyala KJ, 2011, DIABETES, V60, P17, DOI 10.2337/db10-0909
   Kamphuis MMJW, 2003, INT J OBESITY, V27, P840, DOI 10.1038/sj.ijo.0802304
   Kennedy A, 2010, J LIPID RES, V51, P1906, DOI 10.1194/jlr.M005447
   Knowler WC, 2002, NEW ENGL J MED, V346, P393
   Komatsu M, 2010, GENES CELLS, V15, P91, DOI 10.1111/j.1365-2443.2009.01368.x
   Kostogrys RB, 2012, J NUTR HEALTH AGING, V16, P482, DOI 10.1007/s12603-011-0354-4
   Magkos F, 2016, CELL METAB
   Meyer LK, 2013, ADIPOCYTE, V2, P217, DOI 10.4161/adip.24953
   MORRISON WR, 1964, J LIPID RES, V5, P600
   Morton GJ, 2012, AM J PHYSIOL-ENDOC M, V302, pE134, DOI 10.1152/ajpendo.00296.2011
   Nguyen KD, 2011, NATURE, V480, P104, DOI 10.1038/nature10653
   Park Y, 1999, LIPIDS, V34, P235, DOI 10.1007/s11745-999-0358-8
   Perry RJ, 2014, NATURE, V510, P84, DOI 10.1038/nature13478
   Pini M, 2016, FASEB J, V30, P241, DOI 10.1096/fj.15-276675
   Poirier H, 2006, DIABETES, V55, P1634, DOI 10.2337/db06-0036
   Qiu YF, 2014, CELL, V157, P1292, DOI 10.1016/j.cell.2014.03.066
   Rachid TL, 2015, MOL CELL ENDOCRINOL, V402, P86, DOI 10.1016/j.mce.2014.12.027
   Raff M, 2008, J NUTR, V138, P509
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Riserus U, 2004, DIABETOLOGIA, V47, P1016, DOI 10.1007/s00125-004-1421-8
   Riserus U, 2002, DIABETES CARE, V25, P1516, DOI 10.2337/diacare.25.9.1516
   Riserus U, 2001, INT J OBESITY, V25, P1129, DOI 10.1038/sj.ijo.0801659
   Saraf N, 2012, J PHARM PHARMACOL, V64, P161, DOI 10.1111/j.2042-7158.2011.01366.x
   Schwartz A, 2010, OBES REV, V11, P531, DOI 10.1111/j.1467-789X.2009.00654.x
   Sears IB, 1996, MOL CELL BIOL, V16, P3410
   Shen W, 2013, J LIPID RES
   Shen W, 2016, ANNU REV NUTR, V36, P183, DOI 10.1146/annurev-nutr-071715-050924
   Shen W, 2015, J NUTR BIOCHEM, V26, P616, DOI 10.1016/j.jnutbio.2014.12.016
   Shimizu I, 2015, CURR OBES REP, V4, P224, DOI 10.1007/s13679-015-0157-8
   Silveira MB, 2007, PUBLIC HEALTH NUTR, V10, P1181, DOI 10.1017/S1368980007000687
   Steck SE, 2007, J NUTR, V137, P1188
   Subramanian S, 2008, ARTERIOSCL THROM VAS, V28, P685, DOI 10.1161/ATVBAHA.107.157685
   Subramanian S, 2011, J LIPID RES, V52, P1626, DOI 10.1194/jlr.M016246
   Taicher GZ, 2003, ANAL BIOANAL CHEM, V377, P990, DOI 10.1007/s00216-003-2224-3
   WEIR JBD, 1949, J PHYSIOL-LONDON, V109, P1
   West DB, 2000, J NUTR, V130, P2471
   Yen M, 2012, J MED TOXICOL, V8, P145, DOI 10.1007/s13181-012-0213-7
NR 65
TC 9
Z9 9
U1 1
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 28
PY 2017
VL 12
IS 2
AR e0172912
DI 10.1371/journal.pone.0172912
PG 25
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EN4LY
UT WOS:000395980200041
PM 28245284
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Southern, WM
   Nichenko, AS
   Shill, DD
   Spencer, CC
   Jenkins, NT
   McCully, KK
   Call, JA
AF Southern, William M.
   Nichenko, Anna S.
   Shill, Daniel D.
   Spencer, Corey C.
   Jenkins, Nathan T.
   McCully, Kevin K.
   Call, Jarrod A.
TI Skeletal muscle metabolic adaptations to endurance exercise training are
   attainable in mice with simvastatin treatment
SO PLOS ONE
LA English
DT Article
ID E-DEFICIENT MICE; OXIDATIVE STRESS; APOLIPOPROTEIN-E; STATIN THERAPY;
   ATORVASTATIN TREATMENT; MUSCULAR-DYSTROPHY; HEART-FAILURE; OLDER-ADULTS;
   AUTOPHAGY; INCREASES
AB We tested the hypothesis that a 6-week regimen of simvastatin would attenuate skeletal muscle adaptation to low-intensity exercise. Male C57BLI6J wildtype mice were subjected to 6-weeks of voluntary wheel running or normal cage activities with or without simvastatin treatment (20 mg/kg/d, n = 7-8 per group). Adaptations in in vivo fatigue resistance were determined by a treadmill running test, and by ankle plantarflexor contractile assessment. The tibialis anterior, gastrocnemius, and plantaris muscles were evaluated for exercised induced mitochondrial adaptations (i.e., biogenesis, function, autophagy). There was no difference in weekly wheel running distance between control and simvastatin-treated mice (P = 0.51). Trained mice had greater treadmill running distance (296%, P<0.001), and ankle plantarflexor contractile fatigue resistance (9%, P<0.05) compared to sedentary mice, independent of simvastatin treatment. At the cellular level, trained mice had greater mitochondrial biogenesis (e.g., similar to 2-fold greater PGC1 alpha expression, P<0.05) and mitochondrial content (e.g., 25% greater citrate synthase activity, P<0.05), independent of simvastatin treatment. Mitochondrial autophagy-related protein contents were greater in trained mice (e.g., 40% greater Bnip3, P<0.05), independent of simvastatin treatment. However, Drp1, a marker of mitochondrial fission, was less in simvastatin treated mice, independent of exercise training, and there was a significant interaction between training and statin treatment (P<0.022) for LC3-II protein content, a marker of autophagy flux. These data indicate that whole body and skeletal muscle adaptations to endurance exercise training are attainable with simvastatin treatment, but simvastatin may have side effects on muscle mitochondrial maintenance via autophagy, which could have long-term implications on muscle health.
C1 [Southern, William M.; Nichenko, Anna S.; Shill, Daniel D.; Spencer, Corey C.; Jenkins, Nathan T.; McCully, Kevin K.; Call, Jarrod A.] Univ Georgia, Dept Kinesiol, Athens, GA 30602 USA.
   [Call, Jarrod A.] Univ Georgia, Regenerat Biosci Ctr, Athens, GA 30602 USA.
RP Call, JA (reprint author), Univ Georgia, Dept Kinesiol, Athens, GA 30602 USA.; Call, JA (reprint author), Univ Georgia, Regenerat Biosci Ctr, Athens, GA 30602 USA.
EM call@uga.edu
RI McCully, Kevin K./P-5141-2015
OI McCully, Kevin K./0000-0001-9850-487X; Call, Jarrod/0000-0002-1094-4940
CR Ashfield TA, 2010, AGE AGEING, V39, P185, DOI 10.1093/ageing/afp203
   Ballard KD, 2013, ATHEROSCLEROSIS, V230, P121, DOI 10.1016/j.atherosclerosis.2013.07.001
   Baltgalvis KA, 2012, MED SCI SPORT EXER, V44, P1671, DOI 10.1249/MSS.0b013e31825703f0
   Baltgalvis KA, 2009, MUSCLE NERVE, V40, P443, DOI 10.1002/mus.21327
   Bea F, 2003, ATHEROSCLEROSIS, V167, P187, DOI 10.1016/S0021-9150(02)00387-8
   Bea F, 2002, ARTERIOSCL THROM VAS, V22, P1832, DOI 10.1161/01.ATV.0000036081.01231.16
   Bjorkhem-Bergman L, 2011, BRIT J CLIN PHARMACO, V72, P164, DOI 10.1111/j.1365-2125.2011.03907.x
   Bonifacio A, 2015, BBA-MOL CELL RES, V1853, P1841, DOI 10.1016/j.bbamcr.2015.04.010
   Bouitbir J, 2012, MUSCLE NERVE, V46, P367, DOI 10.1002/mus.23309
   Bouitbir J, 2011, J APPL PHYSIOL, V111, P1477, DOI 10.1152/japplphysiol.00107.2011
   Bruckert E, 2005, CARDIOVASC DRUG THER, V19, P403, DOI 10.1007/s10557-005-5686-z
   Call JA, 2015, CIRC-HEART FAIL, V8, P188, DOI 10.1161/CIRCHEARTFAILURE.114.001540
   Call JA, 2011, J APPL PHYSIOL, V111, P200, DOI 10.1152/japplphysiol.00248.2011
   Call JA, 2010, MUSCLE NERVE, V42, P871, DOI 10.1002/mus.21764
   Choudhury RP, 2004, J VASC RES, V41, P75, DOI 10.1159/000076436
   Davis ME, 2015, J SHOULDER ELB SURG, V24, P280, DOI 10.1016/j.jse.2014.06.048
   Fox J. G., 2007, MOUSE BIOMEDICAL RES, V3
   Ganga HV, 2014, AM HEART J, V168, P6, DOI 10.1016/j.ahj.2014.03.019
   Garcia-Cazarin ML, 2011, J VIS EXP
   Goodman CA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128398
   Gorassini M, 2000, J NEUROPHYSIOL, V83, P2002
   Gu Q, 2014, NCHS DATA BRIEF, P1
   Hanai JI, 2007, J CLIN INVEST, V117, P3940, DOI 10.1172/JCI32741
   Hood DA, 2001, J APPL PHYSIOL, V90, P1137
   Ikeda Y, 2015, CIRC RES, V116, P264, DOI 10.1161/CIRCRESAHA.116.303356
   Jenkins NT, 2011, J PHYSIOL-LONDON, V589, P5539, DOI 10.1113/jphysiol.2011.215277
   Krishnan GM, 2010, CURR OPIN LIPIDOL, V21, P324, DOI 10.1097/MOL.0b013e32833c1edf
   Kwak HB, 2012, FREE RADICAL BIO MED, V52, P198, DOI 10.1016/j.freeradbiomed.2011.10.449
   Larsen S, 2012, J PHYSIOL-LONDON, V590, P3349, DOI 10.1113/jphysiol.2012.230185
   Leung BP, 2003, J IMMUNOL, V170, P1524, DOI 10.4049/jimmunol.170.3.1524
   Li P, 2007, AM J PATHOL, V170, P599, DOI 10.2353/ajpath.2007.060505
   Lira VA, 2013, FASEB J, V27, P4184, DOI 10.1096/fj.13-228486
   Mallinson JE, 2009, J PHYSIOL-LONDON, V587, P219, DOI 10.1113/jphysiol.2008.164699
   Mikus CR, 2013, J AM COLL CARDIOL, V62, P709, DOI 10.1016/j.jacc.2013.02.074
   Miller RA, 2011, J GERONTOL A-BIOL, V66, P191, DOI 10.1093/gerona/glq178
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI 10.1161/CIR.0000000000000152
   Muraki A, 2012, J APPL PHYSIOL, V113, P479, DOI 10.1152/japplphysiol.01362.2011
   Nichenko AS, 2016, AM J PHYSIOL-CELL PH, V311, pC190, DOI 10.1152/ajpcell.00066.2016
   Okutsu M, 2014, CIRC-HEART FAIL, V7, P519, DOI 10.1161/CIRCHEARTFAILURE.113.000841
   Otera H, 2013, BBA-MOL CELL RES, V1833, P1256, DOI 10.1016/j.bbamcr.2013.02.002
   Paiva H, 2005, CLIN PHARMACOL THER, V78, P60, DOI 10.1016/j.clpt.2005.03.006
   Palmer G, 2004, ARTHRITIS RHEUM-US, V50, P4051, DOI 10.1002/art.20673
   Panza GA, 2015, J CLIN LIPIDOL, V9, P351, DOI 10.1016/j.jacl.2015.01.004
   Parker BA, 2013, CIRCULATION, V127, P96, DOI 10.1161/CIRCULATIONAHA.112.136101
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Rengo JL, 2016, MUSCLE NERVE, V53, P242, DOI 10.1002/mus.24722
   Schick BA, 2007, CLIN PHARMACOL THER, V81, P650, DOI 10.1038/sj.clpt.6100124
   Scott D, 2009, QJM-INT J MED, V102, P625, DOI 10.1093/qjmed/hcp093
   Shiroma EJ, 2010, CIRCULATION, V122, P743, DOI 10.1161/CIRCULATIONAHA.109.914721
   Sirvent P, 2012, TOXICOL APPL PHARM, V259, P263, DOI 10.1016/j.taap.2012.01.008
   Skoglund RN, 2004, SIMVASTATIN IMPROVES, V17, P2004
   Taylor FC, 2013, JAMA-J AM MED ASSOC, V310, P2451, DOI 10.1001/jama.2013.281348
   Tong XK, 2012, J NEUROSCI, V32, P4705, DOI 10.1523/JNEUROSCI.0169-12.2012
   Traustadottir T, 2008, AGE, V30, P283, DOI 10.1007/s11357-008-9070-3
   Wang YX, 2002, ATHEROSCLEROSIS, V162, P23, DOI 10.1016/S0021-9150(01)00678-5
   Whitehead NP, 2016, AUTOPHAGY, V12, P705, DOI 10.1080/15548627.2016.1144005
   Whitehead NP, 2015, P NATL ACAD SCI USA, V112, P12864, DOI 10.1073/pnas.1509536112
   Wu JS, 2011, MUSCLE NERVE, V43, P76, DOI 10.1002/mus.21847
   Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X
NR 60
TC 8
Z9 9
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 16
PY 2017
VL 12
IS 2
AR e0172551
DI 10.1371/journal.pone.0172551
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EL2BG
UT WOS:000394424500145
PM 28207880
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Symington, B
   Mapanga, RF
   Norton, GR
   Essop, MF
AF Symington, Burger
   Mapanga, Rudo F.
   Norton, Gavin R.
   Essop, M. Faadiel
TI Resveratrol Co-Treatment Attenuates the Effects of HIV Protease
   Inhibitors on Rat Body Weight and Enhances Cardiac Mitochondrial
   Respiration
SO PLOS ONE
LA English
DT Article
ID INFECTED PATIENTS; CARDIOVASCULAR-DISEASE; ANTIRETROVIRAL THERAPY;
   POSITIVE ADULTS; DATA-COLLECTION; DYSFUNCTION; LOPINAVIR/RITONAVIR;
   MECHANISMS; RISK; CARDIOMYOPATHY
AB Since the early 1990s human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) emerged as a global health pandemic, with sub-Saharan Africa the hardest hit. While the successful roll-out of antiretroviral (ARV) therapy provided significant relief to HIV-positive individuals, such treatment can also elicit damaging side-effects. Here especially HIV protease inhibitors (PIs) are implicated in the onset of cardio-metabolic complications such as type-2 diabetes and coronary heart disease. As there is a paucity of data regarding suitable co-treatments within this context, this preclinical study investigated whether resveratrol (RSV), aspirin (ASP) or vitamin C (VitC) co-treatment is able to blunt side-effects in a rat model of chronic PI exposure (Lopinavir/Ritonavir treatment for 4 months). Body weights and weight gain, blood metabolite levels (total cholesterol, HDL, LDL, triglycerides), echocardiography and cardiac mitochondrial respiration were assessed in PI-treated rats + various co-treatments. Our data reveal that PI treatment significantly lowered body weight and cardiac respiratory function while no significant changes were found for heart function and blood metabolite levels. Moreover, all co-treatments ameliorated the PI-induced decrease in body weight after 4 months of PI treatment, while RSV co-treatment enhanced cardiac mitochondrial respiratory capacity in PI-treated rats. This pilot study therefore provides novel hypotheses regarding RSV co-treatment that should be further assessed in greater detail.
C1 [Symington, Burger; Mapanga, Rudo F.; Essop, M. Faadiel] Univ Stellenbosch, Dept Physiol Sci, Cardiometab Res Grp CMRG, Stellenbosch, South Africa.
   [Norton, Gavin R.] Univ Witwatersrand, Sch Physiol, Cardiovasc Pathophysiol & Genom Res Unit, Fac Hlth Sci, Johannesburg, South Africa.
RP Essop, MF (reprint author), Univ Stellenbosch, Dept Physiol Sci, Cardiometab Res Grp CMRG, Stellenbosch, South Africa.
EM mfessop@sun.ac.za
OI Norton, Gavin/0000-0001-6416-6104; Essop, Faadiel/0000-0002-8434-4294
FU National Research Foundation of South Africa [78768]; Stellenbosch
   University
FX This work was supported by the National Research Foundation of South
   Africa, Grant #: 78768, and Stellenbosch University. The funder had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.; We thank the National Research
   Foundation of South Africa and Stellenbosch University for providing us
   with financial support.
CR Arenas-Pinto A, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0889-9
   Arzi A, 2004, PHARMACOL RES, V49, P249, DOI 10.1016/j.phrs.2003.10.004
   Bacchetti P, 2005, JAIDS-J ACQ IMM DEF, V40, P121
   Badiou S, 2003, ATHEROSCLEROSIS, V168, P107, DOI 10.1016/S0021-9150(03)00058-3
   Beaudoin MS, 2014, J PHYSIOL-LONDON, V592, P2519, DOI 10.1113/jphysiol.2013.270538
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999
   Cote HCF, 2007, CURR OPIN HIV AIDS, V2, P253, DOI 10.1097/COH.0b013e3281df3410
   Cummins NW, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.77
   Essop MF, 2004, BIOCHEM BIOPH RES CO, V314, P561, DOI 10.1016/j.bbrc.2003.12.121
   Estabrook R. W., 1967, METHOD ENZYMOL, V10, P41, DOI [10.1016/0076-6879(67)10010-4, DOI 10.1016/0076-6879(67)10010-4]
   Fisher SD, 2005, AM HEART J, V150, P439, DOI 10.1016/j.ahj.2005.06.012
   Freitas P, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-246
   Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376
   Friis-Moller N, 2007, CLIN INFECT DIS, V45, P1082, DOI 10.1086/521936
   Friis-Moller N, 2010, EUR J CARDIOV PREV R, V17, P491, DOI 10.1097/HJR.0b013e328336a150
   Gitau SC, 2015, FRONT MED-PRC, V9, P444, DOI 10.1007/s11684-015-0421-z
   Grundy SM., 2011, ATLAS ATHEROSCLEROSI
   GUPTA MB, 1969, EUR J PHARMACOL, V6, P67, DOI 10.1016/0014-2999(69)90067-3
   Ho JE, 2009, HEART, V95, P1193, DOI 10.1136/hrt.2008.161463
   Johri MK, 2011, EXPERT OPIN BIOL TH, V11, P269, DOI 10.1517/14712598.2011.546339
   Kamble P, 2013, EUR J PHARMACOL, V699, P55, DOI 10.1016/j.ejphar.2012.11.051
   Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013
   Meng QY, 2002, J ACQ IMMUN DEF SYND, V30, P306, DOI 10.1097/01.QAI.0000017995.56638.F8
   Mondy KE, 2011, CLIN INFECT DIS, V52, P378, DOI 10.1093/cid/ciq066
   Norton GR, 2008, AM J PHYSIOL-HEART C, V294, pH372, DOI 10.1152/ajpheart.01024.2007
   Ortblad KF, 2013, AIDS, V27, P2003, DOI 10.1097/QAD.0b013e328362ba67
   PALMER JW, 1977, J BIOL CHEM, V252, P8731
   Phenix BN, 2001, BLOOD, V98, P1078, DOI 10.1182/blood.V98.4.1078
   Pistell PJ, 2010, ANTIVIR RES, V88, P334, DOI 10.1016/j.antiviral.2010.10.006
   Porter KM, 2012, FREE RADICAL BIO MED, V53, P143, DOI 10.1016/j.freeradbiomed.2012.03.019
   Prot M, 2006, ANTIMICROB AGENTS CH, V50, P3998, DOI 10.1128/ACC.00625-06
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Reyskens KMSE, 2014, BBA-MOL BASIS DIS, V1842, P256, DOI 10.1016/j.bbadis.2013.11.019
   Reyskens KMSE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073347
   Reyskens KMSE, 2013, INT J CARDIOL, V168, P3047, DOI 10.1016/j.ijcard.2013.04.128
   Rosas S, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-442
   Sierra S, 2005, J CLIN VIROL, V34, P233, DOI 10.1016/j.jcv.2005.09.004
   Spector AA, 2006, ARTERIOSCL THROM VAS, V26, P7, DOI 10.1161/01.ATV.0000198749.28422.29
   Srinivasa S, 2014, EUR J ENDOCRINOL, V170, pR185, DOI 10.1530/EJE-13-0967
   Stein JH, 2001, CIRCULATION, V104, P257
   UNAIDS/World Health Organisation (WHO), 2016, FACT SHEET END AIDS
   White AJ, 2001, SEX TRANSM INFECT, V77, P158, DOI 10.1136/sti.77.3.158
   WHO, 2011, GLOBAL HIV AIDS RESP
   World Health Organisation (WHO) & UNICEF, 2008, EP FACTS SHEET HIV A
   Worm SW, 2010, J INFECT DIS, V201, P318, DOI 10.1086/649897
   Zhou HP, 2005, MOL PHARMACOL, V68, P690, DOI 10.1124/mol.105.012898
   Zhou HP, 2006, AM J PHYSIOL-GASTR L, V291, pG1071, DOI 10.1152/ajpgi.00182.2006
   Zungu M, 2008, MOL CELL BIOCHEM, V318, P175, DOI 10.1007/s11010-008-9867-5
NR 48
TC 1
Z9 1
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 20
PY 2017
VL 12
IS 1
AR e0170344
DI 10.1371/journal.pone.0170344
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EI3QC
UT WOS:000392405300116
PM 28107484
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Kram, DE
   Krasnow, SM
   Levasseur, PR
   Zhu, XX
   Stork, LC
   Marks, DL
AF Kram, David E.
   Krasnow, Stephanie M.
   Levasseur, Peter R.
   Zhu, Xinxia
   Stork, Linda C.
   Marks, Daniel L.
TI Dexamethasone Chemotherapy Does Not Disrupt Orexin Signaling
SO PLOS ONE
LA English
DT Article
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; OF-THE-LITERATURE; PEDIATRIC-PATIENTS;
   DIURNAL-VARIATION; GENE-EXPRESSION; REM-SLEEP; RAT-BRAIN; FATIGUE;
   NARCOLEPSY; HYPOCRETIN
AB Background
   Steroid-induced sleep disturbance is a common and highly distressing morbidity for children receiving steroid chemotherapy for the treatment of pediatric acute lymphoblastic leukemia (ALL). Sleep disturbance can negatively impact overall quality of life, neurodevelopment, memory consolidation, and wound healing. Hypothalamic orexin neurons are influential wake-promoting neurons, and disturbances in orexin signaling leads to abnormal sleep behavior. A new class of drug, the orexin receptor antagonists, could be an intriguing option for sleep disorders caused by increased orexinergic output. Our aim was to examine the impact of ALL treatment doses of corticosteroids on the orexin system in rodents and in children undergoing treatment for childhood ALL.
   Methods
   We administered repeated injections of dexamethasone to rodents and measured responsive orexin neural activity compared to controls. In children with newly diagnosed standard risk B-cell ALL receiving dexamethasone therapy per Children's Oncology Group (COG) induction therapy from 2014-2016, we collected pre- and during-steroids matched CSF samples and measured the impact of steroids on CSF orexin concentration.
   Results
   In both rodents, all markers orexin signaling, including orexin neural output and orexin receptor expression, were preserved in the setting of dexamethasone. Additionally, we did not detect a difference in pre-and during-dexamethasone CSF orexin concentrations in children receiving dexamethasone.
   Conclusions
   Our results demonstrate that rodent and human orexin physiology is largely preserved in the setting of high dose dexamethasone. The data obtained in our experimental model fail to demonstrate a causative role for disruption of the orexin pathway in steroid-induced sleep disturbance.
C1 [Kram, David E.; Stork, Linda C.] Oregon Hlth & Sci Univ, Doernbecher Childrens Hosp, Div Pediat Hematol Oncol, Portland, OR 97201 USA.
   [Krasnow, Stephanie M.; Levasseur, Peter R.; Zhu, Xinxia; Marks, Daniel L.] Oregon Hlth & Sci Univ, Pape Family Pediat Res Inst, Portland, OR 97201 USA.
RP Marks, DL (reprint author), Oregon Hlth & Sci Univ, Pape Family Pediat Res Inst, Portland, OR 97201 USA.
EM marksd@ohsu.edu
RI Marks, Daniel/C-3712-2009
OI Kram, David/0000-0002-1928-001X
FU National Institutes of Health, National Cancer Institute [CM 84324]
FX This work was supported by National Institutes of Health, National
   Cancer Institute, CM 84324. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Abercrombie HC, 2004, PSYCHONEUROENDOCRINO, V29, P1082, DOI 10.1016/j.psyneuen.2003.11.003
   Ancoli-Israel S, 2003, SLEEP, V26, P342, DOI 10.1093/sleep/26.3.342
   BORN J, 1986, NEUROPSYCHOBIOLOGY, V15, P165, DOI 10.1159/000118261
   Brisbare-Roch C, 2007, NAT MED, V13, P150, DOI 10.1038/nm1544
   Chemelli RM, 1999, CELL, V98, P437, DOI 10.1016/S0092-8674(00)81973-X
   Davis JF, 2009, NEUROSCIENCE, V162, P23, DOI 10.1016/j.neuroscience.2009.04.039
   de Lecea L, 2012, PROG BRAIN RES, V198, P15, DOI 10.1016/B978-0-444-59489-1.00003-3
   Desarnaud F, 2004, SLEEP, V27, P851, DOI 10.1093/sleep/27.5.851
   Fronczek R, 2009, SLEEP MED REV, V13, P9, DOI 10.1016/j.smrv.2008.05.002
   Gaynon PS, 2010, LEUKEMIA, V24, P285, DOI 10.1038/leu.2009.262
   Grady SP, 2006, SLEEP, V29, P295, DOI 10.1093/sleep/29.3.295
   Grossberg AJ, 2011, J NEUROSCI, V31, P11376, DOI 10.1523/JNEUROSCI.2311-11.2011
   Hara J, 2001, NEURON, V30, P345, DOI 10.1016/S0896-6273(01)00293-8
   Harris GC, 2006, TRENDS NEUROSCI, V29, P571, DOI 10.1016/j.tins.2006.08.002
   Hinds PS, 2007, CANCER-AM CANCER SOC, V110, P2321, DOI 10.1002/cncr.23039
   Hunger SP, 2013, PEDIATR BLOOD CANCER, V60, P957, DOI 10.1002/pbc.24420
   Lin L, 1999, CELL, V98, P365, DOI 10.1016/S0092-8674(00)81965-0
   Makela KA, 2010, ACTA PHYSIOL, V198, P237, DOI 10.1111/j.1748-1716.2009.02068.x
   Malik SW, 2005, PRIMARY CARE, V32, P475, DOI 10.1016/j.pop.2005.02.011
   Marcus JN, 2001, J COMP NEUROL, V435, P6, DOI 10.1002/cne.1190
   Michelson D, 2014, LANCET NEUROL, V13, P461, DOI 10.1016/S1474-4422(14)70053-5
   Moser NJ, 1996, PHARMACOL TOXICOL, V79, P100, DOI 10.1111/j.1600-0773.1996.tb00249.x
   Nakamura T, 2000, BRAIN RES, V873, P181, DOI 10.1016/S0006-8993(00)02555-5
   Perez-Leighton CE, 2012, AM J PHYSIOL-ENDOC M, V303, pE865, DOI 10.1152/ajpendo.00119.2012
   Porkka-Heiskanen T, 2004, NEUROBIOL AGING, V25, P231, DOI 10.1016/S0197-4580(03)00043-5
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Ripley B, 2001, NEUROLOGY, V57, P2253, DOI 10.1212/WNL.57.12.2253
   Sakurai T, 2007, NAT REV NEUROSCI, V8, P171, DOI 10.1038/nrn2092
   Saligan LN, 2015, SUPPORT CARE CANCER, V23, P2461, DOI 10.1007/s00520-015-2763-0
   Salomon RM, 2003, BIOL PSYCHIAT, V54, P96, DOI 10.1016/S0006-3223(03)01740-7
   Scammell TE, 2007, NAT MED, V13, P126, DOI 10.1038/nm0207-126
   Spinazzi R, 2006, PHARMACOL REV, V58, P46, DOI 10.1124/pr.58.1.4
   Stricker-Krongrad A, 2002, BIOCHEM BIOPH RES CO, V296, P129, DOI 10.1016/S0006-291X(02)00848-3
   Stuart FA, 2005, ARCH DIS CHILD, V90, P500, DOI 10.1136/adc.2003.041541
   Thompson MD, 2000, ANESTHESIOLOGY, V93, P1279, DOI 10.1097/00000542-200011000-00022
   Vallance Kelly, 2011, Oncol Nurs Forum, V38, pE365, DOI 10.1188/11.ONF.E365-E372
   Vallance K, 2010, EUR J CANCER, V46, P1848, DOI 10.1016/j.ejca.2010.03.026
   Vgontzas AN, 2004, J CLIN ENDOCR METAB, V89, P2119, DOI 10.1210/jc.2003-031562
   Vgontzas AN, 1999, J CLIN ENDOCR METAB, V84, P2603, DOI 10.1210/jc.84.8.2603
   Walter LM, 2015, SLEEP MED REV, V24, P71, DOI 10.1016/j.smrv.2015.01.001
   Wass CT, 1996, ANESTHESIOLOGY, V84, P644, DOI 10.1097/00000542-199603000-00020
   Weymann KB, 2014, BRAIN BEHAV IMMUN, V37, P84, DOI 10.1016/j.bbi.2013.11.003
   Willie JT, 2011, J MOL NEUROSCI, V43, P155, DOI 10.1007/s12031-010-9437-7
   Willie JT, 2003, NEURON, V38, P715, DOI 10.1016/S0896-6273(03)00330-1
   Zeitzer JM, 2003, J NEUROSCI, V23, P3555
   Zisapel N, 2007, CELL MOL LIFE SCI, V64, P1174, DOI 10.1007/s00018-007-6529-9
   Zupanec S, 2010, J PEDIATR ONCOL NURS, V27, P217, DOI 10.1177/1043454209358890
NR 47
TC 1
Z9 1
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 20
PY 2016
VL 11
IS 12
AR e0168731
DI 10.1371/journal.pone.0168731
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EI9QF
UT WOS:000392842900071
PM 27997622
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Enos, RT
   Velazquez, KT
   Carson, MS
   McClellan, JL
   Nagarkatti, P
   Nagarkatti, M
   Davis, JM
   Murphy, EA
AF Enos, Reilly T.
   Velazquez, Kandy T.
   Carson, Meredith S.
   McClellan, Jamie L.
   Nagarkatti, Prakash
   Nagarkatti, Mitzi
   Davis, J. Mark
   Murphy, E. Angela
TI A Low Dose of Dietary Quercetin Fails to Protect against the Development
   of an Obese Phenotype in Mice
SO PLOS ONE
LA English
DT Article
ID ENDOPLASMIC-RETICULUM STRESS; FATTY-LIVER-DISEASE; BODY-MASS INDEX;
   INSULIN-RESISTANCE; METABOLIC SYNDROME; SATURATED FAT; C57BL/6J MICE;
   RATS; INFLAMMATION; CANCER
AB The purpose of this study was to examine the effect of a 40% high-fat diet (HFD) supplemented with a dietary attainable level of quercetin (0.02%) on body composition, adipose tissue (AT) inflammation, Non-Alcoholic Fatty-Liver Disease (NAFLD), and metabolic outcomes. Diets were administered for 16 weeks to C57BL/6J mice (n = 10/group) beginning at 4 weeks of age. Body composition and fasting blood glucose, insulin, and total cholesterol concentrations were examined intermittently. AT and liver mRNA expression (RT-PCR) of inflammatory mediators (F4/80, CD206 (AT only), CD11c (AT only) TLR-2 (AT only), TLR-4 (AT only), MCP-1, TNF-alpha, IL-6 (AT only), and IL-10 (AT only)) were measured along with activation of NF kappa B-p65, and JNK (western blot). Hepatic lipid accumulation, gene expression (RT-PCR) of hepatic metabolic markers (ACAC1, SREBP-1, PPAR-gamma), protein content of Endoplasmic Reticulum (ER) Stress markers (BiP, phosphorylated and total EIF2 alpha, phosphorylated and total IRE1 alpha, CHOP), and hepatic oxidative capacity were assessed (western blot). Quercetin administration had no effect at mitigating increases in visceral AT, AT inflammation, hepatic steatosis, ER Stress, decrements in hepatic oxidative capacity, or the development of insulin resistance and hypercholesterolemia. In conclusion, 0.02% quercetin supplementation is not an effective therapy for attenuating HFD-induced obesity development. It is likely that a higher dose of quercetin supplementation is needed to elicit favorable outcomes in obesity.
C1 [Enos, Reilly T.; Velazquez, Kandy T.; Carson, Meredith S.; McClellan, Jamie L.; Nagarkatti, Prakash; Nagarkatti, Mitzi; Murphy, E. Angela] Univ South Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC 29208 USA.
   [Davis, J. Mark] Univ South Carolina, Dept Exercise Sci, Columbia, SC 29208 USA.
RP Murphy, EA (reprint author), Univ South Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC 29208 USA.
EM Angela.Murphy@uscmed.sc.edu
OI Nagarkatti, Prakash/0000-0003-2663-0759
FU NIH/NCI [R21CA175636]; NIH/NCCIH [K01AT007824]
FX This work was supported by grants R21CA175636 (NIH/NCI) and K01AT007824
   (NIH/NCCIH) to EAM. The funders had no role in study design, data
   collection, and analysis, decision to publish, or preparation of the
   manuscript.
CR Ables GP, 2012, PPAR RES, DOI 10.1155/2012/912351
   Aldridge GM, 2008, J NEUROSCI METH, V172, P250, DOI 10.1016/j.jneumeth.2008.05.003
   Arias N, 2016, EUR J NUTR, V55, P341, DOI 10.1007/s00394-015-0854-9
   Arias N, 2015, J PHYSIOL BIOCHEM, V71, P569, DOI 10.1007/s13105-015-0403-2
   Carson JA, 2002, J APPL PHYSIOL, V93, P242, DOI 10.1152/japplphysiol.01212.2001
   Chikka MR, 2013, J BIOL CHEM, V288, P4405, DOI 10.1074/jbc.M112.432344
   Davis JM, 2009, AM J PHYSIOL-REG I, V296, pR1071, DOI 10.1152/ajpregu.90925.2008
   Dong J, 2014, J LIPID RES, V55, P363, DOI 10.1194/jlr.M038786
   Enos RT, 2015, NUTR RES, V35, P449, DOI 10.1016/j.nutres.2015.04.003
   Enos RT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094897
   Enos RT, 2014, J NUTR BIOCHEM, V25, P600, DOI 10.1016/j.jnutbio.2014.01.011
   Enos RT, 2013, J LIPID RES, V54, P152, DOI 10.1194/jlr.M030700
   FOLCH J, 1957, J BIOL CHEM, V226, P497
   Grotto D, 2010, NUTR CLIN PRACT, V25, P603, DOI 10.1177/0884533610386234
   Henagan TM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089365
   Hoek-van den Hil EF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051588
   Jung CH, 2012, PHYTOTHER RES
   Jung CH, 2013, PHYTOTHER RES, V27, P139, DOI 10.1002/ptr.4687
   Jung JY, 2011, NUTR METAB, V8, DOI 10.1186/1743-7075-8-18
   Kim CS, 2015, NUTR METAB, V12, DOI 10.1186/s12986-015-0030-5
   Kobori M, 2016, MOL NUTR FOOD RES, V60, P300, DOI 10.1002/mnfr.201500595
   Kobori M, 2011, MOL NUTR FOOD RES, V55, P530, DOI 10.1002/mnfr.201000392
   Luedde T, 2011, NAT REV GASTRO HEPAT, V8, P108, DOI 10.1038/nrgastro.2010.213
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   Murphy EA, 2011, NUTR CANCER, V63, P421, DOI 10.1080/01635581.2011.535954
   Nguyen DM, 2010, GASTROENTEROL CLIN N, V39, P1, DOI 10.1016/j.gtc.2009.12.014
   Pagliassotti MJ, 2012, ANNU REV NUTR, V32, P17, DOI 10.1146/annurev-nutr-071811-150644
   Panchal SK, 2012, J NUTR, V142, P1026, DOI 10.3945/jn.111.157263
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Reeves GK, 2007, BRIT MED J, V335, P1134, DOI 10.1136/bmj.39367.495995.AE
   Renehan AG, 2008, LANCET, V371, P569, DOI 10.1016/S0140-6736(08)60269-X
   Rivera L, 2008, OBESITY, V16, P2081, DOI 10.1038/oby.2008.315
   Russo M, 2012, BIOCHEM PHARMACOL, V83, P6, DOI 10.1016/j.bcp.2011.08.010
   Seki E, 2012, GASTROENTEROLOGY, V143, P307, DOI 10.1053/j.gastro.2012.06.004
   Seo MJ, 2015, J NUTR BIOCHEM, V26, P1308, DOI 10.1016/j.jnutbio.2015.06.005
   Simopoulos AP, 2008, EXP BIOL MED, V233, P674, DOI 10.3181/0711-MR-311
   Steiner JL, 2014, CANCER BIOL THER, V15, P1456, DOI 10.4161/15384047.2014.955444
   Stewart LK, 2009, DIABETOLOGIA, V52, P514, DOI 10.1007/s00125-008-1252-0
   Stewart LK, 2008, METABOLISM, V57, pS39, DOI 10.1016/j.metabol.2008.03.003
   van Kruijsdijk RCM, 2009, CANCER EPIDEM BIOMAR, V18, P2569, DOI 10.1158/1055-9965.EPI-09-0372
   Wein S, 2010, EUR J PHARM SCI, V41, P16, DOI 10.1016/j.ejps.2010.05.004
   Wein SA, 2015, J NUTR BIOCHEM, V26, P1660, DOI 10.1016/j.jnutbio.2015.08.010
   Wyatt SB, 2006, AM J MED SCI, V331, P166, DOI 10.1097/00000441-200604000-00002
   Ying HZ, 2013, FOOD CHEM TOXICOL, V52, P53, DOI 10.1016/j.fct.2012.10.030
   Ying HZ, 2012, FOOD CHEM TOXICOL
   Zhang LF, 2010, J AGR FOOD CHEM, V58, P7252, DOI 10.1021/jf101192k
   Zhang XQ, 2014, WORLD J GASTROENTERO, V20, P1768, DOI 10.3748/wjg.v20.i7.1768
NR 47
TC 8
Z9 9
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 13
PY 2016
VL 11
IS 12
AR e0167979
DI 10.1371/journal.pone.0167979
PG 21
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EI8JY
UT WOS:000392753900029
PM 27959936
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Berressem, D
   Koch, K
   Franke, N
   Klein, J
   Eckert, GP
AF Berressem, Dirk
   Koch, Konrad
   Franke, Nicole
   Klein, Jochen
   Eckert, Gunter P.
TI Intravenous Treatment with a Long-Chain Omega-3 Lipid Emulsion Provides
   Neuroprotection in a Murine Model of Ischemic Stroke - A Pilot Study
SO PLOS ONE
LA English
DT Article
ID FATTY-ACIDS; CEREBRAL-ISCHEMIA; MITOCHONDRIAL DYSFUNCTION;
   EICOSAPENTAENOIC ACID; INFLAMMATORY RESPONSE; MOLECULAR-MECHANISMS;
   BRAIN ISCHEMIA; CELL-DEATH; TRANSIENT; INJURY
AB Single long-chain omega-3 fatty acids (e.g. docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA)) are known for their neuroprotective properties associated with ischemic stroke. This pilot study aimed to test the effectiveness of an acute treatment with a long-chain omega-3 lipid emulsion (Omegaven 10%(R), OGV) that contains fish oil (DHA 18 mg/ml; EPA 21 mg/ml) and a-tocopherol (0.2 mg/ml) in a transient middle cerebral artery occlusion (MCAO) model of ischemic stroke in mice. For this purpose, female CD-1 mice were anesthetized and subjected to 90 minutes of MCAO. To reflect a clinically relevant situation for an acute treatment, either after induction of stroke or after reperfusion, a single dose of OGV was injected intravenously into the tail vein (5 ml/kg b.w.). A neurological severity score was used to assess motor function and neurological outcome. Stroke-related parameters were determined 24 hours after MCAO. Microdialysis was used to collect samples from extracellular space of the striatum. Mitochondrial function was determined in isolated mitochondria or dissociated brain cells. Inflammation markers were measured in brain homogenate. According to control experiments, neuroprotective effects could be attributed to the long-chain omega-3 content of the emulsion. Intravenous injection of OGV reduced size and severity of stroke, restored mitochondrial function, and prevented excitotoxic glutamate release. Increases of pro-inflammatory markers (COX-2 and IL-6) were attenuated. Neurological severity scoring and neurochemical data demonstrated that acute OGV treatment shortly after induction of stroke was most efficient and able to improve short-term neurological outcome, reflecting the importance of an acute treatment to improve the outcome. Summarising, acute treatment of stroke with a single intravenous dose of OGV provided strong neuroprotective effects and was most effective when given immediately after onset of ischemia. As OGV is an approved fishoil emulsion for parenteral nutrition in humans, our results may provide first translational data for a possible early management of ischemic stroke with administration of OGV to prevent further brain damage.
C1 [Berressem, Dirk; Koch, Konrad; Franke, Nicole; Klein, Jochen; Eckert, Gunter P.] Goethe Univ Frankfurt, Dept Pharmacol, Frankfurt, Germany.
   [Eckert, Gunter P.] Justus Liebig Univ Giessen, Inst Nutr Sci, Giessen, Germany.
RP Berressem, D (reprint author), Goethe Univ Frankfurt, Dept Pharmacol, Frankfurt, Germany.
EM dberressem@gmx.net
RI Klein, Jochen/B-9730-2008
OI Klein, Jochen/0000-0001-6971-3381
FU Fresenius Kabi Deutschland GmbH, Bad Homburg, Deutschland
FX This study was partly supported by Fresenius Kabi Deutschland GmbH, Bad
   Homburg, Deutschland. The funder had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Amusquivar E, 2008, LIPIDS, V43, P713, DOI 10.1007/s11745-008-3180-7
   Bannenberg G, 2010, BBA-MOL CELL BIOL L, V1801, P1260, DOI 10.1016/j.bbalip.2010.08.002
   Bazan NG, 2009, J LIPID RES, V50, pS400, DOI 10.1194/jlr.R800068-JLR200
   Belayev L, 2011, TRANSL STROKE RES, V2, P33, DOI 10.1007/s12975-010-0046-0
   Belayev L, 2009, STROKE, V40, P3121, DOI 10.1161/STROKEAHA.109.555979
   Blondeau N, 2015, BIOMED RES INT, DOI 10.1155/2015/519830
   Borow KM, 2015, ATHEROSCLEROSIS, V242, P357, DOI 10.1016/j.atherosclerosis.2015.07.035
   Bourourou M, 2016, NEUROPHARMACOLOGY, V108, P60, DOI 10.1016/j.neuropharm.2016.04.040
   Byrne J, 2011, J THORAC CARDIOV SUR, V141, P803, DOI 10.1016/j.jtcvs.2010.04.030
   Calder PC, 2009, POSTGRAD MED, V121, P148, DOI 10.3810/pgm.2009.11.2083
   Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005
   Eady TN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077237
   Eady Tiffany N, 2012, Exp Transl Stroke Med, V4, P19, DOI 10.1186/2040-7378-4-19
   Eckert GP, 2013, NEUROCHEM INT, V62, P595, DOI 10.1016/j.neuint.2013.02.014
   Eckert GP, 2013, PROSTAG LEUKOTR ESS, V88, P105, DOI 10.1016/j.plefa.2012.05.006
   Eltzschig HK, 2011, NAT MED, V17, P1391, DOI 10.1038/nm.2507
   Emon ST, 2011, TURK NEUROSURG, V21, P197, DOI 10.5137/1019-5149.JTN.3523-10.2
   Franke C, 2007, NEUROBIOL DIS, V25, P438, DOI 10.1016/j.nbd.2006.10.004
   Gercek A, JPEN J PARENTER ENTE, V31, P161
   Gesellschaft fur Versuchstierkunde (GV-SOLAS), 2010, TIER VER TIERSCH EMP, P4
   Hagl S, 2013, PHARMACOL RES, V76, P17, DOI 10.1016/j.phrs.2013.06.008
   Harvey KA, 2015, LIPIDS HEALTH DIS, V14, DOI 10.1186/s12944-015-0005-6
   Hong SH, 2014, J NEUROL SCI, V338, P135, DOI 10.1016/j.jns.2013.12.033
   Horn T, 2013, NEUROCHEM INT, V62, P251, DOI 10.1016/j.neuint.2012.12.017
   Jauch EC, 2013, STROKE, V44, P870, DOI 10.1161/STR.0b013e318284056a
   Kiewert C, 2010, BRAIN RES, V1312, P101, DOI 10.1016/j.brainres.2009.11.068
   Kilian M, 2009, PANCREAS, V38, P436, DOI 10.1097/MPA.0b013e318198283b
   Kleinschnitz C, 2013, BLOOD, V121, P679, DOI 10.1182/blood-2012-04-426734
   Lang D, 2011, BRAIN RES, V1425, P155, DOI 10.1016/j.brainres.2011.10.005
   Larsen S, 2012, J PHYSIOL-LONDON, V590, P3349, DOI 10.1113/jphysiol.2012.230185
   Larsson SC, 2012, EUR J EPIDEMIOL, V27, P895, DOI 10.1007/s10654-012-9748-9
   Lin Y, 2015, NEUROSCIENCE, V301, P471, DOI 10.1016/j.neuroscience.2015.06.024
   Lipton P, 1999, PHYSIOL REV, V79, P1431
   Lopez-Armada MJ, 2013, MITOCHONDRION, V13, P106, DOI 10.1016/j.mito.2013.01.003
   Lukiw WJ, 2005, J CLIN INVEST, V115, P2774, DOI 10.1172/JCI25420
   Maldonado NJ, 2014, CRIT CARE CLIN, V30, P673, DOI 10.1016/j.ccc.2014.06.002
   Molina CA, 2011, STROKE, V42, pS16, DOI 10.1161/STROKEAHA.110.598763
   Mozaffarian D, 2011, J AM COLL CARDIOL, V58, P2047, DOI 10.1016/j.jacc.2011.06.063
   Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101
   Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386
   NAKAHARA I, 1991, J NEUROCHEM, V57, P839, DOI 10.1111/j.1471-4159.1991.tb08227.x
   Niizuma K, 2009, J NEUROCHEM, V109, P133, DOI 10.1111/j.1471-4159.2009.05897.x
   Orr SK, 2013, PROSTAG LEUKOTR ESS, V88, P97, DOI 10.1016/j.plefa.2012.05.008
   Pan HC, 2009, J NUTR BIOCHEM, V20, P715, DOI 10.1016/j.jnutbio.2008.06.014
   Pascoe MC, 2015, NEUROPSYCH DIS TREAT, V11, P153, DOI 10.2147/NDT.S72925
   Pastor-Clerigues A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115404
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Sanderson TH, 2013, MOL NEUROBIOL, V47, P9, DOI 10.1007/s12035-012-8344-z
   Schwarzkopf TM, 2015, NEUROSCIENCE, V300, P201, DOI 10.1016/j.neuroscience.2015.05.014
   Schwarzkopf TM, 2013, PHARMAZIE, V68, P584, DOI 10.1691/ph.2013.6513
   Schwarzkopf TM, 2013, BRAIN RES, V1529, P178, DOI 10.1016/j.brainres.2013.07.003
   Serhan CN., 2008, RESOLVINS PROTECTINS, P1
   Spera PA, 1998, NEUROSCI LETT, V251, P189, DOI 10.1016/S0304-3940(98)00537-0
   Spite M, 2014, CELL METAB, V19, P21, DOI 10.1016/j.cmet.2013.10.006
   Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019
   SUN DD, 1994, J NEUROCHEM, V62, P1921
   Szydlowska K, 2010, CELL CALCIUM, V47, P122, DOI 10.1016/j.ceca.2010.01.003
   Tanaka K, 2008, STROKE, V39, P2052, DOI 10.1161/STROKEAHA.107.509455
   U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), GUID IND EST MAX SAF
   Vosler PS, 2009, STROKE, V40, P3149, DOI 10.1161/STROKEAHA.108.543769
   Wachira JK, 2014, BRIT J NUTR, V111, P1652, DOI 10.1017/S000711451300425X
   Waje-Andreassen U, 2005, ACTA NEUROL SCAND, V111, P360, DOI 10.1111/j.1600-0404.2005.00416.x
   Wang Q, 2007, J NEUROIMMUNOL, V184, P53, DOI 10.1016/j.jneuroim.2006.11.014
   Williams JJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056233
   Woodruff TM, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-11
NR 65
TC 10
Z9 10
U1 1
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 30
PY 2016
VL 11
IS 11
AR e0167329
DI 10.1371/journal.pone.0167329
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EE3FV
UT WOS:000389474100072
PM 27902774
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Xiao, GJ
   Jiang, SW
   Qian, LL
   Cai, CB
   Wang, QQ
   Ma, DZ
   Li, B
   Xie, SS
   Cui, WT
   Li, K
AF Xiao, Gao-Jun
   Jiang, Sheng-Wang
   Qian, Li-Li
   Cai, Chun-Bo
   Wang, Qing-Qing
   Ma, De-Zun
   Li, Biao
   Xie, Shan-Shan
   Cui, Wen-Tao
   Li, Kui
TI A 90-Day Feeding Study in Rats to Assess the Safety of Genetically
   Engineered Pork
SO PLOS ONE
LA English
DT Article
ID GENE; GUIDANCE; CATTLE
AB Our laboratory recently produced genetically engineered (GE) Meishan pigs containing a ZFN-edited myostatin loss-of-function mutant. These GE pigs develop and grow as normal as wild type pigs but produce pork with greater lean yield and lower fat mass. To assess any potential subchronic toxicity risks of this GE pork, a 90-day feeding study was conducted in Sprague-Dawley rats. Rats were randomly divided into five groups, and fed for 90 days with basic diet and basic diets formulated with low dose and high dose pork prepared from wild type pigs and GE pigs, respectively. Animal behaviors and clinical signs were monitored twice daily, and body weight and food consumption were measured and recorded weekly. At days 45 and 90, blood tests (lipid panel, electrolytes, parameters related to liver and kidney functions, and complete blood counts) were performed. Additionally, gross pathology and histopathological analyses were performed for major organs in each group. Data analysis shows that there were no significant differences in growth rate, food consumption, and blood test parameters between rat groups fed with GE pork and wild type pork. Although differences in some liver function parameters (such as aspartate aminotransferase, total proteins, albumin, and alkaline phosphatase) and white blood cell counts (such as lymphocyte percentage and monocyte percentage) were observed between rats fed with high dose GE pork and basic diet, all test results in rats fed with GE pork are in the normal range. Additionally, there are no apparent lesions noted in all organs isolated from rats in all five feeding groups on days 45 and 90. Overall, our results clearly indicate that food consumption of GE pork produced by ZFN-edited myostatin loss-of-function mutant pigs did not have any long-term adverse effects on the health status in rats.
C1 [Xiao, Gao-Jun; Jiang, Sheng-Wang; Cai, Chun-Bo; Wang, Qing-Qing; Ma, De-Zun; Li, Biao; Xie, Shan-Shan; Cui, Wen-Tao; Li, Kui] Chinese Acad Agr Sci, Inst Anim Sci, Beijing 100193, Peoples R China.
   [Qian, Li-Li; Cai, Chun-Bo] China Agr Univ, State Key Lab Agrobiotechnol, Beijing 100193, Peoples R China.
RP Cui, WT (reprint author), Chinese Acad Agr Sci, Inst Anim Sci, Beijing 100193, Peoples R China.
EM cuiwentao@caas.cn
FU National Transgenic Project of China [2011ZX08006-003]; Agricultural
   Science and Technology Innovation Program [ASTIP-IA505]; Safety
   Evaluation Project of Transgenic Animals and Feeding Materials
   [2011-G11]
FX This work was supported by the National Transgenic Project of China
   (2011ZX08006-003) the Agricultural Science and Technology Innovation
   Program (ASTIP-IA505), and Safety Evaluation Project of Transgenic
   Animals and Feeding Materials (2011-G11). K.L. received the above
   funding. The funding agents had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Andersson HC, 2012, EFSA J, V10, DOI 10.2903/j.efsa.2012.2501
   Antunovic B, 2011, EFSA J, V9, DOI 10.2903/j.efsa.2011.2438
   Bai H, 2015, PLOS ONE, V10
   Beumer KJ, 2008, P NATL ACAD SCI USA, V105, P19821, DOI 10.1073/pnas.0810475105
   CHINA SAOTPSRO, 2003, DET AM AC FOODS, p6P
   CHINA SAOTPSRO, 2003, DET FAT FOODS, p4P
   CHINA SAOTPSRO, 2006, FEED STUFF DET CRUD, p12P
   CHINA SAOTPSRO, 2010, NAT FOOD SAF STAND D, p6P
   CHINA SAOTPSRO, 2010, NAT FOOD SAF STAND D, p9P
   Clop A, 2006, NAT GENET, V38, P813, DOI 10.1038/ng1810
   Cui XX, 2011, NAT BIOTECHNOL, V29, P64, DOI 10.1038/nbt.1731
   Ge K. Y Y, 2008, ACTA NUTRIMENTA SINI, V30, P1
   Geurts AM, 2009, SCIENCE, V325, P433, DOI 10.1126/science.1172447
   Gupta RM, 2014, J CLIN INVEST, V124, P4154, DOI 10.1172/JCI72992
   Hashimoto W, 1999, BIOSCI BIOTECH BIOCH, V63, P1942, DOI 10.1271/bbb.63.1942
   Hatada I, 2016, ENDOCR J, V63, P105, DOI 10.1507/endocrj.EJ15-0716
   Jinek M, 2012, SCIENCE, V337, P816, DOI 10.1126/science.1225829
   Kim YG, 1996, P NATL ACAD SCI USA, V93, P1156, DOI 10.1073/pnas.93.3.1156
   Li HJ, 2011, NATURE, V475, P217, DOI 10.1038/nature10177
   Liu S, 2013, FOOD CHEM TOXICOL, V57, P314, DOI 10.1016/j.fct.2013.04.003
   McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0
   McPherron AC, 1997, P NATL ACAD SCI USA, V94, P12457, DOI 10.1073/pnas.94.23.12457
   Meng XD, 2008, NAT BIOTECHNOL, V26, P695, DOI 10.1038/nbt1398
   Miller JC, 2011, NAT BIOTECHNOL, V29, P143, DOI 10.1038/nbt.1755
   Mosher DS, 2007, PLOS GENET, V3, P779, DOI 10.1371/journal.pgen.0030079
   Porteus MH, 2005, NAT BIOTECHNOL, V23, P967, DOI 10.1038/nbt1125
   Qian LL, 2015, SCI REP-UK, V5, DOI 10.1038/srep14435
   Ramirez CL, 2012, NUCLEIC ACIDS RES, V40, P5560, DOI 10.1093/nar/gks179
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Richardson C, 2000, NATURE, V405, P697
   Schuelke M, 2004, NEW ENGL J MED, V350, P2682, DOI 10.1056/NEJMoa040933
   Shukla VK, 2009, NATURE, V459, P437, DOI 10.1038/nature07992
   Song H, 2015, TRANSGENIC RES, V24, P295, DOI 10.1007/s11248-014-9844-6
   Townsend JA, 2009, NATURE, V459, P442, DOI 10.1038/nature07845
   Yusa K, 2011, NATURE, V478, P391, DOI 10.1038/nature10424
   Zhang F, 2010, P NATL ACAD SCI USA, V107, P12028, DOI 10.1073/pnas.0914991107
   Zhu YX, 2013, FOOD CHEM TOXICOL, V51, P280, DOI 10.1016/j.fct.2012.09.008
NR 37
TC 1
Z9 1
U1 2
U2 21
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 3
PY 2016
VL 11
IS 11
AR e0165843
DI 10.1371/journal.pone.0165843
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EA8SX
UT WOS:000386910000069
PM 27812153
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Kim, JE
   Go, J
   Koh, EK
   Song, SH
   Sung, JE
   Lee, HA
   Lee, YH
   Hong, JT
   Hwang, DY
AF Kim, Ji Eun
   Go, Jun
   Koh, Eun Kyoung
   Song, Sung Hwa
   Sung, Ji Eun
   Lee, Hyun Ah
   Lee, Young Hee
   Hong, Jin Tae
   Hwang, Dae Youn
TI Gallotannin-Enriched Extract Isolated from Galla Rhois May Be a
   Functional Candidate with Laxative Effects for Treatment of
   Loperamide-Induced Constipation of SD Rats
SO PLOS ONE
LA English
DT Article
ID TANNINS; POMEGRANATE; INHIBITION; GROWTH; LEAVES; CELLS
AB Several natural products containing tannins are used as traditional medicines for treatment of constipation; however, their pharmacological mechanism is not well understood. The laxative effects of gallotannin-enriched extract isolated from Galla Rhois (GEGR) were investigated using a constipation model induced by loperamide (Lop) injection. After analysis for antioxidant activity of GEGR, alterations in the excretion parameters, histological structure, mucin secretion, and related protein levels were measured in the transverse colon of Sprague Dawley (SD) rats with Lop-induced constipation following treatment with 250, 500 and 1,000 mg/ml of GEGR. The number and weight of feces increased significantly by 48-79% and 128-159%, respectively, in the Lop+GEGR treated group relative to the Lop+vehicle treated group, while food intake and water consumption were maintained at a constant level. The thickness of mucosa, muscle and flat luminal surface, as well as the number of goblet cells and crypt of lieberkuhnwere enhanced in the Lop+GEGR treated group. Moreover, mucin secretion increased significantly in a dose dependent manner in the Lop+GEGR treated group. Furthermore, the downstream signaling pathway of the muscarinic acetylcholine receptors (mAChR) M2 and M3 was recovered by GEGR treatment, although the expression level varied. The levels of Ga expression and inositol triphosphate (IP3) concentration were also recovered in the Lop+GEGR treated group relative to the Lop+vehicle treated group. The results of the present study provide strong evidence that tannins distributed in various medicinal plants are important candidates for improving chronic constipation induced by Lop treatment in animal models.
C1 [Kim, Ji Eun; Go, Jun; Koh, Eun Kyoung; Song, Sung Hwa; Sung, Ji Eun; Lee, Hyun Ah; Hwang, Dae Youn] Pusan Natl Univ, Dept Biomat Sci, Coll Nat Resources & Life Sci, Life & Ind Convergence Res Inst, Miryang, South Korea.
   [Lee, Young Hee] Pusan Natl Univ, Dept Organ Mat Sci & Engn, Busan, South Korea.
   [Hong, Jin Tae] Chungbuk Natl Univ, Coll Pharm, Chungju, South Korea.
RP Hwang, DY (reprint author), Pusan Natl Univ, Dept Biomat Sci, Coll Nat Resources & Life Sci, Life & Ind Convergence Res Inst, Miryang, South Korea.
EM dyhwang@pusan.ac.kr
RI Lee, Young Hee/A-5424-2013
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Ministry of Education [2014R1A1A2058360]; Korea
   Institute of Planning Evaluation for Technology of Food, Agriculture,
   Forestry and Fisheries [114034-03-1-HD030]
FX This research was supported by the Basic Science Research Program
   through the National Research Foundation of Korea (NRF) funded by the
   Ministry of Education (2014R1A1A2058360).; We thank Jin Hyang Hwang and
   the animal technicians for directing the Animal Facility and Care at the
   Laboratory Animal Resources Center. This research was supported by the
   Basic Science Research Program through the National Research Foundation
   of Korea (NRF) funded by the Ministry of Education (2014R1A1A2058360)
   and the Korea Institute of Planning Evaluation for Technology of Food,
   Agriculture, Forestry and Fisheries (grant no. 114034-03-1-HD030).
CR Abbas S, 2012, PHYTOTHER RES, V26, P704, DOI 10.1002/ptr.3634
   AHN T, 1994, BIOCHEM BIOPH RES CO, V203, P326, DOI 10.1006/bbrc.1994.2185
   Ahn YJ, 1998, J APPL MICROBIOL, V84, P439, DOI 10.1046/j.1365-2672.1998.00363.x
   [Anonymous], 1969, FOOD COSMET TOXICOL, V7, P364
   Ata N, 1996, ONCOL RES, V8, P503
   Barbehenn RV, 2011, PHYTOCHEMISTRY, V72, P1551, DOI 10.1016/j.phytochem.2011.01.040
   Burleigh DE, 1998, EUR J PHARMACOL, V152, P39
   CELIK AF, 1995, ALIMENT PHARM THER, V9, P63
   ChaChunNam, 2013, [Journal of Veterinary Clinics, 한국임상수의학회지], V30, P353
   Chae HS, 2010, AM J CHINESE MED, V38, P973, DOI 10.1142/S0192415X10008391
   Clinton C ND, 2009, NAT MED J, V1, P1
   De Lillo AR, 2000, AM J GASTROENTEROL, V95, P901, DOI 10.1016/S0002-9270(00)00718-8
   Go Jun, 2015, Lab Anim Res, V31, P101, DOI 10.5625/lar.2015.31.3.101
   Guarize L, 2012, NAT PROD RES, V26, P331, DOI 10.1080/14786411003754264
   Hs S Oz, 2005, J NUTR BIOCH, V16, P297
   Karlsson NG, 1997, J BIOL CHEM, V272, P27025, DOI 10.1074/jbc.272.43.27025
   Khalif IL, 2005, DIGEST LIVER DIS, V37, P838, DOI 10.1016/j.dld.2005.06.008
   Khan N, 2007, CANCER RES, V67, P3475, DOI 10.1158/0008-5472.CAN-06-3941
   Kim JE, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-333
   Kim SH, 2005, INT IMMUNOPHARMACOL, V5, P1820, DOI 10.1016/j.intimp.2005.06.007
   KUMARI M, 2012, RES J RECENT SCI, V1, P70
   Lee HY, 2012, FOOD CHEM TOXICOL, V50, P895, DOI 10.1016/j.fct.2011.12.001
   Lee Hu Jang, 2013, [Journal of Food Hygiene and Safety, 한국식품위생안전성학회지], V28, P95, DOI 10.13103/JFHS.2013.28.2.095
   Lee JJ, 2012, AVIAN PATHOL, V41, P403, DOI 10.1080/03079457.2012.702888
   Lee S. M., 1997, J APPL ENTOMOL, V36, P83
   Lee TY, 2006, J PHARM PHARMACOL, V58, P659, DOI 10.1211/jpp.58.5.0011
   Lee YH, 2015, TEXT RES J, V85, P1045, DOI 10.1177/0040517514559580
   Lee YH, 2009, MATERIALS, V2, P10, DOI 10.3390/ma2010010
   Meite S, 2010, BMC COMPLEM ALTERN M, V10, DOI 10.1186/1472-6882-10-7
   Najeeb-ur-Rehman, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-16
   Oh H, 2003, PHYTOTHER RES, V17, P417, DOI 10.1002/ptr.1148
   Philippe D, 2003, J CLIN INVEST, V111, P1329, DOI 10.1172/JCI200316750
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Shimotoyodome A, 2000, COMP BIOCHEM PHYS A, V126, P203, DOI 10.1016/S1095-6433(00)00194-X
   Voderholzer WA, 1997, AM J GASTROENTEROL, V92, P95
   Walia R, 2009, CURR OPIN PEDIATR, V21, P661, DOI 10.1097/MOP.0b013e32832ff241
   Wettschureck N, 2005, PHYSIOL REV, V85, P1159, DOI 10.1152/physrev.00003.2005
   Wintola OA, 2010, BMC GASTROENTEROL, V10, DOI 10.1186/1471-230X-10-95
   Zoppi G, 1998, ACTA PAEDIATR, V87, P836, DOI 10.1080/080352598750013590
NR 39
TC 9
Z9 9
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 12
PY 2016
VL 11
IS 9
AR e0161144
DI 10.1371/journal.pone.0161144
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DW5AC
UT WOS:000383653100006
PM 27618438
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Hadrup, N
   Svingen, T
   Mandrup, K
   Skov, K
   Pedersen, M
   Frederiksen, H
   Frandsen, HL
   Vinggaard, AM
AF Hadrup, Niels
   Svingen, Terje
   Mandrup, Karen
   Skov, Kasper
   Pedersen, Mikael
   Frederiksen, Hanne
   Frandsen, Henrik Lauritz
   Vinggaard, Anne Marie
TI Juvenile Male Rats Exposed to a Low-Dose Mixture of Twenty-Seven
   Environmental Chemicals Display Adverse Health Effects
SO PLOS ONE
LA English
DT Article
ID BISPHENOL-A; PHTHALATE METABOLITES; DISRUPTING CHEMICALS; DIETARY
   EXPOSURE; DANISH CHILDREN; UNITED-STATES; LIVER; PESTICIDES; PLASMA;
   TCDD
AB Humans are exposed to a large number of environmental chemicals in their daily life, many of which are readily detectable in blood or urine. It remains uncertain if these chemicals can cause adverse health effects when present together at low doses. In this study we have tested whether a mixture of 27 chemicals administered orally to juvenile male rats for three months could leave a pathophysiological footprint. The mixture contained metals, perfluorinated compounds, PCB, dioxins, pesticides, heterocyclic amines, phthalate, PAHs and others, with a combined dose of 0.16 (Low dose), 0.47 (Mid dose) or 1.6 (High dose) mg/kg bw/day. The lowest dose was designed with the aim of obtaining plasma or urine concentrations in rats at levels approaching those observed in humans. Some single congeners were administered at doses representative of combined doses for chemical groups. With this baseline, we found effects on weight, histology and gene expression in the liver, as well as changes to the blood plasma metabolome in all exposure groups, including low-dose. Additional adverse effects were observed in the higher dosed groups, including enlarged kidneys and alterations to the metabolome. No significant effects on reproductive parameters were observed.
C1 [Hadrup, Niels; Svingen, Terje; Mandrup, Karen; Vinggaard, Anne Marie] Tech Univ Denmark, Natl Food Inst, Div Diet Dis Prevent & Toxicol, DK-2400 Soborg, Denmark.
   [Skov, Kasper; Pedersen, Mikael; Frandsen, Henrik Lauritz] Tech Univ Denmark, Natl Food Inst, Div Food Chem, DK-2400 Soborg, Denmark.
   [Frederiksen, Hanne] Copenhagen Univ Hosp, Rigshosp, Dept Growth & Reprod, DK-2100 Copenhagen, Denmark.
RP Hadrup, N (reprint author), Tech Univ Denmark, Natl Food Inst, Div Diet Dis Prevent & Toxicol, DK-2400 Soborg, Denmark.
EM niels.hadrup@gmail.com
RI Svingen, Terje/I-3505-2019; Svingen, Terje/A-5283-2010; Frederiksen,
   Hanne/N-8632-2013
OI Svingen, Terje/0000-0003-4650-7651; Vinggaard, Anne
   Marie/0000-0002-6822-3572; Pedersen, Mikael/0000-0001-6540-4805;
   Frederiksen, Hanne/0000-0002-3180-9879; Hadrup,
   Niels/0000-0002-1188-445X
FU Ministry of Food, Agriculture and Fisheries of Denmark; Danish
   Veterinary and Food Administration; EDMaRC - International Center for
   Research and Research Training in Endocrine Disrupting Effects on Male
   Reproduction and Child Health
FX This work was supported by The Ministry of Food, Agriculture and
   Fisheries of Denmark and the Danish Veterinary and Food Administration
   and EDMaRC - International Center for Research and Research Training in
   Endocrine Disrupting Effects on Male Reproduction and Child Health. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Androutsopoulos VP, 2013, TOXICOLOGY, V307, P89, DOI 10.1016/j.tox.2012.09.011
   BAKKER M, 2003, INDICATOR PCBS FOODS
   Bashir S, 2006, TOXICOLOGY, V217, P63, DOI 10.1016/j.tox.2005.08.023
   Browning JD, 2004, HEPATOLOGY, V40, P1387, DOI 10.1002/hep.20466
   Chen HL, 2010, BIRTH DEFECTS RES C, V90, P272, DOI 10.1002/bdrc.20192
   Christiansen S, 2014, REPRODUCTION, V147, P477, DOI 10.1530/REP-13-0377
   Chu I, 1996, J APPL TOXICOL, V16, P121, DOI 10.1002/(SICI)1099-1263(199603)16:2<121::AID-JAT320>3.0.CO;2-G
   Crofton KM, 2005, ENVIRON HEALTH PERSP, V113, P1549, DOI 10.1289/ehp.8195
   Demur C, 2013, TOXICOLOGY, V308, P74, DOI 10.1016/j.tox.2013.03.004
   DEVITO MJ, 1995, ENVIRON HEALTH PERSP, V103, P820, DOI 10.2307/3432395
   EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4
   Frederiksen H, 2013, INT J HYG ENVIR HEAL, V216, P710, DOI 10.1016/j.ijheh.2013.01.007
   Frederiksen H, 2011, ENVIRON RES, V111, P656, DOI 10.1016/j.envres.2011.03.005
   Frederiksen H, 2010, J ANAL TOXICOL, V34, P400, DOI 10.1093/jat/34.7.400
   GUSTAFSSON J, 1985, J CLIN INVEST, V75, P604, DOI 10.1172/JCI111737
   Hadrup N., 2015, ARCH TOXICOL
   HERA (Human and Environmental Risk Assessment on Ingredients of Household Cleaning Products), 2004, HERA RISK ASS AHTN 6
   Karami-Mohajeri S, 2011, HUM EXP TOXICOL, V30, P1119, DOI 10.1177/0960327110388959
   KOCIBA RJ, 1976, TOXICOL APPL PHARM, V35, P553, DOI 10.1016/0041-008X(76)90078-8
   Kortenkamp A, 2014, REPRODUCTION, V147, P515, DOI 10.1530/REP-13-0440
   Krueger SK, 2005, PHARMACOL THERAPEUT, V106, P357, DOI 10.1016/j.pharmthera.2005.01.001
   Lee KY, 2004, TOXICOLOGY, V203, P221, DOI 10.1016/j.tox.2004.06.013
   Maranghi F, 2013, FOOD CHEM TOXICOL, V56, P443, DOI 10.1016/j.fct.2013.02.056
   Merhi M, 2010, TOXICOLOGY, V267, P80, DOI 10.1016/j.tox.2009.10.024
   NHANES, 2009, 4 CDCP
   Nukaya M, 2009, P NATL ACAD SCI USA, V106, P4923, DOI 10.1073/pnas.0809613106
   R Core Team, 2012, R LANG ENV STAT COMP
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Rey RA, 2014, ANN ENDOCRINOL-PARIS, V75, P58, DOI 10.1016/j.ando.2014.03.001
   Ronn M, 2013, TOXICOLOGY, V303, P125, DOI 10.1016/j.tox.2012.09.013
   Ruhl CE, 2015, ALIMENT PHARM THER, V41, P65, DOI 10.1111/apt.13012
   Rui LY, 2014, COMPR PHYSIOL, V4, P177, DOI 10.1002/cphy.c130024
   Shintyapina AB, 2014, B EXP BIOL MED+, V157, P473, DOI 10.1007/s10517-014-2594-x
   Skov K, 2015, J CHROMATOGR B, V978, P83, DOI 10.1016/j.jchromb.2014.11.033
   Stanko JP, 2010, REPROD TOXICOL, V30, P540, DOI 10.1016/j.reprotox.2010.07.006
   Sun H, 2013, ONCOGENE, V32, P234, DOI 10.1038/onc.2012.34
   Svingen T, 2016, J EPIDEMIOL COMMUN H, V70, P322, DOI 10.1136/jech-2015-206268
   Svingen T, 2015, PEERJ, V3, DOI 10.7717/peerj.855
   Svingen T, 2013, GENE DEV, V27, P2409, DOI 10.1101/gad.228080.113
   Veeravalli S, 2014, BIOCHEM PHARMACOL, V90, P88, DOI 10.1016/j.bcp.2014.04.007
   Wade MG, 2002, TOXICOL SCI, V67, P131, DOI 10.1093/toxsci/67.1.131
   Wakabayashi K, 1993, ENVIRON HEALTH PERSP, P129, DOI [10.1289/ehp.9399129, DOI 10.1289/EHP.9399129]
   Wan HT, 2013, J HAZARD MATER, V261, P763, DOI 10.1016/j.jhazmat.2013.01.034
   Wishart DS, 2013, NUCLEIC ACIDS RES, V41, pD801, DOI 10.1093/nar/gks1065
   Xia JG, 2009, NUCLEIC ACIDS RES, V37, pW652, DOI 10.1093/nar/gkp356
   Xia W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090443
   Xu DM, 2014, ENVIRON TOXICOL PHAR, V37, P1212, DOI 10.1016/j.etap.2014.04.022
NR 47
TC 4
Z9 4
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 6
PY 2016
VL 11
IS 9
AR e0162027
DI 10.1371/journal.pone.0162027
PG 22
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DV9IT
UT WOS:000383254800033
PM 27598887
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Lee, KH
   Nam, H
   Jeong, DE
   Kim, SS
   Song, HJ
   Pyeon, HJ
   Kang, K
   Hong, SC
   Nam, DH
   Joo, KM
AF Lee, Kee Hang
   Nam, Hyun
   Jeong, Da Eun
   Kim, Sung Soo
   Song, Hye Jin
   Pyeon, Hee Jang
   Kang, Kyeongjin
   Hong, Seung-Cheol
   Nam, Do-Hyun
   Joo, Kyeung Min
TI Sensitive Tumorigenic Potential Evaluation of Adult Human Multipotent
   Neural Cells Immortalized by hTERT Gene Transduction
SO PLOS ONE
LA English
DT Article
ID STEM-CELL; STRUCTURAL VARIATION; MODELS; TRANSLATION; PROTEIN; BONE
AB Stem cells and therapeutic genes are emerging as a new therapeutic approach to treat various neurodegenerative diseases with few effective treatment options. However, potential formation of tumors by stem cells has hampered their clinical application. Moreover, adequate preclinical platforms to precisely test tumorigenic potential of stem cells are controversial. In this study, we compared the sensitivity of various animal models for in vivo stem cell tumorigenicity testing to identify the most sensitive platform. Then, tumorigenic potential of adult human multipotent neural cells (ahMNCs) immortalized by the human telomerase reverse transcriptase (hTERT) gene was examined as a stem cell model with therapeutic genes. When human glioblastoma (GBM) cells were injected into adult (4-6-week-old) Balb/c-nu, adult NOD/SCID, adult NOG, or neonate (1-2-week-old) NOG mice, the neonate NOG mice showed significantly faster tumorigenesis than that of the other groups regardless of intracranial or subcutaneous injection route. Two kinds of ahMNCs (682TL and 779TL) were primary cultured from surgical samples of patients with temporal lobe epilepsy. Although the ahMNCs were immortalized by lentiviral hTERT gene delivery (hTERT-682TL and hTERT-779TL), they did not form any detectable masses, even in the most sensitive neonate NOG mouse platform. Moreover, the hTERT-ahMNCs had no gross chromosomal abnormalities on a karyotype analysis. Taken together, our data suggest that neonate NOG mice could be a sensitive animal platform to test tumorigenic potential of stem cell therapeutics and that ahMNCs could be a genetically stable stem cell source with little tumorigenic activity to develop regenerative treatments for neurodegenerative diseases.
C1 [Lee, Kee Hang; Jeong, Da Eun; Kim, Sung Soo; Hong, Seung-Cheol; Nam, Do-Hyun; Joo, Kyeung Min] Sungkyunkwan Univ, SAIHST, Dept Hlth Sci & Technol, Seoul, South Korea.
   [Nam, Hyun; Nam, Do-Hyun] Sungkyunkwan Univ, Dept Neurosurg, Samsung Med Ctr, Seoul, South Korea.
   [Song, Hye Jin; Pyeon, Hee Jang; Kang, Kyeongjin; Joo, Kyeung Min] Sungkyunkwan Univ, Sch Med, Dept Anat & Cell Biol, Seoul, South Korea.
   [Lee, Kee Hang; Nam, Hyun; Jeong, Da Eun; Kim, Sung Soo; Song, Hye Jin; Pyeon, Hee Jang; Hong, Seung-Cheol; Nam, Do-Hyun; Joo, Kyeung Min] Samsung Med Ctr, Res Inst Future Med, Stem Cell & Regenerat Med Ctr, Seoul 06351, South Korea.
RP Joo, KM (reprint author), Sungkyunkwan Univ, SAIHST, Dept Hlth Sci & Technol, Seoul, South Korea.; Joo, KM (reprint author), Sungkyunkwan Univ, Sch Med, Dept Anat & Cell Biol, Seoul, South Korea.; Joo, KM (reprint author), Samsung Med Ctr, Res Inst Future Med, Stem Cell & Regenerat Med Ctr, Seoul 06351, South Korea.
EM kmjoo@skku.edu
FU Ministry of Food and Drug Safety [14172MFDS974]; National Research
   Foundation [NRF-2013R1A1A2058169]
FX This research was supported by grants from Ministry of Food and Drug
   Safety in 2014 (14172MFDS974) and National Research Foundation
   (NRF-2013R1A1A2058169). KMJ received grants, which supported salary,
   materials and fees for equipment. The URL of Ministry of Food and Drug
   Safety is (http://www.mfds.go.kr/index.do). The URL of National Research
   Foundation is
   (http://www.nrf.re.kr/nrf_tot_cms/index.jsp?pmi-sso-return2=none).; This
   research was supported by grants from Ministry of Food and Drug Safety
   in 2014 (14172MFDS974) and National Research Foundation
   (NRF-2013R1A1A2058169).
CR Baraniak PR, 2010, REGEN MED, V5, P121, DOI [10.2217/rme.09.74, 10.2217/RME.09.74]
   Beck B, 2013, NAT REV CANCER, V13, P727, DOI 10.1038/nrc3597
   Bocker W, 2008, J CELL MOL MED, V12, P1347, DOI [10.1111/j.1582-4934.2008.00299.x, 10.1111/j.1582-4934.2008.0299.x]
   BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0
   Bullwinkel J, 2006, J CELL PHYSIOL, V206, P624, DOI 10.1002/jcp.20494
   Chen B, 2009, BRAIN RES, V1284, P1, DOI 10.1016/j.brainres.2009.05.100
   Clark MJ, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000832
   Conrad DF, 2006, NAT GENET, V38, P75, DOI 10.1038/ng1697
   Denton PW, 2011, AIDS REV, V13, P135
   Drost J, 2015, NATURE, V521, P43, DOI 10.1038/nature14415
   Feuk L, 2006, NAT REV GENET, V7, P85, DOI 10.1038/nrg1767
   Flammang TJ, 1997, REGUL TOXICOL PHARM, V26, P230, DOI 10.1006/rtph.1997.1125
   FOGH J, 1977, JNCI-J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221
   Frey-Vasconcells J, 2012, STEM CELL TRANSL MED, V1, P353, DOI 10.5966/sctm.2012-0018
   Fuentealba LC, 2015, CELL, V161, P1644, DOI 10.1016/j.cell.2015.05.041
   GANICK DJ, 1980, INT ARCH ALLER A IMM, V62, P330, DOI 10.1159/000232530
   Goldring CEP, 2011, CELL STEM CELL, V8, P618, DOI 10.1016/j.stem.2011.05.012
   Gupta B, 2007, CANCER IMMUNOL IMMUN, V56, P1215, DOI 10.1007/s00262-006-0273-0
   Hahn WC, 2001, ANN MED, V33, P123, DOI 10.3109/07853890109002067
   Harding J, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt171
   Hinds DA, 2006, NAT GENET, V38, P82, DOI 10.1038/ng1695
   Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416
   Ishikawa F, 2005, BLOOD, V106, P1565, DOI 10.1182/blood-2005-02-0516
   Johnson DR, 2012, J NEURO-ONCOL, V107, P359, DOI 10.1007/s11060-011-0749-4
   Joo KM, 2013, CELL REP, V3, P260, DOI 10.1016/j.celrep.2012.12.013
   Joo KM, 2013, EXP NEUROL, V240, P168, DOI 10.1016/j.expneurol.2012.11.021
   Kanemura H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085336
   Kawamata S, 2015, J CLIN MED, V4, P159, DOI 10.3390/jcm4010159
   Korbel JO, 2007, SCIENCE, V318, P420, DOI 10.1126/science.1149504
   Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006
   Lee HJ, 2010, J NEUROSCI RES, V88, P3282, DOI 10.1002/jnr.22474
   Lindvall O, 2010, J CLIN INVEST, V120, P29, DOI 10.1172/JCI40543
   Lu P, 2003, EXP NEUROL, V181, P115, DOI 10.1016/S0014-4886(03)00037-2
   Lunn JS, 2011, ANN NEUROL, V70, P353, DOI 10.1002/ana.22487
   Marei HES, 2015, J CELL PHYSIOL, V230, P116, DOI 10.1002/jcp.24688
   Martino G, 2011, PHYSIOL REV, V91, P1281, DOI 10.1152/physrev.00032.2010
   McCarroll SA, 2006, NAT GENET, V38, P86, DOI 10.1038/ng1696
   McClain RM, 2001, TOXICOL PATHOL, V29, P128, DOI 10.1080/019262301753178537
   Nam H, 2015, WORLD J STEM CELLS, V7, P126, DOI 10.4252/wjsc.v7.i1.126
   Nombela-Arrieta C, 2011, NAT REV MOL CELL BIO, V12, P126, DOI 10.1038/nrm3049
   Oh JE, 2011, J BIOL CHEM, V286, P38757, DOI 10.1074/jbc.M111.244939
   PIETRA G, 1959, NATURE, V183, P1689, DOI 10.1038/1831689a0
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Reddel RR, 2000, CARCINOGENESIS, V21, P477, DOI 10.1093/carcin/21.3.477
   Roy NS, 2007, NAT PROTOC, V2, P2815, DOI 10.1038/nprot.2007.402
   Sakaguchi Y, 2005, ARTHRITIS RHEUM-US, V52, P2521, DOI 10.1002/art.21212
   SHULTZ LD, 1995, J IMMUNOL, V154, P180
   Tuzun E, 2005, NAT GENET, V37, P727, DOI 10.1038/ng1562
   Urraca N, 2015, STEM CELL RES, V15, P722, DOI 10.1016/j.scr.2015.11.004
   Wilson R, 2015, STEM CELL TRANSL MED, V4, P905, DOI 10.5966/sctm.2014-0196
   Worthley DL, 2015, CELL, V160, P269, DOI 10.1016/j.cell.2014.11.042
NR 51
TC 3
Z9 3
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 8
PY 2016
VL 11
IS 7
AR e0158639
DI 10.1371/journal.pone.0158639
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DR6IK
UT WOS:000380005400095
PM 27391353
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Tweedie, D
   Fukui, K
   Li, YZ
   Yu, QS
   Barak, S
   Tamargo, IA
   Rubovitch, V
   Holloway, HW
   Lehrmann, E
   Wood, WH
   Zhang, YQ
   Becker, KG
   Perez, E
   Van Praag, H
   Luo, Y
   Hoffer, BJ
   Becker, RE
   Pick, CG
   Greig, NH
AF Tweedie, David
   Fukui, Koji
   Li, Yazhou
   Yu, Qian-sheng
   Barak, Shani
   Tamargo, Ian A.
   Rubovitch, Vardit
   Holloway, Harold W.
   Lehrmann, Elin
   Wood, William H., III
   Zhang, Yongqing
   Becker, Kevin G.
   Perez, Evelyn
   Van Praag, Henriette
   Luo, Yu
   Hoffer, Barry J.
   Becker, Robert E.
   Pick, Chaim G.
   Greig, Nigel H.
TI Cognitive Impairments Induced by Concussive Mild Traumatic Brain Injury
   in Mouse Are Ameliorated by Treatment with Phenserine via Multiple
   Non-Cholinergic and Cholinergic Mechanisms
SO PLOS ONE
LA English
DT Article
ID OBJECT RECOGNITION MEMORY; FLUID-PERCUSSION INJURY; CORTICAL IMPACT
   INJURY; ALZHEIMERS-DISEASE; HEAD-INJURY; OXIDATIVE STRESS;
   CHOLINESTERASE-INHIBITORS; ACETYLCHOLINESTERASE INHIBITION; PARKINSON
   DISEASE; RECEPTOR-BINDING
AB Traumatic brain injury (TBI), often caused by a concussive impact to the head, affects an estimated 1.7 million Americans annually. With no approved drugs, its pharmacological treatment represents a significant and currently unmet medical need. In our prior development of the anti-cholinesterase compound phenserine for the treatment of neurodegenerative disorders, we recognized that it also possesses non-cholinergic actions with clinical potential. Here, we demonstrate neuroprotective actions of phenserine in neuronal cultures challenged with oxidative stress and glutamate excitotoxicity, two insults of relevance to TBI. These actions translated into amelioration of spatial and visual memory impairments in a mouse model of closed head mild TBI (mTBI) two days following cessation of clinically translatable dosing with phenserine (2.5 and 5.0 mg/kg BID x 5 days initiated post mTBI) in the absence of anti-cholinesterase activity. mTBI elevated levels of thiobarbituric acid reactive substances (TBARS), a marker of oxidative stress. Phenserine counteracted this by augmenting homeostatic mechanisms to mitigate oxidative stress, including superoxide dismutase [SOD] 1 and 2, and glutathione peroxidase [GPx], the activity and protein levels of which were measured by specific assays. Microarray analysis of hippocampal gene expression established that large numbers of genes were exclusively regulated by each individual treatment with a substantial number of them co-regulated between groups. Molecular pathways associated with lipid peroxidation were found to be regulated by mTBI, and treatment of mTBI animals with phenserine effectively reversed injury-induced regulations in the 'Blalock Alzheimer's Disease Up' pathway. Together these data suggest that multiple phenserine-associated actions underpin this compound's ability to ameliorate cognitive deficits caused by mTBI, and support the further evaluation of the compound as a therapeutic for TBI.
C1 [Tweedie, David; Fukui, Koji; Li, Yazhou; Yu, Qian-sheng; Tamargo, Ian A.; Holloway, Harold W.; Becker, Robert E.; Greig, Nigel H.] NIA, Translat Gerontol Branch, Intramural Res Program, NIH, Baltimore, MD 21224 USA.
   [Fukui, Koji] Shibaura Inst Technol, Div Biosci & Engn, Saitama 3378570, Japan.
   [Barak, Shani; Rubovitch, Vardit; Pick, Chaim G.] Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel.
   [Lehrmann, Elin; Wood, William H., III; Zhang, Yongqing; Becker, Kevin G.] NIA, Lab Genet & Genom, Intramural Res Program, NIH, Baltimore, MD 21224 USA.
   [Perez, Evelyn] NIA, Lab Behav Neurosci, Intramural Res Program, NIH, Baltimore, MD 21224 USA.
   [Van Praag, Henriette] NIA, Neurosci Lab, Intramural Res Program, NIH, Baltimore, MD 21224 USA.
   [Luo, Yu; Hoffer, Barry J.] Case Western Reserve Univ, Sch Med, Dept Neurosurg, Cleveland, OH USA.
   [Becker, Robert E.] 7123 Pinebrook Rd, Park City, UT 84098 USA.
   [Pick, Chaim G.] Tel Aviv Univ, Sagol Sch Neurosci, IL-69978 Tel Aviv, Israel.
RP Greig, NH (reprint author), NIA, Translat Gerontol Branch, Intramural Res Program, NIH, Baltimore, MD 21224 USA.
EM greign@mail.nih.gov
RI Fukui, Koji/I-7067-2019
OI Fukui, Koji/0000-0003-2748-3228; van Praag,
   Henriette/0000-0002-5727-434X; Luo, Yu/0000-0002-7939-5505; Lehrmann,
   Elin/0000-0002-9869-9475
FU Intramural Research Program of the National Institute on Aging, National
   Institutes of Health; Ari and Regine Aprijaskis Fund, at Tel-Aviv
   University; Israel Science Foundation [108/09]
FX This research was supported in part by (i) the Intramural Research
   Program of the National Institute on Aging, National Institutes of
   Health, (ii) the Ari and Regine Aprijaskis Fund, at Tel-Aviv University,
   and (iii) a grant from the Israel Science Foundation, grant number
   108/09. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.; This
   research was supported in part by (i) the Intramural Research Program of
   the National Institute on Aging, National Institutes of Health, (ii) the
   Ari and Regine Aprijaskis Fund, at Tel-Aviv University, and (iii) a
   grant from the Israel Science Foundation, grant number 108/09.
CR AGGLETON JP, 1986, BEHAV BRAIN RES, V19, P133, DOI 10.1016/0166-4328(86)90011-2
   Allen TGJ, 2006, J NEUROSCI, V26, P1588, DOI 10.1523/JNEUROSCI.3979-05.2006
   [Anonymous], 2010, LANCET NEUROL, V9, P331, DOI 10.1016/S1474-4422(10)70069-7
   Araujo JA, 2011, J ALZHEIMERS DIS, V26, P143, DOI 10.3233/JAD-2011-110005
   Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017
   Ballesteros J, 2008, J HEAD TRAUMA REHAB, V23, P171, DOI 10.1097/01.HTR.0000319935.99837.96
   Baratz R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0237-4
   Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x
   Barger SW, 2004, FRONT BIOSCI-LANDMRK, V9, P3286, DOI 10.2741/1481
   Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001
   Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616
   BORNSTEIN MB, 1946, J NEUROPHYSIOL, V9, P349
   Boyajyan A, 2015, RECENT ADV DNA GENE
   Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9
   Broadbent NJ, 2010, LEARN MEMORY, V17, P794, DOI 10.1101/lm.1650110
   Campbell N, 2009, CLIN INTERV AGING, V4, P225
   Chen J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099818
   Chuah YML, 2004, BRAIN COGNITION, V56, P304, DOI 10.1016/j.bandc.2004.08.002
   Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981
   Cox CD, 2008, J NEUROTRAUM, V25, P1355, DOI 10.1089/neu.2008.0671
   Crepaldi L, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003699
   Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009
   Dewar D, 1996, J NEUROTRAUM, V13, P181, DOI 10.1089/neu.1996.13.181
   Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019
   Dix SL, 1999, BEHAV BRAIN RES, V99, P191, DOI 10.1016/S0166-4328(98)00079-5
   Dixon CE, 1979, EXP NEUROL, V146, P479
   Djordjevic J, 2016, CURR ALZHEIMER RES
   Donat CK, 2008, BRAIN RES, V1246, P167, DOI 10.1016/j.brainres.2008.09.059
   Donat CK, 2007, BRAIN INJURY, V21, P1031, DOI 10.1080/02699050701630359
   Doyle KM, 2011, J CELL MOL MED, V15, P2025, DOI 10.1111/j.1582-4934.2011.01374.x
   Dumas JA, 2011, PHARMACOL BIOCHEM BE, V99, P254, DOI 10.1016/j.pbb.2011.02.022
   Edut S, 2011, PSYCHOPHARMACOLOGY, V214, P877, DOI 10.1007/s00213-010-2098-y
   Faul M. D, 2010, TRAUMATIC BRAIN INJU
   Finnie JW, 2013, INFLAMMOPHARMACOLOGY, V21, P309, DOI 10.1007/s10787-012-0164-2
   Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857
   Frankola KA, 2011, CNS NEUROL DISORD-DR, V10, P391
   Fujiki M, 2008, J CLIN NEUROSCI, V15, P791, DOI 10.1016/j.jocn.2007.07.002
   Gao X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024566
   Gardner RC, 2015, MOL CELL NEUROSCI, V66, P75, DOI 10.1016/j.mcn.2015.03.001
   Gardner RC, 2015, ANN NEUROL, V77, P987, DOI 10.1002/ana.24396
   Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668
   Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457
   Greig NH, 2000, ACTA NEUROL SCAND, V102, P74, DOI 10.1034/j.1600-0404.2000.00311.x
   Greig Nigel H., 2005, Current Alzheimer Research, V2, P483, DOI 10.2174/156720505774330564
   Hendrickx A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099467
   HEPPNER F, 1958, Monatsschr Unfallheilkd Versicherungsmed, V61, P257
   Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd
   HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405
   Hoffer ME, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054163
   Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972
   Holschneider DP, 2011, J NEUROTRAUM, V28, P1909, DOI 10.1089/neu.2011.1978
   IKARI H, 1995, NEUROREPORT, V6, P481, DOI 10.1097/00001756-199502000-00019
   Jafari S, 2013, MOVEMENT DISORD, V28, P1222, DOI 10.1002/mds.25458
   Jenkner FL, 1954, NERVENARZT, V25, P77
   Jessberger S, 2009, LEARN MEMORY, V16, P147, DOI 10.1101/lm.1172609
   Kadir A, 2008, ANN NEUROL, V63, P621, DOI 10.1002/ana.21345
   Kim SY, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-144
   Klein BD, 2004, EPILEPSY RES, V62, P13, DOI 10.1016/j.eplepsyres.2004.06.007
   Lahiri D. K., 2003, Journal of Alzheimer's Disease, V5, P81
   Lahiri DK, 2007, J PHARMACOL EXP THER, V320, P386, DOI 10.1124/jpet.106.112102
   LECHNER H, 1963, Wien Klin Wochenschr, V75, ppassim
   LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379
   Lilja AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058752
   Lilja AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054887
   Lusardi TA, 2009, CURR NEUROPHARMACOL, V7, P228, DOI 10.2174/157015909789152137
   LYETH BG, 1993, BRAIN RES, V617, P69, DOI 10.1016/0006-8993(93)90614-S
   LYETH BG, 1993, MOL CHEM NEUROPATHOL, V18, P247, DOI 10.1007/BF03160117
   LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A
   Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9
   Marutle A, 2007, P NATL ACAD SCI USA, V104, P12506, DOI 10.1073/pnas.0705346104
   McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731
   Messier C, 1997, NEUROBIOL LEARN MEM, V67, P172, DOI 10.1006/nlme.1996.3755
   METZ B, 1971, J NEUROSURG, V35, P523, DOI 10.3171/jns.1971.35.5.0523
   Mikkilineni S, 2012, PARKINSONS DIS-US, DOI 10.1155/2012/142372
   Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003
   Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128
   MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28
   Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295
   Murdoch I, 2002, J NEUROTRAUM, V19, P279, DOI 10.1089/08977150252807018
   Ostberg A, 2011, NEUROLOGY, V76, P1046, DOI 10.1212/WNL.0b013e318211c1c4
   Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282
   Parsons CG, 2013, NEUROTOX RES, V24, P358, DOI 10.1007/s12640-013-9398-z
   Perry E, 1999, TRENDS NEUROSCI, V22, P273, DOI 10.1016/S0166-2236(98)01361-7
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Pike BR, 1997, J NEUROTRAUM, V14, P897, DOI 10.1089/neu.1997.14.897
   Pilipovic K, 2011, NEUROCHEM RES, V36, P913, DOI 10.1007/s11064-011-0424-3
   Poole NA, 2008, BRAIN INJURY, V22, P519, DOI 10.1080/02699050802132495
   Rachmany L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079837
   Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Reale M, 2014, CURR ALZHEIMER RES, V11, P608, DOI 10.2174/1567205010666131212113218
   Rodriguez-Rodriguez A, 2014, CURR MED CHEM, V21, P1201, DOI 10.2174/0929867321666131217153310
   Rubovitch V, 2010, NEUROBIOL DIS, V38, P299, DOI 10.1016/j.nbd.2010.01.021
   RUGE D, 1954, J NEUROSURG, V11, P77, DOI 10.3171/jns.1954.11.1.0077
   Ruszkiewicz J, 2015, NEUROCHEM INT, V88, P66, DOI 10.1016/j.neuint.2014.12.012
   SACHS E, 1957, J NEUROSURG, V14, P22, DOI 10.3171/jns.1957.14.1.0022
   SAIJA A, 1988, BRAIN RES, V452, P303, DOI 10.1016/0006-8993(88)90034-0
   Salmond CH, 2005, J NEUROTRAUM, V22, P613, DOI 10.1089/neu.2005.22.613
   Sambamurti K, 2002, NEUROMOL MED, V1, P1, DOI 10.1385/NMM:1:1:1
   Saso L, 2014, CURR DRUG TARGETS, V15, P1177, DOI 10.2174/1389450115666141024113925
   Saykally JN, 2012, NEUROSCIENCE, V223, P305, DOI 10.1016/j.neuroscience.2012.07.070
   Scarr E, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00055
   Schliebs R, 2006, J NEURAL TRANSM, V113, P1625, DOI 10.1007/s00702-006-0579-2
   SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496
   Schwarzbold ML, 2010, J NEUROTRAUM, V27, P1883, DOI 10.1089/neu.2010.1318
   Scremin OU, 2012, J NEUROTRAUM, V29, P2457, DOI 10.1089/neu.2012.2465
   Shaw KE, 2013, J NEUROTRAUM, V30, P557, DOI 10.1089/neu.2012.2782
   Shaw KTY, 2001, P NATL ACAD SCI USA, V98, P7605, DOI 10.1073/pnas.131152998
   Squire LR, 2007, NAT REV NEUROSCI, V8, P872, DOI 10.1038/nrn2154
   Tashlykov V, 2009, J MOL NEUROSCI, V37, P16, DOI 10.1007/s12031-008-9094-2
   Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032
   TOWER DB, 1949, CAN J RES E, V27, P105, DOI 10.1139/cjr49e-016
   Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160
   Tweedie D, 2013, NEUROBIOL DIS, V54, P1, DOI 10.1016/j.nbd.2013.02.006
   Tweedie D, 2013, EXP NEUROL, V239, P170, DOI 10.1016/j.expneurol.2012.10.001
   Verbois SL, 2000, J NEUROTRAUM, V17, P1001, DOI 10.1089/neu.2000.17.1001
   Verbois SL, 2002, J NEUROTRAUM, V19, P1569, DOI 10.1089/089771502762300238
   Wang XD, 1999, NEUROSCI LETT, V272, P21, DOI 10.1016/S0304-3940(99)00567-4
   Wang XK, 2010, FRONT AGING NEUROSCI, V2, DOI 10.3389/fnagi.2010.00012
   WARD A, 1950, J NEUROSURG, V7, P398, DOI 10.3171/jns.1950.7.5.0398
   Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131
   Winblad B, 2010, J ALZHEIMERS DIS, V22, P1201, DOI 10.3233/JAD-2010-101311
   Winters BD, 2008, NEUROSCI BIOBEHAV R, V32, P1055, DOI 10.1016/j.neubiorev.2008.04.004
   Yang LY, 2015, EXP NEUROL, V269, P56, DOI 10.1016/j.expneurol.2015.03.015
   Yu QS, 2001, J MED CHEM, V44, P4062, DOI 10.1021/jm010080x
   Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4
   Zohar O, 2011, ACTA NEUROBIOL EXP, V71, P36
NR 127
TC 14
Z9 14
U1 2
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 2
PY 2016
VL 11
IS 6
AR e0156493
DI 10.1371/journal.pone.0156493
PG 26
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DN6XB
UT WOS:000377218700033
PM 27254111
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU De Souza, EO
   Lowery, RP
   Wilson, JM
   Sharp, MH
   Mobley, CB
   Fox, CD
   Lopez, HL
   Shields, KA
   Rauch, JT
   Healy, JC
   Thompson, RM
   Ormes, JA
   Joy, JM
   Roberts, MD
AF De Souza, Eduardo O.
   Lowery, Ryan P.
   Wilson, Jacob M.
   Sharp, Matthew H.
   Mobley, Christopher Brooks
   Fox, Carlton D.
   Lopez, Hector L.
   Shields, Kevin A.
   Rauch, Jacob T.
   Healy, James C.
   Thompson, Richard M.
   Ormes, Jacob A.
   Joy, Jordan M.
   Roberts, Michael D.
TI Effects of Arachidonic Acid Supplementation on Acute Anabolic Signaling
   and Chronic Functional Performance and Body Composition Adaptations
SO PLOS ONE
LA English
DT Article
ID SKELETAL-MUSCLE PHOSPHOLIPIDS; PROTEIN-SYNTHESIS; RESISTANCE EXERCISE;
   CELL-GROWTH; INSULIN SENSITIVITY; INCREASES; IBUPROFEN; CALCIUM; AMPK;
   PHOSPHORYLATION
AB Background
   The primary purpose of this investigation was to examine the effects of arachidonic acid (ARA) supplementation on functional performance and body composition in trained males. In addition, we performed a secondary study looking at molecular responses of ARA supplementation following an acute exercise bout in rodents.
   Methods
   Thirty strength-trained males (age: 20.4 +/- 2.1 yrs) were randomly divided into two groups: ARA or placebo (i.e. CTL). Then, both groups underwent an 8-week, 3-day per week, non-periodized training protocol. Quadriceps muscle thickness, whole-body composition scan (DEXA), muscle strength, and power were assessed at baseline and post-test. In the rodent model, male Wistar rats (similar to 250 g, similar to 8 weeks old) were pre-fed with either ARA or water (CTL) for 8 days and were fed the final dose of ARA prior to being acutely strength trained via electrical stimulation on unilateral plantar flexions. A mixed muscle sample was removed from the exercised and non-exercised leg 3 hours post-exercise.
   Results
   Lean body mass (2.9%, p<0.0005), upper-body strength (8.7%, p<0.0001), and peak power (12.7%, p<0.0001) increased only in the ARA group. For the animal trial, GSK-beta (Ser9) phosphorylation (p<0.001) independent of exercise and AMPK phosphorylation after exercise (p-AMPK less in ARA, p = 0.041) were different in ARA-fed versus CTL rats.
   Conclusions
   Our findings suggest that ARA supplementation can positively augment strength-training induced adaptations in resistance-trained males. However, chronic studies at the molecular level are required to further elucidate how ARA combined with strength training affect muscle adaptation.
C1 [De Souza, Eduardo O.; Lowery, Ryan P.; Wilson, Jacob M.; Sharp, Matthew H.; Shields, Kevin A.; Rauch, Jacob T.; Ormes, Jacob A.; Joy, Jordan M.] Univ Tampa, Dept Hlth Sci & Human Performance, Tampa, FL 33606 USA.
   [Mobley, Christopher Brooks; Fox, Carlton D.; Healy, James C.; Thompson, Richard M.; Roberts, Michael D.] Auburn Univ, Sch Kinesiol, Mol & Appl Sci Lab, Auburn, AL 36849 USA.
   [Lopez, Hector L.] Ctr Appl Hlth Sci, 4302 Allen Rd,STE 120, Stow, OH 44224 USA.
RP De Souza, EO (reprint author), Univ Tampa, Dept Hlth Sci & Human Performance, Tampa, FL 33606 USA.
EM desouza.eo@gmail.com
OI Mobley, Christopher Brooks/0000-0002-4045-9962
FU Molecular Nutrition TM; Molecular Nutrition; Molecular and Applied
   Sciences Laboratory (Auburn University); Human Performance Laboratory
   (University of Tampa)
FX This study was funded in part by Molecular Nutrition TM. The funder
   provided support by paying the reagents for the muscle samples analysis.
   Molecular Nutrition TM did not have any additional roles in the study
   conception, data collection and analysis, input on the decision to
   publish or mannuscript preparation. All the other costs other than
   aforementioned were supported by Molecular and Applied Sciences
   Laboratory (Auburn University) and Human Performance Laboratory
   (University of Tampa).; This research was funded in part by Molecular
   Nutrition.
CR Andersson A, 1998, AM J PHYSIOL-ENDOC M, V274, pE432
   Andersson A, 2000, AM J PHYSIOL-ENDOC M, V279, pE744
   Atherton PJ, 2005, FASEB J, V19, P786, DOI 10.1096/fj.04-2179fje
   Ayre KJ, 1996, J NUTR, V126, P653
   Baar K, 1999, AM J PHYSIOL-CELL PH, V276, pC120
   Bolster DR, 2002, J BIOL CHEM, V277, P23977, DOI 10.1074/jbc.C200171200
   Bondesen BA, 2004, AM J PHYSIOL-CELL PH, V287, pC475, DOI 10.1152/ajpcell.00088.2004
   BORKMAN M, 1993, NEW ENGL J MED, V328, P238, DOI 10.1056/NEJM199301283280404
   BRAMHAM CR, 1994, NEUROSCIENCE, V60, P737, DOI 10.1016/0306-4522(94)90501-0
   CURRIE WD, 1992, ENDOCRINOLOGY, V130, P1837, DOI 10.1210/en.130.4.1837
   Dreyer HC, 2006, J PHYSIOL-LONDON, V576, P613, DOI 10.1113/jphysiol.2006.113175
   Goodman CA, 2013, EXERC SPORT SCI REV, V41, P107, DOI 10.1097/JES.0b013e3182798a95
   Helge JW, 2001, J APPL PHYSIOL, V90, P670, DOI 10.1063/1.1380406
   Horsley V, 2003, J CELL BIOL, V161, P111, DOI 10.1083/jcb.200208085
   Jorgensen SB, 2006, J PHYSIOL-LONDON, V574, P17, DOI 10.1113/jphysiol.2006.109942
   Kelley DS, 1998, LIPIDS, V33, P125, DOI 10.1007/s11745-998-0187-9
   Krentz JR, 2008, APPL PHYSIOL NUTR ME, V33, P470, DOI 10.1139/H08-019
   KULMACZ RJ, 1994, J BIOL CHEM, V269, P5527
   Markworth JF, 2013, AM J PHYSIOL-CELL PH, V304, pC56, DOI 10.1152/ajpcell.00038.2012
   Markworth JF, 2011, AM J PHYSIOL-CELL PH, V300, pC671, DOI 10.1152/ajpcell.00549.2009
   Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329
   Novak ML, 2009, AM J PHYSIOL-REG I, V296, pR1132, DOI 10.1152/ajpregu.90874.2008
   PALMER RM, 1990, PROSTAG LEUKOTR ESS, V39, P95, DOI 10.1016/0952-3278(90)90017-F
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Roberts MD, 2007, J INT SOC SPORT NUTR, V4, DOI 10.1186/1550-2783-4-21
   ROUDBARAKI MM, 1995, AM J PHYSIOL-ENDOC M, V268, pE1215
   Smith HJ, 2004, BRIT J CANCER, V91, P408, DOI 10.1038/sj.bjc.6601981
   Soldati L, 2002, BIOCHEM BIOPH RES CO, V293, P974, DOI 10.1016/S0006-291X(02)00327-3
   Strokin M, 2004, INT J DEV NEUROSCI, V22, P551, DOI 10.1016/j.ijdevneu.2004.07.002
   Toedebusch RG, 2012, J INT SOC SPORT NUTR, V9, DOI 10.1186/1550-2783-9-24
   Trappe RA, 2002, AM J PHYSIOL-ENDOC M, V282, pE551, DOI 10.1152/ajpendo.00352.2001
   Trappe TA, 2001, J CLIN ENDOCR METAB, V86, P5067, DOI 10.1210/jc.86.10.5067
   Trappe TA, 2013, AM J PHYSIOL-REG I, V304, pR198, DOI 10.1152/ajpregu.00245.2012
   Trappe TA, 2011, AM J PHYSIOL-REG I, V300, pR655, DOI 10.1152/ajpregu.00611.2010
   VANDENBURGH HH, 1995, J CELL PHYSIOL, V163, P285, DOI 10.1002/jcp.1041630209
   VESSBY B, 1994, DIABETOLOGIA, V37, P1044, DOI 10.1007/s001250050215
   Welsh GI, 1998, FEBS LETT, V421, P125, DOI 10.1016/S0014-5793(97)01548-2
   WIEPZ GJ, 1993, PROSTAGLANDINS, V45, P167, DOI 10.1016/0090-6980(93)90032-3
   Zhou L, 2001, J LIPID RES, V42, P1521
NR 39
TC 5
Z9 5
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 16
PY 2016
VL 11
IS 5
AR e0155153
DI 10.1371/journal.pone.0155153
PG 20
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DM3XH
UT WOS:000376279500024
PM 27182886
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Simonaro, CM
   Tomatsu, S
   Sikora, T
   Kubaski, F
   Frohbergh, M
   Guevara, JM
   Wang, RY
   Vera, M
   Kang, JL
   Smith, LJ
   Schuchman, EH
   Haskins, ME
AF Simonaro, Calogera M.
   Tomatsu, Shunji
   Sikora, Tracy
   Kubaski, Francyne
   Frohbergh, Michael
   Guevara, Johana M.
   Wang, Raymond Y.
   Vera, Moin
   Kang, Jennifer L.
   Smith, Lachlan J.
   Schuchman, Edward H.
   Haskins, Mark E.
TI Pentosan Polysulfate: Oral Versus Subcutaneous Injection in
   Mucopolysaccharidosis Type I Dogs
SO PLOS ONE
LA English
DT Article
ID ENZYME REPLACEMENT THERAPY; CREUTZFELDT-JAKOB-DISEASE; CELL
   TRANSPLANTATION; HURLER-SYNDROME; MPS-I; STORAGE; OSTEOARTHRITIS;
   INVOLVEMENT; PROGRESSION; INFUSION
AB Background
   We previously demonstrated the therapeutic benefits of pentosan polysulfate (PPS) in a rat model of mucopolysaccharidosis (MPS) type VI. Reduction of inflammation, reduction of glycosaminoglycan (GAG) storage, and improvement in the skeletal phenotype were shown. Herein, we evaluate the long-term safety and therapeutic effects of PPS in a large animal model of a different MPS type, MPS I dogs. We focused on the arterial phenotype since this is one of the most consistent and clinically significant features of the model.
   Methodology/Principal Findings
   MPS I dogs were treated with daily oral or biweekly subcutaneous (subQ) PPS at a human equivalent dose of 1.6 mg/kg for 17 and 12 months, respectively. Safety parameters were assessed at 6 months and at the end of the study. Following treatment, cytokine and GAG levels were determined in fluids and tissues. Assessments of the aorta and carotid arteries also were performed. No drug-related increases in liver enzymes, coagulation factors, or other adverse effects were observed. Significantly reduced IL-8 and TNF-alpha were found in urine and cerebrospinal fluid (CSF). GAG reduction was observed in urine and tissues. Increases in the luminal openings and reduction of the intimal media thickening occurred in the carotids and aortas of PPS-treated animals, along with a reduction of storage vacuoles. These results were correlated with a reduction of GAG storage, reduction of clusterin 1 staining, and improved elastin integrity. No significant changes in the spines of the treated animals were observed.
   Conclusions
   PPS treatment led to reductions of pro-inflammatory cytokines and GAG storage in urine and tissues of MPS I dogs, which were most evident after subQ administration. SubQ administration also led to significant cytokine reductions in the CSF. Both treatment groups exhibited markedly reduced carotid and aortic inflammation, increased vessel integrity, and improved histopathology. We conclude that PPS may be a safe and useful therapy for MPS I, either as an adjunct or as a stand-alone treatment that reduces inflammation and GAG storage.
C1 [Simonaro, Calogera M.; Frohbergh, Michael; Guevara, Johana M.; Schuchman, Edward H.] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA.
   [Tomatsu, Shunji; Kubaski, Francyne] Nemours Alfred I duPont Hosp Children, Skeletal Dysplasia Lab, Wilmington, DE USA.
   [Sikora, Tracy; Haskins, Mark E.] Univ Penn, Sch Vet Med, Philadelphia, PA 19104 USA.
   [Guevara, Johana M.] Pontificia Univ Javeriana, Bogota, Colombia.
   [Wang, Raymond Y.; Vera, Moin] Childrens Hosp Orange Cty, Div Metab Disorders, Orange, CA 92668 USA.
   [Wang, Raymond Y.] Harbor UCLA Med Ctr, Dept Pediat, Div Med Genet, Torrance, CA 90509 USA.
   [Kang, Jennifer L.; Smith, Lachlan J.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA.
RP Simonaro, CM (reprint author), Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA.
EM calogera.simonaro@mssm.edu
RI Kubaski, Francyne/M-2410-2017; Wang, Raymond Y/H-8870-2019
OI Kubaski, Francyne/0000-0002-9330-0154; Wang, Raymond
   Y/0000-0001-6494-7613; GUEVARA, JOHANA/0000-0002-9467-4430
FU Ryan Foundation; MPS1 Research Foundation; National Center for Research
   Resources [1S10OD018523-01]; National Institute of Diabetes and
   Digestive and Kidney Diseases [5R21DK096182, 1R01DK087185, P40OD010939];
   National Institute of Arthritis and Musculoskeletal and Skin Diseases
   [1R01AR057397]
FX This study was funded by The Ryan Foundation, recipient: Calogera Maria
   Simonaro; MPS1 Research Foundation, recipient: Calogera Maria Simonaro;
   National Center for Research Resources, award number: 1S10OD018523-01;
   National Institute of Diabetes and Digestive and Kidney Diseases, award
   number: 5R21DK096182, recipient: Calogera Maria Simonaro; National
   Institute of Diabetes and Digestive and Kidney Diseases, award number:
   1R01DK087185, recipient: Calogera Maria Simonaro; National Institute of
   Diabetes and Digestive and Kidney Diseases, award number: P40OD010939,
   recipient: Mark E. Haskins; National Institute of Arthritis and
   Musculoskeletal and Skin Diseases, award number: 1R01AR057397,
   recipient: Mark E. Haskins.
CR Al-Sannaa NA, 2015, ORPHANET J RARE DIS, V10, DOI 10.1186/s13023-015-0344-4
   Aldenhoven M, 2015, BLOOD, V125, P2164, DOI 10.1182/blood-2014-11-608075
   Anger JT, 2011, INT UROGYNECOL J, V22, P395, DOI 10.1007/s00192-010-1252-8
   Budsberg SC, 2007, VET SURG, V36, P234, DOI 10.1111/j.1532-950X.2007.00256.x
   Chiaro JA, 2014, J BONE MINER RES, V29, P2610, DOI 10.1002/jbmr.2290
   Chiaro JA, 2013, BONE, V55, P78, DOI 10.1016/j.bone.2013.03.014
   Clarke LA, 2015, BEST PRACT RES CL EN, V29, P219, DOI 10.1016/j.beem.2014.08.010
   Clarke LA, 2011, RHEUMATOLOGY, V50, pV13, DOI 10.1093/rheumatology/ker395
   Dickson PI, 2010, MOL GENET METAB, V101, P115, DOI 10.1016/j.ymgme.2010.06.020
   DIEMER V, 1992, J BIOL CHEM, V267, P5257
   Eliyahu E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022447
   FRANCIS DJ, 1993, RHEUMATOL INT, V13, P61, DOI 10.1007/BF00307735
   Frohbergh M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100882
   Ghosh P, 2001, BEST PRACT RES CL RH, V15, P693, DOI 10.1053/berh.2001.0188
   Herrero LJ, 2015, J VIROL, V89, P8063, DOI 10.1128/JVI.00224-15
   Honda H, 2012, NEUROPATHOLOGY, V32, P124, DOI 10.1111/j.1440-1789.2011.01245.x
   Ishii T, 2001, ATHEROSCLEROSIS, V158, P215, DOI 10.1016/S0021-9150(01)00416-6
   Khalid O, 2016, PLOS ONE IN PRESS
   Kilgore KS, 1998, J PHARMACOL EXP THER, V285, P987
   Kramer CM, 2014, AUST VET J, V92, P482, DOI 10.1111/avj.12266
   Lampe C, 2013, RHEUM DIS CLIN N AM, V39, P431, DOI 10.1016/j.rdc.2013.03.004
   Langereis EJ, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-155
   Losonczy Hajna, 1993, Orvosi Hetilap, V134, P291
   Lyons JA, 2011, LAB INVEST, V91, P665, DOI 10.1038/labinvest.2011.7
   MENON KP, 1992, GENOMICS, V14, P763, DOI 10.1016/S0888-7543(05)80182-X
   Muenzer J, 2014, MOL GENET METAB, V111, P63, DOI 10.1016/j.ymgme.2013.11.015
   Neufeld EF, 2001, METABOLIC MOL BASES, P3421
   Nickel JC, 2015, J UROLOGY, V193, P857, DOI 10.1016/j.juro.2014.09.036
   Oguma T, 2007, ANAL BIOCHEM, V368, P79, DOI 10.1016/j.ab.2007.05.016
   Parry A, 2007, J NEUROL NEUROSUR PS, V78, P733, DOI 10.1136/jnnp.2006.104505
   Pfirrmann CWA, 2001, SPINE, V26, P1873, DOI 10.1097/00007632-200109010-00011
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Schuchman EH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054459
   SHULL RM, 1982, AM J PATHOL, V109, P244
   SHULL RM, 1984, AM J PATHOL, V114, P487
   SHULL RM, 1994, P NATL ACAD SCI USA, V91, P12937, DOI 10.1073/pnas.91.26.12937
   Sifuentes M, 2007, MOL GENET METAB, V90, P171, DOI 10.1016/j.ymgme.2006.08.007
   Simonaro CM, 2010, P NATL ACAD SCI USA, V107, P222, DOI 10.1073/pnas.0912937107
   Simonaro CM, 2001, LAB INVEST, V81, P1319, DOI 10.1038/labinvest.3780345
   Todd NV, 2005, J INFECTION, V50, P394, DOI 10.1016/j.jinf.2004.07.015
   Tomatsu S, 2015, DRUG DES DEV THER, V9, P1937, DOI 10.2147/DDDT.S68562
   Walter BA, 2015, SPINE, V40, P955, DOI 10.1097/BRS.0000000000000932
   Wu J, 2011, LAB INVEST, V91, P1459, DOI 10.1038/labinvest.2011.93
   Yano S, 2014, J INHERIT METAB DIS, V37, P255, DOI 10.1007/s10545-013-9642-y
NR 44
TC 8
Z9 8
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 11
PY 2016
VL 11
IS 4
AR e0153136
DI 10.1371/journal.pone.0153136
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DJ0KH
UT WOS:000373891000033
PM 27064989
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Chiu, HW
   Hua, KF
AF Chiu, Huan-Wen
   Hua, Kuo-Feng
TI Hepatoprotective Effect of Wheat-Based Solid-State Fermented Antrodia
   cinnamomea in Carbon Tetrachloride-Induced Liver Injury in Rat
SO PLOS ONE
LA English
DT Article
ID INFLAMMATORY MEDIATOR EXPRESSION; DEPRIVATION-INDUCED APOPTOSIS;
   NF-KAPPA-B; DEHYDROEBURICOIC ACID; SUBMERGED CULTURE; CAMPHORATA
   PROTECTS; LIPID-PEROXIDATION; HEPATIC-FIBROSIS; OXIDATIVE STRESS;
   FRUITING BODIES
AB Antrodia cinnamomea (A. cinnamomea) is an indigenous medical fungus in Taiwan and has multiple biological functions, including hepatoprotective and immune-modulatory effects. Currently, the commercially available A. cinnamomea are mainly liquid- and solid-state fermented A. cinnamomea. However, the hepatoprotective effect of solid-state fermented A. cinnamomea has never been reported. Here we evaluate the ability of air-dried, ground and non-extracted wheat-based solid-state fermented A. cinnamomea (WFAC) to protect against carbon tetrachloride (CCl4)-induced hepatic injury in vivo. The results showed that oral administration of WFAC dose dependently (180, 540 and 1080 mg/kg) ameliorated the increase in plasma aspartate aminotransferase and alanine aminotransferase levels caused by chronic repeated CCl4 intoxication in rats. WFAC significantly reduced the CCl4-induced increase in hepatic lipid peroxidation levels and hydroxyproline contents, as well as reducing the spleen weight and water content of the liver. WFAC also restored the hepatic soluble protein synthesis and plasma albumin concentration in CCl4-intoxicated rats, but it did not affect the activities of superoxide dismutase, catalase, or glutathione peroxidase. In addition, a hepatic morphological analysis showed that the hepatic fibrosis and necrosis induced by CCl4 were significantly ameliorated by WFAC. Furthermore, the body weights of control rats and WFAC-administered rats were not significantly different, and no adverse effects were observed in WFAC-administered rats. These results indicate that WFAC is a nontoxic hepatoprotective agent against chronic CCl4-induced hepatic injury.
C1 [Chiu, Huan-Wen; Hua, Kuo-Feng] Natl Ilan Univ, Dept Biotechnol & Anim Sci, Ilan, Taiwan.
   [Hua, Kuo-Feng] Triserv Gen Hosp, Natl Def Med Ctr, Dept Pathol, Taipei, Taiwan.
RP Hua, KF (reprint author), Natl Ilan Univ, Dept Biotechnol & Anim Sci, Ilan, Taiwan.; Hua, KF (reprint author), Triserv Gen Hosp, Natl Def Med Ctr, Dept Pathol, Taipei, Taiwan.
EM kuofenghua@gmail.com
FU Ministry of Science and Technology, Taiwan [102-2628-B-197-001-MY3,
   103-2923-B-197-001-MY3]
FX This work was supported by Ministry of Science and Technology, Taiwan
   (https://www.most.gov.tw/). Grant number: 102-2628-B-197-001-MY3 (KFH);
   103-2923-B-197-001-MY3 (KFH). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR AEBI H, 1984, METHOD ENZYMOL, V105, P121
   Ao ZH, 2009, J ETHNOPHARMACOL, V121, P194, DOI 10.1016/j.jep.2008.10.039
   Bataller R, 2005, J CLIN INVEST, V115, P209, DOI 10.1172/JCI200524282
   CAMPS J, 1992, CLIN SCI, V83, P695, DOI 10.1042/cs0830695
   Chen CC, 2006, J NAT PROD, V69, P689, DOI 10.1021/np0581263
   Chen XW, 2013, INT IMMUNOPHARMACOL, V17, P543, DOI 10.1016/j.intimp.2013.08.006
   Chen YC, 2011, ACTA PHARMACOL SIN, V32, P904, DOI 10.1038/aps.2011.36
   Deng JS, 2013, J AGR FOOD CHEM, V61, P5064, DOI 10.1021/jf303820k
   Dhiman RK, 2005, DIGEST DIS SCI, V50, P1807, DOI 10.1007/s10620-005-2942-9
   Du YC, 2012, PHYTOMEDICINE, V19, P788, DOI 10.1016/j.phymed.2012.03.014
   Garbuzenko DV, 2015, WORLD J GASTROENTERO, V21, P6117, DOI 10.3748/wjg.v21.i20.6117
   Geethangili M, 2011, EVID-BASED COMPL ALT, P1, DOI 10.1093/ecam/nep108
   Geng Y, 2016, HEPATOL RES, V46, pE15, DOI 10.1111/hepr.12516
   HALL PD, 1994, J GASTROEN HEPATOL, V9, P250, DOI 10.1111/j.1440-1746.1994.tb01719.x
   Han HF, 2006, CHEM PHARM BULL, V54, P496, DOI 10.1248/cpb.54.496
   Hsiao G, 2003, J AGR FOOD CHEM, V51, P3302, DOI 10.1021/jf021159t
   Hsieh YC, 2011, J AGR FOOD CHEM, V59, P10943, DOI 10.1021/jf202771d
   Huang CH, 2010, J AGR FOOD CHEM, V58, P3859, DOI 10.1021/jf100530c
   Huang GJ, 2014, J AGR FOOD CHEM, V62, P5321, DOI 10.1021/jf405113g
   Huang GJ, 2013, FOOD CHEM, V141, P3020, DOI 10.1016/j.foodchem.2013.03.061
   Huang YL, 2015, J AGR FOOD CHEM, V63, P4561, DOI 10.1021/jf5059304
   Jacobs BP, 2002, AM J MED, V113, P506, DOI 10.1016/S0002-9343(02)01244-5
   Kumar KJS, 2011, J ETHNOPHARMACOL, V136, P168, DOI 10.1016/j.jep.2011.04.030
   Kuo YH, 2015, J AGR FOOD CHEM, V63, P10140, DOI 10.1021/acs.jafc.5b04400
   Kuo YH, 2015, J AGR FOOD CHEM, V63, P2479, DOI 10.1021/acs.jafc.5b00073
   Lee IH, 2002, FEMS MICROBIOL LETT, V209, P63, DOI 10.1111/j.1574-6968.2002.tb11110.x
   Lee WT, 2015, FOOD CHEM TOXICOL, V78, P33, DOI 10.1016/j.fct.2015.01.012
   LETTERON P, 1990, BIOCHEM PHARMACOL, V39, P2027, DOI 10.1016/0006-2952(90)90625-U
   Liaw CC, 2013, J NAT PROD, V76, P489, DOI 10.1021/np300443p
   LIEN HM, 2011, EVID-BASED COMPL ALT, P1, DOI DOI 10.1093/ECAM/NEP020
   Lien HM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105286
   Liu DZ, 2007, BIOSCI BIOTECH BIOCH, V71, P23, DOI 10.1271/bbb.60268
   Liu KJ, 2010, IMMUNOLOGY, V129, P351, DOI 10.1111/j.1365-2567.2009.03175.x
   Liu Yen-Wenn, 2012, J Tradit Complement Med, V2, P284
   Lu MK, 2008, J AGR FOOD CHEM, V56, P865, DOI 10.1021/jf072828b
   Lu MK, 2006, LIFE SCI, V79, P252, DOI 10.1016/j.lfs.2005.12.042
   Lu ZM, 2007, J ETHNOPHARMACOL, V110, P160, DOI 10.1016/j.jep.2006.09.029
   Lu ZM, 2011, NAT PROD RES, V25, P684, DOI 10.1080/14786410802525487
   Luper S, 1998, Altern Med Rev, V3, P410
   MCCAY PB, 1984, J BIOL CHEM, V259, P2135
   Meng LM, 2012, NUTRITION, V28, P942, DOI 10.1016/j.nut.2012.01.006
   Muir AJ, 2015, CLIN THER
   Muriel P, 2005, BASIC CLIN PHARMACOL, V96, P375, DOI 10.1111/j.1742-7843.2005.pto_06.x
   Palmes D, 2004, BIOMATERIALS, V25, P1601, DOI 10.1016/S0142-9612(03)00508-8
   Park DK, 2013, J MED FOOD, V16, P681, DOI 10.1089/jmf.2012.2605
   Park DK, 2013, EVID-BASED COMPL ALT, DOI 10.1155/2013/914524
   PAULOVA J, 1990, VET MED-CZECH, V35, P629
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Song TY, 2003, J AGR FOOD CHEM, V51, P1571, DOI 10.1021/jf0209701
   Sturgill MG, 1997, CLIN CHEM, V43, P1512
   Toyoki Y, 1998, HEPATO-GASTROENTEROL, V45, P2261
   Tsai PY, 2012, ARTHRITIS RHEUM-US, V64, P232, DOI 10.1002/art.33328
   Tsai PY, 2011, FREE RADICAL BIO MED, V50, P1503, DOI 10.1016/j.freeradbiomed.2011.02.029
   Tsai TC, 2015, J ETHNOPHARMACOL, V159, P113, DOI 10.1016/j.jep.2014.11.015
   Vani MG, 2013, EVID-BASED COMPL ALT, DOI 10.1155/2013/296082
   Wang LC, 2013, APPL MICROBIOL BIOT, V97, P9955, DOI 10.1007/s00253-013-5214-1
   Wang SC, 2014, J AGR FOOD CHEM, V62, P5625, DOI 10.1021/jf4056924
   Wu MT, 2011, J AGR FOOD CHEM, V59, P4248, DOI 10.1021/jf104561h
   Wu SH, 1997, BOT BULL ACAD SINICA, V38, P273
   XIA EN, 1995, J NUTR, V125, P195
   Yang PY, 2013, AM J CHINESE MED, V41, P1169, DOI 10.1142/S0192415X13500791
   Yang SM, 2013, FREE RADICAL BIO MED, V61, P285, DOI 10.1016/j.freeradbiomed.2013.03.024
   Yeh CT, 2013, CARCINOGENESIS, V34, P2918, DOI 10.1093/carcin/bgt255
   Yeh CT, 2009, CANCER LETT, V285, P73, DOI 10.1016/j.canlet.2009.05.002
   Yue PYK, 2013, CHIN MED-UK, V8, DOI 10.1186/1749-8546-8-21
NR 65
TC 20
Z9 20
U1 0
U2 28
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 5
PY 2016
VL 11
IS 4
AR e0153087
DI 10.1371/journal.pone.0153087
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DI6HK
UT WOS:000373599600067
PM 27046059
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Zeng, XZ
   Wang, HL
   Xing, XC
   Wang, Q
   Li, WZ
AF Zeng, Xianzhang
   Wang, Honglei
   Xing, Xichun
   Wang, Qi
   Li, Wenzhi
TI Dexmedetomidine Protects against Transient Global Cerebral
   Ischemia/Reperfusion Induced Oxidative Stress and Inflammation in
   Diabetic Rats
SO PLOS ONE
LA English
DT Article
ID ISCHEMIA-REPERFUSION INJURY; NADPH OXIDASE; BRAIN-INJURY;
   ALPHA(2)-AGONIST DEXMEDETOMIDINE; GLUCOSE DEPRIVATION; RISK-FACTORS;
   CELL-DEATH; DAMAGE; RECEPTORS; STROKE
AB Background
   Transient global cerebral ischemia/reperfusion (I/R) is a major perioperative complication, and diabetes increases the response of oxidative stress and inflammation induced by I/R. The objective of this study was to determine the protective effect of dexmedetomidine against transient global cerebral ischemia/reperfusion induced oxidative stress and inflammation in diabetic rats.
   Methods
   Sixty-four rats were assigned into four experimental groups: normoglycemia, normoglycemia + dexmedetomidine, hyperglycemia, and hyperglycemia + dexmedetomidine and all subsequent neurological examinations were evaluated by a blinded observer. Damage to the brain was histologically assessed using the TUNEL staining method while western blotting was used to investigate changes in the expression levels of apoptosis-related proteins as well as the microglia marker, ionized calcium-binding adapter molecule 1 (Iba1). Water content in the brain was also analyzed. In addition, hippocampal concentrations of malondialdehyde (MDA) and Nox2 (a member of the Nox family of NADPH oxidases), and the activity of superoxide dismutase and catalase were analyzed. Finally, changes in serum concentrations of tumor necrosis factor-alpha (TNF-alpha) and interleukin (IL)-6 were detected.
   Results
   Results showed that diabetes increased brain water content, the number of apoptotic neurons, early neurological deficit scores, oxidative stress (MDA and Nox2) and inflammation (pro-inflammatory cytokines including TNF-alpha and IL-6) levels following transient global I/R injury, but that these symptoms were attenuated following administration of dexmedetomidine.
   Conclusions
   These findings suggest that dexmedetomidine can significantly alleviate damage resulting from I/R, and this mechanism may be related to a reduction in both oxidative stress and inflammation which is normally associated with I/R.
C1 [Zeng, Xianzhang; Wang, Honglei; Xing, Xichun; Wang, Qi; Li, Wenzhi] Harbin Med Univ, Dept Anaesthesiol, Affiliated Hosp 2, Harbin, Heilongjiang, Peoples R China.
RP Li, WZ (reprint author), Harbin Med Univ, Dept Anaesthesiol, Affiliated Hosp 2, Harbin, Heilongjiang, Peoples R China.
EM wenzhili9@126.com
FU National Natural Science Foundation of China [81171076]
FX The study was funded by the National Natural Science Foundation of China
   (NO. 81171076). The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Abramov AY, 2007, J NEUROSCI, V27, P1129, DOI 10.1523/JNEUROSCI.4468-06.2007
   Arslan M, 2014, BRATISL MED J, V115, P494, DOI 10.4149/BLL_2014_096
   Bitar MS, 1997, PHARMACOL BIOCHEM BE, V56, P15, DOI 10.1016/S0091-3057(96)00129-3
   Bosca L, 1999, CELL SIGNAL, V11, P239, DOI 10.1016/S0898-6568(98)00064-3
   Brambrink AM, 2006, ANESTHESIOLOGY, V104, P1208, DOI 10.1097/00000542-200606000-00016
   Brambrink AM, 2000, J CEREBR BLOOD F MET, V20, P1425, DOI 10.1097/00004647-200010000-00004
   Chen H, 2011, NEUROBIOL DIS, V42, P341, DOI 10.1016/j.nbd.2011.01.027
   Chen H, 2009, J CEREBR BLOOD F MET, V29, P1262, DOI 10.1038/jcbfm.2009.47
   Crack PJ, 2005, FREE RADICAL BIO MED, V38, P1433, DOI 10.1016/j.freeradbiomed.2005.01.019
   Dahmani S, 2005, ANESTHESIOLOGY, V103, P969, DOI 10.1097/00000542-200511000-00011
   Dahmani S, 2008, ANESTHESIOLOGY, V108, P457, DOI 10.1097/ALN.0b013e318164ca81
   Dahmani S, 2010, ANESTHESIOLOGY, V112, P373, DOI 10.1097/ALN.0b013e3181ca6982
   Dohi K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-41
   Engelhard K, 2002, ANESTHESIOLOGY, V96, P450, DOI 10.1097/00000542-200202000-00034
   Engelhard K, 2003, ANESTH ANALG, V96, P524, DOI 10.1213/01.ANE.0000043381.14137.CD
   Eser O, 2008, BRAIN RES, V1218, P250, DOI 10.1016/j.brainres.2008.04.045
   Feigin VL, 2005, LANCET, V365, P2160, DOI 10.1016/S0140-6736(05)66755-4
   Figiel I, 2007, BRAIN RES, V1131, P17, DOI 10.1016/j.brainres.2006.10.095
   Flaherty JH, 2007, J AM GERIATR SOC, V55, P1295, DOI 10.1111/j.1532-5415.2007.01273.x
   Furie KL, 2011, STROKE, V42, P227, DOI 10.1161/STR.0b013e3181f7d043
   GUO TZ, 1991, PHARMACOL BIOCHEM BE, V39, P383
   Gursoy-Ozdemir Y, 2004, STROKE, V35, P1449, DOI 10.1161/01.STR.0000126044.83777.f4
   GUTTERIDGE JMC, 1995, CLIN CHEM, V41, P1819
   Han Z, 2009, NEUROL RES, V31, P390, DOI 10.1179/174313209X444116
   Hanci V, 2010, UROL INT, V84, P105, DOI 10.1159/000273476
   HOFFMAN WE, 1991, ANESTHESIOLOGY, V75, P328, DOI 10.1097/00000542-199108000-00022
   Huang R, 2000, J CEREBR BLOOD F MET, V20, P895, DOI 10.1097/00004647-200006000-00001
   Kahles T, 2007, STROKE, V38, P3000, DOI 10.1161/STROKEAHA.107.489765
   Kip G, 2015, LIBYAN J MED, V10, DOI 10.3402/ljm.v10.27828
   Kocoglu H, 2009, RENAL FAILURE, V31, P70, DOI 10.1080/08860220802546487
   Kosenko E, 1999, FREE RADICAL BIO MED, V26, P1369, DOI 10.1016/S0891-5849(98)00339-6
   Kowluru A, 2014, BIOCHEM PHARMACOL, V88, P275, DOI 10.1016/j.bcp.2014.01.017
   Li LX, 2011, BRAIN RES BULL, V86, P390, DOI 10.1016/j.brainresbull.2011.09.005
   Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1
   LI PA, 1995, NEUROBIOL DIS, V2, P97, DOI 10.1006/nbdi.1995.0010
   Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9
   MAIER C, 1993, ANESTHESIOLOGY, V79, P306, DOI 10.1097/00000542-199308000-00016
   MCCALL AL, 1992, DIABETES, V41, P557, DOI 10.2337/diabetes.41.5.557
   Milhaud D, 2000, NEUROPHARMACOLOGY, V39, P2244, DOI 10.1016/S0028-3908(00)00085-X
   MOORADIAN AD, 1988, ENDOCR REV, V9, P346, DOI 10.1210/edrv-9-3-346
   Moreira PI, 2004, J NEUROENDOCRINOL, V16, P32, DOI 10.1111/j.1365-2826.2004.01107.x
   Muranyi M, 2006, DIABETES, V55, P349, DOI 10.2337/diabetes.55.02.06.db05-0654
   Muranyi M, 2003, DIABETES, V52, P481, DOI 10.2337/diabetes.52.2.481
   Okada H, 2007, RESUSCITATION, V74, P538, DOI 10.1016/j.resuscitation.2007.01.032
   Rains JL, 2011, FREE RADICAL BIO MED, V50, P567, DOI 10.1016/j.freeradbiomed.2010.12.006
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Reyes RC, 2012, J NEUROSCI, V32, P12973, DOI 10.1523/JNEUROSCI.1597-12.2012
   RYAN CM, 1988, DIABETES CARE, V11, P86, DOI 10.2337/diacare.11.1.86
   Shi HL, 2007, FRONT BIOSCI-LANDMRK, V12, P1318, DOI 10.2741/2150
   SMITH ML, 1984, ACTA NEUROL SCAND, V69, P385, DOI 10.1111/j.1600-0404.1984.tb07822.x
   Straub RH, 1997, J NEUROCHEM, V68, P1633
   Suzuki T, 2008, J SURG RES, V149, P69, DOI 10.1016/j.jss.2008.01.020
   Tsuruta R, 2010, BRAIN RES, V1309, P155, DOI 10.1016/j.brainres.2009.10.065
   Wong CHY, 2008, CURR MED CHEM, V15, P1
   Xiang FL, 2010, DIABETES, V59, P2603, DOI 10.2337/db09-1562
   Zhang FJ, 2012, J PHARM PHARMACOL, V64, P120, DOI 10.1111/j.2042-7158.2011.01382.x
   ZHANG PL, 1991, DIABETES, V40, P338, DOI 10.2337/diabetes.40.3.338
   Zhang XY, 2012, ANESTHESIOLOGY, V116, P1035, DOI 10.1097/ALN.0b013e3182503964
   Zhu YY, 2006, NEUROSCI LETT, V393, P122, DOI 10.1016/j.neulet.2005.08.072
NR 59
TC 35
Z9 40
U1 0
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 16
PY 2016
VL 11
IS 3
AR e0151620
DI 10.1371/journal.pone.0151620
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DH1WF
UT WOS:000372574900105
PM 26982373
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Fotschki, B
   Juskiewicz, J
   Jurgonski, A
   Kolodziejczyk, K
   Milala, J
   Kosmala, M
   Zdunczyk, Z
AF Fotschki, Bartosz
   Juskiewicz, Jerzy
   Jurgonski, Adam
   Kolodziejczyk, Krzysztof
   Milala, Joanna
   Kosmala, Monika
   Zdunczyk, Zenon
TI Anthocyanins in Strawberry Polyphenolic Extract Enhance the Beneficial
   Effects of Diets with Fructooligosaccharides in the Rat Cecal
   Environment
SO PLOS ONE
LA English
DT Article
ID CHAIN FATTY-ACIDS; ELLAGIC ACID; PHENOLIC-COMPOUNDS; HUMAN HEALTH;
   ELLAGITANNINS; PROANTHOCYANIDINS; BIOAVAILABILITY; METABOLITES;
   CONSUMPTION; COMPONENTS
AB The administration of fructooligosaccharides (FOS) beneficially modulates gastrointestinal functions and may enhance the metabolism of polyphenols. However, different polyphenolic components in the diet may have different influences on the activities of the digestive enzymes and microbiota in the gastrointestinal tract. Therefore, a 4-week study of fortyeight male Wistar rats was conducted to investigate the physiological response of the rat cecal environment to diets without and with FOS that contained two different strawberry polyphenolic extracts, specifically EP (polyphenolic profile 60, 35, 5, and 0% ellagitannins, proanthocyanidins, flavonols, anthocyanins, respectively) and EPA (polyphenolic profile: 50, 35, 6, and 9%, respectively). When combined with FOS, both extracts beneficially enhanced the acidification of the cecal digesta (P <= 0.05 vs the groups without extracts), but the dietary combination of EPA and FOS elicited the greatest reduction in putrefactive short-chain fatty acid production and the lowest fecal beta-glucuronidase activity in the cecum (P <= 0.05 vs group EP). Moreover, the addition of dietary FOS elevated the metabolism of the examined strawberry extracts in the cecum and thereby increased the concentrations of the metabolites in the cecal digesta and urine (P <= 0.05 vs the group with cellulose). Overall, both strawberry extracts modulated the effects of FOS in the gastrointestinal tract; however, the combination with EPA extract that contained anthocyanins exhibited greater beneficial effects in the lower gut environment than the EP extract.
C1 [Fotschki, Bartosz; Juskiewicz, Jerzy; Jurgonski, Adam; Zdunczyk, Zenon] Polish Acad Sci, Inst Anim Reprod & Food Res, Div Food Sci, Olsztyn, Poland.
   [Kolodziejczyk, Krzysztof; Milala, Joanna; Kosmala, Monika] Lodz Univ Technol, Inst Food Technol & Anal, Lodz, Poland.
RP Fotschki, B (reprint author), Polish Acad Sci, Inst Anim Reprod & Food Res, Div Food Sci, Olsztyn, Poland.
EM b.fotschki@pan.olsztyn.pl
RI FOTSCHKI, Bartosz/Q-4275-2019; Juskiewicz, Jerzy/H-7193-2017; Jurgonski,
   Adam/A-5864-2009; Zdunczyk, Zenon/H-7272-2017; Kolodziejczyk,
   Krzysztof/M-2951-2018; Fotschki, Bartosz/H-7172-2017
OI FOTSCHKI, Bartosz/0000-0002-9727-7481; Juskiewicz,
   Jerzy/0000-0003-0068-5970; Jurgonski, Adam/0000-0003-3524-3259;
   Zdunczyk, Zenon/0000-0002-0640-7552; Kolodziejczyk,
   Krzysztof/0000-0003-3817-5140; Fotschki, Bartosz/0000-0002-9727-7481;
   Milala, Joanna/0000-0002-4732-1907; Kosmala, Monika/0000-0002-9018-3028
FU National Science Centre of Poland [DEC-2012/05/B/NZ9/03402]
FX This study was financially supported by the National Science Centre of
   Poland (Grant DEC-2012/05/B/NZ9/03402),
   https://www.ncn.gov.pl/?language=en. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Aaby K, 2012, FOOD CHEM, V132, P86, DOI 10.1016/j.foodchem.2011.10.037
   Asgar MA, 2013, INT J FOOD PROP, V16, P91, DOI 10.1080/10942912.2011.595864
   Aviram M, 2004, CLIN NUTR, V23, P423, DOI 10.1016/j.clnu.2003.10.002
   Beecher GR, 2004, PHARM BIOL, V42, P2, DOI 10.1080/13880200490893474
   Blade C, 2010, MOL NUTR FOOD RES, V54, P37, DOI 10.1002/mnfr.200900476
   Clifford MN, 2000, J SCI FOOD AGR, V80, P1118, DOI 10.1002/(SICI)1097-0010(20000515)80:7<1118::AID-JSFA570>3.0.CO;2-9
   DANIEL EM, 1991, J NAT PROD, V54, P946, DOI 10.1021/np50076a004
   Duda-Chodak A, 2015, EUR J NUTR, V54, P325, DOI 10.1007/s00394-015-0852-y
   Duncan SH, 2002, APPL ENVIRON MICROB, V68, P5186, DOI 10.1128/AEM.68.10.5186-5190.2002
   Espin J. C., 2013, EVID-BASED COMPL ALT, V2013, P1
   Fernandes I, 2014, J FUNCT FOODS, V7, P54, DOI 10.1016/j.jff.2013.05.010
   Fotschki B, 2014, POL J FOOD NUTR SCI, V64, P193, DOI 10.2478/pjfns-2013-0001
   Fotschki B, 2014, J AGR FOOD CHEM, V62, P5871, DOI 10.1021/jf405612a
   Gimenez-Bastida JA, 2012, MOL NUTR FOOD RES, V56, P784, DOI 10.1002/mnfr.201100677
   Horwitz W., 2005, OFFICIAL METHODS ANA
   Jakobsdottir G, 2013, J NUTR METAB, DOI 10.1155/2013/202534
   Jurgonski A, 2008, J ANIM FEED SCI, V17, P88, DOI 10.22358/jafs/66473/2008
   Jurgonski A, 2013, NUTRITION, V29, P898, DOI 10.1016/j.nut.2012.11.006
   Juskiewicz J, 2011, BRIT J NUTR, V105, P710, DOI 10.1017/S0007114510004344
   Juskiewicz J, 2011, NUTRITION, V27, P351, DOI 10.1016/j.nut.2010.02.002
   Kennedy JA, 2001, J AGR FOOD CHEM, V49, P1740, DOI 10.1021/jf001030o
   Klewicka E, 2009, EUR FOOD RES TECHNOL, V229, P153, DOI 10.1007/s00217-009-1036-x
   Kosmala M, 2015, J AGR FOOD CHEM, V63, P2989, DOI 10.1021/acs.jafc.5b00648
   Kosmala M, 2014, EUR J NUTR, V53, P521, DOI 10.1007/s00394-013-0557-z
   Landete JM, 2011, FOOD RES INT, V44, P1150, DOI 10.1016/j.foodres.2011.04.027
   Larrosa M, 2006, J NUTR BIOCHEM, V17, P611, DOI 10.1016/j.nutbio.2005.09.004
   Lhoste EF, 2001, J SCI FOOD AGR, V81, P1397, DOI 10.1002/jsfa.957
   McDougall GJ, 2005, J AGR FOOD CHEM, V53, P2760, DOI 10.1021/jf0489926
   Nile SH, 2014, NUTRITION, V30, P134, DOI 10.1016/j.nut.2013.04.007
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Reeves PG, 1997, J NUTR, V127, pS838
   Roberfroid MB, 2005, BRIT J NUTR, V93, pS13, DOI 10.1079/BJN20041350
   Seeram NP, 2004, CLIN CHIM ACTA, V348, P63, DOI 10.1016/j.cccn.2004.04.029
   Sojka M, 2013, EUR FOOD RES TECHNOL, V237, P995, DOI 10.1007/s00217-013-2070-2
   Topping DL, 2001, PHYSIOL REV, V81, P1031
   VISEK WJ, 1978, AM J CLIN NUTR, V31, pS216, DOI 10.1093/ajcn/31.10.S216
   Zdunczyk Z, 2006, NUTRITION, V22, P898, DOI 10.1016/j.nut.2006.05.010
NR 37
TC 14
Z9 14
U1 2
U2 34
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 16
PY 2016
VL 11
IS 2
AR e0149081
DI 10.1371/journal.pone.0149081
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DF3BP
UT WOS:000371219000044
PM 26882456
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Incio, J
   Suboj, P
   Chin, SM
   Vardam-Kaur, T
   Liu, H
   Hato, T
   Babykutty, S
   Chen, I
   Deshpande, V
   Jain, RK
   Fukumura, D
AF Incio, Joao
   Suboj, Priya
   Chin, Shan M.
   Vardam-Kaur, Trupti
   Liu, Hao
   Hato, Tai
   Babykutty, Suboj
   Chen, Ivy
   Deshpande, Vikram
   Jain, Rakesh K.
   Fukumura, Dai
TI Metformin Reduces Desmoplasia in Pancreatic Cancer by Reprogramming
   Stellate Cells and Tumor-Associated Macrophages
SO PLOS ONE
LA English
DT Article
ID HIGH-ENERGY DIET; ANTIDIABETIC DRUG METFORMIN; SP TRANSCRIPTION-FACTORS;
   IN-VIVO; DUCTAL ADENOCARCINOMA; MESENCHYMAL TRANSITION; CHRONIC
   INFLAMMATION; INSULIN-RESISTANCE; DIABETES-MELLITUS; CARCINOMA GROWTH
AB Background
   Pancreatic ductal adenocarcinoma (PDAC) is a highly desmoplastic tumor with a dismal prognosis for most patients. Fibrosis and inflammation are hallmarks of tumor desmoplasia. We have previously demonstrated that preventing the activation of pancreatic stellate cells (PSCs) and alleviating desmoplasia are beneficial strategies in treating PDAC. Metformin is a widely used glucose-lowering drug. It is also frequently prescribed to diabetic pancreatic cancer patients and has been shown to associate with a better outcome. However, the underlying mechanisms of this benefit remain unclear. Metformin has been found to modulate the activity of stellate cells in other disease settings. In this study, we examine the effect of metformin on PSC activity, fibrosis and inflammation in PDACs.
   Methods/Results
   In overweight, diabetic PDAC patients and pre-clinical mouse models, treatment with metformin reduced levels of tumor extracellular matrix (ECM) components, in particular hyaluronan (HA). In vitro, we found that metformin reduced TGF-beta signaling and the production of HA and collagen-I in cultured PSCs. Furthermore, we found that metformin alleviates tumor inflammation by reducing the expression of inflammatory cytokines including IL-1 beta as well as infiltration and M2 polarization of tumor-associated macrophages (TAMs) in vitro and in vivo. These effects on macrophages in vitro appear to be associated with a modulation of the AMPK/STAT3 pathway by metformin. Finally, we found in our preclinical models that the alleviation of desmoplasia by metformin was associated with a reduction in ECM remodeling, epithelial-to-mesenchymal transition (EMT) and ultimately systemic metastasis.
   Conclusion
   Metformin alleviates the fibro-inflammatory microenvironment in obese/diabetic individuals with pancreatic cancer by reprogramming PSCs and TAMs, which correlates with reduced disease progression. Metformin should be tested/explored as part of the treatment strategy in overweight diabetic PDAC patients.
C1 [Incio, Joao; Suboj, Priya; Chin, Shan M.; Vardam-Kaur, Trupti; Liu, Hao; Hato, Tai; Babykutty, Suboj; Chen, Ivy; Jain, Rakesh K.; Fukumura, Dai] Harvard Univ, Sch Med, Massachusetts Gen Hosp,Res Inst, Edwin L Steele Labs,Dept Radiat Oncol, Boston, MA 02115 USA.
   [Incio, Joao] Hosp Sao Joao, Dept Internal Med, Oporto, Portugal.
   [Incio, Joao] Univ Porto, Fac Med, Inst Innovat & Res Heath,I3S, Metab Nutr & Endocrinol Grp,Dept Biochem, P-4100 Oporto, Portugal.
   [Suboj, Priya] St Xaviers Coll, Dept Bot & Biotechnol, Trivandrum, Kerala, India.
   [Liu, Hao] Harvard Univ, Sch Med, Program Biol & Biomed Sci, Boston, MA 02115 USA.
   [Hato, Tai] Keio Univ, Sch Med, Dept Surg, Tokyo 160, Japan.
   [Babykutty, Suboj] Mar Ivanios Coll, Dept Zool, Trivandrum, Kerala, India.
   [Chen, Ivy] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA.
   [Deshpande, Vikram] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02115 USA.
RP Jain, RK (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp,Res Inst, Edwin L Steele Labs,Dept Radiat Oncol, Boston, MA 02115 USA.
EM jain@steele.mgh.harvard.edu; dai@steele.mgh.harvard.edu
RI Chen, Ivy/N-8231-2019; Jain, Rakesh/I-1384-2017
OI Jain, Rakesh/0000-0001-7571-3548
FU National Institutes of Health [R35-CA197743, CA80124, CA85140, CA96915,
   CA115767, CA126642]; Lustgarten Foundation; Foundation for Science and
   Technology (Portugal)
FX This work was supported by National Institutes of Health
   (http://nih.gov/; R35-CA197743, CA80124, CA85140, CA96915, CA115767, and
   CA126642 to RKJ and DF), the Lustgarten Foundation
   (http://www.lustgarten.org/; research grant to RKJ) and the Foundation
   for Science and Technology (http://www.fct.pt/; Portugal, POPH/FSE
   funding program, fellowship and research grant to JI). The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Algire C, 2011, ONCOGENE, V30, P1174, DOI 10.1038/onc.2010.483
   Algire C, 2008, ENDOCR-RELAT CANCER, V15, P833, DOI 10.1677/ERC-08-0038
   Algire C, 2010, ENDOCR-RELAT CANCER, V17, P351, DOI 10.1677/ERC-09-0252
   American Cancer Society, 2015, CANC FACTS FIG
   Bao B, 2011, BBA-REV CANCER, V1815, P135, DOI 10.1016/j.bbcan.2010.11.003
   Bardeesy N, 2006, P NATL ACAD SCI USA, V103, P5947, DOI 10.1073/pnas.0601273103
   Bartosch-Harlid A, 2010, PANCREATOLOGY, V10, P423, DOI 10.1159/000264676
   Calle EE, 2004, ONCOGENE, V23, P6365, DOI 10.1038/sj.onc.1207751
   Chauhan VP, 2014, CANCER CELL, V26, P14, DOI 10.1016/j.ccr.2014.06.003
   Chauhan VP, 2013, NAT MATER, V12, P958, DOI 10.1038/nmat3792
   Chauhan VP, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3516
   Chen SJ, 2015, CURR ONCOL, V22, pE11, DOI 10.3747/co.22.2150
   Choi YK, 2013, MOL CELLS, V36, P279, DOI 10.1007/s10059-013-0169-8
   CHOW WH, 1995, J NATL CANCER I, V87, P930, DOI 10.1093/jnci/87.12.930
   Cifarelli V, 2015, DIABETES, V64, P1632, DOI 10.2337/db14-1132
   Cirri P, 2011, AM J CANCER RES, V1, P482
   Costa Carla, 2007, Angiogenesis, V10, P149, DOI 10.1007/s10456-007-9074-0
   Cufi S, 2010, CELL CYCLE, V9, P4461, DOI 10.4161/cc.9.22.14048
   Franco CCD, 2014, CELL PHYSIOL BIOCHEM, V34, P1920, DOI 10.1159/000366390
   Diop-Frimpong B, 2011, P NATL ACAD SCI USA, V108, P2909, DOI 10.1073/pnas.1018892108
   Dowling RJO, 2012, J MOL ENDOCRINOL, V48, pR31, DOI 10.1530/JME-12-0007
   Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041
   Evans JMM, 2005, BMJ-BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7
   Feig C, 2012, CLIN CANCER RES, V18, P4266, DOI 10.1158/1078-0432.CCR-11-3114
   Foretz M, 2014, CELL METAB, V20, P953, DOI 10.1016/j.cmet.2014.09.018
   Fukumura D, 2003, CIRC RES, V93, pE88, DOI 10.1161/01.RES.0000099243.20096.FA
   Furstenberger G, 2002, LANCET ONCOL, V3, P298, DOI 10.1016/S1470-2045(02)00731-3
   Genkinger JM, 2011, INT J CANCER, V129, P1708, DOI 10.1002/ijc.25794
   Gilkes DM, 2014, NAT REV CANCER, V14, P430, DOI 10.1038/nrc3726
   Godsland IF, 2010, CLIN SCI, V118, P315, DOI 10.1042/CS20090399
   Gong J, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00426
   Goodwin PJ, 2015, ANNU REV MED, V66, P281, DOI 10.1146/annurev-med-051613-012328
   Goodwin PJ, 2011, BREAST, V20, pS31, DOI 10.1016/S0960-9776(11)70291-0
   Gutschalk CM, 2013, CANCER MED-US, V2, P117, DOI 10.1002/cam4.20
   Hirsch HA, 2013, P NATL ACAD SCI USA, V110, P972, DOI 10.1073/pnas.1221055110
   Hori M, 2014, CLIN TRANSL GASTROEN, V5, DOI 10.1038/ctg.2014.5
   Hursting SD, 2012, ANN NY ACAD SCI, V1271, P82, DOI 10.1111/j.1749-6632.2012.06737.x
   Ijichi H, 2012, ONCOIMMUNOLOGY, V1, DOI 10.4161/onci.19402
   Incio J, 2013, TUMOR ANGIOGENESIS REGULATORS, P411
   Inman KS, 2014, WORLD J GASTROENTERO, V20, P11160, DOI 10.3748/wjg.v20.i32.11160
   Isoda K, 2006, ARTERIOSCL THROM VAS, V26, P611, DOI 10.1161/01.ATV.0000201938.78044.75
   Jain RK, 2014, ANNU REV BIOMED ENG, V16, P321, DOI 10.1146/annurev-bioeng-071813-105259
   Jain RK, 2014, SCI AM, V310, P46, DOI 10.1038/scientificamerican0214-46
   Jain RK, 2013, J CLIN ONCOL, V31, P2205, DOI 10.1200/JCO.2012.46.3653
   Joost HG, 2014, DIABETES VASC DIS RE, V11, P390, DOI 10.1177/1479164114550813
   Karnevi E, 2014, IMMUNOL CELL BIOL, V92, P543, DOI 10.1038/icb.2014.22
   Kasenda B, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-728
   Kisfalvi K, 2013, PANCREAS, V42, P781, DOI 10.1097/MPA.0b013e31827aec40
   Kordes S, 2015, LANCET ONCOL, V16, P839, DOI 10.1016/S1470-2045(15)00027-3
   Leone A, 2014, CANCER TREAT RES, V159, P355, DOI 10.1007/978-3-642-38007-5_21
   Li DH, 2012, MOL CARCINOGEN, V51, P64, DOI 10.1002/mc.20771
   Li DH, 2009, GASTROENTEROLOGY, V137, P482, DOI 10.1053/j.gastro.2009.04.013
   Li DH, 2009, JAMA-J AM MED ASSOC, V301, P2553, DOI 10.1001/jama.2009.886
   Li HL, 2014, AM J PHYSIOL-ENDOC M, V306, pE197, DOI 10.1152/ajpendo.00202.2013
   Liu CY, 2013, LAB INVEST, V93, P844, DOI 10.1038/labinvest.2013.69
   Liu J, 2010, J HUAZHONG U SCI-MED, V30, P222, DOI 10.1007/s11596-010-0218-x
   Liu J, 2013, UROL ONCOL-SEMIN ORI, V31, P264, DOI 10.1016/j.urolonc.2011.01.003
   Mace TA, 2013, CANCER RES, V73, P3007, DOI 10.1158/0008-5472.CAN-12-4601
   Martin TL, 2006, J BIOL CHEM, V281, P18933, DOI 10.1074/jbc.M512831200
   Martinez-Outschoorn UE, 2010, CELL CYCLE, V9, P3256, DOI 10.4161/cc.9.16.12553
   Mashhedi H, 2011, CELL CYCLE, V10, P2770, DOI 10.4161/cc.10.16.16219
   Mathsyaraja H, 2015, ONCOGENE, V34, P3651, DOI 10.1038/onc.2014.294
   McCarroll JA, 2014, FRONT PHYSIOL, V5, DOI [10.3389/fphys.2014.00141, 10.3389/fphys.2014.00002]
   MCCARTHY M, 2014, BMJ-BRIT MED J, V348, P23592, DOI DOI 10.1136/BMJ.G3962
   Metlakunta AS, 2008, ENDOCRINOLOGY, V149, P1121, DOI 10.1210/en.2007-1307
   Mohammed A, 2013, TRANSL ONCOL, V6, P649, DOI 10.1593/tlo.13556
   Montgomery MK, 2013, DIABETOLOGIA, V56, P1129, DOI 10.1007/s00125-013-2846-8
   Moore T, 2008, CANCER PREV RES, V1, P65, DOI 10.1158/1940-6207.CAPR-08-0022
   Nair V, 2014, J BIOL CHEM, V289, P27692, DOI 10.1074/jbc.M114.592576
   Nair V, 2013, CARCINOGENESIS, V34, P2870, DOI 10.1093/carcin/bgt231
   Noto H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033411
   Pandol S, 2009, CLIN GASTROENTEROL H, V7, pS44, DOI 10.1016/j.cgh.2009.07.039
   Pannala R, 2009, LANCET ONCOL, V10, P88, DOI 10.1016/S1470-2045(08)70337-1
   Parhar K, 2003, IMMUNOLOGY, V108, P502, DOI 10.1046/j.1365-2567.2003.01603.x
   Perdiguero E, 2011, J CELL BIOL, V195, P307, DOI 10.1083/jcb.201104053
   Phillips P, 2012, PANCREATIC CANC TUMO
   Pischon T, 2008, P NUTR SOC, V67, P128, DOI 10.1017/S0029665108006976
   Qu HM, 2015, CELL BIOCHEM BIOPHYS, V71, P931, DOI 10.1007/s12013-014-0287-8
   Ramos-Nino Maria E, 2013, ISRN Oncol, V2013, P697521, DOI 10.1155/2013/697521
   Rattan R, 2011, NEOPLASIA, V13, P483, DOI 10.1593/neo.11148
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Rider P, 2011, J IMMUNOL, V187, P4835, DOI 10.4049/jimmunol.1102048
   Roongruedee Chaiteerakij DBZ, 2015, METFORMIN USE DOES N
   Sadeghi N, 2012, CLIN CANCER RES, V18, P2905, DOI 10.1158/1078-0432.CCR-11-2994
   Shi WY, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.13
   Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643
   Smyth S, 2006, NAT MED, V12, P75, DOI 10.1038/nm0106-75
   SURWIT RS, 1995, METABOLISM, V44, P645, DOI 10.1016/0026-0495(95)90123-X
   Tam J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004974
   Tan XL, 2015, PANCREAS, V44, P636, DOI 10.1097/MPA.0000000000000308
   Vasamsetti SB, 2015, DIABETES, V64, P2028, DOI 10.2337/db14-1225
   Wang Y, 2012, CURR MOL MED, V12, P331, DOI 10.2174/156652412799218868
   Wu Y, 2008, J IMMUNOL, V181, P6384, DOI 10.4049/jimmunol.181.9.6384
   Xu ZH, 2010, AM J PATHOL, V177, P2585, DOI 10.2353/ajpath.2010.090899
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Yu Ji Hoon, 2014, J Cancer Prev, V19, P97, DOI 10.15430/JCP.2014.19.2.97
   Zechner D, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1047-x
NR 97
TC 49
Z9 49
U1 0
U2 25
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 7
PY 2015
VL 10
IS 12
AR e0141392
DI 10.1371/journal.pone.0141392
PG 23
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CZ1YS
UT WOS:000366902700004
PM 26641266
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Chen, HJ
   Shen, YC
   Shiao, YJ
   Liou, KT
   Hsu, WH
   Hsieh, PH
   Lee, CY
   Chen, YR
   Lin, YL
AF Chen, Hong-Jhang
   Shen, Yuh-Chiang
   Shiao, Young-Ji
   Liou, Kuo-Tong
   Hsu, Wei-Hsiang
   Hsieh, Pei-Hsuan
   Lee, Chi-Ying
   Chen, Yet-Ran
   Lin, Yun-Lian
TI Multiplex Brain Proteomic Analysis Revealed the Molecular Therapeutic
   Effects of Buyang Huanwu Decoction on Cerebral Ischemic Stroke Mice
SO PLOS ONE
LA English
DT Article
ID GLYCOGEN-SYNTHASE KINASE-3-BETA; TISSUE-PLASMINOGEN ACTIVATOR; CHINESE
   MEDICINE; ARTERY OCCLUSION; NEURONAL DEATH; STEM-CELLS; MODEL; RAT;
   RECEPTOR; INJURY
AB Stroke is the second-leading cause of death worldwide, and tissue plasminogen activator (TPA) is the only drug used for a limited group of stroke patients in the acute phase. Buyang Huanwu Decoction (BHD), a traditional Chinese medicine prescription, has long been used for improving neurological functional recovery in stroke. In this study, we characterized the therapeutic effect of TPA and BHD in a cerebral ischemia/reperfusion (CIR) injury mouse model using multiplex proteomics approach. After the iTRAQ-based proteomics analysis, 1310 proteins were identified from the mouse brain with <1% false discovery rate. Among them, 877 quantitative proteins, 10.26% (90/877), 1.71% (15/877), and 2.62% (23/877) of the proteins was significantly changed in the CIR, BHD treatment, and TPA treatment, respectively. Functional categorization analysis showed that BHD treatment preserved the integrity of the blood-brain barrier (BBB) (Alb, Fga, and Trf), suppressed excitotoxicity (Grm5, Gnai, and Gdi), and enhanced energy metabolism (Bdh), thereby revealing its multiple effects on ischemic stroke mice. Moreover, the neurogenesis marker doublecortin was upregulated, and the activity of glycogen synthase kinase 3 (GSK-3) and Tau was inhibited, which represented the neuroprotective effects. However, TPA treatment deteriorated BBB breakdown. This study highlights the potential of BHD in clinical applications for ischemic stroke.
C1 [Chen, Hong-Jhang; Shen, Yuh-Chiang; Shiao, Young-Ji; Hsu, Wei-Hsiang; Lin, Yun-Lian] Natl Res Inst Chinese Med, Taipei, Taiwan.
   [Chen, Hong-Jhang] Natl Taiwan Univ, Inst Food Sci & Technol, Taipei 10764, Taiwan.
   [Liou, Kuo-Tong] Chinese Culture Univ, Dept Chinese Martial Arts, Taipei, Taiwan.
   [Liou, Kuo-Tong] Chinese Culture Univ, Grad Inst Sport Coaching Sci, Taipei, Taiwan.
   [Hsieh, Pei-Hsuan; Lee, Chi-Ying; Chen, Yet-Ran] Acad Sinica, Agr Biotechnol Res Ctr, Taipei 115, Taiwan.
   [Lin, Yun-Lian] China Med Univ, Dept Chinese Pharmaceut Sci & Chinese Med Resourc, Taichung, Taiwan.
   [Lin, Yun-Lian] Natl Taiwan Univ, Sch Pharm, Taipei 10764, Taiwan.
RP Chen, YR (reprint author), Acad Sinica, Agr Biotechnol Res Ctr, Taipei 115, Taiwan.
EM yetran@gate.sinica.edu.tw; yllin5212@gmail.com
FU National Science Council Taiwan [NSC-101-2325-B-077-001,
   NSC102-2325-B-077-001, NSC 103 2320-B-077-001]; Ministry of Science and
   Technology Taiwan (MOST) [103-2320-B-077-003-MY3]
FX This work was supported by the grants from the National Science Council
   Taiwan (NSC-101-2325-B-077-001, NSC102-2325-B-077-001, and NSC 103
   2320-B-077-001) and Ministry of Science and Technology Taiwan (MOST
   103-2320-B-077-003-MY3).
CR Altamura C, 2009, STROKE, V40, P1282, DOI 10.1161/STROKEAHA.108.536714
   Armogida M, 2012, BRIT J PHARMACOL, V166, P1211, DOI 10.1111/j.1476-5381.2012.01912.x
   Bao WL, 2001, BRAIN RES, V922, P173, DOI 10.1016/S0006-8993(01)03062-1
   Beschorner R, 2007, HISTOPATHOLOGY, V50, P897, DOI 10.1111/j.1365-2559.2007.02703.x
   Cai GX, 2007, J ETHNOPHARMACOL, V113, P292, DOI 10.1016/j.jep.2007.06.007
   Chang WH, 2013, ANAL CHEM, V85, P890, DOI 10.1021/ac302281j
   Chen CJ, 2010, ANAL CHEM, V82, P8283, DOI 10.1021/ac1017937
   Chen HJ, 2012, METABOLOMICS, V8, P974, DOI 10.1007/s11306-011-0394-0
   Chen YS, 2001, AM J CHINESE MED, V29, P423, DOI 10.1142/S0192415X01000447
   Chern CM, 2012, FREE RADICAL BIO MED, V52, P1634, DOI 10.1016/j.freeradbiomed.2012.01.030
   Cho WCS, 2007, AM J CHINESE MED, V35, P911, DOI 10.1142/S0192415X07005375
   Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075
   Datta A, 2011, J PROTEOME RES, V10, P5199, DOI 10.1021/pr200673y
   DeSouza L, 2005, J PROTEOME RES, V4, P377, DOI 10.1021/pr04982lj
   Fan LZ, 2006, J FUTURES MARKETS, V26, P153, DOI 10.1002/fut.20191
   Fang XJ, 2002, MOL CELL BIOL, V22, P2099, DOI 10.1128/MCB.22.7.2099-2110.2002
   Feinklestein SP, 1999, STROKE, V30, P2752, DOI 10.1161/01.STR.30.12.2752
   Fernandez-Lopez D, 2012, J NEUROSCI, V32, P9588, DOI 10.1523/JNEUROSCI.5977-11.2012
   Gao MX, 2007, J SEP SCI, V30, P785, DOI 10.1002/jssc.200600372
   Gold AB, 2011, CURR DRUG TARGETS, V12, P243
   Govek EE, 2005, GENE DEV, V19, P1, DOI 10.1101/gad.1256405
   Guo WX, 2012, HUM MOL GENET, V21, P681, DOI 10.1093/hmg/ddr501
   Hao CZ, 2012, EVID-BASED COMPL ALT, DOI 10.1155/2012/630124
   Hotta A, 2005, MOL BIOL CELL, V16, P32, DOI 10.1091/mbc.E04-08-0679
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Imhof A, 2006, NEUROBIOL DIS, V22, P274, DOI 10.1016/j.nbd.2005.11.009
   Jin R, 2010, NEUROBIOL DIS, V38, P376, DOI 10.1016/j.nbd.2010.03.008
   Kaur J, 2004, J CEREBR BLOOD F MET, V24, P945, DOI 10.1097/01.WCB.0000137868.50767.E8
   Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h
   Kelly S, 2004, EXP NEUROL, V188, P378, DOI 10.1016/j.expneurol.2004.04.004
   Kim N, 2006, PROTEOMICS, V6, P1237, DOI 10.1002/pmic.200500291
   Korshunova I, 2008, J NEUROSCI RES, V86, P2201, DOI 10.1002/jnr.21678
   Kunz A, 2008, J NEUROSCI, V28, P1649, DOI 10.1523/JNEUROSCI.5205-07.2008
   Lansberg MG, 2009, STROKE, V40, P2438, DOI 10.1161/STROKEAHA.109.552547
   Leroy K, 1999, J CHEM NEUROANAT, V16, P279, DOI 10.1016/S0891-0618(99)00012-5
   Li HL, 2013, ASN NEURO, V5, DOI 10.1042/AN20130002
   Li XM, 2003, NEUROSCI LETT, V346, P29, DOI 10.1016/S0304-3940(03)00522-6
   Lindvall O, 2011, STROKE, V42, P2369, DOI 10.1161/STROKEAHA.110.599654
   Liu CP, 2003, ACTA PHARMACOL SIN, V24, P1205
   Liu J, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009622.pub2
   Liu X, 2011, BIOCHEM SOC T, V39, P1348, DOI 10.1042/BST0391348
   Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106
   Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27
   Mangi AA, 2003, NAT MED, V9, P1195, DOI 10.1038/nm912
   Marchi N, 2003, J NEUROSCI, V23, P1949
   MARLER JR, 1995, NEW ENGL J MED, V333, P1581
   Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0
   Nelson TJ, 2009, TRENDS BIOCHEM SCI, V34, P136, DOI 10.1016/j.tibs.2008.11.006
   Niswender CM, 2010, ANNU REV PHARMACOL, V50, P295, DOI 10.1146/annurev.pharmtox.011008.145533
   Nochi R, 2012, EUR J NEUROSCI, V36, P2273, DOI 10.1111/j.1460-9568.2012.08128.x
   Prajapati KD, 2010, BRAIN RES, V1327, P118, DOI 10.1016/j.brainres.2010.02.063
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Ryu JK, 2009, J THROMB HAEMOST, V7, P151, DOI 10.1111/j.1538-7836.2009.03438.x
   Shimamura N, 2006, STROKE, V37, P1902, DOI 10.1161/01.STR.0000226991.27540.f2
   Sirerol-Piquer M, 2011, HIPPOCAMPUS, V21, P910, DOI 10.1002/hipo.20805
   Song B, 2010, J BIOL CHEM, V285, P41122, DOI 10.1074/jbc.M110.130351
   Tan ZJ, 2013, STROKE, V44, P3490, DOI 10.1161/STROKEAHA.113.002411
   Urich-Merzenich G, 2007, PHYTOMEDICINE, V14, P70, DOI 10.1016/j.phymed.2006.11.011
   Wang HW, 2011, J ETHNOPHARMACOL, V138, P22, DOI 10.1016/j.jep.2011.06.033
   Whiteley W, 2009, STROKE, V40, pE380, DOI 10.1161/STROKEAHA.108.528752
   World Health Organization, 10 LEAD CAUS DEATH W
   Zhang M, 2007, J CEREBR BLOOD F MET, V27, P1352, DOI 10.1038/sj.jcbfm.9600441
   Zhao H, 2005, J NEUROSCI, V25, P9794, DOI 10.1523/JNEUROSCI.3163-05.2005
   Zheng GQ, 2010, J CELL BIOCHEM, V109, P26, DOI 10.1002/jcb.22408
   Ziegler G, 2009, BBA-MOL BASIS DIS, V1792, P1198, DOI 10.1016/j.bbadis.2009.10.003
NR 65
TC 5
Z9 5
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 22
PY 2015
VL 10
IS 10
AR e0140823
DI 10.1371/journal.pone.0140823
PG 27
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CU0ZU
UT WOS:000363249300014
PM 26492191
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Sarker, MR
   Franks, S
   Sumien, N
   Thangthaeng, N
   Filipetto, F
   Forster, M
AF Sarker, Marjana Rahman
   Franks, Susan
   Sumien, Nathalie
   Thangthaeng, Nopporn
   Filipetto, Frank
   Forster, Michael
TI Curcumin Mimics the Neurocognitive and Anti-Inflammatory Effects of
   Caloric Restriction in a Mouse Model of Midlife Obesity
SO PLOS ONE
LA English
DT Article
ID C-REACTIVE PROTEIN; MILD COGNITIVE IMPAIRMENT; LIFE-SPAN; OXIDATIVE
   STRESS; INFLAMMATORY CYTOKINES; ALZHEIMERS-DISEASE; EXECUTIVE FUNCTION;
   GENE-EXPRESSION; WEIGHT-LOSS; OVERWEIGHT
AB Dietary curcumin was studied for its potential to decrease adiposity and reverse obesity-associated cognitive impairment in a mouse model of midlife sedentary obesity. We hypothesized that curcumin intake, by decreasing adiposity, would improve cognitive function in a manner comparable to caloric restriction (CR), a weight loss regimen. 15-month-old male C57BL/6 mice were assigned in groups to receive the following dietary regimens for 12 weeks: (i) a base diet (Ain93M) fed ad libitum (AL), (ii) the base diet restricted to 70% of ad libitum (CR) or (iii) the base diet containing curcumin fed AL (1000 mg/kg diet, CURAL). Blood markers of inflammation, interleukin 6 (IL-6) and C-reactive protein (CRP), as well as an indicator of redox stress (GSH: GSSG ratio), were determined at different time points during the treatments, and visceral and subcutaneous adipose tissue were measured upon completion of the experiment. After 8 weeks of dietary treatment, the mice were tested for spatial cognition (Morris water maze) and cognitive flexibility (discriminated active avoidance). The CR group showed significant weight loss and reduced adiposity, whereas CURAL mice had stable weight throughout the experiment, consumed more food than the AL group, with no reduction of adiposity. However, both CR and CURAL groups took fewer trials than AL to reach criterion during the reversal sessions of the active avoidance task, suggesting an improvement in cognitive flexibility. The AL mice had higher levels of CRP compared to CURAL and CR, and GSH as well as the GSH: GSSG ratio were increased during curcumin intake, suggesting a reducing shift in the redox state. The results suggest that, independent of their effects on adiposity; dietary curcumin and caloric restriction have positive effects on frontal cortical functions that could be linked to anti-inflammatory or anti-oxidant actions.
C1 [Sarker, Marjana Rahman; Sumien, Nathalie; Thangthaeng, Nopporn; Forster, Michael] Univ N Texas, Hlth Sci Ctr, IAADR, Dept Pharmacol & Neurosci, Ft Worth, TX 76107 USA.
   [Franks, Susan; Filipetto, Frank] Univ N Texas, Texas Coll Osteopath Med, Hlth Sci Ctr, Family Med, Ft Worth, TX 76107 USA.
RP Forster, M (reprint author), Univ N Texas, Hlth Sci Ctr, IAADR, Dept Pharmacol & Neurosci, Ft Worth, TX 76107 USA.
EM Michael.forster@unthsc.edu
RI Sarker, Marjana/J-7214-2019
FU National Institutes of Health, National Institute on Aging [AG022550];
   University of North Texas Health Science Center, Faculty seed grant
   [RI6039]
FX This work was supported by P01 (Program project grant) AG022550 National
   Institutes of Health, National Institute on Aging; and RI6039,
   University of North Texas Health Science Center, Faculty seed grant.
CR Anstey KJ, 2011, OBES REV, V12, pe426, DOI 10.1111/j.1467-789X.2010.00825.x
   Arfanakis K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073107
   Banerjee M, 2003, IMMUNOPHARM IMMUNOT, V25, P213, DOI 10.1081/IPH-120020471
   Bar-Sela G, 2010, CURR MED CHEM, V17, P190, DOI 10.2174/092986710790149738
   Becskei C, 2009, NEUROENDOCRINOLOGY, V90, P371, DOI 10.1159/000251723
   Begum AN, 2008, J PHARMACOL EXP THER, V326, P196, DOI 10.1124/jpet.108.137455
   Bermejo P, 2008, FREE RADICAL RES, V42, P162, DOI 10.1080/10715760701861373
   Black S, 2004, J BIOL CHEM, V279, P48487, DOI 10.1074/jbc.R400025200
   Bradford PG, 2013, BIOFACTORS, V39, P78, DOI 10.1002/biof.1074
   Buckner RL, 2004, NEURON, V44, P195, DOI 10.1016/j.neuron.2004.09.006
   Burke LE, 2008, J AM DIET ASSOC, V108, P640, DOI 10.1016/j.jada.2008.01.012
   Calabro P, 2003, CIRCULATION, V108, P1930, DOI 10.1161/01.CIR.0000096055.62724.C5
   Chaudhari K, 2014, J SPORT HEALTH SCI, V3, P196, DOI 10.1016/j.jshs.2014.04.004
   Chaudhari N, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00213
   Cohen AN, 2009, ARCH OTOLARYNGOL, V135, P190, DOI 10.1001/archotol.135.2.190
   Cooke D, 2006, NAT REV DRUG DISCOV, V5, P919, DOI 10.1038/nrd2136
   de Fiebre NC, 2006, AGE, V28, P235, DOI 10.1007/s11357-006-9027-3
   Deckers K, 2015, INT J GERIATR PSYCH, V30, P234, DOI 10.1002/gps.4245
   Dixit S, 2015, ACS CHEM NEUROSCI
   Dubey A, 1996, ARCH BIOCHEM BIOPHYS, V333, P189, DOI 10.1006/abbi.1996.0380
   Ejaz A, 2009, J NUTR, V139, P919, DOI 10.3945/jn.108.100966
   Forster MJ, 1999, NEUROBIOL AGING, V20, P167, DOI 10.1016/S0197-4580(99)00041-X
   Forster MJ, 2000, J GERONTOL A-BIOL, V55, pB522, DOI 10.1093/gerona/55.11.B522
   Garcia-Ptacek S, 2014, EUR J CLIN NUTR, V68, P1204, DOI 10.1038/ejcn.2014.199
   Guerreiro RJ, 2007, NEURODEGENER DIS, V4, P406, DOI 10.1159/000107700
   Gupta A, 2015, NEUROIMAGE-CLIN, V7, P506, DOI 10.1016/j.nicl.2015.01.005
   Gupta SC, 2013, BIOFACTORS, V39, P2, DOI 10.1002/biof.1079
   Gupta SK, 2011, J OCUL PHARMACOL TH, V27, P123, DOI 10.1089/jop.2010.0123
   Harvie MN, 2011, INT J OBESITY, V35, P714, DOI 10.1038/ijo.2010.171
   Kim T, 2009, BIOCHEM BIOPH RES CO, V388, P377, DOI 10.1016/j.bbrc.2009.08.018
   Kim YW, 2013, J MOL MED, V91, P323, DOI 10.1007/s00109-013-1007-3
   Latham JR, 2009, DIABETES, V58, P2656, DOI 10.2337/db08-1763
   Lee BC, 2014, BBA-MOL BASIS DIS, V1842, P446, DOI 10.1016/j.bbadis.2013.05.017
   Lekander M, 2011, SCAND J PSYCHOL, V52, P229, DOI 10.1111/j.1467-9450.2010.00865.x
   Madeo F, 2014, NAT REV DRUG DISCOV, V13, P727, DOI 10.1038/nrd4391
   Martin B, 2006, AGEING RES REV, V5, P332, DOI 10.1016/j.arr.2006.04.002
   Mazzetti AP, 2015, NEUROCHEM INT, V82, P10, DOI 10.1016/j.neuint.2015.01.008
   Mcdonald SR, 2005, FREE RADICAL BIO MED, V38, P729, DOI 10.1016/j.freeradbiomed.2004.11.014
   Ogden CL, 2014, JAMA-J AM MED ASSOC, V311, P806, DOI 10.1001/jama.2014.732
   Pires RC, 2014, APPL PHYSIOL NUTR ME, V39, P895, DOI 10.1139/apnm-2013-0520
   Priyadarsini KI, 2013, CURR PHARM DESIGN, V19, P2093
   Priyadarsini KI, 2003, FREE RADICAL BIO MED, V35, P475, DOI 10.1016/S0891-5849(03)00325-3
   Pu YF, 2013, CELL PHYSIOL BIOCHEM, V32, P1167, DOI 10.1159/000354516
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Rebrin I, 2011, FREE RADICAL BIO MED, V51, P225, DOI 10.1016/j.freeradbiomed.2011.04.006
   Shen LR, 2013, AGE, V35, P1133, DOI 10.1007/s11357-012-9438-2
   Sohal RS, 2014, FREE RADICAL BIO MED, V73, P366, DOI 10.1016/j.freeradbiomed.2014.05.015
   Spangler EL, 2010, CALORIE RESTRICTION, AGING AND LONGEVITY, P177, DOI 10.1007/978-90-481-8556-6_10
   Sperling RA, 2010, NEUROMOL MED, V12, P27, DOI 10.1007/s12017-009-8109-7
   Spindler SR, 2005, MECH AGEING DEV, V126, P960, DOI 10.1016/j.mad.2005.03.016
   Strong R, 2013, J GERONTOL A-BIOL, V68, P6, DOI 10.1093/gerona/gls070
   Sturm R, 2013, INT J OBESITY, V37, P889, DOI 10.1038/ijo.2012.159
   Sumien N, 2006, AGE, V28, P265, DOI 10.1007/s11357-006-9015-7
   Sweat V, 2008, INFLAMMATION, V31, P198, DOI 10.1007/s10753-008-9065-3
   Sykiotis GP, 2011, CURR OPIN CLIN NUTR, V14, P41, DOI 10.1097/MCO.0b013e32834136f2
   Tang YC, 2014, LAB INVEST, V94, P503, DOI 10.1038/labinvest.2014.42
   TAYLOR AW, 1990, J IMMUNOL, V145, P2507
   Thangthaeng N, 2008, EXP GERONTOL, V43, P1077, DOI 10.1016/j.exger.2008.08.045
   Torres LL, 2011, J ALZHEIMERS DIS, V26, P59, DOI 10.3233/JAD-2011-110284
   Trujillo J, 2014, ARCH PHARM, V347, P873, DOI 10.1002/ardp.201400266
   Turturro A, 1999, J GERONTOL A-BIOL, V54, pB492, DOI 10.1093/gerona/54.11.B492
   Wang J, 2013, NUTR METAB, V10
   Wang S, 2014, J NUTR BIOCHEM, V25, P1, DOI 10.1016/j.jnutbio.2013.09.001
   West XZ, 2010, NATURE, V467, P972, DOI 10.1038/nature09421
   Weuve J, 2006, EPIDEMIOLOGY, V17, P183, DOI 10.1097/01.ede.0000198183.60572.c9
   Xu WL, 2011, NEUROLOGY, V76, P1568, DOI 10.1212/WNL.0b013e3182190d09
   Zheng DM, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-138
NR 67
TC 8
Z9 8
U1 1
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 16
PY 2015
VL 10
IS 10
AR e0140431
DI 10.1371/journal.pone.0140431
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CU0DF
UT WOS:000363185500047
PM 26473740
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Balasubramanian, S
   Pleasant, DL
   Kasiganesan, H
   Quinones, L
   Zhang, YH
   Sundararaj, KP
   Roche, S
   O'Connor, R
   Bradshaw, AD
   Kuppuswamy, D
AF Balasubramanian, Sundaravadivel
   Pleasant, Dorea L.
   Kasiganesan, Harinath
   Quinones, Lakeya
   Zhang, Yuhua
   Sundararaj, Kamala P.
   Roche, Sandra
   O'Connor, Robert
   Bradshaw, Amy D.
   Kuppuswamy, Dhandapani
TI Dasatinib Attenuates Pressure Overload Induced Cardiac Fibrosis in a
   Murine Transverse Aortic Constriction Model
SO PLOS ONE
LA English
DT Article
ID ANGIOTENSIN-ALDOSTERONE SYSTEM; MYOCARDIAL FIBROSIS; HEART-FAILURE;
   HYPERTROPHYING MYOCARDIUM; DIASTOLIC DYSFUNCTION; EJECTION FRACTION;
   BETA-3 INTEGRIN; C-SRC; KINASE; ACTIVATION
AB Reactive cardiac fibrosis resulting from chronic pressure overload (PO) compromises ventricular function and contributes to congestive heart failure. We explored whether nonreceptor tyrosine kinases (NTKs) play a key role in fibrosis by activating cardiac fibroblasts (CFb), and could potentially serve as a target to reduce PO-induced cardiac fibrosis. Our studies were carried out in PO mouse myocardium induced by transverse aortic constriction (TAC). Administration of a tyrosine kinase inhibitor, dasatinib, via an intraperitoneally implanted mini-osmotic pump at 0.44 mg/kg/day reduced PO-induced accumulation of extracellular matrix (ECM) proteins and improved left ventricular geometry and function. Furthermore, dasatinib treatment inhibited NTK activation (primarily Pyk2 and Fak) and reduced the level of FSP1 positive cells in the PO myocardium. In vitro studies using cultured mouse CFb showed that dasatinib treatment at 50 nM reduced: (i) extracellular accumulation of both collagen and fibronectin, (ii) both basal and PDGF-stimulated activation of Pyk2, (iii) nuclear accumulation of Ki67, SKP2 and histone-H2B and (iv) PDGF-stimulated CFb proliferation and migration. However, dasatinib did not affect cardiomyocyte morphologies in either the ventricular tissue after in vivo administration or in isolated cells after in vitro treatment. Mass spectrometric quantification of dasatinib in cultured cells indicated that the uptake of dasatinib by CFb was greater that that taken up by cardiomyocytes. Dasatinib treatment primarily suppressed PDGF but not insulin-stimulated signaling (Erk versus Akt activation) in both CFb and cardiomyocytes. These data indicate that dasatinib treatment at lower doses than that used in chemotherapy has the capacity to reduce hypertrophy-associated fibrosis and improve ventricular function.
C1 [Balasubramanian, Sundaravadivel; Pleasant, Dorea L.; Kasiganesan, Harinath; Quinones, Lakeya; Zhang, Yuhua; Sundararaj, Kamala P.; Bradshaw, Amy D.; Kuppuswamy, Dhandapani] Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Div Cardiol, Charleston, SC 29425 USA.
   [Roche, Sandra; O'Connor, Robert] Dublin City Univ, Dublin 9, Ireland.
RP Kuppuswamy, D (reprint author), Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Div Cardiol, 114 Doughty St, Charleston, SC 29425 USA.
EM kuppusd@musc.edu
OI Roche, Sandra/0000-0002-4363-4607
FU National Institutes of Health [RHL092124A, T32HL07260]; UNCF/Merck
   Graduate Science Research Dissertation Fellowship
FX This study was supported by the National Institutes of Health grant
   (RHL092124A to D. K), by the National Institutes of Health postdoctoral
   fellowship (T32HL07260 to K.S.), and predoctoral fellowships,
   T32HL07260, and 2014 UNCF/Merck Graduate Science Research Dissertation
   Fellowship to D.L.P. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Abi-Gerges N, 2013, J MOL CELL CARDIOL, V64, P108, DOI 10.1016/j.yjmcc.2013.09.004
   Akhmetshina A, 2008, FASEB J, V22, P2214, DOI 10.1096/fj.07-105627
   Albini A, 2010, JNCI-J NATL CANCER I, V102, P14, DOI 10.1093/jnci/djp440
   Balasubramanian S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045076
   Balasubramanian Sundaravadivel, 2009, Cardiovascular & Hematological Agents in Medicinal Chemistry, V7, P52
   Beyer C, 2013, BBA-MOL BASIS DIS, V1832, P897, DOI 10.1016/j.bbadis.2012.06.008
   Bradshaw AD, 1999, MOL BIOL CELL, V10, P1569, DOI 10.1091/mbc.10.5.1569
   Bradshaw AD, 2009, CIRCULATION, V119, P269, DOI 10.1161/CIRCULATIONAHA.108.773424
   Brenner DA, 2012, PROCEEDINGS OF FIBRO, V5, pS17, DOI [10.1186/1755-1536-5-S1-S17, DOI 10.1186/1755-1536-5-S1-S17]
   Brown RD, 2005, ANNU REV PHARMACOL, V45, P657, DOI 10.1146/annurev.pharmtox.45.120403.095802
   Chan D, 2012, ONCOL LETT, V3, P807, DOI 10.3892/ol.2012.579
   Chen MH, 2008, CIRCULATION, V118, P84, DOI 10.1161/CIRCULATIONAHA.108.776831
   Clemente CFMZ, 2007, CIRC RES, V101, P1339, DOI 10.1161/CIRCRESAHA.107.160978
   Distler JHW, 2008, RHEUMATOLOGY, V47, pV10, DOI 10.1093/rheumatology/ken276
   Ekwall B, 1990, SHORT TERM TOXICITY, P76
   Gonzalez A, 2004, MED CLIN N AM, V88, P83, DOI 10.1016/S0025-7125(03)00125-1
   Gratacap MP, 2009, BLOOD
   Harris BS, 2011, AM J PHYSIOL-HEART C, V301, pH841, DOI 10.1152/ajpheart.01247.2010
   He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509
   HENRY WL, 1980, CIRCULATION, V62, P212, DOI 10.1161/01.CIR.62.2.212
   Johnston RK, 2009, FASEB J, V23, P2759, DOI 10.1096/fj.08-127480
   Kai H, 2005, HYPERTENS RES, V28, P483, DOI 10.1291/hypres.28.483
   KENT RL, 1989, AM J PHYSIOL, V257, pH1717
   Kuppuswamy D, 1997, J BIOL CHEM, V272, P4500, DOI 10.1074/jbc.272.7.4500
   Lau ATY, 2011, J BIOL CHEM, V286, P26628, DOI 10.1074/jbc.M110.215590
   Leask A, 2010, CIRC RES, V106, P1675, DOI 10.1161/CIRCRESAHA.110.217737
   Lucas JA, 2010, AM J PHYSIOL-HEART C, V298, pH424, DOI 10.1152/ajpheart.00529.2009
   Mandinov L, 2000, CARDIOVASC RES, V45, P813, DOI 10.1016/S0008-6363(99)00399-5
   Mani SK, 2008, AM J PHYSIOL-HEART C, V295, pH314, DOI 10.1152/ajpheart.00085.2008
   Palanisamy AP, 2015, J CELL BIOCHEM, V116, P2793, DOI 10.1002/jcb.25224
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Ren J, 2007, J MOL CELL CARDIOL, V42, P367, DOI 10.1016/j.yjmcc.2006.11.002
   Roche S, 2009, J CHROMATOGR B, V877, P3982, DOI 10.1016/j.jchromb.2009.10.008
   Shah NP, 2014, BLOOD, V123, P2317, DOI 10.1182/blood-2013-10-532341
   Skhirtladze C, 2008, ARTHRITIS RHEUM, V58, P1475, DOI 10.1002/art.23436
   Snyder DS, 2009, EXPERT REV ANTICANC, V9, P285, DOI 10.1586/14737140.9.3.285
   Sonomura K, 2012, KIDNEY INT, V81, P449, DOI 10.1038/ki.2011.403
   Suryakumar G, 2010, J CARDIOVASC PHARM, V55, P567, DOI 10.1097/FJC.0b013e3181d9f5d4
   Touvron M, 2012, DIS MODEL MECH, V5, P481, DOI 10.1242/dmm.009456
   Vasan RS, 1999, J AM COLL CARDIOL, V33, P1948, DOI 10.1016/S0735-1097(99)00118-7
   Wang XY, 2010, J CELL COMMUN SIGNAL, V4, P15, DOI 10.1007/s12079-009-0083-1
   WEBER KT, 1991, CIRCULATION, V83, P1849, DOI 10.1161/01.CIR.83.6.1849
   WEBER KT, 1992, J AM COLL CARDIOL, V20, P3, DOI 10.1016/0735-1097(92)90130-F
   Willey CD, 2003, J MOL CELL CARDIOL, V35, P671, DOI 10.1016/S0022-2828(03)00112-3
   Wollin L, 2014, J PHARMACOL EXP THER, V349, P209, DOI 10.1124/jpet.113.208223
   Zile MR, 2015, CIRCULATION, V131, P1247, DOI 10.1161/CIRCULATIONAHA.114.013215
   Zile MR, 2013, J CARDIOVASC TRANSL, V6, P501, DOI 10.1007/s12265-013-9472-1
NR 47
TC 12
Z9 12
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 12
PY 2015
VL 10
IS 10
AR e0140273
DI 10.1371/journal.pone.0140273
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CT6YZ
UT WOS:000362961100028
PM 26458186
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Ramsey, LB
   Janke, LJ
   Payton, MA
   Cai, XJ
   Paugh, SW
   Karol, SE
   Kamdem, LK
   Cheng, C
   Williams, RT
   Jeha, S
   Pui, CH
   Evans, WE
   Relling, MV
AF Ramsey, Laura B.
   Janke, Laura J.
   Payton, Monique A.
   Cai, Xiangjun
   Paugh, Steven W.
   Karol, Seth E.
   Kamdem, Landry Kamdem
   Cheng, Cheng
   Williams, Richard T.
   Jeha, Sima
   Pui, Ching-Hon
   Evans, William E.
   Relling, Mary V.
TI Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in
   Murine Models of Acute Lymphoblastic Leukemia
SO PLOS ONE
LA English
DT Article
ID MOUSE MODEL; INDUCED OSTEONECROSIS; MULTIPLE-MYELOMA; GLUCOCORTICOID
   RESISTANCE; PEDIATRIC-PATIENTS; IMPROVES SURVIVAL; INITIATING CELLS;
   GENE-EXPRESSION; CHILDREN; CHILDHOOD
AB Osteonecrosis is one of the most common, serious, toxicities resulting from the treatment of acute lymphoblastic leukemia. In recent years, pediatric acute lymphoblastic leukemia clinical trials have used discontinuous rather than continuous dosing of dexamethasone in an effort to reduce the incidence of osteonecrosis. However, it is not known whether discontinuous dosing would compromise antileukemic efficacy of glucocorticoids. Therefore, we tested the efficacy of discontinuous dexamethasone against continuous dexamethasone in murine models bearing human acute lymphoblastic leukemia xenografts (n = 8 patient samples) or murine BCR-ABL+ acute lymphoblastic leukemia. Plasma dexamethasone concentrations (7.9 to 212 nM) were similar to those achieved in children with acute lymphoblastic leukemia using conventional dosages. The median leukemia-free survival ranged from 16 to 59 days; dexamethasone prolonged survival from a median of 4 to 129 days in all seven dexamethasone-sensitive acute lymphoblastic leukemias. In the majority of cases (7 of 8 xenografts and the murine BCR-ABL model) we demonstrated equal efficacy of the two dexamethasone dosing regimens; whereas for one acute lymphoblastic leukemia sample, the discontinuous regimen yielded inferior antileukemic efficacy (log-rank p = 0.002). Our results support the clinical practice of using discontinuous rather than continuous dexamethasone dosing in patients with acute lymphoblastic leukemia.
C1 [Ramsey, Laura B.; Payton, Monique A.; Cai, Xiangjun; Paugh, Steven W.; Karol, Seth E.; Evans, William E.; Relling, Mary V.] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA.
   [Janke, Laura J.] St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA.
   [Kamdem, Landry Kamdem] Harding Univ Coll Pharm, Searcy, AR USA.
   [Cheng, Cheng] St Jude Childrens Res Hosp, Dept Biostat, Memphis, TN 38105 USA.
   [Williams, Richard T.] Puma Biotechnol Inc, Los Angeles, CA USA.
   [Jeha, Sima; Pui, Ching-Hon] St Jude Childrens Res Hosp, Dept Oncol, Memphis, TN 38105 USA.
RP Relling, MV (reprint author), St Jude Childrens Res Hosp, Dept Pharmaceut Sci, 332 N Lauderdale St, Memphis, TN 38105 USA.
EM mary.relling@stjude.org
RI Karol, Seth/N-2102-2018; Pui, Ching-Hon/N-8076-2018; Janke,
   Laura/N-8121-2018; Jeha, Sima/N-8163-2018; Cheng, Cheng/N-8075-2018;
   Relling, Mary/N-5032-2018; Evans, William E./C-2069-2012
OI Karol, Seth/0000-0001-8113-8180; Pui, Ching-Hon/0000-0003-0303-5658;
   Janke, Laura/0000-0002-9871-6239; Evans, William E./0000-0002-9333-5322;
   Ramsey, Laura/0000-0001-6417-3961
FU NIH; Puma Biotechnology Inc
FX This study was funded by grants provided by the NIH to MVR and WEE. Puma
   Biotechnology Inc provided support in the form of salary for author RTW,
   but did not have any additional role in the study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript. The specific roles of this author are articulated in the
   'author contributions' section.
CR Bachmann PS, 2007, CANCER RES, V67, P4482, DOI 10.1158/0008-5472.CAN-06-4244
   Bachmann PS, 2010, BLOOD, V116, P3013, DOI 10.1182/blood-2010-05-284968
   Berenson JR, 2002, BLOOD, V99, P3163, DOI 10.1182/blood.V99.9.3163
   Boulos N, 2011, BLOOD, V117, P3585, DOI 10.1182/blood-2010-08-301267
   Chiu PPL, 2010, BLOOD, V116, P5268, DOI 10.1182/blood-2010-06-292300
   Coleman M, 2003, SEMIN ONCOL, V30, P270, DOI 10.1053/sonc.2003.50044
   Dutch Children's Oncology Group, 2014, TREATM STUD PROT DUT
   GAYNON PS, 1995, J PEDIAT HEMATOL ONC, V17, P1, DOI 10.1097/00043426-199502000-00001
   GLUCK OS, 1981, ARTHRITIS RHEUM-US, V24, P892, DOI 10.1002/art.1780240705
   HARTER JG, 1963, NEW ENGL J MED, V269, P591, DOI 10.1056/NEJM196309192691201
   Holleman A, 2004, NEW ENGL J MED, V351, P533, DOI 10.1056/NEJMoa033513
   Hyakuna N, 2014, J PEDIAT HEMATOL ONC, V36, P22, DOI 10.1097/MPH.0000000000000039
   Jabs K, 1996, TRANSPLANTATION, V61, P31, DOI 10.1097/00007890-199601150-00008
   Janke LJ, 2013, AM J PATHOL, V183, P19, DOI 10.1016/j.ajpath.2013.03.004
   Jeha S, 2009, HEMATOL ONCOL CLIN N, V23, P973, DOI 10.1016/j.hoc.2009.07.009
   Jing DH, 2015, BLOOD, V125, P273, DOI 10.1182/blood-2014-05-576470
   Kawedia JD, 2012, COMPARATIVE MED, V62, P466
   Kawedia JD, 2011, BLOOD, V117, P2340, DOI 10.1182/blood-2010-10-311969
   Kimura Y, 2000, J RHEUMATOL, V27, P2018
   Kuhlen M, 2014, KLIN PADIATR, V226, P154, DOI 10.1055/s-0033-1358723
   Lacy MQ, 2010, LEUKEMIA, V24, P1934, DOI 10.1038/leu.2010.190
   Lacy MQ, 2011, BLOOD, V118, P2970, DOI 10.1182/blood-2011-04-348896
   Lee JA, 2002, J COMPUT ASSIST TOMO, V26, P839, DOI 10.1097/00004728-200209000-00030
   Liem NLM, 2004, BLOOD, V103, P3905, DOI 10.1182/blood-2003-08-2911
   Liu C, 2012, LEUKEMIA, V26, P2303, DOI 10.1038/leu.2012.102
   Lock RB, 2002, BLOOD, V99, P4100, DOI 10.1182/blood.V99.11.4100
   Maloney KW, 2011, BRIT J HAEMATOL, V155, P420, DOI 10.1111/j.1365-2141.2011.08846.x
   Mattano Jr LA, 2014, BLOOD
   Mattano LA, 2000, J CLIN ONCOL, V18, P3262, DOI 10.1200/JCO.2000.18.18.3262
   Mattano LA, 2012, LANCET ONCOL, V13, P906, DOI 10.1016/S1470-2045(12)70274-7
   MIGLIARESI S, 1994, LUPUS, V3, P37, DOI 10.1177/096120339400300108
   Miller AL, 2014, CANCER CELL INT, V14, DOI 10.1186/1475-2867-14-35
   Notta F, 2011, NATURE, V469, P362, DOI 10.1038/nature09733
   Patel B, 2008, LEUKEMIA, V22, P308, DOI 10.1038/sj.leu.2405032
   Pui CH, 2009, NEW ENGL J MED, V360, P2730, DOI 10.1056/NEJMoa0900386
   Ramsey LB, 2014, PHARMACOGENET GENOM, V24, P263, DOI 10.1097/FPC.0000000000000044
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Rytting ME, 2014, CANCER
   Sarna S, 1997, J CLIN ENDOCR METAB, V82, P75, DOI 10.1210/jc.82.1.75
   Seibel NL, 2008, BLOOD, V111, P2548, DOI 10.1182/blood-2007-02-070342
   Skoner DP, 2000, PEDIATRICS, V105, part. no., DOI 10.1542/peds.105.2.e23
   SMITH RW, 1950, SCIENCE, V112, P295, DOI 10.1126/science.112.2907.295
   Stary J, 2013, J CLIN ONCOL, V3, P174
   Vora A, 2011, BRIT J HAEMATOL, V155, P549, DOI 10.1111/j.1365-2141.2011.08871.x
   Vrooman LM, 2013, J CLIN ONCOL, V31, P1202, DOI 10.1200/JCO.2012.43.2070
   Weber D, 2003, J CLIN ONCOL, V21, P16, DOI 10.1200/JCO.2003.03.139
   Williams RT, 2006, P NATL ACAD SCI USA, V103, P6688, DOI 10.1073/pnas.0602030103
   Winkel MLT, 2011, J CLIN ONCOL, V29, P4143, DOI 10.1200/JCO.2011.37.3217
   Wong NC, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-416
   YAMAMOTO T, 1995, CLIN ORTHOP RELAT R, P235
   Yang L, 2008, J CLIN ONCOL, V26, P1932, DOI 10.1200/JCO.2007.13.8404
   Yang L, 2009, J ORTHOP RES, V27, P169, DOI 10.1002/jor.20733
NR 52
TC 6
Z9 7
U1 1
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 7
PY 2015
VL 10
IS 8
AR e0135134
DI 10.1371/journal.pone.0135134
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CO4HF
UT WOS:000359121100120
PM 26252865
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Boonnate, P
   Waraasawapati, S
   Hipkaeo, W
   Pethlert, S
   Sharma, A
   Selmi, C
   Prasongwattana, V
   Cha'on, U
AF Boonnate, Piyanard
   Waraasawapati, Sakda
   Hipkaeo, Wiphawi
   Pethlert, Supattra
   Sharma, Amod
   Selmi, Carlo
   Prasongwattana, Vitoon
   Cha'on, Ubon
TI Monosodium Glutamate Dietary Consumption Decreases Pancreatic beta-Cell
   Mass in Adult Wistar Rats
SO PLOS ONE
LA English
DT Article
ID GLUCOSE-TOLERANCE; CHINESE ADULTS; BRAIN-LESIONS; OVERWEIGHT; OBESITY;
   MICE; PREVALENCE; METABOLISM; NUTRITION; FIBROSIS
AB Background
   The amount of dietary monosodium glutamate (MSG) is increasing worldwide, in parallel with the epidemics of metabolic syndrome. Parenteral administration of MSG to rodents induces obesity, hyperglycemia, hyperlipidemia, insulin resistance, and type 2 diabetes. However, the impact of dietary MSG is still being debated. We investigated the morphological and functional effects of prolonged MSG consumption on rat glucose metabolism and on pancreatic islet histology.
   Methods
   Eighty adult male Wistar rats were randomly subdivided into 4 groups, and test rats in each group were supplemented with MSG for a different duration (1, 3, 6, or 9 months, n=20 for each group). All rats were fed ad libitum with a standard rat chow and water. Ten test rats in each group were provided MSG 2 mg/g body weight/day in drinking water and the 10 remaining rats in each group served as non-MSG treated controls. Oral glucose tolerance tests (OGTT) were performed and serum insulin measured at 9 months. Animals were sacrificed at 1, 3, 6, or 9 months to examine the histopathology of pancreatic islets.
   Results
   MSG-treated rats had significantly lower pancreatic beta-cell mass at 1, 6 and 9 months of study. Islet hemorrhages increased with age in all groups and fibrosis was significantly more frequent in MSG-treated rats at 1 and 3 months. Serum insulin levels and glucose tolerance in MSG-treated and untreated rats were similar at all time points we investigated.
   Conclusion
   Daily MSG dietary consumption was associated with reduced pancreatic beta-cell mass and enhanced hemorrhages and fibrosis, but did not affect glucose homeostasis. We speculate that high dietary MSG intake may exert a negative effect on the pancreas and such effect might become functionally significant in the presence or susceptibility to diabetes or NaCl; future experiments will take these crucial cofactors into account.
C1 [Boonnate, Piyanard; Pethlert, Supattra; Sharma, Amod; Prasongwattana, Vitoon; Cha'on, Ubon] Khon Kaen Univ, Fac Med, Dept Biochem, Khon Kaen, Thailand.
   [Waraasawapati, Sakda] Khon Kaen Univ, Fac Med, Dept Pathol, Khon Kaen, Thailand.
   [Hipkaeo, Wiphawi] Khon Kaen Univ, Fac Med, Dept Anat, Khon Kaen, Thailand.
   [Selmi, Carlo] Humanitas Clin & Res Ctr, Rheumatol & Clin Immunol, Milan, Italy.
   [Selmi, Carlo] Univ Calif Davis, Rheumatol Allergy & Clin Immunol, Davis, CA 95616 USA.
RP Cha'on, U (reprint author), Khon Kaen Univ, Fac Med, Dept Biochem, Khon Kaen, Thailand.
EM ubocha@kku.ac.th
OI Selmi, Carlo/0000-0002-0323-0376
FU Research and Technology affairs division, Khon Kaen University,
   Incubation research project [MIH-2554-M-11]; NRU-KKU; Invitation
   Research Fund from the Faculty of Medicine [I55227]
FX This work was supported by The Research and Technology affairs division,
   Khon Kaen University, Incubation research project (UC), MIH-2554-M-11,
   NRU-KKU (UC, PB) and Invitation Research Fund from the Faculty of
   Medicine (I55227; UC, PB). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR AREES EA, 1970, SCIENCE, V170, P549, DOI 10.1126/science.170.3957.549
   Beyreuther K, 2007, EUR J CLIN NUTR, V61, P304, DOI 10.1038/sj.ejcn.1602526
   Bouwens L, 2005, PHYSIOL REV, V85, P1255, DOI 10.1152/physrev.000025.2004
   Chevassus H, 2002, BRIT J CLIN PHARMACO, V53, P641, DOI 10.1046/j.1365-2125.2002.01596.x
   Franco CCD, 2014, CELL PHYSIOL BIOCHEM, V34, P1920, DOI 10.1159/000366390
   Dembele K, 2009, CELL BIOL TOXICOL, V25, P141, DOI 10.1007/s10565-008-9067-9
   Di Cairano ES, 2011, J BIOL CHEM, V286, P14007, DOI 10.1074/jbc.M110.183517
   Ferrannini E, 2014, METABOLISM, V63, P1217, DOI 10.1016/j.metabol.2014.05.012
   Gammelsaeter R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022960
   He K, 2008, OBESITY, V16, P1875, DOI 10.1038/oby.2008.274
   He K, 2011, AM J CLIN NUTR, V93, P1328, DOI 10.3945/ajcn.110.008870
   Hong OK, 2007, J CELL BIOCHEM, V101, P665, DOI 10.1002/jcb.21222
   Hull R, 2005, DIABETOLOGIA, V48, P1350, DOI 10.1007/s00125-005-1772-9
   Imaoka M, 2007, TOXICOL PATHOL, V35, P388, DOI 10.1080/01926230701230304
   Insawang T, 2012, NUTR METAB, V9, DOI 10.1186/1743-7075-9-50
   Islam MS, 2009, METHOD FIND EXP CLIN, V31, P249, DOI 10.1358/mf.2009.31.4.1362513
   KADUK B, 1987, HEPATO-GASTROENTEROL, V34, P108
   Katsuda Y, 2014, EXP ANIM TOKYO, V63, P121, DOI 10.1538/expanim.63.121
   Katsuda Y, 2014, ANIM SCI J, V85, P588, DOI 10.1111/asj.12191
   Kim JY, 2010, J BIOL CHEM, V285, P37251, DOI 10.1074/jbc.M110.142315
   Laybutt DR, 2003, J BIOL CHEM, V278, P2997, DOI 10.1074/jbc.M210581200
   Lenzen S, 2008, DIABETOLOGIA, V51, P216, DOI 10.1007/s00125-007-0886-7
   Li L, 2001, ENDOCRINOLOGY, V142, P5379, DOI 10.1210/en.142.12.5379
   Malta A, 2014, J ENDOCRINOL, V221, P285, DOI 10.1530/JOE-13-0473
   Mozaffari MS, 2006, ADV EXP MED BIOL, V583, P173
   Nagata M, 2006, EXP ANIM TOKYO, V55, P109, DOI 10.1538/expanim.55.109
   Nakanishi Y, 2008, J AUTOIMMUN, V30, P42, DOI 10.1016/j.jaut.2007.11.016
   Nakayama D, 2003, OBES RES, V11, P87, DOI 10.1038/oby.2003.14
   OLNEY JW, 1969, SCIENCE, V164, P719, DOI 10.1126/science.164.3880.719
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Reinehr R, 2004, PANCREAS, V28, P129, DOI 10.1097/00006676-200403000-00003
   Sasaki Y, 2011, EUR J PHARMACOL, V662, P1, DOI 10.1016/j.ejphar.2011.04.051
   Sasaki Y, 2009, LIFE SCI, V85, P490, DOI 10.1016/j.lfs.2009.07.017
   Schwitzgebel VM, 2014, J DIABETES INVEST, V5, P121, DOI 10.1111/jdi.12197
   Sharma A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075546
   Shi ZM, 2011, J HYPERTENS, V29, P846, DOI 10.1097/HJH.0b013e328344da8e
   Shi ZM, 2010, BRIT J NUTR, V104, P457, DOI 10.1017/S0007114510000760
   Simeone DM, 2006, AM J PHYSIOL-ENDOC M, V291, pE1305, DOI 10.1152/ajpendo.00561.2005
   STEGINK LD, 1973, J NUTR, V103, P1146
   Topp BB, 2004, DIABETOLOGIA, V47, P1602, DOI 10.1007/s00125-004-1493-5
   Hien VTT, 2013, PUBLIC HEALTH NUTR, V16, P922, DOI 10.1017/S1368980012003552
   Walker R, 2000, J NUTR, V130, p1049S, DOI 10.1093/jn/130.4.1049S
   Wang X, 2014, DIABETES METAB SYNDR, V7, P531, DOI 10.2147/DMSO.S69891
   Yin GS, 2013, INT J ENDOCRINOL, DOI 10.1155/2013/493828
NR 44
TC 9
Z9 9
U1 3
U2 18
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 29
PY 2015
VL 10
IS 6
AR e0131595
DI 10.1371/journal.pone.0131595
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CN1BL
UT WOS:000358150400128
PM 26121281
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Ekstrand, M
   Trajkovska, MG
   Perman-Sundelin, J
   Fogelstrand, P
   Adiels, M
   Johansson, M
   Mattsson-Hulten, L
   Boren, J
   Levin, M
AF Ekstrand, Matias
   Trajkovska, Maria Gustafsson
   Perman-Sundelin, Jeanna
   Fogelstrand, Per
   Adiels, Martin
   Johansson, Martin
   Mattsson-Hulten, Lillemor
   Boren, Jan
   Levin, Max
TI Imaging of Intracellular and Extracellular ROS Levels in Atherosclerotic
   Mouse Aortas Ex Vivo: Effects of Lipid Lowering by Diet or Atorvastatin
SO PLOS ONE
LA English
DT Article
ID SUPEROXIDE ANION PRODUCTION; OXIDATIVE STRESS; VASCULAR CELLS; MICE;
   PLAQUES; HYPERCHOLESTEROLEMIA; ATHEROGENESIS; DYSFUNCTION; ATHERECTOMY;
   EXPRESSION
AB Objective
   The first objective was to investigate if intracellular and extracellular levels of reactive oxygen species (ROS) within the mouse aorta increase before or after diet-induced lesion formation. The second objective was to investigate if intracellular and extracellular ROS correlates to cell composition in atherosclerotic lesions. The third objective was to investigate if intracellular and extracellular ROS levels within established atherosclerotic lesions can be reduced by lipid lowering by diet or atorvastatin.
   Approach and Results
   To address our objectives, we established a new imaging technique to visualize and quantify intracellular and extracellular ROS levels within intact mouse aortas ex vivo. Using this technique, we found that intracellular, but not extracellular, ROS levels increased prior to lesion formation in mouse aortas. Both intracellular and extracellular ROS levels were increased in advanced lesions. Intracellular ROS correlated with lesion content of macrophages. Extracellular ROS correlated with lesion content of smooth muscle cells. The high levels of ROS in advanced lesions were reduced by 5 days high dose atorvastatin treatment but not by lipid lowering by diet. Atorvastatin treatment did not affect lesion inflammation (aortic arch mRNA levels of CXCL 1, ICAM-1, MCP-1, TNF-alpha, VCAM, IL-6, and IL-1 beta) or cellular composition (smooth muscle cell, macrophage, and T-cell content).
   Conclusions
   Aortic levels of intracellular ROS increase prior to lesion formation and may be important in initiation of atherosclerosis. Our results suggest that within lesions, macrophages produce mainly intracellular ROS whereas smooth muscle cells produce extracellular ROS. Short term atorvastatin treatment, but not lipid lowering by diet, decreases ROS levels within established advanced lesions; this may help explain the lesion stabilizing and anti-inflammatory effects of long term statin treatment.
C1 [Ekstrand, Matias; Trajkovska, Maria Gustafsson; Perman-Sundelin, Jeanna; Fogelstrand, Per; Adiels, Martin; Mattsson-Hulten, Lillemor; Boren, Jan; Levin, Max] Univ Gothenburg, Dept Mol & Clin Med Wallenberg Lab, SE-41345 Gothenburg, Sweden.
   [Ekstrand, Matias; Trajkovska, Maria Gustafsson; Perman-Sundelin, Jeanna; Fogelstrand, Per; Adiels, Martin; Mattsson-Hulten, Lillemor; Boren, Jan; Levin, Max] Sahlgrens Univ Hosp, SE-41345 Gothenburg, Sweden.
   [Levin, Max] Sahlgrens Univ Hosp, Dept Oncol, SE-41345 Gothenburg, Sweden.
   [Johansson, Martin] Lund Univ, Dept Pathol, Malmo Univ Hosp, SE-20502 Malmo, Sweden.
RP Levin, M (reprint author), Univ Gothenburg, Dept Mol & Clin Med Wallenberg Lab, SE-41345 Gothenburg, Sweden.
EM max.levin@wlab.gu.se
OI Ekstrand, Matias/0000-0002-0403-9266
FU Swedish research council; Swedish heart and lung foundation; Swedish
   foundation for Strategic Research; Sahlgrenska University Hospital; Ake
   Wibergs fond; Jubileumsklinikens fond; Emelle fond; Novo Nordisk Fonden
   [NNF14OC0010799]
FX This work was supported by grants from The Swedish research council, The
   Swedish heart and lung foundation, The Swedish foundation for Strategic
   Research, ALF grants from Sahlgrenska University Hospital, Ake Wibergs
   fond, Jubileumsklinikens fond, and Emelle fond. The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Azumi H, 2002, ARTERIOSCL THROM VAS, V22, P1838, DOI 10.1161/01.ATV.0000037101.40667.62
   Ballinger SW, 2002, CIRCULATION, V106, P544, DOI 10.1161/01.CIR.0000023921.93743.89
   Benati D, 2010, J LEUKOCYTE BIOL, V87, P433, DOI 10.1189/jlb.0409273
   Bernal-Mizrachi C, 2005, NATURE, V435, P502, DOI 10.1038/nature03527
   BJORNHEDEN T, 1987, ARTERIOSCLEROSIS, V7, P238, DOI 10.1161/01.ATV.7.3.238
   Brasen JH, 2007, J AM COLL CARDIOL, V50, P2249, DOI 10.1016/j.jacc.2007.08.038
   Bylund J, 2014, METHODS MOL BIOL, V1124, P321, DOI 10.1007/978-1-62703-845-4_21
   Cai Hua, 2007, V139, P293
   Crisby M, 2001, CIRCULATION, V103, P926
   De Keulenaer GW, 1998, CIRC RES, V82, P1094, DOI 10.1161/01.RES.82.10.1094
   Gutierrez J, 2006, CIRC RES, V99, P924, DOI 10.1161/01.RES.0000248212.86638.e9
   Guzik TJ, 2005, METH MOLEC MED, V108, P73
   Hulten LM, 2009, CURR OPIN LIPIDOL, V20, P409, DOI 10.1097/MOL.0b013e3283307be8
   Lassegue B, 2012, CIRC RES, V110, P1364, DOI 10.1161/CIRCRESAHA.111.243972
   Lee R, 2012, CURR MED CHEM, V19, P2504, DOI 10.2174/092986712800493057
   Leppanen O, 2006, ATHEROSCLEROSIS, V188, P323, DOI 10.1016/j.atherosclerosis.2005.11.017
   Levin M, 2003, ARTERIOSCL THROM VAS, V23, P1801, DOI 10.1161/01.ATV.0000092872.54026.8D
   Madamanchi NR, 2007, CIRC RES, V100, P460, DOI 10.1161/01.RES.0000258450.44413.96
   NAKASHIMA Y, 1994, ARTERIOSCLER THROMB, V14, P133, DOI 10.1161/01.ATV.14.1.133
   OHARA Y, 1993, J CLIN INVEST, V91, P2546, DOI 10.1172/JCI116491
   OHARA Y, 1995, CIRCULATION, V92, P898, DOI 10.1161/01.CIR.92.4.898
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Sentman ML, 2001, ARTERIOSCL THROM VAS, V21, P1477, DOI 10.1161/hq0901.094248
   Sepac A, 2010, ANESTHESIOLOGY, V113, P906, DOI 10.1097/ALN.0b013e3181eff6b7
   Solem J, 2006, J INTERN MED, V259, P267, DOI 10.1111/j.1365-2796.2006.01608.x
   van der Hoorn JWA, 2007, J HYPERTENS, V25, P2454, DOI 10.1097/HJH.0b013e3282ef79f7
   Vecchione C, 2002, CIRC RES, P91
   Verreth W, 2007, BRIT J PHARMACOL, V151, P347, DOI 10.1038/sj.bjb.0707231
   Wassmann S, 2001, HYPERTENSION, V37, P1450, DOI 10.1161/01.HYP.37.6.1450
   Wassmann S, 2001, MOL PHARMACOL, V59, P646
   Williams KJ, 2008, NAT CLIN PRACT CARD, V5, P91, DOI 10.1038/ncpcardio1086
   WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499
NR 32
TC 14
Z9 14
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 22
PY 2015
VL 10
IS 6
AR e0130898
DI 10.1371/journal.pone.0130898
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CL3FM
UT WOS:000356835800120
PM 26098110
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Repetto-Llamazares, AHV
   Larsen, RH
   Patzke, S
   Fleten, KG
   Didierlaurent, D
   Pichard, A
   Pouget, JP
   Dahle, J
AF Repetto-Llamazares, Ada H. V.
   Larsen, Roy H.
   Patzke, Sebastian
   Fleten, Karianne G.
   Didierlaurent, David
   Pichard, Alexandre
   Pouget, Jean Pierre
   Dahle, Jostein
TI Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting
   Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma
SO PLOS ONE
LA English
DT Article
ID B-CELL LYMPHOMA; IBRITUMOMAB TIUXETAN RADIOIMMUNOTHERAPY; ANTIBODY-DRUG
   CONJUGATE; MONOCLONAL-ANTIBODIES; NUDE-MICE; ANTITUMOR-ACTIVITY;
   PRETARGETED RADIOIMMUNOTHERAPY; INTERNALIZATION; XENOGRAFTS; RITUXIMAB
AB Lu-177-DOTA-HH1 (Lu-177-HH1) is a novel anti-CD37 radioimmunoconjugate developed to treat non-Hodgkin lymphoma. Mice with subcutaneous Ramos xenografts were treated with different activities of Lu-177-HH1, Lu-177-DOTA-rituximab (Lu-177-rituximab) and non-specific Lu-177-DOTA-IgG(1) (Lu-177-IgG(1)) and therapeutic effect and toxicity of the treatment were monitored. Significant tumor growth delay and increased survival of mice were observed in mice treated with 530 MBq/kg Lu-177-HH1 as compared with mice treated with similar activities of Lu-177-rituximab or non-specific Lu-177-IgG1, 0.9% NaCl or unlabeled HH1. All mice injected with 530 MBq/kg of Lu-177-HH1 tolerated the treatment well. In contrast, 6 out of 10 mice treated with 530 MBq/kg Lu-177-rituximab experienced severe radiation toxicity. The retention of Lu-177-rituximab in organs of the mononuclear phagocyte system was longer than for Lu-177-HH1, which explains the higher toxicity observed in mice treated with Lu-177-rituximab. In vitro internalization studies showed that Lu-177-HH1 internalizes faster and to a higher extent than Lu-177-rituximab which might be the reason for the better therapeutic effect of Lu-177-HH1.
C1 [Repetto-Llamazares, Ada H. V.; Dahle, Jostein] Nord Nanovector ASA, N-0884 Oslo, Norway.
   [Repetto-Llamazares, Ada H. V.; Patzke, Sebastian] Oslo Univ Hosp, Inst Canc Res, Dept Radiat Biol, N-0310 Oslo, Norway.
   [Larsen, Roy H.] Sciencons AS, N-0884 Oslo, Norway.
   [Fleten, Karianne G.] Oslo Univ Hosp, Inst Canc Res, Dept Tumor Biol, Montebello, N-0310 Oslo, Norway.
   [Didierlaurent, David] Ctr Rech Canc Toulouse, INSERM, UMR 1037, UPS, F-31062 Toulouse, France.
   [Pichard, Alexandre; Pouget, Jean Pierre] Univ Montpellier, Inst Natl Sante & Rech Med, Inst Rech Cancerol Montpellier, U896, F-34059 Montpellier, France.
RP Repetto-Llamazares, AHV (reprint author), Nord Nanovector ASA, Kjelsasveien 168, N-0884 Oslo, Norway.
EM arepetto@nordicnanovector.com
RI Patzke, Sebastian/G-9909-2019; Patzke, Sebastian/R-5579-2019; POUGET,
   Jean-Pierre/R-6697-2019
OI Patzke, Sebastian/0000-0001-6821-197X; Patzke,
   Sebastian/0000-0001-6821-197X; POUGET, Jean-Pierre/0000-0001-8551-2029
FU Norwegian Research Council [213633, 219454]; Nordic Nanovector ASA
FX This study was partially funded by the Norwegian Research Council
   (http://www.forskningsradet.no) grant numbers 213633 and 219454 and by
   Nordic Nanovector ASA (http://www.nordicnanovector.com). Co-authors Ada
   H. V. Repetto-Llamazares and Jostein Dahle are employed by Nordic
   Nanovector ASA. Nordic Nanovector ASA provided support in the form of
   salaries for authors AHVR-L and JD, but did not have any additional role
   in the study design, data collection and analysis, decision to publish,
   or preparation of the manuscript. Co-author Roy H. Larsen is affiliated
   to Sciencons AS. Sciencons AS is a shareholder of Nordic Nanovector ASA.
   Sciencons AS did not provide support in the form of salary for author
   RHL, and did not have any additional role in the study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript. The specific roles of these authors are articulated in the
   'author contributions' section.
CR Ansell SM, 2014, BLOOD
   Beckwith KA, 2014, LEUKEMIA, V28, P1501, DOI 10.1038/leu.2014.32
   Beers SA, 2010, BLOOD, V115, P5191, DOI 10.1182/blood-2010-01-263533
   Beers SA, 2010, SEMIN HEMATOL, V47, P107, DOI 10.1053/j.seminhematol.2010.01.001
   Beum PV, 2011, J IMMUNOL, V187, P3438, DOI 10.4049/jimmunol.1101189
   Boross P, 2012, AM J CANCER RES, V2, P676
   BRASLAWSKY GR, 1991, CANCER IMMUNOL IMMUN, V33, P367, DOI 10.1007/BF01741596
   Brown RS, 1997, NUCL MED BIOL, V24, P657, DOI 10.1016/S0969-8051(97)00099-1
   BUCHSBAUM DJ, 1992, CANCER RES, V52, P6476
   CAVACINI LA, 1992, CELL IMMUNOL, V144, P296, DOI 10.1016/0008-8749(92)90246-L
   Dahle J, 2013, ANTICANCER RES, V33, P85
   Davis TA, 2000, J CLIN ONCOL, V18, P3135, DOI 10.1200/JCO.2000.18.17.3135
   Deckert J, 2013, BLOOD, V122, P3500, DOI 10.1182/blood-2013-05-505685
   EARY JF, 1990, J NUCL MED, V31, P1257
   Flinn IW, 2014, BLOOD, V123, P2944, DOI 10.1182/blood-2013-11-531327
   Forrer F, 2013, J NUCL MED, V54, P1045, DOI 10.2967/jnumed.112.115170
   FREIREICH EMIL J., 1966, CANCER CHEMOTHERAP REP, V50, P219
   FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0
   GOLDSMITH MA, 1975, CANCER RES, V35, P1354
   Gopal AK, 2014, INVEST NEW DRUGS
   Graff BA, 2003, BRIT J CANCER, V88, P291, DOI 10.1038/sj.bjc.6600680
   Greaves P, 2004, NAT REV DRUG DISCOV, V3, P226, DOI 10.1038/nrd1329
   Heider KH, 2011, BLOOD, V118, P4159, DOI 10.1182/blood-2011-04-351932
   Kaminski MS, 2005, NEW ENGL J MED, V352, P441, DOI 10.1056/NEJMoa041511
   Kaminski MS, 2000, BLOOD, V96, P1259
   KAMINSKI MS, 1992, J CLIN ONCOL, V10, P1696, DOI 10.1200/JCO.1992.10.11.1696
   Kvinnsland Y, 2001, RADIAT RES, V155, P288, DOI 10.1667/0033-7587(2001)155[0288:RWAPEM]2.0.CO;2
   LINDMO T, 1984, J IMMUNOL METHODS, V72, P77, DOI 10.1016/0022-1759(84)90435-6
   Manders JMB, 2002, COMPARATIVE MED, V52, P36
   Martin SM, 2011, J HEMATOL ONCOL, V4, DOI 10.1186/1756-8722-4-49
   Mattes MJ, 2008, CLIN CANCER RES, V14, P6154, DOI 10.1158/1078-0432.CCR-08-0404
   Michel RB, 2002, CLIN CANCER RES, V8, P2701
   Miller WH, 2005, CANCER BIOTHER RADIO, V20, P436, DOI 10.1089/cbr.2005.20.436
   Moldenhauer G, 2000, J BIOL REG HOMEOS AG, V14, P281
   National Nuclear Data Center, ENSDF DEC DAT MIRD M
   Naumovski L, 2005, MOL CANCER THER, V4, P968, DOI 10.1158/1535-7163.MCT-04-0339
   NAUTA MM, 1986, BRIT J CANCER, V54, P331, DOI 10.1038/bjc.1986.181
   Olson H, 2000, REGUL TOXICOL PHARM, V32, P56, DOI 10.1006/rtph.2000.1399
   Oostra DR, 2014, BREAST CANCER-TARGET, V6, P103, DOI 10.2147/BCTT.S67297
   Park SI, 2010, BLOOD, V116, P4231, DOI 10.1182/blood-2010-05-282327
   Pham T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014498
   Postema EJ, 2003, CANCER BIOTHER RADIO, V18, P525, DOI 10.1089/108497803322287592
   PRESS OW, 1989, J CLIN ONCOL, V7, P1027, DOI 10.1200/JCO.1989.7.8.1027
   PRESS OW, 1993, NEW ENGL J MED, V329, P1219, DOI 10.1056/NEJM199310213291702
   PRESS OW, 1989, CANCER RES, V49, P4906
   PRESS OW, 1994, BLOOD, V83, P1390
   Press OW, 2001, BLOOD, V98, P2535, DOI 10.1182/blood.V98.8.2535
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Repetto-Llamazares A, 2014, ANTICANCER RES, V34, P3263
   Repetto-Llamazares AHV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103070
   Repetto-Llamazares AHV, 2013, CURR RADIOPHARM, V6, P20, DOI 10.2174/1874471011306010004
   Robak T, 2013, 55 AM SOC HEM ANN M
   SHARKEY RM, 1990, CANCER RES, V50, pS964
   Sieber T, 2003, BRIT J HAEMATOL, V121, P458, DOI 10.1046/j.1365-2141.2003.04305.x
   SILOBRCIC V, 1990, INT J CANCER, V45, P325, DOI 10.1002/ijc.2910450220
   SMELAND E, 1985, SCAND J IMMUNOL, V21, P205, DOI 10.1111/j.1365-3083.1985.tb01422.x
   Vaughan AT, 2014, BLOOD, V123, P669, DOI 10.1182/blood-2013-04-490821
   Vervoordeldonk SF, 1996, CANCER IMMUNOL IMMUN, V42, P24, DOI 10.1007/s002620050247
   Witzig TE, 2002, J CLIN ONCOL, V20, P3262, DOI 10.1200/JCO.2002.11.017
   Witzig TE, 2002, J CLIN ONCOL, V20, P2453, DOI 10.1200/JCO.2002.11.076
NR 60
TC 13
Z9 13
U1 1
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 11
PY 2015
VL 10
IS 6
AR e0128816
DI 10.1371/journal.pone.0128816
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CK3FB
UT WOS:000356100900030
PM 26066655
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Bandeira, LG
   Bortolot, BS
   Cecatto, MJ
   Monte-Alto-Costa, A
   Romana-Souza, B
AF Bandeira, Luana Graziella
   Bortolot, Beatriz Salari
   Cecatto, Matheus Jorand
   Monte-Alto-Costa, Andrea
   Romana-Souza, Bruna
TI Exogenous Tryptophan Promotes Cutaneous Wound Healing of Chronically
   Stressed Mice through Inhibition of TNF-alpha and IDO Activation
SO PLOS ONE
LA English
DT Article
ID INDOLEAMINE 2,3-DIOXYGENASE; PSYCHOLOGICAL STRESS; T-CELLS; EXPRESSION;
   RESTRAINT; TOLERANCE; RATS; INDUCTION; NUTRITION; MELATONIN
AB Stress prolongs the inflammatory response compromising the dermal reconstruction and wound closure. Acute stress-induced inflammation increases indoleamine 2, 3-dioxygenase-stimulated tryptophan catabolism. To investigate the role of indoleamine 2, 3-dioxygenase expression and tryptophan administration in adverse effects of stress on cutaneous wound healing, mice were submitted to chronic restraint stress and treated with tryptophan daily until euthanasia. Excisional lesions were created on each mouse and 5 or 7 days later, the lesions were analyzed. In addition, murine skin fibroblasts were exposed to elevated epinephrine levels plus tryptophan, and fibroblast activity was evaluated. Tryptophan administration reversed the reduction of the plasma tryptophan levels and the increase in the plasma normetanephrine levels induced by stress 5 and 7 days after wounding. Five days after wounding, stress-induced increase in the protein levels of tumor necrosis factor-alpha and indoleamine 2, 3-dioxygenase, and this was inhibited by tryptophan. Stress-induced increase in the lipid peroxidation and the amount of the neutrophils, macrophages and T cells number was reversed by tryptophan 5 days after wounding. Tryptophan administration inhibited the reduction of myofibroblast density, collagen deposition, re-epithelialization and wound contraction induced by stress 5 days after wounding. In dermal fibroblast culture, the tryptophan administration increased the cell migration and AKT phosphorylation in cells treated with high epinephrine levels. In conclusion, tryptophan-induced reduction of inflammatory response and indoleamine 2, 3-dioxygenase expression may have accelerated cutaneous wound healing of chronically stressed mice.
C1 [Bandeira, Luana Graziella; Bortolot, Beatriz Salari; Cecatto, Matheus Jorand; Monte-Alto-Costa, Andrea; Romana-Souza, Bruna] Univ Estado Rio De Janeiro, Dept Histol & Embryol, Lab Tissue Repair, Rio De Janeiro, Brazil.
RP Monte-Alto-Costa, A (reprint author), Univ Estado Rio De Janeiro, Dept Histol & Embryol, Lab Tissue Repair, Rio De Janeiro, Brazil.
EM amacosta@uerj.br
RI Monte-Alto-Costa, Andrea/C-5224-2013
OI Monte-Alto-Costa, Andrea/0000-0001-6572-7882
FU Carlos Chagas Filho Foundation for Research Support in the State of Rio
   de Janeiro (FAPERJ) [E-26/110.134/2014, E-26/112.1210/2012]; National
   Council for Scientific and Technological Development (CNPq)
   [302918/2012-4]
FX Funding for this study was received from Carlos Chagas Filho Foundation
   for Research Support in the State of Rio de Janeiro (FAPERJ No
   E-26/110.134/2014; FAPERJ No E-26/112.1210/2012) and the National
   Council for Scientific and Technological Development (CNPq),
   #302918/2012-4. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR de Brito TLA, 2014, LIFE SCI, V100, P138, DOI [10.1016/j.lfs2014.02.007, 10.1016/j.lfs.2014.02.007]
   BADDELEY AJ, 1986, J MICROSC-OXFORD, V142, P259, DOI 10.1111/j.1365-2818.1986.tb04282.x
   Cardoso JE, 2007, TOXICOL PATHOL, V35, P890, DOI 10.1080/01926230701459986
   Chandran A, 2013, PROG NEURO-PSYCHOPH, V40, P240, DOI 10.1016/j.pnpbp.2012.08.001
   Cohen S, 1999, PSYCHOSOM MED, V61, P175, DOI 10.1097/00006842-199903000-00009
   Costa RA, 2011, WOUND REPAIR REGEN, V19, P487, DOI 10.1111/j.1524-475X.2011.00700.x
   Cruz FC, 2012, INT J DEV NEUROSCI, V30, P19, DOI 10.1016/j.ijdevneu.2011.10.005
   de Almeida TF, 2013, EXP DERMATOL, V22, P524, DOI 10.1111/exd.12186
   Dunn Jeffrey H, 2013, Dermatol Online J, V19, P18561
   Forouzandeh F, 2008, MOL CELL BIOCHEM, V309, P1, DOI 10.1007/s11010-007-9635-y
   Freshney R. I., 2010, CULTURE ANIMAL CELLS, P163
   Glaser R, 2005, NAT REV IMMUNOL, V5, P243, DOI 10.1038/nri1571
   GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x
   Hoyer D, 2002, PHARMACOL BIOCHEM BE, V71, P533, DOI 10.1016/S0091-3057(01)00746-8
   Hsu HR, 2007, EUR J PHARMACOL, V566, P124, DOI 10.1016/j.ejphar.2007.03.040
   Hughes MM, 2012, BRAIN BEHAV IMMUN, V26, P979, DOI 10.1016/j.bbi.2012.05.010
   Jaworek J, 2004, J PINEAL RES, V37, P161, DOI 10.1111/j.1600-079X.2004.00153.x
   Kiank C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011825
   KIECOLTGLASER JK, 1995, LANCET, V346, P1194, DOI 10.1016/S0140-6736(95)92899-5
   Konturek PC, 2008, J PHYSIOL PHARMACOL, V59, P53
   Koopmans SJ, 2005, PHYSIOL BEHAV, V85, P469, DOI 10.1016/j.physbeh.2005.05.010
   LAUER JW, 1958, ARCH NEURO PSYCHIATR, V80, P122, DOI 10.1001/archneurpsyc.1958.02340070140021
   Le Floc'h N, 2011, AMINO ACIDS, V41, P1195, DOI 10.1007/s00726-010-0752-7
   Lieberman HR, 2003, APPETITE, V40, P245, DOI 10.1016/S0195-6663(03)00010-2
   Majewska M, 2007, J PHYSIOL PHARMACOL, V58, P125
   Markus CR, 2010, CLIN NUTR, V29, P610, DOI 10.1016/j.clnu.2010.01.003
   Markus R, 2000, PHYSIOL BEHAV, V70, P333, DOI 10.1016/S0031-9384(00)00265-1
   Marucha PT, 1998, PSYCHOSOM MED, V60, P362, DOI 10.1097/00006842-199805000-00025
   MATSUSHIMA K, 1989, J EXP MED, V169, P1485, DOI 10.1084/jem.169.4.1485
   Mellor AL, 2004, NAT REV IMMUNOL, V4, P762, DOI 10.1038/nri1457
   Mercado AM, 2002, J NEUROIMMUNOL, V129, P74, DOI 10.1016/S0165-5728(02)00174-1
   Metz R, 2012, ONCOIMMUNOLOGY, V1, P1460, DOI 10.4161/onci.21716
   Muller Norbert, 2006, Expert Rev Neurother, V6, P1017, DOI 10.1586/14737175.6.7.1017
   Munn DH, 2007, J CLIN INVEST, V117, P1147, DOI 10.1172/JCI31178
   Munn DH, 2005, IMMUNITY, V22, P633, DOI 10.1016/j.immuni.2005.03.013
   Nascimento AP, 2006, BRIT J NUTR, V96, P1069, DOI 10.1017/BJN20061955
   NOUROOZZADEH J, 1994, ANAL BIOCHEM, V220, P403, DOI 10.1006/abio.1994.1357
   Padgett DA, 1998, BRAIN BEHAV IMMUN, V12, P64, DOI 10.1006/brbi.1997.0512
   PISANO JJ, 1960, CLIN CHIM ACTA, V5, P406
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Romana-Souza B, 2014, BRAIN BEHAV IMMUN, V36, P101, DOI 10.1016/j.bbi.2013.10.015
   Romana-Souza B, 2011, EXP DERMATOL, V20, P413, DOI 10.1111/j.1600-0625.2010.01239.x
   Romana-Souza B, 2010, EXP DERMATOL, V19, P821, DOI 10.1111/j.1600-0625.2010.01113.x
   Romana-Souza B, 2010, BRAIN BEHAV IMMUN, V24, P427, DOI 10.1016/j.bbi.2009.11.012
   Rosa AD, 2014, WOUND REPAIR REGEN, V22, P537, DOI 10.1111/wrr.12191
   Saito Y, 2008, J INVEST DERMATOL, V128, P1838, DOI 10.1038/sj.jid.5701258
   Sivamani RK, 2009, PLOS MED, V6, P105, DOI 10.1371/journal.pmed.1000012
   SPIES JR, 1949, ANAL CHEM, V21, P1249, DOI 10.1021/ac60034a033
   Squarize CH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010643
   Tanke MAC, 2008, NEUROCHEM INT, V52, P272, DOI 10.1016/j.neuint.2007.05.022
   THOMSON J, 1982, PSYCHOL MED, V12, P741, DOI 10.1017/S0033291700049047
   VARGA J, 1995, J CLIN INVEST, V96, P475, DOI 10.1172/JCI118058
   Vedhara K, 1999, LANCET, V353, P627, DOI 10.1016/S0140-6736(98)06098-X
   Wu HL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089663
NR 54
TC 13
Z9 15
U1 1
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 9
PY 2015
VL 10
IS 6
AR e0128439
DI 10.1371/journal.pone.0128439
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CK6PC
UT WOS:000356349000022
PM 26057238
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Bai, H
   Wang, ZX
   Hu, R
   Kan, TT
   Li, Y
   Zhang, XS
   Zhang, JL
   Lian, L
   Han, HB
   Lian, ZX
AF Bai, Hai
   Wang, Zhixian
   Hu, Rui
   Kan, Tongtong
   Li, Yan
   Zhang, Xiaosheng
   Zhang, Jinlong
   Lian, Ling
   Han, Hongbing
   Lian, Zhengxing
TI A 90-Day Toxicology Study of Meat from Genetically Modified Sheep
   Overexpressing TLR4 in Sprague-Dawley Rats
SO PLOS ONE
LA English
DT Article
ID SIGNAL-TRANSDUCTION; SAFETY ASSESSMENT; RECEPTOR 4; PROTEIN;
   LIPOPOLYSACCHARIDE; MICROINJECTION; ANIMALS; CATTLE; GENE; MICE
AB Genetic modification offers alternative strategies to traditional animal breeding. However, the food safety of genetically modified (GM) animals has attracted increasing levels of concern. In this study, we produced GM sheep overexpressing TLR4, and the transgene-positive off springs (F1) were confirmed using the polymerase chain reaction (PCR) and Southern blot. The expression of TLR4 was 2.5-fold compared with that of the wild-type (WT) sheep samples. During the 90-day safety study, Sprague-Dawley rats were fed with three different dietary concentrations (3.75%, 7.5%, and 15% wt/wt) of GM sheep meat, WT sheep meat or a commercial diet (CD). Blood samples from the rats were collected and analyzed for hematological and biochemical parameters, and then compared with hematological and biochemical reference ranges. Despite a few significant differences among the three groups in some parameters, all other values remained within the normal reference intervals and thus were not considered to be affected by the treatment. No adverse diet-related differences in body weights or relative organ weights were observed. Furthermore, no differences were observed in the gross necropsy findings or microscopic pathology of the rats whose diets contained the GM sheep meat compared with rats whose diets contained the WT sheep meat. Therefore, the present 90-day rat feeding study suggested that the meat of GM sheep overexpressing TLR4 had no adverse effect on Sprague-Dawley rats in comparison with WT sheep meat. These results provide valuable information regarding the safety assessment of meat derived from GM animals.
C1 [Bai, Hai; Wang, Zhixian; Hu, Rui; Kan, Tongtong; Li, Yan; Lian, Ling; Han, Hongbing; Lian, Zhengxing] China Agr Univ, Beijing Key Lab Anim Genet Improvement, Beijing 100094, Peoples R China.
   [Bai, Hai] Shanxi Datong Univ, Sch Life Sci, Datong, Shanxi, Peoples R China.
   [Zhang, Xiaosheng; Zhang, Jinlong] Tianjin Inst Anim Sci, Tianjin, Peoples R China.
RP Han, HB (reprint author), China Agr Univ, Beijing Key Lab Anim Genet Improvement, Beijing 100094, Peoples R China.
EM hanhongbing@cau.edu.cn; lianzhx@cau.edu.cn
FU Chinese Universities Scientific Fund [2014JD016]; National Transgenic
   Creature Breeding Grand Project [2013ZX08008-005]
FX This work was supported by grants from Chinese Universities Scientific
   Fund (2014JD016) and National Transgenic Creature Breeding Grand Project
   (2013ZX08008-005). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Andersson HC, 2012, EFSA J, V10, DOI 10.2903/j.efsa.2012.2501
   Bihl F, 2003, J IMMUNOL, V170, P6141, DOI 10.4049/jimmunol.170.12.6141
   Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689
   CLEMENTS JE, 1994, VIROLOGY, V200, P370, DOI 10.1006/viro.1994.1201
   Deng SL, 2013, THERIOGENOLOGY, V80, P50, DOI 10.1016/j.theriogenology.2013.03.008
   Deng SL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047118
   European Commission, 2013, OFFICIAL J EUROPEA L, V157/1, P1
   HAMMER RE, 1985, NATURE, V315, P680, DOI 10.1038/315680a0
   Hoshino K, 1999, J IMMUNOL, V162, P3749
   Huang Jikun, 2003, BIOTECHNOLOGY POLICY, V4
   Huang YJ, 2007, P NATL ACAD SCI USA, V104, P13603, DOI 10.1073/pnas.0702756104
   Kampfmann I, 2012, VET CLIN PATH, V41, P228, DOI 10.1111/j.1939-165X.2012.00427.x
   Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210
   Lee JY, 2003, J BIOL CHEM, V278, P37041, DOI 10.1074/jbc.M305213200
   Liu S, 2013, FOOD CHEM TOXICOL, V57, P314, DOI 10.1016/j.fct.2013.04.003
   Lu YC, 2008, CYTOKINE, V42, P145, DOI 10.1016/j.cyto.2008.01.006
   Lyall J, 2011, SCIENCE, V331, P223, DOI 10.1126/science.1198020
   MULLER M, 1994, REPROD FERT DEVELOP, V6, P605, DOI 10.1071/RD9940605
   MURRAY JD, 1989, REPROD FERT DEVELOP, V1, P147, DOI 10.1071/RD9890147
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Richards HA, 2003, J NUTR, V133, P1909
   Richt JA, 2007, NAT BIOTECHNOL, V25, P132, DOI 10.1038/nbt1271
   Schroder M, 2007, FOOD CHEM TOXICOL, V45, P339, DOI 10.1016/j.fct.2006.09.001
   Sengupta P, 2012, BIOMED INT, V2, P81
   Swanson KS, 2004, J ANIM SCI, V82, P1713
   Tang MX, 2012, TRANSGENIC RES, V21, P499, DOI 10.1007/s11248-011-9550-6
   Tang XM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052507
   Wall RJ, 2005, NAT BIOTECHNOL, V23, P445, DOI 10.1038/nbt1078
   Wang YZ, 2007, BLOOD, V110, P962, DOI 10.1182/blood-2007-01-066027
   Whitelaw CBA, 2005, REV SCI TECH OIE, V24, P275, DOI 10.20506/rst.24.1.1569
   Williams P. G, 2007, NUTR DIET, V64, P113
   Xu WT, 2009, FOOD CHEM TOXICOL, V47, P1459, DOI 10.1016/j.fct.2009.03.029
   Yang XZ, 2007, P NATL ACAD SCI USA, V104, P13859, DOI 10.1073/pnas.0706163104
   Zhou GH, 2012, MEAT SCI, V92, P188, DOI 10.1016/j.meatsci.2012.04.016
NR 34
TC 4
Z9 5
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 13
PY 2015
VL 10
IS 4
AR UNSP e0121636
DI 10.1371/journal.pone.0121636
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CF8XK
UT WOS:000352845100044
PM 25874566
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Zhang, Y
   Wang, H
   Cui, LJ
   Zhang, YY
   Liu, Y
   Chu, X
   Liu, ZY
   Zhang, JP
   Chu, L
AF Zhang, Ying
   Wang, Hao
   Cui, Lijing
   Zhang, Yuanyuan
   Liu, Yang
   Chu, Xi
   Liu, Zhenyi
   Zhang, Jianping
   Chu, Li
TI Continuing Treatment with Salvia miltiorrhiza Injection Attenuates
   Myocardial Fibrosis in Chronic Iron-Overloaded Mice
SO PLOS ONE
LA English
DT Article
ID CALCIUM-CHANNEL BLOCKER; THALASSEMIA MAJOR; OXIDATIVE STRESS; COMPOUND
   ASTRAGALUS; COLLAGEN-SYNTHESIS; DANSHEN INJECTION; HEPATIC-FIBROSIS;
   CARDIAC FIBROSIS; CA2+ CHANNELS; EXTRACT
AB Iron overload cardiomyopathy results from iron accumulation in the myocardium that is closely linked to iron-mediated myocardial fibrosis. Salvia miltiorrhiza (SM, also known as Danshen), a traditional Chinese medicinal herb, has been widely used for hundreds of years to treat cardiovascular diseases. Here, we investigated the effect and potential mechanism of SM on myocardial fibrosis induced by chronic iron overload (CIO) in mice. Kunming male mice (8 weeks old) were randomized to six groups of 10 animals each: control (CONT), CIO, low-dose SM (L-SM), high-dose SM (H-SM), verapamil (VRP) and deferoxamine (DFO) groups. Normal saline was injected in the CONT group. Mice in the other five groups were treated with iron dextran at 50 mg/kg per day intraperitoneally for 7 weeks, and those in the latter four groups also received corresponding daily treatments, including 3 g/kg or 6 g/kg of SM, 100 mg/kg of VRP, or 100 mg/kg of DFO. The iron deposition was estimated histologically using Prussian blue staining. Myocardial fibrosis was determined by Masson's trichrome staining and hydroxyproline (Hyp) quantitative assay. Superoxide dismutase (SOD) activity, malondialdehyde (MDA) content and protein expression levels of type I collagen (COL I), type I collagen (COL III), transforming growth factor-beta(1) (TGF-beta(1)) and matrix metalloproteinase-9 (MMP-9) were analyzed to investigate the mechanisms underlying the effects of SM against iron-overloaded fibrosis. Treatment of chronic iron-overloaded mice with SM dose-dependently reduced iron deposition levels, fibrotic area percentage, Hyp content, expression levels of COL I and COL III, as well as upregulated the expression of TGF-beta(1) and MMP-9 proteins in the heart. Moreover, SM treatment decreased MDA content and increased SOD activity. In conclusion, SM exerted activities against cardiac fibrosis induced by CIO, which may be attributed to its inhibition of iron deposition, as well as collagen metabolism and oxidative stress.
C1 [Zhang, Ying; Cui, Lijing; Liu, Yang; Zhang, Jianping; Chu, Li] Hebei Med Univ, Dept Pharmacol, Shijiazhuang, Peoples R China.
   [Wang, Hao] Hebei Med Univ, Dept Chinese Mat Med, Shijiazhuang, Peoples R China.
   [Zhang, Yuanyuan; Liu, Zhenyi] Hebei Univ Chinese Med, Dept Pharmaceut, Shijiazhuang, Peoples R China.
   [Chu, Xi] Hebei Med Univ, Hosp 4, Shijiazhuang, Peoples R China.
RP Chu, L (reprint author), Hebei Med Univ, Dept Pharmacol, Shijiazhuang, Peoples R China.
EM chuli0614@126.com
FU Nature Fund of Hebei Province, China [C2011206025, H2014206244]; Fund of
   Hebei Science and Technology Bureau [10276105D-2]
FX This study was supported by the Nature Fund of Hebei Province, China
   http://hensf.hebstd.gov.cn/(No. C2011206025 and H2014206244) and the
   Fund of Hebei Science and Technology Bureau
   http://www.hebstd.gov.cn/(No. 10276105D-2). In this study, the funder
   conceived and designed the experiments, and wrote the paper.
CR Andrews NC, 1999, NEW ENGL J MED, V341, P1986, DOI 10.1056/NEJM199912233412607
   Arezzini B, 2003, INT J BIOCHEM CELL B, V35, P486, DOI 10.1016/S1357-2725(02)00298-4
   Barton JC, 1996, NAT MED, V2, P394, DOI 10.1038/nm0496-394
   Berdoukas V, 2012, J BLOOD MED, V3, P119, DOI 10.2147/JBM.S27400
   Boin F, 2014, ORPHANET J RARE DIS, V9, DOI 10.1186/s13023-014-0123-7
   Borgna-Pignatti C, 2005, ANN NY ACAD SCI, V1054, P40, DOI 10.1196/annals.1345.006
   Borgna-Pignatti C, 2006, BLOOD, V107, P3733, DOI 10.1182/blood-2005-07-2933
   Borgna-Pignatti C, 2004, HAEMATOLOGICA, V89, P1187
   Cao CM, 2003, LIFE SCI, V72, P2451, DOI 10.1016/S0024-3205(03)00142-5
   Cappellini Maria D, 2009, Hemoglobin, V33 Suppl 1, pS58, DOI 10.3109/03630260903346924
   Chang WT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097455
   Chen L, 2009, PLANTA MED, V75, P1573, DOI 10.1055/s-0029-1185905
   Chern JPS, 2007, PEDIATR BLOOD CANCER, V48, P550, DOI 10.1002/pbc.21028
   Ding M, 2006, J ALTERN COMPLEM MED, V12, P5, DOI 10.1089/acm.2006.12.5
   Fernandes JL, 2013, AM J MED, V126, P834, DOI 10.1016/j.amjmed.2013.05.002
   Fraga CG, 2002, TOXICOLOGY, V180, P23, DOI 10.1016/S0300-483X(02)00379-7
   Franchini M, 2004, HEMATOL J, V5, P287, DOI 10.1038/sj.thj.6200407
   FRIDOVICH I, 1989, FREE RADICAL BIO MED, V7, P557, DOI 10.1016/0891-5849(89)90032-4
   Galey JB, 2000, J MED CHEM, V43, P1418, DOI 10.1021/jm9911635
   Gao YG, 2014, J ETHNOPHARMACOL, V158, P397, DOI 10.1016/j.jep.2014.10.049
   Gao YG, 2013, J ETHNOPHARMACOL, V145, P254, DOI 10.1016/j.jep.2012.10.060
   Ge GH, 2014, GENE, V546, P97, DOI 10.1016/j.gene.2014.05.021
   Guan SJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074318
   Gujja P, 2010, J AM COLL CARDIOL, V56, P1001, DOI 10.1016/j.jacc.2010.03.083
   GUTTERIDGE JMC, 1995, CLIN CHEM, V41, P1819
   He S, 2012, BRIT J DERMATOL, V166, P564, DOI 10.1111/j.1365-2133.2011.10674.x
   Hentze MW, 2010, CELL, V142, P24, DOI 10.1016/j.cell.2010.06.028
   Hou J., 1999, CHINESE J TUBERCULOS, V22, P43
   Hsu YC, 2005, J BIOMED SCI, V12, P185, DOI 10.1007/s11373-004-8167-7
   IKEDA H, 1992, HEPATOLOGY, V15, P282, DOI 10.1002/hep.1840150218
   Jesmin S, 2002, DIABETOLOGIA, V45, P402, DOI 10.1007/s00125-001-0765-6
   Karwinski W, 1996, J SURG RES, V64, P150, DOI 10.1006/jsre.1996.0321
   Kudo H, 2008, TOXICOLOGY, V246, P143, DOI 10.1016/j.tox.2008.01.004
   Kumfu S, 2011, EUR J HAEMATOL, V86, P156, DOI 10.1111/j.1600-0609.2010.01549.x
   Lam FFY, 2006, EUR J PHARMACOL, V553, P240, DOI 10.1016/j.ejphar.2006.09.030
   Lee SH, 2011, J ETHNOPHARMACOL, V137, P1409, DOI 10.1016/j.jep.2011.08.007
   Lee TY, 2006, J PHARM PHARMACOL, V58, P659, DOI 10.1211/jpp.58.5.0011
   Lian WS, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-26
   Lin H, 2013, MOL PHARMACOL, V84, P275, DOI 10.1124/mol.112.083964
   Liu L, 2012, MOL MED REP, V6, P1231, DOI 10.3892/mmr.2012.1076
   Lu HY, 2014, BIOL PHARM BULL, V37, P961, DOI 10.1248/bpb.b13-00921
   Matsui T, 2010, BIOCHEM BIOPH RES CO, V396, P566, DOI 10.1016/j.bbrc.2010.04.149
   Murphy CJ, 2010, J CARD FAIL, V16, P888, DOI 10.1016/j.cardfail.2010.05.009
   Nan JX, 2001, J PHARM PHARMACOL, V53, P197, DOI 10.1211/0022357011775406
   Oudit GY, 2006, J MOL MED, V84, P349, DOI 10.1007/s00109-005-0029-x
   Oudit GY, 2003, NAT MED, V9, P1187, DOI 10.1038/nm920
   Patel R, 2006, J VASC SURG, V43, P364, DOI 10.1016/j.jvs.2005.10.032
   Pepe A, 2009, HEART, V95, P1688, DOI 10.1136/hrt.2008.156497
   Poggiali E, 2012, BLOOD TRANSFUS-ITALY, V10, P411, DOI 10.2450/2012.0008-12
   Psaltis PJ, 2011, INT J CARDIOVAS IMAG, V27, P25, DOI 10.1007/s10554-010-9657-5
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Reed AL, 2011, AM J PHYSIOL-HEART C, V301, pH824, DOI 10.1152/ajpheart.00407.2010
   Reeder BJ, 2008, FREE RADICAL BIO MED, V44, P264, DOI 10.1016/j.freeradbiomed.2007.08.006
   Rui WJ, 2014, J ETHNOPHARMACOL, V151, P198, DOI 10.1016/j.jep.2013.10.022
   Saewong T, 2010, MED CHEM, V6, P57, DOI 10.2174/157340610791321479
   Santos MM, 2000, AM J PATHOL, V157, P1883, DOI 10.1016/S0002-9440(10)64827-4
   Selim M, 2010, TRANSL STROKE RES, V1, P35, DOI 10.1007/s12975-009-0001-0
   Sugishita K, 2009, INT HEART J, V50, P829, DOI 10.1536/ihj.50.829
   Tian Xiao-hui, 2005, Zhongguo Zhong Xi Yi Jie He Za Zhi, V25, P404
   Usunier Benoit, 2014, Stem Cells Int, V2014, P340257, DOI 10.1155/2014/340257
   Verrecchia F, 2001, J BIOL CHEM, V276, P17058, DOI 10.1074/jbc.M100754200
   Wang M, 2012, J ETHNOPHARMACOL, V141, P96, DOI 10.1016/j.jep.2012.02.005
   Wang XH, 2007, MED RES REV, V27, P133, DOI 10.1002/med.20077
   Wasser S, 1998, J HEPATOL, V29, P760, DOI 10.1016/S0168-8278(98)80257-2
   Weatherall DJ, 1996, NAT MED, V2, P847, DOI 10.1038/nm0896-847
   Wu WY, 2012, ACTA PHARMACOL SIN, V33, P1119, DOI 10.1038/aps.2012.126
   Yang Y, 2008, J ETHNOPHARMACOL, V118, P264, DOI 10.1016/j.jep.2008.04.012
   Yu QL, 2014, MYCOPATHOLOGIA, V177, P167, DOI 10.1007/s11046-014-9735-7
   Zeisberg EM, 2007, NAT MED, V13, P952, DOI 10.1038/nm1613
   Zhang JP, 2013, PLANTA MED, V79, P744, DOI 10.1055/s-0032-1328588
   Zhang Y, 2012, EUR J PHARMACOL, V680, P95, DOI 10.1016/j.ejphar.2012.01.010
   Zhang Y, 2013, J ETHNOPHARMACOL, V148, P671, DOI 10.1016/j.jep.2013.05.028
   Zhou XL, 2012, PHYTOMEDICINE, V19, P1263, DOI 10.1016/j.phymed.2012.08.011
   Zou CB, 2013, ENDOCRINE, V44, P666, DOI 10.1007/s12020-013-9907-0
NR 74
TC 16
Z9 17
U1 2
U2 17
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 7
PY 2015
VL 10
IS 4
AR UNSP e0124061
DI 10.1371/journal.pone.0124061
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CF3VU
UT WOS:000352477800261
PM 25850001
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Kakehashi, A
   Kato, A
   Ishii, N
   Wei, M
   Morimura, K
   Fukushima, S
   Wanibuchi, H
AF Kakehashi, Anna
   Kato, Ayumi
   Ishii, Naomi
   Wei, Min
   Morimura, Keiichirou
   Fukushima, Shoji
   Wanibuchi, Hideki
TI Valerian Inhibits Rat Hepatocarcinogenesis by Activating GABA(A)
   Receptor-Mediated Signaling
SO PLOS ONE
LA English
DT Article
ID LIVER CELL-PROLIFERATION; VALERENIC ACID; FUNCTIONAL REGULATION;
   OXIDATIVE STRESS; HEPATIC FOCI; STEM; PHARMACOLOGY; EXPRESSION;
   APOPTOSIS; SUBTYPES
AB Valerian is widely used as a traditional medicine to improve the quality of sleep due to interaction of several active components with the c-aminobutyric acid (GABA) A receptor (GABA(A)R) system. Recently, activation of GABA signaling in stem cells has been reported to suppress cell cycle progression in vivo. Furthermore, possible inhibitory effects of GABA(A) R agonists on hepatocarcinogenesis have been reported. The present study was performed to investigate modulating effects of Valerian on hepatocarcinogenesis using a medium-term rat liver bioassay. Male F344 rats were treated with one of the most powerful Valerian species (Valeriana sitchensis) at doses of 0, 50, 500 and 5000 ppm in their drinking water after initiation of hepatocarcinogenesis with diethylnitrosamine (DEN). Formation of glutathione S-transferase placental form positive (GST-P+) foci was significantly inhibited by Valerian at all applied doses compared with DEN initiation control rats. Generation of 8-hydroxy-29-deoxyguanosine in the rat liver was significantly suppressed by all doses of Valerian, likely due to suppression of Nrf2, CYP7A1 and induction of catalase expression. Cell proliferation was significantly inhibited, while apoptosis was induced in areas of GST-P+ foci of Valerian groups associated with suppression of c-myc, Mafb, cyclin D1 and induction of p21(Waf1/Cip1), p53 and Bax mRNA expression. Interestingly, expression of the GABA(A) R alpha 1 subunit was observed in GST-P+ foci of DEN control rats, with significant elevation associated with Valerian treatment. These results indicate that Valerian exhibits inhibitory effects on rat hepatocarcinogenesis by inhibiting oxidative DNA damage, suppressing cell proliferation and inducing apoptosis in GST-P+ foci by activating GABA(A) R-mediated signaling.
C1 [Kakehashi, Anna; Kato, Ayumi; Ishii, Naomi; Wei, Min; Morimura, Keiichirou; Fukushima, Shoji; Wanibuchi, Hideki] Osaka City Univ, Dept Mol Pathol, Grad Sch Med, Osaka 558, Japan.
RP Kakehashi, A (reprint author), Osaka City Univ, Dept Mol Pathol, Grad Sch Med, Osaka 558, Japan.
EM anna@med.osaka-cu.ac.jp
FU Ministry of Health, Labor and Welfare of Japan
FX This research was supported by Grant-in-Aid for Scientific Research from
   the Ministry of Health, Labor and Welfare of Japan. URL:
   http://www.mhlw.go.jp/english/. No number was supported. The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Al-Wadei HAN, 2012, CURR CANCER DRUG TAR, V12, P97
   Andang M, 2008, NATURE, V451, P460, DOI 10.1038/nature06488
   Beaubrun G, 2000, PSYCHIATR SERV, V51, P1130, DOI 10.1176/appi.ps.51.9.1130
   Behar TN, 1998, J NEUROSCI, V18, P6378
   Biju Mangatt P, 2002, J Biochem Mol Biol Biophys, V6, P209, DOI 10.1080/10258140290018667
   Biju MP, 2002, NEUROCHEM RES, V27, P905, DOI 10.1023/A:1020391514995
   Biju MP, 2001, HEPATOL RES, V21, P136, DOI 10.1016/S1386-6346(01)00092-4
   Bos R, 1998, PLANTA MED, V64, P143, DOI 10.1055/s-2006-957392
   BOUNTHANH C, 1981, PLANTA MED, V41, P21, DOI 10.1055/s-2007-971668
   Chen K, 2005, BRAIN RES BULL, V67, P310, DOI 10.1016/j.brainresbull.2005.07.004
   Cho HY, 2002, AM J RESP CELL MOL, V26, P175, DOI 10.1165/ajrcmb.26.2.4501
   Da Settimo F, 2007, CURR MED CHEM, V14, P2680, DOI 10.2174/092986707782023190
   Eadie MJ, 2004, EPILEPSIA, V45, P1338, DOI 10.1111/j.0013-9580.2004.27904.x
   FOERSTER W, 1984, PLANTA MED, V50, P7, DOI 10.1055/s-2007-969605
   Ganguly K, 2001, CELL, V105, P521, DOI 10.1016/S0092-8674(01)00341-5
   GESSNER B, 1984, EEG-EMG-Z ELEK ELEKT, V15, P45
   Haydar TF, 2000, J NEUROSCI, V20, P5764
   IMAIDA K, 1989, JPN J CANCER RES, V80, P326, DOI 10.1111/j.1349-7006.1989.tb02314.x
   JONES HB, 1993, ARCH TOXICOL, V67, P622, DOI 10.1007/BF01974069
   Kakehashi A, 2009, TOXICOL APPL PHARM, V238, P71, DOI 10.1016/j.taap.2009.04.018
   Karim N, 2013, AMINO ACIDS, V44, P1139, DOI 10.1007/s00726-012-1456-y
   KASAI H, 1986, CARCINOGENESIS, V7, P1849, DOI 10.1093/carcin/7.11.1849
   Khom S, 2007, NEUROPHARMACOLOGY, V53, P178, DOI 10.1016/j.neuropharm.2007.04.018
   Kinoshita A, 2003, CARCINOGENESIS, V24, P1389, DOI 10.1093/carcin/bgg079
   Kinoshita A, 2002, CARCINOGENESIS, V23, P341, DOI 10.1093/carcin/23.2.341
   Kitano M, 1998, CARCINOGENESIS, V19, P1475, DOI 10.1093/carcin/19.8.1475
   LEATHWOOD PD, 1985, PLANTA MED, V51, P144
   LU FC, 1988, REGUL TOXICOL PHARM, V8, P45, DOI 10.1016/0273-2300(88)90006-2
   Morazzoni P., 1995, Fitoterapia, V66, P99
   Mowrey D, 1986, MEANING VALERIAN ROO, P12
   Navarrete A, 2006, J AOAC INT, V89, P8
   Obrietan K, 1998, J NEUROPHYSIOL, V79, P1360
   Olsen RW, 2009, NEUROPHARMACOLOGY, V56, P141, DOI 10.1016/j.neuropharm.2008.07.045
   Pradeep K, 2007, EUR J PHARMACOL, V560, P110, DOI 10.1016/j.ejphar.2006.12.023
   Ramharter J, 2009, ORG LETT, V11, P1151, DOI 10.1021/ol9000137
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Sanders S, 1999, CARCINOGENESIS, V20, P41, DOI 10.1093/carcin/20.1.41
   Sando R, 2012, CELL, V151, P821, DOI 10.1016/j.cell.2012.09.037
   Schuller HM, 2012, CURR CANCER THER REV, V8, P116, DOI 10.2174/157339412800675351
   SCHULTZ V, 1998, RATIONAL PHYTOTHERAP
   Sieghart W, 2012, BRIT J PHARMACOL, V166, P476, DOI 10.1111/j.1476-5381.2011.01779.x
   Tsuda H, 2003, TOXICOL PATHOL, V31, P80, DOI 10.1080/01926230390173879
   Weng Y, 2009, ANESTH ANALG, V108, P1538, DOI 10.1213/ane.0b013e31819cd964
   Xu WH, 2008, LAB INVEST, V88, P1068, DOI 10.1038/labinvest.2008.75
   Young SZ, 2009, PHYSIOLOGY, V24, P171, DOI 10.1152/physiol.00002.2009
NR 45
TC 7
Z9 8
U1 2
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 24
PY 2014
VL 9
IS 11
AR e113610
DI 10.1371/journal.pone.0113610
PG 21
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AX2IM
UT WOS:000346766900056
PM 25419570
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Cao, B
   Qi, YF
   Yang, Y
   Liu, XC
   Xu, D
   Guo, W
   Zhan, Y
   Xiong, ZG
   Zhang, A
   Wang, AR
   Fu, XQ
   Zhang, HT
   Zhao, LJ
   Gu, JK
   Dong, Y
AF Cao, Bo
   Qi, Yanfeng
   Yang, Yan
   Liu, Xichun
   Xu, Duo
   Guo, Wei
   Zhan, Yang
   Xiong, Zhenggang
   Zhang, Allen
   Wang, Alun R.
   Fu, Xueqi
   Zhang, Haitao
   Zhao, Lijing
   Gu, Jingkai
   Dong, Yan
TI 20(S)-Protopanaxadiol Inhibition of Progression and Growth of
   Castration-Resistant Prostate Cancer
SO PLOS ONE
LA English
DT Article
ID TRUNCATED ANDROGEN RECEPTOR; DE-NOVO STEROIDOGENESIS; FULL-LENGTH;
   SPLICE VARIANTS; TUMOR-GROWTH; CELLS; ANTIANDROGEN; SUPPRESSION;
   EXPRESSION; MECHANISM
AB Castration-resistant progression of prostate cancer after androgen deprivation therapies remains the most critical challenge in the clinical management of prostate cancer. Resurgent androgen receptor (AR) activity is an established driver of castration-resistant progression, and upregulation of the full-length AR (AR-FL) and constitutively-active AR splice variants (AR-Vs) has been implicated to contribute to the resurgent AR activity. We reported previously that ginsenoside 20(S)-protopanaxadiol-aglycone (PPD) can reduce the abundance of both AR-FL and AR-Vs. In the present study, we further showed that the effect of PPD on AR expression and target genes was independent of androgen. PPD treatment resulted in a suppression of ligand-independent AR transactivation. Moreover, PPD delayed castration-resistant regrowth of LNCaP xenograft tumors after androgen deprivation and inhibited the growth of castration-resistant 22Rv1 xenograft tumors with endogenous expression of AR-FL and AR-Vs. This was accompanied by a decline in serum prostate-specific antigen levels as well as a decrease in AR levels and mitoses in the tumors. Notably, the 22Rv1 xenograft tumors were resistant to growth inhibition by the next-generation anti-androgen enzalutamide. The present study represents the first to show the preclinical efficacy of PPD in inhibiting castration-resistant progression and growth of prostate cancer. The findings provide a rationale for further developing PPD or its analogues for prostate cancer therapy.
C1 [Cao, Bo; Yang, Yan; Xu, Duo; Guo, Wei; Fu, Xueqi; Gu, Jingkai; Dong, Yan] Jilin Univ, Coll Life Sci, Changchun 130023, Peoples R China.
   [Cao, Bo; Qi, Yanfeng; Zhan, Yang; Zhang, Allen; Dong, Yan] Tulane Univ, Sch Med, Dept Struct & Cellular Biol, Tulane Canc Ctr, New Orleans, LA 70112 USA.
   [Liu, Xichun; Xiong, Zhenggang; Wang, Alun R.; Zhang, Haitao] Tulane Univ, Sch Med, Dept Pathol & Lab Med, Tulane Canc Ctr, New Orleans, LA 70112 USA.
   [Zhao, Lijing] Jilin Univ, Coll Basic Med Sci, Changchun 130023, Peoples R China.
   [Dong, Yan] Jilin Univ, Natl Engn Lab AIDS Vaccine, Changchun 130023, Peoples R China.
RP Zhao, LJ (reprint author), Jilin Univ, Coll Basic Med Sci, Changchun 130023, Peoples R China.
EM zhao_lj@jlu.edu.cn; gujk@jlu.edu.cn; ydong@tulane.edu
OI Zhang, Allen/0000-0002-5780-9121
FU National Cancer Institute of the National Institutes of Health
   [R01CA188609]; Department of Defense [W81XWH-12-1-0112,
   W81XWH-12-1-0275]; National Natural Science Foundation of China
   [81272851, 30973587, 81102383, 81302206, 81430087]; Louisiana
   Board-of-Regents Grant [LEQSF(2012-15)-RD-A-25]; Louisiana Cancer
   Research Consortium Fund; Tulane Cancer Center Developmental Fund;
   Tulane University School of Medicine
FX This work was supported by the National Cancer Institute of the National
   Institutes of Health grant R01CA188609, Department of Defense grants
   W81XWH-12-1-0112 and W81XWH-12-1-0275, National Natural Science
   Foundation of China Projects 81272851, 30973587, 81102383, 81302206, and
   81430087, Louisiana Board-of-Regents Grant LEQSF(2012-15)-RD-A-25,
   Louisiana Cancer Research Consortium Fund, Tulane Cancer Center
   Developmental Fund, and Tulane University School of Medicine Pilot Fund
   and Bridge Fund. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Cao B, 2014, ONCOTARGET, V5, P1646, DOI 10.18632/oncotarget.1802
   Cao B, 2013, INT J CANCER, V132, P1277, DOI 10.1002/ijc.27754
   Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972
   Cheng H, 2006, CANCER RES, V66, P10613, DOI 10.1158/0008-5472.CAN-06-0028
   Culig Z, 1998, PROSTATE, V35, P63, DOI 10.1002/(SICI)1097-0045(19980401)35:1<63::AID-PROS9>3.0.CO;2-I
   Dehm SM, 2008, CANCER RES, V68, P5469, DOI 10.1158/0008-5472.CAN-08-0594
   Dong Y, 2004, CANCER RES, V64, P19, DOI 10.1158/0008-5472.CAN-03-2789
   Dong Y, 2003, CANCER RES, V63, P52
   Dong Y, 2005, MOL CANCER THER, V4, P1047, DOI 10.1158/1535-7163.MCT-05-0124
   Egan A, 2014, CANCER TREAT REV, V40, P426, DOI 10.1016/j.ctrv.2013.09.011
   Fizazi K, 2012, LANCET ONCOL, V13, P983, DOI 10.1016/S1470-2045(12)70379-0
   Freedland SJ, 2011, CANCER-AM CANCER SOC, V117, P1123, DOI 10.1002/cncr.25477
   GLEAVE ME, 1992, CANCER RES, V52, P1598
   Gregory CW, 2004, J BIOL CHEM, V279, P7119, DOI 10.1074/jbc.M307649200
   Guo ZY, 2009, CANCER RES, V69, P2305, DOI 10.1158/0008-5472.CAN-08-3795
   Hara T, 2003, CANCER RES, V63, P149
   Hornberg E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019059
   Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115
   Hu R, 2012, CANCER RES, V72, P3457, DOI 10.1158/0008-5472.CAN-11-3892
   Hu R, 2011, PROSTATE, V71, P1656, DOI 10.1002/pros.21382
   Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764
   Jackson JK, 2000, CANCER RES, V60, P4146
   Kim HG, 2011, FOOD CHEM TOXICOL, V49, P2229, DOI 10.1016/j.fct.2011.06.020
   Knudsen KE, 2009, CLIN CANCER RES, V15, P4792, DOI 10.1158/1078-0432.CCR-08-2660
   Koivisto P, 1997, CANCER RES, V57, P314
   Lamont KR, 2011, MOL ENDOCRINOL, V25, P897, DOI 10.1210/me.2010-0469
   Lamoureux F, 2011, CLIN CANCER RES, V17, P2301, DOI 10.1158/1078-0432.CCR-10-3077
   Lee NH, 2012, J ALTERN COMPLEM MED, V18, P1061, DOI 10.1089/acm.2011.0591
   Li J, 2011, MOL CANCER THER, V10, P1346, DOI 10.1158/1535-7163.MCT-10-0985
   Li XS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031213
   Li Y., 2012, CANCER RES, V73, P483
   Liu LL, 2014, ONCOGENE, V33, P3140, DOI 10.1038/onc.2013.284
   Locke JA, 2008, CANCER RES, V68, P6407, DOI 10.1158/0008-5472.CAN-07-5997
   Lubik AA, 2011, CANCER RES, V71, P5754, DOI 10.1158/0008-5472.CAN-10-2470
   Mashima T, 2010, MOL PHARMACOL, V78, P846, DOI 10.1124/mol.110.064790
   Miyake H, 2000, CANCER RES, V60, P3058
   Montgomery RB, 2008, CANCER RES, V68, P4447, DOI 10.1158/0008-5472.CAN-08-0249
   Mostaghel EA, 2011, CLIN CANCER RES, V17, P5913, DOI 10.1158/1078-0432.CCR-11-0728
   Nadiminty N, 2013, MOL CANCER THER, V12, P1629, DOI 10.1158/1535-7163.MCT-13-0027
   Narizhneva NV, 2009, CELL CYCLE, V8, P4155, DOI 10.4161/cc.8.24.10316
   O'Hara M, 1998, ARCH FAM MED, V7, P523, DOI 10.1001/archfami.7.6.523
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506
   Snoek R, 2009, CLIN CANCER RES, V15, P39, DOI 10.1158/1078-0432.CCR-08-1726
   Sun SH, 2010, J CLIN INVEST, V120, P2715, DOI 10.1172/JCI41824
   Tepper CG, 2002, CANCER RES, V62, P6606
   Toren P, 2015, EUR UROL, V67, P986, DOI 10.1016/j.eururo.2014.08.006
   Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175
   Tsuta K, 2011, AM J CLIN PATHOL, V136, P252, DOI 10.1309/AJCPDXFOPXGEF0RP
   VELDSCHOLTE J, 1992, J STEROID BIOCHEM, V41, P665, DOI 10.1016/0960-0760(92)90401-4
   VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401
   Wafa LA, 2012, INT J CANCER, V130, P2835, DOI 10.1002/ijc.26287
   Waltering KK, 2009, CANCER RES, V69, P8141, DOI 10.1158/0008-5472.CAN-09-0919
   Watson PA, 2010, P NATL ACAD SCI USA, V107, P16759, DOI 10.1073/pnas.1012443107
   Yamashita S, 2012, NEOPLASIA, V14, P74, DOI 10.1593/neo.111436
   Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517
   Yoshida T, 2005, CANCER RES, V65, P9611, DOI 10.1158/0008-5472.CAN-05-0817
   Yuan CS, 2010, J GINSENG RES, V34, P160, DOI 10.5142/jgr.2010.34.3.160
   Zengerling F, 2012, INT J MOL SCI, V13, P11530, DOI 10.3390/ijms130911530
   Zhan Y, 2013, INT J CANCER, V133, P2225, DOI 10.1002/ijc.28202
   Zhao XY, 2000, NAT MED, V6, P703
NR 61
TC 25
Z9 25
U1 0
U2 19
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 6
PY 2014
VL 9
IS 11
AR e111201
DI 10.1371/journal.pone.0111201
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AS6XM
UT WOS:000344402600029
PM 25375370
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU DiGiandomenico, A
   Veach, RA
   Zienkiewicz, J
   Moore, DJ
   Wylezinski, LS
   Hutchens, MA
   Hawiger, J
AF DiGiandomenico, Antonio
   Veach, Ruth Ann
   Zienkiewicz, Jozef
   Moore, Daniel J.
   Wylezinski, Lukasz S.
   Hutchens, Martha A.
   Hawiger, Jacek
TI The "Genomic Storm" Induced by Bacterial Endotoxin Is Calmed by a
   Nuclear Transport Modifier That Attenuates Localized and Systemic
   Inflammation
SO PLOS ONE
LA English
DT Article
ID NF-KAPPA-B; CARE-ASSOCIATED INFECTIONS; RHEUMATOID-ARTHRITIS; NOSOCOMIAL
   PNEUMONIA; INNATE IMMUNITY; MORTALITY; THERAPY; IMPORT; SEPSIS;
   HYDROCORTISONE
AB Lipopolysaccharide (LPS) is a potent microbial virulence factor that can trigger production of proinflammatory mediators involved in the pathogenesis of localized and systemic inflammation. Importantly, the role of nuclear transport of stress responsive transcription factors in this LPS-generated "genomic storm" remains largely undefined. We developed a new nuclear transport modifier (NTM) peptide, cell-penetrating cSN50.1, which targets nuclear transport shuttles importin alpha 5 and importin beta 1, to analyze its effect in LPS-induced localized (acute lung injury) and systemic (lethal endotoxic shock) murine inflammation models. We analyzed a human genome database to match 46 genes that encode cytokines, chemokines and their receptors with transcription factors whose nuclear transport is known to be modulated by NTM. We then tested the effect of cSN50.1 peptide on proinflammatory gene expression in murine bone marrow-derived macrophages stimulated with LPS. This NTM suppressed a proinflammatory transcriptome of 37 out of 84 genes analyzed, without altering expression of housekeeping genes or being cytotoxic. Consistent with gene expression analysis in primary macrophages, plasma levels of 23 out of 26 LPS-induced proinflammatory cytokines, chemokines, and growth factors were significantly attenuated in a murine model of LPS-induced systemic inflammation (lethal endotoxic shock) while the anti-inflammatory cytokine, interleukin 10, was enhanced. This anti-inflammatory reprogramming of the endotoxin-induced genomic response was accompanied by complete protection against lethal endotoxic shock with prophylactic NTM treatment, and 75% protection when NTM was first administered after LPS exposure. In a murine model of localized lung inflammation caused by direct airway exposure to LPS, expression of cytokines and chemokines in the bronchoalveolar space was suppressed with a concomitant reduction of neutrophil trafficking. Thus, calming the LPS-triggered "genomic storm" by modulating nuclear transport with cSN50.1 peptide attenuates the systemic inflammatory response associated with lethal shock as well as localized lung inflammation.
C1 [DiGiandomenico, Antonio; Hutchens, Martha A.] Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37212 USA.
   [Veach, Ruth Ann; Zienkiewicz, Jozef; Moore, Daniel J.; Wylezinski, Lukasz S.; Hutchens, Martha A.; Hawiger, Jacek] Vanderbilt Univ, Sch Med, Immunotherapy Program, Nashville, TN 37212 USA.
   [Veach, Ruth Ann; Zienkiewicz, Jozef; Hawiger, Jacek] Vanderbilt Univ, Sch Med, Dept Med, Div Allergy Pulm & Crit Care Med, Nashville, TN 37212 USA.
   [Moore, Daniel J.] Vanderbilt Univ, Sch Med, Dept Pediat, Ian Burr Div Endocrinol & Diabet, Nashville, TN 37212 USA.
   [Moore, Daniel J.] Vanderbilt Univ, Sch Med, Dept Microbiol Pathol & Immunol, Nashville, TN 37212 USA.
   [Wylezinski, Lukasz S.; Hawiger, Jacek] Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37212 USA.
RP Hawiger, J (reprint author), Vanderbilt Univ, Sch Med, Immunotherapy Program, Nashville, TN 37212 USA.
EM jacek.hawiger@vanderbilt.edu
RI Moore, Daniel J/A-4924-2008
OI Moore, Daniel J/0000-0002-6889-9345; Veach, Ruth Ann/0000-0003-0038-8802
FU National Institutes of Health [R01HL087531, R01HL069452, T32HL069765,
   5K08DK090146, F32HL087531]; Vanderbilt University Medical Center's
   Digestive Disease Research Center - NIH [P30DK058404]; Vanderbilt Ingram
   Cancer Center - NIH [2P30CA68485]; Vanderbilt University Medical Center
   Immunotherapy Program; Vanderbilt Clinical and Translational Science
   Award (CTSA)
FX This work was supported by the National Institutes of Health grants
   R01HL087531, R01HL069452, T32HL069765 (JH), 5K08DK090146 (DJM) and
   F32HL087531 (AD). Scholarships for core services were provided by
   Vanderbilt University Medical Center's Digestive Disease Research Center
   supported by NIH grant P30DK058404 and the Vanderbilt Ingram Cancer
   Center supported by NIH grant 2P30CA68485. Additional support was
   provided through the Vanderbilt University Medical Center Immunotherapy
   Program and the Vanderbilt Clinical and Translational Science Award
   (CTSA). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Aird WC, 2007, CIRC RES, V100, P158, DOI 10.1161/01.RES.0000255691.76142.4a
   Andaluz-Ojeda D, 2012, CYTOKINE, V57, P332, DOI 10.1016/j.cyto.2011.12.002
   Angus DC, 2013, NEW ENGL J MED, V369, P840, DOI 10.1056/NEJMra1208623
   Annane D, 2002, JAMA-J AM MED ASSOC, V288, P862, DOI 10.1001/jama.288.7.862
   Bannerman DD, 2003, AM J PHYSIOL-LUNG C, V284, pL899, DOI 10.1152/ajplung.00338.2002
   Barcia AM, 2005, CLIN INFECT DIS, V41, pS498, DOI 10.1086/432005
   Bernard GR, 1997, NEW ENGL J MED, V336, P912, DOI 10.1056/NEJM199703273361303
   Beutler B, 2004, MOL IMMUNOL, V40, P845, DOI 10.1016/j.molimm.2003.10.005
   Beutler BA, 2009, BLOOD, V113, P1399, DOI 10.1182/blood-2008-07-019307
   Bohrer H, 1997, J CLIN INVEST, V100, P972, DOI 10.1172/JCI119648
   Boyer A, 2011, CRIT CARE, V15, DOI 10.1186/cc10026
   Bozza FA, 2007, CRIT CARE, V11, DOI 10.1186/cc5783
   Chopra I, 2008, LANCET INFECT DIS, V8, P133, DOI 10.1016/S1473-3099(08)70018-5
   Dauphinee SM, 2006, LAB INVEST, V86, P9, DOI 10.1038/labinvest.3700366
   Duffy JY, 2009, CRIT CARE MED, V37, P577, DOI 10.1097/CCM.0b013e318194ab65
   FAGON JY, 1993, AM J MED, V94, P281, DOI 10.1016/0002-9343(93)90060-3
   Frank KM, 2012, INFECT IMMUN, V80, P3161, DOI 10.1128/IAI.00191-12
   GALANOS C, 1979, P NATL ACAD SCI USA, V76, P5939, DOI 10.1073/pnas.76.11.5939
   Hawiger J, 2001, IMMUNOL RES, V23, P99, DOI 10.1385/IR:23:2-3:099
   Hawiger J, 2011, CRIT CARE, V15, DOI 10.1186/cc10482
   Hoffken G, 2002, CHEST, V122, P2183, DOI 10.1378/chest.122.6.2183
   Jans DA, 1996, PHYSIOL REV, V76, P651
   Jarvis WR, 2007, J HOSP INFECT, V65, P3, DOI 10.1016/S0195-6701(07)60005-X
   Kumar A, 2006, CRIT CARE MED, V34, P1589, DOI 10.1097/01.CCM.0000217961.75225.E9
   Lee SJ, 2003, SCIENCE, V302, P1571, DOI 10.1126/science.1088372
   Lehr HA, 2001, CIRCULATION, V104, P914, DOI 10.1161/hc3401.093153
   Lemke U, 2008, CELL METAB, V8, P212, DOI 10.1016/j.cmet.2008.08.001
   LEVIN J, 1972, ANN INTERN MED, V76, P1, DOI 10.7326/0003-4819-76-1-1
   LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255
   Liu DY, 2009, MOL THER, V17, P796, DOI 10.1038/mt.2009.18
   Liu DY, 2004, J BIOL CHEM, V279, P48434, DOI 10.1074/jbc.M407190200
   Liu XY, 2000, J BIOL CHEM, V275, P16774
   Liu Y, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000093
   Lorente JA, 2005, SHOCK, V24, P107, DOI 10.1097/01.shk.0000191343.21228.78
   Lorenz HM, 1996, J IMMUNOL, V156, P1646
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   Miller SI, 2005, NAT REV MICROBIOL, V3, P36, DOI 10.1038/nrmicro1068
   Moore DJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013235
   Nakahara H, 2003, ARTHRITIS RHEUM, V48, P1521, DOI 10.1002/art.11143
   O'Sullivan AW, 2009, J SURG RES, V152, P46, DOI 10.1016/j.jss.2008.04.030
   Opal SM, 2010, INT J ANTIMICROB AG, V36, pS70, DOI 10.1016/j.ijantimicag.2010.11.008
   Peleg AY, 2010, NEW ENGL J MED, V362, P1804, DOI 10.1056/NEJMra0904124
   Raghavendran K, 2005, AM J PHYSIOL-LUNG C, V289, pL134, DOI 10.1152/ajplung.00390.2004
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Reutershan J, 2006, J CLIN INVEST, V116, P695, DOI 10.1172/JCI27009
   Rose WE, 2012, J INFECT DIS, V206, P1604, DOI 10.1093/infdis/jis552
   Rosenberg HF, 2003, FUNDAMENTAL IMMUNOLO, P1151
   Seok J, 2013, P NATL ACAD SCI USA, V110, P3507, DOI 10.1073/pnas.1222878110
   Sjovall F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097673
   Sprung CL, 2008, NEW ENGL J MED, V358, P111, DOI 10.1056/NEJMoa071366
   Stanbury RM, 1998, BRIT J OPHTHALMOL, V82, P704, DOI 10.1136/bjo.82.6.704
   Takao K, 2015, P NATL ACAD SCI USA, V112, P1167, DOI 10.1073/pnas.1401965111
   Torgerson TR, 1998, J IMMUNOL, V161, P6084
   Tweedell A, 2011, METABOLISM, V60, P92, DOI 10.1016/j.metabol.2009.12.022
   Veach RA, 2004, J BIOL CHEM, V279, P11425, DOI 10.1074/jbc.M311089200
   Veach RA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030527
   VIAL T, 1995, DRUG SAFETY, V13, P371, DOI 10.2165/00002018-199513060-00006
   Vincent JL, 2009, JAMA-J AM MED ASSOC, V302, P2323, DOI 10.1001/jama.2009.1754
   Wang JC, 2012, CELL BIOSCI, V2, DOI 10.1186/2045-3701-2-19
   Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5
   WENDLING D, 1993, J RHEUMATOL, V20, P259
   Xiao WZ, 2011, J EXP MED, V208, P2581, DOI 10.1084/jem.20111354
   Zienkiewicz J, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000386
NR 63
TC 7
Z9 9
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 20
PY 2014
VL 9
IS 10
AR e110183
DI 10.1371/journal.pone.0110183
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AS0AY
UT WOS:000343942100042
PM 25329889
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Chuang, HY
   Chang, YF
   Liu, RS
   Hwang, JJ
AF Chuang, Hui-Yen
   Chang, Ya-Fang
   Liu, Ren-Shyan
   Hwang, Jeng-Jong
TI Serial Low Doses of Sorafenib Enhance Therapeutic Efficacy of Adoptive T
   Cell Therapy in a Murine Model by Improving Tumor Microenvironment
SO PLOS ONE
LA English
DT Article
ID HEPATOCELLULAR-CARCINOMA; IN-VIVO; EFFECTOR FUNCTIONS;
   ANTITUMOR-ACTIVITY; SUPPRESSOR-CELLS; TRANSCRIPTION 3; FAS LIGAND;
   CANCER; IMMUNOTHERAPY; IMMUNITY
AB Requirements of large numbers of transferred T cells and various immunosuppressive factors and cells in the tumor microenvironment limit the applications of adoptive T cells therapy (ACT) in clinic. Accumulating evidences show that chemotherapeutic drugs could act as immune supportive instead of immunosuppressive agents when proper dosage is used, and combined with immunotherapy often results in better treatment outcomes than monotherapy. Controversial immunomodulation effects of sorafenib, a multi-kinases inhibitor, at high and low doses have been reported in several types of cancer. However, what is the range of the low-dose sorafenib will influence the host immunity and responses of ACT is still ambiguous. Here we used a well-established E.G7/OT-1 murine model to understand the effects of serial low doses of sorafenib on both tumor microenvironment and transferred CD8+ T cells and the underlying mechanisms. Sorafenib lowered the expressions of immunosuppressive factors, and enhanced functions and migrations of transferred CD8+ T cells through inhibition of STAT3 and other immunosuppressive factors. CD8+ T cells were transduced with granzyme B promoter for driving imaging reporters to visualize the activation and distribution of transferred CD8+ T cells prior to adoptive transfer. Better activations of CD8+ T cells and tumor inhibitions were found in the combinational group compared with CD8+ T cells or sorafenib alone groups. Not only immunosuppressive factors but myeloid derived suppressive cells (MDSCs) and regulatory T cells (Tregs) were decreased in sorafenib-treated group, indicating that augmentation of tumor inhibition and function of CD8+ T cells by serial low doses of sorafenib were via reversing the immunosuppressive microenvironment. These results revealed that the tumor inhibitions of sorafenib not only through eradicating tumor cells but modifying tumor microenvironment, which helps outcomes of ACT significantly.
C1 [Chuang, Hui-Yen; Chang, Ya-Fang; Hwang, Jeng-Jong] Natl Yang Ming Univ, Dept Biomed Imaging & Radiol Sci, Taipei 112, Taiwan.
   [Liu, Ren-Shyan] Taipei Vet Gen Hosp, Natl PET Cyclotron Ctr, Taipei, Taiwan.
   [Liu, Ren-Shyan] Taipei Vet Gen Hosp, Dept Nucl Med, Taipei, Taiwan.
RP Hwang, JJ (reprint author), Natl Yang Ming Univ, Dept Biomed Imaging & Radiol Sci, Taipei 112, Taiwan.
EM jjhwang@ym.edu.tw
FU National Science Council, Taiwan [NSC 100-2321-B-010-013, NSC
   101-2321-B-010-006, NSC 102-2321-B-010-005]
FX This work was supported by the National Science Council, Taiwan. NSC
   100-2321-B-010-013, NSC 101-2321-B-010-006 and NSC 102-2321-B-010-005
   (JJH). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Al-Lazikani B, 2012, NAT BIOTECHNOL, V30, P679, DOI 10.1038/nbt.2284
   Azad NS, 2009, CLIN CANCER RES, V15, P1411, DOI 10.1158/1078-0432.CCR-08-1141
   Breart B, 2008, J CLIN INVEST, V118, P1390, DOI 10.1172/JCI34388
   Brose MS, 2014, LANCET, V384, P319, DOI 10.1016/S0140-6736(14)60421-9
   Busse A, 2011, EUR J CANCER, V47, P690, DOI 10.1016/j.ejca.2010.11.021
   Cabrera R, 2013, CANCER IMMUNOL IMMUN, V62, P737, DOI 10.1007/s00262-012-1380-8
   Cao MD, 2011, LAB INVEST, V91, P598, DOI 10.1038/labinvest.2010.205
   Chang YF, 2012, CANCER PREV RES, V5, P444, DOI 10.1158/1940-6207.CAPR-11-0308
   Charo J, 2005, CANCER RES, V65, P2001, DOI 10.1158/0008-5472.CAN-04-2006
   Chen ML, 2014, INT J CANCER, V134, P319, DOI 10.1002/ijc.28362
   Chen WJ, 2011, NAT IMMUNOL, V12, P809, DOI 10.1038/ni.2088
   Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117
   Desar IME, 2011, INT J CANCER, V129, P507, DOI 10.1002/ijc.25674
   El Tal AK, 2013, INT J DERMATOL, V52, P1538, DOI 10.1111/j.1365-4632.2012.05485.x
   Escudier B, 2009, J CLIN ONCOL, V27, P3312, DOI 10.1200/JCO.2008.19.5511
   Fridlender ZG, 2010, CANCER RES, V70, P109, DOI 10.1158/0008-5472.CAN-09-2326
   Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506
   Galluzzi L, 2012, NAT REV DRUG DISCOV, V11, P215, DOI 10.1038/nrd3626
   Ghiringhelli F, 2004, EUR J IMMUNOL, V34, P336, DOI 10.1002/eji.200324181
   Ghiringhelli F, 2007, CANCER IMMUNOL IMMUN, V56, P641, DOI 10.1007/s00262-006-0225-8
   Gillies RJ, 2012, NAT REV CANCER, V12, P487, DOI 10.1038/nrc3298
   Gutzmer R, 2012, DTSCH ARZTEBL INT, V109, P133, DOI 10.3238/arztebl.2012.0133
   Hawkins RE, 2010, HUM GENE THER, V21, P665, DOI 10.1089/hum.2010.086
   Hipp MM, 2008, BLOOD, V111, P5610, DOI 10.1182/blood-2007-02-075945
   Hosoi A, 2014, INT J CANCER, V134, P1810, DOI 10.1002/ijc.28506
   Huang YH, 2012, P NATL ACAD SCI USA, V109, P17561, DOI 10.1073/pnas.1215397109
   Kharaziha P, 2012, CANCER RES, V72, P5348, DOI 10.1158/0008-5472.CAN-12-0658
   Knight DA, 2013, J CLIN INVEST, V123, P1371, DOI 10.1172/JCI66236
   Krysko DV, 2006, APOPTOSIS, V11, P1709, DOI 10.1007/s10495-006-9527-8
   Kudo-Saito C, 2013, CLIN EXP METASTAS, V30, P393, DOI 10.1007/s10585-012-9545-6
   Kujawski M, 2010, CANCER RES, V70, P9599, DOI 10.1158/0008-5472.CAN-10-1293
   Kuo YC, 2012, BIOMED PHARMACOTHER, V66, P12, DOI 10.1016/j.biopha.2011.09.011
   Lacour S, 2001, CANCER RES, V61, P1645
   Leen AM, 2007, ANNU REV IMMUNOL, V25, P243, DOI 10.1146/annurev.immunol.25.022106.141527
   Liu CW, 2013, CLIN CANCER RES, V19, P393, DOI 10.1158/1078-0432.CCR-12-1626
   Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857
   Menard C, 2008, CANCER IMMUNOL IMMUN, V57, P1579, DOI 10.1007/s00262-008-0505-6
   Micheau O, 1997, J NATL CANCER I, V89, P783, DOI 10.1093/jnci/89.11.783
   Mitchem JB, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3149
   Molhoek KR, 2009, CANCER IMMUNOL IMMUN, V58, P867, DOI 10.1007/s00262-008-0602-6
   Mondino A, 2010, HUM GENE THER, V21, P533, DOI 10.1089/hum.2010.033
   OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075
   Rabinovich GA, 2007, ANNU REV IMMUNOL, V25, P267, DOI 10.1146/annurev.immunol.25.022106.141609
   Ramakrishnan R, 2008, CANCER IMMUNOL IMMUN, V57, P1523, DOI 10.1007/s00262-008-0531-4
   Ramakrishnan R, 2010, J CLIN INVEST, V120, P1111, DOI 10.1172/JCI40269
   RASMUSSEN L, 1982, ENVIRON HEALTH PERSP, V43, P21, DOI 10.2307/3429163
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Ryan AE, 2005, CANCER RES, V65, P9817, DOI 10.1158/0008-5472.CAN-05-1462
   Sprinzl MF, 2013, HEPATOLOGY, V57, P2358, DOI 10.1002/hep.26328
   Tai WT, 2011, J HEPATOL, V55, P1041, DOI 10.1016/j.jhep.2011.06.005
   Takahashi Y, 2013, ENDOSCOPY, V45, pE179, DOI 10.1055/s-0032-1326641
   Tartour E, 2011, CANCER METAST REV, V30, P83, DOI 10.1007/s10555-011-9281-4
   Toaldo MB, 2015, MOL IMAGING BIOL, V17, P29, DOI 10.1007/s11307-014-0764-x
   Vanneman M, 2012, NAT REV CANCER, V12, P237, DOI 10.1038/nrc3237
   Wilhelm S, 2006, NAT REV DRUG DISCOV, V5, P835, DOI 10.1038/nrd2130
   Yang F, 2010, MOL CANCER THER, V9, P953, DOI 10.1158/1535-7163.MCT-09-0947
   Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734
   Zhang B, 2007, J EXP MED, V204, P49, DOI 10.1081/jem.20062056
NR 58
TC 12
Z9 12
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 15
PY 2014
VL 9
IS 10
AR e109992
DI 10.1371/journal.pone.0109992
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AX2IH
UT WOS:000346766200072
PM 25333973
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Gonzalez-Mateo, GT
   Fernandez-Millara, V
   Bellon, T
   Liappas, G
   Ruiz-Ortega, M
   Lopez-Cabrera, M
   Selgas, R
   Aroeira, LS
AF Gonzalez-Mateo, Guadalupe T.
   Fernandez-Millara, Vanessa
   Bellon, Teresa
   Liappas, Georgios
   Ruiz-Ortega, Marta
   Lopez-Cabrera, Manuel
   Selgas, Rafael
   Aroeira, Luiz S.
TI Paricalcitol Reduces Peritoneal Fibrosis in Mice through the Activation
   of Regulatory T Cells and Reduction in IL-17 Production
SO PLOS ONE
LA English
DT Article
ID VITAMIN-D; 1,25-DIHYDROXYVITAMIN D-3; MURINE MODEL; ALTERNATIVE
   ACTIVATION; DIALYSIS; INFLAMMATION; RECEPTOR; DIFFERENTIATION;
   CYTOKINES; SOLUTE
AB Fibrosis is a significant health problem associated with a chronic inflammatory reaction. The precise mechanisms involved in the fibrotic process are still poorly understood. However, given that inflammation is a major causative factor, immunomodulation is a possible therapeutic approach to reduce fibrosis. The vitamin D receptor (VDR) that is present in all hematopoietic cells has been associated with immunomodulation. We investigated whether the intraperitoneal administration of paricalcitol, a specific activator of the VDR, modulates peritoneal dialysis fluid (PDF)-induced peritoneal fibrosis. We characterized the inflammatory process in the peritoneal cavity of mice treated or not treated with paricalcitol and analyzed the ensuing fibrosis. The treatment reduced peritoneal IL-17 levels, which strongly correlated with a significantly lower peritoneal fibrotic response. In vitro studies demonstrate that both CD4(+) and CD8(+) regulatory T cells appear to impact the regulation of IL-17. Paricalcitol treatment resulted in a significantly increased frequency of CD8(+) T cells showing a regulatory phenotype. The frequency of CD4(+) Tregs tends to be increased, but it did not achieve statistical significance. However, paricalcitol treatment increased the number of CD4(+) and CD8(+) Treg cells in vivo. In conclusion, the activation of immunological regulatory mechanisms by VDR signaling could prevent or reduce fibrosis, as shown in peritoneal fibrosis induced by PDF exposure in mice.
C1 [Gonzalez-Mateo, Guadalupe T.; Fernandez-Millara, Vanessa; Bellon, Teresa; Selgas, Rafael] Hosp La Paz, Inst Invest Sanitaria Hosp Univ La Paz IdiPA, Res Dept, Madrid, Spain.
   [Gonzalez-Mateo, Guadalupe T.; Liappas, Georgios; Lopez-Cabrera, Manuel] CSIC UAM, Mol Biol Ctr Severo Ochoa, Madrid, Spain.
   [Ruiz-Ortega, Marta] Autonomous Univ Madrid, IIS Fdn Jimenez Daiz, Cellular Biol Renal Dis Lab, E-28049 Madrid, Spain.
   [Selgas, Rafael] Hosp Univ La Paz, Dept Nephrol, Madrid, Spain.
   [Selgas, Rafael] Red Invest Renal REDinREN, Madrid, Spain.
   [Selgas, Rafael] IRSIN, Madrid, Spain.
   [Aroeira, Luiz S.] Univ Vigo, Ctr Invest Biomed CINBIO, Inst Invest Biomed Vigo IBIV, Dept Immunol, Vigo 36310, Spain.
RP Aroeira, LS (reprint author), Univ Vigo, Ctr Invest Biomed CINBIO, Inst Invest Biomed Vigo IBIV, Dept Immunol, Vigo 36310, Spain.
EM lstark@uvigo.es
RI Aroeira, Luiz Stark/D-7558-2014; Gonzalez-Mateo, Guadalupe/G-2551-2016;
   Ruiz-Ortega, Marta/D-3584-2012; ruiz-ortega, marta/D-3584-2012
OI Aroeira, Luiz Stark/0000-0001-9391-1409; Gonzalez-Mateo,
   Guadalupe/0000-0002-8144-904X; Ruiz-Ortega, Marta/0000-0002-1495-6535;
   ruiz-ortega, marta/0000-0002-1403-2690; Lopez Cabrera,
   Manuel/0000-0002-0976-9719
FU European Union Seventh Framework Programme [FP7/REGPOT-2012-2013.1,
   316265]; Fondo de Investigaciones Sanitarias (Health Research Fund)
   [RETICS 06/0016, FIS PI 09/0064]; Ministerio de Economia y
   competitividad [SAF 2013-47611-R, SAF 2010-21249, SAF 2007-61201];
   Comunidad Autonoma de Madrid [RETICS 12/0021, S2012DMD2321]; Fondo
   Investigaciones Sanitarias [PI 11/01854]; Renal Foundation Inigo Alvarez
   de Toledo, FIBHULP; Severo Ochoa Foundation; EuTRiPD program (European
   Training and Research in Peritoneal Dialysis) [ITN-2011-287813]; AbbVie
   Spain
FX LSA is funded by the European Union Seventh Framework Programme
   [FP7/REGPOT-2012-2013.1] under grant agreement no 316265, BIOCAPS. This
   study was supported by RETICS 06/0016 (VFM, RS) and FIS PI 09/0064 (RS)
   from the Fondo de Investigaciones Sanitarias (Health Research Fund). MLC
   was funded by SAF 2013-47611-R, SAF 2010-21249, and SAF 2007-61201 from
   the Ministerio de Economia y competitividad. MRO was supported by RETICS
   12/0021, S2012DMD2321 from the Comunidad Autonoma de Madrid, PI 11/01854
   from Fondo Investigaciones Sanitarias. GTGM was supported by Renal
   Foundation Inigo Alvarez de Toledo, FIBHULP, and by Severo Ochoa
   Foundation. GL is funded from the EuTRiPD program (European Training and
   Research in Peritoneal Dialysis, ITN-2011-287813). The research was also
   partially sponsored by AbbVie Spain. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Aroeira LS, 2009, J AM SOC NEPHROL
   Artaza JN, 2009, J ENDOCRINOL, V200, P207, DOI 10.1677/JOE-08-0241
   Bellon T, 2011, NEPHROL DIAL TRANSPL, V26, P2995, DOI 10.1093/ndt/gfq771
   Bikle Daniel D, 2009, Curr Osteoporos Rep, V7, P58
   Cantorna MT, 1998, J IMMUNOL, V160, P5314
   Chaudhry A, 2009, SCIENCE, V326, P986, DOI 10.1126/science.1172702
   Daniels MD, 2008, AUTOIMMUNITY, V41, P490, DOI 10.1080/08916930802167902
   Darby IA, 2007, INT REV CYTOL, V257, P143, DOI 10.1016/S0074-7696(07)57004-X
   Deluca HF, 2001, FASEB J, V15, P2579, DOI 10.1096/fj.01-0433rev
   Doucet C, 2008, AM J PHYSIOL-RENAL, V295, pF179, DOI 10.1152/ajprenal.00252.2007
   Faust WC, 2009, J UROLOGY, V181, P290, DOI 10.1016/j.juro.2008.09.039
   Ghoreishi M, 2009, J IMMUNOL, V182, P6071, DOI 10.4049/jimmunol.0804064
   Ginanjar Eka, 2007, Acta Med Indones, V39, P133
   Gonzalez-Mateo GT, 2009, PERITON DIALYSIS INT, V29, P227
   Hirata H, 2008, RESPIROLOGY, V13, P788, DOI 10.1111/j.1440-1843.2008.01361.x
   Jeffery LE, 2009, J IMMUNOL, V183, P5458, DOI 10.4049/jimmunol.0803217
   Krediet RT, 2000, ADV RENAL REPLACE TH, V7, P271, DOI 10.1053/jarr.2000.16269
   Lee JW, 2014, BIOCHEM BIOPH RES CO, V444, P121, DOI 10.1016/j.bbrc.2014.01.005
   Li YJ, 2005, KIDNEY INT, V68, P1500, DOI 10.1111/j.1523-1755.2005.00562.x
   Liesz A, 2009, NAT MED, V15, P192, DOI 10.1038/nm.1927
   Marra F, 2009, SEMIN IMMUNOPATHOL, V31, P345, DOI 10.1007/s00281-009-0169-0
   Martin JG, 2006, PULM PHARMACOL THER, V19, P377, DOI 10.1016/j.pupt.2005.10.005
   Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532
   Meems LMG, 2012, J STEROID BIOCHEM, V132, P282, DOI 10.1016/j.jsbmb.2012.06.004
   Mortier S, 2003, J AM SOC NEPHROL, V14, P1296, DOI 10.1097/01.ASN.0000060681.97079.30
   Musi B, 1998, PERITON DIALYSIS INT, V18, P303
   Nevado J, 2005, BRIT J PHARMACOL, V146, P268, DOI 10.1038/sj.bjp.0706309
   Pecoits-Filho R, 2004, PERITON DIALYSIS INT, V24, P327
   Pecoits-Filho R, 2002, NEPHROL DIAL TRANSPL, V17, P1480, DOI 10.1093/ndt/17.8.1480
   Pomie C, 2008, HUM IMMUNOL, V69, P708, DOI 10.1016/j.humimm.2008.08.288
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Roberts GW, 2009, J AM SOC NEPHROL, V20, P1895, DOI 10.1681/ASN.2008101127
   Rodrigues-Diez R, 2014, KIDNEY INT
   Shao DD, 2008, J LEUKOCYTE BIOL, V83, P1323, DOI 10.1189/jlb.1107782
   Simonian PL, 2009, J IMMUNOL, V182, P657, DOI 10.4049/jimmunol.182.1.657
   Tan XY, 2008, J AM SOC NEPHROL, V19, P1741, DOI 10.1681/ASN.2007060666
   Theiss AL, 2005, GASTROENTEROLOGY, V129, P204, DOI 10.1053/j.gastro.2005.05.019
   Tzianabos AO, 2008, J IMMUNOL, V180, P6970, DOI 10.4049/jimmunol.180.10.6970
   Wynn TA, 2008, J PATHOL, V214, P199, DOI 10.1002/path.2277
   Yokoyama T, 2001, NEPHRON, V89, P215, DOI 10.1159/000046070
   Zamauskaite A, 1999, NEPHROL DIAL TRANSPL, V14, P49, DOI 10.1093/ndt/14.1.49
   Zhang LN, 2010, INVEST OPHTH VIS SCI, V51, P2109, DOI 10.1167/iovs.09-3993
   Zhang QZ, 2009, PLOS ONE, V4, pA192, DOI 10.1371/journal.pone.0007798
   Zhang Y, 2010, J AM SOC NEPHROL, V21, P966, DOI 10.1681/ASN.2009080872
NR 44
TC 31
Z9 32
U1 1
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 3
PY 2014
VL 9
IS 10
AR e108477
DI 10.1371/journal.pone.0108477
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AQ3DZ
UT WOS:000342670800017
PM 25279459
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Yan, QR
   Du, F
   Huang, XF
   Fu, Q
   Chen, S
   Dai, D
   Bao, CD
AF Yan, Qingran
   Du, Fang
   Huang, Xinfang
   Fu, Qiong
   Chen, Sheng
   Dai, Dai
   Bao, Chunde
TI Prevention of Immune Nephritis by the Small Molecular Weight
   Immunomodulator Iguratimod in MRL/lpr Mice
SO PLOS ONE
LA English
DT Article
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; ACTIVE RHEUMATOID-ARTHRITIS; T-CELL
   SUBSETS; B-CELLS; THERAPEUTIC TARGETS; ANTIRHEUMATIC DRUG; MURINE LUPUS;
   DOUBLE-BLIND; T-614; DISEASE
AB Objective: This study was performed to investigate the therapeutic effects of iguratimod in a lupus mouse model.
   Methods: Female MRL/lpr mice were treated with iguratimod, vehicle solution or cyclophosphamide. Proteinuria was monitored and kidney injury was blindly scored by a renal pathologist. Serum anti-double-stranded DNA antibodies were monitored by radioimmunoassay. Kidney IgG and CD20 were stained by immunohistochemistry. Splenic lymphocyte phenotypes were analyzed by flow cytometry. BAFF, IL-17A, IL-6, and IL-21 levels in serum and splenic lymphocytes were detected by ELISA or quantitative PCR.
   Results: Compared with the vehicle-treated controls, MRL/lpr mice treated with iguratimod showed less protenuria, less acute pathological lesions and no chronic changes in the kidneys. There were significant differences in glomerular injury and vasculitis scores, as well as in the semi-quantitave analysis of immune complex deposition between the two groups. Disease activity markers in sera (anti-dsDNA antibodies and immunoglobulin levels) were reduced and hypocomplementemia was attenuated. Lymphocyte expression of BAFF, IL-6, IL-17A and IL-21 was decreased. The abnormal splenic B220+ T cell and plasma cell populations in MRL/lpr mice were reduced by iguratimod treatment, with recovery of the total B cell population and inhibition of B cell infiltration of the kidney tissue. The dosage of iguratimod used in this study showed no significant cytotoxic effects in vivo and no overt side-effects were observed.
   Conclusion: Iguratimod ameliorates immune nephritis in MRL/lpr mice via a non-antiproliferative mechanism. Our data suggest a potential therapeutic role of iguratimod in lupus.
C1 [Yan, Qingran; Du, Fang; Huang, Xinfang; Fu, Qiong; Chen, Sheng; Bao, Chunde] Shanghai Jiao Tong Univ, Shanghai Inst Rheumatol, Sch Med, Dept Rheumatol,Renji Hosp, Shanghai 200030, Peoples R China.
   [Dai, Dai] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, Shanghai, Peoples R China.
   [Dai, Dai] Shanghai Jiao Tong Univ, Sch Med, Lab Mol Rheumatol, Shanghai 200030, Peoples R China.
RP Bao, CD (reprint author), Shanghai Jiao Tong Univ, Shanghai Inst Rheumatol, Sch Med, Dept Rheumatol,Renji Hosp, Shanghai 200030, Peoples R China.
EM baochunde_1678@126.com
FU National Natural Science Foundation of China [81373207]; Doctoral
   Innovation Fund of Shanghai Jiao Tong University School of Medicine
   [bxj201221]
FX This work was supported by grants from National Natural Science
   Foundation of China (grant no. 81373207) and Doctoral Innovation Fund of
   Shanghai Jiao Tong University School of Medicine (grant no. bxj201221).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Aikawa Y, 1998, J NEUROIMMUNOL, V89, P35, DOI 10.1016/S0165-5728(98)00056-3
   Bossen C, 2008, BLOOD, V111, P1004, DOI 10.1182/blood-2007-09-110874
   COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331
   Cunnane G, 2004, ARTHRITIS RHEUM-US, V50, P1539, DOI 10.1002/art.20147
   Du F, 2008, ARTHRITIS RES THERAP, V10
   Du F, 2012, INT IMMUNOPHARMACOL, V13, P54, DOI 10.1016/j.intimp.2012.03.003
   Espeli M, 2011, J AM SOC NEPHROL, V22, P296, DOI 10.1681/ASN.2010050515
   GIESE T, 1992, J IMMUNOL, V149, P3097
   Hara M, 2007, MOD RHEUMATOL, V17, P10
   Hara Masako, 2007, Mod Rheumatol, V17, P1, DOI 10.1007/s10165-006-0542-y
   HUNSICKER LG, 1972, NEW ENGL J MED, V287, P835, DOI 10.1056/NEJM197210262871701
   Jiang C, 2011, J IMMUNOL, V186, P6136, DOI 10.4049/jimmunol.1001931
   KAWANO MM, 1995, BLOOD, V85, P487
   Kohno M, 2001, J RHEUMATOL, V28, P2591
   Kyttaris VC, 2010, J IMMUNOL, V184, P4605, DOI 10.4049/jimmunol.0903595
   Lacotte S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058140
   Lee HT, 2010, J RHEUMATOL, V37, P45, DOI 10.3899/jrheum.090450
   Lu LJ, 2008, CHINESE MED J-PEKING, V121, P615, DOI 10.1097/00029330-200804010-00008
   Lu LJ, 2009, ARTHRIT RHEUM-ARTHR, V61, P979, DOI 10.1002/art.24643
   Luo Q, 2013, J IMMUNOL, V191, P4969, DOI 10.4049/jimmunol.1300832
   Martin JC, 2014, CLIN IMMUNOL, V154, P1, DOI 10.1016/j.clim.2014.05.004
   MORSE HC, 1982, J IMMUNOL, V129, P2612
   MURRAY LJ, 1990, EUR J IMMUNOL, V20, P163, DOI 10.1002/eji.1830200124
   Nijnik A, 2006, INT IMMUNOL, V18, P1127, DOI 10.1093/intimm/dxl047
   Rankin AL, 2012, J IMMUNOL, V188, P1656, DOI 10.4049/jimmunol.1003871
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Ronnblom L, 2010, NAT REV RHEUMATOL, V6, P339, DOI 10.1038/nrrheum.2010.64
   Sanz I, 2010, NAT REV RHEUMATOL, V6, P326, DOI 10.1038/nrrheum.2010.68
   Sawada T, 2000, IMMUNOPHARMACOLOGY, V49, P285, DOI 10.1016/S0162-3109(00)00242-3
   Schiffer L, 2003, J IMMUNOL, V171, P489, DOI 10.4049/jimmunol.171.1.489
   SMITH HR, 1984, CLIN IMMUNOL IMMUNOP, V30, P51, DOI 10.1016/0090-1229(84)90006-0
   Sun C-Y, 2013, INT J RHEUMATOLOGY, V2013, P9
   Tanaka K, 2003, RHEUMATOLOGY, V42, P1365, DOI 10.1093/rheumatology/keg381
   Tsokos GC, 2011, NEW ENGL J MED, V365, P2110, DOI 10.1056/NEJMra1100359
   WATSON ML, 1992, J EXP MED, V176, P1645, DOI 10.1084/jem.176.6.1645
   Wong HK, 1999, J IMMUNOL, V163, P1682
   Zhou X, 2014, INT REV IMMUNOLOGY
NR 37
TC 6
Z9 7
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 1
PY 2014
VL 9
IS 10
AR e108273
DI 10.1371/journal.pone.0108273
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AR6ZM
UT WOS:000343729600037
PM 25271634
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Aldini, R
   Micucci, M
   Cevenini, M
   Fato, R
   Bergamini, C
   Nanni, C
   Cont, M
   Camborata, C
   Spinozzi, S
   Montagnani, M
   Roda, G
   D'Errico-Grigioni, A
   Rosini, F
   Roda, A
   Mazzella, G
   Chiarini, A
   Budriesi, R
AF Aldini, Rita
   Micucci, Matteo
   Cevenini, Monica
   Fato, Romana
   Bergamini, Christian
   Nanni, Cristina
   Cont, Massimiliano
   Camborata, Cecilia
   Spinozzi, Silvia
   Montagnani, Marco
   Roda, Giulia
   D'Errico-Grigioni, Antonia
   Rosini, Francesca
   Roda, Aldo
   Mazzella, Giuseppe
   Chiarini, Alberto
   Budriesi, Roberta
TI Antiinflammatory Effect of Phytosterols in Experimental Murine Colitis
   Model: Prevention, Induction, Remission Study
SO PLOS ONE
LA English
DT Article
ID INFLAMMATORY-BOWEL-DISEASE; NF-KAPPA-B; INTESTINAL EPITHELIAL-CELLS;
   SULFATE-INDUCED COLITIS; PLANT STANOL ESTERS; BETA-SITOSTEROL;
   BILE-ACIDS; IN-VITRO; CHOLESTEROL-METABOLISM; PENTACYCLIC TRITERPENE
AB Phytosterols, besides hypocholesterolemic effect, present anti-inflammatory properties. Little information is available about their efficacy in Inflammatory Bowel Disease (IBD). Therefore, we have evaluated the effect of a mixture of phytosterols on prevention/induction/remission in a murine experimental model of colitis. Phytosterols were administered x os before, during and after colitis induction with Dextran Sodium Sulfate (DSS) in mice. Disease Activity Index (DAI), colon length, histopathology score, F-18-FDG microPET, oxidative stress in the intestinal tissue (ileum and colon) and gallbladder ileum and colon spontaneous and carbachol (CCh) induced motility, plasma lipids and plasma, liver and biliary bile acids (BA) were evaluated. A similar longitudinal study was performed in a DSS colitis control group. Mice treated with DSS developed severe colitis as shown by DAI, colon length, histopathology score, F-18-FDG microPET, oxidative stress. Both spontaneous and induced ileal and colonic motility were severely disturbed. The same was observed with gallbladder. DSS colitis resulted in an increase in plasma cholesterol, and a modification of the BA pattern. Phytosterols feeding did not prevent colitis onset but significantly reduced the severity of the disease and improved clinical and histological remission. It had strong antioxidant effects, almost restored colon, ileal and gallbladder motility. Plasmatic levels of cholesterol were also reduced. DSS induced a modification in the BA pattern consistent with an increase in the intestinal BA deconjugating bacteria, prevented by phytosterols. Phytosterols seem a potential nutraceutical tool for gastrointestinal inflammatory diseases, combining metabolic systematic and local anti-inflammatory effects.
C1 [Aldini, Rita; Micucci, Matteo; Fato, Romana; Bergamini, Christian; Chiarini, Alberto; Budriesi, Roberta] Univ Bologna, Dept Pharm & Biotecnol, Bologna, Italy.
   [Cevenini, Monica; Montagnani, Marco; Roda, Giulia; Mazzella, Giuseppe] Univ Bologna, Dept Med & Surg, Policlin S Orsola, Bologna, Italy.
   [Nanni, Cristina; Cont, Massimiliano] Univ Bologna, Dept Nucl Med, Azienda Osped, Policlin S Orsola Malpighi, Bologna, Italy.
   [Camborata, Cecilia; Spinozzi, Silvia; Roda, Aldo] Univ Bologna, Dept Chem Giacomo Ciamician, Bologna, Italy.
   [D'Errico-Grigioni, Antonia; Rosini, Francesca] Univ Bologna, DIMES Dept, Policlin S Orsola, Bologna, Italy.
RP Aldini, R (reprint author), Univ Bologna, Dept Pharm & Biotecnol, Bologna, Italy.
EM rita.aldini@unibo.it; roberta.budriesi@unibo.it
OI Mazzella, Giuseppe/0000-0001-8656-8112; Roda, Aldo/0000-0001-7649-4797;
   MONTAGNANI, MARCO/0000-0003-0103-0327
FU Alisal [Mazz100136- 2010]; Ministero delle Politiche Agricole,
   Alimentari e Forestali [D.M. 11008/7303/10]
FX This work was supported by Alisal (Mazz100136- 2010). ALISAL is a
   project supported by the Ministero delle Politiche Agricole, Alimentari
   e Forestali, with D.M 11008/7303/10, dated 17/05/2010. The title of the
   project is: Miglioramento delle proprieta igienico-sanitarie,
   salutistiche e funzionali di commodity per l'alimentazione dell'uomo e/o
   degli animali (Improvement of sanitary properties, healthy and
   functional food commodities for human and/or animals). Prof. Mazzella
   was supported with materials, reagents, animals. The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Aldini R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044650
   [Anonymous], GRAPHPAD VERS 5 0
   Aragao Gislei Frota, 2007, Journal of Herbal Pharmacotherapy, V7, P31, DOI 10.1300/J157v07n02_03
   Ardizzone S, 2005, DRUGS, V65, P2253, DOI 10.2165/00003495-200565160-00002
   Arunlakshana D, 1959, BRIT J PHARMACOL, V14, P48
   Bak MJ, 2012, MOLECULES, V17, P13769, DOI 10.3390/molecules171213769
   Baskar AA, 2010, BMC COMPLEM ALTERN M, V10, DOI 10.1186/1472-6882-10-24
   Baskar AA, 2012, J MED FOOD, V15, P335, DOI 10.1089/jmf.2011.1780
   Brewer S, 2008, GASTROENTEROLOGY, V135, P744, DOI 10.1053/j.gastro.2008.06.040
   Brufau G, 2008, NUTR RES, V28, P217, DOI 10.1016/j.nutres.2008.02.003
   Buege J A, 1978, Methods Enzymol, V52, P302
   Calpe-Berdiel L, 2007, LIFE SCI, V80, P1951, DOI 10.1016/j.lfs.2007.02.032
   Cheon JH, 2006, INFLAMM BOWEL DIS, V12, P1152, DOI 10.1097/01.mib.0000235830.94057.c6
   Choi M, 2006, NAT MED, V12, P1253, DOI 10.1038/nm1501
   De Jong A, 2008, EUR J CLIN NUTR, V62, P263, DOI 10.1038/sj.ejcn.1602733
   de Jong A, 2003, J NUTR BIOCHEM, V14, P362, DOI 10.1016/S0955-2863(03)00002-0
   De Smet E, 2012, MOL NUTR FOOD RES, V56, P1058, DOI 10.1002/mnfr.201100722
   Demonty I, 2005, LIPIDS, V40, P695, DOI 10.1007/s11745-005-1432-y
   Durkee BY, 2010, METHODS, V50, P36, DOI 10.1016/j.ymeth.2009.07.008
   Fenoglio-Preiser CM, 2008, GASTROINTESTINAL PAT, P64
   Fitzpatrick LR, 2000, DIGEST DIS SCI, V45, P2327, DOI 10.1023/A:1005630723111
   Gilani AH, 2008, FUND CLIN PHARMACOL, V22, P87, DOI 10.1111/j.1472-8206.2007.00561.x
   GROSSI L, 1993, GASTROENTEROLOGY, V104, P1049, DOI 10.1016/0016-5085(93)90273-F
   Hac-Wydro K, 2013, COLLOID SURFACE B, V110, P113, DOI 10.1016/j.colsurfb.2013.04.041
   Hallikainen M, 2008, ATHEROSCLEROSIS, V199, P432, DOI 10.1016/j.atherosclerosis.2007.10.033
   Heylen M, 2013, INFLAMM BOWEL DIS, V19, P967, DOI 10.1097/MIB.0b013e3182802c7c
   Hindryckx P, 2011, INFLAMM BOWEL DIS, V17, P2058, DOI 10.1002/ibd.21578
   Hirota TCL, 2006, BRIT J PHARMACOL, V149, P463
   Hokama A, 2012, INTERN EMERG MED, V7, P487, DOI 10.1007/s11739-012-0834-5
   Hur SJ, 2012, NUTR RES, V32, P801, DOI 10.1016/j.nutres.2012.09.013
   Islam MS, 2008, BRIT J PHARMACOL, V154, P812, DOI 10.1038/bjp.2008.137
   KERR PM, 1995, BRIT J PHARMACOL, V115, P1518, DOI 10.1111/j.1476-5381.1995.tb16645.x
   Khan MRI, 2014, BBA-MOL BASIS DIS, V1842, P635, DOI 10.1016/j.bbadis.2013.12.007
   Khan MRI, 2013, J GASTROENTEROL, V48, P885, DOI 10.1007/s00535-012-0718-5
   Kilkenny C, 2010, J PHARMACOL PHARMACO, V1, P94, DOI 10.4103/0976-500X.72351
   Kim JM, 2010, LAB INVEST, V90, P1004, DOI 10.1038/labinvest.2010.54
   Ko JK, 2014, CURR PHARM DESIGN, V20, P1082, DOI 10.2174/13816128113199990416
   Lavoie B, 2010, J PHYSIOL-LONDON, V588, P3295, DOI 10.1113/jphysiol.2010.192146
   Lee IA, 2012, PLANTA MED, V78, P896, DOI 10.1055/s-0031-1298486
   Li TT, 2011, MOL ENDOCRINOL, V25, P1066, DOI 10.1210/me.2010-0460
   Libby P, 2002, NATURE, V420, P868, DOI 10.1038/nature01323
   Liz R, 2013, J PHARM PHARMACOL, V65, P115, DOI 10.1111/j.2042-7158.2012.01568.x
   Liz R, 2011, INT IMMUNOPHARMACOL, V11, P1991, DOI 10.1016/j.intimp.2011.08.009
   Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362
   Manz M, 2012, DIGESTION, V86, P11, DOI 10.1159/000341952
   Maruyama T, 2002, BIOCHEM BIOPH RES CO, V298, P714, DOI 10.1016/S0006-291X(02)02550-0
   McGrath JC, 2010, BRIT J PHARMACOL, V160, P1573, DOI 10.1111/j.1476-5381.2010.00873.x
   Medeiros R, 2007, EUR J PHARMACOL, V559, P227, DOI 10.1016/j.ejphar.2006.12.005
   Melgar S, 2005, AM J PHYSIOL-GASTR L, V288, pG1328, DOI 10.1152/ajpgi.00467.2004
   Micucci M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080925
   Moghadasian MH, 2000, LIFE SCI, V67, P605, DOI 10.1016/S0024-3205(00)00665-2
   Moreau RA, 2002, PROG LIPID RES, V41, P457, DOI 10.1016/S0163-7827(02)00006-1
   Moreno JJ, 2003, FREE RADICAL BIO MED, V35, P1073, DOI 10.1016/S0891-5849(03)00465-9
   Naito Y, 2000, TOXICOL LETT, V116, P209, DOI 10.1016/S0378-4274(00)00224-1
   O'Hara JR, 2007, GUT, V56, P186, DOI 10.1136/gut.2006.102780
   Ostlund RE, 2002, ANNU REV NUTR, V22, P533, DOI 10.1146/annurev.nutr.22.020702.075220
   Ostlund Richard E Jr, 2006, Curr Atheroscler Rep, V8, P487, DOI 10.1007/s11883-006-0024-x
   Othman RA, 2011, NUTR REV, V69, P371, DOI 10.1111/j.1753-4887.2011.00399.x
   Perlman SB, 2013, SEMIN NUCL MED, V43, P420, DOI 10.1053/j.semnuclmed.2013.06.006
   Pinto S. A. Holanda, 2008, Inflammopharmacology, V16, P48, DOI 10.1007/s10787-007-1609-x
   Plat J, 2000, EUR J CLIN NUTR, V54, P671, DOI 10.1038/sj.ejcn.1601071
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   RODA A, 1995, J CHROMATOGR B, V665, P281, DOI 10.1016/0378-4347(94)00544-F
   Shi XZ, 2011, AM J PHYSIOL-GASTR L, V300, pG41, DOI 10.1152/ajpgi.00358.2010
   Shishodia S, 2004, J BIOL CHEM, V279, P47148, DOI 10.1074/jbc.M408093200
   Strober W, 2002, ANNU REV IMMUNOL, V20, P495, DOI 10.1146/annurev.immunol.20.100301.064816
   TAKADA M, 1984, METHOD ENZYMOL, V105, P147
   Tallarida R., 1987, MANUAL PHARM CALCULA
   Vaughn Byron P, 2014, Curr Treat Options Gastroenterol, V12, P103, DOI 10.1007/s11938-013-0008-1
   Villanacci V, 2008, NEUROGASTROENT MOTIL, V20, P1009, DOI 10.1111/j.1365-2982.2008.01146.x
   Villasenor IM, 2002, PHYTOTHER RES, V164, P17
   Vitor CE, 2009, BRIT J PHARMACOL, V157, P1034, DOI 10.1111/j.1476-5381.2009.00271.x
   Waldner MJ, 2009, CURR PROTOC PHARM, V46
   Wells RW, 2004, PFLUG ARCH EUR J PHY, V448, P515, DOI 10.1007/s00424-004-1286-1
   Wirtz S, 2007, NAT PROTOC, V2, P541, DOI 10.1038/nprot.2007.41
NR 75
TC 33
Z9 33
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 30
PY 2014
VL 9
IS 9
AR e108112
DI 10.1371/journal.pone.0108112
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AR6CW
UT WOS:000343671700064
PM 25268769
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Mathis, SE
   Alberico, A
   Nande, R
   Neto, W
   Lawrence, L
   McCallister, DR
   Denvir, J
   Kimmey, GA
   Mogul, M
   Oakley, G
   Denning, KL
   Dougherty, T
   Valluri, JV
   Claudio, PP
AF Mathis, Sarah E.
   Alberico, Anthony
   Nande, Rounak
   Neto, Walter
   Lawrence, Logan
   McCallister, Danielle R.
   Denvir, James
   Kimmey, Gerrit A.
   Mogul, Mark
   Oakley, Gerard, III
   Denning, Krista L.
   Dougherty, Thomas
   Valluri, Jagan V.
   Claudio, Pier Paolo
TI Chemo-Predictive Assay for Targeting Cancer Stem-Like Cells in Patients
   Affected by Brain Tumors
SO PLOS ONE
LA English
DT Article
ID INTRADURAL EXTRAMEDULLARY EPENDYMOMA; RADICAL SURGICAL RESECTION;
   EX-VIVO CHEMOSENSITIVITY; SPINAL-CORD EPENDYMOMAS; CHEMORESPONSE ASSAY;
   OVARIAN-CANCER; CLINICAL-RESPONSE; ISOTHIOCYANATES; CHEMOTHERAPY;
   MECHANISM
AB Administration of ineffective anticancer therapy is associated with unnecessary toxicity and development of resistant clones. Cancer stem-like cells (CSLCs) resist chemotherapy, thereby causing relapse of the disease. Thus, development of a test that identifies the most effective chemotherapy management offers great promise for individualized anticancer treatments. We have developed an ex vivo chemotherapy sensitivity assay (ChemoID), which measures the sensitivity of CSLCs as well as the bulk of tumor cells to a variety of chemotherapy agents. Two patients, a 21-year old male (patient 1) and a 5-month female (patient 2), affected by anaplastic WHO grade-III ependymoma were screened using the ChemoID assay. Patient 1 was found sensitive to the combination of irinotecan and bevacizumab, which resulted in a prolonged disease progression free period of 18 months. Following recurrence, the combination of various chemotherapy drugs was tested again with the ChemoID assay. We found that benzyl isothiocyanate (BITC) greatly increased the chemosensitivity of the ependymoma cells to the combination of irinotecan and bevacizumab. After patient 1 was treated for two months with irinotecan, bevacizumab and supplements of cruciferous vegetable extracts containing BITC, we observed over 50% tumoral regression in comparison with pre-ChemoID scan as evidenced by MRI. Patient 2 was found resistant to all treatments tested and following 6 cycles of vincristine, carboplatin, cyclophosphamide, etoposide, and cisplatin in various combinations, the tumor of this patient rapidly progressed and proton beam therapy was recommended. As expected animal studies conducted with patient derived xenografts treated with ChemoID screened drugs recapitulated the clinical observation. This assay demonstrates that patients with the same histological stage and grade of cancer may vary considerably in their clinical response, suggesting that ChemoID testing which measures the sensitivity of CSLCs as well as the bulk of tumor cells to a variety of chemotherapy agents could lead to more effective and personalized anticancer treatments in the future.
C1 [Mathis, Sarah E.; Nande, Rounak; Neto, Walter; Lawrence, Logan; McCallister, Danielle R.; Denvir, James; Claudio, Pier Paolo] Marshall Univ, Dept Biochem & Microbiol, Joan C Edwards Sch Med, Huntington, WV 25755 USA.
   [Mathis, Sarah E.; Nande, Rounak; Neto, Walter; Lawrence, Logan; McCallister, Danielle R.; Denvir, James; Claudio, Pier Paolo] Marshall Univ, Translat Genom Res Inst, Huntington, WV USA.
   [Alberico, Anthony] Marshall Univ, Dept Neurosurg, Joan C Edwards Sch Med, Huntington, WV USA.
   [Kimmey, Gerrit A.] St Marys Hosp, Dept Med Oncol, Huntington, WV USA.
   [Mogul, Mark] Marshall Univ, Dept Pediat, Joan C Edwards Sch Med, Huntington, WV USA.
   [Oakley, Gerard, III; Denning, Krista L.; Dougherty, Thomas] Marshall Univ, Dept Pathol, Joan C Edwards Sch Med, Huntington, WV USA.
   [Valluri, Jagan V.] Marshall Univ, Dept Biol, Huntington, WV USA.
   [Claudio, Pier Paolo] Marshall Univ, Dept Surg, Joan C Edwards Sch Med, Huntington, WV USA.
RP Claudio, PP (reprint author), Marshall Univ, Dept Biochem & Microbiol, Joan C Edwards Sch Med, Huntington, WV 25755 USA.
EM claudiop@marshall.edu
OI Claudio, Pier Paolo/0000-0001-7790-1622
FU National Center for Advancing Translational Sciences, National
   Institutes of Health through the National Center for Research Resources
   (NCRR) [UL1TR000117]; National Cancer Institute [5P20RR020180]; WV-INBRE
   [5P20RR016477]; Marshall University; Marshall University Department of
   Neuroscience
FX The present studies were supported in part by the National Center for
   Advancing Translational Sciences, National Institutes of Health, through
   grant number UL1TR000117 from the National Center for Research Resources
   (NCRR), and 5P20RR020180 from the National Cancer Institute, WV-INBRE
   5P20RR016477, and in part by a Marshall University Translational Award,
   and an award from the Marshall University Department of Neuroscience (to
   PPC). The content of this manuscript is solely the responsibility of the
   authors and does not necessarily represent the official views of NCRR
   and NIH. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Aimola P, 2010, DRUG NEWS PERSPECT, V23, P175, DOI 10.1358/dnp.2010.23.3.1489979
   Ballard KS, 2010, INT J GYNECOL CANCER, V20, P561, DOI 10.1111/IGC.0b013e3181d320dd
   Bouffet E, 1999, CHILD NERV SYST, V15, P563, DOI 10.1007/s003810050544
   Breidenbach M, 2002, ANTI-CANCER DRUG, V13, P173, DOI 10.1097/00001813-200202000-00010
   Brower Stacey L., 2008, V414, P57
   Chamberlain MC, 2011, CURR NEUROL NEUROSCI, V11, P320, DOI 10.1007/s11910-011-0190-2
   Chou PM, 1996, PEDIATR PATHOL LAB M, V16, P551, DOI 10.1080/107710496175499
   COOPER IS, 1951, SURG GYNECOL OBSTET, V92, P183
   Di Pasqua AJ, 2010, CHEM RES TOXICOL, V23, P1307, DOI 10.1021/tx100187f
   Duffau H, 2000, SPINE, V25, P1993, DOI 10.1097/00007632-200008010-00021
   Duncan John A. Iii, 1995, P493
   Gallion H, 2006, INT J GYNECOL CANCER, V16, P194, DOI 10.1111/j.1525-1438.2006.00301.x
   Hanbali F, 2002, NEUROSURGERY, V51, P1162, DOI 10.1227/01.NEU.0000032539.78913.4C
   Herzog TJ, 2010, AM J OBSTET GYNECOL, V203, pe61
   Huh WK, 2011, INT J GYNECOL CANCER, V21, P494, DOI 10.1097/IGC.0b013e31820c4cb5
   Iunes EA, 2011, J NEUROSURG-SPINE, V14, P65, DOI 10.3171/2010.9.SPINE09963
   Kelloff GJ, 1999, ANN NY ACAD SCI, V889, P1, DOI 10.1111/j.1749-6632.1999.tb08718.x
   Kelly SE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010035
   Kleinhans R, 2012, MED BIOL ENG COMPUT, V50, P117, DOI 10.1007/s11517-011-0855-7
   Kocak Z, 2004, J EXP CLIN CANC RES, V23, P201
   Lamy E, 2011, DRUG METAB REV, V43, P387, DOI 10.3109/03602532.2011.569551
   Lin YH, 2005, J NEURO-ONCOL, V71, P205, DOI 10.1007/s11060-004-1386-y
   Malik Babar, 2012, Front Biosci (Elite Ed), V4, P2142
   McCormick P C, 1990, Neurosurg Clin N Am, V1, P591
   Merchant TE, 2002, ONCOLOGY-NY, V16, P629
   Metellus P, 2008, CANCER, V113, P175, DOI 10.1002/cncr.23530
   Mi LX, 2011, CHEM RES TOXICOL, V24, P1735, DOI 10.1021/tx2002806
   Michalova E, 2008, Klin Onkol, V21, P93
   Modena P, 2012, NEURO-ONCOLOGY, V14, P1346, DOI 10.1093/neuonc/nos245
   Myatt N, 1997, ANTI-CANCER DRUG, V8, P756, DOI 10.1097/00001813-199709000-00004
   Ness RB, 2002, ANTICANCER RES, V22, P1145
   O'Brien CA, 2010, CLIN CANCER RES, V16, P3113, DOI 10.1158/1078-0432.CCR-09-2824
   Ochs RL, 2005, METH MOLEC MED, V110, P155
   Pejavar S, 2012, J NEURO-ONCOL, V106, P367, DOI 10.1007/s11060-011-0671-9
   Peters D, 2005, MOL CANCER THER, V4, P1605, DOI 10.1158/1535-7163.MCT-04-0311
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Reni M, 2004, CANCER, V100, P1221, DOI 10.1002/cncr.20074
   Reni M, 2007, CRIT REV ONCOL HEMAT, V63, P81, DOI 10.1016/j.critrevonc.2007.03.004
   Rice SD, 2011, CANCER BIOL THER, V11, P196, DOI 10.4161/cbt.11.2.13701
   Rice SD, 2010, ANTICANCER RES, V30, P2805
   Song KW, 2009, CLIN ORTHOP SURG, V1, P74, DOI 10.4055/cios.2009.1.2.74
   Suchy SL, 2011, CANCER BIOL THER, V11, P1059, DOI 10.4161/cbt.11.12.15710
   Tsubouchi H, 2000, Hum Cell, V13, P203
   van Meerloo J, 2011, METHODS MOL BIOL, V731, P237, DOI 10.1007/978-1-61779-080-5_20
   Vandertop WP, 2003, NEUROSURGERY, V53, P246, DOI 10.1227/01.NEU.0000072306.16102.BD
   Wichmann G, 2009, ONKOLOGIE, V32, P264, DOI 10.1159/000209148
   Wu X, 2009, ACTA PHARMACOL SIN, V30, P501, DOI 10.1038/aps.2009.50
   Yu Yang, 2012, Front Biosci (Elite Ed), V4, P1528
   Zhang YS, 2001, CARCINOGENESIS, V22, P425, DOI 10.1093/carcin/22.3.425
NR 49
TC 5
Z9 6
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 21
PY 2014
VL 9
IS 8
AR e105710
DI 10.1371/journal.pone.0105710
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AO1WL
UT WOS:000341106100113
PM 25144312
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Lian, JM
   Huang, XF
   Pai, N
   Deng, C
AF Lian, Jiamei
   Huang, Xu-Feng
   Pai, Nagesh
   Deng, Chao
TI Preventing Olanzapine-Induced Weight Gain Using Betahistine: A Study in
   a Rat Model with Chronic Olanzapine Treatment
SO PLOS ONE
LA English
DT Article
ID BROWN ADIPOSE-TISSUE; 2ND-GENERATION ANTIPSYCHOTICS; 1ST-EPISODE
   SCHIZOPHRENIA; FOOD-INTAKE; RECEPTORS; AMPK; H1; THERMOGENESIS;
   PHARMACOLOGY; ADOLESCENTS
AB Olanzapine is the one of first line antipsychotic drug for schizophrenia and other serious mental illness. However, it is associated with troublesome metabolic side-effects, particularly body weight gain and obesity. The antagonistic affinity to histamine H-1 receptors (H1R) of antipsychotic drugs has been identified as one of the main contributors to weight gain/obesity side-effects. Our previous study showed that a short term (2 weeks) combination treatment of betahistine (an H1R agonist and H3R antagonist) and olanzapine (O+B) reduced (-45%) body weight gain induced by olanzapine in drug-naive rats. A key issue is that clinical patients suffering with schizophrenia, bipolar disease and other mental disorders often face chronic, even life-time, antipsychotic treatment, in which they have often had previous antipsychotic exposure. Therefore, we investigated the effects of chronic O+B co-treatment in controlling body weight in female rats with chronic and repeated exposure of olanzapine. The results showed that co-administration of olanzapine (3 mg/kg, t.i.d.) and betahistine (9.6 mg/kg, t.i.d.) significantly reduced (-51.4%) weight gain induced by olanzapine. Co-treatment of O+B also led to a decrease in feeding efficiency, liver and fat mass. Consistently, the olanzapine-only treatment increased hypothalamic H1R protein levels, as well as hypothalamic pAMPK alpha, AMPK alpha and NPY protein levels, while reducing the hypothalamic POMC, and UCP1 and PGC-1 alpha protein levels in brown adipose tissue (BAT). The olanzapine induced changes in hypothalamic H1R, pAMPK alpha, BAT UCP1 and PGC-1 alpha could be reversed by co-treatment of O+B. These results supported further clinical trials to test the effectiveness of co-treatment of O+B for controlling weight gain/obesity side-effects in schizophrenia with chronic antipsychotic treatment.
C1 [Lian, Jiamei; Deng, Chao] Univ Wollongong, Illawarra Hlth & Med Res Inst, Antipsychot Res Lab, Wollongong, NSW, Australia.
   [Lian, Jiamei; Huang, Xu-Feng; Pai, Nagesh; Deng, Chao] Univ Wollongong, Sch Med, Ctr Translat Neurosci, Wollongong, NSW, Australia.
   [Lian, Jiamei; Huang, Xu-Feng; Pai, Nagesh; Deng, Chao] Univ Wollongong, Illawarra Hlth & Med Res Inst, Wollongong, NSW, Australia.
   [Huang, Xu-Feng; Deng, Chao] Schizophrenia Res Inst, Sydney, NSW, Australia.
RP Deng, C (reprint author), Univ Wollongong, Illawarra Hlth & Med Res Inst, Antipsychot Res Lab, Wollongong, NSW, Australia.
EM chao@uow.edu.au
RI Deng, Chao/F-4417-2016; Huang, Xu-Feng/H-7408-2015
OI Deng, Chao/0000-0003-1147-5741; Huang, Xu-Feng/0000-0002-5895-2253;
   Lian, Jiamei/0000-0002-8850-2536
FU Australian National Health and Medical Research Council (NHMRC)
   [APP1027493, APP1008473]; Schizophrenia Research Institute (SRI); New
   South Wales Health
FX This study was supported by the Australian National Health and Medical
   Research Council (NHMRC, www.nhmrc.gov.au) Project Grants (APP1027493 to
   XH and CD; APP1008473 to CD), and by the Schizophrenia Research
   Institute (SRI, www.schizophreniaresearch.org.au), utilising
   infrastructure funding from New South Wales Health. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Allison DB, 1999, AM J PSYCHIAT, V156, P1686
   Aravagiri M, 1999, BIOPHARM DRUG DISPOS, V20, P369, DOI 10.1002/1099-081X(199911)20:8<369::AID-BDD200>3.3.CO;2-Y
   Balu DT, 2008, BRAIN RES, V1211, P37, DOI 10.1016/j.brainres.2008.03.023
   Botta L, 2001, Acta Otorhinolaryngol Ital, V21, P24
   Bustillo JR, 2003, NEUROPSYCHOPHARMACOL, V28, P527, DOI 10.1038/sj.npp.1300089
   Cinti S, 2006, NUTR METAB CARDIOVAS, V16, P569, DOI 10.1016/j.numecd.2006.07.009
   Coccurello R, 2010, PHARMACOL THERAPEUT, V127, P210, DOI 10.1016/j.pharmthera.2010.04.008
   Cooper GD, 2005, PSYCHOPHARMACOLOGY, V181, P80, DOI 10.1007/s00213-005-2224-4
   Correll CU, 2010, EUR PSYCHIAT, V25, pS12, DOI 10.1016/S0924-9338(10)71701-6
   Correll CU, 2008, INT REV PSYCHIATR, V20, P195, DOI 10.1080/09540260801889179
   Correll CU, 2011, TRENDS MOL MED, V17, P97, DOI 10.1016/j.molmed.2010.10.010
   Dalvi PS, 2011, AM J PHYSIOL-REG I, V300, pR1030, DOI 10.1152/ajpregu.00649.2010
   Das Chandan, 2012, Ann Clin Psychiatry, V24, P225
   Davoodi N, 2008, BEHAV PHARMACOL, V19, P121, DOI 10.1097/FBP.0b013e3282f62c66
   Deng C, 2007, PROG NEURO-PSYCHOPH, V31, P915, DOI 10.1016/j.pnpbp.2007.02.009
   Deng C, 2013, ENDOCRIN METAB CLIN, V42, P545, DOI 10.1016/j.ecl.2013.05.006
   Deng C, 2012, J PSYCHOPHARMACOL, V26, P1271, DOI 10.1177/0269881112449396
   Deng C, 2010, PROG NEURO-PSYCHOPH, V34, P1, DOI 10.1016/j.pnpbp.2009.11.009
   Depping AM, 2010, COCHRANE DB SYST REV, V12
   FDA, 2005, EST SAF START DOS CL
   Fell MJ, 2004, J PSYCHOPHARMACOL, V18, P149, DOI 10.1177/0269881104042613
   Ferno J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020571
   Gebhardt S, 2009, J PSYCHIATR RES, V43, P620, DOI 10.1016/j.jpsychires.2008.11.001
   Goudie AJ, 2002, J PSYCHOPHARMACOL, V16, P291, DOI 10.1177/026988110201600402
   Han M, 2008, PSYCHONEUROENDOCRINO, V33, P569, DOI 10.1016/j.psyneuen.2008.01.018
   He M, 2014, PSYCHONEUROENDOCRINO, V42, P153, DOI 10.1016/j.psyneuen.2014.01.018
   He M, 2013, CNS DRUGS, V27, P423, DOI 10.1007/s40263-013-0062-1
   Hillebrand JJG, 2002, PEPTIDES, V23, P2283, DOI 10.1016/S0196-9781(02)00269-3
   Hu YS, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0093310, 10.1371/journal.pone.0092099]
   Jeck-Thole S, 2006, DRUG SAFETY, V29, P1049, DOI 10.2165/00002018-200629110-00004
   Kahn RS, 2008, LANCET, V371, P1085, DOI 10.1016/S0140-6736(08)60486-9
   Kim DH, 2009, NEUROTHERAPEUTICS, V6, P78, DOI 10.1016/j.nurt.2008.10.020
   Kim SF, 2007, P NATL ACAD SCI USA, V104, P3456, DOI 10.1073/pnas.0611417104
   Komossa K, 2010, COCHRANE DB SYST REV, V17
   Kroeze WK, 2003, NEUROPSYCHOPHARMACOL, V28, P519, DOI 10.1038/sj.npp.1300027
   Kwok AKH, 2001, AM J OPHTHALMOL, V132, P178, DOI 10.1016/S0002-9394(01)00976-X
   Lian JM, 2010, PROG NEURO-PSYCHOPH, V34, P1157, DOI 10.1016/j.pnpbp.2010.03.035
   Lieberman JA, 2005, NEW ENGL J MED, V353, P1209, DOI 10.1056/NEJMoa051688
   Lopez M, 2010, NAT MED, V16, P1001, DOI 10.1038/nm.2207
   Maffulli N, 2000, AM J SPORT MED, V28, P857, DOI 10.1177/03635465000280061401
   Martins PJF, 2010, DIABETES, V59, P2418, DOI 10.2337/db10-0449
   Matsui-Sakata Akiko, 2005, Drug Metab Pharmacokinet, V20, P368, DOI 10.2133/dmpk.20.368
   Meltzer HY, 2011, CURR OPIN PHARMACOL, V11, P59, DOI 10.1016/j.coph.2011.02.007
   Morrison SF, 2014, CELL METAB, V19, P741, DOI 10.1016/j.cmet.2014.02.007
   Nasrallah HA, 2008, MOL PSYCHIATR, V13, P27, DOI 10.1038/sj.mp.4002066
   Nedergaard J, 2010, ANN NY ACAD SCI, V1212, pE20, DOI 10.1111/j.1749-6632.2010.05905.x
   Oh JE, 2012, EXP MOL MED, V44, P545, DOI 10.3858/emm.2012.44.9.062
   Olds RJ, 1979, COLOUR ATLAS RAT DIS
   Osuntokun O, 2011, J PSYCHOPHARMACOL, V25, P630, DOI 10.1177/0269881110368872
   Pai N, 2012, ASIAN J PSYCHIATR, V5, P315, DOI 10.1016/j.ajp.2012.05.005
   Patel JK, 2009, SCHIZOPHR RES, V111, P9, DOI 10.1016/j.schres.2009.03.025
   Paxinos G., 2007, RAT BRAIN STEROTAXIC
   Perez-Iglesias R, 2008, J CLIN PSYCHOPHARM, V28, P289, DOI 10.1097/JCP.0b013e318172b8e6
   Poyurovsky M, 2005, INT CLIN PSYCHOPHARM, V20, P101, DOI 10.1097/00004850-200503000-00007
   Poyurovsky M, 2007, PSYCHOPHARMACOLOGY, V192, P441, DOI 10.1007/s00213-007-0731-1
   Poyurovsky M, 2013, PSYCHOPHARMACOLOGY, V226, P615, DOI 10.1007/s00213-012-2935-2
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Remington G, 2011, PHARMACOL BIOCHEM BE, V100, P86, DOI 10.1016/j.pbb.2011.07.019
   Richelson E, 1996, J CLIN PSYCHIAT, V57, P4
   Sejima E, 2011, CELL MOL NEUROBIOL, V31, P985, DOI 10.1007/s10571-011-9663-8
   Sethi J, 2012, NEUROSCIENCE, V217, P84, DOI 10.1016/j.neuroscience.2012.04.068
   Skrede S, 2014, INT J NEUROPSYCHOPH, V17, P91, DOI 10.1017/S1461145713000862
   Souza RP, 2012, J PSYCHIATR RES, V46, P462, DOI 10.1016/j.jpsychires.2012.01.010
   Stahl SM, 2009, ACTA PSYCHIAT SCAND, V119, P171, DOI 10.1111/j.1600-0447.2008.01334.x
   Stefanidis A, 2009, OBESITY, V17, P16, DOI 10.1038/oby.2008.468
   Tauscher J, 2002, MOL PSYCHIATR, V7, P317, DOI 10.1038/sj/mp/4001009
   TECOTT LH, 1995, NATURE, V374, P542, DOI 10.1038/374542a0
   Uldry M, 2006, CELL METAB, V3, P333, DOI 10.1016/j.cmet.2006.04.002
   Vehof J, 2011, PSYCHOPHARMACOLOGY, V216, P257, DOI 10.1007/s00213-011-2211-x
   Wan ZX, 2014, OBESITY, V22, P730, DOI 10.1002/oby.20605
   Weston-Green K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033548
   Weston-Green K, 2012, EUR NEUROPSYCHOPHARM, V22, P364, DOI 10.1016/j.euroneuro.2011.09.003
   Weston-Green K, 2011, BEHAV BRAIN RES, V217, P337, DOI 10.1016/j.bbr.2010.10.039
   Zhang Q, 2014, INT J NEUROPSYCHOPHA, V17
   Zhang QS, 2014, PROG NEURO-PSYCHOPH, V51, P172, DOI 10.1016/j.pnpbp.2014.02.003
   Zipursky RB, 2005, BRIT J PSYCHIAT, V187, P537, DOI 10.1192/bjp.187.6.537
   Zuddas A, 2011, EUR NEUROPSYCHOPHARM, V21, P600, DOI 10.1016/j.euroneuro.2011.04.001
NR 77
TC 29
Z9 31
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 1
PY 2014
VL 9
IS 8
AR e104160
DI 10.1371/journal.pone.0104160
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AM4JL
UT WOS:000339819800127
PM 25084453
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Zanardelli, M
   Micheli, L
   Cinci, L
   Failli, P
   Ghelardini, C
   Mannelli, LD
AF Zanardelli, Matteo
   Micheli, Laura
   Cinci, Lorenzo
   Failli, Paola
   Ghelardini, Carla
   Mannelli, Lorenzo Di Cesare
TI Oxaliplatin Neurotoxicity Involves Peroxisome Alterations. PPAR gamma
   Agonism as Preventive Pharmacological Approach
SO PLOS ONE
LA English
DT Article
ID ACTIVATED-RECEPTOR-GAMMA; INDUCED OXIDATIVE STRESS; EXPERIMENTAL
   AUTOIMMUNE ENCEPHALOMYELITIS; ALZHEIMERS-DISEASE; COLORECTAL-CANCER;
   NERVOUS-SYSTEM; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); DOPAMINERGIC
   NEURODEGENERATION; PERIPHERAL NEUROPATHY; 1ST-LINE TREATMENT
AB The development of neuropathic syndromes is an important, dose limiting side effect of anticancer agents like platinum derivates, taxanes and vinca alkaloids. The causes of neurotoxicity are still unclear but the impairment of the oxidative equilibrium is strictly related to pain. Two intracellular organelles, mitochondria and peroxisomes cooperate to the maintaining of the redox cellular state. Whereas a relationship between chemotherapy-dependent mitochondrial alteration and neuropathy has been established, the role of peroxisome is poor explored. In order to study the mechanisms of oxaliplatin-induced neurotoxicity, peroxisomal involvement was evaluated in vitro and in vivo. In primary rat astrocyte cell culture, oxaliplatin (10 mu M for 48 h or 1 mu M for 5 days) increased the number of peroxisomes, nevertheless expression and functionality of catalase, the most important antioxidant defense enzyme in mammalian peroxisomes, were significantly reduced. Five day incubation with the selective Peroxisome Proliferator Activated Receptor-gamma (PPAR-gamma) antagonist G3335 (30 mu M) induced a similar peroxisomal impairment suggesting a relationship between PPAR gamma signaling and oxaliplatin neurotoxicity. The PPAR gamma agonist rosiglitazone (10 mu M) reduced the harmful effects induced both by G3335 and oxaliplatin. In vivo, in a rat model of oxaliplatin induced neuropathy, a repeated treatment with rosiglitazone (3 and 10 mg kg(-1) per os) significantly reduced neuropathic pain evoked by noxious (Paw pressure test) and non-noxious (Cold plate test) stimuli. The behavioral effect paralleled with the prevention of catalase impairment induced by oxaliplatin in dorsal root ganglia. In the spinal cord, catalase protection was showed by the lower rosiglitazone dosage without effect on the astrocyte density increase induced by oxaliplatin. Rosiglitazone did not alter the oxaliplatin-induced mortality of the human colon cancer cell line HT-29. These results highlight the role of peroxisomes in oxaliplatin-dependent nervous damage and suggest PPAR gamma stimulation as a candidate to counteract oxaliplatin neurotoxicity.
C1 [Zanardelli, Matteo; Micheli, Laura; Cinci, Lorenzo; Failli, Paola; Ghelardini, Carla; Mannelli, Lorenzo Di Cesare] Univ Florence, Dept Neurosci Psychol Drug Res & Child Hlth, Neurofarba Pharmacol & Toxicol Sect, Florence, Italy.
RP Mannelli, LD (reprint author), Univ Florence, Dept Neurosci Psychol Drug Res & Child Hlth, Neurofarba Pharmacol & Toxicol Sect, Florence, Italy.
EM lorenzo.mannelli@unifi.it
RI Di Cesare Mannelli, Lorenzo/A-1641-2015
OI Di Cesare Mannelli, Lorenzo/0000-0001-8374-4432; Failli,
   Paola/0000-0003-3879-9068; GHELARDINI, CARLA/0000-0001-9856-8144
FU Italian Ministry of Instruction, University and Research (MIUR);
   University of Florence
FX This research was funded by the Italian Ministry of Instruction,
   University and Research (MIUR) and by the University of Florence. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Alberts B., 2002, MOL BIOL CELL
   Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709
   Benedusi V, 2012, J BIOL CHEM, V287, P35899, DOI 10.1074/jbc.M112.366419
   Bernardo A, 2008, PPAR RES, DOI 10.1155/2008/864140
   Blanquicett Carmelo, 2008, Cancer Ther, V6, P25
   Boivin A, 2007, J NEUROSCI, V27, P12565, DOI 10.1523/JNEUROSCI.3027-07.2007
   Bottelbergs A, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-61
   Carniglia L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057313
   Cavaletti G, 2001, EUR J CANCER, V37, P2457, DOI 10.1016/S0959-8049(01)00300-8
   Cavaletti G, 2010, NAT REV NEUROL, V6, P657, DOI 10.1038/nrneurol.2010.160
   Chen YM, 2001, GLIA, V33, P343, DOI 10.1002/1098-1136(20010315)33:4<343::AID-GLIA1033>3.0.CO;2-H
   Choi JH, 2007, EUR J PHARMACOL, V571, P106, DOI 10.1016/j.ejphar.2007.06.042
   Cimini A, 2009, J ALZHEIMERS DIS, V18, P935, DOI 10.3233/JAD-2009-1199
   Crosby MB, 2006, CLIN IMMUNOL, V118, P276, DOI 10.1016/j.clim.2005.09.018
   D'Amico A, 2013, HAND CLINIC, V113, P1437, DOI 10.1016/B978-0-444-59565-2.00013-7
   de Gramont A, 2000, J CLIN ONCOL, V18, P2938, DOI 10.1200/JCO.2000.18.16.2938
   DEDUVE C, 1966, PHYSIOL REV, V46, P323
   Diab A, 2002, J IMMUNOL, V168, P2508, DOI 10.4049/jimmunol.168.5.2508
   ELLIOTT BM, 1986, CARCINOGENESIS, V7, P795, DOI 10.1093/carcin/7.5.795
   Feinstein DL, 2002, ANN NEUROL, V51, P694, DOI 10.1002/ana.60612
   Festuccia WT, 2008, ENDOCRINOLOGY, V149, P2121, DOI 10.1210/en.2007-1553
   Fransen M, 2012, BBA-MOL BASIS DIS, V1822, P1363, DOI 10.1016/j.bbadis.2011.12.001
   FREIREICH EMIL J., 1966, CANCER CHEMOTHERAP REP, V50, P219
   Gao YJ, 2010, NEUROTHERAPEUTICS, V7, P482, DOI 10.1016/j.nurt.2010.05.016
   Girnun GD, 2002, MOL ENDOCRINOL, V16, P2793, DOI 10.1210/me.2002-0020
   Goulle JP, 2005, FORENSIC SCI INT, V153, P39, DOI 10.1016/j.forsciint.2005.04.020
   Graham MA, 2000, CLIN CANCER RES, V6, P1205
   Gray E, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-63
   Grisold W, 2012, NEURO-ONCOLOGY, V14, P45, DOI 10.1093/neuonc/nos203
   Han CH, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-495
   Heneka MT, 2007, NAT CLIN PRACT NEURO, V3, P496, DOI 10.1038/ncpneuro0586
   Hunter RL, 2007, J NEUROCHEM, V100, P1375, DOI 10.1111/j.1471-4159.2006.04327.x
   ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0
   Joshi H, 2014, EXPERT OPIN INV DRUG, V23, P501, DOI 10.1517/13543784.2014.884708
   Kamboj SS, 2010, J NEUROCHEM, V112, P77, DOI 10.1111/j.1471-4159.2009.06435.x
   Kannarkat G, 2007, CURR OPIN NEUROL, V20, P719
   Khan MM, 2010, BRAIN RES, V1328, P139, DOI 10.1016/j.brainres.2010.02.031
   Kou JQ, 2011, ACTA NEUROPATHOL, V122, P271, DOI 10.1007/s00401-011-0836-9
   Landreth G, 2008, NEUROTHERAPEUTICS, V5, P481, DOI 10.1016/j.nurt.2008.05.003
   Lee EY, 2012, TOXICOL LETT, V213, P332, DOI 10.1016/j.toxlet.2012.07.016
   Lee YM, 2010, ARCH PHARM RES, V33, P231, DOI 10.1007/s12272-010-0207-4
   LEIGHTON GE, 1988, BRIT J PHARMACOL, V93, P553, DOI 10.1111/j.1476-5381.1988.tb10310.x
   Lourenco MV, 2013, J NEUROSCI, V33, P5083, DOI 10.1523/JNEUROSCI.0172-13.2013
   Lu M, 2011, NAT MED, V17, P618, DOI 10.1038/nm.2332
   Mannelli LD, 2013, FREE RADICAL BIO MED, V61, P143, DOI 10.1016/j.freeradbiomed.2013.03.019
   Mannelli LD, 2014, NEUROPHARMACOLOGY, V79, P37, DOI 10.1016/j.neuropharm.2013.10.034
   Mannelli LD, 2012, J PAIN, V13, P276, DOI 10.1016/j.jpain.2011.11.009
   Masoud A, 2012, HUM EXP TOXICOL, V31, P1214, DOI 10.1177/0960327112446842
   MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890
   Milligan ED, 2009, NAT REV NEUROSCI, V10, P23, DOI 10.1038/nrn2533
   Morrison JG, 2000, J PHARMACEUT BIOMED, V24, P1, DOI 10.1016/S0731-7085(00)00377-0
   Napolitano M, 2011, BRAIN RES BULL, V85, P231, DOI 10.1016/j.brainresbull.2011.03.011
   Perdomo MC, 2011, DOMEST ANIM ENDOCRIN, V41, P118, DOI 10.1016/j.domaniend.2011.05.005
   Powers JM, 1998, BRAIN PATHOL, V8, P101
   Powers SK, 2008, PHYSIOL REV, V88, P1243, DOI 10.1152/physrev.00031.2007
   Powers SK, 1999, P NUTR SOC, V58, P1025, DOI 10.1017/S0029665199001342
   Putnam CD, 2000, J MOL BIOL, V296, P295, DOI 10.1006/jmbi.1999.3458
   Raikwar HP, 2006, J NEUROIMMUNOL, V178, P76, DOI 10.1016/j.jneuroim.2006.05.013
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Ribeiro D, 2012, HISTOL HISTOPATHOL, V27, P661, DOI 10.14670/HH-27.661
   Salvemini D, 2010, LIFE SCI, V86, P604, DOI 10.1016/j.lfs.2009.06.011
   Sarruf DA, 2009, ENDOCRINOLOGY, V150, P707, DOI 10.1210/en.2008-0899
   Scholz J, 2007, NAT NEUROSCI, V10, P1361, DOI 10.1038/nn1992
   Schrader M, 2006, BBA-MOL CELL RES, V1763, P1755, DOI 10.1016/j.bbamcr.2006.09.006
   Sheu WHH, 2011, J PHARMACEUT BIOMED, V54, P759, DOI 10.1016/j.jpba.2010.10.008
   Souglakos J, 2002, J CLIN ONCOL, V20, P2651, DOI 10.1200/JCO.2002.08.015
   Stolz DB, 2002, HEPATOLOGY, V36, P81, DOI 10.1053/jhep.2002.33716
   Strum JC, 2007, J ALZHEIMERS DIS, V11, P45
   Sun H, 2012, NEUROL SCI, V33, P559, DOI 10.1007/s10072-011-0774-2
   Swanson CR, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-91
   Trompier D, 2014, BIOCHIMIE, V98, P102, DOI 10.1016/j.biochi.2013.09.009
   Venkateshappa C, 2012, NEUROCHEM RES, V37, P1601, DOI 10.1007/s11064-012-0755-8
   Wang B, 2013, FREE RADICAL BIO MED, V65, P882, DOI 10.1016/j.freeradbiomed.2013.08.173
   Wolf S, 2008, EUR J CANCER, V44, P1507, DOI 10.1016/j.ejca.2008.04.018
   Ye F, 2006, CHEMBIOCHEM, V7, P74, DOI 10.1002/cbic.200500186
   Zanardelli M, 2013, P 36 C IT SOC PHARM
   Zheng HE, 2011, EXP NEUROL, V232, P154, DOI 10.1016/j.expneurol.2011.08.016
   ZWACKA RM, 1994, EMBO J, V13, P5129, DOI 10.1002/j.1460-2075.1994.tb06842.x
NR 78
TC 33
Z9 35
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 18
PY 2014
VL 9
IS 7
AR e102758
DI 10.1371/journal.pone.0102758
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AM1OC
UT WOS:000339615200084
PM 25036594
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Raveendran, VV
   Smith, DD
   Tan, XY
   Sweeney, ME
   Reed, GA
   Flynn, CA
   Tawfik, OW
   Milne, G
   Dileepan, KN
AF Raveendran, Vineesh V.
   Smith, Donald D.
   Tan, Xiaoyu
   Sweeney, Matthew E.
   Reed, Gregory A.
   Flynn, Colleen A.
   Tawfik, Ossama W.
   Milne, Ginger
   Dileepan, Kottarappat N.
TI Chronic Ingestion of H1-Antihistamines Increase Progression of
   Atherosclerosis in Apolipoprotein E-/- Mice
SO PLOS ONE
LA English
DT Article
ID ARTERY ENDOTHELIAL-CELLS; APOE-DEFICIENT MICE; E-NULL MICE; LESION
   FORMATION; THROMBOXANE A(2); MAST-CELLS; HISTAMINE; EXPRESSION;
   ATHEROGENESIS; PERMEABILITY
AB Although increased serum histamine levels and H1R expression in the plaque are seen in atherosclerosis, it is not known whether H1R activation is a causative factor in the development of the disease, or is a host defense response to atherogenic signals. In order to elucidate how pharmacological inhibition of histamine receptor 1 (H1R) signaling affects atherogenesis, we administered either cetirizine (1 and 4 mg/kg. b.w) or fexofenadine (10 and 40 mg/kg. b.w) to ApoE(-/-) mice maintained on a high fat diet for three months. Mice ingesting a low dose of cetirizine or fexofenadine had significantly higher plaque coverage in the aorta and cross-sectional lesion area at the aortic root. Surprisingly, the higher doses of cetirizine or fexofenadine did not enhance atherosclerotic lesion coverage over the controls. The low dose of fexofenadine, but not cetirizine, increased serum LDL cholesterol. Interestingly, the expression of iNOS and eNOS mRNA was increased in aortas of mice on high doses of cetirizine or fexofenadine. This may be a compensatory nitric oxide (NO)-mediated vasodilatory mechanism that accounts for the lack of increase in the progression of atherosclerosis. Although the administration of cetirizine did not alter blood pressure between the groups, there was a positive correlation between blood pressure and lesion/media ratio at the aortic root in mice receiving the low dose of cetirizine. However, this association was not observed in mice treated with the high dose of cetirizine or either doses of fexofenadine. The macrophages or T lymphocytes densities were not altered by low doses of H1-antihistamines, whereas, high doses decreased the number of macrophages but not T lymphocytes. The number of mast cells was decreased only in mice treated with low dose of fexofenadine. These results demonstrate that chronic ingestion of low therapeutic doses of cetirizine or fexofenadine enhance progression of atherosclerosis.
C1 [Raveendran, Vineesh V.; Smith, Donald D.; Tan, Xiaoyu; Sweeney, Matthew E.; Dileepan, Kottarappat N.] Univ Kansas, Med Ctr, Dept Med, Div Allergy Clin Immunol & Rheumatol, Kansas City, KS 66103 USA.
   [Reed, Gregory A.; Flynn, Colleen A.] Univ Kansas, Med Ctr, Dept Pharmacol Toxicol & Therapeut, Kansas City, KS 66103 USA.
   [Tawfik, Ossama W.] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66103 USA.
   [Milne, Ginger] Vanderbilt Univ, Med Ctr, Nashville, TN USA.
RP Dileepan, KN (reprint author), Univ Kansas, Med Ctr, Dept Med, Div Allergy Clin Immunol & Rheumatol, Kansas City, KS 66103 USA.
EM kdileepan@kumc.edu
RI Milne, Ginger/D-7648-2014
OI Milne, Ginger/0000-0003-3890-151X
FU National Institutes of Health [R01-HL070101, 3R01-HL070101-04S1]; Joseph
   and Elizabeth Carey Arthritis Fund; Audrey E. Smith Medical Research
   Fund from KU Endowment Association; Department of Internal Medicine
   Research Office; Research Institute at the University of Kansas Medical
   Center
FX This study was supported by National Institutes of Health grants
   R01-HL070101 and 3R01-HL070101-04S1, the Joseph and Elizabeth Carey
   Arthritis Fund and the Audrey E. Smith Medical Research Fund from KU
   Endowment Association and Department of Internal Medicine Research
   Office, and Lied Grant from the Research Institute at the University of
   Kansas Medical Center. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR ATKINSON JB, 1994, HUM PATHOL, V25, P154, DOI 10.1016/0046-8177(94)90271-2
   Benarroch EE, 2010, NEUROLOGY, V75, P1472, DOI 10.1212/WNL.0b013e3181f884b1
   Bourassa PAK, 1996, P NATL ACAD SCI USA, V93, P10022, DOI 10.1073/pnas.93.19.10022
   CHALDAKOV GN, 1995, HUM PATHOL, V26, P1286, DOI 10.1016/0046-8177(95)90209-0
   Church DS, 2011, WORLD ALLERGY ORGAN, V4, pS22, DOI 10.1097/WOX.0b013e3181f385d9
   Daugherty A, 2002, CIRC RES, V90, P1039, DOI 10.1161/01.RES.0000021397.28936.F9
   Deml KF, 2009, MOL PHARMACOL, V76, P1019, DOI 10.1124/mol.109.058651
   Flynn CA, 2011, RAPID COMMU IN PRESS
   GILL DS, 1989, METABOLISM, V38, P243, DOI 10.1016/0026-0495(89)90082-6
   HARMAN D, 1969, J ATHEROSCLER RES, V10, P77, DOI 10.1016/S0368-1319(69)80084-0
   Jin H, 2006, EUR J PHARMACOL, V529, P136, DOI 10.1016/j.ejphar.2005.10.060
   Jutel A, 2006, CHEM IMMUNOL ALLERGY, V91, P174
   Kobayashi T, 2004, J CLIN INVEST, V114, P784, DOI 10.1172/JCI200421446
   Leurs R, 2002, CLIN EXP ALLERGY, V32, P489, DOI 10.1046/j.0954-7894.2002.01314.x
   Li Y, 2001, MICROVASC RES, V61, P253, DOI 10.1006/mvre.2001.2304
   Ludewig B, 2004, P NATL ACAD SCI USA, V101, P11529, DOI 10.1073/pnas.0404612101
   OWENS GK, 1979, ATHEROSCLEROSIS, V34, P365, DOI 10.1016/0021-9150(79)90061-3
   Ozaki M, 2002, J CLIN INVEST, V110, P331, DOI 10.1172/JCI200215215
   Parsons ME, 2006, BRIT J PHARMACOL, V147, pS127, DOI 10.1038/sj.bjp.0706440
   Raveendran VV, 2011, IMMUNOLOGY, V132, P578, DOI 10.1111/j.1365-2567.2010.03403.x
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Rozenberg I, 2010, ARTERIOSCL THROM VAS, V30, P923, DOI 10.1161/ATVBAHA.109.201079
   Sakata Y, 1996, AM J CARDIOL, V77, P1121, DOI 10.1016/S0002-9149(96)00147-6
   Smith DD, 2010, J PHYSIOL PHARMACOL, V61, P309
   Smith DD, 2012, AM J PHYSIOL-HEART C, V302, pH2612, DOI 10.1152/ajpheart.00879.2011
   TAKAGISHI T, 1995, AM J PATHOL, V146, P981
   Talreja J, 2004, IMMUNOLOGY, V113, P224, DOI 10.1111/j.1365-2567.2004.01946.x
   Tan X, 2007, J IMMUNOL, V179, P7899, DOI 10.4049/jimmunol.179.11.7899
   Tanimoto A, 2006, TRENDS CARDIOVAS MED, V16, P280, DOI 10.1016/j.tcm.2006.06.001
   Villablanca A, 2004, ARTERIOSCL THROM VAS, V24, P1055, DOI 10.1161/01.ATV.0000130467.65290.d4
   Vimala Raveendran V, 2014, AM J PHYSIOL-GASTR L
   Wang KY, 2011, ARTERIOSCL THROM VAS, V31, P800, DOI 10.1161/ATVBAHA.110.215228
   Woollard KJ, 2010, NAT REV CARDIOL, V7, P77, DOI 10.1038/nrcardio.2009.228
   Yarnal J R, 1975, J Am Osteopath Assoc, V74, P561
   Zhou XH, 1998, J CLIN INVEST, V101, P1717, DOI 10.1172/JCI1216
NR 35
TC 5
Z9 5
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 14
PY 2014
VL 9
IS 7
AR e102165
DI 10.1371/journal.pone.0102165
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AM1PC
UT WOS:000339618600050
PM 25020133
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Liu, SZ
   Jiang, LG
   Meng, XQ
   Han, XY
   Cheng, D
   Zhang, TL
   Miao, YL
AF Liu, ShuZhen
   Jiang, LiGang
   Meng, XiaoQian
   Han, XiaoYing
   Cheng, Dong
   Zhang, TianLiang
   Miao, YiLiang
TI Effects of Aroclor 1254 on In Vivo Oocyte Maturation in the Mouse
SO PLOS ONE
LA English
DT Article
ID HUMAN FOLLICULAR-FLUID; POLYCHLORINATED BIPHENYL MIXTURES; PERSISTENT
   ORGANIC POLLUTANTS; VITRO MATURATION; GENE-EXPRESSION; ENVIRONMENTAL
   CONTAMINANTS; ORGANOCHLORINE COMPOUNDS; REPRODUCTIVE TOXICITY; PORCINE
   OOCYTES; CUMULUS CELLS
AB Polychlorinated biphenyls (PCBs) are stable, lipophilic compounds that accumulate in the environment and in the food chain. Though some studies provided evidence that PCBs had adverse effects on reproductive function, most of these results were from in vitro models. Therefore we investigated the effect of Aroclor 1254 (a commercial PCBs mixture) treatments on in vivo maturation and developmental potential of mouse oocytes. In the present study, female ICR mice were treated with different doses (12.5, 25 and 50 mg/kg) of Aroclor 1254 (a commercial PCB mixture) once every 72 hours by intraperitoneal injection for 9 days. After three treatments of Aroclor 1254, the mice were superovulated to collect oocytes one day after the last exposure. The effects of Aroclor 1254 on oocyte maturation, fertilization, and preimplantation embryonic development were investigated. Immunofluorescence-stained oocytes were observed under a confocal microscope to assess the effects of Aroclor 1254 on spindle morphology. Parthenogenic activation and the incidence of cumulus apoptosis in cumulus-oocyte complexes were observed as well. Oocytes exposed to different doses of Aroclor 1254 in vivo were associated with a significant decrease in outgrowth potential, abnormal spindle configurations, and the inhibition of parthenogenetic activation of ovulated oocytes. Furthermore, the incidence of apoptosis in cumulus cells was increased after exposed to Aroclor 1254. These results may provide reference for the treatment of reproductive diseases such as infertility or miscarriage caused by environmental contaminants.
C1 [Liu, ShuZhen; Meng, XiaoQian; Han, XiaoYing] Shandong Normal Univ, Coll Life Sci, Key Lab Anim Resistance Res, Jinan, Peoples R China.
   [Jiang, LiGang] Shandong Univ, Ctr Reprod Med, Qilu Hosp, Jinan 250100, Peoples R China.
   [Cheng, Dong; Zhang, TianLiang] Shandong Ctr Dis Control & Prevent, Dept Toxicol, Jinan, Peoples R China.
   [Miao, YiLiang] Huazhong Agr Univ, Coll Anim Sci & Technol, Minist Educ, Key Lab Anim Genet Breeding & Reprod, Wuhan, Peoples R China.
RP Liu, SZ (reprint author), Shandong Normal Univ, Coll Life Sci, Key Lab Anim Resistance Res, Jinan, Peoples R China.
EM shuzhen26@163.com
FU National Nature Science Foundation of China [31101068]; Shandong
   Province Postdoctoral Innovation Project [201103102]
FX This study was supported by the National Nature Science Foundation of
   China (number 31101068) and Shandong Province Postdoctoral Innovation
   Project (number 201103102). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Albertini David F, 2003, Reprod Biomed Online, V6, P410
   Arena SM, 2003, ARCH ENVIRON CON TOX, V44, P272, DOI 10.1007/s00244-002-2022-5
   Bake MA, 2007, INT J HYG ENVIR HEAL, V210, P483, DOI 10.1016/j.ijheh.2007.01.016
   BERGMAN A, 1994, ENVIRON HEALTH PERSP, V102, P464, DOI 10.2307/3432042
   Brevini T, 2009, EUR J HISTOCHEM, V48, P347
   Cai JL, 2011, TOXICOLOGY, V287, P21, DOI 10.1016/j.tox.2011.05.010
   Campagna C, 2006, MOL REPROD DEV, V73, P83, DOI 10.1002/mrd.20365
   Czaja K, 1999, ARCH ENVIRON CON TOX, V36, P498, DOI 10.1007/PL00006623
   De Felip E, 2004, CHEMOSPHERE, V54, P1445, DOI 10.1016/j.chemosphere.2003.10.040
   DUARTEDAVIDSON R, 1994, ENVIRON POLLUT, V84, P69, DOI 10.1016/0269-7491(94)90072-8
   Foster W, 2000, J CLIN ENDOCR METAB, V85, P2954, DOI 10.1210/jc.85.8.2954
   Frame GM, 1996, CHEMOSPHERE, V33, P603, DOI 10.1016/0045-6535(96)00214-7
   Fromberg A, 1999, CHEMOSPHERE, V38, P3075, DOI 10.1016/S0045-6535(98)00514-1
   Guillette LJ, 1999, ARCH ENVIRON CON TOX, V36, P447, DOI 10.1007/PL00006617
   Kato Y, 2009, DRUG METAB DISPOS, V38, P697
   Katz-Jaffe MG, 2009, THERIOGENOLOGY, V71, P939, DOI 10.1016/j.theriogenology.2008.10.024
   KHOLKUTE SD, 1994, REPROD TOXICOL, V8, P487, DOI 10.1016/0890-6238(94)90031-0
   Kietz S, 2003, MOL REPROD DEV, V64, P251, DOI 10.1002/mrd.10226
   KIMBROUGH RD, 1995, CRIT REV TOXICOL, V25, P133, DOI 10.3109/10408449509021611
   Kostyniak P, 1999, ENVIRON RES, V80, P166
   Kruger N, 2008, CURR BIOL, V18, P646
   Ma SF, 2005, THERIOGENOLOGY, V64, P1142, DOI 10.1016/j.theriogenology.2005.03.002
   Meeker JD, 2011, ENVIRON HEALTH PERSP, V119, P1010, DOI 10.1289/ehp.1002922
   Meo SC, 2005, THERIOGENOLOGY, V63, P2089, DOI 10.1016/j.theriogenology.2004.08.012
   Miao YL, 2007, THERIOGENOLOGY, V68, P640, DOI 10.1016/j.theriogenology.2007.04.061
   Miao YL, 2009, ENVIRON MOL MUTAGEN, V50, P666, DOI 10.1002/em.20506
   Mori T, 2000, BIOL REPROD, V62, P913, DOI 10.1095/biolreprod62.4.913
   Norstrom K, 2010, ENVIRON INT, V36, P855, DOI 10.1016/j.envint.2009.03.005
   Olivero J, 2001, BIOCHEM PHARMACOL, V62, P1125, DOI 10.1016/S0006-2952(01)00768-7
   Pahlavan G, 2000, DEV BIOL, V220, P392, DOI 10.1006/dbio.2000.9656
   Pauwels A, 2000, ENVIRON HEALTH PERSP, V108, P553, DOI 10.1289/ehp.00108553
   Pocar P, 2005, REPRODUCTION, V130, P857, DOI 10.1530/rep.1.00761
   Pocar P, 2001, MOL REPROD DEV, V58, P411, DOI 10.1002/1098-2795(20010401)58:4<411::AID-MRD8>3.0.CO;2-R
   Pocar P, 2006, REPROD TOXICOL, V22, P242, DOI 10.1016/j.reprotox.2006.04.023
   Ptak G, 2012, HUM REPROD, V27, P1034, DOI 10.1093/humrep/der454
   Ramos L, 1999, CHEMOSPHERE, V38, P3141, DOI 10.1016/S0045-6535(98)00521-9
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   SAFE SH, 1994, CRIT REV TOXICOL, V24, P87, DOI 10.3109/10408449409049308
   Segre M, 2002, TOXICOLOGY, V174, P163, DOI 10.1016/S0300-483X(02)00039-2
   SIMMONS GJ, 1992, FUND APPL TOXICOL, V19, P446, DOI 10.1016/0272-0590(92)90184-J
   Stack AS, 1999, TOXICOLOGY, V139, P137
   Sun QY, 2009, CELL CYCLE, V8, P2741, DOI 10.4161/cc.8.17.9471
   TRAPP M, 1984, FERTIL STERIL, V42, P146
   Van Emon JM, 2013, SCI TOTAL ENVIRON, V463, P326, DOI 10.1016/j.scitotenv.2013.05.020
   van Woudenberg AB, 2012, REPROD TOXICOL, V34, P251, DOI 10.1016/j.reprotox.2012.05.098
   Wang Wei-Hua, 2002, Cloning and Stem Cells, V4, P269, DOI 10.1089/15362300260339557
   Xia L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023996
   Younglai EV, 2002, ARCH ENVIRON CON TOX, V43, P121, DOI 10.1007/s00244-001-0048-8
   Zhang XQ, 2005, FERTIL STERIL, V83, P1169, DOI 10.1016/j.fertnstert.2004.11.030
NR 49
TC 6
Z9 6
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 11
PY 2014
VL 9
IS 7
AR e102064
DI 10.1371/journal.pone.0102064
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AL8HH
UT WOS:000339378400060
PM 25013911
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Zaafar, DK
   Zaitone, SA
   Moustafa, YM
AF Zaafar, Dalia K.
   Zaitone, Sawsan A.
   Moustafa, Yasser M.
TI Role of Metformin in Suppressing 1,2-Dimethylhydrazine-Induced Colon
   Cancer in Diabetic and Non-Diabetic Mice: Effect on Tumor Angiogenesis
   and Cell Proliferation
SO PLOS ONE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; IN-VITRO; 1ST-LINE TREATMENT;
   COLORECTAL-CANCER; RAT-LIVER; MELLITUS; INSULIN; RISK; OXALIPLATIN;
   CARCINOMA
AB Several studies indicated that type 2 diabetes mellitus and insulin resistance are associated with increased colon cancer risk. Recently, studies suggest that metformin can reduce cancer risk in diabetic or non-diabetic patients with unclear mechanisms. This work aimed to determine the effect of metformin on chemically-induced colon cancer in mice. Colon cancer was induced using 1,2-dimethylhydrazine (DMH, 20 mg/kg/week, s.c.) for fifteen weeks. Experiment I: healthy mice were fed with basal diet for four weeks and then allocated into seven groups, (i) saline, (ii) DMH, (iii) oxaliplatin, (iv-v): metformin (100 or 200 mg/kg) and (vi-vii): oxaliplatin+metformin (100 or 200 mg/kg), respectively. Experiment II: type 2 diabetes mellitus was induced by injection of STZ (30 mg/kg) after four weeks of high-fat feeding and then mice were allocated into seven groups similar to those reported in experiment I. Examination of the colonic tissue at the end of the experiment highlighted an increase in angiogenic markers and cell proliferation and showed a greater immunostaining for insulin growth factor I receptors and CD34 in the colon of diabetic mice compared to non-diabetics. In general, metformin downregulated tumor angiogenesis and augmented the antitumor effect of oxaliplatin. Overall, the current results showed that metformin protected against DMH-induced colon cancer in non-diabetic and diabetic mice. This therapeutic effect was, at least in part, attributed to its anti-angiogenic and anti-proliferative mechanisms.
C1 [Zaafar, Dalia K.] Directorate Hlth & Populat, Ismailia, Egypt.
   [Zaitone, Sawsan A.; Moustafa, Yasser M.] Suez Canal Univ, Fac Pharm, Dept Pharmacol & Toxicol, Ismailia, Egypt.
RP Zaitone, SA (reprint author), Directorate Hlth & Populat, Ismailia, Egypt.
EM Sawsan_zaytoon@pharm.suez.edu.eg
RI Zaitone, Sawsan A/G-8930-2017; Zaafar, Dalia/T-2301-2019
OI Zaitone, Sawsan A/0000-0002-9688-7683; Zaafar, Dalia/0000-0002-7201-3658
CR Anisimov VN, 2005, EXP GERONTOL, V40, P685, DOI 10.1016/j.exger.2005.07.007
   Arcaro A, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00030
   Awata T, 2002, DIABETES, V51, P1635, DOI 10.2337/diabetes.51.5.1635
   Banchroft J., 1996, THEORY PRACTICE HIST
   Barone BB, 2008, JAMA-J AM MED ASSOC, V300, P2754, DOI 10.1001/jama.2008.824
   Bhattacharyya S, 2012, J AM HEART ASSOC, V1, DOI 10.1161/JAHA.112.005967
   Bowker SL, 2006, DIABETES CARE, V29, P254, DOI 10.2337/diacare.29.02.06.dc05-1558
   Boyd D Barry, 2003, Integr Cancer Ther, V2, P315, DOI 10.1177/1534735403259152
   Castleden, 1979, J CANC, V39, P731
   Chiarelli F, 2000, DIABETIC MED, V17, P650, DOI 10.1046/j.1464-5491.2000.00350.x
   Colussi C, 2001, J NATL CANCER I, V93, P1534, DOI 10.1093/jnci/93.20.1534
   Coughlin SS, 2004, AM J EPIDEMIOL, V159, P1160, DOI 10.1093/aje/kwh161
   de Gramont A, 2000, J CLIN ONCOL, V18, P2938, DOI 10.1200/JCO.2000.18.16.2938
   El-Serag HB, 2006, CLIN GASTROENTEROL H, V4, P369, DOI 10.1016/j.cgh.2005.12.007
   Engel S, 2003, NEW ENGL J MED, V348, P2294
   Evans JMM, 2005, BMJ-BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7
   EVERHART J, 1995, JAMA-J AM MED ASSOC, V273, P1605, DOI 10.1001/jama.273.20.1605
   Ferguson RD, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3089
   FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18
   FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27
   Friberg E, 2007, DIABETOLOGIA, V50, P1365, DOI 10.1007/s00125-007-0681-5
   Gerstein HC, 2010, JAMA-J AM MED ASSOC, V303, P446, DOI 10.1001/jama.2010.60
   Giacchetti S, 2000, J CLIN ONCOL, V18, P136, DOI 10.1200/JCO.2000.18.1.136
   Haisa M, 2013, J INT MED RES, V41, P253, DOI 10.1177/0300060513476585
   Hanahan D, 1998, NAT MED, V4, P13, DOI 10.1038/nm0198-013
   HAYES MA, 1987, CARCINOGENESIS, V8, P1155, DOI 10.1093/carcin/8.8.1155
   Hirsch HA, 2009, CANCER RES, V69, P7507, DOI 10.1158/0008-5472.CAN-09-2994
   Hoeben A, 2004, PHARMACOL REV, V56, P549, DOI 10.1124/pr.56.4.3
   Hosono K, 2010, MOL CARCINOGEN, V49, P662, DOI 10.1002/mc.20637
   Hvid H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079710
   Ikemura M, 2013, J CONTROL RELEASE, V170, P191, DOI 10.1016/j.jconrel.2013.05.028
   Inoue M, 2006, ARCH INTERN MED, V166, P1871, DOI 10.1001/archinte.166.17.1871
   Ito K, 2013, CANCER SCI, V104, P835, DOI 10.1111/cas.12162
   Jackson PE, 1999, CARCINOGENESIS, V20, P509, DOI 10.1093/carcin/20.3.509
   Janjetovic K, 2011, EUR J PHARMACOL, V668, P373, DOI 10.1016/j.ejphar.2011.07.004
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Jiralerspong S, 2009, J CLIN ONCOL, V27, P3297, DOI 10.1200/JCO.2009.19.6410
   Kisfalvi K, 2009, CANCER RES, V69, P6539, DOI 10.1158/0008-5472.CAN-09-0418
   Larsson SC, 2005, J NATL CANCER I, V97, P1679, DOI 10.1093/jnci/dji375
   LEWIS JG, 1982, CANCER RES, V42, P89
   Libby G, 2009, DIABETES CARE, V32, P1620, DOI 10.2337/dc08-2175
   Liu J, 2013, UROL ONCOL-SEMIN ORI, V31, P264, DOI 10.1016/j.urolonc.2011.01.003
   Martin A, 2003, MED RES REV, V23, P117, DOI 10.1002/med.10024
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   McFarland MS, 2010, PHARMACOTHERAPY, V30, P1159, DOI 10.1592/phco.30.11.1159
   Memmott RM, 2010, CANCER PREV RES, V3, P1066, DOI 10.1158/1940-6207.CAPR-10-0055
   Michels KB, 2003, DIABETES CARE, V26, P1752, DOI 10.2337/diacare.26.6.1752
   Micic D, 2011, HORM-INT J ENDOCRINO, V10, P5, DOI 10.14310/horm.2002.1288
   Nathan DM, 2005, NEW ENGL J MED, V353, P2643
   Oh JS, 2002, NEOPLASIA, V4, P204, DOI 10.1038/sj/neo/7900229
   Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536
   Rattan R, 2011, NEOPLASIA, V13, P483, DOI 10.1593/neo.11148
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Renehan AG, 2004, LANCET, V363, P1346, DOI 10.1016/S0140-6736(04)16044-3
   Rothenberg ML, 2000, ONCOLOGY-NY, V14, P9
   Saito T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070010
   Shank JJ, 2012, GYNECOL ONCOL, V127, P390, DOI 10.1016/j.ygyno.2012.07.115
   Srinivasan K, 2005, PHARMACOL RES, V52, P313, DOI 10.1016/j.phrs.2005.05.004
   Stenina OI, 2005, CURR PHARM DESIGN, V11, P2367, DOI 10.2174/1381612054367283
   Vigneri P, 2009, ENDOCR-RELAT CANCER, V16, P1103, DOI 10.1677/ERC-09-0087
   Will JC, 1998, AM J EPIDEMIOL, V147, P816, DOI 10.1093/oxfordjournals.aje.a009534
   Yabe Y, 2001, J PHARMACOL EXP THER, V298, P894
   Yilmaz A, 1999, J ANIM SCI, V77, P835
   YING TS, 1979, CHEM-BIOL INTERACT, V28, P363, DOI 10.1016/0009-2797(79)90176-5
NR 64
TC 22
Z9 24
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 27
PY 2014
VL 9
IS 6
AR e100562
DI 10.1371/journal.pone.0100562
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AK6BK
UT WOS:000338512200042
PM 24971882
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Frohbergh, M
   Ge, Y
   Meng, FL
   Karabul, N
   Solyom, A
   Lai, A
   Iatridis, J
   Schuchman, EH
   Simonaro, CM
AF Frohbergh, Michael
   Ge, Yi
   Meng, Fanli
   Karabul, Nesrin
   Solyom, Alexander
   Lai, Alon
   Iatridis, James
   Schuchman, Edward H.
   Simonaro, Calogera M.
TI Dose Responsive Effects of Subcutaneous Pentosan Polysulfate Injection
   in Mucopolysaccharidosis Type VI Rats and Comparison to Oral Treatment
SO PLOS ONE
LA English
DT Article
ID ENZYME REPLACEMENT THERAPY; SYNOVIAL-FLUID; OSTEOARTHRITIS; JOINT;
   IDENTIFICATION; PROTEINS; DISEASE; HORSES
AB Background: We previously demonstrated the benefits of daily, oral pentosan polysulfate (PPS) treatment in a rat model of mucopolysaccharidosis (MPS) type VI. Herein we compare these effects to once weekly, subcutaneous (sc) injection. The bioavailability of injected PPS is greater than oral, suggesting better delivery to difficult tissues such as bone and cartilage. Injected PPS also effectively treats osteoarthritis in animals, and has shown success in osteoarthritis patients.
   Methodology/Principal Findings: One-month-old MPS VI rats were given once weekly sc injections of PPS (1, 2 and 4 mg/kg, human equivalent dose (HED)), or daily oral PPS (4 mg/kg HED) for 6 months. Serum inflammatory markers and total glycosaminoglycans (GAGs) were measured, as were several histological, morphological and functional endpoints. Overall, weekly sc PPS injections led to similar or greater therapeutic effects as daily oral administration. Common findings between the two treatment approaches included reduced serum inflammatory markers, improved dentition and skull lengths, reduced tracheal deformities, and improved mobility. Enhanced effects of sc treatment included GAG reduction in urine and tissues, greater endurance on a rotarod, and better improvements in articular cartilage and bone in some dose groups. Optimal therapeutic effects were observed at 2 mg/kg, sc. No drug-related increases in liver enzymes, coagulation factor abnormalities or other adverse effects were identified following 6 months of sc PPS administration.
   Conclusions: Once weekly sc administration of PPS in MPS VI rats led to equal or better therapeutic effects than daily oral administration, including a surprising reduction in urine and tissue GAGs. No adverse effects from sc PPS administration were observed over the 6-month study period.
C1 [Frohbergh, Michael; Ge, Yi; Meng, Fanli; Lai, Alon; Iatridis, James; Schuchman, Edward H.; Simonaro, Calogera M.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
   [Karabul, Nesrin; Solyom, Alexander] Johannes Gutenberg Univ Mainz, Dept Pediat, Mainz, Germany.
   [Solyom, Alexander] Univ Pecs, Dept Pediat, Pecs, Hungary.
RP Simonaro, CM (reprint author), Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
EM calogera.simonaro@mssm.edu
OI Lai, Alon/0000-0002-0163-4588; Iatridis, James/0000-0002-2186-0590
FU National Institutes of Health [1R01DK087185, 5R21DK096182, 1R01AR057397]
FX National Institutes of Health grant numbers 1R01DK087185, 5R21DK096182
   and 1R01AR057397 received by CMS and EHS (www.nih.gov). The MPS 1
   Research Foundation, CMS (helpmps1.org). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Algahim MF, 2013, THER CLIN RISK MANAG, V9, P45, DOI 10.2147/TCRM.S24771
   Anger JT, 2011, INT UROGYNECOL J, V22, P395, DOI 10.1007/s00192-010-1252-8
   Archer LD, 2014, J INHERIT METAB DIS, V37, P1, DOI 10.1007/s10545-013-9613-3
   Beck M, 2010, J PEDIATR REHAB MED, V3, P39, DOI 10.3233/PRM-2010-0100
   Clarke LA, 2009, PEDIATRICS, V123, P229, DOI 10.1542/peds.2007-3847
   Ghosh P, 1999, SEMIN ARTHRITIS RHEU, V28, P211, DOI 10.1016/S0049-0172(99)80021-3
   Giugliani R, 2010, GENET MOL BIOL, V33, P589, DOI 10.1590/S1415-47572010005000093
   Grevers LC, 2011, ARTHRITIS RHEUM-US, V63, P1365, DOI 10.1002/art.30290
   Hanno PM, 2011, J UROLOGY, V185, P2162, DOI 10.1016/j.juro.2011.03.064
   JOFFE S, 1976, ARCH SURG-CHICAGO, V111, P37
   KUNIEDA T, 1995, GENOMICS, V29, P582, DOI 10.1006/geno.1995.9962
   Kwan C, 2012, AUST VET J, V90, P315, DOI 10.1111/j.1751-0813.2012.00959.x
   Lampe C, 2013, RHEUM DIS CLIN N AM, V39, P431, DOI 10.1016/j.rdc.2013.03.004
   Langereis EJ, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-155
   McIlwraith CW, 2012, AM J VET RES, V73, P628, DOI 10.2460/ajvr.73.5.628
   Muenzer J, 2011, RHEUMATOLOGY, V50, pV4, DOI 10.1093/rheumatology/ker394
   Newman PK, 2014, J NEUROL NEUROSUR PS, V85, P919, DOI 10.1136/jnnp-2013-305590
   Noh H, 2014, J CLIN PHARM THER, V39, P215, DOI 10.1111/jcpt.12136
   Ohashi Toya, 2012, Pediatr Endocrinol Rev, V10 Suppl 1, P26
   Polgreen LE, 2014, J CLIN DENSITOM, V17, P200, DOI 10.1016/j.jocd.2013.03.004
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Schelbergen RFP, 2012, ARTHRITIS RHEUM-US, V64, P1477, DOI 10.1002/art.33495
   Schuchman EH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054459
   Sillence D, 2012, JIMD REP, V2, P103, DOI 10.1007/8904_2011_56
   Simonaro CM, 2010, P NATL ACAD SCI USA, V107, P222, DOI 10.1073/pnas.0912937107
   Simonaro CM, 2005, PEDIATR RES, V57, P701, DOI 10.1203/01.PDR.0000156510.96253.5A
   Simonaro CM, 2001, LAB INVEST, V81, P1319, DOI 10.1038/labinvest.3780345
   Valayannopoulos V, 2011, RHEUMATOLOGY, V50, pV49, DOI 10.1093/rheumatology/ker396
   Valcamonica E, 2014, CLIN EXP RHEUMATOL, V32, P243
   van Lent PLEM, 2008, ANN RHEUM DIS, V67, P1750, DOI 10.1136/ard.2007.077800
   VandeBerg JR, 2004, ARCH ORAL BIOL, V49, P477, DOI 10.1016/j.archoralbio.2003.12.007
   Vera M, 2013, PEDIATR RES, V74, P712, DOI 10.1038/pr.2013.158
   Vinazzer H, 1989, Folia Haematol Int Mag Klin Morphol Blutforsch, V116, P927
   White KK, 2011, RHEUMATOLOGY, V50, pV26, DOI 10.1093/rheumatology/ker393
   YAN SD, 1994, J BIOL CHEM, V269, P9889
NR 35
TC 18
Z9 18
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 25
PY 2014
VL 9
IS 6
AR e100882
DI 10.1371/journal.pone.0100882
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AK8WO
UT WOS:000338709500095
PM 24964042
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Martinez-Clemente, J
   Lopez-Arnau, R
   Abad, S
   Pubill, D
   Escubedo, E
   Camarasa, J
AF Martinez-Clemente, Jose
   Lopez-Arnau, Raul
   Abad, Sonia
   Pubill, David
   Escubedo, Elena
   Camarasa, Jorge
TI Dose and Time-Dependent Selective Neurotoxicity Induced by Mephedrone in
   Mice
SO PLOS ONE
LA English
DT Article
ID MDMA-INDUCED NEUROTOXICITY; SELF-INJURIOUS-BEHAVIOR; BATH SALTS;
   3,4-METHYLENEDIOXYPYROVALERONE MDPV; DESIGNER STIMULANT; DOPAMINE; DRUG;
   SEROTONIN; RATS; ECSTASY
AB Mephedrone is a drug of abuse marketed as 'bath salts". There are discrepancies concerning its long-term effects. We have investigated the neurotoxicity of mephedrone in mice following different exposition schedules. Schedule 1: four doses of 50 mg/kg. Schedule 2: four doses of 25 mg/kg. Schedule 3: three daily doses of 25 mg/kg, for two consecutive days. All schedules induced, in some animals, an aggressive behavior and hyperthermia as well as a decrease in weight gain. Mephedrone (schedule 1) induced dopaminergic and serotoninergic neurotoxicity that persisted 7 days after exposition. At a lower dose (schedule 2) only a transient dopaminergic injury was found. In the weekend consumption pattern (schedule 3), mephedrone induced dopamine and serotonin transporter loss that was accompanied by a decrease in tyrosine hydroxylase and tryptophan hydroxylase 2 expression one week after exposition. Also, mephedrone induced a depressive-like behavior, as well as a reduction in striatal D2 density, suggesting higher susceptibility to addictive drugs. In cultured cortical neurons, mephedrone induced a concentration-dependent cytotoxic effect. Using repeated doses for 2 days in an elevated ambient temperature we evidenced a loss of frontal cortex dopaminergic and hippocampal serotoninergic neuronal markers that suggest injuries at nerve endings.
C1 [Escubedo, Elena] Univ Barcelona, Fac Pharm, Dept Pharmacol & Therapeut Chem, Pharmacol Sect, Barcelona, Spain.
   Univ Barcelona, Fac Pharm, Inst Biomed IBUB, Barcelona, Spain.
RP Escubedo, E (reprint author), Univ Barcelona, Fac Pharm, Dept Pharmacol & Therapeut Chem, Pharmacol Sect, Barcelona, Spain.
EM eescubedo@ub.edu
RI Sanchez, David Pubill/H-3013-2016; Escubedo, Elena/K-5295-2014;
   Lopez-Arnau, Raul/Q-5896-2018
OI Sanchez, David Pubill/0000-0002-6627-4501; Escubedo,
   Elena/0000-0002-5078-366X; Lopez-Arnau, Raul/0000-0001-8904-7398; Sonia,
   ABAD/0000-0001-8238-0016
FU Generalitat de Catalunya [SGR977]; Plan Nacional sobre Drogas [2010/005,
   2012/102]; Ministerio de Ciencia e Innovacion [SAF2010-15948]; Plan
   Nacional sobre Drogas; Generalitat de Catalunya
FX Funding for this study was provided by grants from Generalitat de
   Catalunya (SGR977), Plan Nacional sobre Drogas (2010/005; 2012/102) and
   Ministerio de Ciencia e Innovacion (SAF2010-15948). Martinez-Clemente is
   a recipient of a fellowship from the Plan Nacional sobre Drogas and
   Lopez-Arnau is a recipient of a fellowship from Generalitat de
   Catalunya. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Angoa-Perez M, 2012, J NEUROCHEM, V120, P1097, DOI 10.1111/j.1471-4159.2011.07632.x
   BATTAGLIA G, 1988, PHARMACOL BIOCHEM BE, V29, P269, DOI 10.1016/0091-3057(88)90155-4
   Baumann MH, 2013, NEUROPSYCHOPHARMACOL, V38, P552, DOI 10.1038/npp.2012.204
   Baumann MH, 2012, NEUROPSYCHOPHARMACOL, V37, P1192, DOI 10.1038/npp.2011.304
   Biezonski DK, 2011, CURR NEUROPHARMACOL, V9, P84, DOI 10.2174/157015911795017146
   Borek HA, 2012, ANN EMERG MED, V60, P103, DOI 10.1016/j.annemergmed.2012.01.005
   Brunt TM, 2011, J PSYCHOPHARMACOL, V25, P1543, DOI 10.1177/0269881110378370
   Calapai G, 2001, PHARMACOPSYCHIATRY, V34, P45, DOI 10.1055/s-2001-15180
   Cameron K, 2013, PSYCHOPHARMACOLOGY, V227, P493, DOI 10.1007/s00213-013-2967-2
   Capela JP, 2013, NEUROTOXICOLOGY, V34, P254, DOI 10.1016/j.neuro.2012.09.005
   Clark RA, 2012, J PSYCHOPHARMACOL, V26, P1136, DOI 10.1177/0269881111420313
   de la Torre R, 2004, THER DRUG MONIT, V26, P137, DOI 10.1097/00007691-200404000-00009
   den Hollander B, 2013, PHARMACOL BIOCHEM BE, V103, P501, DOI 10.1016/j.pbb.2012.10.006
   EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X
   Escubedo E, 2005, J PHARMACOL EXP THER, V315, P658, DOI 10.1124/jpet.105.089748
   Fantegrossi WE, 2013, NEUROPSYCHOPHARMACOL, V38, P563, DOI 10.1038/npp.2012.233
   Groman SM, 2012, J NEUROSCI, V32, P5843, DOI 10.1523/JNEUROSCI.0029-12.2012
   Gunderson EW, 2013, J ADDICT MED, V7, P153, DOI 10.1097/ADM.0b013e31829084b7
   Hadlock GC, 2011, J PHARMACOL EXP THER, V339, P530, DOI 10.1124/jpet.111.184119
   HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9
   Kasick DP, 2012, AM J DRUG ALCOHOL AB, V38, P176, DOI 10.3109/00952990.2011.643999
   Kehr J, 2011, BRIT J PHARMACOL, V164, P1949, DOI 10.1111/j.1476-5381.2011.01499.x
   Kuhn DM, 2007, J NEUROCHEM, V103, P1567, DOI 10.1111/j.1471-4159.2007.04855.x
   LOGAN BJ, 1988, EUR J PHARMACOL, V152, P227, DOI 10.1016/0014-2999(88)90717-0
   Lopez-Arnau R, 2012, BRIT J PHARMACOL, V167, P407, DOI 10.1111/j.1476-5381.2012.01998.x
   Martinez-Clemente J, 2013, PSYCHOPHARMACOLOGY, V229, P295, DOI 10.1007/s00213-013-3108-7
   Martinez-Clemente J, 2012, EUR NEUROPSYCHOPHARM, V22, P231, DOI 10.1016/j.euroneuro.2011.07.009
   Maskell PD, 2011, J ANAL TOXICOL, V35, P188, DOI 10.1093/anatox/35.3.188
   McElrath K, 2011, INT J DRUG POLICY, V22, P120, DOI 10.1016/j.drugpo.2010.11.001
   McGregor IS, 2003, PSYCHOPHARMACOLOGY, V168, P465, DOI 10.1007/s00213-003-1452-8
   Measham F, 2010, DRUGS ALCOHOL TODAY, V10, P14, DOI 10.5042/daat.2010.0123
   Meng H, 2012, TOXICOL LETT, V208, P62, DOI 10.1016/j.toxlet.2011.10.010
   Motbey CP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045473
   O'Shea E, 2006, BRIT J PHARMACOL, V148, P778, DOI 10.1038/sj.bjp.0706783
   PORSOLT RD, 1978, EUR J PHARMACOL, V47, P379, DOI 10.1016/0014-2999(78)90118-8
   Prosser JM, 2012, J MED TOXICOL, V8, P33, DOI 10.1007/s13181-011-0193-z
   PU CF, 1993, DEV BRAIN RES, V72, P325
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Rockhold RW, 1997, ANN EMERG MED, V29, P383, DOI 10.1016/S0196-0644(97)70351-2
   Sanchez V, 2004, J PSYCHOPHARMACOL, V18, P412, DOI 10.1177/0269881104044583
   SCHEFFEL U, 1992, NEUROPHARMACOLOGY, V31, P881, DOI 10.1016/0028-3908(92)90126-A
   Schifano F, 2011, PSYCHOPHARMACOLOGY, V214, P593, DOI 10.1007/s00213-010-2070-x
   Schroter CJ, 1999, J IMMUNOL METHODS, V227, P161, DOI 10.1016/S0022-1759(99)00079-4
   Shishido T, 2000, PHARMACOL BIOCHEM BE, V66, P579, DOI 10.1016/S0091-3057(00)00219-7
   Simmler LD, 2013, BRIT J PHARMACOL, V168, P458, DOI 10.1111/j.1476-5381.2012.02145.x
   Vardakou I, 2011, TOXICOL LETT, V201, P191, DOI 10.1016/j.toxlet.2010.12.014
   Varner KJ, 2013, PSYCHOPHARMACOLOGY, V225, P675, DOI 10.1007/s00213-012-2855-1
   Verdaguer E, 2002, NEUROREPORT, V13, P413, DOI 10.1097/00001756-200203250-00010
   Vidal-Infer A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043107
   Volkow ND, 2004, MOL PSYCHIATR, V9, P557, DOI 10.1038/sj.mp.4001507
   Wagner GC, 2004, NEUROPHARMACOLOGY, V46, P700, DOI 10.1016/j.neuropharm.2003.11.009
   Wikstrom M, 2010, J ANAL TOXICOL, V34, P594, DOI 10.1093/jat/34.9.594
   Winstock A, 2011, ADDICTION, V106, P1991, DOI 10.1111/j.1360-0443.2011.03502.x
   Winstock A, 2010, LANCET, V376, P1537, DOI 10.1016/S0140-6736(10)62021-1
   Wood DM, 2011, EMERG MED J, V28, P280, DOI 10.1136/emj.2010.092288
   Wright MJ, 2012, BRIT J PHARMACOL, V167, P1342, DOI 10.1111/j.1476-5381.2012.02091.x
   Wright MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044652
NR 57
TC 23
Z9 23
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 3
PY 2014
VL 9
IS 6
AR e99002
DI 10.1371/journal.pone.0099002
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AI5ML
UT WOS:000336911400119
PM 24892744
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Zheng, SG
   Xu, HX
   Guo, LH
   Liu, LN
   Lu, F
AF Zheng, Shu-Guang
   Xu, Hui-Xiong
   Guo, Le-Hang
   Liu, Lin-Na
   Lu, Feng
TI The Safety and Treatment Response of Combination Therapy of
   Radioimmunotherapy and Radiofrequency Ablation for Solid Tumor: A Study
   In Vivo
SO PLOS ONE
LA English
DT Article
ID ADVANCED LUNG-CANCER; HEPATOCELLULAR-CARCINOMA; INJECTION; TOSITUMOMAB;
   DELIVERY; ANTIBODY; IMPROVES
AB Objection: To investigate the safety and treatment response of radioimmunotherapy (RIT) in combination with radiofrequency ablation (RFA) for the treatment of VX2 tumor on rabbit.
   Materials and Methods: A total of 36 rabbits bearing VX2 tumor on the thigh were randomly assigned into 3 groups (group I: 1-2 cm; group II: 2-3 cm; group III: 3-4 cm) and 4 subgroups (A: as control, just puncture the tumor using the RFA electrode without power output; B: RFA alone; C: I-131-chTNT intratumoral injection alone; D: RFA+ I-131-chTNT intratumoral injection 3 days later). The variation of blood assay, weight and survival among different groups and subgroups were used to assess the treatment safety. Ultrasound (US) was used to monitor and assess the tumor response after treatment.
   Results: According to the results of the weight and the blood assay among different groups, subgroups, and at two time points (one day before and the 16th day after treatment), no damages to the liver, kidney function and myelosuppression resulting from the treatment were found. No significant differences in survivals among the four subgroups (p = 0.087) were found. In addition, I-131-chTNT did not show significant inhibition effect on VX2 tumor progression according to US measurements.
   Conclusion: I-131-chTNT intratumoral injection alone or in combination with RFA is relatively safe for rabbit without significant toxicity and shows no significant effect on the survival. The treatment response is not as satisfactory as anticipated.
C1 [Zheng, Shu-Guang; Xu, Hui-Xiong; Guo, Le-Hang; Liu, Lin-Na; Lu, Feng] Tongji Univ, Peoples Hosp 10, Shanghai Peoples Hosp 10, Dept Med Ultrasound, Shanghai 200092, Peoples R China.
   [Zheng, Shu-Guang; Xu, Hui-Xiong] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Med Ultrason, Guangzhou 510275, Guangdong, Peoples R China.
RP Xu, HX (reprint author), Tongji Univ, Peoples Hosp 10, Shanghai Peoples Hosp 10, Dept Med Ultrasound, Shanghai 200092, Peoples R China.
EM xuhuixiong@hotmail.com
FU National Scientific Foundation Committee of China [30970837, 81371570,
   81301229]
FX Supported by National Scientific Foundation Committee of China, No.
   30970837, 81371570, 81301229. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Barbet J, 2011, EUR J NUCL MED MOL I, V38, P271, DOI 10.1007/s00259-010-1707-7
   Brace CL, 2009, CURR PROBL DIAGN RAD, V38, P135, DOI 10.1067/j.cpradiol.2007.10.001
   Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199
   Chatal JF, 2009, J CANCER RES THER, V5, P36, DOI 10.4103/0973-1482.55139
   Chen SL, 2005, J CLIN ONCOL, V23, P1538, DOI 10.1200/JCO.2005.06.108
   de Jong G, 2011, EJSO-EUR J SURG ONC, V37, P258, DOI 10.1016/j.ejso.2010.12.009
   Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0
   Frampas E, 2011, NUCL MED COMMUN, V32, P147, DOI 10.1097/MNM.0b013e328341b268
   Goldenberg DM, 2008, J NUCL MED, V49, P158, DOI 10.2967/jnumed.107.046185
   Hanaoka H, 2009, ANN NUCL MED, V23, P479, DOI 10.1007/s12149-009-0265-1
   Horning SJ, 2005, J CLIN ONCOL, V23, P712, DOI 10.1200/JCO.2005.07.040
   Huang CY, 2012, CANCER TREAT REV, V38, P854, DOI 10.1016/j.ctrv.2011.12.005
   Lindegren S, 2011, CURR RADIOPHARM, V4, P248, DOI 10.2174/1874471011104030248
   Navarro-Teulon I, 2013, IMMUNOTHERAPY-UK, V5, P467, DOI [10.2217/IMT.13.34, 10.2217/imt.13.34]
   Pasquetto MV, 2011, J IMMUNOTHER, V34, P611, DOI 10.1097/CJI.0b013e318234ecf5
   Pohlman B, 2006, EXPERT REV ANTICANC, V6, P445, DOI 10.1586/14737140.6.3.445
   PRESSMAN D, 1953, CANCER, V6, P619, DOI 10.1002/1097-0142(195305)6:3<619::AID-CNCR2820060319>3.0.CO;2-Y
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Sharkey RM, 2012, FUTURE ONCOLOGY, V8, P659
   Sharkey RM, 2011, MOL CANCER THER, V10, P1072, DOI 10.1158/1535-7163.MCT-11-0115
   Song H, 2011, CURR DRUG DELIV, V8, P26, DOI 10.2174/156720111793663651
   Srinivasan A, 2011, AM J NEURORADIOL, V32, P637, DOI 10.3174/ajnr.A2593
   Tomblyn M, 2012, CANCER CONTROL, V19, P196, DOI 10.1177/107327481201900304
   Tracy CR, 2010, CANCER-AM CANCER SOC, V116, P3135, DOI 10.1002/cncr.25002
   Wang H, 2008, CANCER IMMUNOL IMMUN, V57, P677, DOI 10.1007/s00262-007-0406-0
   Wu L, 2010, CANCER BIOTHER RADIO, V25, P657, DOI 10.1089/cbr.2010.0801
   Yu LK, 2006, CANCER BIOTHER RADIO, V21, P5, DOI 10.1089/cbr.2006.21.5
   Zheng SG, 2013, CANCER BIOTHER RADIO, V28, P725, DOI 10.1089/cbr.2012.1418
NR 28
TC 1
Z9 2
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 2
PY 2014
VL 9
IS 5
AR e96539
DI 10.1371/journal.pone.0096539
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AI1ZS
UT WOS:000336655700111
PM 24787957
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Zhang, YL
   Ou, P
   Lu, XH
   Chen, YP
   Xu, JM
   Dai, RP
AF Zhang, Yan-Ling
   Ou, Peng
   Lu, Xiang-Hang
   Chen, Yan-Ping
   Xu, Jun-Mei
   Dai, Ru-Ping
TI Effect of Intraoperative High-Dose Remifentanil on Postoperative Pain: A
   Prospective, Double Blind, Randomized Clinical Trial
SO PLOS ONE
LA English
DT Article
ID OPIOID-INDUCED HYPERALGESIA; ANESTHESIA; TOLERANCE; PROPOFOL
AB Background: Remifentanil, an ultra-short-acting opioid, is widely used for pain control during surgery. However, regular dose (RD) remifentanil exacerbates postoperative pain in a dose-dependent manner. Recent studies suggest that high-dose (HD) remifentanil offers sustained analgesia in experimental studies. We thus hypothesized that intraoperative administration of high-dose remifentanil may attenuate postoperative pain.
   Methods: In this prospective, randomized, double blind, controlled clinical study, sixty patients undergoing thyroidectomy (18-60 years-of-age) received an intraoperative infusion of 0.2 (RD group) or 1.2 mu g kg(-1) min(-1) (HD group) remifentanil during thyroidectomy. A visual analogue scale (VAS) was used to measure pain intensity. Mechanical pain threshold on the forearm was assessed using von Frey filaments before surgery (baseline), 2 h postoperatively and 18-24 h postoperatively. The primary outcome was to compare the difference of VAS score at different time points after operation and morphine consumption 24 h postoperatively between RD and HD groups. The second outcome was to compare the difference of mechanical pain thresholds in the forearm postoperatively between RD and the HD groups.
   Results: VAS scores were lower 30 min postoperatively in the HD group (1.29 +/- 1.67, 95% CI 0.64-1.94) compared with the RD group (2.21 +/- 1.67, 95% CI 1.57-2.84) (t = 3.427, p = 0.0043, RD group vs. HD group). Postoperative morphine consumption was much lower in the HD group compared with the RD group (1.27 +/- 1.88 mg vs. 0.35 +/- 1.25 mg, p = 0.033). In both groups, mechanical pain threshold was decreased 18-24 h postoperatively (2.93 +/- 0.209 Ln(g) vs. 3.454 +/- 2.072 Ln(g), p = 0.032 in RD group; 2.910 +/- 0.196 Ln(g) vs. 3.621 +/- 0.198 Ln(g), p = 0.006 in HD group, 18-24 h postoperatively vs baseline).
   Conclusions: Intraoperative administration of high-dose remifentanil decreased VAS scores and morphine consumption postoperatively. Thus, modulation of intraoperative opiates may be a simple and effective method of postoperative pain management.
C1 [Zhang, Yan-Ling; Ou, Peng; Lu, Xiang-Hang; Chen, Yan-Ping; Xu, Jun-Mei; Dai, Ru-Ping] Cent S Univ, Xiangya Hosp 2, Dept Anesthesiol, Changsha, Hunan, Peoples R China.
RP Dai, RP (reprint author), Cent S Univ, Xiangya Hosp 2, Dept Anesthesiol, Changsha, Hunan, Peoples R China.
EM xyeyyrupingdai@gmail.com
FU National Natural Science Foundation of China [NSFC 81070897]; Program
   for New Century Excellent Talents in University [NCET-12-0543]; Hunan
   Provincial Natural Science Foundation [13JJ1007]
FX The work is supported by the funding from the National Natural Science
   Foundation of China (NSFC 81070897), Program for New Century Excellent
   Talents in University (NCET-12-0543) and Hunan Provincial Natural
   Science Foundation (13JJ1007) to R. Dai. The development and Reform
   Foundation of Hunan Province to Y.L. Zhang. The authors declare that the
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Angst MS, 2006, ANESTHESIOLOGY, V104, P570, DOI 10.1097/00000542-200603000-00025
   Burkle H, 1996, ANESTH ANALG, V83, P646, DOI 10.1097/00000539-199609000-00038
   Chang G, 2007, MED CLIN N AM, V91, P199, DOI 10.1016/j.mcna.2006.10.003
   Cheng SS, 2008, ANESTH ANALG, V106, P264, DOI 10.1213/01.ane.0000287653.77372.d9
   Drdla R, 2009, SCIENCE, V325, P207, DOI 10.1126/science.1171759
   Drdla-Schutting R, 2012, SCIENCE, V335, P235, DOI 10.1126/science.1211726
   Echevarria G, 2011, BRIT J ANAESTH, V107, P959, DOI 10.1093/bja/aer323
   Joly V, 2005, ANESTHESIOLOGY, V103, P147, DOI 10.1097/00000542-200507000-00022
   Kim SH, 2013, ANESTHESIOLOGY, V118, P337, DOI 10.1097/ALN.0b013e31827bd108
   Manering NA, 2013, BRIT J ANAESTH, V110, P287, DOI 10.1093/bja/aes360
   Mills C, 2012, J PAIN, V13, P519, DOI 10.1016/j.jpain.2012.02.009
   Pogatzki-Zahn EM, 2007, BEST PRACT RES-CLIN, V21, P3, DOI 10.1016/j.bpa.2006.11.003
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Schmidt S, 2007, CLIN J PAIN, V23, P605, DOI 10.1097/AJP.0b013e318122d1e4
   Singler B, 2007, ANESTH ANALG, V104, P1397, DOI 10.1213/01.ane.0000261305.22324.f3
   Song JW, 2011, ANESTH ANALG, V113, P390, DOI 10.1213/ANE.0b013e31821d72bc
   Zahn PK, 2005, PAIN, V114, P499, DOI 10.1016/j.pain.2005.01.018
   Zhao M, 2008, ANESTHESIOLOGY, V109, P308, DOI 10.1097/ALN.0b013e31817f4c5d
NR 18
TC 0
Z9 0
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 25
PY 2014
VL 9
IS 3
AR e91454
DI 10.1371/journal.pone.0091454
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AE0SD
UT WOS:000333675600008
PM 24667391
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Wu, HH
   Yin, JB
   Zhang, T
   Cui, YY
   Dong, YL
   Chen, GZ
   Wang, W
AF Wu, Huang-Hui
   Yin, Jun-Bin
   Zhang, Ting
   Cui, Yuan-Yuan
   Dong, Yu-Lin
   Chen, Guo-Zhong
   Wang, Wen
TI Inhibiting Spinal Neuron-Astrocytic Activation Correlates with
   Synergistic Analgesia of Dexmedetomidine and Ropivacaine
SO PLOS ONE
LA English
DT Article
ID NEUROPATHIC PAIN; NERVE LIGATION; MECHANICAL ALLODYNIA; CAUSES
   NEUROTOXICITY; GLIAL ACTIVATION; JNK ACTIVATION; RAT MODEL; KETAMINE;
   CELLS; CORD
AB Background: This study aims to identify that intrathecal (i.t.) injection of dexmedetomidine (Dex) and ropivacaine (Ropi) induces synergistic analgesia on chronic inflammatory pain and is accompanied with corresponding "neuron-astrocytic" alterations.
   Methods: Male, adult Sprague-Dawley rats were randomly divided into sham, control and i.t. medication groups. The analgesia profiles of i.t. Dex, Ropi, and their combination detected by Hargreaves heat test were investigated on the subcutaneous (s.c.) injection of complete Freund adjuvant (CFA) induced chronic pain in rat and their synergistic analgesia was confirmed by using isobolographic analysis. During consecutive daily administration, pain behavior was daily recorded, and immunohistochemical staining was applied to investigate the number of Fos-immunoreactive (Fos-ir) neurons on hour 2 and day 1, 3 and 7, and the expression of glial fibrillary acidic protein (GFAP) within the spinal dorsal horn (SDH) on day 1, 3, 5 and 7 after s.c. injection of CFA, respectively, and then Western blot to examine spinal GFAP and beta-actin levels on day 3 and 7.
   Results: i.t. Dex or Ropi displayed a short-term analgesia in a dose-dependent manner, and consecutive daily administrations of their combination showed synergistic analgesia and remarkably down-regulated neuronal and astrocytic activations indicated by decreases in the number of Fos-ir neurons and the GFAP expression within the SDH, respectively.
   Conclusion: i.t. co-delivery of Dex and Ropi shows synergistic analgesia on the chronic inflammatory pain, in which spinal "neuron-astrocytic activation" mechanism may play an important role.
C1 [Wu, Huang-Hui; Chen, Guo-Zhong] Fuzhou Gen Hosp Nanjing Mil Reg, Dept Anesthesiol, Fuzhou, Peoples R China.
   [Yin, Jun-Bin; Zhang, Ting; Cui, Yuan-Yuan; Dong, Yu-Lin; Wang, Wen] Fourth Mil Med Univ, Preclin Sch Med, Dept Anat Histol & Embryol, Xian 710032, Peoples R China.
   [Yin, Jun-Bin; Zhang, Ting; Cui, Yuan-Yuan; Dong, Yu-Lin; Wang, Wen] Fourth Mil Med Univ, Preclin Sch Med, KK Leung Brain Res Ctr, Xian 710032, Peoples R China.
RP Chen, GZ (reprint author), Fuzhou Gen Hosp Nanjing Mil Reg, Dept Anesthesiol, Fuzhou, Peoples R China.
EM cgzssq2000@sina.com; wangwen@fmmu.edu.cn
FU NSFC [31070976, 81271230]; Fourth Military Medical University
FX This work is partly supported by the NSFC (31070976, 81271230) and
   intramural grant of the Fourth Military Medical University. The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR ABBOTT FV, 1984, BRAIN RES, V295, P77, DOI 10.1016/0006-8993(84)90817-5
   Al-Mustafa MM, 2009, SAUDI MED J, V30, P365
   Bai L, 2012, PAIN PHYSICIAN, V15, P311
   BOURGOIN S, 1993, NEUROPHARMACOLOGY, V32, P633, DOI 10.1016/0028-3908(93)90076-F
   Bruzzone A, 2008, BRIT J PHARMACOL, V155, P494, DOI 10.1038/bjp.2008.278
   Chichorro JG, 2004, BRIT J PHARMACOL, V141, P1175, DOI 10.1038/sj.bjp.0705724
   Dadure C, 2012, PEDIATR ANESTH, V22, P93, DOI 10.1111/j.1460-9592.2011.03730.x
   Gandhi Kishor, 2012, Anesthesiol Clin, V30, pe1
   GOLDMAN JA, 1958, BRIT J ANAESTH, V30, P377, DOI 10.1093/bja/30.8.377
   Grosu Irina, 2010, F1000 Med Rep, V2, P90, DOI 10.3410/M2-90
   Guo BL, 2013, MITOCHONDRION, V13, P292, DOI 10.1016/j.mito.2013.03.007
   Guo W, 2007, J NEUROSCI, V27, P6006, DOI 10.1523/JNEUROSCI.0176-07.2007
   Gupta R, 2011, INDIAN J ANAESTH, V55, P347, DOI 10.4103/0019-5049.84841
   Gupta Rajni, 2011, J Anaesthesiol Clin Pharmacol, V27, P339, DOI 10.4103/0970-9185.83678
   HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7
   Harsten A, 2013, BRIT J ANAESTHESIA
   HOLZ GG, 1989, J NEUROSCI, V9, P657
   Huang R, 2000, BRAIN RES, V873, P297, DOI 10.1016/S0006-8993(00)02525-7
   Ihmsen H, 2012, ANAESTHESIST, V61, P1059, DOI 10.1007/s00101-012-2114-1
   Jones L, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009234.pub2
   Jourdain P, 2007, NAT NEUROSCI, V10, P331, DOI 10.1038/nn1849
   Kanazi GE, 2006, ACTA ANAESTH SCAND, V50, P222, DOI 10.1111/j.1399-6576.2006.00919.x
   Katsura H, 2008, GLIA, V56, P723, DOI 10.1002/glia.20648
   Kimura M, 2012, NEUROSCI LETT, V529, P70, DOI 10.1016/j.neulet.2012.08.008
   Li SS, 2013, CNS NEUROSCI THER, V19, P364, DOI 10.1111/cns.12100
   Li XH, 2001, J PHARMACOL EXP THER, V299, P939
   Liang LL, 2013, BRAIN RES, V1513, P17, DOI 10.1016/j.brainres.2013.04.003
   Liu L, 2012, BRAIN RES, V1427, P1, DOI 10.1016/j.brainres.2011.08.019
   Mei XP, 2011, NEUROSIGNALS, V19, P44, DOI 10.1159/000324293
   Mei XP, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-6
   Mei XP, 2010, MOL PAIN, V6, DOI 10.1186/1744-8069-6-50
   Mei XP, 2009, J NEUROCHEM, V109, P1691, DOI 10.1111/j.1471-4159.2009.06087.x
   Mohamed AA, 2012, PAIN PHYSICIAN, V15, P339
   Mori K, 2002, NEUROPHARMACOLOGY, V43, P1026, DOI 10.1016/S0028-3908(02)00211-3
   Nishimori M, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005059.pub3
   Oka M, 2006, BIOCHEM BIOPH RES CO, V341, P874, DOI 10.1016/j.bbrc.2006.01.039
   Perrott DH, 2008, CURR OPIN ANESTHESIO, V21, P480, DOI 10.1097/ACO.0b013e3283063499
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Sanders RD, 2010, ACTA ANAESTH SCAND, V54, P710, DOI 10.1111/j.1399-6576.2009.02177.x
   Scholz J, 2007, NAT NEUROSCI, V10, P1361, DOI 10.1038/nn1992
   Shukla Deepika, 2011, J Anaesthesiol Clin Pharmacol, V27, P495, DOI 10.4103/0970-9185.86594
   Simmons SW, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003401.pub3
   Sites BD, 2012, REGION ANESTH PAIN M, V37, P478, DOI 10.1097/AAP.0b013e31825cb3d6
   Solanki SL, 2013, ANAESTH INTENS CARE, V41, P51, DOI 10.1177/0310057X1304100110
   Stone LS, 1998, J NEUROSCI, V18, P5928
   Sun YH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076603
   Sun ZH, 2012, ANAESTH INTENS CARE, V40, P825, DOI 10.1177/0310057X1204000427
   Sun ZH, 2012, MOL MED REP, V6, P1455, DOI 10.3892/mmr.2012.1115
   Suter MR, 2007, NEURON GLIA BIOL, V3, P255, DOI 10.1017/S1740925X08000100
   Tallarida RJ, 2001, J PHARMACOL EXP THER, V298, P865
   Thorlin T, 1998, NEUROPHARMACOLOGY, V37, P299, DOI 10.1016/S0028-3908(98)00026-4
   Toda S, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-2
   Wang W, 2008, ANAT REC, V291, P513, DOI 10.1002/ar.20673
   Wang W, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006973
   Watkins LR, 2001, TRENDS NEUROSCI, V24, P450, DOI 10.1016/S0166-2236(00)01854-3
   Werdehausen R, 2009, BRIT J ANAESTH, V103, P711, DOI 10.1093/bja/aep236
   Wirkner K, 2007, CEREB CORTEX, V17, P621, DOI 10.1093/cercor/bhk012
   Xu B, 2010, CLIN EXP PHARMACOL P, V37, pe158, DOI 10.1111/j.1440-1681.2010.05426.x
   Yan M, 2011, NEUROCHEM INT, V58, P549, DOI 10.1016/j.neuint.2011.01.013
   Yaster M, 2011, ANESTHESIOLOGY, V114, P412, DOI 10.1097/ALN.0b013e318205df50
   Yuan X, 2013, EUROPEAN J ANAESTHES
   Zhang HX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055556
   Zhong Z, 2009, ANAESTH INTENS CARE, V37, P929, DOI 10.1177/0310057X0903700612
   Zhuang ZY, 2005, PAIN, V114, P149, DOI 10.1016/j.pain.2004.12.022
   Zhuang ZY, 2006, J NEUROSCI, V26, P3551, DOI 10.1523/JNEUROSCI.5290-05.2006
   ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4
NR 66
TC 11
Z9 14
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 21
PY 2014
VL 9
IS 3
AR e92374
DI 10.1371/journal.pone.0092374
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AD6GL
UT WOS:000333355300076
PM 24658263
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Takahashi, S
   Saito, K
   Jia, HJ
   Kato, H
AF Takahashi, Shoko
   Saito, Kenji
   Jia, Huijuan
   Kato, Hisanori
TI An Integrated Multi-Omics Study Revealed Metabolic Alterations
   Underlying the Effects of Coffee Consumption
SO PLOS ONE
LA English
DT Article
ID RISK; CYCLE
AB Many epidemiological studies have indicated that coffee consumption may reduce the risks of developing obesity and diabetes, but the underlying mechanisms of these effects are poorly understood. Our previous study revealed the changes on gene expression profiles in the livers of C57BL/6J mice fed a high-fat diet containing three types of coffee (caffeinated, decaffeinated and green unroasted coffee), using DNA microarrays. The results revealed remarkable alterations in lipid metabolism-related molecules which may be involved in the anti-obesity effects of coffee. We conducted the present study to further elucidate the metabolic alterations underlying the effects of coffee consumption through comprehensive proteomic and metabolomic analyses. Proteomics revealed an up-regulation of isocitrate dehydrogenase (a key enzyme in the TCA cycle) and its related proteins, suggesting increased energy generation. The metabolomics showed an upregulation of metabolites involved in the urea cycle, with which the transcriptome data were highly consistent, indicating accelerated energy expenditure. The TCA cycle and the urea cycle are likely be accelerated in a concerted manner, since they are directly connected by mutually providing each other's intermediates. The up-regulation of these pathways might result in a metabolic shift causing increased ATP turnover, which is related to the alterations of lipid metabolism. This mechanism may play an important part in the suppressive effects of coffee consumption on obesity, inflammation, and hepatosteatosis. This study newly revealed global metabolic alterations induced by coffee intake, providing significant insights into the association between coffee intake and the prevention of type 2 diabetes, utilizing the benefits of multi-omics analyses.
C1 [Takahashi, Shoko] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Tokyo, Japan.
   [Takahashi, Shoko; Saito, Kenji; Jia, Huijuan; Kato, Hisanori] Univ Tokyo, Org Interdisciplinary Res Projects, Tokyo, Japan.
RP Kato, H (reprint author), Univ Tokyo, Org Interdisciplinary Res Projects, Tokyo, Japan.
EM akatoq@mail.ecc.u-tokyo.ac.jp
FU All Japan Coffee Association
FX This study was partly supported by a grant from the All Japan Coffee
   Association. No additional external funding received for this study. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR BARBER T, 1985, BIOCHEM J, V230, P675, DOI 10.1042/bj2300675
   Carlsson S, 2004, INT J EPIDEMIOL, V33, P616, DOI 10.1093/ije/dyh185
   Evans GA, 2000, NAT BIOTECHNOL, V18, P127, DOI 10.1038/72480
   Fukushima Y, 2009, J AGR FOOD CHEM, V57, P11100, DOI 10.1021/jf901278u
   Goodman N, 2002, CURR OPIN BIOTECH, V13, P68, DOI 10.1016/S0958-1669(02)00287-2
   Jia HJ, 2013, MOL NUTR FOOD RES, V57, P291, DOI 10.1002/mnfr.201200538
   Kato H, 2008, ASIA PAC J CLIN NUTR, V17, P12
   Kato Hisanori, 2011, J Tradit Complement Med, V1, P25
   Monton MRN, 2007, J CHROMATOGR A, V1168, P237, DOI 10.1016/j.chroma.2007.02.065
   Murase T, 2011, AM J PHYSIOL-ENDOC M, V300, pE122, DOI 10.1152/ajpendo.00441.2010
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Satapati S, 2012, J LIPID RES, V53, P1080, DOI 10.1194/jlr.M023382
   SHAMBAUGH GE, 1977, AM J CLIN NUTR, V30, P2083
   Takahashi S, 2013, J FUNCT FOO IN PRESS
   Takahashi S, 2011, BIOCHEM BIOPH RES CO, V405, P462, DOI 10.1016/j.bbrc.2011.01.054
   van Dam RM, 2005, JAMA-J AM MED ASSOC, V294, P97, DOI 10.1001/jama.294.1.97
   van Dam RM, 2002, LANCET, V360, P1477, DOI 10.1016/S0140-6736(02)11436-X
   Yamauchi R, 2010, J AGR FOOD CHEM, V58, P5597, DOI 10.1021/jf904062c
NR 18
TC 5
Z9 6
U1 1
U2 30
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 11
PY 2014
VL 9
IS 3
AR e91134
DI 10.1371/journal.pone.0091134
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AC9GM
UT WOS:000332842400049
PM 24618914
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU van der Valk, F
   Hassing, C
   Visser, M
   Thakkar, P
   Mohanan, A
   Pathak, K
   Dutt, C
   Chauthaiwale, V
   Ackermans, M
   Nederveen, A
   Serlie, M
   Nieuwdorp, M
   Stroes, E
AF van der Valk, Fleur
   Hassing, Carlijne
   Visser, Maartje
   Thakkar, Purav
   Mohanan, Anookh
   Pathak, Kaushal
   Dutt, Chaitanya
   Chauthaiwale, Vijay
   Ackermans, Mariette
   Nederveen, Aart
   Serlie, Mireille
   Nieuwdorp, Max
   Stroes, Erik
TI The Effect of a Diiodothyronine Mimetic on Insulin Sensitivity in Male
   Cardiometabolic Patients: A Double-Blind Randomized Controlled Trial
SO PLOS ONE
LA English
DT Article
ID HIGH-FAT-DIET; THYROID-HORMONE; FUNCTIONAL ANALOG; SKELETAL-MUSCLE;
   ADIPOSE-TISSUE; WHOLE-BODY; RESISTANCE; 3,5-DIIODO-L-THYRONINE;
   METABOLISM; OBESITY
AB Background and aims: Obesity and its associated cardiometabolic co-morbidities are increasing worldwide. Since thyroid hormone mimetics are capable of uncoupling the beneficial metabolic effects of thyroid hormones from their deleterious effects on heart, bone and muscle, this class of drug is considered as adjacent therapeutics to weight-lowering strategies. This study investigated the safety and efficacy of TRC150094, a thyroid hormone mimetic.
   Materials and Methods: This 4-week, randomized, placebo-controlled, double-blind trial was conducted in India and The Netherlands. Forty subjects were randomized at a 1: 1 ratio to receive either TRC150094 dosed at 50 mg or placebo once daily for 4 weeks. Hyperinsulinemic euglycemic clamp and 1 H-Magnetic Resonance Spectroscopy (MRS) were performed before and after treatment.
   Results: At baseline, subjects were characterized by markedly impaired hepatic and peripheral insulin sensitivity. TRC150094 dosed 50 mg once daily was safe and well tolerated. Hepatic nor peripheral insulin sensitivity improved after TRC150094 treatment, expressed as the suppression of Endogenous Glucose Production from 59.5 to 62.1%; p = 0.477, and the rate of glucose disappearance from 28.8 to 26.4 mu mol kg(-1) min(-1), p = 0.185. TRC150094 administration did not result in differences in fasting plasma free fatty acids from 0.51 to 0.51 mmol/L, p = 0.887 or in insulin-mediated suppression of lipolysis from 57 to 54%, p = 0.102. Also, intrahepatic triglyceride content was unaltered.
   Conclusion: Collectively, these data show that, in contrast to the potent metabolic effects in experimental models, TRC150094 at a dose of 50 mg daily does not improve the metabolic homeostasis in subjects at an increased cardiometabolic risk. Further studies are needed to evaluate whether TRC150094 has beneficial effects in patients with more severe metabolic derangement, such as overt diabetes mellitus and hypertriglyceridemia.
C1 [van der Valk, Fleur; Hassing, Carlijne; Visser, Maartje; Nieuwdorp, Max; Stroes, Erik] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands.
   [Thakkar, Purav; Mohanan, Anookh; Pathak, Kaushal; Dutt, Chaitanya; Chauthaiwale, Vijay] Torrent Pharmaceut Ltd, Dept Clin Res, Village Bhat, India.
   [Ackermans, Mariette] Univ Amsterdam, Acad Med Ctr, Dept Clin Chem, Lab Endocrinol, NL-1105 AZ Amsterdam, Netherlands.
   [Nederveen, Aart] Univ Amsterdam, Acad Med Ctr, Dept Radiol, NL-1105 AZ Amsterdam, Netherlands.
   [Serlie, Mireille] Univ Amsterdam, Acad Med Ctr, Dept Endocrinol, NL-1105 AZ Amsterdam, Netherlands.
RP van der Valk, F (reprint author), Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.
EM f.m.valkvander@amc.nl
FU Torrent Pharmaceuticals, Ahmedabad, India
FX This research was funded by a research grant from Torrent
   Pharmaceuticals, Ahmedabad, India. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Alberti KGMM, 2009, CIRCULATION, V120, P1640, DOI 10.1161/CIRCULATIONAHA.109.192644
   Ball SG, 1997, J MOL ENDOCRINOL, V19, P137, DOI 10.1677/jme.0.0190137
   Bengtsson Per, 2012, KARO BIO TERMINSATES
   Brenta G, 2009, THYROID, V19, P665, DOI 10.1089/thy.2009.0108
   Bryzgalova G, 2008, J STEROID BIOCHEM, V111, P262, DOI 10.1016/j.jsbmb.2008.06.010
   Cheng SY, 2010, ENDOCR REV, V31, P139, DOI 10.1210/er.2009-0007
   Cioffi F, 2010, FASEB J, V24, P3451, DOI 10.1096/fj.10-157115
   de Lange P, 2011, DIABETES, V60, P2730, DOI 10.2337/db11-0207
   Eckel RH, 2011, ARTERIOSCL THROM VAS, V31, P1946, DOI 10.1161/ATVBAHA.111.233049
   Hickner RC, 1999, J CLIN ENDOCR METAB, V84, P3886, DOI 10.1210/jc.84.11.3886
   HORST C, 1989, BIOCHEM J, V261, P945, DOI 10.1042/bj2610945
   Klein I, 2001, NEW ENGL J MED, V344, P501, DOI 10.1056/NEJM200102153440707
   Klieverik LP, 2009, ENDOCRINOLOGY, V150, P5639, DOI 10.1210/en.2009-0297
   Ladenson PW, 2010, NEW ENGL J MED, V362, P906, DOI 10.1056/NEJMoa0905633
   Moreno M, 2008, THYROID, V18, P239, DOI 10.1089/thy.2007.0248
   Moreno M, 2011, FASEB J, V25, P3312, DOI 10.1096/fj.11-181982
   Ogden CL, 2012, JAMA-J AM MED ASSOC, V307, P483, DOI 10.1001/jama.2012.40
   Pasarica M, 2010, J CLIN ENDOCR METAB, V95, P4052, DOI 10.1210/jc.2009-2377
   Pinna G, 1998, J CLIN ENDOCR METAB, V83, P3071, DOI 10.1210/jc.83.9.3071
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Rezzonico J, 2011, THYROID, V21, P945, DOI 10.1089/thy.2010.0402
   Ribeiro MO, 2008, THYROID, V18, P197, DOI 10.1089/thy.2007.0288
   Silvestri E, 2012, MOL BIOSYST, V8, P1987, DOI 10.1039/c2mb25055a
   Skarulis MC, 2010, J CLIN ENDOCR METAB, V95, P256, DOI 10.1210/jc.2009-0543
   Soeters MR, 2009, AM J CLIN NUTR, V90, P1244, DOI 10.3945/ajcn.2008.27327
   van Raalte DH, 2011, DIABETOLOGIA, V54, P2103, DOI 10.1007/s00125-011-2174-9
   Vrieze A, 2012, GASTROENTEROLOGY, V143, P913, DOI 10.1053/j.gastro.2012.06.031
   Zambad SP, 2011, DIABETES METAB SYNDR, V4, P5, DOI 10.2147/DMSOTT.S15323
NR 28
TC 13
Z9 13
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 21
PY 2014
VL 9
IS 2
AR e86890
DI 10.1371/journal.pone.0086890
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AB3VI
UT WOS:000331717900006
PM 24586256
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Jang, M
   Lee, MJ
   Lee, JM
   Bae, CS
   Kim, SH
   Ryu, JH
   Cho, IH
AF Jang, Minhee
   Lee, Min Jung
   Lee, Jin Moo
   Bae, Chun-Sik
   Kim, Sung-Hoon
   Ryu, Jong Hoon
   Cho, Ik-Hyun
TI Oriental Medicine Kyung-Ok-Ko Prevents and Alleviates
   Dehydroepiandrosterone-Induced Polycystic Ovarian Syndrome in Rats
SO PLOS ONE
LA English
DT Article
ID DRIED REHMANNIAE RADIX; GENE-EXPRESSION; SYNDROME PCOS; T-CELLS; WOMEN;
   METFORMIN; MICE; INFLAMMATION; ADOLESCENTS; INFERTILITY
AB Kyung-Ok-Ko (KOK), a traditional herbal prescription composed of Rehmannia glutinosa Liboschitz var. purpurae, Lycium chinense, Aquillaria agallocha, Poria cocos, Panax ginseng, and honey, has been widely used in traditional Oriental medicine as a vitalizing medicine or as the prescription for patients with age-associated disorders such as amnesia and stroke. However, the potential protective value of KOK for the treatment of polycystic ovarian syndrome (PCOS) is largely unknown. We investigated whether pre-administration (daily from 2 hours before PCOS induction) and post-administration (daily after induction of PCOS) of KOK (0.5, 1.0, and 2.0 g/kg/day, p.o.) could have a protective effect in a dehydroepiandrosterone (DHEA, s. c.)-induced PCOS rat model. Pre-administration of KOK significantly decreased the elevated body weight and ovary weight, elevated size and number of follicular cysts, elevated level of serum glucose, and estradiol after DHEA injection. KOK reduced the elevated percentage of CD8 (+) T lymphocytes in lymph nodes, the elevated mRNA expression of CD11b and CD3 in ovaries, and infiltration of macrophages in ovarian tissue with PCOS. KOK diminished the increased mRNA expression of pro-inflammatory cytokines (IL-1 beta, IL-6, TNF-alpha), chemokines (IL-8, MCP-1), and iNOS in the ovaries, and increased the reduced mRNA expression of growth factors (EGF, TGF-b) by DHEA injection. Post-administration of KOK also improved the DHEA-induced PCOS-like symptoms, generally similar to those evident from pre-administration of KOK. KOK may effectively prevent and improve DHEA-induced PCOS via anti-inflammatory action, indicating its preventive and therapeutic potential for suppressing PCOS.
C1 [Jang, Minhee; Lee, Min Jung; Cho, Ik-Hyun] Kyung Hee Univ, Dept Convergence Med Sci, Seoul, South Korea.
   [Jang, Minhee; Lee, Min Jung; Kim, Sung-Hoon] Kyung Hee Univ, Dept Canc Prevent Mat Dev, Seoul, South Korea.
   [Lee, Jin Moo] Kyung Hee Univ, Coll Korean Med, Dept Gynecol, Seoul, South Korea.
   [Bae, Chun-Sik] Chonnam Natl Univ, Coll Vet Med, Kwangju, South Korea.
   [Bae, Chun-Sik] Chonnam Natl Univ, Anim Med Inst, Kwangju, South Korea.
   [Cho, Ik-Hyun] Kyung Hee Univ, Inst Korean Med, Seoul, South Korea.
   [Ryu, Jong Hoon] Kyung Hee Univ, Coll Pharm, Dept Oriental Pharmaceut Sci, Seoul, South Korea.
   [Ryu, Jong Hoon] Kyung Hee Univ, Dept Life & Nanopharmaceut Sci, Seoul, South Korea.
RP Cho, IH (reprint author), Kyung Hee Univ, Dept Convergence Med Sci, Seoul, South Korea.
EM ihcho@khu.ac.kr
FU Kwang Dong Pharmaceutical Co., Ltd; National Research Foundation of
   Korea (NRF); Korea government (MSIP) [2007-0054931]
FX Original study was supported by supported by grant from the Kwang Dong
   Pharmaceutical Co., Ltd. And study for revision was supported by
   supported by the National Research Foundation of Korea (NRF) grant
   funded by the Korea government (MSIP) (No. 2007-0054931). The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Amato G, 2003, OBSTET GYNECOL, V101, P1177, DOI 10.1016/S0029-7844(03)00233-3
   Andrikopoulos S, 2008, AM J PHYSIOL-ENDOC M, V295, pE1323, DOI 10.1152/ajpendo.90617.2008
   Attele AS, 1999, BIOCHEM PHARMACOL, V58, P1685, DOI 10.1016/S0006-2952(99)00212-9
   Benson S, 2008, BRAIN BEHAV IMMUN, V22, P177, DOI 10.1016/j.bbi.2007.07.003
   Cai M, 2011, J ETHNOPHARMACOL, V138, P723, DOI 10.1016/j.jep.2011.10.016
   Carmina E, 1999, J CLIN ENDOCR METAB, V84, P1897, DOI 10.1210/jc.84.6.1897
   Cho IH, 2012, J GINSENG RES, V36, P342, DOI 10.5142/jgr.2012.36.4.342
   Diamanti-Kandarakis E, 2007, Minerva Endocrinol, V32, P35
   Elia E, 2006, MOL HUM REPROD, V12, P475, DOI 10.1093/molehr/gal057
   Franks S, 2008, HUM REPROD UPDATE, V14, P367, DOI 10.1093/humupd/dmn015
   Ropelato MG, 2009, J CLIN ENDOCR METAB, V94, P3602, DOI 10.1210/jc.2009-0402
   Glintborg D, 2009, CLIN ENDOCRINOL, V71, P652, DOI 10.1111/j.1365-2265.2009.03523.x
   Goodarzi MO, 2011, FERTIL STERIL, V95, P1736, DOI 10.1016/j.fertnstert.2011.01.015
   Goodarzi MO, 2011, NAT REV ENDOCRINOL, V7, P219, DOI 10.1038/nrendo.2010.217
   Hahn S, 2005, EUR J ENDOCRINOL, V153, P853, DOI 10.1530/eje.1.02024
   Hatzirodos N, 2011, FASEB J, V25, P2256, DOI 10.1096/fj.11-181099
   Huh J, 1610, DONGUIBOGAM
   Ibanez L, 2006, FERTIL STERIL, V86, pS24, DOI 10.1016/j.fertnstert.2006.03.006
   Jang M, 2013, EVID-BASED COMPL ALT, DOI 10.1155/2013/237207
   Johnson N, 2011, AUST NZ J OBSTET GYN, V51, P125, DOI 10.1111/j.1479-828X.2010.01274.x
   Kousta E, 1997, HUM REPROD UPDATE, V3, P359, DOI 10.1093/humupd/3.4.359
   Krinke G. R., 2000, LAB RAT
   KUBO M, 1994, BIOL PHARM BULL, V17, P1282
   Lee E. S., 2002, KOR J HERBOL, V17, P101
   Lee JC, 2003, AM J CHINESE MED, V31, P885, DOI 10.1142/S0192415X03001636
   Lee SM, 2012, J ETHNOPHARMACOL, V141, P368, DOI 10.1016/j.jep.2012.02.048
   Legro RS, 2007, AM J OBSTET GYNECOL, V196, DOI 10.1016/j.ajog.2006.12.025
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lu FX, 2002, CLIN EXP IMMUNOL, V128, P10, DOI 10.1046/j.1365-2249.2002.01780.x
   Luchetti CG, 2004, J REPROD IMMUNOL, V64, P59, DOI 10.1016/j.jri.2004.04.002
   Maharjan R, 2011, J AYURVEDA INTEGR ME, V1, P273
   Manneras L, 2008, ENDOCRINOLOGY, V149, P3559, DOI 10.1210/en.2008-0053
   Manneras L, 2007, ENDOCRINOLOGY, V148, P3781, DOI 10.1210/en.2007-0168
   MARCONDES F. K., 2002, Braz. J. Biol., V62, P609, DOI 10.1590/S1519-69842002000400008
   MEIKLE AW, 1992, J STEROID BIOCHEM, V42, P293, DOI 10.1016/0960-0760(92)90132-3
   Musso C, 2005, CLIN ENDOCRINOL, V63, P73, DOI 10.1111/j.1365-2265.2005.02302.x
   Nestler JE, 2002, FERTIL STERIL, V77, P209, DOI 10.1016/S0015-0282(01)02963-6
   Norman RJ, 2006, ENDOCRINE, V30, P35, DOI 10.1385/ENDO:30:1:35
   Obradovic S, 2001, PHARMAZIE, V56, P235
   Park Hyun-Jung, 2011, Exp Neurobiol, V20, P137, DOI 10.5607/en.2011.20.3.137
   Raja-Khan N, 2011, AM J PHYSIOL-ENDOC M, V301, pE1, DOI 10.1152/ajpendo.00667.2010
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Rios JL, 2011, PLANTA MED, V77, P681, DOI 10.1055/s-0030-1270823
   Ross R, 2004, OBES RES, V12, P789, DOI 10.1038/oby.2004.95
   Safadi FF, 2000, ENDOCRINE, V12, P81, DOI 10.1385/ENDO:12:1:81
   Sander V, 2006, REPRODUCTION, V131, P591, DOI 10.1530/rep.1.00941
   Sapino A, 2003, AM J PATHOL, V163, P1313, DOI 10.1016/S0002-9440(10)63490-6
   Schindler AE, 2009, MATURITAS, V65, pS3, DOI 10.1016/j.maturitas.2009.10.011
   Sekiya N, 2003, PHYTOTHER RES, V17, P160, DOI 10.1002/ptr.1097
   Shin BumYoung, 2009, Journal of Traditional Medicines, V26, P35
   Solano ME, 2011, J REPROD IMMUNOL, V92, P33, DOI 10.1016/j.jri.2011.09.003
   Taylor AE, 1997, J CLIN ENDOCR METAB, V82, P2248, DOI 10.1210/jc.82.7.2248
   Wu RJ, 2004, HUM REPROD UPDATE, V10, P119, DOI 10.1093/humupd/dmh011
   Yan G, 2000, J WOMEN HEALTH GEN-B, V9, P275, DOI 10.1089/152460900318461
   Ye Y, 2010, J ETHNOPHARMACOL, V129, P387, DOI 10.1016/j.jep.2010.04.009
   Yokozawa T, 2004, AM J CHINESE MED, V32, P829, DOI 10.1142/S0192415X04002442
   Zhang R, 2010, J ETHNOPHARMACOL, V130, P299, DOI 10.1016/j.jep.2010.05.007
   Zhang Y, 2004, EUR J PHARMACOL, V504, P39, DOI 10.1016/j.ejphar.2004.09.051
   이소연, 2008, [The Korea Journal of Herbology, 대한본초학회지], V23, P123
NR 59
TC 15
Z9 18
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 10
PY 2014
VL 9
IS 2
AR e87623
DI 10.1371/journal.pone.0087623
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AA7CL
UT WOS:000331254600025
PM 24520334
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Xu, GG
   McMahan, CA
   Walter, CA
AF Xu, Guogang
   McMahan, C. Alex
   Walter, Christi A.
TI Early-Life Exposure to Benzo[a]pyrene Increases Mutant Frequency in
   Spermatogenic Cells in Adulthood
SO PLOS ONE
LA English
DT Article
ID NUCLEOTIDE EXCISION-REPAIR; LUNG-CANCER RISK; MALE GERM-CELLS;
   DNA-ADDUCTS; CHILDRENS HEALTH; SPONTANEOUS MUTATION; PHAGOCYTIC
   FUNCTION; SECONDHAND SMOKE; GENE-EXPRESSION; TRANSGENIC MICE
AB Children are vulnerable to environmental mutagens, and the developing germline could also be affected. However, little is known about whether exposure to environmental mutagens in childhood will result in increased germline mutations in subsequent adult life. In the present study, male transgenic lacI mice at different ages (7, 25 and 60 days old) were treated with a known environmental mutagen (benzo[a]pyrene, B[a]P) at different doses (0, 50, 200 or 300 mg/kg body weight). Mutant frequency was then determined in a meiotic cell type (pachytene spermatocyte), a post-meiotic cell type (round spermatid) and epididymal spermatozoa after at least one cycle of spermatogenesis. Our results show that 1) mice treated with B[a]P at 7 or 25 days old, both being pre-adult ages, had significantly increased mutant frequencies in all spermatogenic cell types tested when they were 60 days old; 2) spermatogenic cells from mice treated before puberty were more susceptible to B[a]P-associated mutagenesis compared to adult mice; and 3) unexpectedly, epididymal spermatozoa had the highest mutant frequency among the spermatogenic cell types tested. These data show that pre-adult exposure to B[a]P increases the male germline mutant frequency in young adulthood. The data demonstrate that exposure to environmental genotoxins at different life phases (e.g., pre-adult and adult) can have differential effects on reproductive health.
C1 [Xu, Guogang; Walter, Christi A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
   [McMahan, C. Alex] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
   [Walter, Christi A.] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA.
   [Walter, Christi A.] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Sci, San Antonio, TX 78229 USA.
   [Walter, Christi A.] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Walter, CA (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
EM walter@uthscsa.edu
FU  [AG021163]
FX Funding was provided by AG021163, http://www.nih.gov/. The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Anderson LM, 2000, ENVIRON HEALTH PERSP, V108, P573, DOI 10.2307/3454549
   Asomaning K, 2008, LUNG CANCER, V61, P13, DOI 10.1016/j.lungcan.2007.11.013
   Barker DJP, 2007, J INTERN MED, V261, P412, DOI 10.1111/j.1365-2796.2007.01809.x
   Barton HA, 2005, ENVIRON HEALTH PERSP, V113, P1125, DOI 10.1289/ehp.7667
   Bartsch H, 1996, MUTAT RES-REV GENET, V340, P67, DOI 10.1016/S0165-1110(96)90040-8
   BEARER CF, 1995, ENVIRON HEALTH PERSP, V103, P7, DOI 10.2307/3432337
   BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68
   BELLVE AR, 1993, METHOD ENZYMOL, V225, P84
   Bieche I, 2007, PHARMACOGENET GENOM, V17, P731, DOI 10.1097/FPC.0b013e32810f2e58
   Bostrom CE, 2002, ENVIRON HEALTH PERSP, V110, P451, DOI 10.1289/ehp.02110s3451
   Braun RE, 1998, NAT GENET, V18, P202, DOI 10.1038/ng0398-202
   CHEMES H, 1986, ENDOCRINOLOGY, V119, P1673, DOI 10.1210/endo-119-4-1673
   CONNEY AH, 1994, DRUG METAB REV, V26, P125, DOI 10.3109/03602539409029788
   COSMAN M, 1992, P NATL ACAD SCI USA, V89, P1914, DOI 10.1073/pnas.89.5.1914
   Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430
   Dym M, 1970, Biology Reprod., V3, P308
   DYM M, 1994, P NATL ACAD SCI USA, V91, P11287, DOI 10.1073/pnas.91.24.11287
   GENEROSO WM, 1982, MUTAT RES, V94, P155, DOI 10.1016/0027-5107(82)90178-6
   Gillet LCJ, 2006, CHEM REV, V106, P253, DOI 10.1021/cr040483f
   Godschalk RWL, 2003, J BIOCHEM MOL BIOL, V36, P1
   Grandjean V, 1997, DEV BIOL, V184, P165, DOI 10.1006/dbio.1997.8518
   Hecht SS, 1999, JNCI-J NATL CANCER I, V91, P1194, DOI 10.1093/jnci/91.14.1194
   Hill KA, 1999, MUTAT RES-REV MUTAT, V436, P11, DOI 10.1016/S1383-5742(98)00024-6
   Hill KA, 2004, ENVIRON MOL MUTAGEN, V43, P110, DOI 10.1002/em.20004
   Hill KA, 1999, MUTAT RES-FUND MOL M, V425, P47, DOI 10.1016/S0027-5107(98)00248-6
   *IARC, 1983, POL AR COMP 1
   Jansen J, 2001, NUCLEIC ACIDS RES, V29, P1791, DOI 10.1093/nar/29.8.1791
   KADLUBAR FF, 1980, CHEM-BIOL INTERACT, V31, P255, DOI 10.1016/0009-2797(80)90014-9
   KOHLER SW, 1991, P NATL ACAD SCI USA, V88, P7958, DOI 10.1073/pnas.88.18.7958
   Landrigan PJ, 2011, MT SINAI J MED, V78, P1, DOI 10.1002/msj.20236
   Landrigan PJ, 2004, ENVIRON HEALTH PERSP, V112, P731, DOI 10.1289/ehp.6702
   Landrigan PJ, 2004, ENVIRON HEALTH PERSP, V112, P257, DOI 10.1289/ehp.6115
   Leavitt SA, 2008, MUTAGENESIS, V23, P445, DOI 10.1093/mutage/gen033
   Lioy PJ, 2002, ENVIRON HEALTH PERSP, V110, P703, DOI 10.1289/ehp.02110703
   MACKENZIE KM, 1981, BIOL REPROD, V24, P183, DOI 10.1095/biolreprod24.1.183
   Marchetti F, 2011, P NATL ACAD SCI USA, V108, P12811, DOI 10.1073/pnas.1106896108
   McCullagh P., 1989, GEN STAT MODELS
   Mohamed ESA, 2010, HUM REPROD, V25, P2427, DOI 10.1093/humrep/deq205
   Nishino H, 1996, ENVIRON MOL MUTAGEN, V28, P299
   OAKBERG EF, 1956, AM J ANAT, V99, P507, DOI 10.1002/aja.1000990307
   Oh SM, 2009, ENVIRON TOXICOL, V24, P225, DOI 10.1002/tox.20422
   Olivo-Marston SE, 2009, CANCER EPIDEM BIOMAR, V18, P3375, DOI 10.1158/1055-9965.EPI-09-0986
   Olsen AK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011349
   PANIAGUA R, 1984, J ANAT, V139, P535
   PINEAU C, 1991, CELL TISSUE RES, V264, P589, DOI 10.1007/BF00319048
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   RUSSELL LD, 1985, INT REV CYTOL, V94, P177, DOI 10.1016/S0074-7696(08)60397-6
   RUSSELL LD, 1977, ANAT RECORD, V187, P347, DOI 10.1002/ar.1091870307
   RUSSELL LD, 1989, AM J ANAT, V184, P179, DOI 10.1002/aja.1001840302
   Shane BS, 2000, CARCINOGENESIS, V21, P715, DOI 10.1093/carcin/21.4.715
   Somers CM, 2004, SCIENCE, V304, P1008, DOI 10.1126/science.1095815
   Somers CM, 2002, P NATL ACAD SCI USA, V99, P15904, DOI 10.1073/pnas.252499499
   Svanes C, 2004, THORAX, V59, P295, DOI 10.1136/thx.2003.009746
   Verhofstad N, 2011, TOXICOL SCI, V119, P218, DOI 10.1093/toxsci/kfq325
   Verhofstad N, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-333
   Verhofstad N, 2010, ENVIRON MOL MUTAGEN, V51, P123, DOI 10.1002/em.20516
   Walter CA, 2004, DNA REPAIR, V3, P495, DOI 10.1016/j.dnarep.2004.01.005
   Walter CA, 1998, P NATL ACAD SCI USA, V95, P10015, DOI 10.1073/pnas.95.17.10015
   Wei QY, 2000, J NATL CANCER I, V92, P1764
   Whitlock JP, 1999, ANNU REV PHARMACOL, V39, P103, DOI 10.1146/annurev.pharmtox.39.1.103
   Wijker CA, 1996, MUTAT RES-FUND MOL M, V349, P229, DOI 10.1016/0027-5107(95)00187-5
   Wild CP, 2003, CANCER EPIDEM BIOMAR, V12, P1389
   Wu X, 2009, P NATL ACAD SCI USA, V106, P21672, DOI 10.1073/pnas.0912432106
   Xu GG, 2005, BIOL REPROD, V73, P123, DOI 10.1095/biolreprod.104.039123
   Xu GG, 2008, MUTAT RES-GEN TOX EN, V654, P150, DOI 10.1016/j.mrgentox.2008.05.012
   Yauk CL, 1996, P NATL ACAD SCI USA, V93, P12137, DOI 10.1073/pnas.93.22.12137
   Yun KU, 2010, ARCH TOXICOL, V84, P939, DOI 10.1007/s00204-010-0520-1
   Zenzes MT, 1999, FERTIL STERIL, V72, P330, DOI 10.1016/S0015-0282(99)00230-7
   2008, MMWR MORB MORTAL WKL, V57, P744
NR 69
TC 6
Z9 6
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 29
PY 2014
VL 9
IS 1
AR e87439
DI 10.1371/journal.pone.0087439
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 301ZC
UT WOS:000330570000145
PM 24489914
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Chen, Z
   Tao, ZZ
   Chen, SM
   Chen, C
   Li, F
   Xiao, BK
AF Chen, Zhe
   Tao, Ze-Zhang
   Chen, Shi-Ming
   Chen, Chen
   Li, Fen
   Xiao, Bo-kui
TI Indole-3-Carbinol Inhibits Nasopharyngeal Carcinoma Growth through Cell
   Cycle Arrest In Vivo and In Vitro
SO PLOS ONE
LA English
DT Article
ID PROSTATE-CANCER CELLS; ACID CONDENSATION PRODUCTS; FACTOR-KAPPA-B;
   INDUCE APOPTOSIS; DOWN-REGULATION; EXPRESSION; PATHWAY;
   3,3'-DIINDOLYLMETHANE; PHARMACOKINETICS; PROLIFERATION
AB Nasopharyngeal carcinoma is a common malignant tumor in the head and neck. Because of frequent recurrence and distant metastasis which are the main causes of death, better treatment is needed. Indole-3-carbinol (I3C), a natural phytochemical found in the vegetables of the cruciferous family, shows anticancer effect through various signal pathways. I3C induces G1 arrest in NPC cell line with downregulation of cell cycle-related proteins, such as CDK4, CDK6, cyclin D1 and pRb. In vivo, nude mice receiving I3C protectively or therapeutically exhibited smaller tumors than control group after they were inoculated with nasopharyngeal carcinoma cells. The expression of CDK4, CDK6, cyclin D1 and pRb in preventive treatment group and drug treatment group both decreased compared with the control group. We conclude that I3C can inhibit the growth of NPC in vitro and in vivo by suppressing the expression of CDK and cyclin families. The drug was safe and had no toxic effects on normal tissues and organs.
C1 [Chen, Zhe; Tao, Ze-Zhang; Chen, Shi-Ming; Chen, Chen; Li, Fen; Xiao, Bo-kui] Wuhan Univ, Renmin Hosp, Dept Otolaryngol Head & Neck Surg, Wuhan 430072, Peoples R China.
RP Tao, ZZ (reprint author), Wuhan Univ, Renmin Hosp, Dept Otolaryngol Head & Neck Surg, Wuhan 430072, Peoples R China.
EM taozezhang@hotmail.com
OI Chen, Shi-Ming/0000-0002-1216-004X
FU Fundamental Research Funds for the Central Universities
   [201130202020009]
FX This study supported by the Fundamental Research Funds for the Central
   Universities 201130202020009. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Aggarwal BB, 2005, CELL CYCLE, V4, P1201, DOI 10.4161/cc.4.9.1993
   Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003
   Anderton MJ, 2004, CLIN CANCER RES, V10, P5233, DOI 10.1158/1078-0432.CCR-04-0163
   Anderton MJ, 2003, J CHROMATOGR B, V787, P281, DOI 10.1016/S1570-0232(02)00923-6
   Chan ATC, 2010, ANN ONCOL, V21, P308, DOI 10.1093/annonc/mdq277
   Chen DZ, 2001, J NUTR, V131, P3294
   Chinni SR, 2001, ONCOGENE, V20, P2927, DOI 10.1038/sj.onc.1204365
   Choi HS, 2010, FOOD CHEM TOXICOL, V48, P883, DOI 10.1016/j.fct.2009.12.028
   GROSE KR, 1992, CHEM RES TOXICOL, V5, P188, DOI 10.1021/tx00026a007
   Han JB, 2011, CANCER LETT, V309, P162, DOI 10.1016/j.canlet.2011.05.028
   HIRAMA T, 1995, BLOOD, V86, P841
   Hsu JC, 2006, BIOCHEM PHARMACOL, V72, P1714, DOI 10.1016/j.bcp.2006.08.012
   Kim DS, 2006, CELL MOL LIFE SCI, V63, P2661, DOI 10.1007/s00018-006-6306-1
   Lee AWM, 2005, INT J RADIAT ONCOL, V61, P1107, DOI 10.1016/j.ijrobp.2004.07.702
   Liu DB, 2012, ACTA PHARMACOL SIN, V33, P682, DOI 10.1038/aps.2012.18
   Ma BBY, 2005, CANCER-AM CANCER SOC, V103, P22, DOI 10.1002/cncr.20768
   Marconett CN, 2011, CARCINOGENESIS, V32, P1315, DOI 10.1093/carcin/bgr116
   Moiseeva EP, 2006, APOPTOSIS, V11, P799, DOI 10.1007/s10495-006-5877-5
   Nachshon-Kedmi M, 2003, FOOD CHEM TOXICOL, V41, P745, DOI 10.1016/S0278-6915(03)00004-8
   Ong CS, 2010, CANCER LETT, V298, P167, DOI 10.1016/j.canlet.2010.07.001
   Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4
   Paggi MG, 1996, J CELL BIOCHEM, V62, P418
   Ping J, 2011, J PHARMACOL EXP THER, V339, P694, DOI 10.1124/jpet.111.179820
   Ping J, 2011, EUR J PHARMACOL, V650, P656, DOI 10.1016/j.ejphar.2010.10.057
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Reed GA, 2005, CANCER EPIDEM BIOMAR, V14, P1953, DOI 10.1158/1055-9965.EPI-05-0121
   Reed GA, 2006, CANCER EPIDEM BIOMAR, V15, P2477, DOI 10.1158/1055-9655.EPI-06-0396
   SHAM JST, 1990, BRIT J RADIOL, V63, P108, DOI 10.1259/0007-1285-63-746-108
   SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2
   Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672
   Takada Y, 2005, BLOOD, V106, P641, DOI 10.1182/blood-2004-12-4589
   Teo PML, 1996, CANCER-AM CANCER SOC, V77, P2423, DOI 10.1002/(SICI)1097-0142(19960615)77:12<2423::AID-CNCR2>3.0.CO;2-N
   Wang Y, 2008, CANCER BIOL THER, V7, P896, DOI 10.4161/cbt.7.6.5910
   Weng JR, 2007, CANCER RES, V67, P7815, DOI 10.1158/0008-5472.CAN-07-0794
   Wu AB, 2013, CANCER LETT, V330, P181, DOI 10.1016/j.canlet.2012.11.046
   Wu HT, 2005, J AGR FOOD CHEM, V53, P5164, DOI 10.1021/jf050034w
   Xie Y, 2013, ORAL ONCOL
   Xu Y, 2011, MED ONCOL, V28, P1343, DOI 10.1007/s12032-010-9619-8
   Yang YX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062869
   Ye M, 2007, CANCER LETT, V258, P199, DOI 10.1016/j.canlet.2007.09.001
   Zhang J, 2003, CANCER-AM CANCER SOC, V98, P2511, DOI 10.1002/cncr.11844
   Zhang WL, 2009, ACTA BIOCH BIOPH SIN, V41, P414, DOI 10.1093/abbs/gmp025
   Zhao P, 2013, CHEM-BIOL INTERACT, V205, P81, DOI 10.1016/j.cbi.2013.06.014
   Zhu W, 2010, INT J TOXICOL, V29, P185, DOI 10.1177/1091581809356481
   Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97
NR 45
TC 13
Z9 13
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 16
PY 2013
VL 8
IS 12
AR e82288
DI 10.1371/journal.pone.0082288
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 276GD
UT WOS:000328735700054
PM 24358165
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Zhou, R
   Yang, ZL
   Tang, XR
   Tan, Y
   Wu, XF
   Liu, F
AF Zhou, Rong
   Yang, Zailiang
   Tang, Xurong
   Tan, Yan
   Wu, Xiaofeng
   Liu, Feng
TI Propofol Protects Against Focal Cerebral Ischemia via Inhibition of
   Microglia-Mediated Proinflammatory Cytokines in a Rat Model of
   Experimental Stroke
SO PLOS ONE
LA English
DT Article
ID INFLAMMATORY RESPONSE; BRAIN-INJURY; CELLS; ACTIVATION; NEUROPROTECTION;
   ISCHEMIA/REPERFUSION; NEURODEGENERATION; PROLIFERATION; INTERLEUKIN-1;
   TRANSLATION
AB Ischemic stroke induces microglial activation and release of proinflammatory cytokines, contributing to the expansion of brain injury and poor clinical outcome. Propofol has been shown to ameliorate neuronal injury in a number of experimental studies, but the precise mechanisms involved in its neuroprotective effects remain unclear. We tested the hypothesis that propofol confers neuroprotection against focal ischemia by inhibiting microglia-mediated inflammatory response in a rat model of ischemic stroke. Sprague-Dawley rats were subjected to middle cerebral artery occlusion (MCAO) for 2 h followed by 24 h of reperfusion. Propofol (50 mg/kg/h) or vehicle was infused intravenously at the onset of reperfusion for 30 minutes. In vehicle-treated rats, MCAO resulted in significant cerebral infarction, higher neurological deficit scores and decreased time on the rotarod compared with sham-operated rats. Propofol treatment reduced infarct volume and improved the neurological functions. In addition, molecular studies demonstrated that mRNA expression of microglial marker Cd68 and Emr1 was significantly increased, and mRNA and protein expressions of proinflammatory cytokines tumor necrosis factor-alpha, interleukin-1 beta and interleukin-6 were augmented in the peri-infarct cortical regions of vehicle-treated rats 24 h after MCAO. Immunohistochemical study revealed that number of total microglia and proportion of activated microglia in the peri-infarct cortical regions were markedly elevated. All of these findings were ameliorated in propofol-treated rats. Furthermore, vehicle-treated rats had higher plasma levels of interleukin-6 and C-reactive protein 24 h after MCAO, which were decreased after treatment with propofol. These results suggest that propofol protects against focal cerebral ischemia via inhibition of microglia-mediated proinflammatory cytokines. Propofol may be a promising therapeutic agent for the treatment of ischemic stroke and other neurodegenerative diseases associated with microglial activation.
C1 [Zhou, Rong; Tang, Xurong] Chongqing Med Univ, Childrens Hosp, Dept Operating Room, Chongqing, Peoples R China.
   [Zhou, Rong; Liu, Feng] Chongqing Med Univ, Childrens Hosp, Key Lab Child Dev & Disorders, Minist Educ, Chongqing, Peoples R China.
   [Yang, Zailiang] Acad Mil Med Sci, Affiliated Hosp, Hematopoiet Stem Cell Transplantat & Gene Therapy, Beijing, Peoples R China.
   [Yang, Zailiang] Third Mil Med Univ, Daping Hosp, State Key Lab Trauma Burn & Combined Injury, Chongqing, Peoples R China.
   [Yang, Zailiang; Tan, Yan; Wu, Xiaofeng] Third Mil Med Univ, Daping Hosp, Inst Surg Res, Chongqing, Peoples R China.
   [Liu, Feng] Chongqing Med Univ, Childrens Hosp, Dept Anesthesiol, Chongqing, Peoples R China.
RP Liu, F (reprint author), Chongqing Med Univ, Childrens Hosp, Key Lab Child Dev & Disorders, Minist Educ, Chongqing, Peoples R China.
EM liuf-cmu@hotmail.com
FU Chongqing Medical University Research Foundation
FX The work was supported by Chongqing Medical University Research
   Foundation. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR An K, 2008, ANAESTHESIA, V63, P1187, DOI 10.1111/j.1365-2044.2008.05627.x
   Arrick DM, 2012, J APPL PHYSIOL, V113, P1121, DOI 10.1152/japplphysiol.00437.2012
   BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117
   Barone FC, 1997, STROKE, V28, P1233, DOI 10.1161/01.STR.28.6.1233
   Barreto George, 2011, Central Nervous System Agents in Medicinal Chemistry, V11, P164
   Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004
   Chen HI, 2008, CRIT CARE MED, V36, P1214, DOI 10.1097/CCM.0b013e31816a0607
   Chen YL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040165
   Corcoran TB, 2004, J CARDIOTHOR VASC AN, V18, P592, DOI 10.1053/j.jvca.2004.07.018
   DiNapoli VA, 2010, NEUROSCIENCE, V170, P633, DOI 10.1016/j.neuroscience.2010.07.011
   Dinarello CA, 2000, CHEST, V118, P503, DOI 10.1378/chest.118.2.503
   Donnan GA, 2008, LANCET, V371, P1612, DOI 10.1016/S0140-6736(08)60694-7
   Emsley HCA, 2003, J NEUROIMMUNOL, V139, P93, DOI 10.1016/S0165-5728(03)00134-6
   Ferrarese C, 1999, J CEREBR BLOOD F MET, V19, P1004, DOI 10.1097/00004647-199909000-00008
   Gui B, 2012, INFLAMMATION, V35, P1632, DOI 10.1007/s10753-012-9478-x
   Jin R, 2010, J LEUKOCYTE BIOL, V87, P779, DOI 10.1189/jlb.1109766
   Li DL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073334
   Liang C, 2013, J NEUROSURG ANESTH, V25, P311, DOI 10.1097/ANA.0b013e31828c6af5
   LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84
   Marik PE, 2005, PHARMACOTHERAPY, V25, P28, DOI DOI 10.1592/PHC0.2005.25.5_
   Mizoguchi K, 2002, PHARMACOL BIOCHEM BE, V71, P79, DOI 10.1016/S0091-3057(01)00636-0
   Patzer A, 2008, EUR J NEUROSCI, V28, P1786, DOI 10.1111/j.1460-9568.2008.06478.x
   Rana I, 2010, BRAIN RES, V1326, P96, DOI 10.1016/j.brainres.2010.02.028
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Rothwell N, 1997, J CLIN INVEST, V100, P2648, DOI 10.1172/JCI119808
   Schellinger PD, 2004, CURR OPIN NEUROL, V17, P69, DOI 10.1097/01.wco.0000113941.12823.3b
   Smith CJ, 2013, J NEUROIMMUNE PHARM, V8, P867, DOI 10.1007/s11481-013-9469-1
   Stolp HB, 2009, NEUROPATH APPL NEURO, V35, P132, DOI 10.1111/j.1365-2990.2008.01005.x
   Taniguchi T, 2000, CRIT CARE MED, V28, P1101, DOI 10.1097/00003246-200004000-00032
   Taniguchi T, 2002, CRIT CARE MED, V30, P904, DOI 10.1097/00003246-200204000-00032
   Tikka T, 2001, J NEUROSCI, V21, P2580, DOI 10.1523/JNEUROSCI.21-08-02580.2001
   Vila N, 2000, STROKE, V31, P2325, DOI 10.1161/01.STR.31.10.2325
   Wang HY, 2011, J NEUROCHEM, V119, P210, DOI 10.1111/j.1471-4159.2011.07400.x
   Wang XK, 2005, EXPERT OPIN INV DRUG, V14, P393, DOI 10.1517/13543784.14.4.393
   Wang YY, 2013, MOL CELL ENDOCRINOL, V367, P50, DOI 10.1016/j.mce.2012.12.016
   Wei ZL, 2011, STROKE, V42, P2589, DOI 10.1161/STROKEAHA.111.614834
   YAMASAKI Y, 1995, STROKE, V26, P676, DOI 10.1161/01.STR.26.4.676
   Yang SC, 2013, J IMMUNOL, V190, P6511, DOI 10.4049/jimmunol.1202215
   Ye XF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052887
   Yilmaz G, 2008, NEUROL RES, V30, P783, DOI 10.1179/174313208X341085
   Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769
   Yu GX, 2011, SURGERY, V150, P887, DOI 10.1016/j.surg.2011.04.002
   Zhao XC, 2013, NEUROCHEM RES, V38, P530, DOI 10.1007/s11064-012-0945-4
   Zhao Y, 2005, EUR J NEUROSCI, V22, P278, DOI 10.1111/j.1460-9568.2005.04200.x
   Zhou HT, 2012, MOL MED REP, V5, P842, DOI 10.3892/mmr.2011.719
NR 45
TC 34
Z9 39
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 9
PY 2013
VL 8
IS 12
AR e82729
DI 10.1371/journal.pone.0082729
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 275VD
UT WOS:000328705200095
PM 24349350
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Micucci, M
   Aldini, R
   Cevenini, M
   Colliva, C
   Spinozzi, S
   Roda, G
   Montagnani, M
   Camborata, C
   Camarda, L
   Chiarini, A
   Mazzella, G
   Budriesi, R
AF Micucci, Matteo
   Aldini, Rita
   Cevenini, Monica
   Colliva, Carolina
   Spinozzi, Silvia
   Roda, Giulia
   Montagnani, Marco
   Camborata, Cecilia
   Camarda, Luca
   Chiarini, Alberto
   Mazzella, Giuseppe
   Budriesi, Roberta
TI Curcuma longa L. as a Therapeutic Agent in Intestinal Motility
   Disorders. 2: Safety Profile in Mouse
SO PLOS ONE
LA English
DT Article
ID IRRITABLE-BOWEL-SYNDROME; SALT EXPORT PUMP; INDUCED CHOLESTASIS;
   INHIBITION; ACTIVATION; SUPPRESSION; METABOLISM; EXPRESSION; SEROTONIN;
   APOPTOSIS
AB Background: Curcuma extract exerts a myorelaxant effect on the mouse intestine. In view of a possible use of curcuma extract in motor functional disorders of the gastrointestinal tract, a safety profile study has been carried out in the mouse.
   Methods: Thirty mice were used to study the in vitro effect of curcuma on gallbladder, bladder, aorta and trachea smooth muscular layers and hearth inotropic and chronotropic activity. The myorelaxant effect on the intestine was also thoroughly investigated. Moreover, curcuma extract (200 mg/Kg/day) was orally administered to twenty mice over 28 days and serum liver and lipids parameters were evaluated. Serum, bile and liver bile acids qualitative and quantitative composition was were also studied.
   Results: In the intestine, curcuma extract appeared as a not competitive inhibitor through cholinergic, histaminergic and serotoninergic receptors and showed spasmolytic effect on K+ induced contraction at the level of L type calcium channels. No side effect was observed on bladder, aorta, trachea and heart when we used a dose that is effective on the intestine. An increase in gallbladder tone and contraction was observed. Serum liver and lipids parameters were normal, while a slight increase in serum and liver bile acids concentration and a decrease in bile were observed.
   Conclusions: Although these data are consistent with the safety of curcuma extract as far as its effect on the smooth muscular layers of different organs and on the heart, the mild cholestatic effect observed in absence of alteration of liver function tests must be further evaluated and the effective dose with minimal side effects considered.
C1 [Micucci, Matteo; Aldini, Rita; Camarda, Luca; Chiarini, Alberto; Budriesi, Roberta] Univ Bologna, Dipartimento Farm & Biotecnol, Bologna, Italy.
   [Cevenini, Monica; Roda, Giulia; Montagnani, Marco; Mazzella, Giuseppe] Univ Bologna, Dipartimento Sci Med & Chirurg, Bologna, Italy.
   [Colliva, Carolina; Spinozzi, Silvia; Camborata, Cecilia] Univ Bologna, Dipartimento Chim G Ciamician, I-40126 Bologna, Italy.
RP Aldini, R (reprint author), Univ Bologna, Dipartimento Farm & Biotecnol, Bologna, Italy.
EM rita.aldini@unibo.it; roberta.budriesi@unibo.it
OI MONTAGNANI, MARCO/0000-0003-0103-0327; Mazzella,
   Giuseppe/0000-0001-8656-8112
FU Fondazione del Monte di Bologna e Ravenna; Alisal [Mazz100136-2010];
   MINISTERO DELLE POLITICHE AGRICOLE, ALIMENTARI E FORESTALI
   [11008/7303/10]
FX This work was supported by grants from Fondazione del Monte di Bologna e
   Ravenna and from Alisal (Mazz100136-2010). ALISAL is a project supported
   by the MINISTERO DELLE POLITICHE AGRICOLE, ALIMENTARI E FORESTALI, with
   D. M. 11008/7303/10, dated 17/05/2010. The title of the project is:
   Miglioramento delle proprieta igienico-sanitarie, salutistiche e
   funzionali di commodity per l'alimentazione dell'uomo e/o degli animali
   (Improvement of sanitary properties, healthy and functional food
   commodities for human and/or animals). Prof. GM was supported with
   materials, reagents, animals. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR AHMED T, 2008, PHARM BIOCH BEHAV, V91, P554
   Anand P, 2007, MOL PHARMACEUT, V4, P807, DOI 10.1021/mp700113r
   Balestra B, 2012, NEUROGASTROENT MOTIL, V24, P1118, DOI 10.1111/nmo.12000
   BHAVANISHANKAR TN, 1980, INDIAN J EXP BIOL, V18, P73
   Budriesi R, 2011, J MED CHEM, V54, P3885, DOI 10.1021/jm200199r
   Budriesi R, 2010, J MED FOOD, V13, P1104, DOI 10.1089/jmf.2009.0210
   Carosati E, 2006, J MED CHEM, V49, P5206, DOI 10.1021/jm0604373
   Chainani-Wu N, 2003, J ALTERN COMPLEM MED, V9, P161, DOI 10.1089/107555303321223035
   Cremon C, 2011, AM J GASTROENTEROL, V106, P1290, DOI 10.1038/ajg.2011.86
   Cuomo J, 2011, J NAT PROD, V74, P664, DOI 10.1021/np1007262
   De Ponti F, 2004, GUT, V53, P1520, DOI 10.1136/gut.2003.035568
   De Ponti F, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00007
   Deters M, 2003, PLANTA MED, V69, P337, DOI 10.1055/s-2003-38870
   Elguero J, 2009, BIOORGAN MED CHEM, V17, P8027, DOI 10.1016/j.bmc.2009.10.006
   Ervin CM, 2013, REV RECENT CLIN TRIA, V8, P9, DOI 10.2174/1574887111308010003
   Fan X, 2013, CURR PHARM DESIGN, V19, P2011
   Gerloff T, 1998, J BIOL CHEM, V273, P10046, DOI 10.1074/jbc.273.16.10046
   Gupta SC, 2013, AAPS J, V15, P195, DOI 10.1208/s12248-012-9432-8
   Hanai H, 2006, CLIN GASTROENTEROL H, V4, P1502, DOI 10.1016/j.cgh.2006.08.008
   HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292
   Hurley LL, 2013, BEHAV BRAIN RES, V239, P27, DOI 10.1016/j.bbr.2012.10.049
   ITTHIPANICHPONG C, 2003, J MED ASS THAI S2, V86, pS2999
   Jitoe-Masuda A, 2013, CURR PHARM DESIGN, V19, P2084
   Kaur CD, 2011, J COSMET DERMATOL-US, V10, P260, DOI 10.1111/j.1473-2165.2011.00586.x
   Khaw AK, 2013, J CELL BIOCHEM, V114, P1257, DOI 10.1002/jcb.24466
   Kim Darrick S H L, 2012, Recent Pat CNS Drug Discov, V7, P184
   Kurapati Kesava Rao V., 2012, Journal of Basic and Clinical Physiology and Pharmacology, V23, P139, DOI 10.1515/jbcpp-2012-0021
   Lao Christopher D, 2006, BMC Complement Altern Med, V6, P10, DOI 10.1186/1472-6882-6-10
   Lee JH, 2012, BIOL PHARM BULL, V35, P777, DOI 10.1248/bpb.35.777
   Leray V, 2011, BRIT J NUTR, V106, pS198, DOI 10.1017/S0007114511002492
   Liju VB, 2013, FOOD CHEM TOXICOL, V53, P52, DOI 10.1016/j.fct.2012.11.027
   Luo CF, 2011, INT J PHARMACEUT, V410, P138, DOI 10.1016/j.ijpharm.2011.02.064
   Madkor HR, 2011, BRIT J NUTR, V105, P1210, DOI 10.1017/S0007114510004927
   Marzio L, 2003, DIGEST LIVER DIS, V35, pS17, DOI 10.1016/S1590-8658(03)00088-4
   Orellana-Paucar AM, 2012, EPILEPSY BEHAV, V24, P14, DOI 10.1016/j.yebeh.2012.02.020
   Motulsky H., 2003, FITTING MODELS BIOL
   Moynihan R, 2002, BRIT MED J, V325, P592, DOI 10.1136/bmj.325.7364.592
   Negi PS, 1999, J AGR FOOD CHEM, V47, P4297, DOI 10.1021/jf990308d
   Noorafshan A, 2013, CURR PHARM DESIGN, V19, P2032
   Pan MH, 1999, DRUG METAB DISPOS, V27, P486
   Qin XY, 2012, NEUROSCI BULL, V28, P606, DOI 10.1007/s12264-012-1275-x
   Rahimi R, 2012, WORLD J GASTROENTERO, V18, P589, DOI 10.3748/wjg.v18.i7.589
   Rasyid A, 1999, ALIMENT PHARM THERAP, V13, P245
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Reuland DJ, 2013, FREE RADICAL BIO MED, V56, P102, DOI 10.1016/j.freeradbiomed.2012.11.016
   RODA A, 1995, J CHROMATOGR B, V665, P281, DOI 10.1016/0378-4347(94)00544-F
   Saelee C, 2011, MOLECULES, V16, P3908, DOI 10.3390/molecules16053908
   SAHEBKAR A, 2012, BIOFACTORS, V39, DOI DOI 10.1002/BI0F.1062.PUBMED:23239418
   Sharma RA, 2007, ADV EXP MED BIOL, V595, P453
   Singh AK, 1996, CANCER LETT, V107, P109, DOI 10.1016/0304-3835(96)04357-1
   *SOFTW INC, VERS 3 0 GRAPHPAD
   STIEGER B, 1992, BIOCHEM J, V284, P67, DOI 10.1042/bj2840067
   STIEGER B, 1994, GASTROENTEROLOGY, V107, P1781, DOI 10.1016/0016-5085(94)90821-4
   Stieger B, 2000, GASTROENTEROLOGY, V118, P422, DOI 10.1016/S0016-5085(00)70224-1
   Su J, 2010, J ETHNOPHARMACOL, V130, P70, DOI 10.1016/j.jep.2010.04.012
   Sun XD, 2012, MOL MED REP, V6, P1267, DOI 10.3892/mmr.2012.1103
   Tallarida R., 1987, MANUAL PHARM CALCULA
   Trendle MC, 1997, CANCER, V79, P830, DOI 10.1002/(SICI)1097-0142(19970215)79:4<830::AID-CNCR20>3.0.CO;2-#
   Tsai YM, 2011, INT J PHARMACEUT, V416, P331, DOI 10.1016/j.ijpharm.2011.06.030
   Venneman NG, 2006, BEST PRACT RES CL GA, V20, P1063, DOI 10.1016/j.bpg.2006.03.008
   Wortelboer HM, 2003, CHEM RES TOXICOL, V16, P1642, DOI 10.1021/tx034101x
   Xia Q, 2012, THROMB RES, V130, P409, DOI 10.1016/j.thromres.2012.04.005
   Xu YX, 1997, EXP HEMATOL, V25, P413
   Zhao JF, 2012, MOL NUTR FOOD RES, V56, P691, DOI 10.1002/mnfr.201100735
NR 64
TC 4
Z9 4
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 18
PY 2013
VL 8
IS 11
AR UNSP e80925
DI 10.1371/journal.pone.0080925
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 256KH
UT WOS:000327308500183
PM 24260512
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Kim, SK
   Kim, H
   Lee, DH
   Kim, TS
   Kim, T
   Chung, C
   Koh, GY
   Kim, H
   Lim, DS
AF Kim, Sang Kyum
   Kim, Honsoul
   Lee, Da-hye
   Kim, Tae-shin
   Kim, Tackhoon
   Chung, Chaeuk
   Koh, Gou Young
   Kim, Hoguen
   Lim, Dae-Sik
TI Reversing the Intractable Nature of Pancreatic Cancer by Selectively
   Targeting ALDH-High, Therapy-Resistant Cancer Cells
SO PLOS ONE
LA English
DT Article
ID ALDEHYDE DEHYDROGENASE 1; TWICE-WEEKLY GEMCITABINE; PHASE-II TRIAL;
   STEM-CELLS; PROGENITOR CELLS; IN-VITRO; KAPPA-B; DISULFIRAM;
   CHEMOTHERAPY; CARCINOMA
AB Human pancreatic ductal adenocarcinoma (PDAC) is a cancer with a dismal prognosis. The efficacy of PDAC anticancer therapies is often short-lived; however, there is little information on how this disease entity so frequently gains resistance to treatment. We adopted the concept of cancer stem cells (CSCs) to explain the mechanism of resistance and evaluated the efficacy of a candidate anticancer drug to target these therapy-resistant CSCs. We identified a subpopulation of cells in PDAC with CSC features that were enriched for aldehyde dehydrogenase (ALDH), a marker expressed in certain stem/progenitor cells. These cells were also highly resistant to, and were further enriched by, treatment with gemcitabine. Similarly, surgical specimens from PDAC patients showed that those who had undergone preoperative chemo-radiation therapy more frequently displayed cancers with ALDH strongly positive subpopulations compared with untreated patients. Importantly, these ALDH-high cancer cells were sensitive to disulfiram, an ALDH inhibitor, when tested in vitro. Furthermore, in vivo xenograft studies showed that the effect of disulfiram was additive to that of low-dose gemcitabine when applied in combination. In conclusion, human PDAC-derived cells that express high levels of ALDH show CSC features and have a key role in the development of resistance to anticancer therapies. Disulfiram can be used to suppress this therapy-resistant subpopulation.
C1 [Kim, Sang Kyum; Chung, Chaeuk; Koh, Gou Young] South Korea Adv Inst Sci & Technol KAIST, Grad Sch Med Sci & Engn, Taejon, South Korea.
   [Kim, Honsoul] Yonsei Univ, Coll Med, Dept Radiol, Seoul, South Korea.
   [Lee, Da-hye; Kim, Tae-shin; Kim, Tackhoon; Lim, Dae-Sik] Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.
   [Kim, Hoguen] Yonsei Univ, Coll Med, Dept Pathol, Seoul, South Korea.
RP Kim, SK (reprint author), Yonsei Univ, Coll Med, Dept Pathol, Seoul, South Korea.
EM nicekyumi@kaist.ac.kr; daesiklim@kaist.ac.kr
RI Lim, Dae-Sik/C-1599-2011
OI Lim, Dae-Sik/0000-0003-2356-7555; Chung, Chaeuk/0000-0002-3978-0484;
   Kim, Sang Kyum/0000-0003-0768-9923
FU National Creative Research Initiatives Program [2010-001827]
FX This work was supported by grants from the National Creative Research
   Initiatives Program (2010-001827, http://www.nrf.re.kr). The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR BAKKEVOLD KE, 1993, EUR J CANCER, V29A, P698, DOI 10.1016/S0959-8049(05)80349-1
   Balber AE, 2011, STEM CELLS, V29, P570, DOI 10.1002/stem.613
   Blackstock AW, 1999, J CLIN ONCOL, V17, P2208, DOI 10.1200/JCO.1999.17.7.2208
   Brar SS, 2004, MOL CANCER THER, V3, P1049
   Chen D, 2006, CANCER RES, V66, P10425, DOI 10.1158/0008-5472.CAN-06-2126
   Cho HJ, 2007, J BIOCHEM MOL BIOL, V40, P1069
   Cvek B, 2007, CURR PHARM DESIGN, V13, P3155, DOI 10.2174/138161207782110390
   Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590
   Dorado J, 2011, STEM CELLS BIOL REG, P79, DOI 10.1007/978-1-61779-246-5_5
   Dylla SJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002428
   Edge SB, 2010, AJCC CANC STAGING MA
   ENEANYA DI, 1981, ANNU REV PHARMACOL, V21, P575, DOI 10.1146/annurev.pa.21.040181.003043
   Fuller RK, 2004, ADDICTION, V99, P21, DOI 10.1111/j.1360-0443.2004.00597.x
   GASSLANDER T, 1992, SCAND J GASTROENTERO, V27, P564, DOI 10.3109/00365529209000120
   Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014
   Girard N, 2010, INT J RADIAT ONCOL, V77, P1426, DOI 10.1016/j.ijrobp.2009.06.053
   GORDON MY, 1985, LEUKEMIA RES, V9, P1017, DOI 10.1016/0145-2126(85)90072-4
   Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002
   Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557
   Huang EH, 2009, CANCER RES, V69, P3382, DOI 10.1158/0008-5472.CAN-08-4418
   Jiang F, 2009, MOL CANCER RES, V7, P330, DOI 10.1158/1541-7786.MCR-08-0393
   Jimeno A, 2009, MOL CANCER THER, V8, P310, DOI 10.1158/1535-7163.MCT-08-0924
   JOHANSSON B, 1992, ACTA PSYCHIAT SCAND, V86, P15, DOI 10.1111/j.1600-0447.1992.tb03310.x
   Kim MP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020636
   Klinkenbijl JH, 1999, ANN SURG, V230, P776, DOI 10.1097/00000658-199912000-00006
   Li T, 2010, LAB INVEST, V90, P234, DOI 10.1038/labinvest.2009.127
   Maeda S, 2007, BRIT J CANCER, V97, P405, DOI 10.1038/sj.bjc.6603879
   Magnino A, 2005, ONCOLOGY-BASEL, V68, P493, DOI 10.1159/000086993
   Mishra G, 2005, AM J CLIN ONCOL-CANC, V28, P345, DOI 10.1097/01.coc.0000159559.42311.c5
   Moreb JS, 1995, LEUKEMIA LYMPHOMA, V20, P77, DOI 10.3109/10428199509054756
   Nagasao J, 2003, ANN ANAT, V185, P211, DOI 10.1016/S0940-9602(03)80025-0
   Neoptolemos JP, 2004, NEW ENGL J MED, V350, P1200, DOI 10.1056/NEJMoa032295
   Pozza ED, 2011, FREE RADICAL BIO MED, V50, P926, DOI 10.1016/j.freeradbiomed.2011.01.001
   RAINEY JM, 1977, AM J PSYCHIAT, V134, P371
   Rasheed ZA, 2010, JNCI-J NATL CANCER I, V102, P340, DOI 10.1093/jnci/djp535
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Rovira M, 2010, P NATL ACAD SCI USA, V107, P75, DOI 10.1073/pnas.0912589107
   SAHOVIC EA, 1988, CANCER RES, V48, P1223
   SAIF MW, 2011, JOP, V20, P12
   Sauna ZE, 2004, MOL PHARMACOL, V65, P675, DOI 10.1124/mol.65.3.675
   Shankar S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016530
   Singh B, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-82
   Smeenk HG, 2007, ANN SURG, V246, P734, DOI 10.1097/SLA.0b013e318156eef3
   Strobel O, 2007, GASTROENTEROLOGY, V133, P1999, DOI 10.1053/j.gastro.2007.09.009
   Takada T, 2002, CANCER, V95, P1685, DOI 10.1002/cncr.10831
   Wang F, 2011, CANCER LETT, V300, P87, DOI 10.1016/j.canlet.2010.09.010
   Wang WG, 2003, INT J CANCER, V104, P504, DOI 10.1002/ijc.10972
   Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153
   Yao J, 2010, ONCOL REP, V23, P1375, DOI 10.3892/or_00000774
NR 49
TC 26
Z9 27
U1 0
U2 17
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 23
PY 2013
VL 8
IS 10
AR UNSP e78130
DI 10.1371/journal.pone.0078130
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 239PE
UT WOS:000326037000087
PM 24194908
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Huehnchen, P
   Boehmerle, W
   Endres, M
AF Huehnchen, Petra
   Boehmerle, Wolfgang
   Endres, Matthias
TI Assessment of Paclitaxel Induced Sensory Polyneuropathy with "Catwalk"
   Automated Gait Analysis in Mice
SO PLOS ONE
LA English
DT Article
ID CHANNEL ALPHA(2)DELTA-1 SUBUNIT; PAINFUL PERIPHERAL NEUROPATHY;
   SCIATIC-NERVE INJURY; MECHANICAL ALLODYNIA; UP-REGULATION; RAT; MODELS;
   GABAPENTIN; EXPRESSION; NOCICEPTION
AB Neuropathic pain as a symptom of sensory nerve damage is a frequent side effect of chemotherapy. The most common behavioral observation in animal models of chemotherapy induced polyneuropathy is the development of mechanical allodynia, which is quantified with von Frey filaments. The data from one study, however, cannot be easily compared with other studies owing to influences of environmental factors, inter-rater variability and differences in test paradigms. To overcome these limitations, automated quantitative gait analysis was proposed as an alternative, but its usefulness for assessing animals suffering from polyneuropathy has remained unclear. In the present study, we used a novel mouse model of paclitaxel induced polyneuropathy to compare results from electrophysiology and the von Frey method to gait alterations measured with the Catwalk test. To mimic recently improved clinical treatment strategies of gynecological malignancies, we established a mouse model of dose-dense paclitaxel therapy on the common C57Bl/6 background. In this model paclitaxel treated animals developed mechanical allodynia as well as reduced caudal sensory nerve action potential amplitudes indicative of a sensory polyneuropathy. Gait analysis with the Catwalk method detected distinct alterations of gait parameters in animals suffering from sensory neuropathy, revealing a minimized contact of the hind paws with the floor. Treatment of mechanical allodynia with gabapentin improved altered dynamic gait parameters. This study establishes a novel mouse model for investigating the side effects of dose-dense paclitaxel therapy and underlines the usefulness of automated gait analysis as an additional easy-to-use objective test for evaluating painful sensory polyneuropathy.
C1 [Huehnchen, Petra; Boehmerle, Wolfgang; Endres, Matthias] Charite, Klin & Hsch Ambulanz Neurol, D-13353 Berlin, Germany.
   [Huehnchen, Petra; Boehmerle, Wolfgang; Endres, Matthias] Charite, Cluster Excellence NeuroCure, D-13353 Berlin, Germany.
   [Endres, Matthias] Charite, Ctr Stroke Res Berlin, D-13353 Berlin, Germany.
RP Boehmerle, W (reprint author), Charite, Klin & Hsch Ambulanz Neurol, D-13353 Berlin, Germany.
EM wolfgang.boehmerle@charite.de
OI Huehnchen, Petra/0000-0002-6825-7270; Boehmerle,
   Wolfgang/0000-0001-7195-3894
FU federal ministry of education and research via the grant center for
   stroke research Berlin [01 EO 0801]; Volkswagen foundation; Deutsche
   Forschungsgemeinschaft DFG (NeuroCure)
FX The research leading to these results has received funding for the
   procurement of equipment and consumables from the federal ministry of
   education and research via the grant center for stroke research Berlin
   (01 EO 0801), the Volkswagen foundation (Lichtenberg program to Matthias
   Endres), and Deutsche Forschungsgemeinschaft DFG (NeuroCure). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Ahmet A, 2006, INT J PEDIATR OTORHI, V70, P779, DOI 10.1016/j.ijporl.2005.11.011
   Authier N, 2009, NEUROTHERAPEUTICS, V6, P620, DOI 10.1016/j.nurt.2009.07.003
   Boroujerdi A, 2008, PAIN, V139, P358, DOI 10.1016/j.pain.2008.05.004
   Bozkurt A, 2008, J NEUROSCI METH, V173, P91, DOI 10.1016/j.jneumeth.2008.05.020
   Carozzi VA, 2010, EXP NEUROL, V226, P301, DOI 10.1016/j.expneurol.2010.09.004
   Cendelin J, 2010, BEHAV BRAIN RES, V210, P8, DOI 10.1016/j.bbr.2010.01.035
   CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9
   Cunha TM, 2004, BRAZ J MED BIOL RES, V37, P401, DOI 10.1590/S0100-879X2004000300018
   Deumens R, 2007, J NEUROSCI METH, V164, P120, DOI 10.1016/j.jneumeth.2007.04.009
   Ferland CE, 2011, PHARMACOL BIOCHEM BE, V97, P603, DOI 10.1016/j.pbb.2010.11.003
   Gabriel AF, 2007, J NEUROSCI METH, V163, P9, DOI 10.1016/j.jneumeth.2007.02.003
   Gauchan P, 2009, BIOL PHARM BULL, V32, P732, DOI 10.1248/bpb.32.732
   Hess V, 2003, ANN ONCOL, V14, P638, DOI 10.1093/annonc/mdg176
   Katsumata N, 2011, ANN ONCOL S8, V22
   Kim KJ, 1997, EXP BRAIN RES, V113, P200, DOI 10.1007/BF02450318
   Koopmans GC, 2007, PHYSIOL BEHAV, V92, P993, DOI 10.1016/j.physbeh.2007.07.018
   Leandri M, 2012, J NEUROSCI METH, V209, P403, DOI 10.1016/j.jneumeth.2012.07.005
   Lindenlaub T, 2000, BRAIN RES, V866, P15, DOI 10.1016/S0006-8993(00)02190-9
   Luo ZD, 2002, J PHARMACOL EXP THER, V303, P1199, DOI 10.1124/jpet.102.041574
   Luo ZD, 2001, J NEUROSCI, V21, P1868, DOI 10.1523/JNEUROSCI.21-06-01868.2001
   Matsumoto M, 2006, J PHARMACOL EXP THER, V318, P735, DOI 10.1124/jpet.106.103614
   Mo M, 2012, FASEB J
   Mogil JS, 2004, PAIN, V112, P12, DOI 10.1016/j.pain.2004.09.028
   Naujokat C, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/950658
   Newton RA, 2001, MOL BRAIN RES, V95, P1, DOI 10.1016/S0169-328X(01)00188-7
   OCHOA JL, 1994, CURR OPIN NEUROL, V7, P407, DOI 10.1097/00019052-199410000-00008
   Piesla MJ, 2009, BRAIN RES, V1295, P89, DOI 10.1016/j.brainres.2009.07.091
   Polomano RC, 2001, PAIN, V94, P293, DOI 10.1016/S0304-3959(01)00363-3
   Quasthoff S, 2002, J NEUROL, V249, P9, DOI 10.1007/PL00007853
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Sato J, 1999, NEUROSCI LETT, V266, P21, DOI 10.1016/S0304-3940(99)00260-8
   Scripture CD, 2006, CURR NEUROPHARMACOL, V4, P165, DOI 10.2174/157015906776359568
   Smith SB, 2004, LIFE SCI, V74, P2593, DOI 10.1016/j.lfs.2004.01.002
   Sparano JA, 2008, NEW ENGL J MED, V358, P1663, DOI 10.1056/NEJMoa0707056
   Vrinten DH, 2003, PAIN, V102, P203, DOI 10.1016/S0304-3959(02)00382-2
   Wang MS, 2002, ANN NEUROL, V52, P442, DOI 10.1002/ana.10300
   Wang MS, 2004, BRAIN, V127, P671, DOI 10.1093/brain/awh078
   Windebank AJ, 2008, J PERIPHER NERV SYST, V13, P27, DOI 10.1111/j.1529-8027.2008.00156.x
   Xiao W, 2007, NEUROSCIENCE, V144, P714, DOI 10.1016/j.neuroscience.2006.09.044
NR 39
TC 29
Z9 29
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 15
PY 2013
VL 8
IS 10
AR e76772
DI 10.1371/journal.pone.0076772
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 237TP
UT WOS:000325894100029
PM 24143194
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Sun, YH
   Dong, YL
   Wang, YT
   Zhao, GL
   Lu, GJ
   Yang, J
   Wu, SX
   Gu, ZX
   Wang, W
AF Sun, Yong-Hai
   Dong, Yu-Lin
   Wang, Yu-Tong
   Zhao, Guo-Li
   Lu, Gui-Jun
   Yang, Jing
   Wu, Sheng-Xi
   Gu, Ze-Xu
   Wang, Wen
TI Synergistic Analgesia of Duloxetine and Celecoxib in the Mouse Formalin
   Test: A Combination Analysis
SO PLOS ONE
LA English
DT Article
ID PERIPHERAL NEUROPATHIC PAIN; NORADRENERGIC REUPTAKE INHIBITOR; RATS
   INFRAORBITAL NERVE; INFLAMMATORY PAIN; ANTINOCICEPTIVE ACTIVITY;
   POSTOPERATIVE PAIN; OROFACIAL PAIN; MODULATION; MORPHINE; NEURONS
AB Duloxetine, a serotonin and noradrenaline reuptake inhibitor, and celecoxib, a non-steroidal anti-inflammatory drug, are commonly used analgesics for persistent pain, however with moderate gastrointestinal side effects or analgesia tolerance. One promising analgesic strategy is to give a combined prescription, allowing the maximal or equal efficacy with fewer side effects. In the current study, the efficacy and side effects of combined administration of duloxetine and celecoxib were tested in the mouse formalin pain model. The subcutaneous (s.c.) injection of formalin into the left hindpaw induced significant somatic and emotional pain evaluated by the biphasic spontaneous flinching of the injected hindpaw and interphase ultrasonic vocalizations (USVs) during the 1 h after formalin injection, respectively. Pretreatment with intraperitoneal (i.p.) injection of duloxetine or celecoxib at 1 h before formalin injection induced the dose-dependent inhibition on the second but not first phase pain responses. Combined administration of duloxetine and celecoxib showed significant analgesia for the second phase pain responses. Combination analgesia on the first phase was observed only with higher dose combination. A statistical difference between the theoretical and experimental ED50 for the second phase pain responses was observed, which indicated synergistic interaction of the two drugs. Concerning the emotional pain responses revealed with USVs, we assumed that the antinociceptive effects were almost completely derived from duloxetine, since celecoxib was ineffective when administered alone or reduced the dosage of duloxetine when given in combination. Based on the above findings, acute concomitant administration of duloxetine and celecoxib showed synergism on the somatic pain behavior but not emotional pain behaviors.
C1 [Sun, Yong-Hai; Zhao, Guo-Li; Lu, Gui-Jun; Yang, Jing] Chinese Peoples Liberat Army Gen Hosp, Anesthesia & Operat Ctr, Dept Anesthesiol, Beijing, Peoples R China.
   [Dong, Yu-Lin; Wu, Sheng-Xi; Wang, Wen] Fourth Mil Med Univ, Dept Anat Histol & Embryol, Preclin Sch Med, Xian 710032, Peoples R China.
   [Dong, Yu-Lin; Wu, Sheng-Xi; Wang, Wen] Fourth Mil Med Univ, KK Leung Brain Res Ctr, Preclin Sch Med, Xian 710032, Peoples R China.
   [Wang, Yu-Tong] Fourth Mil Med Univ, Dept Emergency, Xijing Hosp, Xian 710032, Peoples R China.
   [Gu, Ze-Xu] Fourth Mil Med Univ, Dept Orthodont, Sch Stomatol, Xian 710032, Peoples R China.
RP Gu, ZX (reprint author), Fourth Mil Med Univ, Dept Orthodont, Sch Stomatol, Xian 710032, Peoples R China.
EM guzexu@fmmu.edu.cn; wangwen@fmmu.edu.cn
FU Natural Science Foundation of China [81271230, 81171050, 81171052,
   30971123, 31010103909]; International Science & Technology Cooperation
   Program of China [2011DFA32560]; Program for Shaanxi Province Key
   Research Team of Science and Technology Innovation
FX The study was supported by grants from the Natural Science Foundation of
   China (Nos 81271230, 81171050, 81171052, 30971123 and 31010103909),
   International Science & Technology Cooperation Program of China
   (2011DFA32560) and Program for Shaanxi Province Key Research Team of
   Science and Technology Innovation. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR ABBOTT FV, 1984, BRAIN RES, V295, P77, DOI 10.1016/0006-8993(84)90817-5
   Bai L, 2012, PAIN PHYSICIAN, V15, P311
   Bajic D, 1999, J COMP NEUROL, V405, P359
   Bardin L, 2010, NEUROSCI RES, V66, P135, DOI 10.1016/j.neures.2009.10.009
   Bardin L, 2011, BEHAV PHARMACOL, V22, P390, DOI 10.1097/FBP.0b013e328349aae4
   Bovill JG, 1997, EUR J ANAESTH, V14, P9, DOI 10.1097/00003643-199705001-00003
   Boyle J, 2012, DIABETES CARE, V35, P2451, DOI 10.2337/dc12-0656
   Burian M, 2005, PHARMACOL THERAPEUT, V107, P139, DOI 10.1016/j.pharmthera.2005.02.004
   Buvanendran A, 2009, CURR OPIN ANESTHESIO, V22, P588, DOI 10.1097/ACO.0b013e328330373a
   Capuano A, 2009, EUR J PHARMACOL, V605, P57, DOI 10.1016/j.ejphar.2008.12.029
   Chen HS, 2003, ANESTHESIOLOGY, V98, P1231, DOI 10.1097/00000542-200305000-00027
   CHICHORRO J, 2004, BR J PHARM, V141
   DALLEL R, 1995, PAIN, V61, P11, DOI 10.1016/0304-3959(94)00212-W
   Deeks JJ, 2002, BRIT MED J, V325, P619, DOI 10.1136/bmj.325.7365.619
   Deumens R, 2013, PROG NEUROBIOL, V104, P1, DOI 10.1016/j.pneurobio.2013.01.002
   ENGLEMAN EA, 1995, NEUROPSYCHOPHARMACOL, V12, P287, DOI 10.1016/0893-133X(94)00093-F
   Fekadu A, 2012, BRIT J PSYCHIAT, V201, P369, DOI 10.1192/bjp.bp.111.102665
   Frakes EP, 2011, CURR MED RES OPIN, V27, P2361, DOI 10.1185/03007995.2011.633502
   Gregoire S, 2012, PAIN, V153, P1657, DOI 10.1016/j.pain.2012.04.023
   Han JS, 2005, J NEUROSCI METH, V141, P261, DOI 10.1016/j.jneumeth.2004.07.005
   HAPPICH M, 2012, DEPRESS RES TREAT
   Huang J, 2006, EXP NEUROL, V200, P124, DOI 10.1016/j.expneurol.2006.01.036
   Jones CK, 2007, EUR J PAIN, V11, P208, DOI 10.1016/j.ejpain.2006.02.008
   Jones CK, 2005, J PHARMACOL EXP THER, V312, P726, DOI 10.1124/jpet.104.075960
   Koch S, 2003, NEUROPHARMACOLOGY, V45, P935, DOI 10.1016/S0028-3908(03)00268-5
   Liu JL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007548
   Mallen SR, 2011, CURR MED RES OPIN, V27, P1359, DOI 10.1185/03007995.2011.581274
   McNamara CR, 2007, P NATL ACAD SCI USA, V104, P13525, DOI 10.1073/pnas.0705924104
   McRoberts JA, 2011, NEUROSCIENCE, V172, P474, DOI 10.1016/j.neuroscience.2010.10.045
   Millan MJ, 2002, PROG NEUROBIOL, V66, P355, DOI 10.1016/S0301-0082(02)00009-6
   Miranda HF, 2012, INFLAMMATION, V35, P1132, DOI 10.1007/s10753-011-9420-7
   Mixcoatl-Zecuatl T, 2011, BRIT J PHARMACOL, V164, P159, DOI 10.1111/j.1476-5381.2011.01334.x
   MOORE PK, 1991, BRIT J PHARMACOL, V102, P198, DOI 10.1111/j.1476-5381.1991.tb12153.x
   Muller Norbert, 2008, Expert Rev Neurother, V8, P527, DOI 10.1586/14737175.8.4.527
   Munro G, 2009, EUR J PHARMACOL, V605, P95, DOI 10.1016/j.ejphar.2009.01.004
   Niederberger E, 2001, FASEB J, V15, P1622, DOI 10.1096/fj.00-0716fje
   Nishiyama T, 2006, ACTA ANAESTH SCAND, V50, P228, DOI 10.1111/j.1399-6576.2006.00921.x
   Nuseir K, 2000, NEUROSCIENCE, V96, P773, DOI 10.1016/S0306-4522(99)00603-X
   Oliveira AR, 2006, ANESTH ANALG, V102, P832, DOI 10.1213/01.ane.0000196530.72813.d9
   Ormseth MJ, 2011, PATIENT PREFER ADHER, V5, P343, DOI 10.2147/PPA.S16358
   Penning TD, 1997, J MED CHEM, V40, P1347, DOI 10.1021/jm960803q
   Pertovaara A, 2006, PROG NEUROBIOL, V80, P53, DOI 10.1016/j.pneurobio.2006.08.001
   RAHMAN AFMM, 1994, JPN J PHARMACOL, V65, P313, DOI 10.1254/jjp.65.313
   Raskin J, 2006, J PALLIAT MED, V9, P29, DOI 10.1089/jpm.2006.9.29
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Rezende RM, 2012, PHARMACOLOGY, V89, P127, DOI 10.1159/000336346
   Rezende RM, 2010, NEUROPHARMACOLOGY, V59, P551, DOI 10.1016/j.neuropharm.2010.07.022
   SAGEN J, 1985, BRAIN RES, V331, P285, DOI 10.1016/0006-8993(85)91554-9
   Shi M, 2010, J PAIN, V11, P219, DOI 10.1016/j.jpain.2009.07.002
   Shi SJ, 2008, EUR J CLIN PHARMACOL, V64, P233, DOI 10.1007/s00228-007-0400-7
   Shibazaki T, 2009, ANGLE ORTHOD, V79, P1169, DOI 10.2319/121108-629.1
   SKAGERBERG G, 1985, NEUROSCIENCE, V15, P445, DOI 10.1016/0306-4522(85)90225-8
   Skljarevski V, 2012, PAIN RES TREAT, V2012
   Smith T, 2007, VASC HEALTH RISK MAN, V3, P833
   Su YL, 2010, NEUROSCI BULL, V26, P429, DOI 10.1007/s12264-010-0932-1
   Tallarida RJ, 2001, J PHARMACOL EXP THER, V298, P865
   Tamaddonfard E, 2011, PHARMACOL REP, V63, P423, DOI 10.1016/S1734-1140(11)70508-4
   Taylor BK, 2000, J PAIN, V1, P218, DOI 10.1054/jpai.2000.7308
   Vellani V, 2010, MOL PAIN, V6, DOI 10.1186/1744-8069-6-61
   Vos BP, 1998, PAIN, V76, P173, DOI 10.1016/S0304-3959(98)00039-6
   VOS BP, 1994, J NEUROSCI, V14, P2708
   Wang W, 2008, NEUROSCI LETT, V441, P237, DOI 10.1016/j.neulet.2008.06.031
   Wu LA, 2009, NEUROSCI LETT, V457, P36, DOI 10.1016/j.neulet.2009.03.107
NR 63
TC 21
Z9 21
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 7
PY 2013
VL 8
IS 10
AR UNSP e76603
DI 10.1371/journal.pone.0076603
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 232NS
UT WOS:000325501300072
PM 24116126
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Sharma, A
   Prasongwattana, V
   Cha'on, U
   Selmi, C
   Hipkaeo, W
   Boonnate, P
   Pethlert, S
   Titipungul, T
   Intarawichian, P
   Waraasawapati, S
   Puapiroj, A
   Sitprija, V
   Reungjui, S
AF Sharma, Amod
   Prasongwattana, Vitoon
   Cha'on, Ubon
   Selmi, Carlo
   Hipkaeo, Wiphawi
   Boonnate, Piyanard
   Pethlert, Supattra
   Titipungul, Tanin
   Intarawichian, Piyapharom
   Waraasawapati, Sakda
   Puapiroj, Anucha
   Sitprija, Visith
   Reungjui, Sirirat
TI Monosodium Glutamate (MSG) Consumption Is Associated with Urolithiasis
   and Urinary Tract Obstruction in Rats
SO PLOS ONE
LA English
DT Article
ID CHINESE ADULTS; IN-VIVO; KIDNEY; METABOLISM; CALCIUM; CITRATE; TUBULE;
   PH; OVERWEIGHT; NUTRITION
AB Background: The peritoneal injection of monosodium glutamate (MSG) can induce kidney injury in adult rats but the effects of long-term oral intake have not been determined.
   Methods: We investigated the kidney histology and function in adult male Wistar rats that were fed ad libitum with a standard rat chow pellet and water with or without the addition of 2 mg/g body weight MSG/day in drinking water (n=10 per group). Both MSG-treated and control animals were sacrificed after 9 months when renal function parameters, blood and urine electrolytes, and tissue histopathology were determined.
   Results: MSG-treated rats were more prone to kidney stone formation, as represented by the alkaline urine and significantly higher activity product of calcium phosphate. Accordingly, 3/10 MSG-treated rats developed kidney stones over 9 months versus none of the control animals. Further, 2/10 MSG-treated rats but none (0/10) of the controls manifested hydronephrosis. MSG-treated rats had significantly higher levels of serum creatinine and potassium including urine output volume, urinary excretion sodium and citrate compared to controls. In contrast, MSG-treated rats had significantly lower ammonium and magnesium urinary excretion.
   Conclusion: Oral MSG consumption appears to cause alkaline urine and may increase the risks of kidney stones with hydronephrosis in rats. Similar effects in humans must be verified by dedicated studies.
C1 [Sharma, Amod; Prasongwattana, Vitoon; Cha'on, Ubon; Boonnate, Piyanard; Pethlert, Supattra] Khon Kaen Univ, Fac Med, Dept Biochem, Khon Kaen, Thailand.
   [Selmi, Carlo] Humanitas Clin & Res Ctr, Milan, Italy.
   [Selmi, Carlo] Univ Milan, BIOMETRA Dept, Milan, Italy.
   [Hipkaeo, Wiphawi] Khon Kaen Univ, Fac Med, Dept Anat, Khon Kaen, Thailand.
   [Titipungul, Tanin] Mahasarakham Hosp, Dept Pathol, Maha Sarakham, Thailand.
   [Intarawichian, Piyapharom; Waraasawapati, Sakda; Puapiroj, Anucha] Khon Kaen Univ, Fac Med, Dept Pathol, Khon Kaen, Thailand.
   [Sitprija, Visith] Queen Saovabha Mem Inst, Bangkok, Thailand.
   [Reungjui, Sirirat] Khon Kaen Univ, Fac Med, Dept Internal Med, Khon Kaen, Thailand.
RP Cha'on, U (reprint author), Khon Kaen Univ, Fac Med, Dept Biochem, Khon Kaen, Thailand.
EM ubocha@kku.ac.th
OI Selmi, Carlo/0000-0002-0323-0376
FU Research and Technology affairs division, Khon Kaen University; Faculty
   of Medicine [I54139, I56124]
FX UC received the grants from the Research and Technology affairs
   division, Khon Kaen University, under incubation research project and
   the invitation research fund from the Faculty of Medicine (I54139 and
   I56124). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Bai Y, 2004, SPECTROSC SPECT ANAL, V24, P1016
   Barnes JL, 2011, KIDNEY INT, V79, P944, DOI 10.1038/ki.2010.516
   Bellisle F, 1999, NEUROSCI BIOBEHAV R, V23, P423, DOI 10.1016/S0149-7634(98)00043-8
   BRENNAN S, 1988, AM J PHYSIOL, V255, pF301
   CHANEY AL, 1962, CLIN CHEM, V8, P130
   Chauvin MF, 1997, J BIOL CHEM, V272, P4705, DOI 10.1074/jbc.272.8.4705
   Cheema-Dhadli S, 2002, AM J PHYSIOL-RENAL, V282, pF1049, DOI 10.1152/ajprenal.00006.2001
   Chevassus H, 2002, BRIT J CLIN PHARMACO, V53, P641, DOI 10.1046/j.1365-2125.2002.01596.x
   Collison KS, 2012, NUTR METAB, V9, DOI 10.1186/1743-7075-9-58
   Collison KS, 2010, PHYSIOL BEHAV, V99, P334, DOI 10.1016/j.physbeh.2009.11.010
   DEGROOT AP, 1988, FOOD CHEM TOXICOL, V26, P425, DOI 10.1016/0278-6915(88)90053-1
   GOLDENBERG H, 1966, CLIN CHEM, V12, P871
   GRUNERT RR, 1950, J NUTR, V42, P609
   Halpern BP, 2000, J NUTR, V130, p910S, DOI 10.1093/jn/130.4.910S
   He K, 2008, OBESITY, V16, P1875, DOI 10.1038/oby.2008.274
   He K, 2011, AM J CLIN NUTR, V93, P1328, DOI 10.3945/ajcn.110.008870
   Hediger MA, 1999, AM J PHYSIOL-RENAL, V277, pF487
   Insawang T, 2012, NUTR METAB, V9, DOI 10.1186/1743-7075-9-50
   Kamel KS, 2007, NEPHROL DIAL TRANSPL, V22, P424, DOI 10.1093/ndt/gfl588
   KAUFMAN AM, 1988, AM J PHYSIOL, V255, pF182
   LEVIN M, 1989, MINER ELECTROL METAB, V15, P214
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   NATH KA, 1992, AM J KIDNEY DIS, V20, P1
   OHARA I, 1977, PHYSIOL BEHAV, V19, P627, DOI 10.1016/0031-9384(77)90037-3
   Ortiz GG, 2006, BIOMED PHARMACOTHER, V60, P86, DOI 10.1016/j.biopha.2005.07.012
   Paul MVS, 2012, TOXICOL MECH METHOD, V22, P625, DOI 10.3109/15376516.2012.714008
   PETRARULO M, 1995, CLIN CHEM, V41, P1518
   PETTERSSON BA, 1984, KIDNEY INT, V26, P122, DOI 10.1038/ki.1984.145
   Rao GN, 2002, TOXICOL PATHOL, V30, P651, DOI 10.1080/01926230290166733
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Roson MI, 2011, J NEPHROL, V24, P119
   Sampson N, 2011, MOL ENDOCRINOL, V25, P503, DOI 10.1210/me.2010-0340
   Shi ZM, 2011, J HYPERTENS, V29, P846, DOI 10.1097/HJH.0b013e328344da8e
   Shi ZM, 2010, BRIT J NUTR, V104, P457, DOI 10.1017/S0007114510000760
   SLOT C, 1965, SCAND J CLIN LAB INV, V17, P381, DOI 10.3109/00365516509077065
   STEGINK LD, 1973, J NUTR, V103, P1146
   Thomas M, 2010, PHYSIOL BEHAV, V99, P334, DOI [10.1016/j.physbeh.2009.11.010, DOI 10.1016/J.PHYSBEH.2009.11.010.PUBMED:19945473]
   Thu Hien VT, 2012, PUBLIC HEALTH NUTR, P1
   TISELIUS HG, 1984, EUR UROL, V10, P191
   Tucker MJ, 2003, DIS WISTAR RAT
   Vercoutere B, 2004, BIOCHEM J, V378, P485, DOI 10.1042/BJ20031088
   VINAY P, 1986, KIDNEY INT, V29, P68, DOI 10.1038/ki.1986.9
   Wagner CA, 2010, J NEPHROL, V23, pS165
   Walker R, 2000, J NUTR, V130, p1049S, DOI 10.1093/jn/130.4.1049S
   WYBENGA DR, 1971, CLIN CHEM, V17, P891
   Yatabe MS, 2012, BMC NEPHROL, V13, DOI 10.1186/1471-2369-13-160
NR 46
TC 8
Z9 8
U1 0
U2 34
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 26
PY 2013
VL 8
IS 9
AR e75546
DI 10.1371/journal.pone.0075546
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 228VP
UT WOS:000325220000026
PM 24086562
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Cong, WN
   Wang, R
   Cai, H
   Daimon, CM
   Scheibye-Knudsen, M
   Bohr, VA
   Turkin, R
   Wood, WH
   Becker, KG
   Moaddel, R
   Maudsley, S
   Martin, B
AF Cong, Wei-na
   Wang, Rui
   Cai, Huan
   Daimon, Caitlin M.
   Scheibye-Knudsen, Morten
   Bohr, Vilhelm A.
   Turkin, Rebecca
   Wood, William H., III
   Becker, Kevin G.
   Moaddel, Ruin
   Maudsley, Stuart
   Martin, Bronwen
TI Long-Term Artificial Sweetener Acesulfame Potassium Treatment Alters
   Neurometabolic Functions in C57BL/6J Mice
SO PLOS ONE
LA English
DT Article
ID MITOCHONDRIAL COMPLEX-I; TACHYKININ NK2 RECEPTOR; BODY-SURFACE AREA;
   ALZHEIMERS-DISEASE; NONNUTRITIVE SWEETENERS; SYNAPTIC PLASTICITY;
   GLUCOSE-HOMEOSTASIS; METABOLIC SYNDROME; CEREBRAL-ISCHEMIA;
   ENERGY-METABOLISM
AB With the prevalence of obesity, artificial, non-nutritive sweeteners have been widely used as dietary supplements that provide sweet taste without excessive caloric load. In order to better understand the overall actions of artificial sweeteners, especially when they are chronically used, we investigated the peripheral and central nervous system effects of protracted exposure to a widely used artificial sweetener, acesulfame K (ACK). We found that extended ACK exposure (40 weeks) in normal C57BL/6J mice demonstrated a moderate and limited influence on metabolic homeostasis, including altering fasting insulin and leptin levels, pancreatic islet size and lipid levels, without affecting insulin sensitivity and bodyweight. Interestingly, impaired cognitive memory functions (evaluated by Morris Water Maze and Novel Objective Preference tests) were found in ACK-treated C57BL/6J mice, while no differences in motor function and anxiety levels were detected. The generation of an ACK-induced neurological phenotype was associated with metabolic dysregulation (glycolysis inhibition and functional ATP depletion) and neurosynaptic abnormalities (dysregulation of TrkB-mediated BDNF and Akt/Erk-mediated cell growth/survival pathway) in hippocampal neurons. Our data suggest that chronic use of ACK could affect cognitive functions, potentially via altering neuro-metabolic functions in male C57BL/6J mice.
C1 [Cong, Wei-na; Wang, Rui; Cai, Huan; Daimon, Caitlin M.; Turkin, Rebecca; Martin, Bronwen] NIA, Metab Unit, Clin Invest Lab, Baltimore, MD 21224 USA.
   [Scheibye-Knudsen, Morten; Bohr, Vilhelm A.] NIA, Sect DNA Repair, Lab Mol Gerontol, Baltimore, MD 21224 USA.
   [Wood, William H., III; Becker, Kevin G.] NIA, Gene Express & Genom Unit, Genet Lab, Baltimore, MD 21224 USA.
   [Maudsley, Stuart] NIA, Receptor Pharmacol Unit, Neurosci Lab, Baltimore, MD 21224 USA.
   [Moaddel, Ruin] NIA, Bioanalyt Chem & Drug Discovery Sect, Clin Invest Lab, Baltimore, MD 21224 USA.
RP Martin, B (reprint author), NIA, Metab Unit, Clin Invest Lab, Baltimore, MD 21224 USA.
EM martinbro@mail.nih.gov
RI Wang, Rui/I-5643-2019; Cai, Huan/B-6578-2016; Maudsley,
   Stuart/Q-4782-2019
OI Wang, Rui/0000-0001-7015-0272; Cai, Huan/0000-0001-7731-8891; Becker,
   Kevin/0000-0002-6794-6656; Scheibye-Knudsen, Morten/0000-0002-6637-1280
FU Intramural Research Program of the National Institute on Aging at the
   National Institutes of Health
FX This work was carried out with the support of the Intramural Research
   Program of the National Institute on Aging at the National Institutes of
   Health. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Andreasson KI, 2001, J NEUROSCI, V21, P8198
   Bandyopadhyay A, 2008, DRUG CHEM TOXICOL, V31, P447, DOI [10.1080/01480540802390270, 10.1080/01480540802390270 ]
   Bolognani F, 2007, NEUROCHEM RES, V32, P2142, DOI 10.1007/s11064-007-9388-8
   Borgesius NZ, 2011, J NEUROSCI, V31, P10141, DOI 10.1523/JNEUROSCI.5105-10.2011
   Brown RJ, 2009, DIABETES CARE, V32, P2184, DOI 10.2337/dc09-1185
   Cai H, 2012, CURR ALZHEIMER RES, V9, P5, DOI 10.2174/156720512799015064
   Chadwick W, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021660
   Chadwick W, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021638
   Chadwick W, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014352
   Chiba T, 2007, ANN NY ACAD SCI, V1119, P216, DOI 10.1196/annals.1404.013
   CLAUSS K, 1976, Z LEBENSM UNTERS FOR, V162, P37, DOI 10.1007/BF01104359
   Damak S, 2003, SCIENCE, V301, P850, DOI 10.1126/science.1087155
   de Araujo IE, 2009, FRONT INTEGR NEUROSC, V3, P1, DOI DOI 10.3389/NEURO.07.001.2009
   de Koning L, 2012, CIRCULATION, V125, P1735, DOI 10.1161/CIRCULATIONAHA.111.067017
   Dhingra R, 2007, CIRCULATION, V116, P480, DOI 10.1161/CIRCULATIONAHA.107.689935
   Donnelly D, 1999, BIOCHEM J, V339, P55, DOI 10.1042/0264-6021:3390055
   Duffy VB, 2004, J AM DIET ASSOC, V104, P255, DOI 10.1016/j.jada.2003.12.001
   Fehm HL, 2006, PROG BRAIN RES, V153, P129, DOI 10.1016/S0079-6123(06)53007-9
   Fowler SP, 2008, OBESITY, V16, P1894, DOI 10.1038/oby.2008.284
   FRIEDMAN DL, 1994, J COMP NEUROL, V343, P500, DOI 10.1002/cne.903430311
   Grice HC, 2000, FOOD CHEM TOXICOL, V38, pS1, DOI 10.1016/S0278-6915(00)00023-5
   Grotz VL, 2009, REGUL TOXICOL PHARM, V55, P1, DOI 10.1016/j.yrtph.2009.05.011
   Hamdan FF, 2011, EUR J HUM GENET, V19, P607, DOI 10.1038/ejhg.2010.183
   Herrmann AG, 2013, J CEREB BLOOD FLOW M
   Huang G, 2007, CELL DEATH DIFFER, V14, P327, DOI 10.1038/sj.cdd.4402004
   Hur J, 2010, BIOCHEM BIOPH RES CO, V391, P1526, DOI 10.1016/j.bbrc.2009.12.114
   Ilieva H, 2003, J NEUROL SCI, V215, P57, DOI 10.1016/S0022-510X(03)00186-2
   Inoue K, 2006, J NEUROCHEM, V96, P598, DOI 10.1111/j.1471-4159.2005.03560.x
   Inoue M, 2001, CHEM SENSES, V26, P915, DOI 10.1093/chemse/26.7.915
   Li F, 2003, BRAIN RES, V962, P21, DOI 10.1016/S0006-8993(02)03774-5
   Li HS, 2001, PHYSIOL GENOMICS, V6, P91
   Lloret A, 2011, J ALZHEIMERS DIS, V27, P701, DOI 10.3233/JAD-2011-110890
   Lutsey PL, 2008, CIRCULATION, V117, P754, DOI 10.1161/CIRCULATIONAHA.107.716159
   Mace OJ, 2007, J PHYSIOL-LONDON, V582, P379, DOI 10.1113/jphysiol.2007.130906
   Magnuson BA, 2007, CRIT REV TOXICOL, V37, P629, DOI 10.1080/10408440701516184
   Majda BT, 2001, MOL BRAIN RES, V93, P173, DOI 10.1016/S0169-328X(01)00203-0
   Malaisse WJ, 1998, CELL SIGNAL, V10, P727, DOI 10.1016/S0898-6568(98)00017-5
   Margolskee RF, 2007, P NATL ACAD SCI USA, V104, P15075, DOI 10.1073/pnas.0706678104
   Martin B, 2008, HISTOL HISTOPATHOL, V23, P237, DOI 10.14670/HH-23.237
   Martin B, 2007, ENDOCRINOLOGY, V148, P4318, DOI 10.1210/en.2007-0161
   Martin B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036911
   Martin B, 2010, DIABETES, V59, P1143, DOI 10.2337/db09-0807
   Martin B, 2009, TRENDS ENDOCRIN MET, V20, P163, DOI 10.1016/j.tem.2009.01.006
   Martin B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004146
   Martin B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002750
   Martin B, 2009, DIABETES, V58, P318, DOI 10.2337/db08-0799
   Martins-de-Souza Daniel, 2012, BMC Res Notes, V5, P146, DOI 10.1186/1756-0500-5-146
   Mateo I, 2009, ACTA NEUROL SCAND, V120, P130, DOI 10.1111/j.1600-0404.2008.01128.x
   Mattes RD, 2009, AM J CLIN NUTR, V89, P1, DOI 10.3945/ajcn.2008.26792
   Maudsley S, 2005, J PHARMACOL EXP THER, V314, P485, DOI 10.1124/jpet.105.083121
   Maudsley S, 2012, MINI-REV MED CHEM, V12, P831, DOI 10.2174/138955712800959071
   Maudsley S, 1998, BRIT J PHARMACOL, V124, P675, DOI 10.1038/sj.bjp.0701889
   Maudsley S, 2007, CURR ALZHEIMER RES, V4, P3, DOI 10.2174/156720507779939850
   Maudsley S, 2011, ENDOCRINOLOGY, V152, P3592, DOI 10.1210/en.2011-1615
   Mukherjee A, 1997, FOOD CHEM TOXICOL, V35, P1177, DOI 10.1016/S0278-6915(97)85469-5
   Murray J, 2003, J BIOL CHEM, V278, P37223, DOI 10.1074/jbc.M305694200
   Nakagawa Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005106
   Nelson G, 2001, CELL, V106, P381, DOI 10.1016/S0092-8674(01)00451-2
   Pellerin L, 2003, J CEREBR BLOOD F MET, V23, P1282, DOI 10.1097/01.WCB.0000096064.12129.3D
   Pepino MY, 2011, CURR OPIN CLIN NUTR, V14, P391, DOI 10.1097/MCO.0b013e3283468e7e
   Potter WB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008996
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Riera CE, 2008, BIOCHEM BIOPH RES CO, V376, P653, DOI 10.1016/j.bbrc.2008.09.029
   Riera CE, 2007, AM J PHYSIOL-REG I, V293, pR626, DOI 10.1152/ajpregu.00286.2007
   Russo VC, 2012, NEUROCHEM RES, V37, P1768, DOI 10.1007/s11064-012-0789-y
   Sato S, 2013, AM J PHYSIOL-GASTR L
   Sawyer M, 2001, INVEST NEW DRUG, V19, P171, DOI 10.1023/A:1010639201787
   Scheibye-Knudsen M, 2012, J EXP MED, V209, P855, DOI 10.1084/jem.20111721
   Schneider L, 2011, FREE RADICAL BIO MED, V51, P2007, DOI 10.1016/j.freeradbiomed.2011.08.030
   Scribner KB, 2008, AM J PHYSIOL-ENDOC M, V295, pE1126, DOI 10.1152/ajpendo.90487.2008
   Shin SJ, 2004, PROTEOMICS, V4, P3359, DOI 10.1002/pmic.200400961
   Shin YK, 2012, J GERONTOL A-BIOL, V67, P336, DOI 10.1093/gerona/glr192
   Storch A, 2000, BRAIN RES, V855, P67, DOI 10.1016/S0006-8993(99)02272-6
   Sung JY, 2008, P NATL ACAD SCI USA, V105, P3112, DOI 10.1073/pnas.0712180105
   Swerdlow RH, 2013, BBA-GEN SUBJECTS, V1830, P2891, DOI 10.1016/j.bbagen.2013.01.002
   Swithers SE, 2012, BEHAV BRAIN RES, V233, P1, DOI 10.1016/j.bbr.2012.04.024
   Swithers SE, 2009, BEHAV NEUROSCI, V123, P772, DOI 10.1037/a0016139
   van de Woestijne AP, 2011, OBES REV, V12, P829
   VanGuilder HD, 2011, NEUROBIOL DIS, V43, P201, DOI 10.1016/j.nbd.2011.03.012
   Verbraecken J, 2006, METABOLISM, V55, P515, DOI 10.1016/j.metabol.2005.11.004
   Vitale M, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/728178
   Volz M., 1976, 01L42017776 WHO HOEC
   Yamada K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008596
   Yamamoto H, 2011, J BIOL CHEM, V286, P26158, DOI 10.1074/jbc.M111.256446
   Yang Qing, 2010, Yale Journal of Biology and Medicine, V83, P101
   Zeigerer A, 2008, EXP CELL RES, V314, P2249, DOI 10.1016/j.yexcr.2008.04.003
   Zhang GH, 2011, CHEM SENSES, V36, P763, DOI 10.1093/chemse/bjr050
   Zhao GQ, 2003, CELL, V115, P255, DOI 10.1016/S0092-8674(03)00844-4
   Zheng Y, 2013, J GASTROINTEST SURG, V17, P153, DOI 10.1007/s11605-012-1998-z
NR 89
TC 17
Z9 17
U1 1
U2 54
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 7
PY 2013
VL 8
IS 8
AR e70257
DI 10.1371/journal.pone.0070257
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 200ZE
UT WOS:000323109700025
PM 23950916
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Zhang, J
   Lazarenko, OP
   Kang, J
   Blackburn, ML
   Ronis, MJJ
   Badger, TM
   Chen, JR
AF Zhang, Jian
   Lazarenko, Oxana P.
   Kang, Jie
   Blackburn, Michael L.
   Ronis, Martin J. J.
   Badger, Thomas M.
   Chen, Jin-Ran
TI Feeding Blueberry Diets to Young Rats Dose-Dependently Inhibits Bone
   Resorption through Suppression of RANKL in Stromal Cells
SO PLOS ONE
LA English
DT Article
ID PPAR-GAMMA; OSTEOBLAST DIFFERENTIATION; PHENOLIC-ACIDS; OSTEOPOROSIS;
   OBESITY; OSTEOCLASTOGENESIS; ADIPOGENESIS; PPAR-GAMMA-2; PROGENITORS;
   EXPRESSION
AB Previous studies have demonstrated that weanling rats fed AIN-93G semi-purified diets supplemented with 10% whole blueberry (BB) powder for two weeks beginning on postnatal day 21 (PND21) significantly increased bone formation at PND35. However, the minimal level of dietary BB needed to produce these effects is, as yet, unknown. The current study examined the effects of three different levels of BB diet supplementation (1, 3, and 5%) for 35 days beginning on PND25 on bone quality, and osteoclastic bone resorption in female rats. Peripheral quantitative CT scan (pQCT) of tibia, demonstrated that bone mineral density (BMD) and content (BMC) were dose-dependently increased in BB-fed rats compared to controls (P<0.05). Significantly increased bone mass after feeding 5% BB extracts was also observed in a TEN (total enteral nutrition) rat model in which daily caloric and food intake was precisely controlled. Expression of RANKL (receptor activator of nuclear factor-kappa B ligand) a protein essential for osteoclast formation was dose-dependently decreased in the femur of BB animals. In addition, expression of PPAR gamma (peroxisome proliferator-activated receptor gamma) which regulates bone marrow adipogenesis was suppressed in BB diet rats compared to non-BB diet controls. Finally, a set of in vitro cell cultures revealed that the inhibitory effect of BB diet rat serum on RANKL expression was more profound in mesenchymal stromal cells compared to its effect on mature osteoblasts, pre-adipocytes and osteocytes. These results suggest that inhibition of bone resorption may contribute to increased bone mass during early development after BB consumption.
C1 [Zhang, Jian; Lazarenko, Oxana P.; Kang, Jie; Blackburn, Michael L.; Ronis, Martin J. J.; Badger, Thomas M.; Chen, Jin-Ran] Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA.
   [Zhang, Jian; Lazarenko, Oxana P.; Kang, Jie; Blackburn, Michael L.; Ronis, Martin J. J.; Badger, Thomas M.; Chen, Jin-Ran] Arkansas Childrens Nutr Ctr, Little Rock, AR USA.
   [Ronis, Martin J. J.] Univ Arkansas Med Sci, Dept Pharmacol & Toxicol, Little Rock, AR 72205 USA.
RP Chen, JR (reprint author), Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA.
EM chenjinran@uams.edu
FU United States Department of Agriculture (USDA)/Agriculture Research
   Service [CRIS 6251-51000-006-03s]
FX This work was supported by United States Department of Agriculture
   (USDA)/Agriculture Research Service CRIS 6251-51000-006-03s to the
   Arkansas Children's Nutrition Center. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900
   Backesjo CM, 2006, J BONE MINER RES, V21, P993, DOI 10.1359/JBMR.060415
   Chen JR, 2006, J PHARMACOL EXP THER, V319, P1182, DOI 10.1124/jpet.106.109454
   Chen JR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013704
   Chen JR, 2010, J BONE MINER RES, V25, P2399, DOI 10.1002/jbmr.137
   Chen JR, 2009, J NUTR, V139, P1839, DOI 10.3945/jn.109.109041
   Cho SW, 2011, J BONE MINER RES, V26, P1939, DOI 10.1002/jbmr.366
   CUZICK J, 1985, STAT MED, V4, P87, DOI 10.1002/sim.4780040112
   Jones JR, 2005, P NATL ACAD SCI USA, V102, P6207, DOI 10.1073/pnas.0306743102
   Khateeb J, 2010, ATHEROSCLEROSIS, V208, P119, DOI 10.1016/j.atherosclerosis.2009.08.051
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Kong YY, 1999, NATURE, V397, P315
   Lanham-New SA, 2006, AM J CLIN NUTR, V83, P1254
   Lazarenko OP, 2007, ENDOCRINOLOGY, V148, P2669, DOI 10.1210/en.2006-1587
   Lecka-Czernik B, 1999, J CELL BIOCHEM, V74, P357, DOI 10.1002/(SICI)1097-4644(19990901)74:3<357::AID-JCB5>3.0.CO;2-7
   Li Y, 2008, DIABETES OBES METAB, V10, P10, DOI 10.1111/j.1463-1326.2007.00708.x
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Marecki JC, 2011, J NUTR BIOCHEM, V22, P142, DOI 10.1016/j.jnutbio.2010.01.001
   O'Brien CA, 2010, BONE, V46, P911, DOI 10.1016/j.bone.2009.08.050
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Rosen CJ, 2006, NAT CLIN PRACT RHEUM, V2, P35, DOI 10.1038/ncprheum0070
   Shankar K, 2010, ENDOCRINOLOGY, V151, P2577, DOI 10.1210/en.2010-0017
   Siegel S., 1988, NONPARAMETRIC STAT B
   Sommerfeldt DW, 2001, EUR SPINE J, V10, pS86, DOI 10.1007/s005860100283
   TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X
   Tylavsky FA, 2004, AM J CLIN NUTR, V79, P311
   Wan YH, 2007, NAT MED, V13, P1496, DOI 10.1038/nm1672
   Wedge DE, 2001, J MED FOOD, V4, P49, DOI DOI 10.1089/10966200152053703
   Wei W, 2011, MOL CELL BIOL, V31, P4692, DOI 10.1128/MCB.05979-11
   Weivoda MM, 2012, BONE, V50, P467, DOI 10.1016/j.bone.2011.09.056
   Wu XL, 2009, MOL NUTR FOOD RES, V53, pS76, DOI 10.1002/mnfr.200800231
   Wu XL, 2004, J AGR FOOD CHEM, V52, P4026, DOI 10.1021/jf049696w
   Zhang J, 2013, AGE, V35, P807, DOI 10.1007/s11357-012-9412-z
   Zhang J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024486
   Zhao LJ, 2008, J BONE MINER RES, V23, P17, DOI 10.1359/JBMR.070813
NR 36
TC 13
Z9 13
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 6
PY 2013
VL 8
IS 8
AR e70438
DI 10.1371/journal.pone.0070438
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 217ZG
UT WOS:000324401500035
PM 23936431
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Courtin, A
   Richards, FM
   Bapiro, TE
   Bramhall, JL
   Neesse, A
   Cook, N
   Krippendorff, BF
   Tuveson, DA
   Jodrell, DI
AF Courtin, Aurelie
   Richards, Frances M.
   Bapiro, Tashinga E.
   Bramhall, Jo L.
   Neesse, Albrecht
   Cook, Natalie
   Krippendorff, Ben-Fillippo
   Tuveson, David A.
   Jodrell, Duncan I.
TI Anti-Tumour Efficacy of Capecitabine in a Genetically Engineered Mouse
   Model of Pancreatic Cancer
SO PLOS ONE
LA English
DT Article
ID ORAL FLUOROPYRIMIDINE CARBAMATE; GEMCITABINE PLUS CAPECITABINE; CYTIDINE
   DEAMINASE; NUCLEOSIDE TRANSPORTER; CELLULAR PHARMACOLOGY;
   RANDOMIZED-TRIAL; IN-VITRO; CHEMOTHERAPY; CELLS; XENOGRAFTS
AB Capecitabine (CAP) is a 5-FU pro-drug approved for the treatment of several cancers and it is used in combination with gemcitabine (GEM) in the treatment of patients with pancreatic adenocarcinoma (PDAC). However, limited pre-clinical data of the effects of CAP in PDAC are available to support the use of the GEMCAP combination in clinic. Therefore, we investigated the pharmacokinetics and the efficacy of CAP as a single agent first and then in combination with GEM to assess the utility of the GEMCAP therapy in clinic. Using a model of spontaneous PDAC occurring in Kras(G12D); p53(R172H); Pdx1-Cre (KPC) mice and subcutaneous allografts of a KPC PDAC-derived cell line (K8484), we showed that CAP achieved tumour concentrations (similar to 25 mu M) of 5-FU in both models, as a single agent, and induced survival similar to GEM in KPC mice, suggesting similar efficacy. In vitro studies performed in K8484 cells as well as in human pancreatic cell lines showed an additive effect of the GEMCAP combination however, it increased toxicity in vivo and no benefit of a tolerable GEMCAP combination was identified in the allograft model when compared to GEM alone. Our work provides pre-clinical evidence of 5-FU delivery to tumours and anti-tumour efficacy following oral CAP administration that was similar to effects of GEM. Nevertheless, the GEMCAP combination does not improve the therapeutic index compared to GEM alone. These data suggest that CAP could be considered as an alternative to GEM in future, rationally designed, combination treatment strategies for advanced pancreatic cancer.
C1 [Courtin, Aurelie; Richards, Frances M.; Bapiro, Tashinga E.; Bramhall, Jo L.; Krippendorff, Ben-Fillippo; Jodrell, Duncan I.] Canc Res UK Cambridge Res Inst, Pharmacol & Drug Dev Grp, Cambridge, England.
   [Neesse, Albrecht; Cook, Natalie; Tuveson, David A.] Canc Res UK Cambridge Res Inst, Tumour Modelling & Expt Med Grp, Cambridge, England.
   [Courtin, Aurelie; Richards, Frances M.; Bapiro, Tashinga E.; Bramhall, Jo L.; Neesse, Albrecht; Cook, Natalie; Krippendorff, Ben-Fillippo; Tuveson, David A.; Jodrell, Duncan I.] Univ Cambridge, Dept Oncol, Cambridge, England.
RP Richards, FM (reprint author), Canc Res UK Cambridge Res Inst, Pharmacol & Drug Dev Grp, Cambridge, England.
EM fran.richards@cruk.cam.ac.uk
RI Cook, Natalie/O-4871-2015
OI Cook, Natalie/0000-0003-2606-1082; Bramhall, Jo/0000-0002-0996-1583
FU Cancer Research UK [C96/A8333]; CRUK Cambridge Institute Group Leader
   funding; University of Cambridge; Li Ka Shing Foundation;
   Hutchison-Whampoa Ltd.; NIHR Cambridge Biomedical Research Centre;
   Cancer Research UK [15678]
FX This work was funded by Cancer Research UK (www.cancerresearchuk.org)
   via Programme Grant C96/A8333 to DJ and via CRUK Cambridge Institute
   Group Leader funding to DJ and DT. This work was also supported by The
   University of Cambridge, the Li Ka Shing Foundation and by a charitable
   donation to the University of Cambridge from Hutchison-Whampoa Ltd. The
   work was also supported by funding from the NIHR Cambridge Biomedical
   Research Centre (www.nihr.ac.uk). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR ABBRUZZESE JL, 1991, J CLIN ONCOL, V9, P491, DOI 10.1200/JCO.1991.9.3.491
   Aresvik DM, 2010, ANTICANCER RES, V30, P3879
   Blanquicett C, 2005, CLIN CANCER RES, V11, P8773, DOI 10.1158/1078-0432.CCR-05-0627
   Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403
   Cartwright TH, 2002, J CLIN ONCOL, V20, P160, DOI 10.1200/JCO.20.1.160
   Ciccolini J, 2010, J CLIN ONCOL, V28, P160, DOI 10.1200/JCO.2009.24.4491
   Cook N, 2008, METHOD ENZYMOL, V439, P73, DOI 10.1016/S0076-6879(07)00406-5
   Cunningham D, 2009, J CLIN ONCOL, V27, P5513, DOI 10.1200/JCO.2009.24.2446
   Fitzgerald JB, 2006, NAT CHEM BIOL, V2, P458, DOI 10.1038/nchembio817
   Frese KK, 2012, CANCER DISCOV, V2, P260, DOI 10.1158/2159-8290.CD-11-0242
   Guichard SM, 2005, J CHROMATOGR B, V826, P232, DOI 10.1016/j.jchromb.2005.09.010
   Guichard SM, 2008, EUR J CANCER, V44, P310, DOI 10.1016/j.ejca.2007.10.023
   Heinemann V, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-82
   Herrmann R, 2007, J CLIN ONCOL, V25, P2212, DOI 10.1200/JCO.2006.09.0886
   Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023
   Hruban RH, 2006, CANCER RES, V66, P95, DOI 10.1158/0008-5472.CAN-05-2168
   Hubner RA, 2013, PANCREAS, V42, P511, DOI 10.1097/MPA.0b013e31826c6aee
   Hwang IT, 2007, BIOCHEM BIOPH RES CO, V359, P304, DOI 10.1016/j.bbrc.2007.05.088
   Hwang PM, 2001, NAT MED, V7, P1111, DOI 10.1038/nm1001-1111
   Ishikawa T, 1998, BIOCHEM PHARMACOL, V55, P1091, DOI 10.1016/S0006-2952(97)00682-5
   Ishitsuka H, 2000, INVEST NEW DRUG, V18, P343, DOI 10.1023/A:1006497231579
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Keith CT, 2005, NAT REV DRUG DISCOV, V4, P71, DOI 10.1038/nrd1609
   Lin Y, 2012, BRIT J CANCER, V107, P1692, DOI 10.1038/bjc.2012.450
   Mackey JR, 1998, CANCER RES, V58, P4349
   Mercier C, 2009, CANCER CHEMOTH PHARM, V63, P1177, DOI 10.1007/s00280-008-0889-1
   Mini E, 2006, ANN ONCOL, V17, pV7, DOI 10.1093/annonc/mdj941
   Miwa M, 1998, EUR J CANCER, V34, P1274, DOI 10.1016/S0959-8049(98)00058-6
   Morita T, 2003, ONCOLOGY-BASEL, V65, P267, DOI 10.1159/000074480
   Neoptolemos JP, 2010, JAMA-J AM MED ASSOC, V304, P1073, DOI 10.1001/jama.2010.1275
   Neoptolemos JP, 2004, NEW ENGL J MED, V350, P1200, DOI 10.1056/NEJMoa032295
   Ninomiya I, 2004, INT J CANCER, V112, P135, DOI 10.1002/ijc.20360
   Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362
   PRESSACCO J, 1995, BRIT J CANCER, V72, P939, DOI 10.1038/bjc.1995.437
   PRESSACCO J, 1995, CANCER RES, V55, P1505
   Quinney SK, 2005, J PHARMACOL EXP THER, V313, P1011, DOI 10.1124/jpet.104.081265
   Rauchwerger DR, 2000, CANCER RES, V60, P6075
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Reigner B, 2001, CLIN PHARMACOKINET, V40, P85, DOI 10.2165/00003088-200140020-00002
   Schreiber FS, 2004, GASTROENTEROLOGY, V127, P250, DOI 10.1053/j.gastro.2004.03.058
   Shindoh H, 2011, J TOXICOL SCI, V36, P411, DOI 10.2131/jts.36.411
   Workman P, 2010, BRIT J CANCER, V102, P1555, DOI 10.1038/sj.bjc.6605642
   Yoshida T, 2010, DRUG METAB DISPOS, V38, P1814, DOI 10.1124/dmd.110.034397
NR 43
TC 14
Z9 14
U1 1
U2 16
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 28
PY 2013
VL 8
IS 6
AR e67330
DI 10.1371/journal.pone.0067330
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 174IH
UT WOS:000321148400058
PM 23840665
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Geary, SM
   Lemke, CD
   Lubaroff, DM
   Salem, AK
AF Geary, Sean M.
   Lemke, Caitlin D.
   Lubaroff, David M.
   Salem, Aliasger K.
TI The Combination of a Low-Dose Chemotherapeutic Agent, 5-Fluorouracil,
   and an Adenoviral Tumor Vaccine Has a Synergistic Benefit on Survival in
   a Tumor Model System
SO PLOS ONE
LA English
DT Article
ID T-CELL RESPONSES; SUPPRESSOR-CELLS; ANTITUMOR IMMUNITY; CANCER VACCINES;
   IMMUNOTHERAPY; CYCLOPHOSPHAMIDE; ANTIGEN; MICE; IMMUNIZATION;
   DOXORUBICIN
AB Standard cancer therapies, particularly those involving chemotherapy, are in need of modifications that both reduce short-term and long-term side effects as well as improve the overall survival of cancer patients. Here we show that combining low-dose chemotherapy with a therapeutic vaccination using an adenovirus encoding a model tumor-associated antigen, ovalbumin (Ad5-OVA), had a synergistic impact on survival in tumor-challenged mice. Mice that received the combinatorial treatment of Ad5-OVA plus low-dose 5-fluorouracil (5-FU) had a 95% survival rate compared to 7% and 30% survival rates for Ad5-OVA alone and 5-FU alone respectively. The presence of 5-FU enhanced the levels of OVA-specific CD8(+) T lymphocytes in the spleens and draining lymph nodes of Ad5-OVA-treated mice, a phenomenon that was dependent on the mice having been tumor-challenged. Thus 5-FU may have enhanced survival of Ad5-OVA-treated mice by enhancing the tumor-specific immune response combined with eliminating tumor bulk. We also investigated the possibility that the observed therapeutic benefit may have been derived from the capacity of 5-FU to deplete MDSC populations. The findings presented here promote the concept of combining adenoviral cancer vaccines with low-dose chemotherapy.
C1 [Geary, Sean M.; Lemke, Caitlin D.; Salem, Aliasger K.] Univ Iowa, Coll Pharm, Div Pharmaceut, Iowa City, IA 52242 USA.
   [Lubaroff, David M.] Univ Iowa, Holden Comprehens Canc Ctr, Dept Urol, Iowa City, IA 52242 USA.
   [Lubaroff, David M.] Univ Iowa, Holden Comprehens Canc Ctr, Dept Microbiol, Iowa City, IA 52242 USA.
RP Salem, AK (reprint author), Univ Iowa, Coll Pharm, Div Pharmaceut, Iowa City, IA 52242 USA.
EM aliasger-salem@uiowa.edu
RI Salem, Aliasger/J-3674-2012
OI Salem, Aliasger/0000-0002-1923-6633
FU American Cancer Society [RSG-09-015-01-CDD]; National Cancer Institute
   at the National Institutes of Health [1R21CA13345-01/1R21CA128414-
   01A2/UI Mayo Clinic Lymphoma SPORE]
FX The authors gratefully acknowledge support from the American Cancer
   Society (RSG-09-015-01-CDD), and the National Cancer Institute at the
   National Institutes of Health (1R21CA13345-01/1R21CA128414- 01A2/UI Mayo
   Clinic Lymphoma SPORE). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Amato RJ, 2010, EXPERT OPIN BIOL TH, V10, P281, DOI 10.1517/14712590903586213
   American Cancer Society, 2012, CANC FACTS FIG 2012
   Antonia SJ, 2006, CLIN CANCER RES, V12, P878, DOI 10.1158/1078-0432.CCR-05-2013
   ARDALAN B, 1992, INT J RADIAT ONCOL, V22, P511, DOI 10.1016/0360-3016(92)90864-E
   Backus HHJ, 2001, ANN ONCOL, V12, P209, DOI 10.1023/A:1008331525368
   Bass KK, 1998, CANCER IMMUNOL IMMUN, V47, P1, DOI 10.1007/s002620050498
   Cheng C, 2007, PLOS PATHOG, V3, P239, DOI 10.1371/journal.ppat.0030025
   Elzey BD, 2001, INT J CANCER, V94, P842, DOI 10.1002/ijc.1556
   Emens LA, 2009, J CLIN ONCOL, V27, P5911, DOI 10.1200/JCO.2009.23.3494
   Fridlender ZG, 2010, MOL THER, V18, P1947, DOI 10.1038/mt.2010.159
   Gallina G, 2006, J CLIN INVEST, V116, P2777, DOI 10.1172/JCI28828
   Garnett CT, 2008, CLIN CANCER RES, V14, P3536, DOI 10.1158/1078-0432.CCR-07-4025
   Geary SM, 2011, CANCER IMMUNOL IMMUN, V60, P1309, DOI 10.1007/s00262-011-1038-y
   Hodge JW, 2012, SEMIN ONCOL, V39, P323, DOI 10.1053/j.seminoncol.2012.02.006
   Karan D, 2007, INT J CANCER, V121, P1520, DOI 10.1002/ijc.22873
   Kirkwood JM, 2008, J CLIN ONCOL, V26, P3445, DOI 10.1200/JCO.2007.14.6423
   Ko HJ, 2007, CANCER RES, V67, P7477, DOI 10.1158/0008-5472.CAN-06-4639
   Krishnamachari Y, 2011, PHARM RES-DORDR, V28, P215, DOI 10.1007/s11095-010-0241-4
   Liniger M, 2007, EXPERT REV VACCINES, V6, P255, DOI 10.1586/14760584.6.2.255
   Longley DB, 2005, J PATHOL, V205, P275, DOI 10.1002/path.1706
   Lu P, 2005, SEMIN NUCL MED, V35, P197, DOI 10.1053/j.semnuclmed.2005.02.005
   Lutsiak MEC, 2005, BLOOD, V105, P2862, DOI 10.1182/blood-2004-06-2410
   Machiels JPH, 2001, CANCER RES, V61, P3689
   MacLean GD, 1996, J IMMUNOTHER, V19, P309, DOI 10.1097/00002371-199607000-00006
   Matsuzaki J, 2003, CELL IMMUNOL, V224, P98, DOI 10.1016/j.cellimm.2003.08.009
   Mauti LA, 2011, J CLIN INVEST, V121, P2794, DOI 10.1172/JCI41936
   Miller G, 2002, CANCER RES, V62, P5260
   MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4
   Morales JK, 2009, CANCER IMMUNOL IMMUN, V58, P941, DOI 10.1007/s00262-008-0609-z
   Morse MA, 2008, BLOOD, V112, P610, DOI 10.1182/blood-2008-01-135319
   Nowak AK, 2006, ADV DRUG DELIVER REV, V58, P975, DOI 10.1016/j.addr.2006.04.002
   Ooboshi H, 1997, AM J PHYSIOL-HEART C, V273, pH265
   Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239
   Rabinovich GA, 2007, ANNU REV IMMUNOL, V25, P267, DOI 10.1146/annurev.immunol.25.022106.141609
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Siemens DR, 2001, J IMMUNOL, V166, P731, DOI 10.4049/jimmunol.166.2.731
   Sierro SR, 2011, EUR J IMMUNOL, V41, P2217, DOI 10.1002/eji.201041235
   Srivastava MK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040677
   TIPTON JM, 2003, HDB CANC CHEMOTHERAP, P561
   Tvinnereim AR, 2004, J IMMUNOL, V173, P1994, DOI 10.4049/jimmunol.173.3.1994
   Vincent J, 2010, CANCER RES, V70, P3052, DOI 10.1158/0008-5472.CAN-09-3690
   Youn JI, 2008, J IMMUNOL, V181, P5791, DOI 10.4049/jimmunol.181.8.5791
NR 42
TC 25
Z9 29
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 28
PY 2013
VL 8
IS 6
AR e67904
DI 10.1371/journal.pone.0067904
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 174IH
UT WOS:000321148400141
PM 23840786
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Samykutty, A
   Shetty, AV
   Dakshinamoorthy, G
   Bartik, MM
   Johnson, GL
   Webb, B
   Zheng, G
   Chen, AX
   Kalyanasundaram, RS
   Munirathinam, G
AF Samykutty, Abhilash
   Shetty, Aditya Vittal
   Dakshinamoorthy, Gajalakshmi
   Bartik, Mary Margaret
   Johnson, Gary Leon
   Webb, Brian
   Zheng, Guoxing
   Chen, Aoshuang
   Kalyanasundaram, Ramaswamy
   Munirathinam, Gnanasekar
TI Piperine, a Bioactive Component of Pepper Spice Exerts Therapeutic
   Effects on Androgen Dependent and Androgen Independent Prostate Cancer
   Cells
SO PLOS ONE
LA English
DT Article
ID FACTOR-KAPPA-B; INDUCED LUNG CARCINOGENESIS; IN-VIVO; CONSTITUTIVE
   ACTIVATION; GROWTH-INHIBITION; GENE-EXPRESSION; CARCINOMA-CELLS;
   RECEPTOR GENE; TUMOR-GROWTH; APOPTOSIS
AB Prostate cancer is the most common solid malignancy in men, with 32,000 deaths annually. Piperine, a major alkaloid constituent of black pepper, has previously been reported to have anti-cancer activity in variety of cancer cell lines. The effect of piperine against prostate cancer is not currently known. Therefore, in this study, we investigated the anti-tumor mechanisms of piperine on androgen dependent and androgen independent prostate cancer cells. Here, we show that piperine inhibited the proliferation of LNCaP, PC-3, 22RV1 and DU-145 prostate cancer cells in a dose dependent manner. Furthermore, Annexin-V staining demonstrated that piperine treatment induced apoptosis in hormone dependent prostate cancer cells (LNCaP). Using global caspase activation assay, we show that piperine-induced apoptosis resulted in caspase activation in LNCaP and PC-3 cells. Further studies revealed that piperine treatment resulted in the activation of caspase-3 and cleavage of PARP-1 proteins in LNCaP, PC-3 and DU-145 prostate cancer cells. Piperine treatment also disrupted androgen receptor (AR) expression in LNCaP prostate cancer cells. Our evaluations further show that there is a significant reduction of Prostate Specific Antigen (PSA) levels following piperine treatment in LNCaP cells. NF-kB and STAT-3 transcription factors have previously been shown to play a role in angiogenesis and invasion of prostate cancer cells. Interestingly, treatment of LNCaP, PC-3 and DU-145 prostate cancer cells with piperine resulted in reduced expression of phosphorylated STAT-3 and Nuclear factor-kappa B (NF-kB) transcription factors. These results correlated with the results of Boyden chamber assay, wherein piperine treatment reduced the cell migration of LNCaP and PC-3 cells. Finally, we show that piperine treatment significantly reduced the androgen dependent and androgen independent tumor growth in nude mice model xenotransplanted with prostate cancer cells. Taken together, these results support further investigation of piperine as a potential therapeutic agent in the treatment of prostate cancer.
C1 [Samykutty, Abhilash; Shetty, Aditya Vittal; Dakshinamoorthy, Gajalakshmi; Zheng, Guoxing; Chen, Aoshuang; Kalyanasundaram, Ramaswamy; Munirathinam, Gnanasekar] Univ Illinois, Coll Med, Dept Biomed Sci, Rockford, IL 61107 USA.
   [Bartik, Mary Margaret; Johnson, Gary Leon] Midwest SciTech, Bloomington, MN USA.
   [Webb, Brian] Thermo Fisher Sci, Rockford, IL USA.
RP Munirathinam, G (reprint author), Univ Illinois, Coll Med, Dept Biomed Sci, Rockford, IL 61107 USA.
EM mgnanas@uic.edu
OI samykutty, Abhilash/0000-0003-3551-045X
CR Abdulghani J, 2008, AM J PATHOL, V172, P1717, DOI 10.2353/ajpath.2008.071054
   Agarwal C, 2007, CARCINOGENESIS, V28, P1463, DOI 10.1093/carcin/bgm042
   Ahmad A, 2012, CARCINOGENESIS, V33, P2450, DOI 10.1093/carcin/bgs290
   Barton BE, 2001, BMC CANCER, V1, DOI 10.1186/1471-2407-1-19
   Bezerra DP, 2006, BRAZ J MED BIOL RES, V39, P801, DOI 10.1590/S0100-879X2006000600014
   Bezerra DP, 2008, J APPL TOXICOL, V28, P156, DOI 10.1002/jat.1261
   Biroccio A, 2004, ENDOCR-RELAT CANCER, V11, P407, DOI 10.1677/erc.1.00764
   Coffey RNT, 2001, J UROLOGY, V165, P5, DOI 10.1097/00005392-200101000-00003
   Davis JN, 1999, NUTR CANCER, V35, P167, DOI 10.1207/S15327914NC352_11
   Dussel S, 2008, CLIN LAB SCI, V21, P151
   Edwards J, 2003, BRIT J CANCER, V89, P552, DOI 10.1038/sj.bjc.6601127
   Elangovan I, 2012, BIOCHEM BIOPH RES CO, V417, P1133, DOI 10.1016/j.bbrc.2011.12.060
   Fradet V, 2004, CLIN CANCER RES, V10, P8460, DOI 10.1158/1078-0432.CCR-04-0764
   Gasparian AV, 2002, J CELL SCI, V115, P141
   Gnanasekar M, 2009, INT J ONCOL, V34, P1241, DOI 10.3892/ijo_00000252
   Guo S, 2011, PLOS ONE, V3
   Holzbeierlein J, 2004, AM J PATHOL, V164, P217, DOI 10.1016/S0002-9440(10)63112-4
   Huang M, 2000, GYNECOL ONCOL, V79, P67, DOI 10.1006/gyno.2000.5931
   Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.1002/caac.20073, 10.3322/caac.20073]
   Johnson JJ, 2012, CARCINOGENESIS, V33, P413, DOI 10.1093/carcin/bgr291
   JOHRI RK, 1992, J ETHNOPHARMACOL, V37, P85, DOI 10.1016/0378-8741(92)90067-2
   Kakarala M, 2010, BREAST CANCER RES TR, V122, P777, DOI 10.1007/s10549-009-0612-x
   Kakarala M, 2010, J AGR FOOD CHEM, V58, P6594, DOI 10.1021/jf100657r
   KAUFMANN SH, 1993, CANCER RES, V53, P3976
   Kilkenny C, 2011, J CEREBR BLOOD F MET, V31, P991, DOI 10.1038/jcbfm.2010.220
   Krishnakumar N, 2009, FOOD CHEM TOXICOL, V47, P2813, DOI 10.1016/j.fct.2009.08.017
   Li S, 2011, PHYTOMEDICINE, V19, P83, DOI 10.1016/j.phymed.2011.06.031
   Linja MJ, 2001, CANCER RES, V61, P3550
   Makhov P, 2012, PROSTATE, V72, P661, DOI 10.1002/pros.21469
   Marech I, 2012, INT J ONCOL, V40, P1313, DOI 10.3892/ijo.2012.1364
   Pradeep CR, 2004, INT IMMUNOPHARMACOL, V4, P1795, DOI 10.1016/j.intimp.2004.08.005
   Quon H, 2011, BJU INT, V108, P1734, DOI 10.1111/j.1464-410X.2011.10197.x
   Rago, 1998, Cancer Control, V5, P513
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Reddy L, 2003, PHARMACOL THERAPEUT, V99, P1, DOI 10.1016/S0163-7258(03)00042-1
   Ross JS, 2004, CLIN CANCER RES, V10, P2466, DOI 10.1158/1078-0432.CCR-0543-3
   Salami S, 2011, J CANCER RES CLIN, V137, P1151
   Selvendiran K, 2006, PULM PHARMACOL THER, V19, P107, DOI 10.1016/j.pupt.2005.04.002
   Selvendiran K, 2004, BIOMED PHARMACOTHER, V58, P264, DOI 10.1016/j.biopha.2003.08.027
   Shetty AV, 2011, INT J ONCOL, V39, P635, DOI 10.3892/ijo.2011.1061
   Shukla S, 2004, NEOPLASIA, V6, P390, DOI 10.1593/neo.04112
   Spiotto MT, 2000, PROSTATE, V42, P88, DOI 10.1002/(SICI)1097-0045(20000201)42:2<88::AID-PROS2>3.0.CO;2-P
   Srinivasan K, 2007, CRIT REV FOOD SCI, V47, P735, DOI 10.1080/10408390601062054
   Sunila ES, 2004, J ETHNOPHARMACOL, V90, P339, DOI 10.1016/j.jep.2003.10.016
   Sweeney C, 2004, CLIN CANCER RES, V10, P5501, DOI 10.1158/1078-0432.CCR-0571-03
   Tantivejkul K, 2005, J CELL BIOCHEM, V96, P641, DOI 10.1002/jcb.20533
   Yang J, 2012, NEURO-ONCOLOGY, V11, P36
   Yoo J, 2008, J CELL BIOCHEM, V104, P1636, DOI 10.1002/jcb.21729
NR 48
TC 40
Z9 41
U1 1
U2 28
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 18
PY 2013
VL 8
IS 6
AR e65889
DI 10.1371/journal.pone.0065889
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 166SA
UT WOS:000320576400031
PM 23824300
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Wang, J
   Zhao, Z
   Lin, E
   Zhao, W
   Qian, XJ
   Freire, D
   Bilski, AE
   Cheng, A
   Vempati, P
   Ho, L
   Ono, K
   Yamada, M
   Pasinetti, GM
AF Wang, Jun
   Zhao, Zhong
   Lin, Emi
   Zhao, Wei
   Qian, Xianjuan
   Freire, Daniel
   Bilski, Amanda E.
   Cheng, Alice
   Vempati, Prashant
   Ho, Lap
   Ono, Kenjiro
   Yamada, Masahito
   Pasinetti, Giulio M.
TI Unintended Effects of Cardiovascular Drugs on the Pathogenesis of
   Alzheimer's Disease
SO PLOS ONE
LA English
DT Article
ID AMYLOID-BETA-PROTEIN; ANTIHYPERTENSIVE-MEDICATION-USE; MOUSE MODEL;
   SYNAPTIC PLASTICITY; NATURAL OLIGOMERS; MEMORY; A-BETA(1-42);
   PREVENTION; DEMENTIA; THERAPY
AB Alzheimer's disease (AD) is rapidly becoming one of the leading causes of disability and mortality in the elderly. As life-expectancy increases, an increasing number of people will rely on modern medicines to treat age-associated disorders. Among these medications, some might benefit, while others might exacerbate, the pathogenesis of AD. We screened 1,600 FDA approved drugs for beta-amyloid (A beta)-modifying activity and identified drugs that can potentially influence amyloid precursor protein processing. In this study, we focused on cardiovascular drugs and demonstrated that some hypertensive medication can differentially modulate A beta, both in vitro and in vivo. Our study suggests that some commonly prescribed drugs might exert unintended effects and modulate AD and provides the basis for continuing investigation of the role of individual drugs on a case-by-case basis. This line of investigation will lead to the identification of common medications that are potentially beneficial or detrimental to AD as a reference for physicians to consider when prescribing the most appropriate drugs for their patients, particularly for treating chronic disorders among the growing geriatric population.
C1 [Wang, Jun; Zhao, Zhong; Zhao, Wei; Qian, Xianjuan; Freire, Daniel; Bilski, Amanda E.; Cheng, Alice; Vempati, Prashant; Ho, Lap; Pasinetti, Giulio M.] Mt Sinai Sch Med, Dept Neurol, New York, NY USA.
   [Lin, Emi] Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA.
   [Wang, Jun; Ho, Lap; Pasinetti, Giulio M.] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, New York, NY USA.
   [Ono, Kenjiro; Yamada, Masahito] Kanazawa Univ, Grad Sch Med Sci, Dept Neurol & Neurobiol & Aging, Kanazawa, Ishikawa, Japan.
RP Pasinetti, GM (reprint author), Mt Sinai Sch Med, Dept Neurol, New York, NY USA.
EM giulio.pasinetti@mssm.edu
OI Ling, Emi/0000-0001-5287-0284
FU National Institutes of Health [UO1 (AG29310)]; Department of Veterans
   Affairs; Altschul Foundation
FX This work was supported by grants from the National Institutes of Health
   UO1 (AG29310) and Department of Veterans Affairs to GMP, and in part by
   Altschul Foundation. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Arrieta-Cruz I, 2010, J ALZHEIMERS DIS, V21, P649, DOI 10.3233/JAD-2010-100225
   Braak H, 1997, Int Psychogeriatr, V9 Suppl 1, P257, DOI 10.1017/S1041610297004973
   CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0
   Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372
   Cummings Jeffrey L, 2004, Rev Neurol Dis, V1, P60
   Cummings JL, 2004, NEW ENGL J MED, V351, P56, DOI 10.1056/NEJMra040223
   Diaz-Ruiz C, 2009, Cardiovasc Psychiatry Neurol, V2009, P107286, DOI 10.1155/2009/107286
   Emilien G, 2000, ARCH NEUROL-CHICAGO, V57, P176, DOI 10.1001/archneur.57.2.176
   Forette F, 2002, ARCH INTERN MED, V162, P2046, DOI 10.1001/archinte.162.18.2046
   Fox C, 2011, J AM GERIATR SOC, V59, P1477, DOI 10.1111/j.1532-5415.2011.03491.x
   Guo ZC, 1999, ARCH NEUROL-CHICAGO, V56, P991, DOI 10.1001/archneur.56.8.991
   Gylys KH, 2003, J NEUROCHEM, V84, P1442, DOI 10.1046/j.1471-4159.2003.01643.x
   Hajjar I., 2012, ARCH NEUROL-CHICAGO, P1
   Hemming ML, 2005, J BIOL CHEM, V280, P37644, DOI 10.1074/jbc.M508460200
   Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99
   Khachaturian AS, 2006, ARCH NEUROL-CHICAGO, V63, P686, DOI 10.1001/archneur.63.5.noc60013
   Klyubin I, 2005, NAT MED, V11, P556, DOI 10.1038/nm1234
   Kotilinek LA, 2002, J NEUROSCI, V22, P6331
   Lacor PN, 2007, J NEUROSCI, V27, P796, DOI 10.1523/JNEUROSCI.3501-06.2007
   Lacor PN, 2004, J NEUROSCI, V24, P10191, DOI 10.1523/JNEUROSCI.3432-04.2004
   Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448
   Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533
   Lonergan M. H., 2012, J PSYCHIATR NEUROSCI, V37
   Lopez-Arrieta JM, 2002, COCHRANE DB SYST REV, V3
   MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Sano M, 2003, CNS SPECTRUMS, V8, P846, DOI 10.1017/S1092852900019283
   Schwabe L, 2013, BIOL PSYCHOL, V92, P227, DOI 10.1016/j.biopsycho.2012.10.003
   Schwabe L, 2012, BIOL PSYCHIAT, V71, P380, DOI 10.1016/j.biopsych.2011.10.028
   Selkoe DJ, 2001, PHYSIOL REV, V81, P741
   Shankar GM, 2008, NAT MED, V14, P837, DOI 10.1038/nm1782
   Shankar GM, 2007, J NEUROSCI, V27, P2866, DOI 10.1523/JNEUROSCI.4970-06.2007
   Wang J, 2005, FASEB J, V19, P659, DOI 10.1096/fj.04-3182fje
   Wang J, 2010, NEUROBIOL AGING
   Wang J, 2007, J CLIN INVEST, V117, P3393, DOI 10.1172/JC131547
   Zou K, 2007, J NEUROSCI, V27, P8628, DOI 10.1523/JNEUROSCI.1549-07.2007
NR 36
TC 15
Z9 15
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 6
PY 2013
VL 8
IS 6
AR e65232
DI 10.1371/journal.pone.0065232
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 173SK
UT WOS:000321099000046
PM 23762322
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Lu, L
   Sun, HC
   Zhang, W
   Chai, ZT
   Zhu, XD
   Kong, LQ
   Wang, WQ
   Zhang, KZ
   Zhang, YY
   Zhang, QB
   Ao, JY
   Li, JQ
   Wang, L
   Wu, WZ
   Tang, ZY
AF Lu, Lu
   Sun, Hui-Chuan
   Zhang, Wei
   Chai, Zong-Tao
   Zhu, Xiao-Dong
   Kong, Ling-Qun
   Wang, Wen-Quan
   Zhang, Ke-Zhi
   Zhang, Yuan-Yuan
   Zhang, Qiang-Bo
   Ao, Jian-Yang
   Li, Jia-Qi
   Wang, Lu
   Wu, Wei-Zhong
   Tang, Zhao-You
TI Aspirin Minimized the Pro-Metastasis Effect of Sorafenib and Improved
   Survival by Up-Regulating HTATIP2 in Hepatocellular Carcinoma
SO PLOS ONE
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIALS; LOW-DOSE ASPIRIN; IN-VIVO; TUMOR-GROWTH;
   ANTIANGIOGENIC THERAPY; ACETYLSALICYLIC-ACID; OXIDATIVE STRESS; CANCER
   INCIDENCE; LUNG METASTASIS; HEPATITIS-B
AB Background & Aims: We previously demonstrated the pro-metastasis effect of sorafenib in hepatocellular carcinoma (HCC), which is mediated by down-regulation of tumor suppressor HTATIP2. The aim of the present study was to determine whether aspirin minimizes this effect and improves survival.
   Methods: The effects of sorafenib, aspirin, and combined sorafenib and aspirin were observed in HCCLM3 and HepG2 xenograft nude mice. Tumor growth, intrahepatic metastasis (IHM), lung metastasis, and survival were assessed. Polymerase chain reaction (PCR) array, real-time (RT)-PCR, and Western blotting were used to examine gene expression. The antiinvasion and anti-metastasis effects of aspirin were studied in HTATIP2-knockdown and HTATIP2-overexpressing HCC cell lines. The molecular mechanism of HTATIP2 regulation by aspirin was explored.
   Results: Aspirin suppressed the pro-invasion and pro-metastasis effects of sorafenib in HCC and up-regulated HTATIP2 expression. Aspirin did not inhibit the proliferation of HCC cells, but it decreased the invasiveness of HCC with lower expression of HTATIP2 and increased expression of a set of markers, indicating a mesenchymal-to-epithelial transition in tumor cells. The up-regulation of HTATPI2 expression by aspirin is most likely mediated through inhibition of cyclooxygenase (COX) 2 expression.
   Conclusions: Aspirin minimized the pro-metastasis effect of sorafenib by up-regulating the tumor suppressor HTATIP2; this mechanism is mediated through inhibition of COX2.
C1 [Lu, Lu; Sun, Hui-Chuan; Chai, Zong-Tao; Zhu, Xiao-Dong; Kong, Ling-Qun; Zhang, Ke-Zhi; Zhang, Yuan-Yuan; Zhang, Qiang-Bo; Ao, Jian-Yang; Li, Jia-Qi; Wang, Lu; Wu, Wei-Zhong; Tang, Zhao-You] Fudan Univ, Liver Canc Inst, Shanghai 200433, Peoples R China.
   [Lu, Lu; Sun, Hui-Chuan; Chai, Zong-Tao; Zhu, Xiao-Dong; Kong, Ling-Qun; Zhang, Ke-Zhi; Zhang, Yuan-Yuan; Zhang, Qiang-Bo; Ao, Jian-Yang; Li, Jia-Qi; Wang, Lu; Wu, Wei-Zhong; Tang, Zhao-You] Fudan Univ, Zhongshan Hosp, Shanghai 200433, Peoples R China.
   [Lu, Lu; Sun, Hui-Chuan; Chai, Zong-Tao; Zhu, Xiao-Dong; Kong, Ling-Qun; Zhang, Ke-Zhi; Zhang, Yuan-Yuan; Zhang, Qiang-Bo; Ao, Jian-Yang; Li, Jia-Qi; Wang, Lu; Wu, Wei-Zhong; Tang, Zhao-You] Chinese Minist Educ, Key Lab Carcinogenesis & Canc Invas, Shanghai, Peoples R China.
   [Zhang, Wei] Tianjin Med Univ Canc Inst & Hosp TJCIH, Dept Hepatobiliary Surg, Tianjin, Peoples R China.
   [Zhang, Wei] Lab Canc Prevent & Therapy, Tianjin, Peoples R China.
   [Wang, Wen-Quan] Fudan Univ, Dept Hepatobiliary & Pancreat Surg, Inst Canc, Canc Hosp, Shanghai 200433, Peoples R China.
RP Tang, ZY (reprint author), Fudan Univ, Liver Canc Inst, Shanghai 200433, Peoples R China.
EM zytang88@163.com
RI Zhu, Xiao-Dong/A-8197-2010
OI Zhu, Xiao-Dong/0000-0001-9864-6763
FU National Key Project for Infectious Diseases [2012ZX10002012-004];
   National Natural Science Foundation of China [81101564, 81020108025];
   Shanghai Natural Science Foundation [12ZR1442300]; National "211"
   Project for Higher Education
FX This work was supported jointly by the National Key Project for
   Infectious Diseases (2012ZX10002012-004), the National Natural Science
   Foundation of China (No. 81101564, 81020108025), the Shanghai Natural
   Science Foundation (12ZR1442300), and the National "211" Project for
   Higher Education. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Abiru S, 2002, HEPATOLOGY, V35, P1117, DOI 10.1053/jhep.2002.32676
   Allegra CJ, 2011, J CLIN ONCOL, V29, P11, DOI 10.1200/JCO.2010.30.0855
   Cacheux W, 2008, ANN ONCOL, V19, P1659, DOI 10.1093/annonc/mdn540
   Carter CA, 2007, CANCER CHEMOTH PHARM, V59, P183, DOI 10.1007/s00280-006-0257-y
   Casanovas O, 2005, CANCER CELL, V8, P299, DOI 10.1016/j.ccr.2005.09.005
   Chan FKL, 2005, NEW ENGL J MED, V352, P238, DOI 10.1056/NEJMoa042087
   Chan FKL, 2001, NEW ENGL J MED, V344, P967, DOI 10.1056/NEJM200103293441304
   Chang YS, 2007, CANCER CHEMOTH PHARM, V59, P561, DOI 10.1007/s00280-006-0393-4
   Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7
   Collins R, 2009, LANCET, V373, P1849, DOI 10.1016/S0140-6736(09)60503-1
   De Bock K, 2011, NAT REV CLIN ONCOL, V8, P393, DOI 10.1038/nrclinonc.2011.83
   de Groot JF, 2010, NEURO-ONCOLOGY, V12, P233, DOI 10.1093/neuonc/nop027
   Desar IME, 2009, ACTA ONCOL, V48, P927, DOI 10.1080/02841860902974167
   Dinarello CA, 2010, CELL, V140, P935, DOI 10.1016/j.cell.2010.02.043
   Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021
   Futakuchi M, 2004, CANCER SCI, V95, P18, DOI 10.1111/j.1349-7006.2004.tb03165.x
   Futakuchi M, 2002, JPN J CANCER RES, V93, P1175, DOI 10.1111/j.1349-7006.2002.tb01220.x
   Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025
   HIAL V, 1977, J PHARMACOL EXP THER, V202, P446
   Holmes MD, 2010, J CLIN ONCOL, V28, P1467, DOI 10.1200/JCO.2009.22.7918
   Hossain MA, 2012, INT J ONCOL, V40, P1636, DOI 10.3892/ijo.2012.1359
   Huang ES, 2011, AM J MED, V124, P426, DOI 10.1016/j.amjmed.2010.12.022
   Keunen O, 2011, P NATL ACAD SCI USA, V108, P3749, DOI 10.1073/pnas.1014480108
   Lai KC, 2002, NEW ENGL J MED, V346, P2033, DOI 10.1056/NEJMoa012877
   Langley RE, 2011, BRIT J CANCER, V105, P1107, DOI 10.1038/bjc.2011.289
   Li Y, 2004, J CANCER RES CLIN, V130, P460, DOI 10.1007/s00432-004-0564-9
   Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857
   Morgan G, 2009, PUBLIC HEALTH, V123, P787, DOI 10.1016/j.puhe.2009.10.007
   Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Poon D, 2009, LANCET ONCOL, V10, P1111, DOI 10.1016/S1470-2045(09)70241-4
   Powles T, 2011, EUR UROL, V60, P448, DOI 10.1016/j.eururo.2011.05.028
   Raza H, 2011, EUR J PHARMACOL, V668, P15, DOI 10.1016/j.ejphar.2011.06.016
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Rothwell PM, 2012, LANCET, V379, P1591, DOI 10.1016/S0140-6736(12)60209-8
   Rothwell PM, 2012, LANCET, V379, P1602, DOI 10.1016/S0140-6736(11)61720-0
   Rothwell PM, 2011, LANCET, V377, P31, DOI 10.1016/S0140-6736(10)62110-1
   Rothwell PM, 2010, LANCET, V376, P1741, DOI 10.1016/S0140-6736(10)61543-7
   Saad-Hossne R, 2007, ACTA CIR BRAS, V22, P299, DOI 10.1590/S0102-86502007000400012
   Sahasrabuddhe VV, 2012, J NATL CANC I
   Sitia G, 2012, P NATL ACAD SCI USA, V109, pE2165, DOI 10.1073/pnas.1209182109
   Tang ZY, 2005, J SURG ONCOL, V91, P95, DOI 10.1002/jso.20291
   Wu CY, 2012, JAMA-J AM MED ASSOC, V308, P1906, DOI 10.1001/2012.jama.11975
   Yu CR, 2006, MOL CANCER THER, V5, P2378, DOI 10.1158/1535-7163.MCT-06-0235
   Yusuf S, 2001, NEW ENGL J MED, V345, P494
   Zhang W, 2012, GASTROENTEROLOGY
   Zhang W, 2010, CLIN CANCER RES, V16, P3420, DOI 10.1158/1078-0432.CCR-09-2904
   Zhao J, 2008, HEPATOLOGY, V48, P265, DOI 10.1002/hep.22280
   Zhao J, 2008, CANCER RES, V68, P4133, DOI 10.1158/0008-5472.CAN-08-0432
   Zhao J, 2006, HEPATOLOGY, V44, P205, DOI 10.1002/hep.21213
NR 50
TC 26
Z9 31
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 31
PY 2013
VL 8
IS 5
AR e65023
DI 10.1371/journal.pone.0065023
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 156DC
UT WOS:000319799900156
PM 23741443
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Huang, YT
   Wen, CC
   Chen, YH
   Huang, WC
   Huang, LT
   Lin, WC
   Arulselvan, P
   Liao, JW
   Lin, SH
   Hsiao, PW
   Kuo, SC
   Yang, NS
AF Huang, Yuh-Ting
   Wen, Chih-Chun
   Chen, Yung-Hsiang
   Huang, Wen-Ching
   Huang, Li-Ting
   Lin, Wen-Ching
   Arulselvan, Palanisamy
   Liao, Jiunn-Wang
   Lin, Shu-Hui
   Hsiao, Pei-Wen
   Kuo, Sheng-Chu
   Yang, Ning-Sun
TI Dietary Uptake of Wedelia chinensis Extract Attenuates Dextran Sulfate
   Sodium-Induced Colitis in Mice
SO PLOS ONE
LA English
DT Article
ID INFLAMMATORY-BOWEL-DISEASE; TNBS-INDUCED COLITIS; MATRIX
   METALLOPROTEINASES; INTESTINAL INFLAMMATION; ANTIOXIDANT ACTIVITY;
   COLORECTAL-CANCER; NITRIC-OXIDE; MOUSE MODEL; EXPRESSION; ARTICLE
AB Scope: Traditional medicinal herbs are increasingly used as alternative therapies in patients with inflammatory diseases. Here we evaluated the effect of Wedelia chinensis, a medicinal herb commonly used in Asia, on the prevention of dextran sulfate sodium (DSS)-induced acute colitis in mice. General safety and the effect of different extraction methods on the bioactivity of W. chinensis were also explored.
   Methods and Results: C57BL/6 mice were administrated hot water extract of fresh W. chinensis (WCHF) orally for one week followed by drinking water containing 2% DSS for nine days. WCHF significantly attenuated the symptoms of colitis including diarrhea, rectal bleeding and loss of body weight; it also reduced the shortening of colon length and histopathological damage caused by colonic inflammation. Among four W. chinensis extracts prepared using different extraction techniques, WCHF showed the highest anti-colitis efficacy. Analyses of specific T-cell regulatory cytokines (TNF-alpha, IL-4, IFN-gamma, IL-17, TGF-beta, IL-12) revealed that WCHF treatment can suppress the Th1 and Th17, but not Th2, responses in colon tissues and dendritic cells of DSS-induced colitis mice. A 28-day subacute toxicity study showed that daily oral administration of WCHF (100, 500, 1000 mg/kg body weight) was not toxic to mice.
   Conclusion: Together, our findings suggest that specific extracts of W. chinensis have nutritional potential for future development into nutraceuticals or dietary supplements for treatment of inflammatory bowel disease.
C1 [Huang, Yuh-Ting; Chen, Yung-Hsiang; Huang, Wen-Ching; Huang, Li-Ting; Lin, Wen-Ching; Arulselvan, Palanisamy; Hsiao, Pei-Wen; Yang, Ning-Sun] Acad Sinica, Agr Biotechnol Res Ctr, Taipei 115, Taiwan.
   [Kuo, Sheng-Chu] China Med Univ, Grad Inst Pharmaceut Chem, Taichung, Taiwan.
   [Liao, Jiunn-Wang] Natl Chung Hsing Univ, Grad Inst Vet Pathol, Taichung 40227, Taiwan.
   [Wen, Chih-Chun; Lin, Shu-Hui] One Power Bio Technol Co Ltd, Taipei, Taiwan.
RP Yang, NS (reprint author), Acad Sinica, Agr Biotechnol Res Ctr, Taipei 115, Taiwan.
EM nsyang@gate.sinica.edu.tw
RI Arulselvan, Palanisamy/M-6388-2014; Hsiao, Pei-Wen/V-5653-2018
OI Arulselvan, Palanisamy/0000-0002-1835-9738; Hsiao,
   Pei-Wen/0000-0002-3589-6754
FU National Science Council, Taiwan, R.O.C [NSC-97-2317-B-001-010-CC2,
   NSC-98-2324-B-001-002-CC2, NSC-99-2324-B-001-003-CC2]
FX This work was supported by grants (NSC-97-2317-B-001-010-CC2,
   NSC-98-2324-B-001-002-CC2 and NSC-99-2324-B-001-003-CC2) from the
   National Science Council, Taiwan, R.O.C. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Alex P, 2009, INFLAMM BOWEL DIS, V15, P341, DOI 10.1002/ibd.20753
   Amin I, 2006, FOOD CHEM, V94, P47, DOI 10.1016/j.foodchem.2004.10.048
   BABCOCK MB, 1975, AM J ANAT, V143, P399, DOI 10.1002/aja.1001430402
   Berndt BE, 2007, J IMMUNOL, V179, P6255, DOI 10.4049/jimmunol.179.9.6255
   Capecka E, 2005, FOOD CHEM, V93, P223, DOI 10.1016/j.foodchem.2004.09.020
   Chen HM, 2012, CANCER IMMUNOL IMMUN, V61, P1989, DOI 10.1007/s00262-012-1258-9
   Choi YA, 2005, INT J MOL MED, V16, P667
   COOPER HS, 1993, LAB INVEST, V69, P238
   Dijkstra G, 2007, INFLAMM BOWEL DIS, V13, P1467, DOI 10.1002/ibd.20262
   Fiocchi C, 1998, GASTROENTEROLOGY, V115, P182, DOI 10.1016/S0016-5085(98)70381-6
   Garg P, 2009, AM J PHYSIOL-GASTR L, V296, pG175, DOI 10.1152/ajpgi.90454.2008
   Grisham MB, 2002, J INVEST MED, V50, P272, DOI 10.2310/6650.2002.33281
   HAMMAD ESF, 1982, DIGEST DIS SCI, V27, P680, DOI 10.1007/BF01393762
   Hanauer SB, 2006, INFLAMM BOWEL DIS, V12, pS3, DOI 10.1097/01.MIB.0000195385.19268.68
   Hanauer SB, 2004, ALIMENT PHARM THER, V20, P60, DOI 10.1111/j.1365-2036.2004.02048.x
   Huang TC, 1998, FLORA TAIWAN
   Huang TC, 2010, WORLD J GASTROENTERO, V16, P4193, DOI 10.3748/wjg.v16.i33.4193
   Jackson LN, 2008, AM J CHINESE MED, V36, P953, DOI 10.1142/S0192415X08006375
   Kapsenberg ML, 2003, NAT REV IMMUNOL, V3, P984, DOI 10.1038/nri1246
   Kawada M, 2007, WORLD J GASTROENTERO, V13, P5581, DOI 10.3748/wjg.v13.i42.5581
   Krakauer T, 2002, IMMUNOPHARM IMMUNOT, V24, P113, DOI 10.1081/IPH-120003407
   KRAWISZ JE, 1984, GASTROENTEROLOGY, V87, P1344
   Kretzmann NA, 2008, INFLAMM BOWEL DIS, V14, P1504, DOI 10.1002/ibd.20543
   Kunnumakkara AB, 2009, INT J CANCER, V125, P2187, DOI 10.1002/ijc.24593
   Lam W, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001270
   Langmead L, 2006, ALIMENT PHARM THER, V23, P341, DOI 10.1111/j.1365-2036.2006.02761.x
   LEVIN B, 1992, CANCER, V70, P1313, DOI 10.1002/1097-0142(19920901)70:3+<1313::AID-CNCR2820701518>3.0.CO;2-B
   LIN SC, 1994, AM J CHINESE MED, V22, P155, DOI 10.1142/S0192415X9400019X
   Lin WC, 2011, GENETIC DIVERSITY RE
   Lin WY, 2008, PLANTA MED, V74, P464, DOI 10.1055/s-2008-1034325
   Lin Y. L., 2008, J CHINESE MED, V19, P135
   Manel N, 2008, NAT IMMUNOL, V9, P641, DOI 10.1038/ni.1610
   Munkholm P, 2003, ALIMENT PHARM THERAP, V18, P1, DOI 10.1046/j.1365-2036.18.s2.2.x
   O'Connor Mortimer B, 2009, Cases J, V2, P173, DOI 10.1186/1757-1626-2-173
   Pizarro TT, 2007, ANNU REV MED, V58, P433, DOI 10.1146/annurev.med.58.121205.100607
   Podolsky DK, 2002, NEW ENGL J MED, V347, P417, DOI 10.1056/NEJMra020831
   Raina K, 2013, CANCER PREV RES, V6, P40, DOI 10.1158/1940-6207.CAPR-12-0387
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Shackelford C, 2002, TOXICOL PATHOL, V30, P93, DOI 10.1080/01926230252824761
   Shan JH, 2009, INT IMMUNOPHARMACOL, V9, P1042, DOI 10.1016/j.intimp.2009.04.011
   Shyur LF, 2008, CURR OPIN CHEM BIOL, V12, P66, DOI 10.1016/j.cbpa.2008.01.032
   Staniforth V, 2012, J NUTR BIOCHEM, V23, P443, DOI 10.1016/j.jnutbio.2011.01.009
   TARGAN SR, 1995, NAT MED, V1, P1241, DOI 10.1038/nm1295-1241
   Toor RK, 2006, FOOD CHEM, V94, P90, DOI 10.1016/j.foodchem.2004.10.054
   Tsai CH, 2009, CLIN CANCER RES, V15, P5435, DOI 10.1158/1078-0432.CCR-09-0298
   von Lampe B, 2000, GUT, V47, P63, DOI 10.1136/gut.47.1.63
   Wang XS, 2003, AM J CHINESE MED, V31, P927, DOI 10.1142/S0192415X0300165X
   Wirtz S, 2007, NAT PROTOC, V2, P541, DOI 10.1038/nprot.2007.41
   Xu CT, 2004, WORLD J GASTROENTERO, V10, P2311
NR 49
TC 14
Z9 14
U1 0
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 29
PY 2013
VL 8
IS 5
AR e64152
DI 10.1371/journal.pone.0064152
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 155DJ
UT WOS:000319725500079
PM 23734189
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Rendeiro, C
   Vauzour, D
   Rattray, M
   Waffo-Teguo, P
   Merillon, JM
   Butler, LT
   Williams, CM
   Spencer, JPE
AF Rendeiro, Catarina
   Vauzour, David
   Rattray, Marcus
   Waffo-Teguo, Pierre
   Merillon, Jean Michel
   Butler, Laurie T.
   Williams, Claire M.
   Spencer, Jeremy P. E.
TI Dietary Levels of Pure Flavonoids Improve Spatial Memory Performance and
   Increase Hippocampal Brain-Derived Neurotrophic Factor
SO PLOS ONE
LA English
DT Article
ID BDNF MESSENGER-RNA; GINKGO-BILOBA EXTRACT; ELEMENT-BINDING PROTEIN;
   AGE-RELATED DECLINES; FLAVANOL-RICH COCOA; GREEN TEA; BLUEBERRY
   SUPPLEMENTATION; DENTATE GYRUS; AGING BRAIN; SYNAPTIC PLASTICITY
AB Evidence suggests that flavonoid-rich foods are capable of inducing improvements in memory and cognition in animals and humans. However, there is a lack of clarity concerning whether flavonoids are the causal agents in inducing such behavioral responses. Here we show that supplementation with pure anthocyanins or pure flavanols for 6 weeks, at levels similar to that found in blueberry (2% w/w), results in an enhancement of spatial memory in 18 month old rats. Pure flavanols and pure anthocyanins were observed to induce significant improvements in spatial working memory (p = 0.002 and p = 0.006 respectively), to a similar extent to that following blueberry supplementation (p = 0.002). These behavioral changes were paralleled by increases in hippocampal brain-derived neurotrophic factor (R = 0.46, p < 0.01), suggesting a common mechanism for the enhancement of memory. However, unlike protein levels of BDNF, the regional enhancement of BDNF mRNA expression in the hippocampus appeared to be predominantly enhanced by anthocyanins. Our data support the claim that flavonoids are likely causal agents in mediating the cognitive effects of flavonoid-rich foods.
C1 [Rendeiro, Catarina; Vauzour, David; Spencer, Jeremy P. E.] Univ Reading, Sch Chem Food & Pharm, Mol Nutr Grp, Reading, Berks, England.
   [Rendeiro, Catarina; Butler, Laurie T.; Williams, Claire M.] Univ Reading, Sch Psychol & Clin Language Sci, Reading, Berks, England.
   [Rattray, Marcus] Univ Reading, Reading Sch Pharm, Reading, Berks, England.
   [Waffo-Teguo, Pierre; Merillon, Jean Michel] Univ Bordeaux, ISVV, Grp Etud Subst Vegetales Act Biol, Villenave Dornon, France.
RP Spencer, JPE (reprint author), Univ Reading, Sch Chem Food & Pharm, Mol Nutr Grp, Reading, Berks, England.
EM j.p.e.spencer@reading.ac.uk
RI Rattray, Marcus/C-4088-2009; Spencer, Jeremy P. E./F-4757-2010; Vauzour,
   David/C-2245-2008
OI Rattray, Marcus/0000-0002-6620-9830; Spencer, Jeremy P.
   E./0000-0003-2931-7274; Vauzour, David/0000-0001-5952-8756; Rendeiro,
   Catarina/0000-0003-1225-7105; Williams, Claire/0000-0003-4452-671X
FU Biotechnology and Biological Sciences Research Council [BB/F008953/1];
   Fundacao para a Ciencia e a Tecnologia (FCT) [SFRH/BD/69711/2010]
FX This research was supported by the Biotechnology and Biological Sciences
   Research Council (grant BB/F008953/1) and the Fundacao para a Ciencia e
   a Tecnologia (FCT) (grant SFRH/BD/69711/2010). The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abd El Mohsen MM, 2002, FREE RADICAL BIO MED, V33, P1693, DOI 10.1016/S0891-5849(02)01137-1
   Aggleton JP, 1996, BEHAV BRAIN RES, V81, P189, DOI 10.1016/S0166-4328(96)89080-2
   Alonso M, 2004, LEARN MEMORY, V11, P172, DOI 10.1101/lm.67804
   Andres-Lacueva C, 2005, NUTR NEUROSCI, V8, P111, DOI 10.1080/10284150500078117
   Athos J, 2002, NAT NEUROSCI, V5, P1119, DOI 10.1038/nn951
   Augustin S, 2009, J CLIN BIOCHEM NUTR, V45, P315, DOI 10.3164/jcbn.08-248
   Banerjee S, 2003, BIOTECHNIQUES, V35, P450, DOI 10.2144/03353bm02
   Beking K, 2010, PUBLIC HEALTH NUTR, V13, P1403, DOI 10.1017/S1368980009992990
   Bekinschtein P, 2008, P NATL ACAD SCI USA, V105, P2711, DOI 10.1073/pnas.0711863105
   Bekinschtein P, 2007, NEURON, V53, P261, DOI 10.1016/j.neuron.2006.11.025
   Berchtold NC, 2010, NEUROSCIENCE, V167, P588, DOI 10.1016/j.neuroscience.2010.02.050
   Burke SN, 2006, NAT REV NEUROSCI, V7, P30, DOI 10.1038/nrn1809
   Carey AN, 2012, NUTR AGING, V1, P55
   Casadesus G, 2004, NUTR NEUROSCI, V7, P309, DOI 10.1080/10284150400020482
   Chan YC, 2006, J NUTR SCI VITAMINOL, V52, P266, DOI 10.3177/jnsv.52.266
   Cheng AW, 2003, DEV BIOL, V258, P319, DOI 10.1016/S0012-1606(03)00120-9
   Cohen-Salmon C, 1997, J PHYSIOL-PARIS, V91, P291, DOI 10.1016/S0928-4257(97)82409-6
   Conner JM, 1997, J NEUROSCI, V17, P2295
   Coultrap SJ, 2008, AGE, V30, P263, DOI 10.1007/s11357-008-9067-y
   Dinges DF, 2006, J CARDIOVASC PHARM, V47, pS221
   FALKENBERG T, 1992, NEUROSCI LETT, V138, P153, DOI 10.1016/0304-3940(92)90494-R
   Fisher NDL, 2006, J CARDIOVASC PHARM, V47, pS210, DOI 10.1097/00005344-200606001-00017
   Francis ST, 2006, J CARDIOVASC PHARM, V47, pS215, DOI 10.1097/00005344-200606001-00018
   Gallagher M, 2003, ALZ DIS ASSOC DIS, V17, pS45, DOI 10.1097/00002093-200304002-00004
   Garza AA, 2004, PHARMACOL BIOCHEM BE, V77, P209, DOI 10.1016/j.pbb.2003.10.020
   Gooney M, 2004, NEUROBIOL AGING, V25, P1323, DOI 10.1016/j.neurobiolaging.2004.01.003
   Hall J, 2000, NAT NEUROSCI, V3, P533
   Haque AM, 2006, J NUTR, V136, P1043
   Hattiangady B, 2005, EXP NEUROL, V195, P353, DOI 10.1016/j.expneurol.2005.05.014
   Hayashi M, 2001, BRAIN RES, V918, P191, DOI 10.1016/S0006-8993(01)03002-5
   Hou Y, 2010, NEUROPHARMACOLOGY, V58, P911, DOI 10.1016/j.neuropharm.2009.11.002
   Hwang K, 2006, EXP NEUROL, V201, P75, DOI 10.1016/j.expneurol.2006.02.129
   Igaz LM, 2004, NEUROTOX RES, V6, P189, DOI 10.1007/BF03033221
   Izquierdo I, 1997, NEUROBIOL LEARN MEM, V68, P285, DOI 10.1006/nlme.1997.3799
   Jin CH, 2009, J NEUROSCI RES, V87, P3658, DOI 10.1002/jnr.22159
   Joseph JA, 1999, J NEUROSCI, V19, P8114
   Kalt W, 2008, J AGR FOOD CHEM, V56, P705, DOI 10.1021/jf071998l
   Kaur T, 2008, BRAIN COGNITION, V67, P25, DOI 10.1016/j.bandc.2007.10.003
   Kelm MA, 2006, J AGR FOOD CHEM, V54, P1571, DOI 10.1021/jf0525941
   Krikorian R, 2010, J AGR FOOD CHEM, V58, P3996, DOI 10.1021/jf9029332
   Kuriyama S, 2006, AM J CLIN NUTR, V83, P355
   Lai HC, 2004, CANCER LETT, V213, P181, DOI 10.1016/j.canlet.2004.04.031
   Lamport DJ, 2012, NUTR AGING, V1, P5, DOI DOI 10.3233/NUA-2012-0002
   Letenneur L, 2007, AM J EPIDEMIOL, V165, P1364, DOI 10.1093/aje/kwm036
   Leuner B, 2003, J NEUROSCI, V23, P659
   Li Q, 2009, NEUROSCIENCE, V163, P741, DOI 10.1016/j.neuroscience.2009.07.014
   Li Q, 2009, NEUROSCIENCE, V159, P1208, DOI 10.1016/j.neuroscience.2009.02.008
   Li Q, 2006, J NEUROSCI RES, V84, P1656, DOI 10.1002/jnr.21087
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Maher P, 2006, P NATL ACAD SCI USA, V103, P16568, DOI 10.1073/pnas.0607822103
   McGaugh JL, 2000, SCIENCE, V287, P248, DOI 10.1126/science.287.5451.248
   Milbury PE, 2010, J AGR FOOD CHEM, V58, P3950, DOI 10.1021/jf903529m
   Oliveira DR, 2009, BRAIN RES, V1269, P68, DOI 10.1016/j.brainres.2008.11.105
   Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3
   Pang PT, 2004, SCIENCE, V306, P487, DOI 10.1126/science.1100135
   Patel AK, 2008, INT J CLIN EXP MED, V1, P181
   PHILLIPS HS, 1991, NEURON, V7, P695, DOI 10.1016/0896-6273(91)90273-3
   PHILLIPS HS, 1990, SCIENCE, V250, P290, DOI 10.1126/science.1688328
   Poo MM, 2001, NAT REV NEUROSCI, V2, P24, DOI 10.1038/35049004
   Rattray M, 1999, NEUROSCIENCE, V88, P169, DOI 10.1016/S0306-4522(98)00231-0
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Rendeiro C, 2012, PSYCHOPHARMACOLOGY, V223, P319, DOI 10.1007/s00213-012-2719-8
   Robbins RJ, 2009, J CHROMATOGR A, V1216, P4831, DOI 10.1016/j.chroma.2009.04.006
   Rodriguez-Mateos A., 2012, J AGR FOOD CHEM
   Rosenzweig ES, 2003, PROG NEUROBIOL, V69, P143, DOI 10.1016/S0301-0082(02)00126-0
   Saunders C, 2012, NUTR AGING, V1, P69
   Schaaf MJM, 2001, BRAIN RES, V915, P227, DOI 10.1016/S0006-8993(01)02855-4
   Schroeter H, 2006, P NATL ACAD SCI USA, V103, P1024, DOI 10.1073/pnas.0510168103
   Schroeter H, 2007, J NEUROCHEM, V101, P1596, DOI 10.1111/j.1471-4159.2006.04434.x
   Shif O, 2006, PHARMACOL BIOCHEM BE, V84, P17, DOI 10.1016/j.pbb.2006.04.003
   Shukitt-Hale B, 2008, J AGR FOOD CHEM, V56, P636, DOI 10.1021/jf072505f
   Silhol M, 2007, NEUROSCIENCE, V146, P962, DOI 10.1016/j.neuroscience.2007.02.013
   Smith TD, 2000, J NEUROSCI, V20, P6587, DOI 10.1523/JNEUROSCI.20-17-06587.2000
   Spencer JPE, 2008, P NUTR SOC, V67, P238, DOI 10.1017/S0029665108007088
   Tapia-Arancibia L, 2008, BRAIN RES REV, V59, P201, DOI 10.1016/j.brainresrev.2008.07.007
   Tolwani RJ, 2002, NEUROSCIENCE, V114, P795, DOI 10.1016/S0306-4522(02)00301-9
   Tyler WJ, 2002, LEARN MEMORY, V9, P224, DOI 10.1101/lm.51202
   Unno K, 2007, BIOGERONTOLOGY, V8, P89, DOI 10.1007/s10522-006-9036-8
   van Praag H, 2007, J NEUROSCI, V27, P5869, DOI 10.1523/JNEUROSCI.0914-07.2007
   Vauzour D, 2007, J NEUROCHEM, V103, P1355, DOI 10.1111/j.1471-4159.2007.04841.x
   Wang YF, 2006, BRIT J PHARMACOL, V148, P147, DOI 10.1038/sj.bjp.0706720
   Williams B, 2004, NEUROBIOL AGING, V25, P955, DOI 10.1016/j.neurobiolaging.2003.10.008
   Williams CM, 2008, FREE RADICAL BIO MED, V45, P295, DOI 10.1016/j.freeradbiomed.2008.04.008
   Williams RJ, 2004, FREE RADICAL BIO MED, V36, P838, DOI 10.1016/j.freeradbiomed.2004.01.001
NR 84
TC 63
Z9 64
U1 2
U2 75
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 28
PY 2013
VL 8
IS 5
AR e63535
DI 10.1371/journal.pone.0063535
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 155FM
UT WOS:000319733000012
PM 23723987
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Magliano, DC
   Bargut, TCL
   de Carvalho, SN
   Aguila, MB
   Mandarim-de-Lacerda, CA
   Souza-Mello, V
AF Magliano, D'Angelo Carlo
   Lonzetti Bargut, Thereza Cristina
   de Carvalho, Simone Nunes
   Aguila, Marcia Barbosa
   Mandarim-de-Lacerda, Carlos Alberto
   Souza-Mello, Vanessa
TI Peroxisome Proliferator-Activated Receptors-Alpha and Gamma Are Targets
   to Treat Offspring from Maternal Diet-Induced Obesity in Mice
SO PLOS ONE
LA English
DT Article
ID BETA-CELL FUNCTION; HIGH-FAT DIET; ADIPOSE-TISSUE; INSULIN-RESISTANCE;
   PPAR-ALPHA; METABOLIC SYNDROME; TRANSCRIPTION FACTOR; HEPATIC STEATOSIS;
   LIPID-METABOLISM; GENE-EXPRESSION
AB Aim: The aim of the present study was to evaluate whether activation of peroxisome proliferator-activated receptor (PPAR) alpha and PPARgamma by Bezafibrate (BZ) could attenuate hepatic and white adipose tissue (WAT) abnormalities in male offspring from diet-induced obese dams.
   Materials and Methods: C57BL/6 female mice were fed a standard chow (SC; 10% lipids) diet or a high-fat (HF; 49% lipids) diet for 8 weeks before mating and during gestation and lactation periods. Male offspring received SC diet at weaning and were subdivided into four groups: SC, SC/BZ, HF and HF/BZ. Treatment with BZ (100 mg/Kg diet) started at 12 weeks of age and was maintained for three weeks.
   Results: The HF diet resulted in an overweight phenotype and an increase in oral glucose intolerance and fasting glucose of dams. The HF offspring showed increased body mass, higher levels of plasmatic and hepatic triglycerides, higher levels of pro-inflammatory and lower levels of anti-inflammatory adipokines, impairment of glucose metabolism, abnormal fat pad mass distribution, higher number of larger adipocytes, hepatic steatosis, higher expression of lipogenic proteins concomitant to decreased expression of PPARalpha and carnitine palmitoyltransferase I (CPT-1) in liver, and diminished expression of PPARgamma and adiponectin in WAT. Treatment with BZ ameliorated the hepatic and WAT abnormalities generated by diet-induced maternal obesity, with improvements observed in the structural, biochemical and molecular characteristics of the animals' livers and epididymal fat.
   Conclusion: Diet-induced maternal obesity lead to alterations in metabolism, hepatic lipotoxicity and adverse liver and WAT remodeling in the offspring. Targeting PPAR with Bezafibrate has beneficial effects reducing the alterations, mainly through reduction of WAT inflammatory state through PPARgamma activation and enhanced hepatic beta-oxidation due to increased PPARalpha/PPARgamma ratio in liver.
C1 [Magliano, D'Angelo Carlo; Lonzetti Bargut, Thereza Cristina; de Carvalho, Simone Nunes; Aguila, Marcia Barbosa; Mandarim-de-Lacerda, Carlos Alberto; Souza-Mello, Vanessa] Univ Estado Rio De Janeiro, Lab Morphometry Metab & Cardiovasc Dis, Biomed Ctr, Inst Biol, Rio De Janeiro, Brazil.
RP Mandarim-de-Lacerda, CA (reprint author), Univ Estado Rio De Janeiro, Lab Morphometry Metab & Cardiovasc Dis, Biomed Ctr, Inst Biol, Rio De Janeiro, Brazil.
EM mandarim@uerj.br
RI Aguila, Marcia/P-2349-2019; Souza-Mello, Vanessa/E-3463-2014;
   Mandarim-de-Lacerda, Carlos Alberto/P-2360-2019; Mandarim-de-Lacerda,
   Carlos A/F-7125-2012
OI Souza-Mello, Vanessa/0000-0002-2510-9569; Mandarim-de-Lacerda, Carlos
   Alberto/0000-0003-4134-7978; Barbosa Aguila, Marcia/0000-0003-3994-4589
FU CNPq (Brazilian Council of Science and Technology) [470727/2009-8,
   472033/2011-5]; FAPERJ (Rio de Janeiro State Foundation for Scientific
   Research) [E-26/102.289/2010]
FX Financial support was provided by the agencies CNPq (Brazilian Council
   of Science and Technology, www.cnpq.br), grant number 470727/2009-8 for
   CAML and 472033/2011-5 for VSM; and FAPERJ (Rio de Janeiro State
   Foundation for Scientific Research, www.faperj.br), grant number
   E-26/102.289/2010 for VSM. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Aguila M. B., 2010, INSULIN RESISTANCE S, P1
   Barbosa-da-Silva S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039837
   Berg AH, 2002, TRENDS ENDOCRIN MET, V13, P84, DOI 10.1016/S1043-2760(01)00524-0
   Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5
   Brunt EM, 1999, AM J GASTROENTEROL, V94, P2467, DOI 10.1111/j.1572-0241.1999.01377.x
   Cabrero A, 2003, METABOLISM, V52, P652, DOI 10.1053/meta.2003.50100
   Campbell SE, 2004, J BIOL CHEM, V279, P36235, DOI 10.1074/jbc.M400566200
   Catta-Preta M, 2012, NUTRITION, V28, P212, DOI 10.1016/j.nut.2011.05.011
   Catta-Preta M, 2011, VIRCHOWS ARCH, V459, P477, DOI 10.1007/s00428-011-1147-1
   Chen GX, 2004, P NATL ACAD SCI USA, V101, P11245, DOI 10.1073/pnas.0404297101
   Christodoulides C, 2010, MOL CELL ENDOCRINOL, V318, P61, DOI 10.1016/j.mce.2009.09.014
   De Souza CT, 2010, J PHYSIOL-LONDON, V588, P2239, DOI 10.1113/jphysiol.2009.183996
   Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649
   Drake AJ, 2010, REPRODUCTION, V140, P387, DOI 10.1530/REP-10-0077
   Eckel RH, 2005, LANCET, V365, P1415, DOI 10.1016/S0140-6736(05)66378-7
   Fernandes-Santos C, 2009, NUTRITION, V25, P818, DOI 10.1016/j.nut.2008.12.010
   Festi D, 2004, Obes Rev, V5, P27, DOI 10.1111/j.1467-789X.2004.00126.x
   Fox CS, 2007, CIRCULATION, V116, P39, DOI 10.1161/CIRCULATIONAHA.106.675355
   Gavrilova O, 2003, J BIOL CHEM, V278, P34268, DOI 10.1074/jbc.M300043200
   Goto T, 2011, J LIPID RES, V52, P873, DOI 10.1194/jlr.M011320
   GREGORIO BM, 2010, AM J OBSTET GYNECOL, V203
   Gustafson B, 2007, ARTERIOSCL THROM VAS, V27, P2276, DOI 10.1161/ATVBAHA.107.147835
   Hays T, 2005, CARCINOGENESIS, V26, P219, DOI 10.1093/carcin/bgh285
   Howie GJ, 2009, J PHYSIOL-LONDON, V587, P905, DOI 10.1113/jphysiol.2008.163477
   Kleemann R, 2003, BLOOD, V101, P545, DOI 10.1182/blood-2002-06-1762
   Kudoh A, 2011, LIFE SCI, V88, P1055, DOI 10.1016/j.lfs.2011.04.001
   Kwon EY, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-450
   Lee HJ, 2002, BIOCHEM BIOPH RES CO, V296, P293, DOI 10.1016/S0006-291X(02)00822-7
   Lee JK, 2010, KOREAN J PHYSIOL PHA, V14, P185, DOI 10.4196/kjpp.2010.14.3.185
   Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200
   Ma Berger, 2002, ANNU REV MED, V53, P409
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   Nagasawa T, 2006, EUR J PHARMACOL, V536, P182, DOI 10.1016/j.ejphar.2006.02.028
   Okuno A, 1998, J CLIN INVEST, V101, P1354, DOI 10.1172/JCI1235
   Peters JM, 2003, BBA-MOL CELL BIOL L, V1632, P80, DOI 10.1016/S1388-1981(03)00065-9
   Pettinelli P, 2011, J CLIN ENDOCR METAB, V96, P1424, DOI 10.1210/jc.2010-2129
   Pettinelli P, 2009, BBA-MOL BASIS DIS, V1792, P1080, DOI 10.1016/j.bbadis.2009.08.015
   Pou KM, 2007, CIRCULATION, V116, P1234, DOI 10.1161/CIRCULATIONAHA.107.710509
   Rakhshandehroo M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006796
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Samuelsson AM, 2008, HYPERTENSION, V51, P383, DOI 10.1161/HYPERTENSIONAHA.107.101477
   Serviddio G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024084
   Souza-Mello V, 2007, BRIT J NUTR, V98, P1159, DOI 10.1017/S0007114507771878
   Souza-Mello V, 2010, CLIN SCI, V119, P239, DOI 10.1042/CS20100061
   Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000
   Sullivan EL, 2011, NEUROENDOCRINOLOGY, V93, P1, DOI 10.1159/000322038
   Takahashi S, 2006, PHARMACOL RES, V53, P501, DOI 10.1016/j.phrs.2006.03.019
   Tenenbaum A, 2008, ADV CARDIOL, V45, P127, DOI 10.1159/0000115192
   Tenenbaum A, 2005, CARDIOVASC DIABETOL, V4, DOI 10.1186/1475-2840-4-14
   Tenenbaum H, 2007, ATHEROSCLEROSIS, V194, P265, DOI 10.1016/j.atheroselerosis.2006.08.005
   Teramoto T, 2012, CARDIOVASC DIABETOL, V11, DOI 10.1186/1475-2840-11-29
   Tschanz SA, 2011, J MICROSC-OXFORD, V243, P47, DOI 10.1111/j.1365-2818.2010.03481.x
   Vickers MH, 2001, J ENDOCRINOL, V170, P323, DOI 10.1677/joe.0.1700323
   Vosper H, 2001, J BIOL CHEM, V276, P44258, DOI 10.1074/jbc.M108482200
   Way JM, 2001, ENDOCRINOLOGY, V142, P1269, DOI 10.1210/en.142.3.1269
NR 55
TC 47
Z9 49
U1 0
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 20
PY 2013
VL 8
IS 6
AR e64258
DI 10.1371/journal.pone.0064258
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 158JQ
UT WOS:000319966400050
PM 23700465
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Okamoto, S
   Jiang, YY
   Kawamura, K
   Shingyoji, M
   Fukamachi, T
   Tada, Y
   Takiguchi, Y
   Tatsumi, K
   Shimada, H
   Hiroshima, K
   Kobayashi, H
   Tagawa, M
AF Okamoto, Shinya
   Jiang, Yuanyuan
   Kawamura, Kiyoko
   Shingyoji, Masato
   Fukamachi, Toshihiko
   Tada, Yuji
   Takiguchi, Yuichi
   Tatsumi, Koichiro
   Shimada, Hideaki
   Hiroshima, Kenzo
   Kobayashi, Hiroshi
   Tagawa, Masatoshi
TI Zoledronic Acid Produces Combinatory Anti-Tumor Effects with Cisplatin
   on Mesothelioma by Increasing p53 Expression Levels
SO PLOS ONE
LA English
DT Article
ID CELL LUNG-CANCER; GENE-THERAPY; BISPHOSPHONATES; CHEMOTHERAPY; PATIENT;
   MODEL
AB We examined anti-tumor effects of zoledronic acid (ZOL), one of the bisphosphonates agents clinically used for preventing loss of bone mass, on human mesothelioma cells bearing the wild-type p53 gene. ZOL-treated cells showed activation of caspase-3/7, -8 and -9, and increased sub-G1 phase fractions. A combinatory use of ZOL and cisplatin (CDDP), one of the first-line anti-cancer agents for mesothelioma, synergistically or additively produced the cytotoxicity on mesothelioma cells. Moreover, the combination achieved greater anti-tumor effects on mesothelioma developed in the pleural cavity than administration of either ZOL or CDDP alone. ZOL-treated cells as well as CDDP-treated cells induced p53 phosphorylation at Ser 15, a marker of p53 activation, and up-regulated p53 protein expression levels. Down-regulation of p53 levels with siRNA however did not influence the ZOL-mediated cytotoxicity but negated the combinatory effects by ZOL and CDDP. In addition, ZOL treatments augmented cytotoxicity of adenoviruses expressing the p53 gene on mesothelioma. These data demonstrated that ZOL-mediated augmentation of p53, which was not linked with ZOL-induced cytotoxicity, played a role in the combinatory effects with a p53 up-regulating agent, and suggests a possible clinical use of ZOL to mesothelioma with anti-cancer agents.
C1 [Okamoto, Shinya; Fukamachi, Toshihiko; Kobayashi, Hiroshi] Chiba Univ, Grad Sch Pharmaceut Sci, Dept Biochem, Chiba, Japan.
   [Jiang, Yuanyuan; Kawamura, Kiyoko; Tagawa, Masatoshi] Chiba Canc Ctr, Res Inst, Div Pathol & Cell Therapy, Chiba 2608717, Japan.
   [Jiang, Yuanyuan; Tagawa, Masatoshi] Chiba Univ, Grad Sch Med, Dept Mol Biol & Oncol, Chiba, Japan.
   [Shingyoji, Masato] Chiba Canc Ctr, Dept Thorac Dis, Chiba 2608717, Japan.
   [Tada, Yuji; Tatsumi, Koichiro] Chiba Univ, Dept Respirol, Grad Sch Med, Chiba, Japan.
   [Takiguchi, Yuichi] Chiba Univ, Dept Med Oncol, Grad Sch Med, Chiba, Japan.
   [Shimada, Hideaki] Toho Univ, Sch Med, Dept Surg, Tokyo, Japan.
   [Hiroshima, Kenzo] Tokyo Womens Med Univ, Yachiyo Med Ctr, Dept Pathol, Yachiyo, Japan.
RP Tagawa, M (reprint author), Chiba Canc Ctr, Res Inst, Div Pathol & Cell Therapy, 666-2 Nitonacho, Chiba 2608717, Japan.
EM mtagawa@chiba-cc.jp
FU Ministry of Education, Culture, Sports, Science and Technology of Japan;
   Ministry of Health, Labor and Welfare of Japan; Nichias Corporation
FX This study was supported by Grants-in-Aid for Scientific Research from
   the Ministry of Education, Culture, Sports, Science and Technology of
   Japan, the Grant-in-Aid for Cancer Research from the Ministry of Health,
   Labor and Welfare of Japan, and a Grant-in-Aid from the Nichias
   Corporation. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Altomare DA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018828
   Altomare DA, 2009, P NATL ACAD SCI USA, V106, P3420, DOI 10.1073/pnas.0808816106
   Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X
   Benassi MS, 2007, CANCER LETT, V250, P194, DOI 10.1016/j.canlet.2006.10.004
   Clezardin P, 2011, BONE, V48, P71, DOI 10.1016/j.bone.2010.07.016
   Green JR, 2004, ONCOLOGIST, V9, P3, DOI 10.1634/theoncologist.9-90004-3
   Green JR, 2003, CANCER, V97, P840, DOI 10.1002/cncr.11128
   Hopkins-Donaldson S, 2006, NEOPLASIA, V8, P551, DOI 10.1593/neo.06148
   Horie N, 2007, BRIT J CANCER, V96, P255, DOI 10.1038/sj.bjc.6603548
   Horio Y, 2000, CANCER GENE THER, V7, P537, DOI 10.1038/sj.cgt.7700148
   Kim WY, 2006, CELL, V127, P265, DOI 10.1016/j.cell.2006.10.003
   Kuroda J, 2004, CANCER SCI, V95, P186, DOI 10.1111/j.1349-7006.2004.tb03202.x
   Kuroda J, 2003, BLOOD, V102, P2229, DOI 10.1182/blood-2003-01-0305
   Li Q, 2012, CANCER GENE THER, V19, P218, DOI 10.1038/cgt.2011.86
   Liu DH, 2006, CHIN J CANC PREV TRE, V13, P1108
   Nakataki E, 2006, CANCER SCI, V97, P183, DOI 10.1111/j.1349-7006.2006.00163.x
   Ory B, 2007, MOL PHARMACOL, V71, P333, DOI 10.1124/mol.106.028837
   Ottewell PD, 2008, JNCI-J NATL CANCER I, V100, P1167, DOI 10.1093/jnci/djn240
   Prins JB, 1998, INT J CANCER, V75, P649, DOI 10.1002/(SICI)1097-0215(19980209)75:4<649::AID-IJC25>3.3.CO;2-L
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Robinson BWS, 2005, LANCET, V366, P397, DOI 10.1016/S0140-6736(05)67025-0
   Robinson BWS, 2005, NEW ENGL J MED, V353, P1591, DOI 10.1056/NEJMra050152
   Rossi A, 2012, J CLIN ONCOL, V30, P1692, DOI 10.1200/JCO.2011.40.4905
   Senzer N, 2007, MOL CANCER THER, V6, P1478, DOI 10.1158/1535-7163.MCT-07-0125
   Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933
   Skerjanec A, 2003, J CLIN PHARMACOL, V43, P154, DOI 10.1177/0091270002239824
   Tada Y, 2008, ONCOL RES, V17, P239, DOI 10.3727/096504008786991602
   Vogelzang NJ, 2003, J CLIN ONCOL, V21, P2636, DOI 10.1200/JCO.2003.11.136
   Weinrib L, 2001, CANCER GENE THER, V8, P352, DOI 10.1038/sj.cgt.7700319
   Yang CT, 2000, J NATL CANCER I, V92, P636, DOI 10.1093/jnci/92.8.636
   Yuasa T, 2007, CURR MED CHEM, V14, P2126
NR 31
TC 8
Z9 8
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 28
PY 2013
VL 8
IS 3
AR e60297
DI 10.1371/journal.pone.0060297
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 121RP
UT WOS:000317262200106
PM 23555949
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Badiola, N
   Alcalde, V
   Pujol, A
   Munter, LM
   Multhaup, G
   Lleo, A
   Coma, M
   Soler-Lopez, M
   Aloy, P
AF Badiola, Nahuai
   Alcalde, Victor
   Pujol, Albert
   Muenter, Lisa-Marie
   Multhaup, Gerd
   Lleo, Alberto
   Coma, Mireia
   Soler-Lopez, Montserrat
   Aloy, Patrick
TI The Proton-Pump Inhibitor Lansoprazole Enhances Amyloid Beta Production
SO PLOS ONE
LA English
DT Article
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ALZHEIMERS-DISEASE; A-BETA;
   PRECURSOR PROTEIN; A-BETA-42 PRODUCTION; NEURONAL LOSS; PEPTIDE; CELLS;
   OLIGOMERS; BRAIN
AB A key event in the pathogenesis of Alzheimer's disease (AD) is the accumulation of amyloid-beta (A beta) species in the brain, derived from the sequential cleavage of the amyloid precursor protein (APP) by beta- and gamma-secretases. Based on a systems biology study to repurpose drugs for AD, we explore the effect of lansoprazole, and other proton-pump inhibitors (PPIs), on Ab production in AD cellular and animal models. We found that lansoprazole enhances A beta 37, A beta 40 and A beta 42 production and lowers A beta 38 levels on amyloid cell models. Interestingly, acute lansoprazole treatment in wild type and AD transgenic mice promoted higher A beta 40 levels in brain, indicating that lansoprazole may also exacerbate Ab production in vivo. Overall, our data presents for the first time that PPIs can affect amyloid metabolism, both in vitro and in vivo.
C1 [Badiola, Nahuai; Alcalde, Victor; Pujol, Albert; Soler-Lopez, Montserrat; Aloy, Patrick] Inst Res Biomed, Joint IRB BSC Program Computat Biol, Barcelona, Spain.
   [Pujol, Albert; Coma, Mireia] Anax Biotech, Barcelona, Spain.
   [Muenter, Lisa-Marie; Multhaup, Gerd] Free Univ Berlin, Inst Chem & Biochem, Berlin, Germany.
   [Lleo, Alberto] Hosp Santa Creu & Sant Pau, Dept Neurol, Ctr Invest Biomed Red Enfermedades Neurodegenerat, Barcelona, Spain.
   [Aloy, Patrick] ICREA, Barcelona, Spain.
RP Aloy, P (reprint author), Inst Res Biomed, Joint IRB BSC Program Computat Biol, Barcelona, Spain.
EM patrick.aloy@irbbarcelona.org
RI Lleo, Alberto/K-5783-2019; Badiola, Nahuai/C-6526-2011
OI Badiola, Nahuai/0000-0001-9488-5628; Munter, Lisa/0000-0001-5736-1462;
   Aloy, Patrick/0000-0002-3557-0236
FU Spanish Ministerio de Ciencia e Innovacion [PSE-010000-2009-1,
   BIO2010-22073]; ICREA
FX The present work has been supported by the Spanish Ministerio de Ciencia
   e Innovacion (PSE-010000-2009-1; BIO2010-22073) and by the own fund of
   each institute, and the funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Abdul-Hay SO, 2009, J NEUROCHEM, V111, P683, DOI 10.1111/j.1471-4159.2009.06355.x
   ARNOLD R, 1994, ALIMENT PHARM THERAP, V8, P65
   Bien J, 2012, J BIOL CHEM
   Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372
   DaRocha-Souto B, 2011, J NEUROPATH EXP NEUR, V70, P360, DOI 10.1097/NEN.0b013e318217a118
   Dias LM, 2009, CLIN DRUG INVEST, V29, P3, DOI 10.2165/1153121-S0-000000000-00000
   Fukumoto H, 2010, FASEB J, V24, P2716, DOI 10.1096/fj.09-150359
   Geerts H, 2007, IDRUGS, V10, P121
   GomezIsla T, 1997, ANN NEUROL, V41, P17, DOI 10.1002/ana.410410106
   Gong YS, 2003, P NATL ACAD SCI USA, V100, P10417, DOI 10.1073/pnas.1834302100
   Haass C, 2007, NAT REV MOL CELL BIO, V8, P101, DOI 10.1038/nrm2101
   Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994
   Ingelsson M, 2004, NEUROLOGY, V62, P925, DOI 10.1212/01.WNL.0000115115.98960.37
   Kukar T, 2005, NAT MED, V11, P545, DOI 10.1038/nm1235
   Lai KC, 2005, AM J MED, V118, P1271, DOI 10.1016/j.amjmed.2005.04.031
   Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448
   Lazzaroni M, 2009, DRUGS, V69, P51, DOI 10.2165/00003495-200969010-00004
   Li Y, 2006, FASEB J, V20, P285, DOI 10.1096/fj.05-4986com
   Lleo A, 2007, CELL MOL LIFE SCI, V64, P1403, DOI 10.1007/s00018-007-6516-1
   Lleo A, 2006, ANNU REV MED, V57, P513, DOI 10.1146/annurev.med.57.121304.131442
   LONDONG W, 1991, ALIMENT PHARM THERAP, V5, P245
   Lue LF, 1999, AM J PATHOL, V155, P853, DOI 10.1016/S0002-9440(10)65184-X
   McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M
   Meyer-Luehmann M, 2003, NAT NEUROSCI, V6, P370, DOI 10.1038/nn1022
   Morihara T, 2002, J NEUROCHEM, V83, P1009, DOI 10.1046/j.1471-4159.2002.01195.x
   Nakagawa S, 2012, INFLAMMATION, V35, P1062, DOI 10.1007/s10753-011-9412-7
   Narlawar R, 2007, BIOORG MED CHEM LETT, V17, P176, DOI 10.1016/j.bmcl.2006.09.061
   Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3
   Parsons C, 2012, DRUG AGING, V29, P143, DOI 10.2165/11598560-000000000-00000
   Pilotto A, 2009, SURG ONCOL, V19, P167
   Pitschke M, 1998, NAT MED, V4, P832, DOI 10.1038/nm0798-832
   Pospai D, 1998, GASTROEN CLIN BIOL, V22, P801
   Pujol A, 2010, TRENDS PHARMACOL SCI, V31, P115, DOI 10.1016/j.tips.2009.11.006
   Querfurth HW, 2010, NEW ENGL J MED, V362, P329, DOI 10.1056/NEJMra0909142
   QUERFURTH HW, 1994, BIOCHEMISTRY-US, V33, P4550, DOI 10.1021/bi00181a016
   Querfurth HW, 1997, J NEUROCHEM, V69, P1580
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Richter L, 2010, P NATL ACAD SCI USA, V107, P14597, DOI 10.1073/pnas.1003026107
   Rojo LE, 2010, J ALZHEIMERS DIS, V19, P573, DOI 10.3233/JAD-2010-1262
   SATOH H, 1989, J PHARMACOL EXP THER, V248, P806
   Schulz-Geske S, 2009, WORLD J GASTROENTERO, V15, P4392, DOI 10.3748/wjg.15.4392
   Shankar GM, 2008, NAT MED, V14, P837, DOI 10.1038/nm1782
   Sheen E, 2011, DIGEST DIS SCI, V56, P931, DOI 10.1007/s10620-010-1560-3
   Shrestha BR, 2006, MOL CELL NEUROSCI, V33, P274, DOI 10.1016/j.mcn.2006.07.011
   Spires-Jones TL, 2007, AM J PATHOL, V171, P1304, DOI 10.2353/ajpath.2007.070055
   Takagi T, 2009, J PHARMACOL EXP THER, V331, P255, DOI 10.1124/jpet.109.152702
   Tanigawa T, 2009, J CLIN BIOCHEM NUTR, V45, P86, DOI 10.3164/jcbn.08-267
   Vonkeman HE, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2207
   Walsh DM, 2007, J NEUROCHEM, V101, P1172, DOI 10.1111/j.1471-4159.2006.04426.x
   Wang-Dietrich L, 2013, J ALZHEIMERS DIS
   Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591
   Wiltfang J, 2002, J NEUROCHEM, V81, P481, DOI 10.1046/j.1471-4159.2002.00818.x
   Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208
   Younkin SG, 1998, J PHYSIOLOGY-PARIS, V92, P289, DOI 10.1016/S0928-4257(98)80035-1
NR 54
TC 59
Z9 63
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 8
PY 2013
VL 8
IS 3
AR e58837
DI 10.1371/journal.pone.0058837
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 140TZ
UT WOS:000318679900097
PM 23520537
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Salomaki, H
   Vahatalo, LH
   Laurila, K
   Jappinen, NT
   Penttinen, AM
   Ailanen, L
   Ilyasizadeh, J
   Pesonen, U
   Koulu, M
AF Salomaki, Henriikka
   Vahatalo, Laura H.
   Laurila, Kirsti
   Jappinen, Norma T.
   Penttinen, Anna-Maija
   Ailanen, Liisa
   Ilyasizadeh, Juan
   Pesonen, Ullamari
   Koulu, Markku
TI Prenatal Metformin Exposure in Mice Programs the Metabolic Phenotype of
   the Offspring during a High Fat Diet at Adulthood
SO PLOS ONE
LA English
DT Article
ID POLYCYSTIC-OVARY-SYNDROME; ACTIVATED PROTEIN-KINASE; INSULIN-SENSITIZING
   DRUGS; NEONATAL LEPTIN TREATMENT; EPIGENETIC MECHANISMS;
   GENE-EXPRESSION; INDUCED OBESITY; PREGNANCY; AMPK; WOMEN
AB Aims: The antidiabetic drug metformin is currently used prior and during pregnancy for polycystic ovary syndrome, as well as during gestational diabetes mellitus. We investigated the effects of prenatal metformin exposure on the metabolic phenotype of the offspring during adulthood in mice.
   Methods: Metformin (300 mg/kg) or vehicle was administered orally to dams on regular diet from the embryonic day E0.5 to E17.5. Gene expression profiles in liver and brain were analysed from 4-day old offspring by microarray. Body weight development and several metabolic parameters of offspring were monitored both during regular diet (RD-phase) and high fat diet (HFD-phase). At the end of the study, two doses of metformin or vehicle were given acutely to mice at the age of 20 weeks, and Insig-1 and GLUT4 mRNA expressions in liver and fat tissue were analysed using qRT-PCR.
   Results: Metformin exposed fetuses were lighter at E18.5. There was no effect of metformin on the maternal body weight development or food intake. Metformin exposed offspring gained more body weight and mesenteric fat during the HFD-phase. The male offspring also had impaired glucose tolerance and elevated fasting glucose during the HFD-phase. Moreover, the expression of GLUT4 mRNA was down-regulated in epididymal fat in male offspring prenatally exposed to metformin. Based on the microarray and subsequent qRT-PCR analyses, the expression of Insig-1 was changed in the liver of neonatal mice exposed to metformin prenatally. Furthermore, metformin up-regulated the expression of Insig-1 later in development. Gene set enrichment analysis based on preliminary microarray data identified several differentially enriched pathways both in control and metformin exposed mice.
   Conclusions: The present study shows that prenatal metformin exposure causes long-term programming effects on the metabolic phenotype during high fat diet in mice. This should be taken into consideration when using metformin as a therapeutic agent during pregnancy.
C1 [Salomaki, Henriikka; Vahatalo, Laura H.; Jappinen, Norma T.; Penttinen, Anna-Maija; Ailanen, Liisa; Ilyasizadeh, Juan; Pesonen, Ullamari; Koulu, Markku] Univ Turku, Inst Biomed, Dept Pharmacol Drug Dev & Therapeut, Turku, Finland.
   [Laurila, Kirsti] Aalto Univ, Sch Econ, Dept Informat & Serv Econ, Helsinki, Finland.
   [Laurila, Kirsti] Aalto Univ, Sch Sci, Dept Informat & Comp Sci, Helsinki, Finland.
RP Koulu, M (reprint author), Univ Turku, Inst Biomed, Dept Pharmacol Drug Dev & Therapeut, Turku, Finland.
EM markku.koulu@utu.fi
OI Pesonen, Ullamari/0000-0002-9962-212X
FU Academy of Finland [134131]; FinPharma Doctoral Program (Finland)
FX This work was supported by The Academy of Finland (grant number 134131
   to MK) and partially by FinPharma Doctoral Program (Finland). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Abel ED, 2001, NATURE, V409, P729, DOI 10.1038/35055575
   Attig L, 2008, INT J OBESITY, V32, P1153, DOI 10.1038/ijo.2008.39
   BARKER DJP, 1990, BRIT MED J, V301, P1111, DOI 10.1136/bmj.301.6761.1111
   Bhalla K, 2012, CANCER PREV RES, V5, P544, DOI 10.1158/1940-6207.CAPR-11-0228
   Bouret SG, 2004, SCIENCE, V304, P108, DOI 10.1126/science.1095004
   Carone BR, 2010, CELL, V143, P1084, DOI 10.1016/j.cell.2010.12.008
   Caton PW, 2011, DIABETES OBES METAB, V13, P1097, DOI 10.1111/j.1463-1326.2011.01466.x
   Dhahbi JM, 2005, PHYSIOL GENOMICS, V23, P343, DOI 10.1152/physiolgenomics.00069.2005
   Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371
   Gabory A, 2009, MOL CELL ENDOCRINOL, V304, P8, DOI 10.1016/j.mce.2009.02.015
   Gluckman PD, 2009, NAT REV ENDOCRINOL, V5, P401, DOI 10.1038/nrendo.2009.102
   Glueck CJ, 2004, HUM REPROD, V19, P1323, DOI 10.1093/humrep/deh263
   Glueck CJ, 2004, DIABETIC MED, V21, P829, DOI 10.1111/j.1464-5491.2004.01251.x
   Goh JEL, 2011, DIABETIC MED, V28, P1082, DOI 10.1111/j.1464-5491.2011.03361.x
   Goodarzi MO, 2011, NAT REV ENDOCRINOL, V7, P219, DOI 10.1038/nrendo.2010.217
   Hawley SA, 2002, DIABETES, V51, P2420, DOI 10.2337/diabetes.51.8.2420
   Hou M, 2010, BIOCHEM BIOPH RES CO, V397, P537, DOI 10.1016/j.bbrc.2010.05.152
   Hundal RS, 2003, DRUGS, V63, P1879, DOI 10.2165/00003495-200363180-00001
   Hundal RS, 2000, DIABETES, V49, P2063, DOI 10.2337/diabetes.49.12.2063
   Ijas H, 2011, BJOG-INT J OBSTET GY, V118, P880, DOI 10.1111/j.1471-0528.2010.02763.x
   Itoh H, 2011, ACTA PHYSIOL, V202, P159, DOI 10.1111/j.1748-1716.2011.02268.x
   Jakubowicz DJ, 2002, J CLIN ENDOCR METAB, V87, P524, DOI 10.1210/jc.87.2.524
   Kabir M, 2005, AM J PHYSIOL-ENDOC M, V288, pE454, DOI 10.1152/ajpendo.00203.2004
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kanehisa M, 2012, NUCLEIC ACIDS RES, V40, pD109, DOI 10.1093/nar/gkr988
   Legro RS, 2010, J CLIN ENDOCR METAB, V95, P5199, DOI 10.1210/jc.2010-2301
   Leonie E, 2012, ENDOCRINOLOGY, V153, P2861, DOI 10.1210/en.2011-1754
   Levin BE, 2006, PHILOS T R SOC B, V361, P1107, DOI 10.1098/rstb.2006.1851
   Li JP, 2003, P NATL ACAD SCI USA, V100, P9476, DOI 10.1073/pnas.1133426100
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Long YC, 2006, J CLIN INVEST, V116, P1776, DOI 10.1172/JCI29044
   Maida A, 2011, DIABETOLOGIA, V54, P339, DOI 10.1007/s00125-010-1937-z
   Matthews L, 2009, NUCLEIC ACIDS RES, V37, pD619, DOI 10.1093/nar/gkn863
   Meaney MJ, 2007, TRENDS MOL MED, V13, P269, DOI 10.1016/j.molmed.2007.05.003
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   Morin-Papunen L, 2012, J CLIN ENDOCR METAB, V97, P1492, DOI 10.1210/jc.2011-3061
   Nestler JE, 2002, FERTIL STERIL, V77, P209, DOI 10.1016/S0015-0282(01)02963-6
   Nishimura D, 2001, BIOTECT SOFTWARE INT, V2, P117, DOI DOI 10.1089/152791601750294344
   Norman RJ, 2004, CURR OPIN OBSTET GYN, V16, P245, DOI 10.1097/01.gco.0000129424.41434.64
   Onken B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008758
   Pinney SE, 2010, TRENDS ENDOCRIN MET, V21, P223, DOI 10.1016/j.tem.2009.10.002
   Raychaudhuri N, 2008, J BIOL CHEM, V283, P13611, DOI 10.1074/jbc.M800128200
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Roth A, 2008, MOL PHARMACOL, V73, P1282, DOI 10.1124/mol.107.041012
   Rowan JA, 2011, DIABETES CARE, V34, P2279, DOI 10.2337/dc11-0660
   Sandovici I, 2011, P NATL ACAD SCI USA, V108, P5449, DOI 10.1073/pnas.1019007108
   Shang LB, 2011, P NATL ACAD SCI USA, V108, P4788, DOI 10.1073/pnas.1100844108
   Sinnett-Smith J, 2013, BIOCHEM BIOPH RES CO, V430, P352, DOI 10.1016/j.bbrc.2012.11.010
   Steinberg GR, 2009, PHYSIOL REV, V89, P1025, DOI 10.1152/physrev.00011.2008
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Symonds ME, 2009, NAT REV ENDOCRINOL, V5, P604, DOI 10.1038/nrendo.2009.195
   Tertti Kristiina, 2008, Rev Diabet Stud, V5, P95, DOI 10.1900/RDS.2008.5.95
   Vanky E, 2005, FERTIL STERIL, V83, P1575, DOI 10.1016/j.fertnstert.2004.11.051
   Velazquez EM, 1997, METABOLISM, V46, P454, DOI 10.1016/S0026-0495(97)90066-4
   Vickers MH, 2008, ENDOCRINOLOGY, V149, P1906, DOI 10.1210/en.2007-0981
   Vickers MH, 2005, ENDOCRINOLOGY, V146, P4211, DOI 10.1210/en.2005-0581
   Vickers MH, 2000, AM J PHYSIOL-ENDOC M, V279, pE83
   Xie ZL, 2011, DIABETES, V60, P1770, DOI 10.2337/db10-0351
   Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3
   Yura S, 2005, CELL METAB, V1, P371, DOI 10.1016/j.cmet.2005.05.005
   Yura S, 2008, OBESITY, V16, P1289, DOI 10.1038/oby.2008.57
   Zakikhani M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049513
   Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505
NR 63
TC 34
Z9 35
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 15
PY 2013
VL 8
IS 2
AR e56594
DI 10.1371/journal.pone.0056594
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 099EQ
UT WOS:000315603700063
PM 23457588
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Schuchman, EH
   Ge, Y
   Lai, A
   Borisov, Y
   Faillace, M
   Eliyahu, E
   He, XX
   Iatridis, J
   Vlassara, H
   Striker, G
   Simonaro, CM
AF Schuchman, Edward H.
   Ge, Yi
   Lai, Alon
   Borisov, Yury
   Faillace, Meghan
   Eliyahu, Efrat
   He, Xingxuan
   Iatridis, James
   Vlassara, Helen
   Striker, Gary
   Simonaro, Calogera M.
TI Pentosan Polysulfate: A Novel Therapy for the Mucopolysaccharidoses
SO PLOS ONE
LA English
DT Article
ID JOINT DISEASE; BONE; OSTEOARTHRITIS; PROLIFERATION; CHONDROCYTES;
   INVOLVEMENT; INHIBITOR; MECHANISM; SODIUM; INJURY
AB Background: Pentosan polysulfate (PPS) is an FDA-approved, oral medication with anti-inflammatory and pro-chondrogenic properties. We have previously shown that animal models of the mucopolysaccharidoses (MPS) exhibit significant inflammatory disease, contributing to cartilage degeneration. Enzyme replacement therapy (ERT) only partly reduced inflammation, and anti-TNF-alpha antibody therapy significantly enhanced clinical and pathological outcomes. Here we describe the use of PPS for the treatment of MPS type VI rats.
   Methodology/Principal Findings: Treatment began during prenatal development and at 1 and 6 months of age. All animals were treated until they were 9 months old. Significant reductions in the serum and tissue levels of several inflammatory markers (e.g., TNF-alpha, MIP-1alpha and RANTES/CCL5) were observed, as was reduced expression of inflammatory markers in cultured articular chondrocytes. ADAMTS-5/aggrecanase-2 levels also were reduced in chondrocytes, consistent with an elevation of serum tissue inhibitor of metalloproteinase 1. Marked improvements in motility and grooming behavior occurred, along with a reduction in eye and nasal secretions and a lessening of the tracheal deformities. MicroCT and radiographic analyses further revealed that the treated MPS skulls were longer and thinner, and that the teeth malocclusions, misalignments and mineral densities were improved. MicroCT analysis of the femurs and vertebrae revealed improvements in trabecular bone mineral densities, number and spacing in a subset of treated MPS animals. Biomechanical assessments of PPS-treated spines showed partially restored torsional behaviors, suggesting increased spinal stability. No improvements were observed in cortical bone or femur length. The positive changes in the PPS-treated MPS VI rats occurred despite glycosaminoglycan accumulation in their tissues.
   Conclusions: Based on these findings we conclude that PPS could be a simple and effective therapy for MPS that might provide significant clinical benefits alone and in combination with other therapies.
C1 [Schuchman, Edward H.; Ge, Yi; Lai, Alon; Borisov, Yury; Faillace, Meghan; Eliyahu, Efrat; He, Xingxuan; Iatridis, James; Vlassara, Helen; Striker, Gary; Simonaro, Calogera M.] Mt Sinai Sch Med, New York, NY USA.
RP Simonaro, CM (reprint author), Mt Sinai Sch Med, New York, NY USA.
EM Calogera.simonaro@mssm.edu
OI Iatridis, James/0000-0002-2186-0590; Lai, Alon/0000-0002-0163-4588
FU National Institutes of Health [DK087185, AR056639, AR051146];
   Mucopolysaccharidosis Society
FX This work was supported in part by National Institutes of Health grants
   DK087185, AR056639 and AR051146, and a grant from the
   Mucopolysaccharidosis Society. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Anger JT, 2011, INT UROGYNECOL J, V22, P395, DOI 10.1007/s00192-010-1252-8
   Barbir A, 2011, SPINE, V36, P607, DOI 10.1097/BRS.0b013e3181d9b58b
   Beck M, 2010, J PEDIATR REHAB MED, V3, P39, DOI 10.3233/PRM-2010-0100
   Budsberg SC, 2007, VET SURG, V36, P234, DOI 10.1111/j.1532-950X.2007.00256.x
   Cai WJ, 2002, MOL MED, V8, P337, DOI 10.1007/BF03402014
   Deli MA, 2010, J ALZHEIMERS DIS, V22, P777, DOI 10.3233/JAD-2010-100759
   Eliyahu E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022447
   Fotopoulos VC, 2012, KNEE SURG SPORT TR A, V20, P1159, DOI 10.1007/s00167-011-1676-9
   Ghosh P, 1999, SEMIN ARTHRITIS RHEU, V28, P211, DOI 10.1016/S0049-0172(99)80021-3
   Ghosh P, 2001, BEST PRACT RES CL RH, V15, P693, DOI 10.1053/berh.2001.0188
   Ghosh P, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2935
   Giugliani R, 2010, GENET MOL BIOL, V33, P589, DOI 10.1590/S1415-47572010005000093
   Hanno PM, 2011, J UROLOGY, V185, P2162, DOI 10.1016/j.juro.2011.03.064
   Ho STB, 2009, GROWTH FACTORS, V27, P321, DOI 10.1080/08977190903137595
   Honda H, 2011, NEUROPATHOLOGY, V32, P124
   Hyogo H, 2008, CURR PHARM DESIGN, V14, P969, DOI 10.2174/138161208784139701
   Iwamoto K, 2008, J GASTROENTEROL, V43, P298, DOI 10.1007/s00535-007-2152-7
   Kumagai Kenji, 2010, BMC Clin Pharmacol, V10, P7, DOI 10.1186/1472-6904-10-7
   Kunieda T, 1995, GENOMICS, V29, P882
   Kwan C, 2012, AUST VET J, V90, P315, DOI 10.1111/j.1751-0813.2012.00959.x
   Lupia E, 2012, LAB INVEST, V92, P236, DOI 10.1038/labinvest.2011.154
   Mcllwraith CW, 2012, AM J VET RES, V73, P628
   Meunzer J, 2011, RHEUMATOLOGY SUPPL, V5, pv4
   Michalek AJ, 2010, EUR SPINE J, V19, P2110, DOI 10.1007/s00586-010-1473-z
   Miyata N, 2010, CLIN EXP HYPERTENS, V32, P511, DOI 10.3109/10641963.2010.496511
   Oussoren E, 2011, BBA-MOL BASIS DIS, V1812, P1542, DOI 10.1016/j.bbadis.2011.07.013
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Simonaro CM, 2008, AM J PATHOL, V172, P112, DOI 10.2353/ajpath.2008.070564
   Simonaro CM, 2010, P NATL ACAD SCI USA, V107, P222, DOI 10.1073/pnas.0912937107
   Simonaro CM, 2005, PEDIATR RES, V57, P701, DOI 10.1203/01.PDR.0000156510.96253.5A
   Simonaro CM, 2001, LAB INVEST, V81, P1319, DOI 10.1038/labinvest.3780345
   Smit TH, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-38
   Takizawa M, 2008, FEBS LETT, V582, P2945, DOI 10.1016/j.febslet.2008.07.036
   Tommasini SM, 2009, J BONE MINER RES, V24, P606, DOI [10.1359/jbmr.081224, 10.1359/JBMR.081224]
   Troeberg L, 2008, FASEB J, V22, P3515, DOI 10.1096/fj.08-112680
   Troeberg L, 2012, BIOCHEM J, V443, P307, DOI 10.1042/BJ20112159
   White KK, 2011, RHEUMATOLOGY, V50, pV26, DOI 10.1093/rheumatology/ker393
   Wu YP, 2004, P NATL ACAD SCI USA, V101, P8425, DOI 10.1073/pnas.0400625101
   Zhao JG, 2011, MED HYPOTHESES, V76, P610, DOI 10.1016/j.mehy.2011.01.016
NR 39
TC 47
Z9 48
U1 0
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 24
PY 2013
VL 8
IS 1
AR e54459
DI 10.1371/journal.pone.0054459
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 077JK
UT WOS:000314023600056
PM 23365668
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Elfawal, MA
   Towler, MJ
   Reich, NG
   Golenbock, D
   Weathers, PJ
   Rich, SM
AF Elfawal, Mostafa A.
   Towler, Melissa J.
   Reich, Nicholas G.
   Golenbock, Douglas
   Weathers, Pamela J.
   Rich, Stephen M.
TI Dried Whole Plant Artemisia annua as an Antimalarial Therapy
SO PLOS ONE
LA English
DT Article
ID IN-VITRO; THIOREDOXIN REDUCTASE; MALARIA; FLAVONOIDS; RESISTANCE;
   EFFICACY; DRUGS; HEMIN; L.
AB Drugs are primary weapons for reducing malaria in human populations. However emergence of resistant parasites has repeatedly curtailed the lifespan of each drug that is developed and deployed. Currently the most effective anti-malarial is artemisinin, which is extracted from the leaves of Artemisia annua. Due to poor pharmacokinetic properties and prudent efforts to curtail resistance to monotherapies, artemisinin is prescribed only in combination with other anti-malarials composing an Artemisinin Combination Therapy (ACT). Low yield in the plant, and the added cost of secondary anti-malarials in the ACT, make artemisinin costly for the developing world. As an alternative, we compared the efficacy of oral delivery of the dried leaves of whole plant (WP) A. annua to a comparable dose of pure artemisinin in a rodent malaria model (Plasmodium chabaudi). We found that a single dose of WP (containing 24 mg/kg artemisinin) reduces parasitemia more effectively than a comparable dose of purified drug. This increased efficacy may result from a documented 40-fold increase in the bioavailability of artemisinin in the blood of mice fed the whole plant, in comparison to those administered synthetic drug. Synergistic benefits may derive from the presence of other anti-malarial compounds in A. annua. If shown to be clinically efficacious, well-tolerated, and compatible with the public health imperative of forestalling evolution of drug resistance, inexpensive, locally grown and processed A. annua might prove to be an effective addition to the global effort to reduce malaria morbidity and mortality. Citation: Elfawal MA, Towler MJ, Reich NG, Golenbock D, Weathers PJ, et al. (2012) Dried Whole Plant Artemisia annua as an Antimalarial Therapy. PLoS ONE 7(12): e52746. doi:10.1371/journal.pone.0052746
C1 [Elfawal, Mostafa A.; Rich, Stephen M.] Univ Massachusetts, Dept Microbiol, Lab Med Zool, Amherst, MA 01003 USA.
   [Towler, Melissa J.; Weathers, Pamela J.] Worcester Polytech Inst, Dept Biol & Biotechnol, Worcester, MA 01609 USA.
   [Reich, Nicholas G.] Univ Massachusetts, Div Biostat & Epidemiol, Sch Publ Hlth & Hlth Sci, Amherst, MA 01003 USA.
   [Golenbock, Douglas] Univ Massachusetts, Sch Med, Worcester, MA USA.
RP Rich, SM (reprint author), Univ Massachusetts, Dept Microbiol, Lab Med Zool, Amherst, MA 01003 USA.
EM smrich@psis.umass.edu
RI Reich, Nicholas/L-1168-2019
OI Reich, Nicholas/0000-0003-3503-9899
FU UMass Medical School Center for Clinical and Translational Science
   [CCTS-20110001]; National Institutes of Health [R01-AI079293]
FX This work was funded by UMass Medical School Center for Clinical and
   Translational Science (grant CCTS-20110001 and the National Institutes
   of Health (grant R01-AI079293). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR ALIN MH, 1994, AM J TROP MED HYG, V50, P771, DOI 10.4269/ajtmh.1994.50.771
   [Anonymous], 2010, GUID TREATM MAL
   Arsenault PR, 2008, CURR MED CHEM, V15, P2886, DOI 10.2174/092986708786242813
   Atkinson B., 1991, BIOCH ENG BIOTECHNOL
   Avery MA, 2003, J MED CHEM, V46, P4244, DOI 10.1021/jm030181q
   Barbacka K, 2011, CURR PHARM BIOTECHNO, V12, P1743, DOI 10.2174/138920111798376923
   Bilia AR, 2008, NAT PROD COMMUN, V3, P1999
   Bilia AR, 2002, LIFE SCI, V70, P769, DOI 10.1016/S0024-3205(01)01447-3
   Carlton JMR, 2001, TRENDS PARASITOL, V17, P236, DOI 10.1016/S1471-4922(01)01899-2
   Cox F.E.G., 1978, P309
   de Ridder S, 2008, J ETHNOPHARMACOL, V120, P302, DOI 10.1016/j.jep.2008.09.017
   de Vries P, 1999, PRODUCTION APPL ARTE
   Douglas B., 2011, LME4 LINEAR MIXED EF
   Duke J.A, 2001, HDB PHYTOCHEMICAL CO, P70
   Efferth T, 2009, HERBAL DRUGS ETHNOME, P179
   ELFORD BC, 1987, T ROY SOC TROP MED H, V81, P434, DOI 10.1016/0035-9203(87)90161-1
   Ferreira JFS, 2010, MOLECULES, V15, P3135, DOI 10.3390/molecules15053135
   Firestone GL, 2009, MOL ENDOCRINOL, V23, P1940, DOI 10.1210/me.2009-0149
   Gordi T, 2002, ANTIMICROB AGENTS CH, V46, P1026, DOI 10.1128/AAC.46.4.1026-1031.2002
   Graham IA, 2010, SCIENCE, V327, P328, DOI 10.1126/science.1182612
   Hsu E, 2006, T ROY SOC TROP MED H, V100, P505, DOI 10.1016/j.trstmh.2005.09.020
   Kindermans JM, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-125
   Kraft C, 2003, PHYTOTHER RES, V17, P123, DOI 10.1002/ptr.1066
   Krnajski Z, 2002, J BIOL CHEM, V277, P25970, DOI 10.1074/jbc.M203539200
   Kumar S, 2004, IND CROP PROD, V19, P77, DOI 10.1016/j.indcrop.2003.07.003
   LIU KCSC, 1992, PLANT CELL REP, V11, P637, DOI 10.1007/BF00236389
   Lu J, 2006, CANCER RES, V66, P4410, DOI 10.1158/0008-5472.CAN-05-3310
   Meshnick SR, 2002, INT J PARASITOL, V32, P1655, DOI 10.1016/S0020-7519(02)00194-7
   MESHNICK SR, 1991, MOL BIOCHEM PARASIT, V49, P181, DOI 10.1016/0166-6851(91)90062-B
   Mishina YV, 2007, ANTIMICROB AGENTS CH, V51, P1852, DOI 10.1128/AAC.01544-06
   OTT KJ, 1968, J PROTOZOOL, V15, P365, DOI 10.1111/j.1550-7408.1968.tb02138.x
   Rasoanaivo P, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-S1-S4
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Ro DK, 2006, NATURE, V440, P940, DOI 10.1038/nature04640
   Rodger WS, 2012, ORG PROCESS RES DEV, V16, P764
   Sen R, 2007, J MED MICROBIOL, V56, P1213, DOI 10.1099/jmm.0.47364-0
   Sharma V, 2009, BRIT J PHARMACOL, V157, P907, DOI 10.1111/j.1476-5381.2009.00267.x
   Svensson USH, 1999, BRIT J CLIN PHARMACO, V48, P528, DOI 10.1046/j.1365-2125.1999.00044.x
   Team  R. D. C, 2012, R LANG ENV STAT COMP
   Utzinger J, 2001, CURR MED CHEM, V8, P1841, DOI 10.2174/0929867013371581
   van der Kooy F, 2011, PLANTA MED, V77, P1754, DOI 10.1055/s-0030-1271065
   Weathers PJ, 2011, PHYTOCHEM REV, V10, P173, DOI 10.1007/s11101-010-9166-0
   Weathers PJ, 2012, PLANTA MED
   WHO, 2010, WORLD MALARIA REPORT 2010, P1
   Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1
   Willcox M, 2009, J ALTERN COMPLEM MED, V15, P101, DOI 10.1089/acm.2008.0327
   Zhu CY, 2012, J AM CHEM SOC, V134, P13577, DOI 10.1021/ja3061479
NR 47
TC 34
Z9 34
U1 0
U2 30
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 20
PY 2012
VL 7
IS 12
AR e52746
DI 10.1371/journal.pone.0052746
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 060RA
UT WOS:000312794500243
PM 23289055
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Lopez-Hidalgo, M
   Salgado-Puga, K
   Alvarado-Martinez, R
   Medina, AC
   Prado-Alcala, RA
   Garcia-Colunga, J
AF Lopez-Hidalgo, Monica
   Salgado-Puga, Karla
   Alvarado-Martinez, Reynaldo
   Cristina Medina, Andrea
   Prado-Alcala, Roberto A.
   Garcia-Colunga, Jesus
TI Nicotine Uses Neuron-Glia Communication to Enhance Hippocampal Synaptic
   Transmission and Long-term Memory
SO PLOS ONE
LA English
DT Article
ID MOUSE DENTATE GYRUS; D-SERINE; ACETYLCHOLINE-RECEPTORS; IN-VIVO; CA1
   REGION; RAT HIPPOCAMPUS; SUBCUTANEOUS NICOTINE; SPREADING DEPRESSION;
   ALZHEIMERS-DISEASE; COGNITIVE FUNCTION
AB Nicotine enhances synaptic transmission and facilitates long-term memory. Now it is known that bi-directional glia-neuron interactions play important roles in the physiology of the brain. However, the involvement of glial cells in the effects of nicotine has not been considered until now. In particular, the gliotransmitter D-serine, an endogenous co-agonist of NMDA receptors, enables different types of synaptic plasticity and memory in the hippocampus. Here, we report that hippocampal long-term synaptic plasticity induced by nicotine was annulled by an enzyme that degrades endogenous D-serine, or by an NMDA receptor antagonist that acts at the D-serine binding site. Accordingly, both effects of nicotine: the enhancement of synaptic transmission and facilitation of long-term memory were eliminated by impairing glial cells with fluoroacetate, and were restored with exogenous D-serine. Together, these results show that glial D-serine is essential for the long-term effects of nicotine on synaptic plasticity and memory, and they highlight the roles of glial cells as key participants in brain functions.
C1 [Lopez-Hidalgo, Monica; Salgado-Puga, Karla; Alvarado-Martinez, Reynaldo; Garcia-Colunga, Jesus] Univ Nacl Autonoma Mexico, Inst Neurobiol, Dept Neurobiol Celular & Mol, Queretaro, Mexico.
   [Cristina Medina, Andrea; Prado-Alcala, Roberto A.] Univ Nacl Autonoma Mexico, Inst Neurobiol, Dept Neurobiol Conductual & Cognit, Queretaro, Mexico.
RP Garcia-Colunga, J (reprint author), Univ Nacl Autonoma Mexico, Inst Neurobiol, Dept Neurobiol Celular & Mol, Campus Juriquilla, Queretaro, Mexico.
EM garciacolunga@unam.mx
RI Prado-Alcala, Roberto A./J-8395-2019
OI Salgado-Puga, Karla/0000-0002-5215-4760
FU Consejo Nacional de Ciencia y Tecnologia Mexico [81911, 128259];
   Direccion General de Asuntos del Personal Academico, U.N.A.M.
   [IN204809]; CONACyT [213708]
FX This work was supported by Grants from Consejo Nacional de Ciencia y
   Tecnologia Mexico (81911 and 128259) and by a Grant from Direccion
   General de Asuntos del Personal Academico, U.N.A.M. (IN204809). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.; We are grateful
   to Martin Garcia Servin and Angel Mendez for technical assistance. We
   express our gratitude to Drs. Hugo Merchant, Fernando Pena, and Dorothy
   Pless for critically reviewing the manuscript. MLH received a
   scholarship from CONACyT (213708). This paper was part of the Ph.D.
   thesis of MLH in Doctorado en Ciencias Biomedicas, UNAM.
CR Achour SB, 2010, NEUROCHEM INT, V57, P440, DOI 10.1016/j.neuint.2010.02.013
   Albuquerque EX, 2009, PHYSIOL REV, V89, P73, DOI 10.1152/physrev.00015.2008
   Araque A, 2002, J NEUROSCI, V22, P2443, DOI 10.1523/JNEUROSCI.22-07-02443.2002
   Bacci A, 2002, J NEUROPHYSIOL, V88, P2302, DOI 10.1152/jn.00665.2001
   Barros DM, 2004, NEUROSCIENCE, V126, P651, DOI 10.1016/j.neuroscience.2004.03.010
   Ben Menachem-Zidon O, 2011, BRAIN BEHAV IMMUN, V25, P1008, DOI 10.1016/j.bbi.2010.11.007
   BERGJOHNSEN J, 1993, EXP BRAIN RES, V96, P241
   BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0
   Bonansco C, 2011, EUR J NEUROSCI, V33, P1483, DOI 10.1111/j.1460-9568.2011.07631.x
   Brunzell DH, 2012, NEUROPSYCHOPHARMACOL, V37, P1134, DOI 10.1038/npp.2011.299
   Bushong EA, 2002, J NEUROSCI, V22, P183, DOI 10.1523/JNEUROSCI.22-01-00183.2002
   Canals S, 2008, J CEREBR BLOOD F MET, V28, P1835, DOI 10.1038/jcbfm.2008.71
   Ciamei A, 2001, PSYCHOPHARMACOLOGY, V154, P126, DOI 10.1007/s002130000584
   Citri A, 2008, NEUROPSYCHOPHARMACOL, V33, P18, DOI 10.1038/sj.npp.1301559
   Dani JA, 2001, NEURON, V31, P349, DOI 10.1016/S0896-6273(01)00379-8
   DECKER MW, 1992, BRAIN RES, V572, P281, DOI 10.1016/0006-8993(92)90485-R
   Delbro D, 2009, NEUROSCIENCE, V159, P770, DOI 10.1016/j.neuroscience.2009.01.005
   Fellin T, 2006, PHYSIOLOGY, V21, P208, DOI 10.1152/physiol.00161.2005
   de Sevilla DF, 2010, J NEUROSCI, V30, P11032, DOI 10.1523/JNEUROSCI.1848-10.2010
   Fonnum F, 1997, GLIA, V21, P106
   Fossat P, 2012, CEREB CORTEX, V22, P595, DOI 10.1093/cercor/bhr130
   Fucile S, 2004, CELL CALCIUM, V35, P1, DOI 10.1016/j.ceca.2003.08.006
   Gahring LC, 2004, J COMP NEUROL, V468, P322, DOI 10.1002/cne.10942
   Gibbs ME, 2012, NEURON GLIA BIOL, V6, P1
   Greenwood SM, 2010, J NEUROCHEM, V113, P1471, DOI 10.1111/j.1471-4159.2010.06737.x
   Guizzetti M, 2008, J BIOL CHEM, V283, P31884, DOI 10.1074/jbc.M801316200
   Hasselmo ME, 2006, CURR OPIN NEUROBIOL, V16, P710, DOI 10.1016/j.conb.2006.09.002
   He J, 2003, ACTA PHARMACOL SIN, V24, P398
   Heinrich A, 2012, BRIT J PHARMACOL, V167, P1003, DOI 10.1111/j.1476-5381.2012.01932.x
   Henneberger C, 2010, NATURE, V463, P232, DOI 10.1038/nature08673
   Hernandez-Morales M, 2009, NEUROPHARMACOLOGY, V56, P975, DOI 10.1016/j.neuropharm.2009.01.024
   Ikeda H, 2004, J NEUROSCI, V24, P9888, DOI 10.1523/JNEUROSCI.2608-04.2004
   Jia YS, 2009, EUR J NEUROSCI, V29, P1588, DOI 10.1111/j.1460-9568.2009.06706.x
   JONES GMM, 1992, PSYCHOPHARMACOLOGY, V108, P485, DOI 10.1007/BF02247426
   Kanematsu S, 2006, J NEURAL TRANSM, V113, P1717, DOI 10.1007/s00702-006-0517-3
   Kang J, 1998, NAT NEUROSCI, V1, P683, DOI 10.1038/3684
   Kelley AE, 2004, NEURON, V44, P161, DOI 10.1016/j.neuron.2004.09.016
   Kenney JW, 2008, MOL NEUROBIOL, V38, P101, DOI 10.1007/s12035-008-8037-9
   KEYSER DO, 1994, GLIA, V10, P237, DOI 10.1002/glia.440100402
   Larrosa B, 2006, NEUROSCIENCE, V141, P1057, DOI 10.1016/j.neuroscience.2006.04.005
   Le Magueresse C, 2007, HIPPOCAMPUS, V17, P316, DOI 10.1002/hipo.20271
   LEHOUEZEC J, 1994, PSYCHOPHARMACOLOGY, V114, P628, DOI 10.1007/BF02244994
   LEVIN ED, 1993, COGNITIVE BRAIN RES, V1, P137, DOI 10.1016/0926-6410(93)90021-V
   Levin ED, 2006, PSYCHOPHARMACOLOGY, V184, P523, DOI 10.1007/s00213-005-0164-7
   Levin ED, 1998, PSYCHOPHARMACOLOGY, V138, P217, DOI 10.1007/s002130050667
   Lynch MA, 2004, PHYSIOL REV, V84, P87, DOI 10.1152/physrev.00014.2003
   Magistretti PJ, 2006, J EXP BIOL, V209, P2304, DOI 10.1242/jeb.02208
   MALENKA RC, 1993, TRENDS NEUROSCI, V16, P521, DOI 10.1016/0166-2236(93)90197-T
   Malenka RC, 2004, NEURON, V44, P5, DOI 10.1016/j.neuron.2004.09.012
   Mansvelder HD, 2000, NEURON, V27, P349, DOI 10.1016/S0896-6273(00)00042-8
   Matsuyama S, 2003, J PHARMACOL SCI, V93, P180, DOI 10.1254/jphs.93.180
   Matsuyama S, 2000, EUR J NEUROSCI, V12, P3741, DOI 10.1046/j.1460-9568.2000.00259.x
   MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0
   Mineur YS, 2010, TRENDS PHARMACOL SCI, V31, P580, DOI 10.1016/j.tips.2010.09.004
   Miya K, 2008, J COMP NEUROL, V510, P641, DOI 10.1002/cne.21822
   Mothet JP, 2006, AGING CELL, V5, P267, DOI 10.1111/j.1474-9726.2006.00216.x
   Mothet JP, 2005, P NATL ACAD SCI USA, V102, P5606, DOI 10.1073/pnas.0408483102
   Mothet JP, 2000, P NATL ACAD SCI USA, V97, P4926, DOI 10.1073/pnas.97.9.4926
   MUIR D, 1986, BRAIN RES, V380, P336, DOI 10.1016/0006-8993(86)90231-3
   Nakauchi S, 2007, EUR J NEUROSCI, V25, P2666, DOI 10.1111/j.1460-9568.2007.05513.x
   Navarrete M, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001259
   Nestler EJ, 2002, NEUROBIOL LEARN MEM, V78, P637, DOI 10.1006/nlme.2002.4084
   Newhouse P, 2002, AM J GERIAT PSYCHIAT, V10, P483, DOI 10.1176/appi.ajgp.10.4.483
   Newman LA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028427
   Oikawa H, 2005, J NEUROSCI RES, V79, P535, DOI 10.1002/jnr.20398
   Oliet SHR, 2009, NEUROSCIENCE, V158, P275, DOI 10.1016/j.neuroscience.2008.01.071
   OMARA SM, 1995, NEUROPHARMACOLOGY, V34, P983, DOI 10.1016/0028-3908(95)00062-B
   Paxinos G, 2005, RAT BRAIN STEREOTAXI
   Perea G, 2005, J NEUROSCI, V25, P2192, DOI 10.1523/JNEUROSCI.3956-04.2005
   Perea G, 2007, SCIENCE, V317, P1083, DOI 10.1126/science.1144640
   Perea G, 2010, BRAIN RES REV, V63, P93, DOI 10.1016/j.brainresrev.2009.10.005
   Placzek AN, 2009, ACTA PHARMACOL SIN, V30, P752, DOI 10.1038/aps.2009.39
   Quik M, 2007, TRENDS PHARMACOL SCI, V28, P229, DOI 10.1016/j.tips.2007.03.001
   Rangani RJ, 2012, PEPTIDES, V33, P317, DOI 10.1016/j.peptides.2012.01.004
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Rezayof A, 2010, LIFE SCI, V86, P260, DOI 10.1016/j.lfs.2009.12.008
   Robbins TW, 2002, NEUROBIOL LEARN MEM, V78, P625, DOI 10.1006/nlme.2002.4103
   Rosato-Siri M, 2006, J PHYSIOL-LONDON, V576, P361, DOI 10.1113/jphysiol.2006.114587
   Rose JE, 2010, P NATL ACAD SCI USA, V107, P5190, DOI 10.1073/pnas.0909184107
   Rosenberg D, 2010, FASEB J, V24, P2951, DOI 10.1096/fj.09-147967
   SANSONE M, 1991, PHARMACOL BIOCHEM BE, V39, P197, DOI 10.1016/0091-3057(91)90421-W
   Sharma G, 2001, P NATL ACAD SCI USA, V98, P4148, DOI 10.1073/pnas.071540198
   Shen JX, 2012, J MOL NEUROSCI, V48, P14, DOI 10.1007/s12031-012-9719-3
   Shleper M, 2005, J NEUROSCI, V25, P9413, DOI 10.1523/JNEUROSCI.3190-05.2005
   SOCCI DJ, 1995, NEUROBIOL AGING, V16, P857, DOI 10.1016/0197-4580(95)00091-R
   Srivareerat M, 2011, NEUROBIOL AGING, V32, P834, DOI 10.1016/j.neurobiolaging.2009.04.015
   SWANSON RA, 1994, BRAIN RES, V664, P94, DOI 10.1016/0006-8993(94)91958-5
   Szabo SI, 2008, HIPPOCAMPUS, V18, P376, DOI 10.1002/hipo.20401
   Takata N, 2011, J NEUROSCI, V31, P18155, DOI 10.1523/JNEUROSCI.5289-11.2011
   Tang JR, 2009, NEURON, V63, P673, DOI 10.1016/j.neuron.2009.07.025
   Turpin F, 2012, METHODS MOL BIOL, V794, P299, DOI 10.1007/978-1-61779-331-8_20
   Uwechue NM, 2012, J PHYSIOL-LONDON, V590, P2317, DOI 10.1113/jphysiol.2011.226605
   Velez-Fort M, 2009, GLIA, V57, P1104, DOI 10.1002/glia.20834
   Ventura R, 1999, J NEUROSCI, V19, P6897, DOI 10.1523/JNEUROSCI.19-16-06897.1999
   Wang J, 2001, ACTA PHARMACOL SIN, V22, P685
   Waniewski RA, 1998, J NEUROSCI, V18, P5225
   Whitlock JR, 2006, SCIENCE, V313, P1093, DOI 10.1126/science.1128134
   Williams SM, 2006, GLIA, V53, P401, DOI 10.1002/glia.20300
   Wolosker H, 2011, BBA-PROTEINS PROTEOM, V1814, P1558, DOI 10.1016/j.bbapap.2011.01.001
   Yamazaki Y, 2002, BRAIN RES, V946, P148, DOI 10.1016/S0006-8993(02)02935-9
   Yamazaki Y, 2006, EUR J NEUROSCI, V23, P1819, DOI 10.1111/j.1460-9568.2006.04714.x
   Yang YL, 2003, P NATL ACAD SCI USA, V100, P15194, DOI 10.1073/pnas.2431073100
   Zhang TA, 2010, J NEUROSCI, V30, P6443, DOI 10.1523/JNEUROSCI.0458-10.2010
   Zhang Z, 2008, CEREB CORTEX, V18, P2391, DOI 10.1093/cercor/bhn008
   ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.ne.12.030189.000305
   Zucker RS, 2002, ANNU REV PHYSIOL, V64, P355, DOI 10.1146/annurev.physiol.64.092501.114547
NR 106
TC 13
Z9 13
U1 1
U2 19
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 21
PY 2012
VL 7
IS 11
AR e49998
DI 10.1371/journal.pone.0049998
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 047ER
UT WOS:000311821000161
PM 23185511
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Lin, CC
   Yen, JC
   Wu, YT
   Lin, LC
   Tsai, TH
AF Lin, Chia-Chun
   Yen, Jiin-Cherng
   Wu, Yu-Tse
   Lin, Lie-Chwen
   Tsai, Tung-Hu
TI Chemical Analysis and Transplacental Transfer of Oseltamivir and
   Oseltamivir Carboxylic Acid in Pregnant Rats
SO PLOS ONE
LA English
DT Article
ID MATERNAL TISSUE DISTRIBUTION; BLOOD-BRAIN-BARRIER; NEURAMINIDASE
   INHIBITORS; LIQUID-CHROMATOGRAPHY; PRODRUG OSELTAMIVIR; RO 64-0802;
   LC-MS/MS; INFLUENZA; PLASMA; PHOSPHATE
AB In view of the limited information on the pharmacokinetics of oseltamivir (OSE) during pregnancy, this study aims to evaluate the placental transportation of OSE and its active metabolite oseltamivir carboxylic acid (OCA) in rats. A validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) system coupled to an in vivo transplacental model has been developed to determine OSE and OCA in the placenta, amniotic fluids and fetus of 13-day pregnant Sprague-Dawley rats. Concentrations of OSE and OCA in plasma, amniotic fluids, placenta, and fetus were measured by the validated LC-MS/MS after OSE administration (10 mg/kg, iv). The pharmacokinetic data of both analytes were examined by non-compartmental modeling. The area under the concentration-time curve (AUC) of OCA in maternal plasma was found to be 3.6 times larger than that of OSE. The AUCs of OCA in both amniotic fluid and fetus were significantly decreased, in comparison with that in maternal plasma (reduced by 76.7 and 98.1%, respectively). We found that both OSE and OCA can penetrate the placenta, amniotic fluids and fetus in rats during pregnancy; however, the penetration of OCA was much lower than that of OSE. The mother-to-fetus transfer ratio was defined as AUC(fetus)/AUC(mother). The data demonstrated that the mother-to-fetus transfer ratio of OSE and OCA were 1.64 and 0.019, respectively, suggesting that OSE, but not OCA, penetrated through the placenta. Moreover, OCA might not be easily metabolized in the fetus due to the lack of carboxylase in the fetus.
C1 [Wu, Yu-Tse; Lin, Lie-Chwen; Tsai, Tung-Hu] Natl Yang Ming Univ, Inst Tradit Med, Sch Med, Taipei 112, Taiwan.
   [Lin, Chia-Chun; Yen, Jiin-Cherng] Natl Yang Ming Univ, Inst Pharmacol, Sch Med, Taipei 112, Taiwan.
   [Lin, Lie-Chwen] Natl Res Inst Chinese Med, Taipei, Taiwan.
   [Tsai, Tung-Hu] China Med Univ, Grad Inst Acupuncture Sci, Taichung, Taiwan.
   [Wu, Yu-Tse; Tsai, Tung-Hu] Taipei City Hosp, Dept Educ & Res, Taipei, Taiwan.
RP Tsai, TH (reprint author), Natl Yang Ming Univ, Inst Tradit Med, Sch Med, Taipei 112, Taiwan.
EM thtsai@ym.edu.tw
FU National Science Council, Taiwan [NSC99-2113-M-010-001-MY3,
   NSC99-2628-B-010-008-MY3]; Taipei City Hospital, Taiwan [TCH
   99001-62-015]
FX Funding for this study was provided in part by research grants from the
   National Science Council (NSC99-2113-M-010-001-MY3,
   NSC99-2628-B-010-008-MY3) Taiwan and TCH 99001-62-015 from Taipei City
   Hospital, Taiwan. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR [Anonymous], 2010, TAM OS PHOSPH PRESCR
   Bahrami G, 2008, J CHROMATOGR B, V864, P38, DOI 10.1016/j.jchromb.2008.01.048
   Berveiller P, 2012, AM J OBSTET GYNECOL, V206, DOI 10.1016/j.ajog.2011.07.023
   Chang Q, 2009, BIOMED CHROMATOGR, V23, P852, DOI 10.1002/bmc.1195
   Donner B, 2010, DRUG SAFETY, V33, P631, DOI 10.2165/11536370-000000000-00000
   He G, 1999, CLIN PHARMACOKINET, V37, P471, DOI 10.2165/00003088-199937060-00003
   He K, 2008, DRUG METAB DISPOS, V36, P2564, DOI 10.1124/dmd.108.022764
   Heinig K, 2008, J CHROMATOGR B, V876, P129, DOI 10.1016/j.jchromb.2008.10.037
   Hoffmann G, 2009, ANTIMICROB AGENTS CH, V53, P4753, DOI 10.1128/AAC.01541-08
   Holodniy M, 2008, ANTIMICROB AGENTS CH, V52, P3013, DOI 10.1128/AAC.00047-08
   Jabbaribar F, 2008, CHEM PHARM BULL, V56, P1639, DOI 10.1248/cpb.56.1639
   Kanneti R, 2011, BIOMED CHROMATOGR, V25, P727, DOI 10.1002/bmc.1509
   Karpf M, 2001, J ORG CHEM, V66, P2044, DOI 10.1021/jo0057021
   Kim CU, 1997, J AM CHEM SOC, V119, P681, DOI 10.1021/ja963036t
   Lindegardh N, 2007, J CHROMATOGR B, V859, P74, DOI 10.1016/j.jchromb.2007.09.018
   Lindegardh N, 2006, ANTIMICROB AGENTS CH, V50, P3197, DOI 10.1128/AAC.00500-06
   Matuszewski BK, 2003, ANAL CHEM, V75, P3019, DOI 10.1021/ac020361s
   Mendel DB, 1998, ANTIMICROB AGENTS CH, V42, P640, DOI 10.1128/AAC.42.3.640
   Morimoto K, 2008, DRUG METAB DISPOS, V36, P6, DOI 10.1124/dmd.107.017699
   Novotna M, 2004, REPROD TOXICOL, V18, P785, DOI 10.1016/j.reprotox.2004.04.014
   Ose A, 2009, DRUG METAB DISPOS, V37, P315, DOI 10.1124/dmd.108.024018
   PADYKULA HA, 1958, J ANAT, V92, P118
   PERROTTA CA, 1958, J ANAT, V92, P110
   Rasmussen SA, 2008, EMERG INFECT DIS, V14, P95, DOI 10.3201/eid1401.070667
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Shi DS, 2006, J PHARMACOL EXP THER, V319, P1477, DOI 10.1124/jpet.106.111807
   Shin HC, 2003, COMP BIOCHEM PHYS C, V136, P95, DOI 10.1016/j.cca.2003.004
   Tanaka T, 2009, CAN MED ASSOC J, V181, P55, DOI 10.1503/cmaj.090866
   Vahakangas K, 2009, BRIT J PHARMACOL, V158, P665, DOI 10.1111/j.1476-5381.2009.00336.x
   Ward P, 2005, J ANTIMICROB CHEMOTH, V55, P5, DOI 10.1093/jac/dki018
   Wiltshire H, 2000, J CHROMATOGR B, V745, P373, DOI 10.1016/S0378-4347(00)00300-5
   WORLEY KC, 2008, INFECT DIS OBSTET GY
   Zollner P, 2003, LC GC EUR, V16, P163
NR 33
TC 0
Z9 1
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 3
PY 2012
VL 7
IS 10
AR e46062
DI 10.1371/journal.pone.0046062
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 015NU
UT WOS:000309454000014
PM 23056234
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Joshi, AD
   Loilome, W
   Siu, IM
   Tyler, B
   Gallia, GL
   Riggins, GJ
AF Joshi, Avadhut D.
   Loilome, Watcharin
   Siu, I-Mei
   Tyler, Betty
   Gallia, Gary L.
   Riggins, Gregory J.
TI Evaluation of Tyrosine Kinase Inhibitor Combinations for Glioblastoma
   Therapy
SO PLOS ONE
LA English
DT Article
ID PHASE-II TRIAL; RECURRENT GLIOBLASTOMA; EGFR; CELLS; GROWTH; GEFITINIB;
   ERLOTINIB; SENSITIVITY; MULTIFORME; PATHWAYS
AB Glioblastoma multiforme (GBM) is the most common intracranial cancer but despite recent advances in therapy the overall survival remains about 20 months. Whole genome exon sequencing studies implicate mutations in the receptor tyrosine kinase pathways (RTK) for driving tumor growth in over 80% of GBMs. In spite of various RTKs being mutated or altered in the majority of GBMs, clinical studies have not been able to demonstrate efficacy of molecular targeted therapies using tyrosine kinase inhibitors in GBMs. Activation of multiple downstream signaling pathways has been implicated as a possible means by which inhibition of a single RTK has been ineffective in GBM. In this study, we sought a combination of approved drugs that would inhibit in vitro and in vivo growth of GBM oncospheres. A combination consisting of gefitinib and sunitinib acted synergistically in inhibiting growth of GBM oncospheres in vitro. Sunitinib was the only RTK inhibitor that could induce apoptosis in GBM cells. However, the in vivo efficacy testing of the gefitinib and sunitinib combination in an EGFR amplified/PTEN wild type GBM xenograft model revealed that gefitinib alone could significantly improve survival in animals whereas sunitinib did not show any survival benefit. Subsequent testing of the same drug combination in a different syngeneic glioma model that lacked EGFR amplification but was more susceptible to sunitinib in vitro demonstrated no survival benefit when treated with gefitinib or sunitinib or the gefitinib and sunitinib combination. Although a modest survival benefit was obtained in one of two animal models with EGFR amplification due to gefitinib alone, the addition of sunitinib, to test our best in vitro combination therapy, did not translate to any additional in vivo benefit. Improved targeted therapies, with drug properties favorable to intracranial tumors, are likely required to form effective drug combinations for GBM.
C1 [Joshi, Avadhut D.; Loilome, Watcharin; Siu, I-Mei; Tyler, Betty; Gallia, Gary L.; Riggins, Gregory J.] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA.
RP Riggins, GJ (reprint author), Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA.
EM griggin1@jhmi.edu
FU National Institutes of Health (NIH) [R01 NS052507]; Virginia; D.K.
   Ludwig Fund for Cancer Research; Children's Cancer Foundation; Irving J.
   Sherman M. D. Neurosurgery Research Professorship; Matt Trainham ABTA;
   Faculty of Medicine at Khon Kaen University, Thailand
FX This project was supported by National Institutes of Health (NIH) Grant
   R01 NS052507, the Virginia and D.K. Ludwig Fund for Cancer Research, and
   the Children's Cancer Foundation. GJR is supported by the Irving J.
   Sherman M. D. Neurosurgery Research Professorship. AJ was supported by
   Matt Trainham ABTA basic research fellowship (http://www.abta.org/). WL
   was supported by the Faculty of Medicine at Khon Kaen University,
   Thailand. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Bielen A, 2011, MOL CANCER THER, V10, P1407, DOI 10.1158/1535-7163.MCT-11-0205
   Cappuzzo F, 2005, J NATL CANCER I, V97, P868, DOI 10.1093/jnci/dji169
   Cappuzzo F, 2005, JNCI-J NATL CANCER I, V97, P643, DOI 10.1093/jnci/dji112
   Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385
   de Vries NA, 2012, INVEST NEW DRUG, V30, P443, DOI 10.1007/s10637-010-9569-1
   Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219
   Edwards LA, 2006, MOL CANCER THER, V5, P645, DOI 10.1158/1535-7163.MCT-05-0099
   Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364
   Gallia GL, 2009, MOL CANCER THER, V8, P386, DOI 10.1158/1535-7163.MCT-08-0680
   Guillamo JS, 2009, CLIN CANCER RES, V15, P3697, DOI 10.1158/1078-0432.CCR-08-2042
   Hegi ME, 2011, MOL CANCER THER, V10, P1102, DOI 10.1158/1535-7163.MCT-11-0048
   Huang SM, 2004, CANCER RES, V64, P5355, DOI 10.1158/0008-5472.CAN-04-0562
   Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030
   Mellinghoff IK, 2005, NEW ENGL J MED, V353, P2012, DOI 10.1056/NEJMoa051918
   Neyns B, 2011, J NEURO-ONCOL, V103, P491, DOI 10.1007/s11060-010-0402-7
   Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382
   Rao SK, 2009, J NEUROONCOL, V96, P169
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Rich JN, 2004, J CLIN ONCOL, V22, P133, DOI 10.1200/JCO.2004.08.110
   Sarkaria JN, 2007, MOL CANCER THER, V6, P1167, DOI 10.1158/1535-7163.MCT-06-0691
   Sathornsumetee S, 2009, EXPERT OPIN INV DRUG, V18, P277, DOI [10.1517/13543780802692603, 10.1517/13543780802692603 ]
   Stommel JM, 2007, SCIENCE, V318, P287, DOI 10.1126/science.1142946
   Trembath DG, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-30
   van den Bent MJ, 2009, J CLIN ONCOL, V27, P1268, DOI 10.1200/JCO.2008.17.5984
   Wen PY, 2006, CLIN CANCER RES, V12, P4899, DOI 10.1158/1078-0432.CCR-06-0773
NR 25
TC 30
Z9 31
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 2
PY 2012
VL 7
IS 10
AR e44372
DI 10.1371/journal.pone.0044372
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 015NG
UT WOS:000309452600003
PM 23056179
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Heitz, FD
   Erb, M
   Anklin, C
   Robay, D
   Pernet, V
   Gueven, N
AF Heitz, Fabrice D.
   Erb, Michael
   Anklin, Corinne
   Robay, Dimitri
   Pernet, Vincent
   Gueven, Nuri
TI Idebenone Protects against Retinal Damage and Loss of Vision in a Mouse
   Model of Leber's Hereditary Optic Neuropathy
SO PLOS ONE
LA English
DT Article
ID BRAIN MITOCHONDRIA; GLUTAMINE-SYNTHETASE; LIPID-PEROXIDATION; MTDNA
   MUTATIONS; GANGLION-CELLS; INHIBITION; DYSFUNCTION; ROTENONE; TIME; LHON
AB Leber's hereditary optic neuropathy(LHON) is an inherited disease caused by mutations in complex I of the mitochondrial respiratory chain. The disease is characterized by loss of central vision due to retinal ganglion cell (RGC) dysfunction and optic nerve atrophy. Despite progress towards a better understanding of the disease, no therapeutic treatment is currently approved for this devastating disease. Idebenone, a short-chain benzoquinone, has shown promising evidence of efficacy in protecting vision loss and in accelerating recovery of visual acuity in patients with LHON. It was therefore of interest to study suitable LHON models in vitro and in vivo to identify anatomical correlates for this protective activity. At nanomolar concentrations, idebenone protected the rodent RGC cell line RGC-5 against complex I dysfunction in vitro. Consistent with the reported dosing and observed effects in LHON patients, we describe that in mice, idebenone penetrated into the eye at concentrations equivalent to those which protected RGC-5 cells from complex I dysfunction in vitro. Consequently, we next investigated the protective effect of idebenone in a mouse model of LHON, whereby mitochondrial complex I dysfunction was caused by exposure to rotenone. In this model, idebenone protected against the loss of retinal ganglion cells, reduction in retinal thickness and gliosis. Furthermore, consistent with this protection of retinal integrity, idebenone restored the functional loss of vision in this disease model. These results support the pharmacological activity of idebenone and indicate that idebenone holds potential as an effective treatment for vision loss in LHON patients.
C1 [Heitz, Fabrice D.; Erb, Michael; Anklin, Corinne; Robay, Dimitri; Gueven, Nuri] Santhera Pharmaceut, Liestal, Switzerland.
   [Pernet, Vincent] Univ Zurich, Brain Res Inst, Fac Med, Zurich, Switzerland.
   [Gueven, Nuri] Univ Tasmania, Sch Pharm, Hobart, Tas 7001, Australia.
RP Gueven, N (reprint author), Santhera Pharmaceut, Liestal, Switzerland.
EM nuri.guven@utas.edu.au
OI Guven, Nuri/0000-0003-3782-767X
FU Santhera Pharmaceuticals (Switzerland)
FX Santhera Pharmaceuticals (Switzerland) funded and approved the
   publication of this work.
CR Abdejalil J, 2005, VISION RES, V45, P1439, DOI 10.1016/j.visres.2004.12.015
   Barboni P, 2010, OPHTHALMOLOGY, V117, P623, DOI 10.1016/j.ophtha.2009.07.026
   Barcella V, 2010, HUM BRAIN MAPP, V31, P1900, DOI 10.1002/hbm.20985
   Barnils N., 2007, Arch Soc Esp Oftalmol, V82, P377
   Beretta S, 2004, BRAIN, V127, P2183, DOI 10.1093/brain/awh258
   Beretta S, 2006, NEUROBIOL DIS, V24, P308, DOI 10.1016/j.nbd.2006.07.016
   Bringmann A, 2009, PROG RETIN EYE RES, V28, P423, DOI 10.1016/j.preteyeres.2009.07.001
   Bristow EA, 2002, ARCH OPHTHALMOL-CHIC, V120, P791
   Brown MD, 2001, AM J MED GENET, V104, P331, DOI 10.1002/1096-8628(20011215)104:4<331::AID-AJMG10054>3.0.CO;2-W
   Carelli V, 2004, BBA-BIOENERGETICS, V1658, P172, DOI 10.1016/j.bbabio.2004.05.009
   Carelli V, 2004, PROG RETIN EYE RES, V23, P53, DOI 10.1016/j.preteyeres.2003.10.003
   Carelli V, 1998, J NEUROL SCI, V160, P183, DOI 10.1016/S0022-510X(98)00239-1
   Carelli V, 2001, J NEUROL NEUROSUR PS, V71, P813, DOI 10.1136/jnnp.71.6.813
   Carelli V, 2001, OPHTHALMOLOGY, V108, P1172, DOI 10.1016/S0161-6420(01)00618-2
   Carelli V, 2011, BRAIN, V134, DOI 10.1093/brain/awr180
   Chadderton N, 2013, EUR J HUM GENET, V21, P62, DOI 10.1038/ejhg.2012.112
   Cortelli P, 1997, J NEUROL SCI, V148, P25, DOI 10.1016/S0022-510X(96)00311-5
   DEGOTTRAU P, 1992, J CLIN NEURO-OPHTHAL, V12, P89
   Ellouze S, 2008, AM J HUM GENET, V83, P373, DOI 10.1016/j.ajhg.2008.08.013
   Fraser JA, 2010, SURV OPHTHALMOL, V55, P299, DOI 10.1016/j.survophthal.2009.10.002
   Giorgio V, 2011, BIOCHIM BIOPHYS ACTA, V1817, P363
   Haefeli RH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017963
   Hayworth CR, 2008, J TOXICOL ENV HEAL A, V71, P1582, DOI 10.1080/15287390802414190
   HUOPONEN K, 1991, AM J HUM GENET, V48, P1147
   Ishikawa M, 2011, INVEST OPHTH VIS SCI, V52, P6604, DOI 10.1167/iovs.11-7375
   JOHNS DR, 1992, BIOCHEM BIOPH RES CO, V187, P1551, DOI 10.1016/0006-291X(92)90479-5
   Klopstock T, 2011, BRAIN, V134, P2677, DOI 10.1093/brain/awr170
   Krishnamoorthy RR, 2001, MOL BRAIN RES, V86, P1, DOI 10.1016/S0169-328X(00)00224-2
   Li NY, 2003, J BIOL CHEM, V278, P8516, DOI 10.1074/jbc.M210432200
   Marella M, 2010, PLOS ONE, V8
   Mascialino B, 2012, EUR J OPHTHALMOL, V22, P461, DOI 10.5301/ejo.5000055
   Mashima Y, 2000, J NEURO-OPHTHALMOL, V20, P166, DOI 10.1097/00041327-200020030-00006
   MASHIMA Y, 1992, LANCET, V340, P368, DOI 10.1016/0140-6736(92)91442-B
   Mordente A, 1998, CHEM RES TOXICOL, V11, P54, DOI 10.1021/tx970136j
   Nadal-Nicolas FM, 2009, INVEST OPHTH VIS SCI, V50, P3860, DOI 10.1167/iovs.08-3267
   Rauchova H, 2008, J BIOENERG BIOMEMBR, V40, P85, DOI 10.1007/s10863-008-9134-1
   Rauchova H, 2006, BIOCHEM BIOPH RES CO, V339, P362, DOI 10.1016/j.bbrc.2005.11.035
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Rojas JC, 2008, BRAIN RES, V1215, P208, DOI 10.1016/j.brainres.2009.04.001
   Sabet-Peyman EJ, 2012, J NEURO-OPHTHALMOL, V32, P54, DOI 10.1097/WNO.0b013e318241da45
   Sadun A A, 2000, Trans Am Ophthalmol Soc, V98, P223
   Sadun AA, 2011, CURR TREAT OPTION NE, V13, P109, DOI 10.1007/s11940-010-0100-y
   SMITH JL, 1990, J CLIN NEURO-OPHTHAL, V10, P231
   SUGIYAMA Y, 1985, FEBS LETT, V184, P48, DOI 10.1016/0014-5793(85)80650-5
   SUNO M, 1984, BIOCHEM BIOPH RES CO, V125, P1046, DOI 10.1016/0006-291X(84)91389-5
   SUNO M, 1989, ARCH GERONTOL GERIAT, V8, P291, DOI 10.1016/0167-4943(89)90010-1
   Tonska K, 2010, BBA-BIOENERGETICS, V1797, P1119, DOI 10.1016/j.bbabio.2010.02.032
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Yu XH, 2009, EXP EYE RES, V89, P967, DOI 10.1016/j.exer.2009.08.006
   Zanna C, 2005, APOPTOSIS, V10, P997, DOI 10.1007/s10495-005-0742-5
   Zhang X, 2002, NEUROSCI LETT, V326, P97, DOI 10.1016/S0304-3940(02)00327-0
NR 51
TC 38
Z9 38
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 18
PY 2012
VL 7
IS 9
AR e45182
DI 10.1371/journal.pone.0045182
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 040HS
UT WOS:000311313900093
PM 23028832
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Arulselvan, P
   Wen, CC
   Lan, CW
   Chen, YH
   Wei, WC
   Yang, NS
AF Arulselvan, Palanisamy
   Wen, Chih-Chun
   Lan, Chun-Wen
   Chen, Yung-Hsiang
   Wei, Wen-Chi
   Yang, Ning-Sun
TI Dietary Administration of Scallion Extract Effectively Inhibits
   Colorectal Tumor Growth: Cellular and Molecular Mechanisms in Mice
SO PLOS ONE
LA English
DT Article
ID HYPOXIA-INDUCIBLE FACTOR-1; COLON-CANCER CHEMOPREVENTION; CRYPT FOCI
   FORMATION; NITRIC-OXIDE; WELSH ONION; ADHESION MOLECULES;
   DOWN-REGULATION; KAPPA-B; ANGIOGENESIS; EXPRESSION
AB Colorectal cancer is a common malignancy and a leading cause of cancer death worldwide. Diet is known to play an important role in the etiology of colon cancer and dietary chemoprevention is receiving increasing attention for prevention and/or alternative treatment of colon cancers. Allium fistulosum L., commonly known as scallion, is popularly used as a spice or vegetable worldwide, and as a traditional medicine in Asian cultures for treating a variety of diseases. In this study we evaluated the possible beneficial effects of dietary scallion on chemoprevention of colon cancer using a mouse model of colon carcinoma (CT-26 cells subcutaneously inoculated into BALB/c mice). Tumor lysates were subjected to western blotting for analysis of key inflammatory markers, ELISA for analysis of cytokines, and immunohistochemistry for analysis of inflammatory markers. Metabolite profiles of scallion extracts were analyzed by LC-MS/MS. Scallion extracts, particularly hot-water extract, orally fed to mice at 50 mg (dry weight)/kg body weight resulted in significant suppression of tumor growth and enhanced the survival rate of test mice. At the molecular level, scallion extracts inhibited the key inflammatory markers COX-2 and iNOS, and suppressed the expression of various cellular markers known to be involved in tumor apoptosis (apoptosis index), proliferation (cyclin D1 and c-Myc), angiogenesis (VEGF and HIF-1 alpha), and tumor invasion (MMP-9 and ICAM-1) when compared with vehicle control-treated mice. Our findings may warrant further investigation of the use of common scallion as a chemopreventive dietary agent to lower the risk of colon cancer.
C1 [Arulselvan, Palanisamy; Wen, Chih-Chun; Lan, Chun-Wen; Chen, Yung-Hsiang; Wei, Wen-Chi; Yang, Ning-Sun] Acad Sinica, Agr Biotechnol Res Ctr, Taipei 115, Taiwan.
   [Lan, Chun-Wen] Natl Chung Hsing Univ, Taiwan Int Grad Program, Taipei, Taiwan.
   [Lan, Chun-Wen] Natl Chung Hsing Univ, Grad Inst Biotechnol, Taichung 40227, Taiwan.
   [Lan, Chun-Wen] Natl Chung Hsing Univ, Dept Life Sci, Taichung 40227, Taiwan.
   [Wei, Wen-Chi] Natl Sun Yat Sen Univ, Dept Marine Biotechnol & Resources, Kaohsiung 80424, Taiwan.
   [Yang, Ning-Sun] Natl Taiwan Univ, Inst Biotechnol, Taipei 10764, Taiwan.
RP Arulselvan, P (reprint author), Acad Sinica, Agr Biotechnol Res Ctr, Taipei 115, Taiwan.
EM nsyang@gate.sinica.edu.tw
RI Arulselvan, Palanisamy/M-6388-2014
OI Arulselvan, Palanisamy/0000-0002-1835-9738
FU National Science Council grant [NSC-99-2321-B-400-006]; Academia Sinica,
   Taiwan in the form of a Postdoctoral Research Fellowship
FX This study was financially supported by a National Science Council grant
   (NSC-99-2321-B-400-006) and by Academia Sinica, Taiwan in the form of a
   Postdoctoral Research Fellowship. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Aggarwal BB, 2006, BIOCHEM PHARMACOL, V71, P1397, DOI 10.1016/j.bcp.2006.02.009
   Aggarwal BB, 2003, ANTICANCER RES, V23, P363
   Anto RJ, 1996, MUTAT RES-GENET TOX, V370, P127, DOI 10.1016/0165-1218(96)00074-2
   Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028
   Chen JH, 1999, J CARDIOVASC PHARM, V33, P515, DOI 10.1097/00005344-199904000-00001
   Chen JH, 2000, J NUTR, V130, P34
   Chin YW, 2006, AAPS J, V8, pE239, DOI 10.1007/BF02854894
   Chiu SC, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-513
   Choi YL, 2004, J HISTOCHEM CYTOCHEM, V52, P591, DOI 10.1177/002215540405200504
   Dolcetti L, 2008, CANCER LETT, V267, P216, DOI 10.1016/j.canlet.2008.03.012
   Dowlati A, 2008, CLIN CANCER RES, V14, P1407, DOI 10.1158/1078-0432.CCR-07-1154
   Duvoix A, 2005, CANCER LETT, V223, P181, DOI 10.1016/j.canlet.2004.09.041
   Dymicka-Piekarska V, 2009, THROMB RES, V124, P80, DOI 10.1016/j.thromres.2008.11.021
   Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959
   Gupta SC, 2010, CANCER METAST REV, V29, P405, DOI 10.1007/s10555-010-9235-2
   Hagos GK, 2007, MOL CANCER THER, V6, P2230, DOI 10.1158/1535-7163.MCT-07-0069
   Hardy G, 2003, CURR OPIN CLIN NUTR, V6, P661, DOI [10.1097/00075197-200311000-00010, 10.1097/01.mco.0000098092.40916.2d]
   Hirota K, 2006, CRIT REV ONCOL HEMAT, V59, P15, DOI 10.1016/j.citrevonc.2005.12.003
   Hsu CH, 2007, ADV EXP MED BIOL, V595, P471
   Hu CE, 2011, SCAND J GASTROENTERO, V46, P156, DOI 10.3109/00365521.2010.516450
   Huerta S, 2008, EXPERT REV MOL DIAGN, V8, P277, DOI 10.1586/14737159.8.3.277
   Kohno H, 2006, INT J CANCER, V118, P2936, DOI 10.1002/ijc.21719
   La Vecchia C, 2004, PUBLIC HEALTH NUTR, V7, P965, DOI 10.1079/PHN2004562
   Lee SJ, 2007, TOXICOL APPL PHARM, V225, P198, DOI 10.1016/j.taap.2007.07.010
   Lee SI, 2008, J GASTROEN HEPATOL, V23, P138, DOI 10.1111/j.1440-1746.2007.05181.x
   Liang S, 2008, ANN BIOMED ENG, V36, P661, DOI 10.1007/s10439-008-9445-8
   Lin YC, 2006, CLIN CANCER RES, V12, P7165, DOI 10.1158/1078-0432.CCR-06-1393
   Lopez-Lazaro M, 2006, CANCER EPIDEM BIOMAR, V15, P2332, DOI 10.1158/1055-9965.EPI-06-0369
   Mehta RG, 2010, PHARM RES-DORDR, V27, P950, DOI 10.1007/s11095-010-0085-y
   Melillo G, 2006, MOL CANCER RES, V4, P601, DOI 10.1158/1541-7786.MCR-06-0235
   Misra S, 2006, J BIOL CHEM, V281, P34936, DOI 10.1074/jbc.C600138200
   Mousa AS, 2005, NUTR CANCER, V53, P104, DOI 10.1207/s15327914nc5301_12
   Naumov GN, 2006, CELL CYCLE, V5, P1779, DOI 10.4161/cc.5.16.3018
   Patel BB, 2009, AM J PHYSIOL-GASTR L, V296, pG955, DOI 10.1152/ajpgi.90726.2008
   Rao CV, 2004, MUTAT RES-FUND MOL M, V555, P107, DOI 10.1016/j.mrfmmm.2004.05.022
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   SANO H, 1995, CANCER RES, V55, P3785
   Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751
   Singh RP, 2003, CURR CANCER DRUG TAR, V3, P205, DOI 10.2174/1568009033481985
   Singh RP, 2005, ONCOGENE, V24, P1188, DOI 10.1038/sj.onc.1208276
   Singh V, 2006, NUTR CANCER, V55, P178, DOI 10.1207/s15327914nc5502_9
   Sinnamon MJ, 2008, INT J EXP PATHOL, V89, P466, DOI 10.1111/j.1365-2613.2008.00621.x
   Sung YY, 2011, MOL MED REP, V4, P431, DOI 10.3892/mmr.2011.451
   Takahashi M, 2000, CARCINOGENESIS, V21, P1319, DOI 10.1093/carcin/21.7.1319
   Tsai TH, 2005, J FOOD SCI, V70, pC93, DOI 10.1111/j.1365-2621.2005.tb09028.x
   Tu YY, 2011, NAT MED, V17, P1217, DOI 10.1038/nm.2471
   Velmurugan B, 2010, MOL CARCINOGEN, V49, P641, DOI 10.1002/mc.20643
   Wang BS, 2005, FOOD CHEM, V91, P147, DOI 10.1016/j.foodchem.2004.06.009
   Wang SX, 2006, INT J CANCER, V118, P932, DOI 10.1002/ijc.21289
   Warren CA, 2009, J NUTR, V139, P101, DOI 10.3945/jn.108.096271
   Wiseman M, 2008, P NUTR SOC, V67, P253, DOI 10.1017/S002966510800712X
   Yamamoto Y, 2005, BIOSCI BIOTECH BIOCH, V69, P1311, DOI 10.1271/bbb.69.1311
NR 52
TC 16
Z9 16
U1 1
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 14
PY 2012
VL 7
IS 9
AR e44658
DI 10.1371/journal.pone.0044658
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 007AD
UT WOS:000308860100013
PM 23024755
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Aldini, R
   Budriesi, R
   Roda, G
   Micucci, M
   Ioan, P
   D'Errico-Grigioni, A
   Sartini, A
   Guidetti, E
   Marocchi, M
   Cevenini, M
   Rosini, F
   Montagnani, M
   Chiarini, A
   Mazzella, G
AF Aldini, Rita
   Budriesi, Roberta
   Roda, Giulia
   Micucci, Matteo
   Ioan, Pierfranco
   D'Errico-Grigioni, Antonia
   Sartini, Alessandro
   Guidetti, Elena
   Marocchi, Margherita
   Cevenini, Monica
   Rosini, Francesca
   Montagnani, Marco
   Chiarini, Alberto
   Mazzella, Giuseppe
TI Curcuma longa Extract Exerts a Myorelaxant Effect on the Ileum and Colon
   in a Mouse Experimental Colitis Model, Independent of the
   Anti-Inflammatory Effect
SO PLOS ONE
LA English
DT Article
ID NF-KAPPA-B; TRINITROBENZENE SULFONIC-ACID; INFLAMMATORY-BOWEL-DISEASE;
   ENTERIC NERVOUS-SYSTEM; DEXTRAN SULFATE SODIUM; ULCERATIVE-COLITIS;
   SMOOTH-MUSCLE; INTESTINAL INFLAMMATION; MAINTENANCE THERAPY; CELLS
AB Background: Curcuma has long been used as an anti-inflammatory agent in inflammatory bowel disease. Since gastrointestinal motility is impaired in inflammatory states, the aim of this work was to evaluate if Curcuma Longa had any effect on intestinal mortality
   Methods: The biological activity of Curcuma extract was evaluated against Carbachol induced contraction in isolated mice intestine. Acute and chronic colitis were induced in Balb/c mice by Dextran Sulphate Sodium administration (5% and 2.5% respectively) and either Curcuma extract (200 mg/kg/day) or placebo was thereafter administered for 7 and 21 days respectively. Spontaneous contractions and the response to Carbachol and Atropine of ileum and colon were studied after colitis induction and Curcuma administration.
   Results: Curcuma extract reduced the spontaneous contractions in the ileum and colon; the maximal response to Carbachol was inhibited in a non-competitive and reversible manner. Similar results were obtained in ileum and colon from Curcuma fed mice. DSS administration decreased the motility, mainly in the colon and Curcuma almost restored both the spontaneous contractions and the response to Carbachol after 14 days assumption, compared to standard diet, but a prolonged assumption of Curcuma decreased the spontaneous and Carbachol-induced contractions.
   Conclusions: Curcuma extract has a direct and indirect myorelaxant effect on mouse ileum and colon, independent of the anti-inflammatory effect. The indirect effect is reversible and non-competitive with the cholinergic agent. These results suggest the use of curcuma extract as a spasmolytic agent.
C1 [Aldini, Rita; Roda, Giulia; Sartini, Alessandro; Guidetti, Elena; Marocchi, Margherita; Cevenini, Monica; Montagnani, Marco; Mazzella, Giuseppe] Univ Bologna, Dipartimento Med Clin, Osped Policlin S Orsola, Bologna, Italy.
   [Aldini, Rita] Univ Bologna, Dipartimento Sci Metalli Elettrochim & Tecn Chim, Bologna, Italy.
   [Budriesi, Roberta; Micucci, Matteo; Ioan, Pierfranco; Chiarini, Alberto] Univ Bologna, Dipartimento Sci Farmaceut, I-40126 Bologna, Italy.
   [D'Errico-Grigioni, Antonia; Rosini, Francesca] Univ Bologna, Dipartimento Med Interna Invecchiamento & Malatt, Osped Policlin S Orsola, Bologna, Italy.
RP Aldini, R (reprint author), Univ Bologna, Dipartimento Med Clin, Osped Policlin S Orsola, Bologna, Italy.
EM rita.aldini@unibo.it; roberta.budriesi@unibo.it
OI Sartini, Alessandro/0000-0003-1573-6451; MONTAGNANI,
   MARCO/0000-0003-0103-0327; Mazzella, Giuseppe/0000-0001-8656-8112
FU Fondazione del Monte di Bologna e Ravenna; Alisal [Mazz100136- 2010];
   MINISTERO DELLE POLITICHE AGRICOLE, ALIMENTARI E FORESTALI [D.M.
   11008/7303/10]
FX This work was supported by grants from Fondazione del Monte di Bologna e
   Ravenna and from Alisal (Mazz100136- 2010). ALISAL is a project
   supported by the MINISTERO DELLE POLITICHE AGRICOLE, ALIMENTARI E
   FORESTALI, with D.M. 11008/7303/10, dated 17/05/2010. The title of the
   project is: Miglioramento delle proprieta igienico-sanitarie,
   salutistiche e funzionali di commodity per l'alimentazione dell'uomo e/o
   degli animali (Improvement of sanitary properties, healthy and
   functional food commodities for human and/or animals). Prof. Mazzella
   was supported with materials, reagents, animals. The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR AHMED T, 2008, PHARM BIOCH BEHAV, V91, P554
   Akiho Hirotada, 2011, World J Gastrointest Pathophysiol, V2, P72
   AMMON HPT, 1991, PLANTA MED, V57, P1, DOI 10.1055/s-2006-960004
   [Anonymous], VERS 3 0 GRAPHPAD SO
   ARUNLAKSHANA O, 1959, BRIT J PHARM CHEMOTH, V14, P48, DOI 10.1111/j.1476-5381.1959.tb00928.x
   Aube AC, 1999, NEUROGASTROENT MOTIL, V11, P55
   Bharti AC, 2003, BLOOD, V101, P1053, DOI 10.1182/blood-2002-05-1320
   Blandizzi C, 2003, BRIT J PHARMACOL, V139, P309, DOI 10.1038/sj.bjp.0705249
   Camacho-Barquero L, 2007, INT IMMUNOPHARMACOL, V7, P333, DOI 10.1016/j.intimp.2006.11.006
   Claramunt RM, 2009, BIOORGAN MED CHEM, V17, P1290, DOI 10.1016/j.bmc.2008.12.029
   Deguchi Y, 2007, DIGEST DIS SCI, V52, P2993, DOI 10.1007/s10620-006-9138-9
   Fitzpatrick LR, 2000, DIGEST DIS SCI, V45, P2327, DOI 10.1023/A:1005630723111
   Furness JB, 2008, NEUROGASTROENT MOTIL, V20, P32, DOI 10.1111/j.1365-2982.2008.01094.x
   Grundy D, 2005, CURR OPIN GASTROEN, V21, P176, DOI 10.1097/01.mog.0000153315.28327.6e
   Han SS, 2002, J BIOCHEM MOL BIOL, V35, P337
   Hanai H, 2006, CLIN GASTROENTEROL H, V4, P1502, DOI 10.1016/j.cgh.2006.08.008
   HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292
   Ihara E, 2009, MOL PHARMACOL, V75, P1031, DOI 10.1124/mol.108.049858
   Itthipanichpong C, 2006, J MED ASS THAI S2, V86, pS2999
   JACOBSON K, 1995, GASTROENTEROLOGY, V109, P718, DOI 10.1016/0016-5085(95)90378-X
   JAIN SK, 1994, CIBA F SYMP, V185, P153
   Jian YT, 2005, WORLD J GASTROENTERO, V11, P1747
   Kim GY, 2005, J IMMUNOL, V174, P8116, DOI 10.4049/jimmunol.174.12.8116
   Kinoshita K, 2003, AM J PHYSIOL-GASTR L, V285, pG483, DOI 10.1152/ajpgi.00038.2003
   Kohno N, 2006, J MED INVESTIG, V53, P277, DOI 10.2152/jmi.53.277
   Kondo T, 2011, EUR J PHARMACOL, V670, P236, DOI 10.1016/j.ejphar.2011.08.034
   Kumar Anil, 2010, Indian J Physiol Pharmacol, V54, P284
   Larmonier CB, 2011, INFLAMM BOWEL DIS, V17, P503, DOI 10.1002/ibd.21391
   Lim Allen W, 2011, Therap Adv Gastroenterol, V4, P145, DOI 10.1177/1756283X10382816
   Linden D, 2003, BRIT J PHARMACOL, V139, P185, DOI 10.1038/sj.bjp.0705250
   Linden DR, 2004, J PHYSIOL-LONDON, V557, P191, DOI 10.1113/jphysiol.2004.062174
   Lomax AE, 2005, NEUROGASTROENT MOTIL, V17, P4, DOI 10.1111/j.1365-2982.2004.00607.x
   Mattar Mark C, 2011, Gastrointest Cancer Res, V4, P53
   Mizuta Y, 2000, GASTROENTEROLOGY, V118, P714, DOI 10.1016/S0016-5085(00)70141-7
   Motagally MA, 2009, AM J PHYSIOL-GASTR L, V296, pG1077, DOI 10.1152/ajpgi.00006.2009
   Motulsky H., 2003, FITTING MODELS BIOL
   Myers BS, 1997, AM J PHYSIOL-GASTR L, V273, pG928
   Negi PS, 1999, J AGR FOOD CHEM, V47, P4297, DOI 10.1021/jf990308d
   Papadakis KA, 2000, INFLAMM BOWEL DIS, V6, P303, DOI 10.1002/ibd.3780060408
   Pazdrak K, 2004, GASTROENTEROLOGY, V127, P1096, DOI 10.1053/j.gastro.2004.07.008
   Qureshi S, 2010, NEUROGASTROENT MOTIL, V22, DOI 10.1111/j.1365-2982.2009.01406.x
   Qureshi S, 2010, NEUROGASTROENT MOTIL, V22, pe64
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   REDDY SN, 1991, GASTROENTEROLOGY, V101, P1289, DOI 10.1016/0016-5085(91)90079-Z
   Rutgeerts P, 2005, NEW ENGL J MED, V353, P2462, DOI 10.1056/NEJMoa050516
   Salh B, 2003, AM J PHYSIOL-GASTR L, V285, pG235, DOI 10.1152/ajpgi.00449.2002
   Sato K, 2006, BRIT J PHARMACOL, V148, P200, DOI 10.1038/sj.bjp.0706717
   Shimouchi A, 2009, DIGEST DIS SCI, V54, P1725, DOI 10.1007/s10620-008-0550-1
   Singh AK, 1996, CANCER LETT, V107, P109, DOI 10.1016/0304-3835(96)04357-1
   Singh G, 2010, FOOD CHEM TOXICOL, V48, P1026, DOI 10.1016/j.fct.2010.01.015
   SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995
   Strober W, 2007, J CLIN INVEST, V117, P514, DOI 10.1172/JCI30587
   Sugimoto K, 2002, GASTROENTEROLOGY, V123, P1912, DOI 10.1053/gast.2002.37050
   TAKEMASA KENJIRO, 1957, JOUR PHYSIOL SOC JAPAN, V19, P1217
   Tallarida RJ, 1987, MANUAL PHARM CALCULA
   Tomita R, 1998, J GASTROENTEROL, V33, P48, DOI 10.1007/PL00009965
   Triantafillidis JK, 2011, DRUG DES DEV THER, V5, P185, DOI 10.2147/DDDT.S11290
   Ukil A, 2003, BRIT J PHARMACOL, V139, P209, DOI 10.1038/sj.bjp.0705241
   Vasina V, 2006, AUTON NEUROSCI-BASIC, V126, P264, DOI 10.1016/j.autneu.2003.02.025
   Vrees MD, 2002, ARCH SURG-CHICAGO, V137, P439, DOI 10.1001/archsurg.137.4.439
   Wirtz S, 2007, NAT PROTOC, V2, P541, DOI 10.1038/nprot.2007.41
   Xavier RJ, 2007, NATURE, V448, P427, DOI 10.1038/nature06005
   Xu YX, 1997, EXP HEMATOL, V25, P413
   Xu YX, 1998, HEMATOPATHOL MOL HEM, V11, P49
NR 64
TC 12
Z9 12
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 12
PY 2012
VL 7
IS 9
AR e44650
DI 10.1371/journal.pone.0044650
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 005GJ
UT WOS:000308738500071
PM 22984538
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Xu, D
   Zhang, BJ
   Liang, G
   Ping, J
   Kou, H
   Li, XJ
   Xiong, J
   Hu, DC
   Chen, LB
   Magdalou, J
   Wang, H
AF Xu, Dan
   Zhang, Benjian
   Liang, Gai
   Ping, Jie
   Kou, Hao
   Li, Xiaojun
   Xiong, Jie
   Hu, Dongcai
   Chen, Liaobin
   Magdalou, Jacques
   Wang, Hui
TI Caffeine-Induced Activated Glucocorticoid Metabolism in the Hippocampus
   Causes Hypothalamic-Pituitary-Adrenal Axis Inhibition in Fetal Rats
SO PLOS ONE
LA English
DT Article
ID 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-2; INTRAUTERINE GROWTH
   RESTRICTION; GENE-EXPRESSION; MINERALOCORTICOID RECEPTOR; ENVIRONMENTAL
   EPIGENOMICS; PRENATAL OVEREXPOSURE; EPIGENETIC MECHANISMS; INSULIN
   SENSITIVITY; PROTEIN-A; CORTISOL
AB Epidemiological investigations have shown that fetuses with intrauterine growth retardation (IUGR) are susceptible to adult metabolic syndrome. Clinical investigations and experiments have demonstrated that caffeine is a definite inducer of IUGR, as children who ingest caffeine-containing food or drinks are highly susceptible to adult obesity and hypertension. Our goals for this study were to investigate the effect of prenatal caffeine ingestion on the functional development of the fetal hippocampus and the hypothalamic-pituitary-adrenal (HPA) axis and to clarify an intrauterine HPA axis-associated neuroendocrine alteration induced by caffeine. Pregnant Wistar rats were intragastrically administered 20, 60, and 180 mg/kg.d caffeine from gestational days 11-20. The results show that prenatal caffeine ingestion significantly decreased the expression of fetal hypothalamus corticotrophin-releasing hormone. The fetal adrenal cortex changed into slight and the expression of fetal adrenal steroid acute regulatory protein (StAR) and cholesterol side-chain cleavage enzyme (P450scc), as well as the level of fetal adrenal endogenous corticosterone (CORT), were all significantly decreased after caffeine treatment. Moreover, caffeine ingestion significantly increased the levels of maternal and fetal blood CORT and decreased the expression of placental 11 beta-hydroxysteroid dehydrogenase-2 (11 beta-HSD-2). Additionally, both in vivo and in vitro studies show that caffeine can downregulate the expression of fetal hippocampal 11b-HSD-2, promote the expression of 11 beta-hydroxysteroid dehydrogenase 1 and glucocorticoid receptor (GR), and enhance DNA methylation within the hippocampal 11b-HSD-2 promoter. These results suggest that prenatal caffeine ingestion inhibits the development of the fetal HPA axis, which may be associated with the fetal overexposure to maternal glucocorticoid and activated glucocorticoid metabolism in the fetal hippocampus. These results will be beneficial in elucidating the developmental toxicity of caffeine and in exploring the fetal origin of adult HPA axis dysfunction and metabolic syndrome susceptibility for offspring with IUGR induced by caffeine.
C1 [Xu, Dan; Zhang, Benjian; Liang, Gai; Ping, Jie; Kou, Hao; Li, Xiaojun; Xiong, Jie; Wang, Hui] Wuhan Univ, Basic Med Sch, Dept Pharmacol, Wuhan 430072, Peoples R China.
   [Xu, Dan; Ping, Jie; Wang, Hui] Wuhan Univ, Res Ctr Food & Drug Evaluat, Wuhan 430072, Peoples R China.
   [Hu, Dongcai; Chen, Liaobin] Wuhan Univ, Zhongnan Hosp, Dept Orthoped Surg, Wuhan 430072, Peoples R China.
   [Magdalou, Jacques] Univ Nancy, Fac Med, CNRS, UMR 7561, Vandoeuvre Les Nancy, France.
RP Xu, D (reprint author), Wuhan Univ, Basic Med Sch, Dept Pharmacol, Wuhan 430072, Peoples R China.
EM wanghui19@whu.edu.cn
RI Hu, Dongcai/F-2375-2014
OI Hu, Dongcai/0000-0002-1239-7215
FU National Natural Science Foundation of China [30830112, 81072709, 812
   2]; Chinese Ministry of Education [V200801]; Hubei Province Science
   Foundation for Innovation Group of China [2009CDA079]; Specialized
   Research Fund for the Doctoral Program of Higher Education of China
   [20110141120055]; Postdoctoral Science Foundation of China [20110491196]
FX This work was supported by grants from the National Natural Science
   Foundation of China (Nos. 30830112, 81072709, and 812 2), the Key Grant
   Project of the Chinese Ministry of Education (No. V200801), the Hubei
   Province Science Foundation for Innovation Group of China (No.
   2009CDA079), the Specialized Research Fund for the Doctoral Program of
   Higher Education of China (No. 20110141120055) and the Postdoctoral
   Science Foundation of China (No. 20110491196). The funders had no role
   in the study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Alikhani-Koopaei R, 2004, J CLIN INVEST, V114, P1146, DOI 10.1172/JCI200421647
   Anagnostis P, 2009, J CLIN ENDOCR METAB, V94, P2692, DOI 10.1210/jc.2009-0370
   Barbazanges A, 1996, J NEUROSCI, V16, P3943
   Barone JJ, 1996, FOOD CHEM TOXICOL, V34, P119, DOI 10.1016/0278-6915(95)00093-3
   Baserga M, 2010, AM J PHYSIOL-REG I, V299, pR334, DOI 10.1152/ajpregu.00122.2010
   Boylan SM, 2008, BRIT J NUTR, V100, P875, DOI 10.1017/S0007114508939842
   Brabant G, 2005, FASEB J, V19, P1048, DOI 10.1096/fj.04-2846fje
   Brown RW, 1996, ENDOCRINOLOGY, V137, P794, DOI 10.1210/en.137.2.794
   Burton PJ, 1999, BIOL REPROD, V60, P234, DOI 10.1095/biolreprod60.2.234
   Butt MS, 2011, CRIT REV FOOD SCI, V51, P363, DOI 10.1080/10408390903586412
   Cayetanot F, 2009, RESP PHYSIOL NEUROBI, V168, P92, DOI 10.1016/j.resp.2009.04.024
   Chang L, 2004, MOL MED, V10, P65, DOI 10.2119/2005-00029
   Chen M, 2007, EXP TOXICOL PATHOL, V59, P245, DOI 10.1016/j.etp.2007.05.007
   Christian MS, 2001, TERATOLOGY, V64, P51, DOI 10.1002/tera.1047.abs
   Cohen M S, 1982, Drug Ther, P165
   de Quervain DJF, 2009, FRONT NEUROENDOCRIN, V30, P358, DOI 10.1016/j.yfrne.2009.03.002
   Diaz R, 1998, J NEUROSCI, V18, P2570
   Dolinoy DC, 2008, ENVIRON MOL MUTAGEN, V49, P4, DOI 10.1002/em.20366
   Fowden AL, 2005, EARLY HUM DEV, V81, P723, DOI 10.1016/j.earlhumdev.2005.06.007
   Fowden AL, 1998, P NUTR SOC, V57, P113, DOI 10.1079/PNS19980017
   Da Silveira VMF, 2008, REV SAUDE PUBL, V42, P10, DOI 10.1590/S0034-89102008000100002
   Gavrieli A, 2011, J NUTR, V141, P703, DOI 10.3945/jn.110.137323
   Henriquez-Hernandez LA, 2007, J PHARMACOL EXP THER, V320, P695, DOI 10.1124/jpet.106.113209
   Hotta K, 2001, DIABETES, V50, P1126, DOI 10.2337/diabetes.50.5.1126
   Huang J, 2012, CLIN EXP PHARMACOL P, V39, P357, DOI 10.1111/j.1440-1681.2012.05676.x
   James J, 2004, BMJ-BRIT MED J, V328, P1237, DOI 10.1136/bmj.38077.458438.EE
   Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045
   Johren O, 2007, BRAIN RES, V1184, P160, DOI 10.1016/j.brainres.2007.09.036
   Kanaka-Gantenbein C, 2010, ANN NY ACAD SCI, V1205, P99, DOI 10.1111/j.1749-6632.2010.05683.x
   Kjaer SL, 2011, PHYSIOL BEHAV, V102, P444, DOI 10.1016/j.physbeh.2010.12.015
   Kjaer SL, 2010, BRAIN RES, V1320, P106, DOI 10.1016/j.brainres.2010.01.008
   Kuczkowski KM, 2007, CURR OPIN OBSTET GYN, V19, P578, DOI 10.1097/GCO.0b013e3282f1bf17
   Liang G, 2011, EXP TOXICOL PATHOL, V63, P607, DOI 10.1016/j.etp.2010.04.015
   Lin A S, 1997, Depress Anxiety, V5, P21, DOI 10.1002/(SICI)1520-6394(1997)5:1<21::AID-DA4>3.3.CO;2-A
   Liu YS, 2012, TOXICOL APP IN PRESS
   Lopez-Bermejo A, 2004, CLIN ENDOCRINOL, V60, P256, DOI 10.1111/j.1365-2265.2003.01977
   Marret S, 1997, BRAIN RES, V773, P213, DOI 10.1016/S0006-8993(97)00938-4
   McNeil CJ, 2007, REPRODUCTION, V133, P653, DOI 10.1530/rep.1.01198
   Meaney MJ, 2007, TRENDS MOL MED, V13, P269, DOI 10.1016/j.molmed.2007.05.003
   Momoi N, 2008, AM J PHYSIOL-HEART C, V294, pH2248, DOI 10.1152/ajpheart.91469.2007
   Morrow AL, 2001, INT REV NEUROBIOL, V46, P349
   Neitzke U, 2008, PLACENTA, V29, P246, DOI 10.1016/j.placenta.2007.11.014
   Owen D, 2005, J NEUROENDOCRINOL, V17, P220, DOI 10.1111/j.1365-2826.2005.01294.x
   Pettenuzzo LF, 2008, PHYSIOL BEHAV, V95, P295, DOI 10.1016/j.physbeh.2008.06.003
   Ping J, 2012, CHEM-BIOL INTERACT, V195, P68, DOI 10.1016/j.cbi.2011.11.001
   Radosavljevic Tatjana, 2005, Med Pregl, V58, P558, DOI 10.2298/MPNS0512558R
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Reichardt HM, 1996, MOL MED, V2, P735, DOI 10.1007/BF03401657
   Seckl JR, 1997, FRONT NEUROENDOCRIN, V18, P49, DOI 10.1006/frne.1996.0143
   Thayer P S, 1975, CRC Crit Rev Toxicol, V3, P345, DOI 10.3109/10408447509079863
   Thompson A, 2004, J STEROID BIOCHEM, V88, P367, DOI 10.1016/j.jsbmb.2003.12.014
   Valsamakis G, 2006, ANN NY ACAD SCI, V1092, P138, DOI 10.1196/annals.1365.012
   Walker BR, 2006, DIABETIC MED, V23, P1281, DOI 10.1111/j.1464-5491.2006.01998.x
   Wan Shun-Lun, 2002, Shengli Xuebao, V54, P473
   Weaver ICG, 2007, J NEUROSCI, V27, P1756, DOI 10.1523/JNEUROSCI.4164-06.2007
   Weaver ICG, 2009, SEMIN FETAL NEONAT M, V14, P143, DOI 10.1016/j.siny.2008.12.002
   Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276
   WILKINSON JM, 1993, DEV BRAIN RES, V75, P193, DOI 10.1016/0165-3806(93)90023-4
   Xita N, 2010, ANN NY ACAD SCI, V1205, P148, DOI 10.1111/j.1749-6632.2010.05658.x
   Xua D, 2011, ENVIRON TOXICOL PHAR, V32, P356, DOI 10.1016/j.etap.2011.08.003
   Yang Z, 2007, J ENDOCRINOL, V195, P241, DOI 10.1677/JOE-07-0303
NR 61
TC 54
Z9 62
U1 0
U2 25
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 6
PY 2012
VL 7
IS 9
AR e44497
DI 10.1371/journal.pone.0044497
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 001KC
UT WOS:000308458400080
PM 22970234
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Shaw, LH
   Lin, LC
   Tsai, TH
AF Shaw, Lee-Hsin
   Lin, Lie-Chwen
   Tsai, Tung-Hu
TI HPLC-MS/MS Analysis of a Traditional Chinese Medical Formulation of
   Bu-Yang-Huan-Wu-Tang and Its Pharmacokinetics after Oral Administration
   to Rats
SO PLOS ONE
LA English
DT Article
ID PERFORMANCE LIQUID-CHROMATOGRAPHY; RADIX-SCUTELLARIAE EXTRACT;
   CORONARY-HEART-DISEASE; MASS-SPECTROMETRY; GASTRIC PH; LC-MS/MS;
   DECOCTION; METABOLISM; CONSTITUENTS; ASTRAGALI
AB Bu-yang-huan-wu-tang (BYHWT) is one of the most popular formulated traditional Chinese medicine prescriptions, and is widely for prevention of ischemic cardio-cerebral vascular diseases and stroke-induced disability. A specific high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) has been developed and validated for simultaneous quantification of the nine main bioactive components, i.e., astragaloside I, astragaloside II, astragaloside IV, formononetin, ononin, calycosin, calycosin-7-O-beta-d-glucoside, ligustilide and paeoniflorin in rat plasma after oral administration of BYHWT extract. This method was applied to investigate the pharmacokinetics in conscious and freely moving rats. No significant matrix effects were observed. The overall analytical procedure was rapid and reproducible, which makes it suitable for quantitative analysis of a large number of samples. Among them, three astragalosides and four isoflavones in A. membranaceus, ligustilide in Radix Angelicae Sinensis and Rhizoma Ligustici Chuanxiong and paeoniflorin in Radix Paeoniae Rubra were identified. This developed method was then successfully applied to pharmacokinetic studies of the nine bioactive constituents after oral administration of BYHWT extracts in rats. The pharmacokinetic data demonstrated that astragaloside I, astragaloside II, astragaloside IV and ligustilide presented the phenomenon of double peaks. The other herbal ingredients of formononetin, ononin, calycosin, calycosin-7-O-beta-d-glucoside and paeoniflorin appeared together in a single and plateau absorption phase. These phenomenona suggest that these components may have multiple absorption sites, regulation of enterohepatic circulation or the gastric emptying rate, or there is ingredient-ingredient interaction. These pharmacokinetic results provide a constructive contribution to better understand the absorption mechanism of BYHWT and to support additional clinical evaluation.
C1 [Shaw, Lee-Hsin; Lin, Lie-Chwen; Tsai, Tung-Hu] Natl Yang Ming Univ, Inst Tradit Med, Taipei 112, Taiwan.
   [Lin, Lie-Chwen] Natl Res Inst Chinese Med, Taipei, Taiwan.
   [Tsai, Tung-Hu] China Med Univ, Grad Inst Acupuncture Sci, Taichung, Taiwan.
   [Tsai, Tung-Hu] Taipei City Hosp, Dept Educ & Res, Taipei, Taiwan.
RP Shaw, LH (reprint author), Natl Yang Ming Univ, Inst Tradit Med, Taipei 112, Taiwan.
EM thtsai@ym.edu.tw
FU National Science Council, Taiwan [NSC99-2113-M-010-001-MY3,
   NSC99-2628-B-010-008-MY3]; Committee on Chinese Medicine and Pharmacy,
   Department of Health, Taiwan [CCMP99 -RD-024]; Taipei City Hospital,
   Taipei, Taiwan [10001-62-007];  [TCH 96001-62-014]
FX Funding for this study was provided in part by research grants from the
   National Science Council (NSC99-2113-M-010-001-MY3,
   NSC99-2628-B-010-008-MY3) Taiwan; Committee on Chinese Medicine and
   Pharmacy, Department of Health (CCMP99 -RD-024) Taiwan and TCH
   96001-62-014; 10001-62-007 from Taipei City Hospital, Taipei, Taiwan.
CR Chen YJ, 2008, INT J PHARMACEUT, V350, P230, DOI 10.1016/j.ijpharm.2007.08.052
   Hsieh YJ, 2006, J CHROMATOGR B, V844, P1, DOI 10.1016/j.jchromb.2006.06.024
   Huang Y, 2007, BIOPHARM DRUG DISPOS, V28, P361, DOI 10.1002/bdd.556
   Ji Bo, 2006, Zhong Xi Yi Jie He Xue Bao, V4, P30
   Li P, 2007, ANAL BIOANAL CHEM, V389, P2259, DOI 10.1007/s00216-007-1612-5
   Lin LC, 2008, J PHARMACEUT BIOMED, V48, P909, DOI 10.1016/j.jpba.2008.07.013
   Liu EH, 2010, BIOMED CHROMATOGR, V24, P125, DOI 10.1002/bmc.1269
   Liu EH, 2009, BIOMED CHROMATOGR, V23, P828, DOI 10.1002/bmc.1193
   Lu Q, 2006, EUR J PHARMACOL, V542, P136, DOI 10.1016/j.ejphar.2006.04.023
   Lu T, 2007, J ETHNOPHARMACOL, V110, P412, DOI 10.1016/j.jep.2006.09.036
   Ma XF, 2004, J CHROMATOGR A, V1023, P311, DOI 10.1016/j.chroma.2003.10.014
   Mostafavi SA, 2003, INT J PHARM, V255, P81, DOI 10.1016/S0378-5173(03)00037-1
   MUMMANENI V, 1995, PHARMACEUT RES, V12, P780, DOI 10.1023/A:1016284214708
   Qi LW, 2008, J SEP SCI, V31, P97, DOI 10.1002/jssc.200700286
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Tong L, 2010, BIOMED CHROMATOGR, V24, P1324, DOI 10.1002/bmc.1443
   Tsai PL, 2002, ANAL LETT, V35, P2459, DOI 10.1081/AL-120016537
   Tsai TH, 2005, PLANTA MED, V71, P640, DOI 10.1055/s-2005-871270
   Wang D, 2006, J SEP SCI, V29, P2012, DOI 10.1002/jssc.200500486
   Wang HW, 2011, J ETHNOPHARMACOL, V138, P22, DOI 10.1016/j.jep.2011.06.033
   Wang WR, 2011, J ETHNOPHARMACOL, V137, P214, DOI 10.1016/j.jep.2011.05.008
   Wen XD, 2009, J PHARMACEUT BIOMED, V50, P100, DOI 10.1016/j.jpba.2009.03.038
   Wu YT, 2011, J TRADITION COMPLEME, V2, P30
   Wu YT, 2010, J AGR FOOD CHEM, V58, P108, DOI 10.1021/jf902872j
   Xiao HB, 2004, J CHROMATOGR A, V1032, P117, DOI 10.1016/j.chroma.2003.09.032
   Yan R, 2008, DRUG METAB DISPOS, V36, P400, DOI 10.1124/dmd.107.017707
   Yesilada E, 2005, J ETHNOPHARMACOL, V96, P71, DOI 10.1016/j.jep.2004.08.036
   Yin OQP, 2003, CLIN PHARMACOKINET, V42, P179, DOI 10.2165/00003088-200342020-00005
   Zhang Dongqing, 2011, Zhongguo Zhong Yao Za Zhi, V36, P3502
   Zhang H, 2010, J ETHNOPHARMACOL, V130, P98, DOI 10.1016/j.jep.2010.04.017
   Zhang JY, 2011, BIOMED CHROMATOGR, V25, P450, DOI 10.1002/bmc.1466
   Zhao LD, 2012, J ETHNOPHARMACOL, V140, P339, DOI 10.1016/j.jep.2012.01.026
   Zhou SF, 2004, LIFE SCI, V74, P935, DOI 10.1016/j.lfs.2003.09.035
   Zhu ZY, 2010, J CHROMATOGR B, V878, P2184, DOI 10.1016/j.jchromb.2010.06.021
   Zu YG, 2009, J SEP SCI, V32, P517, DOI 10.1002/jssc.200800499
NR 35
TC 39
Z9 43
U1 2
U2 69
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 29
PY 2012
VL 7
IS 8
AR e43848
DI 10.1371/journal.pone.0043848
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 997ZC
UT WOS:000308206000055
PM 22952787
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Vinkers, CH
   van Oorschot, R
   Nielsen, EO
   Cook, JM
   Hansen, HH
   Groenink, L
   Olivier, B
   Mirza, NR
AF Vinkers, Christiaan H.
   van Oorschot, Ruud
   Nielsen, Elsebet O.
   Cook, James M.
   Hansen, Henrik H.
   Groenink, Lucianne
   Olivier, Berend
   Mirza, Naheed R.
TI GABA(A) Receptor alpha Subunits Differentially Contribute to Diazepam
   Tolerance after Chronic Treatment
SO PLOS ONE
LA English
DT Article
ID STRESS-INDUCED HYPERTHERMIA; GAMMA-AMINOBUTYRIC-ACID; IN-SITU
   HYBRIDIZATION; MESSENGER-RNA LEVELS; ELEVATED PLUS-MAZE; A-RECEPTOR;
   SELECTIVE AGONIST; TREATMENT REGIMES; RAT CORTEX; EXPRESSION
AB Background: Within the GABA(A)-receptor field, two important questions are what molecular mechanisms underlie benzodiazepine tolerance, and whether tolerance can be ascribed to certain GABA(A)-receptor subtypes.
   Methods: We investigated tolerance to acute anxiolytic, hypothermic and sedative effects of diazepam in mice exposed for 28-days to non-selective/selective GABA(A)-receptor positive allosteric modulators: diazepam (non-selective), bretazenil (partial non-selective), zolpidem (alpha(1) selective) and TPA023 (alpha(2/3) selective). In-vivo binding studies with [H-3]flumazenil confirmed compounds occupied CNS GABA(A) receptors.
   Results: Chronic diazepam treatment resulted in tolerance to diazepam's acute anxiolytic, hypothermic and sedative effects. In mice treated chronically with bretazenil, tolerance to diazepam's anxiolytic and hypothermic, but not sedative, effects was seen. Chronic zolpidem treatment resulted in tolerance to diazepam's hypothermic effect, but partial anxiolytic tolerance and no sedative tolerance. Chronic TPA023 treatment did not result in tolerance to diazepam's hypothermic, anxiolytic or sedative effects.
   Conclusions: Our data indicate that: (i) GABA(A)-alpha(2)/alpha(3) subtype selective drugs might not induce tolerance; (ii) in rodents quantitative and temporal variations in tolerance development occur dependent on the endpoint assessed, consistent with clinical experience with benzodiazepines (e. g., differential tolerance to antiepileptic and anxiolytic actions); (iii) tolerance to diazepam's sedative actions needs concomitant activation of GABA(A)-alpha(1)/GABA(A)-alpha(5) receptors. Regarding mechanism, in-situ hybridization studies indicated no gross changes in expression levels of GABA(A) alpha(1), alpha(2) or alpha(5) subunit mRNA in hippocampus or cortex. Since selective chronic activation of either GABA(A) alpha(2), or alpha(3) receptors does not engender tolerance development, subtype-selective GABA(A) drugs might constitute a promising class of novel drugs.
C1 [Vinkers, Christiaan H.; van Oorschot, Ruud; Groenink, Lucianne; Olivier, Berend] Univ Utrecht, Div Pharmacol, Utrecht Inst Pharmaceut Sci, Utrecht, Netherlands.
   [Vinkers, Christiaan H.] Univ Med Ctr Utrecht, Rudolf Magnus Inst Neurosci, Dept Psychiat, Utrecht, Netherlands.
   [Nielsen, Elsebet O.; Hansen, Henrik H.; Mirza, Naheed R.] NeuroSearch AS, NsDiscovery, Ballerup, Denmark.
   [Cook, James M.] Univ Wisconsin, Dept Chem & Biochem, Milwaukee, WI 53201 USA.
   [Hansen, Henrik H.] Gubra ApS, Horsholm, Denmark.
   [Olivier, Berend] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA.
   [Mirza, Naheed R.] Aniona ApS, Ballerup, Denmark.
RP Vinkers, CH (reprint author), Univ Utrecht, Div Pharmacol, Utrecht Inst Pharmaceut Sci, Utrecht, Netherlands.
EM c.h.vinkers@uu.nl
RI Groenink, Lucianne/O-6588-2016
OI Groenink, Lucianne/0000-0002-4971-7796
FU National Institute for Mental Health [MH-046851]
FX This work was supported in part by MH-046851 (National Institute for
   Mental Health) (JMC). No additional external funding was received for
   this study. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Ali NJ, 2001, J NEUROCHEM, V79, P1100, DOI 10.1046/j.1471-4159.2001.00664.x
   Allison C, 2006, NEUROPSYCHOPHARMACOL, V31, P602, DOI 10.1038/sj.npp.1300800
   Arnot MI, 2001, J NEUROSCI RES, V64, P617, DOI 10.1002/jnr.1115
   Atack JR, 2009, ADV PHARMACOL, V57, P137, DOI 10.1016/S1054-3589(08)57004-9
   Atack JR, 2006, J PHARMACOL EXP THER, V316, P410, DOI 10.1124/jpet.105.089920
   Atack JR, 1999, NEUROPSYCHOPHARMACOL, V20, P255, DOI 10.1016/S0893-133X(98)00052-9
   Ator NA, 2010, J PHARMACOL EXP THER, V332, P4, DOI 10.1124/jpet.109.158303
   Auta J, 2008, NEUROPHARMACOLOGY, V55, P148, DOI 10.1016/j.neuropharm.2008.05.002
   Bateson AN, 2002, CURR PHARM DESIGN, V8, P5, DOI 10.2174/1381612023396681
   Bosman LWJ, 2002, J PHYSIOL-LONDON, V545, P169, DOI 10.1113/jphysiol.2002.026534
   Bouwknecht JA, 2004, EUR J PHARMACOL, V494, P35, DOI 10.1016/j.ejphar.2004.04.036
   Bouwknecht JA, 2002, BEHAV BRAIN RES, V136, P489, DOI 10.1016/S0166-4328(02)00200-0
   Carling RW, 2005, J MED CHEM, V48, P7089, DOI 10.1021/jm058034a
   de Hass SL, 2007, J PSYCHOPHARMACOL, V21, P374, DOI 10.1177/0269881106072343
   Di Lio A, 2010, NEUROPHARMACOLOGY, V60, P626
   Fahey JM, 2006, BRAIN RES, V1118, P13, DOI 10.1016/j.brainres.2006.08.017
   Fahey JM, 1999, J PSYCHOPHARMACOL, V13, P211, DOI 10.1177/026988119901300301
   Gill KM, 2011, NEUROPSYCHOPHARMACOL, V36, P1903, DOI 10.1038/npp.2011.76
   Groenink L, 2009, CURRENT PROTOCOLS PH, VS45, P51611
   HAEFELY W, 1990, TRENDS PHARMACOL SCI, V11, P452, DOI 10.1016/0165-6147(90)90126-S
   Heldt SA, 2007, NEUROSCIENCE, V150, P370, DOI 10.1016/j.neuroscience.2007.09.008
   HENINGER C, 1990, J MOL NEUROSCI, V2, P101, DOI 10.1007/BF02876917
   Holmes A, 2003, EUR J PHARMACOL, V459, P221, DOI 10.1016/S0014-2999(02)02874-1
   Holt RA, 1997, EUR J PHARMACOL, V329, P129, DOI 10.1016/S0014-2999(97)00168-4
   Huopaniemi L, 2004, J NEUROCHEM, V88, P1059, DOI 10.1046/j.1471-4159.2003.02216.x
   Hutchinson MA, 1996, PROG NEUROBIOL, V49, P73, DOI 10.1016/S0301-0082(96)00011-1
   Impagnatiello F, 1996, MOL PHARMACOL, V49, P822
   KANG I, 1991, BRIT J PHARMACOL, V103, P1285, DOI 10.1111/j.1476-5381.1991.tb09781.x
   Knabl J, 2008, NATURE, V451, P330, DOI 10.1038/nature06493
   LARSEN PJ, 1993, J NEUROSCI, V13, P1138
   McKernan RM, 2000, NAT NEUROSCI, V3, P587, DOI 10.1038/75761
   Mirza NR, 2010, DRUG NEWS PERSPECT, V23, P351, DOI 10.1358/dnp.2010.23.6.1489909
   Mirza NR, 2006, J PHARMACOL EXP THER, V316, P1378, DOI 10.1124/jpet.105.094474
   Mirza NR, 2006, J PHARMACOL EXP THER, V316, P1291, DOI 10.1124/jpet.105.094003
   Paxinos G., 2004, MOUSE BRAIN STEREOTA
   PERSOHN E, 1992, J COMP NEUROL, V326, P193, DOI 10.1002/cne.903260204
   Pesold C, 1997, NEUROSCIENCE, V79, P477, DOI 10.1016/S0306-4522(96)00609-4
   Primus RJ, 1996, J PHARMACOL EXP THER, V276, P882
   PUIA G, 1992, P NATL ACAD SCI USA, V89, P3620, DOI 10.1073/pnas.89.8.3620
   RamseyWilliams VA, 1996, MOL BRAIN RES, V43, P132, DOI 10.1016/S0169-328X(96)00166-0
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   RODGERS RJ, 1993, PSYCHOPHARMACOLOGY, V113, P237, DOI 10.1007/BF02245704
   Rowlett JK, 2005, P NATL ACAD SCI USA, V102, P915, DOI 10.1073/pnas.0405621102
   Rudolph U, 2004, ANNU REV PHARMACOL, V44, P475, DOI 10.1146/annurev.pharmtox.44.101802.121429
   Rudolph U, 2006, CURR OPIN PHARMACOL, V6, P18, DOI 10.1016/j.coph.2005.10.003
   Rudolph U, 1999, NATURE, V401, P796, DOI 10.1038/44579
   Sanger DJ, 1999, PHARMACOL BIOCHEM BE, V64, P269, DOI 10.1016/S0091-3057(99)00081-7
   Savic MM, 2008, NEUROPSYCHOPHARMACOL, V33, P332, DOI 10.1038/sj.npp.1301403
   Sieghart W., 2002, Current Topics in Medicinal Chemistry, V2, P795, DOI 10.2174/1568026023393507
   SIEGHART W, 1995, PHARMACOL REV, V47, P181
   Tietz EI, 1999, NEUROSCIENCE, V91, P327, DOI 10.1016/S0306-4522(98)00516-8
   TIETZ EI, 1993, J MOL NEUROSCI, V4, P277, DOI 10.1007/BF02821559
   Uusi-Oukari M, 2010, PHARMACOL REV, V62, P97, DOI 10.1124/pr.109.002063
   van Rijnsoever C, 2004, J NEUROSCI, V24, P6785, DOI 10.1523/JNEUROSCI.1067-04.2004
   VanderHeyden JAM, 1997, PHYSIOL BEHAV, V62, P463, DOI 10.1016/S0031-9384(97)00157-1
   Vinkers C.H., 2010, OPEN PHARM J, V4, P1
   Vinkers CH, 2008, EUR J PHARMACOL, V585, P407, DOI 10.1016/j.ejphar.2008.02.097
   Vinkers CH, 2012, ADV PHARMACOL SCI, DOI 10.1155/2012/416864
   Vinkers CH, 2010, PSYCHOPHARMACOLOGY, V211, P123, DOI 10.1007/s00213-010-1895-7
   Vinkers CH, 2009, PSYCHOPHARMACOLOGY, V204, P299, DOI 10.1007/s00213-009-1460-4
   Wafford KA, 2005, CURR OPIN PHARMACOL, V5, P47, DOI 10.1016/j.coph.2004.08.006
   WU YX, 1994, J MOL NEUROSCI, V5, P105, DOI 10.1007/BF02736752
   ZHAO TJ, 1994, MOL PHARMACOL, V45, P657
NR 63
TC 16
Z9 16
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 13
PY 2012
VL 7
IS 8
AR e43054
DI 10.1371/journal.pone.0043054
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 988OJ
UT WOS:000307500100058
PM 22912786
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Zhang, X
   Zhao, YF
   Zhang, MH
   Pang, XY
   Xu, J
   Kang, CY
   Li, M
   Zhang, CH
   Zhang, ZG
   Zhang, YF
   Li, XY
   Ning, G
   Zhao, LP
AF Zhang, Xu
   Zhao, Yufeng
   Zhang, Menghui
   Pang, Xiaoyan
   Xu, Jia
   Kang, Chaoying
   Li, Meng
   Zhang, Chenhong
   Zhang, Zhiguo
   Zhang, Yifei
   Li, Xiaoying
   Ning, Guang
   Zhao, Liping
TI Structural Changes of Gut Microbiota during Berberine-Mediated
   Prevention of Obesity and Insulin Resistance in High-Fat Diet-Fed Rats
SO PLOS ONE
LA English
DT Article
ID ACTIVATED PROTEIN-KINASE; WEIGHT-LOSS; MICE; MECHANISM; INFLAMMATION;
   ENDOTOXEMIA; RESPONSES; BIFIDOBACTERIA; ADIPONECTIN; SECRETION
AB Berberine, a major pharmacological component of the Chinese herb Coptis chinensis, which was originally used to treat bacterial diarrhea, has recently been demonstrated to be clinically effective in alleviating type 2 diabetes. In this study, we revealed that berberine effectively prevented the development of obesity and insulin resistance in high-fat diet (HFD)-fed rats, which showed decreased food intake. Increases in the levels of serum lipopolysaccharide-binding protein, monocyte chemoattractant protein-1, and leptin and decrease in the serum level of adiponectin corrected for body fat in HFD-fed rats were also significantly retarded by the co-administration of berberine at 100 mg/kg body weight. Bar-coded pyrosequencing of the V3 region of 16S rRNA genes revealed a significant reduction in the gut microbiota diversity of berberine-treated rats. UniFrac principal coordinates analysis revealed a marked shift of the gut microbiota structure in berberine-treated rats away from that of the controls. Redundancy analysis identified 268 berberine-responding operational taxonomic units (OTUs), most of which were essentially eliminated, whereas a few putative short-chain fatty acid (SCFA)-producing bacteria, including Blautia and Allobaculum, were selectively enriched, along with elevations of fecal SCFA concentrations. Partial least square regression models based on these 268 OTUs were established (Q(2)>0.6) for predicting the adiposity index, body weight, leptin and adiponectin corrected for body fat, indicating that these discrete phylotypes might have a close association with the host metabolic phenotypes. Taken together, our findings suggest that the prevention of obesity and insulin resistance by berberine in HFD-fed rats is at least partially mediated by structural modulation of the gut microbiota, which may help to alleviate inflammation by reducing the exogenous antigen load in the host and elevating SCFA levels in the intestine.
C1 [Zhang, Xu; Zhang, Menghui; Pang, Xiaoyan; Xu, Jia; Zhang, Chenhong; Zhao, Liping] Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, State Key Lab Microbial Metab, Shanghai 200030, Peoples R China.
   [Zhao, Yufeng; Kang, Chaoying; Li, Meng; Zhao, Liping] Shanghai Jiao Tong Univ, Shanghai Ctr Syst Biomed, Shanghai 200030, Peoples R China.
   [Zhang, Zhiguo; Zhang, Yifei; Li, Xiaoying; Ning, Guang] Shanghai Jiao Tong Univ, Rui Jin Hosp, Shanghai Clin Ctr Endocrine & Metab Dis, Shanghai 200030, Peoples R China.
   [Zhang, Zhiguo; Zhang, Yifei; Li, Xiaoying; Ning, Guang] Shanghai Jiao Tong Univ, Rui Jin Hosp, Div Endocrine & Metab Dis, Shanghai 200030, Peoples R China.
RP Zhang, X (reprint author), Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, State Key Lab Microbial Metab, Shanghai 200030, Peoples R China.
EM lpzhao@sjtu.edu.cn
RI zhang, menghui/Q-3752-2016
OI zhang, menghui/0000-0002-9274-487X; Zhang, Xu/0000-0003-2406-9478
FU National Natural Science Foundation of China [30730005, 81170784];
   National Science and Technology Major Project of China
   [2009ZX10004-601]; Scientific Research Foundation of Shanghai Jiao Tong
   University [YG2010MS17]
FX This study was supported by the National Natural Science Foundation of
   China (No. 30730005 and No. 81170784), the National Science and
   Technology Major Project of China (2009ZX10004-601), and the Scientific
   Research Foundation of Shanghai Jiao Tong University (No. YG2010MS17).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Backhed F, 2004, P NATL ACAD SCI USA, V101, P15718, DOI 10.1073/pnas.0407076101
   Bullen JW, 2007, AM J PHYSIOL-ENDOC M, V292, pE1079, DOI 10.1152/ajpendo.00245.2006
   Cani PD, 2007, DIABETOLOGIA, V50, P2374, DOI 10.1007/s00125-007-0791-0
   Cani PD, 2009, GUT, V58, P1091, DOI 10.1136/gut.2008.165886
   Cani PD, 2008, DIABETES, V57, P1470, DOI 10.2337/db07-1403
   Cani PD, 2007, DIABETES, V56, P1761, DOI 10.2337/db06-1491
   Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303
   Chae SH, 1999, J AGR FOOD CHEM, V47, P934, DOI 10.1021/jf980991o
   Crow JM, 2011, NATURE, V480, pS88, DOI 10.1038/480S88a
   De Filippo C, 2010, P NATL ACAD SCI USA, V107, P14691, DOI 10.1073/pnas.1005963107
   Delzenne NM, 2011, NAT REV ENDOCRINOL, V7, P639, DOI 10.1038/nrendo.2011.126
   DeSantis TZ, 2006, NUCLEIC ACIDS RES, V34, pW394, DOI 10.1093/nar/gkl244
   Duncan SH, 2008, INT J OBESITY, V32, P1720, DOI 10.1038/ijo.2008.155
   Flint HJ, 2011, J CLIN GASTROENTEROL, V45, pS128, DOI 10.1097/MCG.0b013e31821f44c4
   Fukuda S, 2011, NATURE, V469, P543, DOI 10.1038/nature09646
   Greetham HL, 2004, ANAEROBE, V10, P301, DOI 10.1016/j.anaeoobe.2004.06.001
   Gu LL, 2011, J INFECT DIS, V203, P1602, DOI 10.1093/infdis/jir147
   Haluzik M, 2004, PHYSIOL RES, V53, P123
   Han JL, 2011, MED SCI MONITOR, V17, pRA164, DOI 10.12659/MSM.881842
   HARIG JM, 1989, NEW ENGL J MED, V320, P23, DOI 10.1056/NEJM198901053200105
   Hong SW, 2000, PLANTA MED, V66, P361, DOI 10.1055/s-2000-8536
   Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485
   Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665
   Hua WY, 2007, J PHARMACEUT BIOMED, V44, P931, DOI 10.1016/j.jpba.2007.03.022
   Jeong HW, 2009, AM J PHYSIOL-ENDOC M, V296, pE955, DOI 10.1152/ajpendo.90599.2008
   Jia W, 2008, NAT REV DRUG DISCOV, V7, P123, DOI 10.1038/nrd2505
   Knight DJW, 2003, LANCET, V361, P1831, DOI 10.1016/S0140-6736(03)12489-0
   Ko BS, 2005, BIOL PHARM BULL, V28, P1431, DOI 10.1248/bpb.28.1431
   Kong WJ, 2009, METABOLISM, V58, P109, DOI 10.1016/j.metabol.2008.08.013
   Kong WJ, 2004, NAT MED, V10, P1344, DOI 10.1038/nm1135
   Larsen N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009085
   Lee YS, 2006, DIABETES, V55, P2256, DOI 10.2337/db06-0006
   Lepper PM, 2007, J AM COLL CARDIOL, V50, P25, DOI 10.1016/j.jacc.2007.02.070
   Ley RE, 2006, NATURE, V444, P1022, DOI 10.1038/nature4441022a
   Li M, 2008, P NATL ACAD SCI USA, V105, P2117, DOI 10.1073/pnas.0712038105
   Li WZ, 2006, BIOINFORMATICS, V22, P1658, DOI 10.1093/bioinformatics/btl158
   Liu YT, 2009, J PHARM SCI-US, V98, P4391, DOI 10.1002/jps.21721
   Lozupone C, 2005, APPL ENVIRON MICROB, V71, P8228, DOI 10.1128/AEM.71.12.8228-8235.2005
   Lu SS, 2009, J ENDOCRINOL, V200, P159, DOI 10.1677/JOE-08-0419
   Ludwig W, 2004, NUCLEIC ACIDS RES, V32, P1363, DOI 10.1093/nar/gkh293
   Maslowski KM, 2009, NATURE, V461, P1282, DOI 10.1038/nature08530
   Murphy EF, 2010, GUT, V59, P1635, DOI 10.1136/gut.2010.215665
   O'Hara AM, 2006, EMBO REP, V7, P688, DOI 10.1038/sj.embor.7400731
   Park SK, 2011, INT J SYST EVOL MICR, V62, P776
   Peng LY, 2009, J NUTR, V139, P1619, DOI 10.3945/jn.109.104638
   Ravussin Y, 2012, OBESITY, V20, P738, DOI 10.1038/oby.2011.111
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Schloss PD, 2005, APPL ENVIRON MICROB, V71, P1501, DOI 10.1128/AEM.71.3.1501-1506.2005
   Sedova L, 2004, INT J OBESITY, V28, P719, DOI 10.1038/sj.ijo.0802613
   Tang J, 2009, J ETHNOPHARMACOL, V126, P5, DOI 10.1016/j.jep.2009.08.009
   Ter Braak CJF, 2002, CANOCO REFERENCE MAN
   Tesch GH, 2008, AM J PHYSIOL-RENAL, V294, pF697, DOI 10.1152/ajprenal.00016.2008
   Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414
   Wang Q, 2007, APPL ENVIRON MICROB, V73, P5261, DOI 10.1128/AEM.00062-07
   Wang T., 2011, ISME J, V6, P320, DOI [10.1038/ismej.2011.109, DOI 10.1038/ISMEJ.2011.109]
   Wang YW, 2010, ATHEROSCLEROSIS, V209, P111, DOI 10.1016/j.atherosclerosis.2009.08.050
   Wold S, 2001, CHEMOMETR INTELL LAB, V58, P109, DOI 10.1016/S0169-7439(01)00155-1
   Xia XA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016556
   Xie WD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024520
   Yin J, 2008, METABOLISM, V57, P712, DOI 10.1016/j.metabol.2008.01.013
   Yin J, 2008, AM J PHYSIOL-ENDOC M, V294, pE148, DOI 10.1152/ajpendo.00211.2007
   Zhang C., 2009, ISME J, V4, P232, DOI DOI 10.1038/ISMEJ.2009.112
   Zhang CH, 2012, ISME J, V6, P1848, DOI 10.1038/ismej.2012.27
   Zhang H, 2010, METABOLISM, V59, P285, DOI 10.1016/j.metabol.2009.07.029
   Zhang QA, 2011, FOOD CHEM TOXICOL, V49, P61, DOI 10.1016/j.fct.2010.09.032
   Zhang X., 2011, MOD TRADIT CHIN MED, V13, P202
   Zhang YF, 2008, J CLIN ENDOCR METAB, V93, P2559, DOI 10.1210/jc.2007-2404
   Zhao LP, 2010, J BIOTECHNOL, V149, P183, DOI 10.1016/j.jbiotec.2010.02.008
   Zhou LB, 2008, ENDOCRINOLOGY, V149, P4510, DOI 10.1210/en.2007-1752
NR 69
TC 43
Z9 84
U1 3
U2 181
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 3
PY 2012
VL 7
IS 8
AR e42529
DI 10.1371/journal.pone.0042529
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 985QT
UT WOS:000307284100120
PM 22880019
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Vaquero, MR
   Yanez-Gascon, MJ
   Villalba, RG
   Larrosa, M
   Fromentin, E
   Ibarra, A
   Roller, M
   Tomas-Barberan, F
   de Gea, JCE
   Garcia-Conesa, MT
AF Romo Vaquero, Maria
   Yanez-Gascon, Maria-Josefa
   Garcia Villalba, Rocio
   Larrosa, Mar
   Fromentin, Emilie
   Ibarra, Alvin
   Roller, Marc
   Tomas-Barberan, Francisco
   Carlos Espin de Gea, Juan
   Garcia-Conesa, Maria-Teresa
TI Inhibition of Gastric Lipase as a Mechanism for Body Weight and Plasma
   Lipids Reduction in Zucker Rats Fed a Rosemary Extract Rich in Carnosic
   Acid
SO PLOS ONE
LA English
DT Article
ID ROSMARINUS-OFFICINALIS L.; HIGH-FAT DIET; IN-VITRO; PANCREATIC LIPASE;
   OXIDATIVE STRESS; LIVER STEATOSIS; DIABETIC-RATS; RISK-FACTORS; OBESE
   RATS; MICE
AB Background: Rosemary (Rosmarinus officinalis L.) extracts (REs) exhibit hepatoprotective, anti-obesity and anti-inflammatory properties and are widely used in the food industry. REs are rich in carnosic acid (CA) and carnosol which may be responsible for some of the biological activities of REs. The aim of this study was to investigate whether inhibition of lipase activity in the gut may be a mechanism by which a RE enriched in CA (40%) modulates body weight and lipids levels in a rat model of metabolic disorders and obesity.
   Methods and Principal Findings: RE was administered for 64 days to lean (fa/+) and obese (fa/fa) female Zucker rats and body weight, food intake, feces weight and blood biochemical parameters were monitored throughout the study. Lipase activity (hydrolysis of p-nitrophenylbutyrate) was measured in the gastrointestinal tract at the end of the study and the contents of CA, carnosol and methyl carnosate were also determined. Sub-chronic administration of RE moderately reduced body weight gain in both lean and obese animals but did not affect food intake. Serum triglycerides, cholesterol and insulin levels were also markedly decreased in the lean animals supplemented with RE. Importantly, lipase activity was significantly inhibited in the stomach of the RE-supplemented animals where the highest content of intact CA and carnosol was detected.
   Conclusions: Our results confirm that long-term administration of RE enriched in CA moderates weight gain and improves the plasma lipids profile, primarily in the lean animals. Our data also suggest that these effects may be caused, at least in part, by a significant inhibition of gastric lipase and subsequent reduction in fat absorption.
C1 [Romo Vaquero, Maria; Yanez-Gascon, Maria-Josefa; Garcia Villalba, Rocio; Larrosa, Mar; Tomas-Barberan, Francisco; Carlos Espin de Gea, Juan; Garcia-Conesa, Maria-Teresa] CSIC, Ctr Edafol & Biol Aplicada Segura, Dept Food Sci & Technol, Res Grp Qual Safety & Bioact Plant Foods, Murcia, Spain.
   [Ibarra, Alvin] Naturex Inc, S Hackensack, NJ USA.
   [Fromentin, Emilie] Naturex SL, Valencia, Spain.
   [Roller, Marc] Naturex SA, Avignon, France.
RP Vaquero, MR (reprint author), CSIC, Ctr Edafol & Biol Aplicada Segura, Dept Food Sci & Technol, Res Grp Qual Safety & Bioact Plant Foods, Campus Espinardo, Murcia, Spain.
EM mtconesa@cebas.csic.es
RI LARROSA, MAR/H-6012-2012; Garcia Villalba, Rocio/G-7217-2015;
   Garcia-Conesa, Maria-Teresa/N-4032-2014; Romo Vaquero,
   Maria/G-6883-2015; Yanez Gascon, Maria Josefa/H-5327-2015; Francisco
   Tomas, Pharmacy/D-6686-2011
OI LARROSA, MAR/0000-0002-8863-4686; Garcia-Conesa,
   Maria-Teresa/0000-0002-4125-853X; Romo Vaquero,
   Maria/0000-0002-0084-6060; Yanez Gascon, Maria
   Josefa/0000-0001-8694-6072; Francisco Tomas,
   Pharmacy/0000-0002-0790-1739; Garcia Villalba,
   Rocio/0000-0003-1883-1673; Ibarra, Alvin/0000-0003-3952-8489
FU Spanish Centre for the Development of Industrial Technology (CDTI)
   [CEN-20091006]
FX This project was financed by the Spanish Centre for the Development of
   Industrial Technology (CDTI) as part of the project SENIFOOD, which
   belongs to the CENIT subvention program (Ref: CEN-20091006). The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Aguilar F, 2008, EFSA J, V721, P1
   Aloulou A, 2008, CELL MOL LIFE SCI, V65, P851, DOI 10.1007/s00018-008-7546-z
   Anadon A, 2008, J FOOD PROTECT, V71, P790, DOI 10.4315/0362-028X-71.4.790
   Ansari JA, 2012, TOXICOL MECH METHOD, V22, P67, DOI 10.3109/15376516.2011.603391
   Bailey DT, 1999, US patent, Patent No. [5.859.293, 5859293]
   Beltran-Debon R, 2011, PHYTOMEDICINE, V18, P414, DOI 10.1016/j.phymed.2010.11.008
   Bermudez-Soto MJ, 2007, FOOD CHEM, V102, P865, DOI [10.1016/j.foodchem.2006.06.025, 10.1016/j.foodchem.2006.06.014]
   Caimari A, 2011, J NUTR BIOCH
   Chaudhari HS, 2012, PLANTA MED, DOI 10.1055
   Chuang CC, 2011, ANNU REV NUTR, V31, P155, DOI 10.1146/annurev-nutr-072610-145149
   Cipriani S, 2010, J LIPID RES, V51, P771, DOI 10.1194/jlr.M001602
   Debersac P, 2001, FOOD CHEM TOXICOL, V39, P907, DOI 10.1016/S0278-6915(01)00034-5
   Debersac P, 2001, FOOD CHEM TOXICOL, V39, P109, DOI 10.1016/S0278-6915(00)00117-4
   Doolaege EHA, 2011, PLANT FOOD HUM NUTR, V66, P196, DOI 10.1007/s11130-011-0233-5
   Fakeye TO, 2008, PHYTOTHER RES, V22, P664, DOI 10.1002/ptr.2370
   Faulds MH, 2012, J ENDOCRINOL, V212, P3, DOI 10.1530/JOE-11-0044
   Fluttert M, 2000, LAB ANIM, V34, P372, DOI 10.1258/002367700780387714
   Fu J, 2005, NEUROPHARMACOLOGY, V48, P1147, DOI 10.1016/j.neuropharm.2005.02.013
   GREENWOOD MRC, 1993, ANN NY ACAD SCI, V676, P253
   Gu YY, 2011, J AGR FOOD CHEM, V59, P5305, DOI 10.1021/jf200180n
   Hamad EM, 2009, BRIT J NUTR, V101, P716, DOI 10.1017/S0007114508043808
   Hamden K, 2010, FOOD SCI BIOTECHNOL, V19, P439, DOI 10.1007/s10068-010-0062-6
   Harach T, 2010, PLANTA MED, V76, P566, DOI 10.1055/s-0029-1240612
   Ibarra A, 2011, BRIT J NUTR, V106, P1182, DOI 10.1017/S0007114511001620
   Ikewuchi JC, 2011, J ETHNOPHARMACOL, V137, P1415, DOI 10.1016/j.jep.2011.08.015
   Johnson JJ, 2010, CANCER PREV RES, V3, P1112, DOI 10.1158/1940-6207.CAPR-10-0168
   Kinsey-Jones JS, 2011, ANN NY ACAD SCI, V1245, P3, DOI 10.1111/j.1749-6632.2011.06343.x
   de la Garza AL, 2011, PLANTA MED, V77, P773, DOI 10.1055/s-0030-1270924
   Lu H, 2003, DRUG METAB DISPOS, V31, P572, DOI 10.1124/dmd.31.5.572
   Ludwig DS, 1999, JAMA-J AM MED ASSOC, V282, P1539, DOI 10.1001/jama.282.16.1539
   Lupp A, 2008, ARZNEIMITTELFORSCH, V58, P225, DOI 10.1055/s-0031-1296499
   Magkos F, 2010, NUTRITION, V26, P686, DOI 10.1016/j.nut.2009.10.013
   Magkos F, 2009, OBSTET GYN CLIN N AM, V36, P245, DOI 10.1016/j.ogc.2009.03.001
   Mark Manuel, 2007, Curr Protoc Mol Biol, VChapter 29, DOI 10.1002/0471142727.mb29b04s78
   McConnell EL, 2008, J PHARM PHARMACOL, V60, P63, DOI 10.1211/jpp.60.1.0008
   Mulinacci N, 2011, TALANTA, V85, P167, DOI 10.1016/j.talanta.2011.03.050
   Nakai M, 2005, J AGR FOOD CHEM, V53, P4593, DOI 10.1016/jf047814+
   Ninomiya K, 2004, BIOORG MED CHEM LETT, V14, P1943, DOI 10.1016/j.bmcl.2004.01.091
   Noh JR, 2011, J MED FOOD, V14, P209, DOI 10.1089/jmf.2010.1152
   Nusier MK, 2007, EXP BIOL MED, V232, P809
   Oana F, 2005, METABOLISM, V54, P995, DOI 10.1016/j.metabol.2005.02.016
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Sanchez D, 2008, J AGR FOOD CHEM, V56, P3574, DOI 10.1021/jf703598j
   Serrano A, 2008, NEUROPHARMACOLOGY, V54, P226, DOI 10.1016/j.neuropharm.2007.03.007
   Soler-Rivas C, 2010, J AGR FOOD CHEM, V58, P1144, DOI 10.1021/jf902087q
   Titta L, 2010, INT J OBESITY, V34, P578, DOI 10.1038/ijo.2009.266
   Ueshima K, 2004, EUR J PHARMACOL, V501, P137, DOI 10.1016/j.ejphar.2004.08.014
   Valdes-Ramos R, 2010, P NUTR SOC, V69, P644, DOI 10.1017/S0029665110002533
   Vickers SP, 2011, BRIT J PHARMACOL, V164, P1248, DOI 10.1111/j.1476-5381.2011.01245.x
   Wang T, 2011, HEPATOL RES, V41, P87, DOI 10.1111/j.1872-034X.2010.00747.x
   Wang XW, 2011, J CLIN ENDOCR METAB, V96, P885, DOI 10.1210/jc.2010-2061
   Yan Haixia, 2009, Zhongguo Zhong Yao Za Zhi, V34, P766
   Yun JW, 2010, PHYTOCHEMISTRY, V71, P1625, DOI 10.1016/j.phytochem.2010.07.011
NR 53
TC 29
Z9 29
U1 0
U2 23
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 22
PY 2012
VL 7
IS 6
AR e39773
DI 10.1371/journal.pone.0039773
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 964XV
UT WOS:000305730900112
PM 22745826
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Nischang, M
   Sutmuller, R
   Gers-Huber, G
   Audige, A
   Li, D
   Rochat, MA
   Baenziger, S
   Hofer, U
   Schlaepfer, E
   Regenass, S
   Amssoms, K
   Stoops, B
   Van Cauwenberge, A
   Boden, D
   Kraus, G
   Speck, RF
AF Nischang, Marc
   Sutmuller, Roger
   Gers-Huber, Gustavo
   Audige, Annette
   Li, Duo
   Rochat, Mary-Aude
   Baenziger, Stefan
   Hofer, Ursula
   Schlaepfer, Erika
   Regenass, Stephan
   Amssoms, Katie
   Stoops, Bart
   Van Cauwenberge, Anja
   Boden, Daniel
   Kraus, Guenter
   Speck, Roberto F.
TI Humanized Mice Recapitulate Key Features of HIV-1 Infection: A Novel
   Concept Using Long-Acting AntiRetroviral Drugs for Treating HIV-1
SO PLOS ONE
LA English
DT Article
ID SCID-HU MOUSE; REVERSE-TRANSCRIPTASE; IN-VIVO; RAG2(-/-)GAMMA(-/-)(C)
   MICE; T-CELLS; VIRUS; MODEL; RILPIVIRINE; THERAPY; PHARMACOKINETICS
AB Background: Humanized mice generate a lymphoid system of human origin subsequent to transplantation of human CD34+ cells and thus are highly susceptible to HIV infection. Here we examined the efficacy of antiretroviral treatment (ART) when added to food pellets, and of long-acting (LA) antiretroviral compounds, either as monotherapy or in combination. These studies shall be inspiring for establishing a gold standard of ART, which is easy to administer and well supported by the mice, and for subsequent studies such as latency. Furthermore, they should disclose whether viral breakthrough and emergence of resistance occurs similar as in HIV-infected patients when ART is insufficient.
   Methods/Principal Findings: NOD/shi-scid/ccnull (NOG) mice were used in all experimentations. We first performed pharmacokinetic studies of the drugs used, either added to food pellets (AZT, TDF, 3TC, RTV) or in a LA formulation that permitted once weekly subcutaneous administration (TMC278: non-nucleoside reverse transcriptase inhibitor, TMC181: protease inhibitor). A combination of 3TC, TDF and TMC278-LA or 3TC, TDF, TMC278-LA and TMC181-LA suppressed the viral load to undetectable levels in 15/19 (79%) and 14/14 (100%) mice, respectively. In successfully treated mice, subsequent monotherapy with TMC278-LA resulted in viral breakthrough; in contrast, the two LA compounds together prevented viral breakthrough. Resistance mutations matched the mutations most commonly observed in HIV patients failing therapy. Importantly, viral rebound after interruption of ART, presence of HIV DNA in successfully treated mice and in vitro reactivation of early HIV transcripts point to an existing latent HIV reservoir.
   Conclusions/Significance: This report is a unique description of multiple aspects of HIV infection in humanized mice that comprised efficacy testing of various treatment regimens, including LA compounds, resistance mutation analysis as well as viral rebound after treatment interruption. Humanized mice will be highly valuable for exploring the antiviral potency of new compounds or compounds targeting the latent HIV reservoir.
C1 [Nischang, Marc; Gers-Huber, Gustavo; Audige, Annette; Li, Duo; Rochat, Mary-Aude; Baenziger, Stefan; Hofer, Ursula; Schlaepfer, Erika; Speck, Roberto F.] Univ Zurich, Univ Zurich Hosp, Div Infect Dis & Hosp Epidemiol, Zurich, Switzerland.
   [Sutmuller, Roger; Amssoms, Katie; Stoops, Bart; Van Cauwenberge, Anja; Boden, Daniel; Kraus, Guenter] Tibotec BVBA, Beerse, Belgium.
RP Nischang, M (reprint author), Univ Zurich, Univ Zurich Hosp, Div Infect Dis & Hosp Epidemiol, Zurich, Switzerland.
EM roberto.speck@usz.ch
RI Infektiologie, USZ/A-6921-2011; Speck, Roberto/O-2433-2016
OI Rochat, Mary-Aude/0000-0003-3414-1330; Speck,
   Roberto/0000-0002-8453-1137
FU Swiss National Science Foundation; Flemish agency for Innovation by
   Science and Technology (IWT), Belgium; Tibotec BVBA
FX This work was supported by the Swiss National Science Foundation and by
   the Flemish agency for Innovation by Science and Technology (IWT),
   Belgium. This work is a collaboration between the University of Zurich
   and Tibotec BVBA. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript. No additional external funding received for this study.; The
   following authors are employees from Tibotec BVBA, Belgium: KA, BS, AvC,
   GK, DB and RS. The laboratory from RFS has been financially supported by
   Tibotec BVBA; in addition, Tibotec BVBA provided reagents to the
   laboratory of RFS and performed a number of assays in the context of the
   collaboration between the laboratory of RFS and Tibotec BVBA. There are
   no patents, products in development or marketed products to declare.
   This does not alter the authors' adherence to all the PLoS ONE policies
   on sharing data materials.
CR Althaus CF, 2010, J VIROL METHODS, V165, P151, DOI 10.1016/j.jviromet.2010.01.012
   Baenziger S, 2006, P NATL ACAD SCI USA, V103, P15951, DOI 10.1073/pnas.0604493103
   Baert L, 2009, EUR J PHARM BIOPHARM, V72, P502, DOI 10.1016/j.ejpb.2009.03.006
   Bazzoli C, 2010, CLIN PHARMACOKINET, V49, P17, DOI 10.2165/11318110-000000000-00000
   Berges BK, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-76
   Bonyhadi ML, 1997, MOL MED TODAY, V3, P246, DOI 10.1016/S1357-4310(97)01046-0
   Camacho Ricardo, 2011, Curr Opin HIV AIDS, V6 Suppl 1, pS3, DOI 10.1097/01.COH.0000410239.88517.00
   Chittick GE, 2006, ANTIMICROB AGENTS CH, V50, P1304, DOI 10.1128/AAC.50.4.1304-1310.2006
   Choudhary SK, 2012, J VIROL, V86, P114, DOI 10.1128/JVI.05590-11
   Choudhary SK, 2009, J VIROL, V83, P8254, DOI 10.1128/JVI.00580-09
   Christopherson C, 2000, J CLIN MICROBIOL, V38, P630
   Chun TW, 2007, J INFECT DIS, V195, P1762, DOI 10.1086/518250
   Cohen CJ, 2011, LANCET, V378, P229, DOI 10.1016/S0140-6736(11)60983-5
   Cordery DV, 2010, ANTIVIR THER, V15, P1035, DOI 10.3851/IMP1647
   Denton PW, 2012, J VIROL, V86, P630, DOI 10.1128/JVI.06120-11
   Fletcher CV, 2000, AIDS, V14, P2137, DOI 10.1097/00002030-200009290-00010
   Fox Z, 2008, AIDS, V22, P2279, DOI 10.1097/QAD.0b013e328311d16f
   Goldstein H, 1996, Semin Immunol, V8, P223, DOI 10.1006/smim.1996.0028
   Gorantla S, 2007, J VIROL, V81, P2700, DOI 10.1128/JVI.02010-06
   Heeney JL, 2006, SCIENCE, V313, P462, DOI 10.1126/science.1123016
   Ito M, 2002, BLOOD, V100, P3175, DOI 10.1182/blood-2001-12-0207
   Jiang Q, 2008, BLOOD, V112, P2858, DOI 10.1182/blood-2008-03-145946
   Kaiser P, 2007, J VIROL, V81, P9693, DOI 10.1128/JVI.00492-07
   Manrique A, 2007, J VIROL, V81, P8793, DOI 10.1128/JVI.00598-07
   Marsden MD, 2012, J VIROL, V86, P339, DOI 10.1128/JVI.06366-11
   MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269
   Miller CD, 2011, DRUG TODAY, V47, P5, DOI 10.1358/dot.2011.47.1.1583188
   Molina JM, 2011, LANCET, V378, P238, DOI 10.1016/S0140-6736(11)60936-7
   NAMIKAWA R, 1988, SCIENCE, V242, P1684, DOI 10.1126/science.3201256
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Sango K, 2010, AIDS RES HUM RETROV, V26, P735, DOI 10.1089/aid.2009.0136
   Schrijvers R, 2011, LANCET, V378, P201, DOI 10.1016/S0140-6736(11)60992-6
   Shultz LD, 2007, NAT REV IMMUNOL, V7, P118, DOI 10.1038/nri2017
   Stoddart CA, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000655
   Taylor S, 2007, AIDS, V21, P1673, DOI 10.1097/QAD.0b013e3281c61394
   Traggiai E, 2004, SCIENCE, V304, P104, DOI 10.1126/science.1093933
   van 't Klooster G, 2010, ANTIMICROB AGENTS CH, V54, P2042, DOI 10.1128/AAC.01529-09
   Vandamme AM, 2011, AIDS REV, V13, P77
   Walensky RP, 2006, J INFECT DIS, V194, P11, DOI 10.1086/505147
   Watanabe S, 2007, J VIROL, V81, P13259, DOI 10.1128/JVI.01353-07
   Watanabe S, 2007, BLOOD, V109, P212, DOI 10.1182/blood-2006-04-017681
   YV T. Pattery, 2012, INTERVIROLOGY, P138
   Zhang LG, 2007, BLOOD, V109, P2978, DOI 10.1182/blood-2006-07-033159
NR 43
TC 40
Z9 40
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 13
PY 2012
VL 7
IS 6
AR e38853
DI 10.1371/journal.pone.0038853
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 959UV
UT WOS:000305341900056
PM 22719966
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Karman, J
   Gumlaw, NK
   Zhang, JH
   Jiang, JL
   Cheng, SH
   Zhu, YX
AF Karman, Jozsef
   Gumlaw, Nathan K.
   Zhang, Jinhua
   Jiang, Ji-Lei
   Cheng, Seng H.
   Zhu, Yunxiang
TI Proteasome Inhibition Is Partially Effective in Attenuating Pre-Existing
   Immunity against Recombinant Adeno-Associated Viral Vectors
SO PLOS ONE
LA English
DT Article
ID ALPHA-GALACTOSIDASE-A; B-CELL DEVELOPMENT; PHASE-I TRIAL; GENE-THERAPY;
   MULTIPLE-MYELOMA; HEMOPHILIA-B; GAUCHER-DISEASE; PLASMA-CELLS; AAV
   VECTORS; MOUSE MODEL
AB Pre-existing immunity against adeno-associated virus (AAV) remains a major challenge facing the clinical use of systemic administration of recombinant AAV vectors for the treatment of genetic and acquired diseases using gene therapy. In this study, we evaluated the potential of bortezomib (marketed under trade name Velcade) to abrogate a pre-existing immunity to AAV in mice, thereby allowing subsequent transduction by a recombinant AAV vector of the same serotype. We demonstrate that bortezomib efficiently reduces AAV-specific IgG titres and moderates the cytotoxic T cell response in mice that have a pre-existing immunity to AAV2/8. Significant depletion of AAV2/8-specific IgG-producing plasma cells in secondary lymphoid organs and bone marrow was observed. However, this inhibition of the immune response by bortezomib was insufficient to allow subsequent re-infection with a recombinant AAV vector of a similar serotype. We show that this shortcoming is probably due to the combination of residual antibody levels and the inability of bortezomib to completely deplete the memory B cells that are re-activated in response to a repeated infection with a recombinant AAV vector. Taken together, the results of this study argue for the use of immunosuppressive therapies that target both plasma and memory B cells for the efficient elimination of pre-existing immunity against AAV2/8 vectors.
C1 [Karman, Jozsef; Gumlaw, Nathan K.; Zhang, Jinhua; Jiang, Ji-Lei; Cheng, Seng H.; Zhu, Yunxiang] Genzyme Corp, Genet Dis Sci, Framingham, MA 01701 USA.
RP Karman, J (reprint author), Genzyme Corp, Genet Dis Sci, Framingham, MA 01701 USA.
EM jozsef.karman@genzyme.com
CR Amanna IJ, 2010, IMMUNOL REV, V236, P125, DOI 10.1111/j.1600-065X.2010.00912.x
   Attar EC, 2008, CLIN CANCER RES, V14, P1446, DOI 10.1158/1078-0432.CCR-07-4626
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Brantly ML, 2006, HUM GENE THER, V17, P1177, DOI 10.1089/hum.2006.17.1177
   Calame KL, 2001, NAT IMMUNOL, V2, P1103, DOI 10.1038/ni1201-1103
   Chao HJ, 2002, MOL THER, V5, P716, DOI 10.1006/mthe.2002.0607
   Chirmule N, 1999, GENE THER, V6, P1574, DOI 10.1038/sj.gt.3300994
   Curran MP, 2009, DRUGS, V69, P859, DOI 10.2165/00003495-200969070-00006
   Finn JD, 2010, MOL THER, V18, P135, DOI 10.1038/mt.2009.257
   Grieger JC, 2005, ADV BIOCHEM ENG BIOT, V99, P119, DOI 10.1007/10_005
   Gu HT, 2008, MOL CANCER THER, V7, P2298, DOI 10.1158/1535-7163.MCT-08-0186
   Hemeryck A, 2007, CANCER CHEMOTH PHARM, V60, P777, DOI 10.1007/s00280-007-0424-9
   Kaplitt MG, 2007, LANCET, V369, P2097, DOI 10.1016/S0140-6736(07)60982-9
   Kay MA, 2000, NAT GENET, V24, P257, DOI 10.1038/73464
   Kloetzel PM, 2004, BBA-MOL CELL RES, V1695, P225, DOI 10.1016/j.bbamcr.2004.10.004
   Kloetzel PM, 2004, CURR OPIN IMMUNOL, V16, P76, DOI 10.1016/j.coi.2003.11.004
   MacLachlan TK, 2011, MOL THER, V19, P326, DOI 10.1038/mt.2010.258
   Manis JP, 2002, TRENDS IMMUNOL, V23, P31, DOI 10.1016/S1471-4906(01)02111-1
   Manning WC, 1998, HUM GENE THER, V9, P477, DOI 10.1089/hum.1998.9.4-477
   Manno CS, 2003, BLOOD, V101, P2963, DOI 10.1182/blood-2002-10-3296
   Marshall J, 2002, MOL THER, V6, P179, DOI 10.1006/mthe.2002.0650
   McEachern KA, 2006, J GENE MED, V8, P719, DOI 10.1002/jgm.901
   McHeyzer-Williams LJ, 2005, ANNU REV IMMUNOL, V23, P487, DOI 10.1146/annurev.immunol.23.021704.115732
   McIntosh JH, 2012, GENE THER, V19, P78, DOI 10.1038/gt.2011.64
   Meister S, 2007, CANCER RES, V67, P1783, DOI 10.1158/0008-5472.CAN-06-2258
   Monahan PE, 2010, MOL THER, V18, P1907, DOI 10.1038/mt.2010.170
   Montenegro-Miranda PS, 2011, HUM GENE THER, V22, P605, DOI 10.1089/hum.2010.222
   Murphy SL, 2008, MOL THER, V16, P138, DOI 10.1038/sj.mt.6300334
   Nathwani AC, 2009, GENE THER, V16, P60, DOI 10.1038/gt.2008.137
   Nathwani AC, 2011, NEW ENGL J MED, V365, P2357, DOI 10.1056/NEJMoa1108046
   Nathwani AC, 2011, MOL THER, V19, P876, DOI 10.1038/mt.2010.274
   Neubert K, 2008, NAT MED, V14, P748, DOI 10.1038/nm1763
   Obeng EA, 2006, BLOOD, V107, P4907, DOI 10.1182/blood-2005-08-3531
   Rajkumar SV, 2011, AM J HEMATOL, V86, P57, DOI 10.1002/ajh.21913
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Scallan CD, 2006, BLOOD, V107, P1810, DOI 10.1182/blood-2005-08-3229
   Xie YM, 2010, J MOL CELL BIOL, V2, P308, DOI 10.1093/jmcb/mjq030
   Ziegler RJ, 2004, MOL THER, V9, P231, DOI 10.1016/j.ymthe.2003.11.015
   Ziegler RJ, 2007, MOL THER, V15, P492, DOI 10.1038/sj.mt.6300066
NR 39
TC 10
Z9 10
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 13
PY 2012
VL 7
IS 4
AR e34684
DI 10.1371/journal.pone.0034684
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 959UT
UT WOS:000305341600060
PM 22514654
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Weston-Green, K
   Huang, XF
   Deng, C
AF Weston-Green, Katrina
   Huang, Xu-Feng
   Deng, Chao
TI Alterations to Melanocortinergic, GABAergic and Cannabinoid
   Neurotransmission Associated with Olanzapine-Induced Weight Gain
SO PLOS ONE
LA English
DT Article
ID MESSENGER-RNA EXPRESSION; Y-LIKE IMMUNOREACTIVITY; GLUTAMIC-ACID
   DECARBOXYLASE; DORSAL VAGAL COMPLEX; DIET-INDUCED OBESITY; RAT ARCUATE
   NUCLEUS; LONG-TERM TREATMENT; NEUROPEPTIDE-Y; FOOD-INTAKE; BODY-WEIGHT
AB Background/Aim: Second generation antipsychotics (SGAs) are used to treat schizophrenia but can cause serious metabolic side-effects, such as obesity and diabetes. This study examined the effects of low to high doses of olanzapine on appetite/metabolic regulatory signals in the hypothalamus and brainstem to elucidate the mechanisms underlying olanzapine-induced obesity.
   Methodology/Results: Levels of pro-opiomelanocortin (POMC), neuropeptide Y (NPY) and glutamic acid decarboxylase (GAD(65), enzyme for GABA synthesis) mRNA expression, and cannabinoid CB1 receptor (CB1R) binding density (using [H-3]SR-141716A) were examined in the arcuate nucleus (Arc) and dorsal vagal complex (DVC) of female Sprague Dawley rats following 0.25, 0.5, 1.0 or 2.0 mg/kg olanzapine or vehicle (3x/day, 14-days). Consistent with its weight gain liability, olanzapine significantly decreased anorexigenic POMC and increased orexigenic NPY mRNA expression in a dose-sensitive manner in the Arc. GAD(65) mRNA expression increased and CB1R binding density decreased in the Arc and DVC. Alterations to neurotransmission signals in the brain significantly correlated with body weight and adiposity. The minimum dosage threshold required to induce weight gain in the rat was 0.5 mg/kg olanzapine.
   Conclusions: Olanzapine-induced weight gain is associated with reduced appetite-inhibiting POMC and increased NPY. This study also supports a role for the CB1R and GABA in the mechanisms underlying weight gain side-effects, possibly by altering POMC transmission. Metabolic dysfunction can be modelled in the female rat using low, clinically-comparable olanzapine doses when administered in-line with the half-life of the drug.
C1 [Weston-Green, Katrina; Huang, Xu-Feng; Deng, Chao] Univ Wollongong, Sch Hlth Sci, Ctr Translat Neurosci, Wollongong, NSW, Australia.
   [Weston-Green, Katrina; Huang, Xu-Feng; Deng, Chao] Schizophrenia Res Inst, Darlinghurst, NSW, Australia.
RP Weston-Green, K (reprint author), Univ Wollongong, Sch Hlth Sci, Ctr Translat Neurosci, Wollongong, NSW, Australia.
EM chao@uow.edu.au
RI Huang, Xu-Feng/H-7408-2015; Huang, Xu-Feng/D-6053-2013; Deng,
   Chao/F-4417-2016
OI Huang, Xu-Feng/0000-0002-5895-2253; Deng, Chao/0000-0003-1147-5741;
   Green, Katrina/0000-0002-4521-8463
FU University of Wollongong University Research Centre (URC); Australian
   National Health and Medical Research Council (NHMRC) [635231];
   Schizophrenia Research Institute (SRI); New South Wales Health
FX This study was supported by a University of Wollongong (www.uow.edu.au)
   University Research Centre (URC) grant to CD, an Australian National
   Health and Medical Research Council (NHMRC, www.nhmrc.gov.au) grant to
   XH and CD (ID 635231), and by the Schizophrenia Research Institute (SRI,
   www.schizophreniaresearch.org.au), utilising infrastructure funding from
   New South Wales Health. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Akbarian S, 2006, BRAIN RES REV, V52, P293, DOI 10.1016/j.brainresrev.2006.04.001
   Albaugh VL, 2006, OBESITY, V14, P36, DOI 10.1038/oby.2006.6
   Alger BE, 2002, PROG NEUROBIOL, V68, P247
   Allison DB, 2009, AM J PREV MED, V36, P341, DOI 10.1016/j.amepre.2008.11.020
   Aravagiri M, 1999, BIOPHARM DRUG DISPOS, V20, P369, DOI 10.1002/1099-081X(199911)20:8<369::AID-BDD200>3.3.CO;2-Y
   Archie S, 2003, CAN J PSYCHIAT, V48, P628, DOI 10.1177/070674370304800910
   Balcombe JP, 2004, CONTEMP TOP LAB ANIM, V43, P42
   Ballard C, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003476.pub2
   Baptista T, 2002, BRAIN RES, V957, P144, DOI 10.1016/S0006-8993(02)03616-8
   Beasley CM, 1996, NEUROPSYCHOPHARMACOL, V14, P111, DOI 10.1016/0893-133X(95)00069-P
   BECK B, 1992, INT J OBESITY, V16, P295
   Beck B, 2006, PHILOS T R SOC B, V361, P1159, DOI 10.1098/rstb.2006.1855
   Bermudez-Silva FJ, 2010, PHARMACOL BIOCHEM BE, V95, P375, DOI 10.1016/j.pbb.2010.03.012
   Berrendero F, 1998, BBA-MOL BASIS DIS, V1407, P205, DOI 10.1016/S0925-4439(98)00042-8
   Berthoud HR, 2002, NEUROSCI BIOBEHAV R, V26, P393, DOI 10.1016/S0149-7634(02)00014-3
   Brambilla F, 2007, PSYCHONEUROENDOCRINO, V32, P402, DOI 10.1016/j.psyneuen.2007.02.005
   Bridle C, 2004, Health Technol Assess, V8, piii
   Broberger C, 2001, PHYSIOL BEHAV, V74, P669, DOI 10.1016/S0031-9384(01)00611-4
   BRONSTEIN DM, 1992, BRAIN RES, V587, P269, DOI 10.1016/0006-8993(92)91007-2
   Brown S, 1999, PSYCHOL MED, V29, P697, DOI 10.1017/S0033291798008186
   Budman CL, 2001, J CLIN PSYCHIAT, V62, P290, DOI 10.4088/JCP.v62n0412
   Bymaster FP, 1996, PSYCHOPHARMACOLOGY, V124, P87, DOI 10.1007/BF02245608
   Bymaster FP, 1996, NEUROPSYCHOPHARMACOL, V14, P87, DOI 10.1016/0893-133X(94)00129-N
   Cavuoto P, 2009, BEST PRACT RES CL EN, V23, P79, DOI 10.1016/j.beem.2008.10.005
   Centorrino F, 2002, AM J PSYCHIAT, V159, P1932, DOI 10.1176/appi.ajp.159.11.1932
   Coccurello R, 2010, PHARMACOL THERAPEUT, V127, P210, DOI 10.1016/j.pharmthera.2010.04.008
   Cone RD, 2005, NAT NEUROSCI, V8, P571, DOI 10.1038/nn1455
   Cope MB, 2005, INT J OBESITY, V29, P607, DOI 10.1038/sj.ijo.0802928
   Cota D, 2003, J CLIN INVEST, V112, P423, DOI 10.1172/JCI200317725
   Cowley MA, 2001, NATURE, V411, P480, DOI 10.1038/35078085
   CSIFFARY A, 1990, BRAIN RES, V506, P215, DOI 10.1016/0006-8993(90)91253-D
   Davoodi N, 2009, PSYCHOPHARMACOLOGY, V203, P693, DOI 10.1007/s00213-008-1415-1
   De Hert M, 2011, EUR PSYCHIAT, V26, P144, DOI 10.1016/j.eurpsy.2010.09.011
   de Meijer VE, 2010, PHYSIOL BEHAV, V100, P387, DOI 10.1016/j.physbeh.2010.04.001
   Deng C, 2007, PROG NEURO-PSYCHOPH, V31, P915, DOI 10.1016/j.pnpbp.2007.02.009
   Deng C, 2010, PROG NEURO-PSYCHOPH, V34, P1, DOI 10.1016/j.pnpbp.2009.11.009
   Deng Chao, 2007, Neurosci Bull, V23, P341, DOI 10.1007/s12264-007-0051-9
   Derbenev AV, 2004, J PHYSIOL-LONDON, V559, P923, DOI 10.1113/jphysiol.2004.067470
   Di Marzo V, 2001, NATURE, V410, P822, DOI 10.1038/35071088
   Eder U, 2001, AM J PSYCHIAT, V158, P1719, DOI 10.1176/appi.ajp.158.10.1719
   Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0
   ESCLAPEZ M, 1994, J NEUROSCI, V14, P1834
   Faulconbridge LF, 2008, BRAIN RES, V1218, P151, DOI 10.1016/j.brainres.2008.04.068
   FELDBLUM S, 1993, J NEUROSCI RES, V34, P689, DOI 10.1002/jnr.490340612
   Ferno J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020571
   Frenchman IB, 2005, DRUG AGING, V22, P257, DOI 10.2165/00002512-200522030-00006
   Gamber KM, 2005, NEUROPHARMACOLOGY, V49, P646, DOI 10.1016/j.neuropharm.2005.04.017
   Gomez R, 2002, J NEUROSCI, V22, P9612
   Gothelf D, 2002, AM J PSYCHIAT, V159, P1055, DOI 10.1176/appi.ajp.159.6.1055
   Gropp E, 2005, NAT NEUROSCI, V8, P1289, DOI 10.1038/nn1548
   Guan XM, 1998, MOL BRAIN RES, V59, P273, DOI 10.1016/S0169-328X(98)00150-8
   Han M, 2008, PSYCHONEUROENDOCRINO, V33, P569, DOI 10.1016/j.psyneuen.2008.01.018
   Harrold JA, 2003, BRIT J NUTR, V90, P729, DOI 10.1079/BJN2003942
   Hartfield AW, 2003, PSYCHOPHARMACOLOGY, V167, P115, DOI 10.1007/s00213-002-1368-8
   HEILIG M, 1988, EUR J PHARMACOL, V157, P205, DOI 10.1016/0014-2999(88)90384-6
   HEILIG M, 1987, REGUL PEPTIDES, V19, P221, DOI 10.1016/0167-0115(87)90278-3
   Heisler LK, 2002, SCIENCE, V297, P609, DOI 10.1126/science.1072327
   Hentges ST, 2005, J NEUROSCI, V25, P9746, DOI 10.1523/JNEUROSCI.2769-05.2005
   Hentges ST, 2004, J NEUROSCI, V24, P1578, DOI 10.1523/JNEUROSCI.3952-03.2004
   Hollopeter G, 1998, REGUL PEPTIDES, V75-6, P383, DOI 10.1016/S0167-0115(98)00092-5
   Horvath TL, 1997, BRAIN RES, V756, P283, DOI 10.1016/S0006-8993(97)00184-4
   Howlett AC, 2004, NEUROPHARMACOLOGY, V47, P345, DOI 10.1016/j.neuropharm.2004.07.030
   Huang XF, 2006, NEUROPEPTIDES, V40, P213, DOI 10.1016/j.npep.2006.01.002
   Huang XF, 2003, BRAIN RES, V992, P9, DOI 10.1016/j.brainres.2003.08.019
   Huang XF, 2006, BEHAV BRAIN RES, V171, P355, DOI 10.1016/j.bbr.2006.03.040
   Kapur S, 2000, CAN J PSYCHIAT, V45, P241, DOI 10.1177/070674370004500302
   Kapur S, 2003, J PHARMACOL EXP THER, V305, P625, DOI 10.1124/jpet.102.046987
   KAUFMAN DL, 1991, J NEUROCHEM, V56, P720, DOI 10.1111/j.1471-4159.1991.tb08211.x
   Kim EM, 2000, BRAIN RES, V862, P11, DOI 10.1016/S0006-8993(00)02060-6
   Kim SF, 2007, P NATL ACAD SCI USA, V104, P3456, DOI 10.1073/pnas.0611417104
   Kirk SL, 2006, J PSYCHOPHARMACOL, V20, P577, DOI 10.1177/0269881106061199
   Kirk SL, 2009, PSYCHOPHARMACOLOGY, V207, P119, DOI 10.1007/s00213-009-1639-8
   Kirkham T, 2008, J NEUROENDOCRINOL, V20, P1099, DOI 10.1111/j.1365-2826.2008.01762.x
   Kirkham TC, 2009, INT REV PSYCHIATR, V21, P163, DOI 10.1080/09540260902782810
   Kroeze WK, 2003, NEUROPSYCHOPHARMACOL, V28, P519, DOI 10.1038/sj.npp.1300027
   Krude H, 1998, NAT GENET, V19, P155, DOI 10.1038/509
   Kuo DY, 2006, BRIT J PHARMACOL, V148, P640, DOI 10.1038/sj.bjp.0706754
   Kuo DY, 2002, J BIOMED SCI, V9, P126, DOI 10.1159/000048208
   Li C, 2011, PHARMACOL THERAPEUT, V129, P307, DOI 10.1016/j.pharmthera.2010.10.006
   Lin S, 2000, BRAIN RES, V875, P89, DOI 10.1016/S0006-8993(00)02580-4
   Lin S, 2004, NEUROPEPTIDES, V38, P189, DOI 10.1016/j.npep.2004.05.005
   Ling LL, 2005, NEUROSCIENCE, V132, P1103, DOI 10.1016/j.neuroscience.2004.12.043
   Marie LS, 2005, P NATL ACAD SCI USA, V102, P18632, DOI 10.1073/pnas.0509240102
   MARTIN DL, 1993, J NEUROCHEM, V60, P395, DOI 10.1111/j.1471-4159.1993.tb03165.x
   Martin NM, 2004, REGUL PEPTIDES, V122, P169, DOI 10.1016/j.regpep.2004.06.012
   MATSUISAKATA, 2005, DRUG METAB PHARMACOK, V20, P368
   MEEKER RB, 1980, BRAIN RES BULL, V5, P253, DOI 10.1016/0361-9230(80)90042-8
   Meister B, 2007, PHYSIOL BEHAV, V92, P263, DOI 10.1016/j.physbeh.2007.05.021
   Meister B, 2006, EUR J NEUROSCI, V24, P2731, DOI 10.1111/j.1460-9568.2006.05157.x
   Menzies JRW, 2010, J NEUROENDOCRINOL, V22, P585, DOI 10.1111/j.1365-2826.2010.01990.x
   Minet-Ringuet J, 2005, BEHAV BRAIN RES, V163, P204, DOI 10.1016/j.bbr.2005.05.044
   Minet-Ringuet J, 2006, APPETITE, V46, P254, DOI 10.1016/j.appet.2006.01.008
   Nasrallah H, 2003, PSYCHONEUROENDOCRINO, V28, P83, DOI 10.1016/S0306-4530(02)00114-2
   Nasrallah HA, 2008, MOL PSYCHIATR, V13, P27, DOI 10.1038/sj.mp.4002066
   Nemeroff CB, 1997, J CLIN PSYCHIAT, V58, P45
   Newcomer JW, 2005, CNS DRUGS, V19, P1
   Nguyen QH, 2006, NEUROENDOCRINOLOGY, V84, P123, DOI 10.1159/000096996
   Nogueiras R, 2009, PHARMACOL RES, V60, P93, DOI 10.1016/j.phrs.2009.04.004
   Obuchowicz E, 1998, NEUROPEPTIDES, V32, P473, DOI 10.1016/S0143-4179(98)90074-9
   Obuchowicz E, 2005, NEUROPEPTIDES, V39, P515, DOI 10.1016/j.npep.2005.04.004
   Obuchowicz E, 2004, NEUROSCI BIOBEHAV R, V28, P595, DOI 10.1016/j.neubiorev.2004.08.006
   Obuchowicz E, 1996, NEUROPEPTIDES, V30, P471, DOI 10.1016/S0143-4179(96)90012-8
   Obuchowicz E, 1999, EUR NEUROPSYCHOPHARM, V9, P329, DOI 10.1016/S0924-977X(99)00003-6
   Ota M, 2002, CLIN EXP PHARMACOL P, V29, P980, DOI 10.1046/j.1440-1681.2002.t01-1-03755.x
   Paxinos G., 2007, RAT BRAIN STEREOTAXI
   PELLETIER G, 1991, NEUROSCI LETT, V127, P96, DOI 10.1016/0304-3940(91)90903-7
   Pertwee RG, 1997, PHARMACOL THERAPEUT, V74, P129, DOI 10.1016/S0163-7258(97)82001-3
   Pickar D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003150
   Pouzet B, 2003, PHARMACOL BIOCHEM BE, V75, P133, DOI 10.1016/S0091-3057(03)00042-X
   Qian S, 2002, MOL CELL BIOL, V22, P5027, DOI 10.1128/MCB.22.14.5027-5035.2002
   Qiu J, 2007, MOL PHARMACOL, V72, P885, DOI 10.1124/mol.107.038083
   Rader DJ, 2007, AM J MED, V120, pS12, DOI 10.1016/j.amjmed.2007.01.003
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Remington G, 2011, PHARMACOL BIOCHEM BE, V100, P86, DOI 10.1016/j.pbb.2011.07.019
   Reynolds GP, 2010, PHARMACOL THERAPEUT, V125, P169, DOI 10.1016/j.pharmthera.2009.10.010
   Richelson E, 2000, LIFE SCI, V68, P29, DOI 10.1016/S0024-3205(00)00911-5
   Roseberry AG, 2004, NEURON, V41, P711, DOI 10.1016/S0896-6273(04)00074-1
   Roth BL, 2000, NEUROSCIENTIST, V6, P252, DOI 10.1177/107385840000600408
   Ryan MCM, 2004, LIFE SCI, V74, P1999, DOI 10.1016/j.lfs.2003.08.044
   Schwartz MW, 2000, NATURE, V404, P661
   Secher A, 2010, NEUROENDOCRINOLOGY, V91, P155, DOI 10.1159/000245220
   Sharkey Keith A, 2005, Sci STKE, V2005, ppe15, DOI 10.1126/stke.2772005pe15
   STANLEY BG, 1986, PEPTIDES, V7, P1189
   Starrenburg FCJ, 2009, EUR PSYCHIAT, V24, P164, DOI 10.1016/j.eurpsy.2009.01.001
   Tauscher J, 2002, MOL PSYCHIATR, V7, P317, DOI 10.1038/sj/mp/4001009
   Tiwari AK, 2010, NEUROPSYCHOPHARMACOL, V35, P1315, DOI 10.1038/npp.2009.235
   Tong QC, 2008, NAT NEUROSCI, V11, P998, DOI 10.1038/nn.2167
   van der Zwaal EM, 2008, EUR J PHARMACOL, V585, P130, DOI 10.1016/j.ejphar.2007.11.078
   Van Sickle MD, 2005, SCIENCE, V310, P329, DOI 10.1126/science.1115740
   Vong L, 2011, NEURON, V71, P142, DOI 10.1016/j.neuron.2011.05.028
   Wai SM, 2004, CELL MOL NEUROBIOL, V24, P667, DOI 10.1023/B:CEMN.0000036404.39432.0c
   Weiden PJ, 2004, SCHIZOPHR RES, V66, P51, DOI 10.1016/S0920-9964(02)00498-X
   Weston-Green K, 2008, INT J NEUROPSYCHOPH, V11, P827, DOI 10.1017/S1461145708008560
   Weston-Green K, 2011, BEHAV BRAIN RES, V217, P337, DOI 10.1016/j.bbr.2010.10.039
   Wilson RI, 2002, SCIENCE, V296, P678, DOI 10.1126/science.1063545
   Wu Q, 2011, EUR J PHARMACOL, V660, P21, DOI 10.1016/j.ejphar.2010.10.110
   Xu B, 1999, ENDOCRINOLOGY, V140, P2868, DOI 10.1210/en.140.6.2868
   Yoshimatsu H, 2006, PEPTIDES, V27, P326, DOI 10.1016/j.peptides.2005.02.028
   Zhang Y, 2010, NEUROSCIENCE, V169, P1662, DOI 10.1016/j.neuroscience.2010.06.001
   Zhang ZJ, 2004, BRIT J PSYCHIAT, V184, P58, DOI 10.1192/bjp.184.1.58
NR 140
TC 50
Z9 50
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 16
PY 2012
VL 7
IS 3
AR e33548
DI 10.1371/journal.pone.0033548
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 932RV
UT WOS:000303309100055
PM 22438946
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Khodja, NI
   Chataigneau, T
   Auger, C
   Schini-Kerth, VB
AF Khodja, Noureddine Idris
   Chataigneau, Thierry
   Auger, Cyril
   Schini-Kerth, Valerie B.
TI Grape-Derived Polyphenols Improve Aging-Related Endothelial Dysfunction
   in Rat Mesenteric Artery: Role of Oxidative Stress and the Angiotensin
   System
SO PLOS ONE
LA English
DT Article
ID RED WINE POLYPHENOLS; EDHF-MEDIATED RELAXATIONS; PORCINE
   CORONARY-ARTERIES; II-INDUCED HYPERTENSION; NITRIC-OXIDE SYNTHASE;
   HYPERPOLARIZING FACTOR; DEPENDENT RELAXATIONS; SUPEROXIDE-PRODUCTION;
   REDUCED EXPRESSION; ENZYME-INHIBITION
AB Aging is characterized by the development of an endothelial dysfunction, which affects both the nitric oxide (NO)- and the endothelium-derived hyperpolarizing factor (EDHF)-mediated relaxations, associated with vascular oxidative stress and the activation of the angiotensin system. This study investigated whether red wine polyphenols (RWPs), antioxidants and potent stimulators of NO-and EDHF-mediated relaxations improve aging-related endothelial dysfunction, and, if so, examined the underlying mechanism. Mesenteric artery reactivity was determined in organ chambers, vascular oxidative stress by dihydroethidine and MitoSOX staining, and expression of target proteins by immunohistochemical staining. Control young rats (16 weeks) received solvent (ethanol, 3% v/v), and middle-aged rats (46 weeks) either solvent or RWPs (100 mg/kg/day) in the drinking water. The acetylcholine-induced endothelium-dependent NO component was slightly reduced whereas the EDHF component was markedly blunted in rings of middle-aged rats compared to young rats. The endothelial dysfunction was associated with oxidative stress, an upregulation of angiotensin II and AT1 receptors and a down-regulation of SKCa, IKCa, and angiotensin converting enzyme. Intake of RWPs for either one or two weeks improved the NO and the EDHF components of the relaxation, and normalized oxidative stress, the expression of SKCa, IKCa and the components of the angiotensin system. The protective effect of the 2-week RWPs treatment persisted for one and two weeks following stopping intake of RWPs. Thus, intake of RWPs caused a persistent improvement of the endothelial function, particularly the EDHF component, in middle-aged rats and this effect seems to involve the normalization of the expression of SKCa, IKCa and the angiotensin system.
C1 [Khodja, Noureddine Idris; Chataigneau, Thierry; Auger, Cyril; Schini-Kerth, Valerie B.] Univ Strasbourg, Fac Pharm, Lab Biophoton & Pharmacol, UMR CNRS 7213, Illkirch Graffenstaden, France.
RP Khodja, NI (reprint author), Univ Strasbourg, Fac Pharm, Lab Biophoton & Pharmacol, UMR CNRS 7213, Illkirch Graffenstaden, France.
EM valerie.schini-kerth@unistra.fr
RI Auger, Cyril/N-4702-2016
FU Office National Interprofessionnel des Fruits, des Legumes, des Vins et
   de l'Horticulture (Action Vin Sante, France)
FX This work was supported, in part, by the Office National
   Interprofessionnel des Fruits, des Legumes, des Vins et de
   l'Horticulture (Action Vin & Sante, France). The funders had no role in
   the study design, data collection and analysis, decision to publish, or
   preparation of the manuscript. No additional external funding was
   received for this study.
CR Aranda R, 2007, FREE RADICAL RES, V41, P1195, DOI 10.1080/10715760701481461
   Armstead WM, 2003, ANESTHESIOLOGY, V98, P1378, DOI 10.1097/00000542-200306000-00012
   ATKINSON J, 1994, AM J PHYSIOL, V267, pR136
   Briones A. M., 2005, Autonomic & Autacoid Pharmacology, V25, P155, DOI 10.1111/j.1474-8673.2005.00344.x
   CELERMAJER DS, 1994, J AM COLL CARDIOL, V24, P471, DOI 10.1016/0735-1097(94)90305-0
   Chen WG, 2010, BIOCHEMISTRY-US, V49, P3129, DOI 10.1021/bi9016632
   Cosentino F, 2001, ARTERIOSCL THROM VAS, V21, P496, DOI 10.1161/01.ATV.21.4.496
   Csiszar A, 2002, CIRC RES, V90, P1159, DOI 10.1161/01.RES.0000020401.61826.EA
   Dal-Ros S, 2011, BIOCHEM BIOPH RES CO, V404, P743, DOI 10.1016/j.bbrc.2010.12.060
   Dal-Ros S, 2010, GASTROENTEROLOGY, V138, P1574, DOI 10.1053/j.gastro.2009.10.040
   Dal-Ros S, 2009, J PHARMACOL EXP THER, V328, P478, DOI 10.1124/jpet.108.145326
   Edwards G, 2010, PFLUG ARCH EUR J PHY, V459, P863, DOI 10.1007/s00424-010-0817-1
   Feletou M, 2006, AM J PHYSIOL-HEART C, V291, pH985, DOI 10.1152/ajpheart.00292.2006
   FRANKEL EN, 1993, LANCET, V341, P1103, DOI 10.1016/0140-6736(93)92472-6
   Goto K, 2000, HYPERTENSION, V36, P581, DOI 10.1161/01.HYP.36.4.581
   Goto K, 2004, CLIN EXP PHARMACOL P, V31, P650, DOI 10.1111/j.1440-1681.2004.04054.x
   Hamilton CA, 2001, HYPERTENSION, V37, P529, DOI 10.1161/01.HYP.37.2.529
   Hilgers RHP, 2007, AM J PHYSIOL-HEART C, V292, pH2275, DOI 10.1152/ajpheart.00949.2006
   HONGO K, 1988, STROKE, V19, P892, DOI 10.1161/01.STR.19.7.892
   Kansui Y, 2002, J HYPERTENS, V20, P439, DOI 10.1097/00004872-200203000-00019
   Kawai Y, 2008, J BIOL CHEM, V283, P9424, DOI 10.1074/jbc.M706571200
   KUNG CF, 1995, HYPERTENSION, V25, P194, DOI 10.1161/01.HYP.25.2.194
   Lavrentyev EN, 2007, CIRC RES, V101, P455, DOI 10.1161/CIRCRESAHA.107.151852
   Lemarie CA, 2010, J RENIN-ANGIO-ALDO S, V11, P19, DOI 10.1177/1470320309347785
   Long DA, 2005, KIDNEY INT, V68, P2154, DOI 10.1111/j.1523-1755.2005.00671.x
   Lorenz M, 2004, J BIOL CHEM, V279, P6190, DOI 10.1074/jbc.M309114200
   Matz RL, 2000, BRIT J PHARMACOL, V131, P303, DOI 10.1038/sj.bjp.0703568
   Modrick ML, 2009, AM J PHYSIOL-HEART C, V296, pH1914, DOI 10.1152/ajpheart.00300.2009
   Mukai Y, 2002, ARTERIOSCL THROM VAS, V22, P1445, DOI 10.1161/01.ATV.0000029121.63691.CE
   NAKASHIMA M, 1993, J CLIN INVEST, V92, P2867, DOI 10.1172/JCI116907
   Ndiaye M, 2004, BRIT J PHARMACOL, V142, P1131, DOI 10.1038/sj.bjp.0705774
   Ndiaye M, 2003, BIOCHEM BIOPH RES CO, V310, P371, DOI 10.1016/j.bbrc.2003.09.028
   Negishi H, 2004, J NUTR, V134, P38
   Newaz MA, 2006, J CARDIOVASC PHARM, V48, P88, DOI 10.1097/01.fjc.0000245402.62864.0a
   Oudot A, 2006, FREE RADICAL BIO MED, V40, P2214, DOI 10.1016/j.freeradbiomed.2006.02.020
   Rajagopalan S, 1996, J CLIN INVEST, V97, P1916, DOI 10.1172/JCI118623
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Sarr M, 2006, CARDIOVASC RES, V71, P794, DOI 10.1016/j.cardiores.2006.05.022
   Schmidt TS, 2007, CLIN SCI, V113, P47, DOI 10.1042/CS20070108
   Shimokawa H, 1996, J CARDIOVASC PHARM, V28, P703, DOI 10.1097/00005344-199611000-00014
   Taddei S, 2001, HYPERTENSION, V38, P274, DOI 10.1161/01.HYP.38.2.274
   Urakami-Harasawa L, 1997, J CLIN INVEST, V100, P2793, DOI 10.1172/JCI119826
   van der Loo B, 2000, J EXP MED, V192, P1731, DOI 10.1084/jem.192.12.1731
   Wong SL, 2009, CIRC RES, V104, P228, DOI 10.1161/CIRCRESAHA.108.179770
   Wu SZ, 2007, GERONTOLOGY, V53, P234, DOI 10.1159/000100961
   Yang YM, 2009, AM J PHYSIOL-HEART C, V297, pH1829, DOI 10.1152/ajpheart.00230.2009
   Ying CJ, 2003, HYPERTENS RES, V26, P823, DOI 10.1291/hypres.26.823
   Zhu JH, 2010, ASIAN J ANDROL, V12, P599, DOI 10.1038/aja.2009.97
NR 48
TC 30
Z9 30
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 27
PY 2012
VL 7
IS 2
AR e32039
DI 10.1371/journal.pone.0032039
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 927OV
UT WOS:000302918500056
PM 22384133
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Wey, MCY
   Fernandez, E
   Martinez, PA
   Sullivan, P
   Goldstein, DS
   Strong, R
AF Wey, Margaret Chia-Ying
   Fernandez, Elizabeth
   Martinez, Paul Anthony
   Sullivan, Patricia
   Goldstein, David S.
   Strong, Randy
TI Neurodegeneration and Motor Dysfunction in Mice Lacking Cytosolic and
   Mitochondrial Aldehyde Dehydrogenases: Implications for Parkinson's
   Disease
SO PLOS ONE
LA English
DT Article
ID HUMAN ALPHA-SYNUCLEIN; ENDOGENOUS DOPAMINERGIC NEUROTOXIN;
   AMYOTROPHIC-LATERAL-SCLEROSIS; ONSET ALZHEIMERS-DISEASE; STRIDE LENGTH
   REGULATION; TREADMILL GAIT ANALYSIS; L-DOPA; HYDROGEN-PEROXIDE;
   3,4-DIHYDROXYPHENYLACETALDEHYDE; SEROTONIN
AB Previous studies have reported elevated levels of biogenic aldehydes in the brains of patients with Parkinson's disease (PD). In the brain, aldehydes are primarily detoxified by aldehyde dehydrogenases (ALDH). Reduced ALDH1 expression in surviving midbrain dopamine neurons has been reported in brains of patients who died with PD. In addition, impaired complex I activity, which is well documented in PD, reduces the availability of the NAD(+) co-factor required by multiple ALDH isoforms to catalyze the removal of biogenic aldehydes. We hypothesized that chronically decreased function of multiple aldehyde dehydrogenases consequent to exposure to environmental toxins and/or reduced ALDH expression, plays an important role in the pathophysiology of PD. To address this hypothesis, we generated mice null for Aldh1a1 and Aldh2, the two isoforms known to be expressed in substantia nigra dopamine neurons. Aldh1a1(-/-) xAldh2(-/-) mice exhibited age-dependent deficits in motor performance assessed by gait analysis and by performance on an accelerating rotarod. Intraperitoneal administration of L-DOPA plus benserazide alleviated the deficits in motor performance. We observed a significant loss of neurons immunoreactive for tyrosine hydroxylase (TH) in the substantia nigra and a reduction of dopamine and metabolites in the striatum of Aldh1a1(-/-) xAldh2(-/-) mice. We also observed significant increases in biogenic aldehydes reported to be neurotoxic, including 4-hydroxynonenal (4-HNE) and the aldehyde intermediate of dopamine metabolism, 3,4-dihydroxyphenylacetaldehyde (DOPAL). These results support the hypothesis that impaired detoxification of biogenic aldehydes may be important in the pathophysiology of PD and suggest that Aldh1a1(-/-) xAldh2(-/-) mice may be a useful animal model of PD.
C1 [Wey, Margaret Chia-Ying; Fernandez, Elizabeth; Strong, Randy] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA.
   [Wey, Margaret Chia-Ying; Fernandez, Elizabeth; Martinez, Paul Anthony; Strong, Randy] Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA.
   [Fernandez, Elizabeth; Strong, Randy] S Texas Vet Hlth Care Network, Ctr Geriatr Res Educ & Clin, San Antonio, TX USA.
   [Sullivan, Patricia; Goldstein, David S.] Natl Inst Neurol Disorders & Stroke, Clin Neurocardiol Sect, Clin Neurosci Program, Div Intramural Res, Bethesda, MD USA.
RP Wey, MCY (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA.
EM FernandezE@uthscsa.edu; Strong@uthscsa.edu
FU Veteran Affairs Office of Research Development; National Institute of
   Aging [T32 AG021890-08]
FX This work was supported by grants from the Veteran Affairs Office of
   Research & Development (to E.F. and R.S.) and the National Institute of
   Aging predoctoral training grant T32 AG021890-08 (to M.C.W.). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Amende Ivo, 2005, J Neuroeng Rehabil, V2, P20, DOI 10.1186/1743-0003-2-20
   Anderson DW, 2011, BRAIN RES, V1408, P81, DOI 10.1016/j.brainres.2011.06.051
   BERNHEIMER H, 1973, J NEUROL SCI, V20, P415, DOI 10.1016/0022-510X(73)90175-5
   Burke WJ, 2008, ACTA NEUROPATHOL, V115, P193, DOI 10.1007/s00401-007-0303-9
   Burke WJ, 2004, NEUROTOXICOLOGY, V25, P101, DOI 10.1016/S0161-813X(03)00090-1
   Burke WJ, 2003, BRAIN RES, V989, P205, DOI 10.1016/S0006-8993(03)03354-7
   CANAVAN AGM, 1990, NEUROPSYCHOLOGIA, V28, P969, DOI 10.1016/0028-3932(90)90112-2
   CARLSSON A, 1957, NATURE, V180, P1200, DOI 10.1038/1801200a0
   Center for Drug Evaluation and Research Center for Biologics Evaluation and Research, 2005, EST SAF START DOS CL
   Chen JB, 2009, INVEST OPHTH VIS SCI, V50, P936, DOI 10.1167/iovs.08-2439
   Duester G, 2001, CHEM-BIOL INTERACT, V130, P469, DOI 10.1016/S0009-2797(00)00292-1
   Fernandez E, 2006, ALCOHOL CLIN EXP RES, V30, P1650, DOI 10.1111/j.1530-0277.2006.00200.x
   Fleming SM, 2006, NEUROSCIENCE, V142, P1245, DOI 10.1016/j.neuroscience.2006.07.005
   Fleming SM, 2004, J NEUROSCI, V24, P9434, DOI 10.1523/JNEUROSCI.3080-04.2004
   Galter D, 2003, NEUROBIOL DIS, V14, P637, DOI 10.1016/j.nbd.2003.09.001
   Gispert S, 2003, MOL CELL NEUROSCI, V24, P419, DOI 10.1016/S1044-7431(03)00198-2
   Goldstein DS, 2011, EUR J NEUROL, V18, P703, DOI 10.1111/j.1468-1331.2010.03246.x
   Grunblatt E, 2010, J NEURAL TRANSM, V117, P1387, DOI 10.1007/s00702-010-0509-1
   Guillot TS, 2008, J MOTOR BEHAV, V40, P568, DOI 10.3200/JMBR.40.6.568-577
   Hampton TG, 2010, J MOTOR BEHAV, V42, P1, DOI 10.1080/00222890903272025
   Hao PP, 2011, CAN J NEUROL SCI, V38, P500, DOI 10.1017/S0317167100011938
   Jinsmaa Y, 2011, CHEM-BIOL INTERACT, V192, P118, DOI 10.1016/j.cbi.2011.01.006
   Jubault T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006154
   Kamino K, 2000, BIOCHEM BIOPH RES CO, V273, P192, DOI 10.1006/bbrc.2000.2923
   Kerenyi L, 2003, ARCH NEUROL-CHICAGO, V60, P1223, DOI 10.1001/archneur.60.9.1223
   Kish SJ, 2008, BRAIN, V131, P120, DOI 10.1093/brain/awm239
   LAMBERTY Y, 1993, PHYSIOL BEHAV, V54, P339, DOI 10.1016/0031-9384(93)90120-5
   Lamensdorf I, 2000, J NEUROSCI RES, V60, P552, DOI 10.1002/(SICI)1097-4547(20000515)60:4<552::AID-JNR14>3.0.CO;2-U
   LEES AJ, 1986, Q J MED, V59, P535
   Lewis GN, 2000, BRAIN, V123, P2077, DOI 10.1093/brain/123.10.2077
   Li SW, 2001, MOL BRAIN RES, V93, P1, DOI 10.1016/S0169-328X(01)00120-6
   Maetzler W, 2009, LANCET NEUROL, V8, P1158, DOI 10.1016/S1474-4422(09)70291-1
   Marchitti SA, 2007, PHARMACOL REV, V59, P125, DOI 10.1124/pr.59.2.1
   MATTAMMAL MB, 1993, J CHROMATOGR-BIOMED, V614, P205, DOI 10.1016/0378-4347(93)80310-Z
   MATTAMMAL MB, 1995, NEURODEGENERATION, V4, P271, DOI 10.1016/1055-8330(95)90016-0
   MAYEUX R, 1988, MOVEMENT DISORD, V3, P237, DOI 10.1002/mds.870030308
   MCCAFFERY P, 1994, P NATL ACAD SCI USA, V91, P7772, DOI 10.1073/pnas.91.16.7772
   MCNAMARA RK, 1993, BRAIN RES REV, V18, P33, DOI 10.1016/0165-0173(93)90006-L
   Meredith GE, 2006, MOVEMENT DISORD, V21, P1595, DOI 10.1002/mds.21010
   Morris ME, 1996, BRAIN, V119, P551, DOI 10.1093/brain/119.2.551
   OWEN AM, 1995, NEUROPSYCHOLOGY, V9, P126, DOI 10.1037/0894-4105.9.1.126
   Panneton WM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015251
   Pavese N, 2010, BRAIN, V133, P3434, DOI 10.1093/brain/awq268
   Picklo MJ, 2001, J NEUROPATH EXP NEUR, V60, P686, DOI 10.1093/jnen/60.7.686
   Pinheiro J., 2011, NLME LINEAR NONLINEA
   Qin ZJ, 2007, J BIOL CHEM, V282, P5862, DOI 10.1074/jbc.M608126200
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Rozas G, 1998, J NEUROSCI METH, V83, P165, DOI 10.1016/S0165-0270(98)00078-8
   SCATTON B, 1983, BRAIN RES, V275, P321, DOI 10.1016/0006-8993(83)90993-9
   SCHAPIRA AHV, 1990, MOVEMENT DISORD, V5, P294, DOI 10.1002/mds.870050406
   SCHNEIDER JS, 1990, BRAIN RES, V519, P122, DOI 10.1016/0006-8993(90)90069-N
   Schulz JB, 2008, J NEUROL, V255, P3, DOI 10.1007/s00415-008-5011-4
   Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166
   Stolze H, 2001, J NEUROL NEUROSUR PS, V70, P289, DOI 10.1136/jnnp.70.3.289
   Tanila H, 1998, BRAIN RES BULL, V45, P577, DOI 10.1016/S0361-9230(97)00452-8
   Team RDC, 2011, R LANG ENV STAT COMP
   TRUGMAN JM, 1991, BRAIN, V114, P1429, DOI 10.1093/brain/114.3.1429
   Vasiliou Vasilis, 2005, Human Genomics, V2, P138
   Wang BB, 2008, J NEUROL SCI, V268, P172, DOI 10.1016/j.jns.2007.12.006
   Westerlund M, 2005, CELL TISSUE RES, V322, P227, DOI 10.1007/s00441-005-0038-7
   Wood PL, 2007, BRAIN RES, V1145, P150, DOI 10.1016/j.brainres.2006.10.004
   Wood PL, 2006, BRAIN RES, V1095, P190, DOI 10.1016/j.brainres.2006.04.038
   Yoritaka A, 1996, P NATL ACAD SCI USA, V93, P2696, DOI 10.1073/pnas.93.7.2696
   Zgaljardic DJ, 2004, J NEURAL TRANSM, V111, P1287, DOI 10.1007/s00702-004-0178-z
   Zhou W, 2008, J BIOL CHEM, V283, P9863, DOI 10.1074/jbc.M710232200
NR 65
TC 78
Z9 79
U1 1
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 22
PY 2012
VL 7
IS 2
AR e31522
DI 10.1371/journal.pone.0031522
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 926ZZ
UT WOS:000302875500023
PM 22384032
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Zhao, XR
   Higashikawa, F
   Noda, M
   Kawamura, Y
   Matoba, Y
   Kumagai, T
   Sugiyama, M
AF Zhao, Xingrong
   Higashikawa, Fumiko
   Noda, Masafumi
   Kawamura, Yusuke
   Matoba, Yasuyuki
   Kumagai, Takanori
   Sugiyama, Masanori
TI The Obesity and Fatty Liver Are Reduced by Plant-Derived Pediococcus
   pentosaceus LP28 in High Fat Diet-Induced Obese Mice
SO PLOS ONE
LA English
DT Article
ID STEAROYL-COA DESATURASE-1; LACTIC-ACID BACTERIA; PPAR-GAMMA; CD36;
   DIFFERENTIATION; CHOLESTEROL; CONTRIBUTES; LIPOPROTEIN; METABOLISM;
   EXPRESSION
AB We evaluated the effect of an oral administration of a plant-derived lactic acid bacterium, Pediococcus pentosaceus LP28 (LP28), on metabolic syndrome by using high fat diet-induced obese mice. The obese mice were divided into 2 groups and fed either a high fat or regular diet for 8 weeks. Each group was further divided into 3 groups, which took LP28, another plant-derived Lactobacillus plantarum SN13T (SN13T) or no lactic acid bacteria (LAB). The lean control mice were fed a regular diet without inducing obesity prior to the experiment. LP28 reduced body weight gain and liver lipid contents (triglyceride and cholesterol), in mice fed a high fat diet for 8 weeks (40%, 54%, and 70% less than those of the control group without LAB, and P = 0.018, P<0.001, and P = 0.021, respectively), whereas SN13T and the heat treated LP28 at 121 degrees C for 15 min were ineffective. Abdominal visceral fat in the high fat diet mice fed with LP28 was also lower than that without LAB by 44%, although it was not significant but borderline (P = 0.076). The sizes of the adipocytes and the lipid droplets in the livers were obviously decreased. A real-time PCR analyses showed that lipid metabolism-related genes, such as CD36 (P = 0.013), SCD1 encoding stearoyl-CoA desaturase 1 (not significant but borderline, P = 0.066), and PPAR gamma encoding peroxisome proliferator-activated receptor gamma (P = 0.039), were down-regulated by taking LP28 continuously, when compared with those of the control group. In conclusion, LP28 may be a useful LAB strain for the prevention and reduction of the metabolic syndrome.
C1 [Zhao, Xingrong; Higashikawa, Fumiko; Noda, Masafumi; Kawamura, Yusuke; Matoba, Yasuyuki; Kumagai, Takanori; Sugiyama, Masanori] Hiroshima Univ, Grad Sch Biomed Sci, Dept Mol Microbiol & Biotechnol, Hiroshima, Japan.
RP Zhao, XR (reprint author), Hiroshima Univ, Grad Sch Biomed Sci, Dept Mol Microbiol & Biotechnol, Hiroshima, Japan.
EM sugi@hiroshima-u.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology, Japan
FX This work was supported by City Area Program for
   Industry-Academia-Government joint research (Hiroshima area) from the
   Ministry of Education, Culture, Sports, Science and Technology, Japan
   (to MS). The funder had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665
   Adolfsson O, 2004, AM J CLIN NUTR, V80, P245
   [Anonymous], 1998, OBES RES, V6, p51s , DOI DOI 10.1002/J.1550-8528.1998.TB00690.X
   Cohen P, 2002, SCIENCE, V297, P240, DOI 10.1126/science.1071527
   de LeBlanc AD, 2007, BRIT J NUTR, V98, pS105, DOI 10.1017/S0007114507839602
   ENDEMANN G, 1993, J BIOL CHEM, V268, P11811
   Gavrilova O, 2003, J BIOL CHEM, V278, P34268, DOI 10.1074/jbc.M300043200
   Greco D, 2008, AM J PHYSIOL-GASTR L, V294, pG1281, DOI 10.1152/ajpgi.00074.2008
   Higashikawa F, 2010, NUTRITION, V26, P367, DOI 10.1016/j.nut.2009.05.008
   HIRAISHI A, 1992, LETT APPL MICROBIOL, V15, P210, DOI 10.1111/j.1472-765X.1992.tb00765.x
   Jin HK, 2010, BIOL PHARM BULL, V33, P289, DOI 10.1248/bpb.33.289
   Koonen DPY, 2007, DIABETES, V56, P2863, DOI 10.2337/db07-0907
   Lane D. J., 1991, NUCL ACID TECHNIQUES, P115, DOI DOI 10.1007/S00227-012-2133-0
   Lau DCW, 2007, CAN MED ASSOC J, V176, P1103, DOI 10.1503/cmaj.070306
   Liong MT, 2006, J DAIRY SCI, V89, P1390, DOI 10.3168/jds.S0022-0302(06)72207-X
   MacDonald MLE, 2008, J LIPID RES, V49, P217, DOI 10.1194/jlr.M700478-JLR200
   Mathieu P, 2008, CAN J CARDIOL, V24, P521
   Nguyen TDT, 2007, INT J FOOD MICROBIOL, V113, P358, DOI 10.1016/j.ijfoodmicro.2006.08.015
   Nomura M, 2006, J APPL MICROBIOL, V101, P396, DOI 10.1111/j.1365-2672.2006.02949.x
   Ntambi JM, 1999, J LIPID RES, V40, P1549
   Ntambi JM, 2002, P NATL ACAD SCI USA, V99, P11482, DOI 10.1073/pnas.132384699
   Obesity: preventing and managing the global epidemic, 2000, WHO TECH REP SER, V894, P1, DOI DOI 10.1017/S0021932003245508
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Rolfe RD, 2000, J NUTR, V130, p396S, DOI 10.1093/jn/130.2.396S
   Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200
   Wada T, 2009, MICROBIOL-SGM, V155, P1726, DOI 10.1099/mic.0.022871-0
   Wang YP, 2009, APPL MICROBIOL BIOT, V84, P341, DOI 10.1007/s00253-009-2012-x
   WEISBURG WG, 1991, J BACTERIOL, V173, P697, DOI 10.1128/jb.173.2.697-703.1991
   West NP, 2009, EXERC IMMUNOL REV, V15, P107
   WHO, 2000, WHO TECH REP SER, V894, P1
   Zabala A, 2006, NUTRITION, V22, P528, DOI 10.1016/j.nut.2005.10.005
   Zhou J, 2008, GASTROENTEROLOGY, V134, P556, DOI 10.1053/j.gastro.2007.11.037
NR 32
TC 29
Z9 30
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 17
PY 2012
VL 7
IS 2
AR e30696
DI 10.1371/journal.pone.0030696
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 926TC
UT WOS:000302853600056
PM 22363472
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Singh, T
   Sharma, SD
   Katiyar, SK
AF Singh, Tripti
   Sharma, Som D.
   Katiyar, Santosh K.
TI Grape Proanthocyanidins Induce Apoptosis by Loss of Mitochondrial
   Membrane Potential of Human Non-Small Cell Lung Cancer Cells In Vitro
   and In Vivo
SO PLOS ONE
LA English
DT Article
ID SKH-1 HAIRLESS MICE; DEPENDENT KINASES; ANTICANCER DRUGS;
   CARCINOMA-CELLS; CYCLE CONTROL; BCL-2 FAMILY; DEATH; INHIBITORS;
   PROTEIN; GROWTH
AB Lung cancer remains the leading cause of cancer-related deaths worldwide, and non-small cell lung cancer (NSCLC) represents approximately 80% of total lung cancer cases. The use of non-toxic dietary phytochemicals can be considered as a chemotherapeutic strategy for the management of the NSCLC. Here, we report that grape seed proanthocyanidins (GSPs) induce apoptosis of NSCLC cells, A549 and H1299, in vitro which is mediated through increased expression of pro-apoptotic protein Bax, decreased expression of anti-apoptotic proteins Bcl2 and Bcl-xl, disruption of mitochondrial membrane potential, and activation of caspases 9, 3 and poly (ADP-ribose) polymerase (PARP). Pre-treatment of A549 and H1299 cells with the caspase-3 inhibitor (z-DEVD-fmk) significantly blocked the GSPs-induced apoptosis of these cells confirmed that GSPs-induced apoptosis is mediated through activation of caspases-3. Treatments of A549 and H1299 cells with GSPs resulted in an increase in G1 arrest. G0/G1 phase of the cell cycle is known to be controlled by cyclin dependent kinases (Cdk), cyclin-dependent kinase inhibitors (Cdki) and cyclins. Our western blot analyses showed that GSPs-induced G1 cell cycle arrest was mediated through the increased expression of Cdki proteins (Cip1/p21 and Kip1/p27), and a simultaneous decrease in the levels of Cdk2, Cdk4, Cdk6 and cyclins. Further, administration of 50, 100 or 200 mg GSPs/kg body weight of mice by oral gavage (5 d/week) markedly inhibited the growth of s.c. A549 and H1299 lung tumor xenografts in athymic nude mice, which was associated with the induction of apoptotic cell death, increased expression of Bax, reduced expression of anti-apoptotic proteins and activation of caspase-3 in tumor xenograft cells. Based on the data obtained in animal study, human equivalent dose of GSPs was calculated, which seems affordable and attainable. Together, these results suggest that GSPs may represent a potential therapeutic agent for the non-small cell lung cancer.
C1 [Singh, Tripti; Sharma, Som D.; Katiyar, Santosh K.] Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA.
   [Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
   [Katiyar, Santosh K.] Univ Alabama Birmingham, Nutr Obes Res Ctr, Birmingham, AL USA.
   [Katiyar, Santosh K.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
RP Singh, T (reprint author), Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA.
EM skatiyar@uab.edu
FU Veterans Administration Merit Review Award
FX This work was supported by funds from the Veterans Administration Merit
   Review Award (SKK). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Akhtar S, 2009, CLIN CANCER RES, V15, P821, DOI 10.1158/1078-0432.CCR-08-1901
   [Anonymous], 2011, CANC FACTS FIG
   Bagchi D, 1997, RES COMMUN MOL PATH, V95, P179
   BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2
   BURSCH W, 1992, TRENDS PHARMACOL SCI, V13, P245, DOI 10.1016/0165-6147(92)90077-J
   Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395
   Donovan M, 2004, BBA-MOL CELL RES, V1644, P133, DOI 10.1016/j.bbamcr.2003.08.011
   Facino RM, 1996, PLANTA MED, V62, P495, DOI 10.1055/s-2006-957956
   Ferrigno D, 2000, LUNG CANCER-J IASLC, V29, P91, DOI 10.1016/S0169-5002(00)00112-4
   Fischer P M, 2001, Curr Opin Drug Discov Devel, V4, P623
   FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5
   GRANA X, 1995, ONCOGENE, V11, P211
   Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309
   HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059
   HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0
   Hoffman PC, 2000, LANCET, V355, P479, DOI 10.1016/S0140-6736(00)82038-3
   HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6
   Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10
   KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207
   Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132
   Mantena SK, 2006, MOL CANCER THER, V5, P296, DOI 10.1158/1535-7163.MCT-05-0448
   Mantena SK, 2006, CARCINOGENESIS, V27, P1682, DOI 10.1093/carcin/bgl030
   Mantena SK, 2006, CARCINOGENESIS, V27, P2018, DOI 10.1093/carcin/bgl043
   Maziak DE, 2004, ANN THORAC SURG, V77, P1484, DOI 10.1016/j.athoracsur.2003.07.017
   McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345
   Mittal A, 2003, CARCINOGENESIS, V24, P1379, DOI 10.1093/carcin/bgg095
   Molinari M, 2000, CELL PROLIFERAT, V33, P261, DOI 10.1046/j.1365-2184.2000.00191.x
   MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0
   Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9
   Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640
   Proctor RN, 2001, NAT REV CANCER, V1, P82, DOI 10.1038/35094091
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012
   Sharma SD, 2007, MOL CANCER THER, V6, P995, DOI 10.1158/1535-7163.MCT-06-0661
   Sharma SD, 2010, MOL CANCER THER, V9, P569, DOI 10.1158/1535-7163.MCT-09-0638
   Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312
   TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8
   Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049
   WRIGHT SC, 1994, FASEB J, V8, P654
   Ye X, 1999, MOL CELL BIOCHEM, V196, P99, DOI 10.1023/A:1006926414683
   Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0
NR 41
TC 49
Z9 52
U1 1
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 8
PY 2011
VL 6
IS 11
AR e27444
DI 10.1371/journal.pone.0027444
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 852HZ
UT WOS:000297349700046
PM 22087318
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Kanaya, N
   Kubo, M
   Liu, Z
   Chu, PG
   Wang, C
   Yuan, YC
   Chen, SA
AF Kanaya, Noriko
   Kubo, Makoto
   Liu, Zheng
   Chu, Peiguo
   Wang, Charles
   Yuan, Yate-Ching
   Chen, Shiuan
TI Protective Effects of White Button Mushroom (Agaricus bisporus) against
   Hepatic Steatosis in Ovariectomized Mice as a Model of Postmenopausal
   Women
SO PLOS ONE
LA English
DT Article
ID HYPERCHOLESTEROLEMIC RATS; PLEUROTUS-OSTREATUS; CHOLESTEROL; METABOLISM;
   EXPRESSION; ERGOSTEROL; MEDICINE; GENE; DIET
AB Nonalcoholic fatty liver disease (NAFLD) includes various hepatic pathologies ranging from hepatic steatosis to nonalcoholic steatohepatitis (NASH), fibrosis and cirrhosis. Estrogen provides a protective effect on the development of NAFLD in women. Therefore, postmenopausal women have a higher risk of developing NAFLD. Hepatic steatosis is an early stage of fatty liver disease. Steatosis can develop to the aggressive stages (nonalcoholic steatohepatitis, fibrosis and cirrhosis). Currently, there is no specific drug to prevent/treat these liver diseases. In this study, we found that white button mushroom (WBM), Agaricus Bisporus, has protective effects against liver steatosis in ovariectomized (OVX) mice (a model of postmenopausal women). OVX mice were fed a high fat diet supplemented with WBM powder. We found that dietary WBM intake significantly lowered liver weight and hepatic injury markers in OVX mice. Pathological examination of liver tissue showed less fat accumulation in the livers of mice on WBM diet; moreover, these animals had improved glucose clearance ability. Microarray analysis revealed that genes related to the fatty acid biosynthesis pathway, particularly the genes for fatty acid synthetase (Fas) and fatty acid elongase 6 (Elovl6), were down-regulated in the liver of mushroom-fed mice. In vitro mechanistic studies using the HepG2 cell line showed that down-regulation of the expression of FAS and ELOVL6 by WBM extract was through inhibition of Liver X receptor (LXR) signaling and its downstream transcriptional factor SREBP1c. These results
C1 [Kanaya, Noriko; Kubo, Makoto; Chen, Shiuan] Beckman Res Inst City Hope, Div Tumor Cell Biol, Duarte, CA USA.
   [Liu, Zheng; Yuan, Yate-Ching] Beckman Res Inst City Hope, Div Bioinformat, Duarte, CA USA.
   [Chu, Peiguo] Res Inst City Hope, Dept Pathol, Duarte, CA USA.
   [Wang, Charles] Beckman Res Inst City Hope, Dept Mol & Cellular Biol, Duarte, CA USA.
RP Kanaya, N (reprint author), Beckman Res Inst City Hope, Div Tumor Cell Biol, Duarte, CA USA.
EM schen@coh.org
OI Liu, Zheng/0000-0002-1635-1556
FU National Institute of Health [ES08258]; US Mushroom Council; Australian
   Mushroom Growers Association
FX This work was supported by grants obtained by SC from the National
   Institute of Health (ES08258) and from the US Mushroom Council and the
   Australian Mushroom Growers Association (SC). The funders had no rule in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscripts.
CR Andersson T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008475
   Bobek P, 1996, NAHRUNG, V40, P222
   Borchers AT, 2008, EXP BIOL MED, V233, P259, DOI 10.3181/0708-MR-227
   Chen S, 2006, CANCER RES, V66, P12026, DOI 10.1158/0008-5472.CAN-06-2206
   Cheng HH, 2002, J AGR FOOD CHEM, V50, P7438, DOI 10.1021/jf020648q
   Edwards PA, 2002, VASC PHARMACOL, V38, P249, DOI 10.1016/S1537-1891(02)00175-1
   Fukushima M, 2001, EXP BIOL MED, V226, P758, DOI 10.1177/153537020222600808
   Gibbons Geoffrey F., 1994, Current Opinion in Lipidology, V5, P191, DOI 10.1097/00041433-199405030-00006
   Grefhorst A, 2002, J BIOL CHEM, V277, P34182, DOI 10.1074/jbc.M204887200
   Grobe YG, 2010, ANN HEPATOL, V9, P402, DOI 10.1016/S1665-2681(19)31616-3
   Hoegh-Andersen P, 2004, ARTHRITIS RES THER, V6, pR169, DOI 10.1186/ar1152
   Hossain S, 2003, CLIN EXP PHARMACOL P, V30, P470, DOI 10.1046/j.1440-1681.2003.03857.x
   Jeong SC, 2010, NUTR RES, V30, P49, DOI 10.1016/j.nutres.2009.12.003
   Jordan VC, 2003, NAT REV DRUG DISCOV, V2, P205, DOI 10.1038/nrd1031
   Kanaya N, 2010, NUTR RES, V30, P714, DOI 10.1016/j.nutres.2010.09.001
   Luk SU, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019804
   Maffei L, 2004, J CLIN ENDOCR METAB, V89, P61, DOI 10.1210/jc.2003-030313
   Miyazaki M, 2004, J BIOL CHEM, V279, P25164, DOI 10.1074/jbc.M402781200
   Nagao K, 2010, J NUTR BIOCHEM, V21, P418, DOI 10.1016/j.jnutbio.2009.01.021
   Nemoto Y, 2000, J CLIN INVEST, V105, P1819, DOI 10.1172/JCI9575
   PALOMARES M, 2011, AM SOC CLIN ONC ASCO
   Pasumarthy L, 2010, SOUTH MED J, V103, P547, DOI 10.1097/SMJ.0b013e3181de0ce0
   Postic C, 2008, J CLIN INVEST, V118, P829, DOI 10.1172/JCI34275
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Rogers NH, 2009, ENDOCRINOLOGY, V150, P2161, DOI 10.1210/en.2008-1405
   Sgarbi DBD, 1997, MYCOPATHOLOGIA, V139, P9
   Shao SQ, 2010, J AGR FOOD CHEM, V58, P11616, DOI 10.1021/jf102285b
   Shimamura K, 2010, EUR J PHARMACOL, V630, P34, DOI 10.1016/j.ejphar.2009.12.033
   Sullivan R, 2006, PERSPECT BIOL MED, V49, P159, DOI 10.1353/pbm.2006.0034
   Sung KC, 2011, J CLIN ENDOCR METAB, V96, P1093, DOI 10.1210/jc.2010-2190
   Suzuki A, 2009, WOMENS HEALTH, V5, P191, DOI 10.2217/17455057.5.2.191
   Xu J, 2008, STEM CELLS DEV, V17, P143, DOI 10.1089/scd.2007.0094
NR 32
TC 21
Z9 22
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 25
PY 2011
VL 6
IS 10
AR e26654
DI 10.1371/journal.pone.0026654
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 841MS
UT WOS:000296517000024
PM 22046322
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Wergeland, S
   Torkildsen, O
   Myhr, KM
   Aksnes, L
   Mork, SJ
   Bo, L
AF Wergeland, Stig
   Torkildsen, Oivind
   Myhr, Kjell-Morten
   Aksnes, Lage
   Mork, Sverre Jarl
   Bo, Lars
TI Dietary Vitamin D3 Supplements Reduce Demyelination in the Cuprizone
   Model
SO PLOS ONE
LA English
DT Article
ID SUPERIOR CEREBELLAR PEDUNCLE; CENTRAL-NERVOUS-SYSTEM;
   MULTIPLE-SCLEROSIS; 1,25-DIHYDROXYVITAMIN D-3; 25-HYDROXYVITAMIN-D
   LEVELS; CELL-DIFFERENTIATION; PARKINSON-DISEASE; MENSTRUAL-CYCLE; SERUM;
   RISK
AB Vitamin D is emerging as a probably important environmental risk factor in multiple sclerosis, affecting both susceptibility and disease progression. It is not known to what extent this effect is due to a modulation of peripheral lymphocyte function, or to intrathecal effects of vitamin D. We investigated the effect of dietary vitamin D3 content on de/remyelination in the cuprizone model, which is a well established toxic model of demyelination, with no associated lymphocyte infiltration. The mice received diets either deficient of (<50 IU/kg), or supplemented with low (500 IU/kg), high (6200 IU/kg) or very high (12500 IU/kg) amounts of vit D3. Cuprizone (0.2%) was added to the diet for six weeks, starting two weeks after onset of the experimental diets. Mouse brain tissue was histopathologically evaluated for myelin and oligodendrocyte loss, microglia/macrophage activation, and lymphocyte infiltration after six weeks of cuprizone exposure, and two weeks after discontinuation of cuprizone exposure. High and very high doses of vitamin D3 significantly reduced the extent of white matter demyelination (p = 0.004) and attenuated microglia activation (p = 0.001). No differences in the density of oligodendrocytes were observed between the diet groups. Two weeks after discontinuation of cuprizone exposure, remyelination was only detectable in the white matter of mice receiving diets deficient of or with low vitamin D3 content. In conclusion, high dietary doses of vitamin D3 reduce the extent of demyelination, and attenuate microglia activation and macrophage infiltration in a toxic model of demyelination, independent of lymphocyte infiltration.
C1 [Wergeland, Stig; Torkildsen, Oivind; Myhr, Kjell-Morten; Bo, Lars] Haukeland Hosp, Norwegian Multiple Sclerosis Competence Ctr, Dept Neurol, N-5021 Bergen, Norway.
   [Wergeland, Stig; Torkildsen, Oivind; Myhr, Kjell-Morten; Bo, Lars] Haukeland Hosp, KG Jebsen Ctr Multiple Sclerosis Res, N-5021 Bergen, Norway.
   [Wergeland, Stig; Torkildsen, Oivind; Myhr, Kjell-Morten; Aksnes, Lage; Bo, Lars] Univ Bergen, Dept Clin Med, Bergen, Norway.
   [Mork, Sverre Jarl] Haukeland Hosp, Dept Pathol, N-5021 Bergen, Norway.
RP Wergeland, S (reprint author), Haukeland Hosp, Norwegian Multiple Sclerosis Competence Ctr, Dept Neurol, N-5021 Bergen, Norway.
EM stig.wergeland@gmail.com
RI Myhr, Kjell-Morten/H-1528-2018; Torkildsen, Oivind/A-1606-2008
OI Myhr, Kjell-Morten/0000-0002-0980-510X; Torkildsen,
   Oivind/0000-0001-5294-2866
FU Western Norway Regional Health Authority; Biogen Idec
FX The study has been funded by the Western Norway Regional Health
   Authority, and supported by a grant from Biogen Idec. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR AARSKOG D, 1983, J CLIN ENDOCR METAB, V57, P1155, DOI 10.1210/jcem-57-6-1155
   ACHESON E. D., 1960, ACTA PSYCHIATR ET NEUROL SCAND SUPPL, V35, P132, DOI 10.1111/j.1600-0447.1960.tb08674.x
   AKSNES L, 1994, J PEDIATR GASTR NUTR, V18, P339, DOI 10.1097/00005176-199404000-00015
   BLAKEMORE WF, 1973, J NEUROL SCI, V20, P63, DOI 10.1016/0022-510X(73)90118-4
   BLAKEMORE WF, 1974, J NEUROL SCI, V22, P121, DOI 10.1016/0022-510X(74)90059-8
   Boonstra A, 2001, J IMMUNOL, V167, P4974, DOI 10.4049/jimmunol.167.9.4974
   Cantorna MT, 1999, J NUTR, V129, P1966
   Cantorna MT, 1996, P NATL ACAD SCI USA, V93, P7861, DOI 10.1073/pnas.93.15.7861
   CHEEMA C, 1989, J CLIN INVEST, V83, P537, DOI 10.1172/JCI113915
   CHEN KS, 1995, BBA-GENE STRUCT EXPR, V1263, P1, DOI 10.1016/0167-4781(95)00060-T
   Chen S, 2007, J IMMUNOL, V179, P1634, DOI 10.4049/jimmunol.179.3.1634
   Compston A, 2008, LANCET, V372, P1502, DOI 10.1016/S0140-6736(08)61620-7
   Elenkov IJ, 2001, J CLIN ENDOCR METAB, V86, P4933, DOI 10.1210/jc.86.10.4933
   Evatt ML, 2008, ARCH NEUROL-CHICAGO, V65, P1348, DOI 10.1001/archneur.65.10.1348
   Eyles DW, 2005, J CHEM NEUROANAT, V29, P21, DOI 10.1016/j.jchemneu.2004.08.006
   Freedman DM, 2000, OCCUP ENVIRON MED, V57, P418, DOI 10.1136/oem.57.6.418
   Garcion E, 2002, TRENDS ENDOCRIN MET, V13, P100, DOI 10.1016/S1043-2760(01)00547-1
   GRAY TK, 1982, AM J OBSTET GYNECOL, V144, P880, DOI 10.1016/0002-9378(82)90177-6
   Griffin MD, 2000, BIOCHEM BIOPH RES CO, V270, P701, DOI 10.1006/bbrc.2000.2490
   Grytten N, 2006, NEUROLOGY, V66, P182, DOI 10.1212/01.wnl.0000195549.95448.b9
   Hesse A, 2010, NEUROBIOL DIS, V37, P362, DOI 10.1016/j.nbd.2009.10.016
   Kampman MT, 2007, J NEUROL, V254, P471, DOI 10.1007/s00415-006-0395-5
   Knekt P, 2010, ARCH NEUROL-CHICAGO, V67, P808, DOI 10.1001/archneurol.2010.120
   Kuhlmann T, 2007, J NEUROPATH EXP NEUR, V66, P238, DOI 10.1097/01.jnen.0000248559.83573.71
   Lindner M, 2008, NEUROPATH APPL NEURO, V34, P105, DOI 10.1111/j.1365-2990.2007.00879.x
   Mackay-Sim A, 2004, INT REV NEUROBIOL, V59, P351
   Matsushima GK, 2001, BRAIN PATHOL, V11, P107
   McGrath J, 2004, SCHIZOPHR RES, V67, P237, DOI 10.1016/j.schres.2003.08.005
   MICHAYLOVA V, 1971, ANAL CHIM ACTA, V53, P194, DOI 10.1016/S0003-2670(01)80088-X
   Munger KL, 2006, JAMA-J AM MED ASSOC, V296, P2832, DOI 10.1001/jama.296.23.2832
   Munger KL, 2004, NEUROLOGY, V62, P60, DOI 10.1212/01.WNL.0000101723.79681.38
   Myhr KM, 2009, J NEUROL SCI, V286, P104, DOI 10.1016/j.jns.2009.05.002
   Oudshoorn C, 2008, DEMENT GERIATR COGN, V25, P539, DOI 10.1159/000134382
   Overbergh L, 2000, CLIN EXP IMMUNOL, V120, P139, DOI 10.1046/j.1365-2249.2000.01204.x
   Paxinos G., 2004, MOUSE BRAIN STEREOTA
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Sato Y, 1997, NEUROLOGY, V49, P1273, DOI 10.1212/WNL.49.5.1273
   Seewann A, 2009, ARCH NEUROL-CHICAGO, V66, P601, DOI 10.1001/archneurol.2009.57
   Simpson S, 2010, ANN NEUROL, V68, P193, DOI 10.1002/ana.22043
   Smolders J, 2008, MULT SCLER J, V14, P1220, DOI 10.1177/1352458508094399
   Smolders J, 2008, J NEUROIMMUNOL, V194, P7, DOI 10.1016/j.jneuroim.2007.11.014
   Smolders J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006635
   Soilu-Hanninen M, 2005, MULT SCLER J, V11, P266, DOI 10.1191/1352458505ms1157oa
   Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154
   SUTHERLAND JM, 1962, BRAIN, V85, P149, DOI 10.1093/brain/85.1.149
   Taylor DL, 2010, J NEUROSCI RES, V88, P1632, DOI 10.1002/jnr.22335
   Taylor LC, 2010, J NEUROSCI RES, V88, P391, DOI 10.1002/jnr.22215
   TJELLESEN L, 1983, ACTA ENDOCRINOL-COP, V102, P476, DOI 10.1530/acta.0.1020476
   Torkildsen O, 2009, CLIN NUTR, V28, P83, DOI 10.1016/j.clnu.2008.10.015
   Torkildsen O, 2009, EXP NEUROL, V215, P160, DOI 10.1016/j.expneurol.2008.09.026
   van der Mei IAF, 2001, NEUROEPIDEMIOLOGY, V20, P168, DOI 10.1159/000054783
   Veldman CM, 2000, ARCH BIOCHEM BIOPHYS, V374, P334, DOI 10.1006/abbi.1999.1605
   Zehnder D, 2001, J CLIN ENDOCR METAB, V86, P888, DOI 10.1210/jc.86.2.888
NR 53
TC 49
Z9 49
U1 3
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 20
PY 2011
VL 6
IS 10
AR e26262
DI 10.1371/journal.pone.0026262
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 841KI
UT WOS:000296510800032
PM 22028844
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Heijmans, J
   Muncan, V
   Jacobs, RJ
   de Jonge-Muller, ESM
   Graven, L
   Biemond, I
   Ederveen, AG
   Groothuis, PG
   Mosselman, S
   Hardwick, JC
   Hommes, DW
   van den Brink, GR
AF Heijmans, Jarom
   Muncan, Vanesa
   Jacobs, Rutger J.
   de Jonge-Muller, Eveline S. M.
   Graven, Laura
   Biemond, Izak
   Ederveen, Antwan G.
   Groothuis, Patrick G.
   Mosselman, Sietse
   Hardwick, James C.
   Hommes, Daniel W.
   van den Brink, Gijs R.
TI Intestinal Tumorigenesis Is Not Affected by Progesterone Signaling in
   Rodent Models
SO PLOS ONE
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; ESTROGEN PLUS PROGESTIN; COLON-CANCER;
   MEDROXYPROGESTERONE ACETATE; POSTMENOPAUSAL WOMEN; COLORECTAL-CANCER;
   TUMOR PROGRESSION; RECEPTOR KNOCKOUT; MAMMARY-GLAND; MOUSE MODELS
AB Clinical data suggest that progestins have chemopreventive properties in the development of colorectal cancer. We set out to examine a potential protective effect of progestins and progesterone signaling on colon cancer development. In normal and neoplastic intestinal tissue, we found that the progesterone receptor (PR) is not expressed. Expression was confined to sporadic mesenchymal cells. To analyze the influence of systemic progesterone receptor signaling, we crossed mice that lacked the progesterone receptor (PRKO) to the Apc(Min/+) mouse, a model for spontaneous intestinal polyposis. PRKO-Apc(Min/+) mice exhibited no change in polyp number, size or localization compared to Apc(Min/+). To examine effects of progestins on the intestinal epithelium that are independent of the PR, we treated mice with MPA. We found no effects of either progesterone or MPA on gross intestinal morphology or epithelial proliferation. Also, in rats treated with MPA, injection with the carcinogen azoxymethane did not result in a difference in the number or size of aberrant crypt foci, a surrogate end-point for adenoma development. We conclude that expression of the progesterone receptor is limited to cells in the intestinal mesenchyme. We did not observe any effect of progesterone receptor signaling or of progestin treatment in rodent models of intestinal tumorigenesis.
C1 [Heijmans, Jarom; Muncan, Vanesa; Jacobs, Rutger J.; de Jonge-Muller, Eveline S. M.; Graven, Laura; Biemond, Izak; Hardwick, James C.; Hommes, Daniel W.; van den Brink, Gijs R.] Leiden Univ, Med Ctr, Dept Gastroenterol & Hepatol, Leiden, Netherlands.
   [Heijmans, Jarom; Muncan, Vanesa; van den Brink, Gijs R.] Univ Amsterdam, Acad Med Ctr, Tytgat Inst Liver & Intestinal Res, NL-1105 AZ Amsterdam, Netherlands.
   [Ederveen, Antwan G.; Groothuis, Patrick G.; Mosselman, Sietse] Womens Hlth Dept, Oss, Netherlands.
   [van den Brink, Gijs R.] Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol & Hepatol, NL-1105 AZ Amsterdam, Netherlands.
RP Heijmans, J (reprint author), Leiden Univ, Med Ctr, Dept Gastroenterol & Hepatol, Leiden, Netherlands.
EM j.heijmans@amc.nl; g.r.vandenbrink@amc.nl
RI Ederveen, Antwan/I-3557-2016; Biemond, Izak/A-3540-2016; Hardwick,
   James/J-4862-2013
OI Ederveen, Antwan/0000-0003-1128-227X; Biemond, Izak/0000-0002-3137-7527;
   Hardwick, James/0000-0002-9575-5099
FU Merck, Sharpe Dohme (MSD)
FX This study was funded with an unrestricted grant from Merck, Sharpe &
   Dohme (MSD). P.G.G., A.G.E. and S.M. are researchers employed by MSD.
   They have contributed to this study by critical appraisal of the data
   and the manuscript and by sharing expert opinion. Furthermore, MSD had
   no role in study design, data collection and analysis, decision to
   publish or preparation of the manuscript.
CR Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701
   Asselin-Labat ML, 2010, NATURE, V465, P798, DOI 10.1038/nature09027
   BeazerBarclay Y, 1996, CARCINOGENESIS, V17, P1757, DOI 10.1093/carcin/17.8.1757
   Becker C, 2004, IMMUNITY, V21, P491, DOI 10.1016/j.immuni.2004.07.020
   Bentel JM, 1999, MOL CELL ENDOCRINOL, V154, P11, DOI 10.1016/S0303-7207(99)00109-4
   BERTHOIS Y, 1986, P NATL ACAD SCI USA, V83, P2496, DOI 10.1073/pnas.83.8.2496
   BIRD RP, 1987, CANCER LETT, V37, P147, DOI 10.1016/0304-3835(87)90157-1
   Blois SM, 2007, NAT MED, V13, P1450, DOI 10.1038/nm1680
   Cao L, 2010, CELL, V142, P52, DOI 10.1016/j.cell.2010.05.029
   Chlebowski RT, 2004, NEW ENGL J MED, V350, P991, DOI 10.1056/NEJMoa032071
   Giardiello FM, 2005, GASTROENTEROLOGY, V128, P1077, DOI 10.1053/j.gastro.2004.10.010
   Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013
   Half E, 2009, EXPERT OPIN PHARMACO, V10, P211, DOI [10.1517/14656560802560153 , 10.1517/14656560802560153]
   Hardwick JCH, 2001, ONCOGENE, V20, P819, DOI 10.1038/sj.onc.1204162
   Hughes GC, 2008, J IMMUNOL, V180, P2029, DOI 10.4049/jimmunol.180.4.2029
   Ismail PM, 2003, STEROIDS, V68, P779, DOI 10.1016/S0039-128X(03)00133-8
   Jones LA, 2010, J IMMUNOL, V185, P4525, DOI 10.4049/jimmunol.0901155
   KIRTON KT, 1974, CONTRACEPTION, V10, P39, DOI 10.1016/0010-7824(74)90130-9
   Mani SK, 2006, MOL ENDOCRINOL, V20, P1322, DOI 10.1210/me.2005-0466
   MARTIN L, 1973, J ENDOCRINOL, V56, P303, DOI 10.1677/joe.0.0560303
   McCart AE, 2008, PATHOL RES PRACT, V204, P479, DOI 10.1016/j.prp.2008.03.004
   MEGGOUH F, 1991, CANCER-AM CANCER SOC, V67, P1964, DOI 10.1002/1097-0142(19910401)67:7<1964::AID-CNCR2820670724>3.0.CO;2-S
   MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722
   Mote PA, 2006, ENDOCRINOLOGY, V147, P5503, DOI 10.1210/en.2006-0040
   Mulac-Jericevic B, 2003, P NATL ACAD SCI USA, V100, P9744, DOI 10.1073/pnas.1732707100
   Neufert C, 2007, NAT PROTOC, V2, P1998, DOI 10.1038/nprot.2007.279
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Rickard DJ, 2008, ENDOCRINOLOGY, V149, P2383, DOI 10.1210/en.2007-1247
   Ritenbaugh C, 2008, CANCER EPIDEM BIOMAR, V17, P2609, DOI 10.1158/1055-9965.EPI-08-0385
   Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321
   SICA V, 1984, CANCER RES, V44, P4670
   SINGH S, 1993, GUT, V34, P611, DOI 10.1136/gut.34.5.611
   Slattery ML, 2000, AM J CLIN PATHOL, V113, P364
   Takayama T, 1998, NEW ENGL J MED, V339, P1277, DOI 10.1056/NEJM199810293391803
   Taketo MM, 2009, GASTROENTEROLOGY, V136, P780, DOI 10.1053/j.gastro.2008.12.049
   Tanaka Y, 2008, MENOPAUSE, V15, P442, DOI 10.1097/gme.0b013e318156fb77
   Wood GA, 2007, REPRODUCTION, V133, P1035, DOI 10.1530/REP-06-0302
   Yamanouchi Keitaro, 2000, Journal of Reproduction and Development, V46, P257, DOI 10.1262/jrd.46.257
   Zhang ZM, 2005, J BIOL CHEM, V280, P28468, DOI 10.1074/jbc.M604144200
NR 39
TC 5
Z9 5
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 27
PY 2011
VL 6
IS 7
AR e22620
DI 10.1371/journal.pone.0022620
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 799JJ
UT WOS:000293282700049
PM 21818351
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Vang, O
   Ahmad, N
   Baile, CA
   Baur, JA
   Brown, K
   Csiszar, A
   Das, DK
   Delmas, D
   Gottfried, C
   Lin, HY
   Ma, QY
   Mukhopadhyay, P
   Nalini, N
   Pezzuto, JM
   Richard, T
   Shukla, Y
   Surh, YJ
   Szekeres, T
   Szkudelski, T
   Walle, T
   Wu, JM
AF Vang, Ole
   Ahmad, Nihal
   Baile, Clifton A.
   Baur, Joseph A.
   Brown, Karen
   Csiszar, Anna
   Das, Dipak K.
   Delmas, Dominique
   Gottfried, Carmem
   Lin, Hung-Yun
   Ma, Qing-Yong
   Mukhopadhyay, Partha
   Nalini, Namasivayam
   Pezzuto, John M.
   Richard, Tristan
   Shukla, Yogeshwer
   Surh, Young-Joon
   Szekeres, Thomas
   Szkudelski, Tomasz
   Walle, Thomas
   Wu, Joseph M.
TI What Is New for an Old Molecule? Systematic Review and Recommendations
   on the Use of Resveratrol
SO PLOS ONE
LA English
DT Article
ID CANCER CHEMOPREVENTIVE AGENT; ACTIVATED PROTEIN-KINASE; TRAUMATIC
   BRAIN-INJURY; ABERRANT CRYPT FOCI; INDUCED DIABETIC-RATS; FATTY
   LIVER-DISEASE; KAPPA-B ACTIVATION; SPINAL-CORD-INJURY; CELLS IN-VITRO;
   RED WINE
AB Background: Resveratrol is a natural compound suggested to have beneficial health effects. However, people are consuming resveratrol for this reason without having the adequate scientific evidence for its effects in humans. Therefore, scientific valid recommendations concerning the human intake of resveratrol based on available published scientific data are necessary. Such recommendations were formulated after the Resveratrol 2010 conference, held in September 2010 in Helsingor, Denmark.
   Methodology: Literature search in databases as PubMed and ISI Web of Science in combination with manual search was used to answer the following five questions: (1)Can resveratrol be recommended in the prevention or treatment of human diseases?; (2)Are there observed "side effects" caused by the intake of resveratrol in humans?; (3)What is the relevant dose of resveratrol?; (4)What valid data are available regarding an effect in various species of experimental animals?; (5)Which relevant (overall) mechanisms of action of resveratrol have been documented?
   Conclusions/Significance: The overall conclusion is that the published evidence is not sufficiently strong to justify a recommendation for the administration of resveratrol to humans, beyond the dose which can be obtained from dietary sources. On the other hand, animal data are promising in prevention of various cancer types, coronary heart diseases and diabetes which strongly indicate the need for human clinical trials. Finally, we suggest directions for future research in resveratrol regarding its mechanism of action and its safety and toxicology in human subjects.
C1 [Vang, Ole] Roskilde Univ, Dept Sci Syst & Models, Roskilde, Denmark.
   [Ahmad, Nihal] Univ Wisconsin, Dept Dermatol, Madison, WI USA.
   [Baile, Clifton A.] Univ Georgia, Dept Anim & Dairy Sci, Athens, GA 30602 USA.
   [Baur, Joseph A.] Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA.
   [Baur, Joseph A.] Univ Penn, Sch Med, Inst Diabet Obes & Metab, Philadelphia, PA 19104 USA.
   [Brown, Karen] Univ Leicester, Dept Canc Studies & Mol Med, Bioctr, Leicester, Great Britain, England.
   [Csiszar, Anna] Univ Oklahoma, Hlth Sci Ctr, Reynolds Oklahoma Ctr Aging, Oklahoma City, OK USA.
   [Das, Dipak K.] Univ Connecticut, Sch Med, Cardiovasc Res Ctr, Farmington, CT USA.
   [Delmas, Dominique] Univ Burgundy, INSERM, U866, Dijon, France.
   [Gottfried, Carmem] Univ Fed Rio Grande do Sul, Dept Biochem, Postgrad Programme Biochem, Inst Basic Hlth Sci, Porto Alegre, RS, Brazil.
   [Lin, Hung-Yun] Ordway Res Inst, Signal Transduct Lab, Albany, NY USA.
   [Ma, Qing-Yong] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Xian 710049, Shaanxi Prov, Peoples R China.
   [Mukhopadhyay, Partha] NIH, Lab Physiol Studies, Sect Oxidat Stress Tissue Injury, Rockville, MD USA.
   [Nalini, Namasivayam] Annamalai Univ, Dept Biochem & Biotechnol, Annamalainagar 608002, Tamil Nadu, India.
   [Pezzuto, John M.] Univ Hawaii, Coll Pharm, Hilo, HI 96720 USA.
   [Richard, Tristan] Univ Bordeaux, UFR Pharmacie, Villenave Dornon, France.
   [Shukla, Yogeshwer] Indian Inst Toxicol Res, Prote Lab, Lucknow, Uttar Pradesh, India.
   [Surh, Young-Joon] Seoul Natl Univ, Coll Pharm, Seoul, South Korea.
   [Szekeres, Thomas] Med Univ Vienna, Gen Hosp Vienna, Clin Inst Med & Chem Lab Diagnost, Vienna, Austria.
   [Szkudelski, Tomasz] Agr Univ Poznan, Dept Anim Physiol & Biochem, Poznan, Poland.
   [Walle, Thomas] Med Univ S Carolina, Dept Cell & Mol Pharmacol & Expt Therapeut, Charleston, SC 29425 USA.
   [Wu, Joseph M.] New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA.
RP Vang, O (reprint author), Roskilde Univ, Dept Sci Syst & Models, Roskilde, Denmark.
EM ov@ruc.dk
RI Shukla, Yogeshwer/B-4144-2012; Baur, Joseph A/D-8163-2011; MUKHOPADHYAY,
   PARTHA/G-3890-2010; Vang, Ole/K-9842-2015
OI MUKHOPADHYAY, PARTHA/0000-0002-1178-1274; Baur,
   Joseph/0000-0001-8262-6549; Brown, Karen/0000-0002-5217-1501;
   Szkudelski, Tomasz/0000-0002-9067-6682; Richard,
   Tristan/0000-0002-5308-8697; Vang, Ole/0000-0002-3901-8545
FU European Union; Cancer Research UK [13101]
FX This study was made as a part of the Resveratrol 2010 conference
   (www.resveratrol2010.com) and did not receive any specific funding from
   third parties. The conference was organized by Roskilde University,
   Danish Society for Biochemistry and Molecular Biology, The Danish
   Society of Engineers, Oresund Food with support from The European Union.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Akar F, 2011, CARDIOVASC DRUG THER, V25, P119, DOI 10.1007/s10557-010-6255-7
   Almeida L, 2009, MOL NUTR FOOD RES, V53, pS7, DOI 10.1002/mnfr.200800177
   Asensi M, 2002, FREE RADICAL BIO MED, V33, P387, DOI 10.1016/S0891-5849(02)00911-5
   Ates O, 2007, MOL CELL BIOCHEM, V294, P137, DOI 10.1007/s11010-006-9253-0
   Ates O, 2007, J CLIN NEUROSCI, V14, P256, DOI 10.1016/j.jocn.2005.12.010
   Ates O, 2006, ACTA PHARMACOL SIN, V27, P1317, DOI 10.1111/j.1745-7254.2006.00416.x
   Aubin MC, 2008, J PHARMACOL EXP THER, V325, P961, DOI 10.1124/jpet.107.135061
   Banerjee S, 2002, CANCER RES, V62, P4945
   Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354
   Behbahani J, 2010, AM J HYPERTENS, V23, P1273, DOI 10.1038/ajh.2010.161
   Berge G, 2004, BRIT J CANCER, V91, P1380, DOI 10.1038/sj.bjc.6602125
   Bhat KPL, 2001, CANCER RES, V61, P7456
   Binienda ZK, 2010, NEUROSCI LETT, V480, P117, DOI 10.1016/j.neulet.2010.06.020
   Bishayee A, 2009, CHEM-BIOL INTERACT, V179, P131, DOI 10.1016/j.cbi.2008.11.015
   Boocock DJ, 2007, CANCER EPIDEM BIOMAR, V16, P1246, DOI 10.1158/1055-9965.EPI-07-0022
   Boocock DJ, 2007, J CHROMATOGR B, V848, P182, DOI 10.1016/j.jchromb.2006.10.017
   Bove K, 2002, BIOCHEM BIOPH RES CO, V291, P1001, DOI 10.1006/bbrc.2002.6554
   Brown VA, 2010, CANCER RES, V70, P9003, DOI 10.1158/0008-5472.CAN-10-2364
   Bujanda L, 2008, BMC GASTROENTEROL, V8, DOI 10.1186/1471-230X-8-40
   Burkon A, 2008, MOL NUTR FOOD RES, V52, P549, DOI 10.1002/mnfr.200700290
   Burstein B, 2007, J PHARMACOL EXP THER, V323, P916, DOI 10.1124/jpet.107.127548
   Caltagirone S, 2000, INT J CANCER, V87, P595, DOI 10.1002/1097-0215(20000815)87:4<595::AID-IJC21>3.0.CO;2-5
   Chan V, 2011, CURR PHARM BIOTECHNO, V12, P429, DOI 10.2174/138920111794480552
   Chen Y, 2004, SURGERY, V136, P57, DOI 10.1016/j.surg.2004.01.017
   Chen YR, 2008, CARDIOVASC DRUG THER, V22, P479, DOI 10.1007/s10557-008-6141-8
   Crowell JA, 2004, TOXICOL SCI, V82, P614, DOI 10.1093/toxsci/kfh263
   Csiszar A, 2008, AM J PHYSIOL-HEART C, V294, pH2721, DOI 10.1152/ajpheart.00235.2008
   Csiszar A, 2009, HYPERTENSION, V54, P668, DOI 10.1161/HYPERTENSIONAHA.109.133397
   Cui XL, 2010, CANCER PREV RES, V3, P549, DOI 10.1158/1940-6207.CAPR-09-0117
   Dal-Pan Alexandre, 2010, BMC Physiology, V10, P11, DOI 10.1186/1472-6793-10-11
   Das S, 2006, J PHARMACOL EXP THER, V317, P980, DOI 10.1124/jpet.105.095133
   Della-Morte D, 2009, NEUROSCIENCE, V159, P993, DOI 10.1016/j.neuroscience.2009.01.017
   Dudley J, 2009, J NUTR BIOCHEM, V20, P443, DOI 10.1016/j.jnutbio.2008.05.003
   El-Mowafy AM, 2010, CHEMOTHERAPY, V56, P60, DOI 10.1159/000298821
   Elliott PJ, 2009, DRUG FUTURE, V34, P291, DOI 10.1358/dof.2009.034.04.1360696
   Fukuda S, 2006, CELL BIOCHEM BIOPHYS, V44, P43, DOI 10.1385/CBB:44:1:043
   Goldberg DA, 2003, CLIN BIOCHEM, V36, P79, DOI 10.1016/S0009-9120(02)00397-1
   Gonzalez-Rodriguez A, 2010, DIABETES, V59, P588, DOI 10.2337/db09-0796
   Harper CE, 2009, PROSTATE, V69, P1668, DOI 10.1002/pros.21017
   Hebbar V, 2005, LIFE SCI, V76, P2299, DOI 10.1016/j.lfs.2004.10.039
   Hecht SS, 1999, CANCER LETT, V137, P123, DOI 10.1016/S0304-3835(98)00326-7
   Hong SW, 2010, ARCH PHARM RES, V33, P601, DOI 10.1007/s12272-010-0415-y
   Horn TL, 2007, FOOD CHEM TOXICOL, V45, P55, DOI 10.1016/j.fct.2006.07.015
   Huang HP, 2010, FREE RADICAL BIO MED, V49, P1710, DOI 10.1016/j.freeradbiomed.2010.08.032
   Inanaga K, 2009, HYPERTENS RES, V32, P466, DOI 10.1038/hr.2009.47
   Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218
   Jin F, 2008, EUR J PHARMACOL, V600, P78, DOI 10.1016/j.ejphar.2008.10.005
   Juan ME, 2002, J NUTR, V132, P257
   Kapadia GJ, 2002, PHARMACOL RES, V45, P499, DOI 10.1006/phrs.2002.0992
   Karuppagounder SS, 2009, NEUROCHEM INT, V54, P111, DOI 10.1016/j.neuint.2008.10.008
   Kennedy DO, 2010, AM J CLIN NUTR, V91, P1590, DOI 10.3945/ajcn.2009.28641
   Khan MM, 2010, BRAIN RES, V1328, P139, DOI 10.1016/j.brainres.2010.02.031
   Kim D, 2007, EMBO J, V26, P3169, DOI 10.1038/sj.emboj.7601758
   Kim YH, 2010, DIABETES, V59, P1825, DOI 10.2337/db09-1431
   Kimura Y, 2001, J NUTR, V131, P1844
   Kineman BD, 2007, NUTR CANCER, V58, P66, DOI 10.1080/01635580701308208
   Kiziltepe U, 2004, J VASC SURG, V40, P138, DOI 10.1016/j.jvs.2004.03.032
   Kowalczyk MC, 2010, CANCER PREV RES, V3, P170, DOI 10.1158/1940-6207.CAPR-09-0196
   Kumar A, 2007, PHARMACOLOGY, V79, P17, DOI 10.1159/000097511
   Kumar A, 2010, BIOCHEM BIOPH RES CO, V394, P360, DOI 10.1016/j.bbrc.2010.03.014
   Kumar P, 2006, BEHAV PHARMACOL, V17, P485, DOI 10.1097/00008877-200609000-00014
   la Porte C, 2010, CLIN PHARMACOKINET, V49, P449, DOI 10.2165/11531820-000000000-00000
   Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013
   Larrosa M, 2010, J MED CHEM, V53, P7365, DOI 10.1021/jm1007006
   Larrosa M, 2009, J AGR FOOD CHEM, V57, P2211, DOI 10.1021/jf803638d
   Lekli I, 2008, AM J PHYSIOL-HEART C, V294, pH859, DOI 10.1152/ajpheart.01048.2007
   Lin JF, 2008, LIFE SCI, V83, P313, DOI 10.1016/j.lfs.2008.06.016
   Liu HS, 2003, WORLD J GASTROENTERO, V9, P1474, DOI 10.3748/wjg.v9.i7.1474
   Lu KT, 2006, J AGR FOOD CHEM, V54, P3126, DOI 10.1021/JF053011Q
   Lu KT, 2008, J AGR FOOD CHEM, V56, P6910, DOI 10.1021/jf8007212
   Macarulla MT, 2009, J PHYSIOL BIOCHEM, V65, P369, DOI 10.1007/BF03185932
   Martin AR, 2006, BRIT J PHARMACOL, V147, P873, DOI 10.1038/sj.bjp.0706469
   Meng XF, 2004, J AGR FOOD CHEM, V52, P935, DOI 10.1021/jf030582e
   Miatello R, 2005, AM J HYPERTENS, V18, P864, DOI 10.1016/j.amjhyper.2004.12.012
   Milne JC, 2007, NATURE, V450, P712, DOI 10.1038/nature06261
   Mokni M, 2007, NEUROCHEM RES, V32, P981, DOI 10.1007/s11064-006-9255-z
   Narayanan NK, 2009, INT J CANCER, V125, P1, DOI 10.1002/ijc.24336
   Niles RM, 2006, J NUTR, V136, P2542
   Oomen CA, 2009, FRONT AGING NEUROSCI, V1, DOI 10.3389/neuro.24.004.2009
   Palsamy P, 2008, BIOMED PHARMACOTHER, V62, P598, DOI 10.1016/j.biopha.2008.06.037
   Palsamy P, 2010, J CELL PHYSIOL, V224, P423, DOI 10.1002/jcp.22138
   Patel KR, 2010, CANCER RES, V70, P7392, DOI 10.1158/0008-5472.CAN-10-2027
   Provinciali M, 2005, INT J CANCER, V115, P36, DOI 10.1002/ijc.20874
   Ramadori G, 2009, ENDOCRINOLOGY, V150, P5326, DOI 10.1210/en.2009-0528
   Ranney A, 2009, BEHAV PHARMACOL, V20, P330, DOI 10.1097/FBP.0b013e32832f0193
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Rivera L, 2009, BIOCHEM PHARMACOL, V77, P1053, DOI 10.1016/j.bcp.2008.11.027
   Robb EL, 2008, BIOCHEM BIOPH RES CO, V372, P254, DOI 10.1016/j.bbrc.2008.05.028
   Robich MP, 2010, CIRCULATION, V122, pS142, DOI 10.1161/CIRCULATIONAHA.109.920132
   Rocha KKR, 2009, FOOD CHEM TOXICOL, V47, P1362, DOI 10.1016/j.fct.2009.03.010
   Roy P, 2009, PHARM RES-DORDR, V26, P211, DOI 10.1007/s11095-008-9723-z
   Sakata Y, 2010, EXP NEUROL, V224, P325, DOI 10.1016/j.expneurol.2010.03.032
   Sale S, 2005, INT J CANCER, V115, P194, DOI 10.1002/ijc.20884
   Saleh MC, 2010, NEUROSCIENCE, V166, P445, DOI 10.1016/j.neuroscience.2009.12.060
   Sanchez-Fidalgo S, 2010, EUR J PHARMACOL, V633, P78, DOI 10.1016/j.ejphar.2010.01.025
   Sato M, 2003, CANCER LETT, V202, P137, DOI 10.1016/j.canlet.2003.08.016
   Schmatz R, 2009, BRAIN RES BULL, V80, P371, DOI 10.1016/j.brainresbull.2009.08.019
   Schneider Y, 2001, NUTR CANCER, V39, P102, DOI 10.1207/S15327914nc391_14
   Seeni A, 2008, ASIAN PAC J CANCER P, V9, P7
   Sener G, 2007, PULM PHARMACOL THER, V20, P642, DOI 10.1016/j.pupt.2006.07.003
   Sengottuvelan M, 2006, BRIT J NUTR, V96, P145, DOI 10.1079/BJN20061789
   Sengottuvelan M, 2009, NUTRITION, V25, P1169, DOI 10.1016/j.nut.2009.03.009
   Shang J, 2008, ACTA PHARMACOL SIN, V29, P698, DOI 10.1111/j.1745-7254.2008.00807.x
   Sharma S, 2007, PHYTOTHER RES, V21, P278, DOI 10.1002/ptr.2070
   Singh UP, 2010, J PHARMACOL EXP THER, V332, P829, DOI 10.1124/jpet.109.160838
   Singleton RH, 2010, J NEUROTRAUM, V27, P1091, DOI 10.1089/neu.2010.1291
   Sinha K, 2002, LIFE SCI, V71, P655, DOI 10.1016/S0024-3205(02)01691-0
   Soleas GJ, 2002, CLIN BIOCHEM, V35, P119, DOI 10.1016/S0009-9120(02)00275-8
   Soleas GJ, 2001, J CHROMATOGR B, V757, P161, DOI 10.1016/S0378-4347(01)00142-6
   Sonmez U, 2007, NEUROSCI LETT, V420, P133, DOI 10.1016/j.neulet.2007.04.070
   Stervbo U, 2007, FOOD CHEM, V101, P449, DOI 10.1016/j.foodchem.2006.01.047
   Sutra T, 2008, J AGR FOOD CHEM, V56, P11683, DOI 10.1021/jf802357g
   Tessitore L, 2000, CARCINOGENESIS, V21, P1619, DOI 10.1093/carcin/21.8.1619
   Thandapilly SJ, 2010, AM J HYPERTENS, V23, P192, DOI 10.1038/ajh.2009.228
   Thirunavukkarasu M, 2007, FREE RADICAL BIO MED, V43, P720, DOI 10.1016/j.freeradbiomed.2007.05.004
   Tsai SK, 2007, J VASC SURG, V46, P346, DOI 10.1016/j.jvs.2007.04.044
   Tunali-Akbay T, 2010, J PHARM PHARM SCI, V13, P303, DOI 10.18433/J30K5Q
   Um JH, 2010, DIABETES, V59, P554, DOI 10.2337/db09-0482
   Vaz-Da-Silva M, 2008, INT J CLIN PHARM TH, V46, P564
   Vazquez-Agell M, 2007, J NUTR, V137, P2279
   Vitaglione P, 2005, MOL NUTR FOOD RES, V49, P495, DOI 10.1002/mnfr.200500002
   Walle T, 2004, DRUG METAB DISPOS, V32, P1377, DOI 10.1124/dmd.104.000885
   Wang Q, 2004, NEUROCHEM RES, V29, P2105, DOI 10.1007/s11064-004-6883-z
   Wang TTY, 2008, CARCINOGENESIS, V29, P2001, DOI 10.1093/carcin/bgn131
   Watzl B, 2004, EUR J CLIN NUTR, V58, P40, DOI 10.1038/sj.ejcn.1601742
   Watzl B, 2002, EUR J NUTR, V41, P264, DOI 10.1007/s00394-002-0384-0
   Whitsett Timothy, 2006, J Carcinog, V5, P15, DOI 10.1186/1477-3163-5-15
   Williams LD, 2009, FOOD CHEM TOXICOL, V47, P2170, DOI 10.1016/j.fct.2009.06.002
   Wojciechowski P, 2010, J NUTR, V140, P962, DOI 10.3945/jn.109.115006
   Wong RHX, 2011, NUTR METAB CARDIOVAS, V21, P851, DOI 10.1016/j.numecd.2010.03.003
   Wong YT, 2009, FREE RADICAL BIO MED, V46, P799, DOI 10.1016/j.freeradbiomed.2008.12.016
   Woodall CE, 2009, ANTI-CANCER DRUG, V20, P437, DOI 10.1097/CAD.0b013e32832afb95
   Wu Z, 2009, NEUROCHEM RES, V34, P1393, DOI 10.1007/s11064-009-9920-0
   Wyke SM, 2004, BRIT J CANCER, V91, P1742, DOI 10.1038/sj.bjc.6602165
   Yang DL, 2010, CLIN EXP PHARMACOL P, V37, P150, DOI 10.1111/j.1440-1681.2009.05231.x
   Yang YB, 2003, ACTA PHARMACOL SIN, V24, P703
   Yao J, 2010, ARCH MED RES, V41, P288, DOI 10.1016/j.arcmed.2010.05.002
   Yousuf S, 2009, BRAIN RES, V1250, P242, DOI 10.1016/j.brainres.2008.10.068
   Yu L, 2003, WORLD J GASTROENTERO, V9, P2341
   Yusuf N, 2009, MOL CARCINOGEN, V48, P713, DOI 10.1002/mc.20517
   Zamora-Ros R, 2006, CLIN CHEM, V52, P1373, DOI 10.1373/clinchem.2005.065870
   Zhang HR, 2010, AM J PHYSIOL-HEART C, V299, pH985, DOI 10.1152/ajpheart.00489.2010
   Zhou HB, 2005, WORLD J GASTROENTERO, V11, P280, DOI 10.3748/wjg.v11.i2.280
   Ziegler CC, 2004, J NUTR, V134, P5
NR 144
TC 263
Z9 272
U1 1
U2 111
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 16
PY 2011
VL 6
IS 6
AR e19881
DI 10.1371/journal.pone.0019881
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 778UW
UT WOS:000291734100003
PM 21698226
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Idelevich, A
   Kerschnitzki, M
   Shahar, R
   Monsonego-Ornan, E
AF Idelevich, Anna
   Kerschnitzki, Michael
   Shahar, Ron
   Monsonego-Ornan, Efrat
TI 1,25(OH)(2)D-3 Alters Growth Plate Maturation and Bone Architecture in
   Young Rats with Normal Renal Function
SO PLOS ONE
LA English
DT Article
ID VITAMIN-D-RECEPTOR; INTERMITTENT CALCITRIOL THERAPY; MINERAL ION
   HOMEOSTASIS; CHRONIC KIDNEY-DISEASE; SECONDARY HYPERPARATHYROIDISM;
   1,25-DIHYDROXYVITAMIN D-3; VASCULAR CALCIFICATION; BIOMECHANICAL
   ANALYSES; NULL MICE; CHONDROCYTES
AB Whereas detrimental effects of vitamin D deficiency are known over century, the effects of vitamin D receptor activation by 1,25(OH)(2)D-3, the principal hormonal form of vitamin D, on the growing bone and its growth plate are less clear. Currently, 1,25(OH)(2)D-3 is used in pediatric patients with chronic kidney disease and mineral and bone disorder (CKD-MBD) and is strongly associated with growth retardation. Here, we investigate the effect of 1,25(OH)(2)D-3 treatment on bone development in normal young rats, unrelated to renal insufficiency. Young rats received daily i.p. injections of 1 mu g/kg 1,25(OH)(2)D-3 for one week, or intermittent 3 mu g/kg 1,25(OH)(2)D-3 for one month. Histological analysis revealed narrower tibial growth plates, predominantly in the hypertrophic zone of 1,25(OH)(2)D-3-treated animals in both experimental protocols. This phenotype was supported by narrower distribution of aggrecan, collagens II and X mRNA, shown by in situ hybridization. Concomitant with altered chondrocyte maturation, 1,25(OH)(2)D-3 increased chondrocyte proliferation and apoptosis in terminal hypertrophic cells. In vitro treatment of the chondrocytic cell line ATDC5 with 1,25(OH)(2)D-3 lowered differentiation and increased proliferation dose and time-dependently. Micro-CT analysis of femurs from 1-week 1,25(OH)(2)D-3-treated group revealed reduced cortical thickness, elevated cortical porosity, and higher trabecular number and thickness. 1-month administration resulted in a similar cortical phenotype but without effect on trabecular bone. Evaluation of fluorochrome binding with confocal microscopy revealed inhibiting effects of 1,25(OH)(2)D-3 on intracortical bone formation. This study shows negative effects of 1,25(OH)(2)D-3 on growth plate and bone which may contribute to the exacerbation of MBD in the CKD pediatric patients.
C1 [Idelevich, Anna; Monsonego-Ornan, Efrat] Hebrew Univ Jerusalem, Inst Biochem Food Sci & Nutr, IL-76100 Rehovot, Israel.
   [Shahar, Ron] Hebrew Univ Jerusalem, Koret Sch Vet Med, Robert H Smith Fac Agr Food & Environm, IL-76100 Rehovot, Israel.
   [Kerschnitzki, Michael] Max Planck Inst Colloids & Interfaces, Dept Biomat, Potsdam, Germany.
RP Idelevich, A (reprint author), Hebrew Univ Jerusalem, Inst Biochem Food Sci & Nutr, IL-76100 Rehovot, Israel.
EM ornanme@agri.huji.ac.il
FU Israel Science Foundation [292/07]; Bundesministerium fur Bildung und
   Forschung (BMBF) [01 EC 1006C, 9133]; DFG through the Berlin-Brandenburg
   School for Regenerative Therapies (BSRT) [GSC 203]
FX This research was supported by The Israel Science Foundation (grant no.
   292/07). M.K. is funded by Bundesministerium fur Bildung und Forschung
   (BMBF, Grant-number: 01 EC 1006C, project 9133) and by DFG funding
   through the Berlin-Brandenburg School for Regenerative Therapies (BSRT)
   GSC 203. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Amling M, 1999, ENDOCRINOLOGY, V140, P4982, DOI 10.1210/en.140.11.4982
   Anderson PH, 2008, MOL ASPECTS MED, V29, P397, DOI 10.1016/j.mam.2008.05.003
   Ben-Zvi T, 2006, J CELL SCI, V119, P380, DOI 10.1242/jcs.02740
   Bouillon R, 2008, ENDOCR REV, V29, P726, DOI 10.1210/er.2008-0004
   Challa TD, 2010, MOL CELL ENDOCRINOL, V323, P282, DOI 10.1016/j.mce.2010.03.025
   Dardenne O, 2003, J BONE MINER RES, V18, P637, DOI 10.1359/jbmr.2003.18.4.637
   Dardenne O, 2003, BONE, V32, P332, DOI 10.1016/S8756-3282(03)00023-1
   Donohue MM, 2002, ENDOCRINOLOGY, V143, P3691, DOI 10.1210/en.2002-220454
   Dusso AS, 2005, AM J PHYSIOL-RENAL, V289, pF8, DOI 10.1152/ajprenal.00336.2004
   Erben RG, 1997, ENDOCRINOLOGY, V138, P4629, DOI 10.1210/en.138.11.4629
   Finch JL, 2010, AM J PHYSIOL-RENAL, V298, pF1315, DOI 10.1152/ajprenal.00552.2009
   GOODMAN WG, 1994, KIDNEY INT, V46, P1160, DOI 10.1038/ki.1994.380
   HIGH WB, 1981, AM J PATHOL, V104, P41
   Hopper TAJ, 2007, J COMPUT ASSIST TOMO, V31, P320, DOI 10.1097/01.rct.0000238007.19258.3d
   Karsenty G, 2009, ANNU REV CELL DEV BI, V25, P629, DOI 10.1146/annurev.cellbio.042308.113308
   Kuizon BD, 1998, KIDNEY INT, V53, P205, DOI 10.1046/j.1523-1755.1998.00724.x
   Li YC, 1997, P NATL ACAD SCI USA, V94, P9831, DOI 10.1073/pnas.94.18.9831
   London GM, 2008, J AM SOC NEPHROL, V19, P1827, DOI 10.1681/ASN.2007050622
   Masuyama R, 2006, J CLIN INVEST, V116, P3150, DOI 10.1172/JCI29463
   Mizobuchi M, 2007, KIDNEY INT, V72, P709, DOI 10.1038/sj.ki.5002406
   Naja RP, 2009, ENDOCRINOLOGY, V150, P4024, DOI 10.1210/en.2008-1410
   Nilsson O, 2005, HORM RES, V64, P157, DOI 10.1159/000088791
   Panda DK, 2004, J BIOL CHEM, V279, P16754, DOI 10.1074/jbc.M310271200
   QUERFELD U, 2010, PEDIAT NEPHROL
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Reich A, 2005, J APPL PHYSIOL, V98, P2381, DOI 10.1152/japplphysiol.01073.2004
   Reich A, 2008, BONE, V43, P766, DOI 10.1016/j.bone.2008.06.004
   Reich A, 2010, J APPL PHYSIOL, V108, P172, DOI 10.1152/japplphysiol.00821.2009
   Salusky IB, 1998, KIDNEY INT, V54, P907, DOI 10.1046/j.1523-1755.1998.00045.x
   Sanchez CP, 2007, KIDNEY INT, V72, P582, DOI 10.1038/sj.ki.5002375
   Sanchez CP, 2008, REV ENDOCR METAB DIS, V9, P131, DOI 10.1007/s11154-007-9071-z
   Sanchez CP, 2010, PEDIATR NEPHROL, V25, P643, DOI 10.1007/s00467-009-1307-6
   Sanchez CP, 2003, J AM SOC NEPHROL, V14, P148, DOI 10.1097/01.ASN.0000039565.56011.BE
   SANDELL LJ, 1994, J ORTHOP RES, V12, P1, DOI 10.1002/jor.1100120102
   Schoenau E, 2004, HORM RES, V61, P257, DOI 10.1159/000076635
   Shapiro F, 2008, EUR CELLS MATER, V15, P53, DOI 10.22203/eCM.v015a05
   Simsa S, 2007, J ANIM SCI, V85, P1393, DOI 10.2527/jas.2006-711
   Simsa S, 2007, AM J PHYSIOL-REG I, V292, pR2216, DOI 10.1152/ajpregu.00864.2006
   Suda T, 2003, J CELL BIOCHEM, V88, P259, DOI 10.1002/jcb.10331
   Takasu H, 2006, J CLIN INVEST, V116, P528, DOI 10.1172/JCI24742
   Tanaka H, 2004, J STEROID BIOCHEM, V89-90, P343, DOI 10.1016/j.jsbmb.2004.03.021
   Wesseling K, 2008, PEDIATR NEPHROL, V23, P195, DOI 10.1007/s00467-007-0671-3
   WRONSKI TJ, 1986, ENDOCRINOLOGY, V119, P2580, DOI 10.1210/endo-119-6-2580
   Xue YB, 2006, ENDOCRINOLOGY, V147, P4801, DOI 10.1210/en.2006-0403
   Zittermann A, 2008, MOL ASPECTS MED, V29, P423, DOI 10.1016/j.mam.2008.04.002
NR 45
TC 14
Z9 14
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 13
PY 2011
VL 6
IS 6
AR e20772
DI 10.1371/journal.pone.0020772
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 777ZG
UT WOS:000291663300020
PM 21695192
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Pramanik, KC
   Boreddy, SR
   Srivastava, SK
AF Pramanik, Kartick C.
   Boreddy, Srinivas Reddy
   Srivastava, Sanjay K.
TI Role of Mitochondrial Electron Transport Chain Complexes in Capsaicin
   Mediated Oxidative Stress Leading to Apoptosis in Pancreatic Cancer
   Cells
SO PLOS ONE
LA English
DT Article
ID BENZYL ISOTHIOCYANATE; CYCLE ARREST; GASTRIC-CANCER; IN-VITRO;
   INDUCTION; ACTIVATION; GENERATION; PEPPER; DEATH; CHILI
AB We evaluated the mechanism of capsaicin-mediated ROS generation in pancreatic cancer cells. The generation of ROS was about 4-6 fold more as compared to control and as early as 1 h after capsaicin treatment in BxPC-3 and AsPC-1 cells but not in normal HPDE-6 cells. The generation of ROS was inhibited by catalase and EUK-134. To delineate the mechanism of ROS generation, enzymatic activities of mitochondrial complex-I and complex-III were determined in the pure mitochondria. Our results shows that capsaicin inhibits about 2.5-9% and 5-20% of complex-I activity and 8-75% of complex-III activity in BxPC-3 and AsPC-1 cells respectively, which was attenuable by SOD, catalase and EUK-134. On the other hand, capsaicin treatment failed to inhibit complex-I or complex-III activities in normal HPDE-6 cells. The ATP levels were drastically suppressed by capsaicin treatment in both BxPC-3 and AsPC-1 cells and attenuated by catalase or EUK-134. Oxidation of mitochondria-specific cardiolipin was substantially higher in capsaicin treated cells. BxPC-3 derived rho(o) cells, which lack mitochondrial DNA, were completely resistant to capsaicin mediated ROS generation and apoptosis. Our results reveal that the release of cytochrome c and cleavage of both caspase-9 and caspase-3 due to disruption of mitochondrial membrane potential were significantly blocked by catalase and EUK-134 in BxPC-3 cells. Our results further demonstrate that capsaicin treatment not only inhibit the enzymatic activity and expression of SOD, catalase and glutathione peroxidase but also reduce glutathione level. Over-expression of catalase by transient transfection protected the cells from capsaicin-mediated ROS generation and apoptosis. Furthermore, tumors from mice orally fed with 2.5 mg/kg capsaicin show decreased SOD activity and an increase in GSSG/GSH levels as compared to controls. Taken together, our results suggest the involvement of mitochondrial complex-I and III in capsaicin-mediated ROS generation and decrease in antioxidant levels resulting in severe mitochondrial damage leading to apoptosis in pancreatic cancer cells.
C1 [Pramanik, Kartick C.] Texas Tech Univ, Hlth Sci Ctr, Dept Biomed Sci, Sch Pharm, Amarillo, TX USA.
   Texas Tech Univ, Hlth Sci Ctr, Canc Biol Ctr, Sch Pharm, Amarillo, TX USA.
RP Pramanik, KC (reprint author), Texas Tech Univ, Hlth Sci Ctr, Dept Biomed Sci, Sch Pharm, Amarillo, TX USA.
EM sanjay.srivastava@ttuhsc.edu
FU National Cancer Institute, National Institutes of Health [R01 CA129038,
   R01 CA106953]
FX This work was supported by the National Cancer Institute, National
   Institutes of Health R01 CA129038; R01 CA106953. The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Athanasiou A, 2007, BIOCHEM BIOPH RES CO, V354, P50, DOI 10.1016/j.bbrc.2006.12.179
   Bhutani M, 2007, CLIN CANCER RES, V13, P3024, DOI 10.1158/1078-0432.CCR-06-2575
   BLOCK G, 1992, NUTR CANCER, V18, P1, DOI 10.1080/01635589209514201
   Boreddy SR, 2011, CLIN CANCER RES, V17, P1784, DOI 10.1158/1078-0432.CCR-10-1891
   BUIATTI E, 1989, INT J CANCER, V44, P611, DOI 10.1002/ijc.2910440409
   BUSCH SHB, 1983, TRENDS PHARMACOL SCI, V4, P4
   CERINIC MM, 1995, J RHEUMATOL, V22, P1447
   CHUNGMAN HJ, 2001, CANCER RES, V61, P8578
   CORDELL GA, 1993, ANN PHARMACOTHER, V27, P330, DOI 10.1177/106002809302700316
   GOVINDARAJAN VS, 1991, CRIT REV FOOD SCI, V29, P435, DOI 10.1080/10408399109527536
   Hail N, 2002, JNCI-J NATL CANCER I, V94, P1281
   Hail N, 2001, CANCER RES, V61, P6698
   Hartel M, 2006, GUT, V55, P519, DOI 10.1136/gut.2005.073205
   Hatefi Y, 1978, Methods Enzymol, V53, P21
   HOLZER P, 1991, PHARMACOL REV, V43, P143
   Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140
   Ito K, 2004, CANCER RES, V64, P1071, DOI 10.1158/0008-5472.CAN-03-1670
   Jemal A, 2010, CA CANC J CLIN
   Jung MY, 2001, CANCER LETT, V165, P139, DOI 10.1016/S0304-3835(01)00426-8
   Kandala PK, 2010, MOL PHARMACOL, V78, P297, DOI 10.1124/mol.110.063750
   Kang HJ, 2003, INT J CANCER, V103, P475, DOI 10.1002/ijc.10855
   KANG JY, 1995, DIGEST DIS SCI, V40, P576, DOI 10.1007/BF02064373
   KELSEN D, 1994, SEMIN ONCOL, V21, P58
   Kim CS, 2004, J MED FOOD, V7, P267, DOI 10.1089/jmf.2004.7.267
   King M P, 1996, Methods Enzymol, V264, P313, DOI 10.1016/S0076-6879(96)64030-0
   Lee YS, 2004, FREE RADICAL RES, V38, P405, DOI 10.1080/10715760410001665262
   Lo YC, 2005, WORLD J GASTROENTERO, V11, P6254, DOI 10.3748/wjg.v11.i40.6254
   LOPEZCARRILLO L, 1994, AM J EPIDEMIOL, V139, P263, DOI 10.1093/oxfordjournals.aje.a116993
   Min JK, 2004, CANCER RES, V64, P644, DOI 10.1158/0008-5472.CAN-03-3250
   MONSEREENUSORN Y, 1983, RES COMMUN CHEM PATH, V41, P95
   Mori A, 2006, CANCER RES, V66, P3222, DOI 10.1158/0008-5472.CAN-05-0087
   Mozsik G, 2005, WORLD J GASTROENTERO, V11, P5180
   Nomura K, 2000, BIOCHEM J, V351, P183, DOI 10.1042/0264-6021:3510183
   RAGAN CI, 1987, SUBFRACTIONATION MIT, P79
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Sahu RP, 2009, CARCINOGENESIS, V30, P1744, DOI 10.1093/carcin/bgp157
   Sahu RP, 2009, JNCI-J NATL CANCER I, V101, P176, DOI 10.1093/jnci/djn470
   Sanchez AM, 2006, APOPTOSIS, V11, P89, DOI 10.1007/s10495-005-3275-z
   Sathyanarayana MN, 2006, CRIT REV FOOD SCI, V46, P275, DOI 10.1080/1040-830491379236
   SICUTERI F, 1989, CLIN J PAIN, V5, P49, DOI 10.1097/00002508-198903000-00010
   Surh YJ, 1998, MUTAT RES-FUND MOL M, V402, P259, DOI 10.1016/S0027-5107(97)00305-9
   Surh YJ, 2002, J NATL CANCER I, V94, P1263
   SUZUKI T, 1994, CONSTITUTION RED PEP, P227
   TAUSSKY HH, 1953, J BIOL CHEM, V202, P675
   Thoennissen NH, 2010, ONCOGENE, V29, P285, DOI 10.1038/onc.2009.335
   Toogood PL, 2008, CURR OPIN CHEM BIOL, V12, P457, DOI 10.1016/j.cbpa.2008.06.002
   Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009
   WATSON CPN, 1988, PAIN, V33, P333, DOI 10.1016/0304-3959(88)90292-8
   Wen JJ, 2010, ANTIOXID REDOX SIGN, V12, P27, DOI [10.1089/ars.2008.2418, 10.1089/ARS.2008.2418]
   Wharton D C, 1978, Methods Enzymol, V53, P646
   Xiao D, 2008, J BIOL CHEM, V283, P30151, DOI 10.1074/jbc.M802529200
   Yun TK, 1999, ANN NY ACAD SCI, V889, P157, DOI 10.1111/j.1749-6632.1999.tb08734.x
   Zhang R, 2008, APOPTOSIS, V13, P1465, DOI 10.1007/s10495-008-0278-6
NR 53
TC 96
Z9 102
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 25
PY 2011
VL 6
IS 5
AR e20151
DI 10.1371/journal.pone.0020151
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 769IQ
UT WOS:000291006500031
PM 21647434
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Liang, YJ
   Luo, J
   Yuan, Q
   Zheng, D
   Liu, YP
   Shi, L
   Zhou, Y
   Chen, AL
   Ren, YY
   Sun, KY
   Sun, Y
   Wang, Y
   Zhang, ZS
AF Liang, Yue-Jin
   Luo, Jie
   Yuan, Quan
   Zheng, Dan
   Liu, Ya-Ping
   Shi, Lei
   Zhou, Ying
   Chen, Ai-Ling
   Ren, Yong-Ya
   Sun, Ke-Yi
   Sun, Yan
   Wang, Yong
   Zhang, Zhao-Song
TI New Insight into the Antifibrotic Effects of Praziquantel on Mice in
   Infection with Schistosoma japonicum
SO PLOS ONE
LA English
DT Article
ID HEPATIC STELLATE CELLS; LIVER FIBROSIS; MURINE SCHISTOSOMIASIS; MATRIX
   METALLOPROTEINASES; TH2 CYTOKINES; RAT-LIVER; IN-VITRO; MANSONI;
   ACTIVATION; EXPRESSION
AB Background: Schistosomiasis is a parasitic disease infecting more than 200 million people in the world. Although chemotherapy targeting on killing schistosomes is one of the main strategies in the disease control, there are few effective ways of dealing with liver fibrosis caused by the parasite infection in the chronic and advanced stages of schistosomiasis. For this reason, new strategies and prospective drugs, which exert antifibrotic effects, are urgently required.
   Methods and Findings: The antifibrotic effects of praziquantel were assessed in the murine models of schistosomiasis japonica. Murine fibrosis models were established by cutaneous infection with 14 +/- 2 Schistosoma japonicum cercariae. Then, the mice of both chronic (8 weeks post-infection) and advanced (15 weeks post-infection) schistosomiasis were treated by gavage of praziquantel (250 mg/kg, once daily for 3 days) to eliminate worms, and followed by praziquantel anti-fibrosis treatment (300 mg/kg, twice daily for 30 days). The fibrosis-related parameters assessed were areas of collagen deposition, content of hydroxyproline and mRNA expressions of Col1 alpha 1, Col3 alpha 1, alpha-SMA, TGF-beta, MMP9, TIMP1, IL-4, IL-10, IL-13 and IFN-gamma of liver. Spleen weight index, alanine aminotransferase activity and liver portal venous pressure were also measured. The results showed that anti-fibrosis treatment improved liver fibrosis, splenomegaly, hepatic function, as well as liver portal hypertension. In order to confirm the anti-fibrotic properties of praziquantel, we established a CCL(4)-induced model and revealed that CCL(4)-induced liver fibrosis was inhibited by PZQ treatment for 30 days. Furthermore, we analyzed the effects of praziquantel on mouse primary hepatic stellate cells (HSCs). It is indicated that mRNA expressions of Col1 alpha 1, Col3 alpha 1, alpha-SMA, TGF-beta, MMP9 and TIMP1 of HSCs were all inhibited after praziquantel anti-parasite treatments.
   Conclusions: The significant amelioration of hepatic fibrosis by praziquantel treatment validates it as a promising drug of anti-fibrosis and offers potential of a new chemotherapy for hepatic fibrosis resulting from schistosomiasis.
C1 [Liang, Yue-Jin; Luo, Jie; Yuan, Quan; Zheng, Dan; Liu, Ya-Ping; Shi, Lei; Zhou, Ying; Chen, Ai-Ling; Sun, Yan; Wang, Yong; Zhang, Zhao-Song] Nanjing Med Univ, Key Lab Pathogen Biol Jiangsu Prov, Dept Pathogen Biol, Nanjing, Jiangsu, Peoples R China.
   [Ren, Yong-Ya] Nanjing Med Univ, Dept Pathol, Nanjing, Jiangsu, Peoples R China.
   [Sun, Ke-Yi] Nanjing Med Univ, Dept Microbiol & Immunol, Nanjing, Jiangsu, Peoples R China.
RP Liang, YJ (reprint author), Nanjing Med Univ, Key Lab Pathogen Biol Jiangsu Prov, Dept Pathogen Biol, Nanjing, Jiangsu, Peoples R China.
EM yongwsh@njmu.edu.cn
OI Liang, Yuejin/0000-0002-9557-1847
FU National Basic Research Program of China (973 Program) [2007CB513102]
FX This work was supported by National Basic Research Program of China (973
   Program) (No. 2007CB513102). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Abdul-Ghani RA, 2010, PARASITOL RES, V107, P1, DOI 10.1007/s00436-010-1855-5
   Andersson Karin L, 2007, Curr Treat Options Gastroenterol, V10, P504, DOI 10.1007/s11938-007-0050-y
   Andrade ZA, 2008, ACTA TROP, V108, P79, DOI 10.1016/j.actatropica.2008.04.003
   Arnaud V, 2008, J INFECT DIS, V198, P418, DOI 10.1086/588826
   Arthur MJP, 1998, J GASTROEN HEPATOL, V13, pS33
   Bachem MG, 1998, GASTROENTEROLOGY, V115, P421, DOI 10.1016/S0016-5085(98)70209-4
   Bartley PB, 2006, INT J PARASITOL, V36, P993, DOI 10.1016/j.ijpara.2006.04.015
   Berhe N, 2008, AM J TROP MED HYG, V78, P228, DOI 10.4269/ajtmh.2008.78.228
   BIEMPICA L, 1983, AM J TROP MED HYG, V32, P316, DOI 10.4269/ajtmh.1983.32.316
   BREITKOPF K, 2005, ALCOHOL CLIN EXP RES, V29, P121
   Burke ML, 2009, PARASITE IMMUNOL, V31, P163, DOI 10.1111/j.1365-3024.2009.01098.x
   Carpino G, 2005, DIGEST LIVER DIS, V37, P349, DOI 10.1016/j.dld.2004.11.009
   CHEEVER AW, 1994, J IMMUNOL, V153, P753
   Cheever AW, 1997, MEM I OSWALDO CRUZ, V92, P689, DOI 10.1590/S0074-02761997000500024
   CHRISTIAN J, 2010, GUT, P827
   Chu D, 2007, PARASITOLOGY, V134, P1611, DOI 10.1017/S0031182007002946
   Constandinou C, 2005, METH MOLEC MED, V117, P237
   Cortez-Pinto H, 2001, HEPATO-GASTROENTEROL, V48, P87
   Coutinho HM, 2007, J INFECT DIS, V195, P288, DOI 10.1086/510313
   DUNN MA, 1977, J CLIN INVEST, V59, P666, DOI 10.1172/JCI108685
   Fenwick A, 2003, TRENDS PARASITOL, V19, P509, DOI 10.1016/j.pt.2003.09.005
   Fichtner-Feigl S, 2006, NAT MED, V12, P99, DOI 10.1038/nm1332
   Freitas CRL, 1999, MEM I OSWALDO CRUZ, V94, P815, DOI 10.1590/S0074-02761999000600019
   Frenzel K, 1999, AM J TROP MED HYG, V60, P927, DOI 10.4269/ajtmh.1999.60.927
   Friedman SL, 2008, GASTROENTEROLOGY, V134, P1655, DOI 10.1053/j.gastro.2008.03.003
   Friedman SL, 2008, PHYSIOL REV, V88, P125, DOI 10.1152/physrev.00013.2007
   Giannelli G, 2006, J INTERF CYTOK RES, V26, P301, DOI 10.1089/jir.2006.26.301
   Gomez DE, 1999, AM J TROP MED HYG, V61, P9, DOI 10.4269/ajtmh.1999.61.9
   Gonzalez-Forero D, 2004, J PHYSIOL-LONDON, V557, P991, DOI 10.1113/jphysiol.2003.059972
   Gryseels B, 2006, LANCET, V368, P1106, DOI 10.1016/S0140-6736(06)69440-3
   Han YP, 2004, J BIOL CHEM, V279, P4820, DOI 10.1074/jbc.M310999200
   Hemmann S, 2007, J HEPATOL, V46, P955, DOI 10.1016/j.jhep.2007.02.003
   Henderson NC, 2006, P NATL ACAD SCI USA, V103, P5060, DOI 10.1073/pnas.0511167103
   HOMEIDA MA, 1991, AM J TROP MED HYG, V45, P360, DOI 10.4269/ajtmh.1991.45.360
   Huang XR, 2008, AM J PHYSIOL-RENAL, V295, pF118, DOI 10.1152/ajprenal.00021.2008
   Jacobs W, 1998, CELL TISSUE RES, V292, P101, DOI 10.1007/s004410051039
   Kaplan MH, 1998, J IMMUNOL, V160, P1850
   Kaviratne M, 2004, J IMMUNOL, V173, P4020, DOI 10.4049/jimmunol.173.6.4020
   Knittel T, 1999, J HEPATOL, V30, P48, DOI 10.1016/S0168-8278(99)80007-5
   Maia MD, 2007, ACTA TROP, V101, P183, DOI 10.1016/j.actatropica.2007.01.004
   Mendias CL, 2008, P NATL ACAD SCI USA, V105, P388, DOI 10.1073/pnas.0707069105
   MORCOS SH, 1985, AM J TROP MED HYG, V34, P314, DOI 10.4269/ajtmh.1985.34.314
   Moreno M, 2010, HEPATOLOGY, V51, P942, DOI 10.1002/hep.23419
   Nagase Y, 2009, J BIOL CHEM, V284, P36659, DOI 10.1074/jbc.M109.016915
   Olds G. Richard, 2001, Curr Infect Dis Rep, V3, P59, DOI 10.1007/s11908-001-0060-1
   Parsons CJ, 2007, J GASTROEN HEPATOL, V22, pS79, DOI 10.1111/j.1440-1746.2006.04659.x
   Peterson TC, 1998, BIOCHEM PHARMACOL, V55, P703, DOI 10.1016/S0006-2952(97)00593-5
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Pinlaor S, 2006, INT J CANCER, V119, P1067, DOI 10.1002/ijc.21893
   Rakotonirina E J, 2010, Sante, V20, P15, DOI 10.1684/san.2009.0175
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Reynaert H, 2002, GUT, V50, P571, DOI 10.1136/gut.50.4.571
   Roderfeld M, 2006, FASEB J, V20, P444, DOI 10.1096/fj.05-4828com
   Ross AGP, 1997, PARASITOL TODAY, V13, P152, DOI 10.1016/S0169-4758(97)01026-0
   Seki E, 2007, NAT MED, V13, P1324, DOI 10.1038/nm1663
   Shimizu I, 1999, GUT, V44, P127, DOI 10.1136/gut.44.1.127
   STELMA FF, 1995, AM J TROP MED HYG, V53, P167, DOI 10.4269/ajtmh.1995.53.167
   Takemura Y, 1998, AM J TROP MED HYG, V59, P551, DOI 10.4269/ajtmh.1998.59.551
   Tao FF, 2009, VACCINE, V27, P4110, DOI 10.1016/j.vaccine.2009.04.073
   Tomanovic NR, 2009, J GASTROINTEST LIVER, V18, P163
   Watson M, 2009, J EXOT PET MED, V18, P229, DOI 10.1053/j.jepm.2009.06.005
   Weiskirchen R, 2005, METH MOLEC MED, V117, P99
   WHO, 2002, WHOCDSCPEPVC20024
   Wu J, 2008, EXP BIOL MED, V233, P377, DOI 10.3181/0710-RM-269
   Xu YongLiang, 2007, Chinese Journal of Schistosomiasis Control, V19, P357
   Yue HY, 2010, GUT, V59, P236, DOI 10.1136/gut.2008.174904
   Zhang L, 2008, MICROBES INFECT, V10, P251, DOI 10.1016/j.micinf.2007.11.009
NR 67
TC 34
Z9 43
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 24
PY 2011
VL 6
IS 5
AR e20247
DI 10.1371/journal.pone.0020247
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 769IJ
UT WOS:000291005800035
PM 21629648
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Hegde, VL
   Nagarkatti, PS
   Nagarkatti, M
AF Hegde, Venkatesh L.
   Nagarkatti, Prakash S.
   Nagarkatti, Mitzi
TI Role of Myeloid-Derived Suppressor Cells in Amelioration of Experimental
   Autoimmune Hepatitis Following Activation of TRPV1 Receptors by
   Cannabidiol
SO PLOS ONE
LA English
DT Article
ID CONCANAVALIN-A-INJECTION; T-CELLS; CONSTITUENT CANNABIDIOL;
   MULTIPLE-SCLEROSIS; IMMUNE-RESPONSES; NEUROPATHIC PAIN; LIVER-INJURY;
   INFLAMMATION; MICE; IDENTIFICATION
AB Background: Myeloid-derived suppressor cells (MDSCs) are getting increased attention as one of the main regulatory cells of the immune system. They are induced at sites of inflammation and can potently suppress T cell functions. In the current study, we demonstrate how activation of TRPV1 vanilloid receptors can trigger MDSCs, which in turn, can inhibit inflammation and hepatitis.
   Methodology/Principal Findings: Polyclonal activation of T cells, following injection of concanavalin A (ConA), in C57BL/6 mice caused acute hepatitis, characterized by significant increase in aspartate transaminase (AST), induction of inflammatory cytokines, and infiltration of mononuclear cells in the liver, leading to severe liver injury. Administration of cannabidiol (CBD), a natural non-psychoactive cannabinoid, after ConA challenge, inhibited hepatitis in a dose-dependent manner, along with all of the associated inflammation markers. Phenotypic analysis of liver infiltrating cells showed that CBD-mediated suppression of hepatitis was associated with increased induction of arginase-expressing CD11b(+)Gr-1(+) MDSCs. Purified CBD-induced MDSCs could effectively suppress T cell proliferation in vitro in arginase-dependent manner. Furthermore, adoptive transfer of purified MDSCs into naive mice conferred significant protection from ConA-induced hepatitis. CBD failed to induce MDSCs and suppress hepatitis in the livers of vanilloid receptor-deficient mice (TRPV1(-/-)) thereby suggesting that CBD primarily acted via this receptor to induce MDSCs and suppress hepatitis. While MDSCs induced by CBD in liver consisted of granulocytic and monocytic subsets at a ratio of similar to 2:1, the monocytic MDSCs were more immunosuppressive compared to granulocytic MDSCs. The ability of CBD to induce MDSCs and suppress hepatitis was also demonstrable in Staphylococcal enterotoxin B-induced liver injury.
   Conclusions/Significance: This study demonstrates for the first time that MDSCs play a critical role in attenuating acute inflammation in the liver, and that agents such as CBD, which trigger MDSCs through activation of TRPV1 vanilloid receptors may constitute a novel therapeutic modality to treat inflammatory diseases.
C1 [Hegde, Venkatesh L.; Nagarkatti, Prakash S.; Nagarkatti, Mitzi] Univ S Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC 29208 USA.
RP Hegde, VL (reprint author), Univ S Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC 29208 USA.
EM mnagark@uscmed.sc.edu
RI Hegde, Venkatesh/E-8519-2014
OI Hegde, Venkatesh/0000-0002-0949-919X; Nagarkatti,
   Prakash/0000-0003-2663-0759
FU National Institutes of Health, USA [R01-DA016545, P01-AT003961]
FX The research was funded by National Institutes of Health, USA grant
   awards, R01-DA016545 and P01-AT003961 to MN and PSN. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Bisogno T, 2001, BRIT J PHARMACOL, V134, P845, DOI 10.1038/sj.bjp.0704327
   Bronte V, 2000, BLOOD, V96, P3838
   Bronte V, 2005, NAT REV IMMUNOL, V5, P641, DOI 10.1038/nri1668
   Bronte V, 2009, EUR J IMMUNOL, V39, P2670, DOI 10.1002/eji.200939892
   Chen DW, 2001, J IMMUNOL, V166, P5889, DOI 10.4049/jimmunol.166.10.5889
   CONSROE P, 1991, PHARMACOL BIOCHEM BE, V40, P701, DOI 10.1016/0091-3057(91)90386-G
   Costa B, 2004, BRIT J PHARMACOL, V143, P247, DOI 10.1038/sj.bjp.0705920
   Costa B, 2004, N-S ARCH PHARMACOL, V369, P294, DOI 10.1007/s00210-004-0871-3
   Costa B, 2007, EUR J PHARMACOL, V556, P75, DOI 10.1016/j.ejphar.2006.11.006
   Croxford JL, 2005, J NEUROIMMUNOL, V166, P3, DOI 10.1016/j.jneuroim.2005.04.023
   CUNHA JM, 1980, PHARMACOLOGY, V21, P175, DOI 10.1159/000137430
   Czaja AJ, 2002, HEPATOLOGY, V36, P479, DOI 10.1053/jhep.2002.34944
   De Wilde V, 2009, AM J TRANSPLANT, V9, P2034, DOI 10.1111/j.1600-6143.2009.02757.x
   Dugast AS, 2008, J IMMUNOL, V180, P7898, DOI 10.4049/jimmunol.180.12.7898
   EGGINK HF, 1982, CLIN EXP IMMUNOL, V50, P17
   Fushimi S, 2009, CLIN IMMUNOL, V133, P437, DOI 10.1016/j.clim.2009.08.015
   Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506
   GALANOS C, 1979, P NATL ACAD SCI USA, V76, P5939, DOI 10.1073/pnas.76.11.5939
   Greifenberg V, 2009, EUR J IMMUNOL, V39, P2865, DOI 10.1002/eji.200939486
   Haile LA, 2008, GASTROENTEROLOGY, V135, P871, DOI 10.1053/j.gastro.2008.06.032
   Hegde VL, 2008, MOL PHARMACOL, V74, P20, DOI 10.1124/mol.108.047035
   Hegde VL, 2010, EUR J IMMUNOL, V40, P3358, DOI 10.1002/eji.201040667
   Hong F, 2002, J CLIN INVEST, V110, P1503, DOI 10.1172/JC1200215841
   Jo D, 2005, NAT MED, V11, P892, DOI 10.1038/nm1269
   Knolle PA, 1996, HEPATOLOGY, V24, P824, DOI 10.1002/hep.510240413
   Li BF, 2006, HEPATOLOGY, V43, P1211, DOI 10.1002/hep.21174
   Liou GI, 2008, INVEST OPHTH VIS SCI, V49, P5526, DOI 10.1167/iovs.08-2196
   Luxon Bruce A, 2006, Curr Gastroenterol Rep, V8, P83, DOI 10.1007/s11894-006-0068-7
   Malfait AM, 2000, P NATL ACAD SCI USA, V97, P9561, DOI 10.1073/pnas.160105897
   Manns MP, 2006, HEPATOLOGY, V43, pS132, DOI 10.1002/hep.21059
   Mechoulam R, 2002, J CLIN PHARMACOL, V42, p11S, DOI 10.1177/0091270002238789
   Mechoulam R, 2002, CHEM PHYS LIPIDS, V121, P35, DOI 10.1016/S0009-3084(02)00144-5
   Mechoulam R, 2007, CHEM BIODIVERS, V4, P1678, DOI 10.1002/cbdv.200790147
   Mizuhara H, 1996, HEPATOLOGY, V23, P1608, DOI 10.1002/hep.510230643
   MIZUHARA H, 1994, J EXP MED, V179, P1529, DOI 10.1084/jem.179.5.1529
   Movahedi K, 2008, BLOOD, V111, P4233, DOI 10.1182/blood-2007-07-099226
   Nakaya M, 2009, J IMMUNOL, V183, P7047, DOI 10.4049/jimmunol.0900547
   Pan H, 2009, J PHARMACOL EXP THER, V328, P708, DOI 10.1124/jpet.108.147181
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Rog DJ, 2007, CLIN THER, V29, P2068, DOI 10.1016/j.clinthera.2007.09.013
   Rosenbaum T, 2004, J GEN PHYSIOL, V123, P53, DOI 10.1085/jgp.200308906
   Sander LE, 2010, J EXP MED, V207, P1453, DOI 10.1084/jem.20091474
   Satoh M, 1996, TOHOKU J EXP MED, V180, P139, DOI 10.1620/tjem.180.139
   Scuderi C, 2009, PHYTOTHER RES, V23, P597, DOI 10.1002/ptr.2625
   Showalter VM, 1996, J PHARMACOL EXP THER, V278, P989
   Sinha P, 2008, J IMMUNOL, V181, P4666, DOI 10.4049/jimmunol.181.7.4666
   Takeda K, 2000, P NATL ACAD SCI USA, V97, P5498, DOI 10.1073/pnas.040566697
   Tiegs G, 1997, ACTA GASTRO-ENT BELG, V60, P176
   TIEGS G, 1992, J CLIN INVEST, V90, P196, DOI 10.1172/JCI115836
   Tomihara K, 2010, J IMMUNOL, V184, P6151, DOI 10.4049/jimmunol.0903519
   Wade DT, 2004, MULT SCLER, V10, P434, DOI 10.1191/1352458504ms1082oa
   Wahl C, 2009, J IMMUNOL, V182, P4521, DOI 10.4049/jimmunol.0802810
   Youn JI, 2008, J IMMUNOL, V181, P5791, DOI 10.4049/jimmunol.181.8.5791
   Zuardi AW, 2006, J PSYCHOPHARMACOL, V20, P683, DOI 10.1177/0269881106060967
NR 54
TC 53
Z9 54
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 1
PY 2011
VL 6
IS 4
AR e18281
DI 10.1371/journal.pone.0018281
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 743ZB
UT WOS:000289058300010
PM 21483776
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Barry, DP
   Asim, M
   Leiman, DA
   de Sablet, T
   Singh, K
   Casero, RA
   Chaturvedi, R
   Wilson, KT
AF Barry, Daniel P.
   Asim, Mohammad
   Leiman, David A.
   de Sablet, Thibaut
   Singh, Kshipra
   Casero, Robert A., Jr.
   Chaturvedi, Rupesh
   Wilson, Keith T.
TI Difluoromethylornithine Is a Novel Inhibitor of Helicobacter pylori
   Growth, CagA Translocation, and Interleukin-8 Induction
SO PLOS ONE
LA English
DT Article
ID GASTRIC EPITHELIAL-CELLS; NITRIC-OXIDE SYNTHASE; COMPLETE GENOME
   SEQUENCE; COCCOID FORMS; ALPHA-DIFLUOROMETHYLORNITHINE;
   ORNITHINE-DECARBOXYLASE; POLYAMINE-BIOSYNTHESIS; MACROPHAGE APOPTOSIS;
   CYTOTOXIN ACTIVITY; GENE-EXPRESSION
AB Helicobacter pylori infects half the world's population, and carriage is lifelong without antibiotic therapy. Current regimens prescribed to prevent infection-associated diseases such as gastroduodenal ulcers and gastric cancer can be thwarted by antibiotic resistance. We reported that administration of 1% D,L-alpha-difluoromethylornithine (DFMO) to mice infected with H. pylori reduces gastritis and colonization, which we attributed to enhanced host immune response due to inhibition of macrophage ornithine decarboxylase (ODC), the rate-limiting enzyme in polyamine biosynthesis. Although no ODC has been identified in any H. pylori genome, we sought to determine if DFMO has direct effects on the bacterium. We found that DFMO significantly reduced the growth rate of H. pylori in a polyamine-independent manner. Two other Gram-negative pathogens possessing ODC, Escherichia coli and Citrobacter rodentium, were resistant to the DFMO effect. The effect of DFMO on H. pylori required continuous exposure to the drug and was reversible when removed, with recovery of growth rate in vitro and the ability to colonize mice. H. pylori exposed to DFMO were significantly shorter in length than those untreated and they contained greater internal levels of ATP, suggesting severe effects on bacterial metabolism. DFMO inhibited expression of the H. pylori virulence factor cytotoxin associated gene A, and its translocation and phosphorylation in gastric epithelial cells, which was associated with a reduction in interleukin-8 expression. These findings suggest that DFMO has effects on H. pylori that may contribute to its effectiveness in reducing gastritis and colonization and may be a useful addition to anti-H. pylori therapies.
C1 [Barry, Daniel P.; Asim, Mohammad; Leiman, David A.; de Sablet, Thibaut; Singh, Kshipra; Chaturvedi, Rupesh; Wilson, Keith T.] Vanderbilt Univ, Med Ctr, Dept Med, Div Gastroenterol, Nashville, TN 37235 USA.
   [Wilson, Keith T.] Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN USA.
   [Barry, Daniel P.; Asim, Mohammad; de Sablet, Thibaut; Singh, Kshipra; Chaturvedi, Rupesh; Wilson, Keith T.] Vet Affairs Tennessee Valley Healthcare Syst, Nashville, TN USA.
   [Casero, Robert A., Jr.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, Baltimore, MD USA.
RP Barry, DP (reprint author), Vanderbilt Univ, Med Ctr, Dept Med, Div Gastroenterol, Nashville, TN 37235 USA.
EM keith.wilson@vanderbilt.edu
RI Barry, Daniel P/B-5647-2008
OI Barry, Daniel P/0000-0002-3972-3914; Wilson, Keith/0000-0003-4421-1830
FU National Institutes of Health (NIH) [R01DK053620, R01AT004821,
   3R01AT004821S1, P01CA028842, P01CA116087, T32DK007673, R01CA051085,
   R01CA098454, CA68485, DK20593, DK58404, HD15052, DK59637, EY08126];
   Office of Medical Research, Department of Veterans Affairs
FX The work was supported by National Institutes of Health (NIH) grants
   R01DK053620, R01AT004821, 3R01AT004821S1, and P01CA028842 (to KTW),
   P01CA116087 (KTW), T32DK007673 (DPB), R01CA051085 and R01CA098454 (to
   RAC), the Vanderbilt University Digestive Disease Research Center
   supported by NIH Grant P30DK058404, and a Merit Review Grant from the
   Office of Medical Research, Department of Veterans Affairs (to KTW).
   Electron microscopy was performed with the help of the Vanderbilt
   University Medical Center Cell Imaging Shared Resource (supported by NIH
   grants CA68485, DK20593, DK58404, HD15052, DK59637 and EY08126). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495
   Andersen LP, 2000, SCAND J GASTROENTERO, V35, P897
   Argent RH, 2004, GASTROENTEROLOGY, V127, P514, DOI 10.1053/j.gastro.2004.06.006
   Argent RH, 2008, J MED MICROBIOL, V57, P145, DOI 10.1099/jmm-0.47465-0
   Backert S, 2000, CELL MICROBIOL, V2, P155, DOI 10.1046/j.1462-5822.2000.00043.x
   BALASUNDARAM D, 1991, P NATL ACAD SCI USA, V88, P5872, DOI 10.1073/pnas.88.13.5872
   Baltrus DA, 2009, J BACTERIOL, V191, P447, DOI 10.1128/JB.01416-08
   Bardhan PK, 1997, CLIN INFECT DIS, V25, P973, DOI 10.1086/516067
   Barnard FM, 2004, MOL MICROBIOL, V51, P15, DOI 10.1046/j.1365-2958.2003.03788.x
   Bartchewsky W, 2009, SCAND J GASTROENTERO, V44, P153, DOI 10.1080/00365520802530853
   Bernstein JA, 2004, P NATL ACAD SCI USA, V101, P2758, DOI 10.1073/pnas.0308747101
   BITONTI AJ, 1984, LIFE SCI, V34, P1513, DOI 10.1016/0024-3205(84)90605-2
   BITONTI AJ, 1982, BIOCHEM J, V208, P435, DOI 10.1042/bj2080435
   BODE G, 1993, EPIDEMIOL INFECT, V111, P483, DOI 10.1017/S0950268800057216
   CASERO RA, 1989, CANCER RES, V49, P639
   CHAN WY, 1994, AM J CLIN PATHOL, V102, P503, DOI 10.1093/ajcp/102.4.503
   Chaturvedi R, 2004, J BIOL CHEM, V279, P40161, DOI 10.1074/jbc.M401370200
   Chaturvedi R, 2007, INFECT IMMUN, V75, P4305, DOI 10.1128/IAI.00578-07
   Chaturvedi R, 2010, GASTROENTEROLOGY, V139, P1686, DOI 10.1053/j.gastro.2010.06.060
   CLARKSON AB, 1984, AM J TROP MED HYG, V33, P1073, DOI 10.4269/ajtmh.1984.33.1073
   Cole SP, 1997, INFECT IMMUN, V65, P843
   Constanza Camargo M., 2007, Acta Gastroenterologica Latinoamericana, V37, P238
   COVER TL, 1990, INFECT IMMUN, V58, P603
   DOUA F, 1987, AM J TROP MED HYG, V37, P525, DOI 10.4269/ajtmh.1987.37.525
   Douillard FP, 2008, J BACTERIOL, V190, P7975, DOI 10.1128/JB.00879-08
   EATON KA, 1995, J INFECT DIS, V171, P459, DOI 10.1093/infdis/171.2.459
   Ferlay J, 2010, INT J CANC
   Fischbach LA, 2002, INT J EPIDEMIOL, V31, P128, DOI 10.1093/ije/31.1.128
   Fischer W, 2001, MOL MICROBIOL, V42, P1337, DOI 10.1046/j.1365-2958.2001.02714.x
   Fox JG, 2007, J CLIN INVEST, V117, P60, DOI 10.1172/JCI30111
   Gobert AP, 2004, J IMMUNOL, V173, P2109, DOI 10.4049/jimmunol.173.3.2109
   Gobert AP, 2002, J IMMUNOL, V168, P6002, DOI 10.4049/jimmunol.168.12.6002
   Gobert AP, 2002, J IMMUNOL, V168, P4692, DOI 10.4049/jimmunol.168.9.4692
   Goodman KJ, 2008, CAN J GASTROENTEROL, V22, P289, DOI 10.1155/2008/258610
   Guo YJ, 2005, CANCER RES, V65, P1146, DOI 10.1158/0008-5472.CAN-04-3244
   HAEGELE KD, 1981, CLIN PHARMACOL THER, V30, P210, DOI 10.1038/clpt.1981.150
   Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147
   Kim SY, 2006, CELL MICROBIOL, V8, P97, DOI 10.1111/j.1462-5822.2005.00603.x
   Kusters JG, 1997, INFECT IMMUN, V65, P3672
   Lee A, 1997, GASTROENTEROLOGY, V112, P1386, DOI 10.1016/S0016-5085(97)70155-0
   Lee MJ, 2005, PROTEIN EXPRES PURIF, V43, P140, DOI 10.1016/j.pep.2005.04.017
   Lewis ND, 2010, J IMMUNOL, V184, P2572, DOI 10.4049/jimmunol.0902436
   Loh JT, 2008, FEMS MICROBIOL LETT, V289, P53, DOI 10.1111/j.1574-6968.2008.01368.x
   MARSHALL BJ, 1984, LANCET, V1, P1311
   Mera R, 2005, GUT, V54, P1536, DOI 10.1136/gut.2005.072009
   Meyskens FL, 2008, CANCER PREV RES, V1, P32, DOI 10.1158/1940-6207.CAPR-08-0042
   Michael AJ, 1999, POLYAMINES HLTH NUTR, P55
   MOSS SF, 1994, GUT, V35, P1567, DOI 10.1136/gut.35.11.1567
   Muller S, 2007, MICROBIOL RES, V162, P1, DOI 10.1016/j.micres.2006.01.003
   NAGATA K, 1993, ANTIMICROB AGENTS CH, V37, P769, DOI 10.1128/AAC.37.4.769
   Nakachi N, 2000, FEMS IMMUNOL MED MIC, V29, P23, DOI 10.1111/j.1574-695X.2000.tb01500.x
   Nilsson JA, 2005, CANCER CELL, V7, P433, DOI 10.1016/j.ccr.2005.03.036
   Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497
   Oh JD, 2006, P NATL ACAD SCI USA, V103, P9999, DOI 10.1073/pnas.0603784103
   Osaki T, 2002, J MED MICROBIOL, V51, P295, DOI 10.1099/0022-1317-51-4-295
   Papadopulos F, 2007, ULTRASTRUCT PATHOL, V31, P401, DOI 10.1080/01913120701719189
   Parsonnet J, 1997, GUT, V40, P297, DOI 10.1136/gut.40.3.297
   Peek RM, 2010, PHYSIOL REV, V90, P831, DOI 10.1152/physrev.00039.2009
   Pendeville H, 2001, MOL CELL BIOL, V21, P6549, DOI 10.1128/MCB.21.19.6549-6558.2001
   Perez-Perez GI, 1999, J PHYSIOL PHARMACOL, V50, P833
   PEREZPEREZ GI, 1992, INFECT IMMUN, V60, P3658
   Philpott DJ, 2002, CELL MICROBIOL, V4, P285, DOI 10.1046/j.1462-5822.2002.00189.x
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Resnick MB, 2006, GUT, V55, P1717, DOI 10.1136/gut.2006.095646
   Salama N, 2000, P NATL ACAD SCI USA, V97, P14668, DOI 10.1073/pnas.97.26.14668
   Selbach M, 2002, J BIOL CHEM, V277, P6775, DOI 10.1074/jbc.C100754200
   Sharma SA, 1998, J IMMUNOL, V160, P2401
   She FF, 2003, WORLD J GASTROENTERO, V9, P516, DOI 10.3748/wjg.v9.i3.516
   Singh K, 2008, J BIOL CHEM, V283, P16752, DOI 10.1074/jbc.M710530200
   Sycuro LK, 2010, CELL, V141, P822, DOI 10.1016/j.cell.2010.03.046
   TABOR H, 1980, J BACTERIOL, V144, P952
   Takaji S, 1997, LETT APPL MICROBIOL, V25, P177, DOI 10.1046/j.1472-765X.1997.00198.x
   TAYLOR DN, 1991, EPIDEMIOL REV, V13, P42, DOI 10.1093/oxfordjournals.epirev.a036078
   Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483
   TUMMURU MKR, 1994, INFECT IMMUN, V62, P2609
   Wang X, 1997, J MED MICROBIOL, V46, P657, DOI 10.1099/00222615-46-8-657
   Wilson KT, 2007, GASTROENTEROLOGY, V133, P288, DOI 10.1053/j.gastro.2007.05.008
   Wilson KT, 1996, GASTROENTEROLOGY, V111, P1524, DOI 10.1016/S0016-5085(96)70014-8
   Xu HX, 2004, CANCER RES, V64, P8521, DOI 10.1158/0008-5472.CAN-04-3511
   Yerushalmi HF, 2006, MOL CARCINOGEN, V45, P764, DOI 10.1002/mc.20246
NR 80
TC 17
Z9 19
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 28
PY 2011
VL 6
IS 2
AR e17510
DI 10.1371/journal.pone.0017510
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 729EM
UT WOS:000287931400083
PM 21386987
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Clouser, CL
   Holtz, CM
   Mullett, M
   Crankshaw, DL
   Briggs, JE
   Chauhan, J
   VanHoutan, IM
   Patterson, SE
   Mansky, LM
AF Clouser, Christine L.
   Holtz, Colleen M.
   Mullett, Mary
   Crankshaw, Duane L.
   Briggs, Jacquie E.
   Chauhan, Jay
   VanHoutan, Ilze Matise
   Patterson, Steven E.
   Mansky, Louis M.
TI Analysis of the Ex Vivo and In Vivo Antiretroviral Activity of
   Gemcitabine
SO PLOS ONE
LA English
DT Article
ID RETROVIRUS-INDUCED IMMUNODEFICIENCY; RIBONUCLEOTIDE REDUCTASE
   INHIBITORS; DEFECTIVE VIRUS; SYNDROME MAIDS; BONE-MARROW; MURINE AIDS;
   CELL-LINES; MICE; DISEASE; INDUCTION
AB Replication of retroviral and host genomes requires ribonucleotide reductase to convert rNTPs to dNTPs, which are then used as substrates for DNA synthesis. Inhibition of ribonucleotide reductase by hydroxyurea (HU) has been previously used to treat cancers as well as HIV. However, the use of HU as an antiretroviral is limited by its associated toxicities such as myelosuppression and hepatotoxicity. In this study, we examined the ribonucleotide reductase inhibitor, gemcitabine, both in cell culture and in C57Bl/6 mice infected with LP-BM5 murine leukemia virus (LP-BM5 MuLV, a murine AIDS model). Gemcitabine decreased infectivity of MuLV in cell culture with an EC50 in the low nanomolar range with no detectable cytotoxicity. Similarly, gemcitabine significantly decreased disease progression in mice infected with LP-BM5. Specifically, gemcitabine treatment decreased spleen size, plasma IgM, and provirus levels compared to LP-BM5 MuLV infected, untreated mice. Gemcitabine efficacy was observed at doses as low as 1 mg/kg/day in the absence of toxicity. Higher doses of gemcitabine (3 mg/kg/day and higher) were associated with toxicity as determined by a loss in body mass. In summary, our findings demonstrate that gemcitabine has antiretroviral activity ex vivo and in vivo in the LP-BM5 MuLV model. These observations together with a recent ex vivo study with HIV-1[1], suggest that gemcitabine has broad antiretroviral activity and could be particularly useful in vivo when used in combination drug therapy.
C1 [Clouser, Christine L.; Holtz, Colleen M.; Patterson, Steven E.; Mansky, Louis M.] Univ Minnesota, Inst Mol Virol, Minneapolis, MN 55455 USA.
   [Holtz, Colleen M.; Mansky, Louis M.] Univ Minnesota, Sch Dent, Dept Diagnost & Biol Sci, MinnCResT Program, Minneapolis, MN 55455 USA.
   [Chauhan, Jay; Patterson, Steven E.; Mansky, Louis M.] Univ Minnesota, Ctr Drug Design, Minneapolis, MN USA.
   [Mansky, Louis M.] Univ Minnesota, Sch Med, Dept Microbiol, Minneapolis, MN 55455 USA.
   [VanHoutan, Ilze Matise] Univ Minnesota, Masonic Canc Ctr Comparat Pathol Shared Resource, Minneapolis, MN USA.
   [Mullett, Mary; Crankshaw, Duane L.; Briggs, Jacquie E.] VA Med Ctr, Dept Food Sci & Nutr, Minneapolis, MN USA.
RP Clouser, CL (reprint author), Univ Minnesota, Inst Mol Virol, Minneapolis, MN 55455 USA.
EM mansky@umn.edu
FU Academic Health Center; NIH [GM56615, T32 CA009138, T32 DE07288]
FX Supported from a Center for Drug Design Funding Agreement, an Academic
   Health Center Translational Research Grant, and NIH grants GM56615, T32
   CA009138 (Cancer Biology Training Grant, to C. L. C.) and T32 DE07288
   (MinnCResT Program, to C. M. H.). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Bartz SR, 1997, METHODS, V12, P337, DOI 10.1006/meth.1997.0487
   BEBENEK K, 1992, J BIOL CHEM, V267, P3589
   Bender DM, 2009, J MED CHEM, V52, P6958, DOI 10.1021/jm901181h
   Casabianca A, 2004, J CLIN MICROBIOL, V42, P4361, DOI 10.1128/JCM.42.9.4361-4364.2004
   CHATTOPADHYAY SK, 1989, P NATL ACAD SCI USA, V86, P3862, DOI 10.1073/pnas.86.10.3862
   CHATTOPADHYAY SK, 1991, J VIROL, V65, P4232
   Clouser CL, 2010, J VIROL, V84, P9301, DOI 10.1128/JVI.01006-10
   Dias ASP, 2006, CURR HIV RES, V4, P431
   HARRINGTON RD, 1993, J VIROL, V67
   HARTLEY JW, 1989, J VIROL, V63, P1223
   HEINEMANN V, 1990, MOL PHARMACOL, V38, P567
   Lombardi VC, 2009, SCIENCE, V326, P585, DOI 10.1126/science.1179052
   Lori F, 1999, ANTIVIR THER, V4, P101
   Mayhew C, 1997, CELL MOL BIOL, V43, P1019
   Mayhew CN, 2002, ANTIVIR RES, V56, P167, DOI 10.1016/S0166-3542(02)00108-0
   MORSE HC, 1992, AIDS, V6, P607, DOI 10.1097/00002030-199207000-00001
   MORSE HC, 1994, SYMP SOC GEN MICROBI, V51, P265
   MOSIER DE, 1987, J EXP MED, V165, P1737, DOI 10.1084/jem.165.6.1737
   NOZAKI A, 2010, ARCH VIROL, V45, P66
   OHNOTA H, 1990, ANTIMICROB AGENTS CH, V34, P605, DOI 10.1128/AAC.34.4.605
   PATTENGALE PK, 1982, AM J PATHOL, V107, P362
   Pear WS, 1998, BLOOD, V92, P3780
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Rossi L, 2002, J ANTIMICROB CHEMOTH, V50, P639, DOI 10.1093/jac/dkf205
   Sakamoto H, 2006, J GASTROENTEROL, V41, P70, DOI 10.1007/s00535-005-1724-7
   SIMARD C, 1995, VIROLOGY, V206, P555, DOI 10.1016/S0042-6822(95)80072-7
   Urisman A, 2006, PLOS PATHOG, V2, P211, DOI 10.1371/journal.ppat.0020025
   Vodicka MA, 1997, VIROLOGY, V233, P193, DOI 10.1006/viro.1997.8606
   Wong A, 2009, DRUG METAB REV, V41, P77, DOI 10.1080/03602530902741828
   YETTER RA, 1988, J EXP MED, V168, P623, DOI 10.1084/jem.168.2.623
NR 30
TC 13
Z9 13
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 14
PY 2011
VL 6
IS 1
AR e15840
DI 10.1371/journal.pone.0015840
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 710MS
UT WOS:000286516500013
PM 21264291
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Neff, CP
   Ndolo, T
   Tandon, A
   Habu, Y
   Akkina, R
AF Neff, C. Preston
   Ndolo, Thomas
   Tandon, Apurva
   Habu, Yuichiro
   Akkina, Ramesh
TI Oral Pre-Exposure Prophylaxis by Anti-Retrovirals Raltegravir and
   Maraviroc Protects against HIV-1 Vaginal Transmission in a Humanized
   Mouse Model
SO PLOS ONE
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; TENOFOVIR DISOPROXIL FUMARATE;
   IMMUNE-RESPONSES; MICE; INFECTION; MACAQUES; CHALLENGES; INHIBITOR;
   ANTAGONIST; PREVENTION
AB Sexual HIV-1 transmission by vaginal route is the most predominant mode of viral transmission, resulting in millions of new infections every year. In the absence of an effective vaccine, there is an urgent need to develop other alternative methods of pre-exposure prophylaxis (PrEP). Many novel drugs that are currently approved for clinical use also show great potential to prevent viral sexual transmission when administered systemically. A small animal model that permits rapid preclinical evaluation of potential candidates for their systemic PrEP efficacy will greatly enhance progress in this area of investigation. We have previously shown that RAG-hu humanized mouse model permits HIV-1 mucosal transmission via both vaginal and rectal routes and displays CD4 T cell loss typical to that seen in the human. Thus far systemic PrEP studies have been primarily limited to RT inhibitors exemplified by tenofovir and emtricitabine. In these proof-of-concept studies we evaluated two new classes of clinically approved drugs with different modes of action namely, an integrase inhibitor raltegravir and a CCR5 inhibitor maraviroc as potential systemically administered chemo-prophylactics. Our results showed that oral administration of either of these drugs fully protects against vaginal HIV-1 challenge in the RAG-hu mouse model. Based on these results both these drugs show great promise for further development as orally administered PrEPs.
C1 [Neff, C. Preston; Ndolo, Thomas; Tandon, Apurva; Habu, Yuichiro; Akkina, Ramesh] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA.
RP Neff, CP (reprint author), Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA.
EM akkina@colostate.edu
FU National Institutes of Health [AI057066, AI073255]
FX Work reported here was supported by National Institutes of Health RO1
   grants AI057066 and AI073255 to RA. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abbas UL, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000875
   An DS, 2007, CLIN VACCINE IMMUNOL, V14, P391, DOI 10.1128/CVI.00403-06
   Baenziger S, 2006, P NATL ACAD SCI USA, V103, P15951, DOI 10.1073/pnas.0604493103
   Barouch DH, 2008, NATURE, V455, P613, DOI 10.1038/nature07352
   Berges BK, 2008, VIROLOGY, V373, P342, DOI 10.1016/j.virol.2007.11.020
   Berges BK, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-76
   Berges BK, 2010, VIROLOGY, V397, P100, DOI 10.1016/j.virol.2009.10.034
   Broder S, 2010, ANTIVIR RES, V85, P1, DOI 10.1016/j.antiviral.2009.10.002
   *CLIN, FEM PREP TRU STUD AS
   D'Cruz OJ, 2007, AM J REPROD IMMUNOL, V57, P353, DOI 10.1111/j.1600-0897.2007.00478.x
   Denton PW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008829
   Denton Paul W, 2009, Curr HIV/AIDS Rep, V6, P13, DOI 10.1007/s11904-009-0003-2
   Denton PW, 2008, PLOS MED, V5, P79, DOI 10.1371/journal.pmed.0050016
   Di Fabio S, 2003, AIDS, V17, P1597, DOI 10.1097/01.aids.0000072663.21517.63
   Di Fabio S, 2001, AIDS, V15, pS19, DOI 10.1097/00002030-200102001-00020
   FREIREICH EMIL J., 1966, CANCER CHEMOTHERAP REP, V50, P219
   Garcia-Lerma JG, 2008, PLOS MED, V5, P291, DOI 10.1371/journal.pmed.0050028
   Garcia-Lerma JG, 2010, TRENDS PHARMACOL SCI, V31, P74, DOI 10.1016/j.tips.2009.10.009
   Gorantla S, 2007, J VIROL, V81, P2700, DOI 10.1128/JVI.02010-06
   Grinsztejn B, 2007, LANCET, V369, P1261, DOI 10.1016/S0140-6736(07)60597-2
   Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646
   *JOINT UN HIV AIDS, 2008, REP GLOB AIDS EP
   Khanna KV, 2002, J CLIN INVEST, V109, P205
   Kromdijk W, 2010, EXPERT OPIN PHARMACO, V11, P1215, DOI 10.1517/14656561003801081
   Kumwenda NI, 2008, NEW ENGL J MED, V359, P119, DOI 10.1056/NEJMoa0801941
   Legrand N, 2009, CELL HOST MICROBE, V6, P5, DOI 10.1016/j.chom.2009.06.006
   Lieberman-Blum SS, 2008, CLIN THER, V30, P1228, DOI 10.1016/j.clinthera.2008.07.008
   MacArthur RD, 2008, CLIN INFECT DIS, V47, P236, DOI 10.1086/589289
   Melkus MW, 2006, NAT MED, V12, P1316, DOI 10.1038/nm1431
   Polhemus ME, 2008, ANTIMICROB AGENTS CH, V52, P1493, DOI 10.1128/AAC.01367-07
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Shultz LD, 2007, NAT REV IMMUNOL, V7, P118, DOI 10.1038/nri2017
   Subbarao S, 2006, J INFECT DIS, V194, P904, DOI 10.1086/507306
   Traggiai E, 2004, SCIENCE, V304, P104, DOI 10.1126/science.1093933
   TSAI CC, 1995, SCIENCE, V270, P1197, DOI 10.1126/science.270.5239.1197
   *US FDA, 2009, ANT DRUGS US TREATM
   Van Duyne R, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-76
   Van Rompay KKA, 1998, AIDS, V12, pF79, DOI 10.1097/00002030-199809000-00001
   Van Rompay KKA, 2006, JAIDS-J ACQ IMM DEF, V43, P6, DOI 10.1097/01.qai.0000224972.60339.7c
   Veazey RS, 2010, J INFECT DIS, V202, P739, DOI 10.1086/655661
   Veazey RS, 2005, NATURE, V438, P99, DOI 10.1038/nature04055
   Volmink J, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003510.pub2
   Watanabe S, 2007, BLOOD, V109, P212, DOI 10.1182/blood-2006-04-017681
   World Health Organization UNAIDS, 2007, NEW DAT MAL CIRC HIV
   Zhang LG, 2007, BLOOD, V109, P2978, DOI 10.1182/blood-2006-07-033159
NR 45
TC 69
Z9 71
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 21
PY 2010
VL 5
IS 12
AR e15257
DI 10.1371/journal.pone.0015257
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 698EY
UT WOS:000285576900024
PM 21203568
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

PT J
AU Liu, JF
   Gu, X
   Robbins, D
   Li, G
   Shi, RH
   McCord, JM
   Zhao, YF
AF Liu, Jianfeng
   Gu, Xin
   Robbins, Delira
   Li, Guohong
   Shi, Runhua
   McCord, Joe M.
   Zhao, Yunfeng
TI Protandim, a Fundamentally New Antioxidant Approach in Chemoprevention
   Using Mouse Two-Stage Skin Carcinogenesis as a Model
SO PLOS ONE
LA English
DT Article
AB Oxidative stress is an important contributor to cancer development. Consistent with that, antioxidant enzymes have been demonstrated to suppress tumorigenesis when being elevated both in vitro and in vivo, making induction of these enzymes a more potent approach for cancer prevention. Protandim, a well-defined combination of widely studied medicinal plants, has been shown to induce superoxide dismutase (SOD) and catalase activities and reduce superoxide generation and lipid peroxidation in healthy human subjects. To investigate whether Protandim can suppress tumor formation by a dietary approach, a two-stage mouse skin carcinogenesis study was performed. At the end of the study, the mice on a Protandim-containing basal diet had similar body weight compared with those on the basal diet, which indicated no overt toxicity by Protandim. After three weeks on the diets, there was a significant increase in the expression levels of SOD and catalase, in addition to the increases in SOD activities. Importantly, at the end of the carcinogenesis study, both skin tumor incidence and multiplicity were reduced in the mice on the Protandim diet by 33% and 57% respectively, compared with those on basal diet. Biochemical and histological studies revealed that the Protandim diet suppressed tumor promoter-induced oxidative stress (evidenced by reduction of protein carbonyl levels), cell proliferation (evidenced by reduction of skin hyperplasia and suppression of PKC/JNK/Jun pathway), and inflammation (evidenced by reduction of ICAM-1/VCAM-1 expression, NF-kappa B binding activity, and nuclear p65/p50 levels). Overall, induction of antioxidant enzymes by Protandim may serve as a practical and potent approach for cancer prevention.
RP Liu, JF (reprint author), Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol Toxicol & Neurosci, Shreveport, LA 71105 USA.
EM yzhao1@lsuhsc.edu
FU NHLBI NIH HHS [R01 HL087990]
CR Apte RN, 2006, CANCER METAST REV, V25, P387, DOI 10.1007/s10555-006-9004-4
   Avila GE, 2005, J PHARMACOL EXP THER, V315, P170, DOI 10.1124/jpet.105.087585
   Ballaz Santiago, 2003, Clin Lung Cancer, V5, P46, DOI 10.3816/CLC.2003.n.021
   Baud V, 2009, NAT REV DRUG DISCOV, V8, P33, DOI 10.1038/nrd2781
   Bauer JA, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001313
   CASTAGNA M, 1982, J BIOL CHEM, V257, P7847
   Cataisson C, 2005, J IMMUNOL, V174, P1686, DOI 10.4049/jimmunol.174.3.1686
   Chaurasia SS, 2000, PHARMACOL RES, V41, P663, DOI 10.1006/phrs.1999.0634
   Chowdhuri DK, 2002, PHYTOTHER RES, V16, P639, DOI 10.1002/ptr.1023
   Clark J, 2006, MOL NUTR FOOD RES, V50, P144, DOI 10.1002/mnfr.200500135
   Das KC, 1997, AM J RESP CELL MOL, V17, P713, DOI 10.1165/ajrcmb.17.6.2809
   DAS M, 2002, PHYTOTHERAPY RES S, pS40
   DiDonato JA, 2000, METHOD ENZYMOL, V322, P393
   DIKSHIT M, 1995, INDIAN J MED RES, V101, P31
   Dressler J, 2000, FORENSIC SCI INT, V113, P173, DOI 10.1016/S0379-0738(00)00258-9
   Farrow B, 2002, SURG ONCOL, V10, P153, DOI 10.1016/S0960-7404(02)00015-4
   Fox JG, 2007, J CLIN INVEST, V117, P60, DOI 10.1172/JCI30111
   Fujiki H, 2005, CHEM REC, V5, P119, DOI 10.1002/tcr.20039
   FUJISAWA H, 1992, Journal of Dermatology (Tokyo), V19, P78
   Gazak R, 2007, CURR MED CHEM, V14, P315, DOI 10.2174/092986707779941159
   Halliwell B, 2007, BIOCHEM J, V401, P1, DOI 10.1042/BJ20061131
   Hoshiyama Y, 2005, J EPIDEMIOL, V15, pS109, DOI 10.2188/jea.15.S109
   Israel A, 2003, NATURE, V423, P596, DOI 10.1038/423596a
   Jakubikova J, 2006, J AGR FOOD CHEM, V54, P1656, DOI 10.1021/jf052717h
   Jayaprakasam B, 2003, LIFE SCI, V74, P125, DOI 10.1016/j.lfs.2003.07.007
   Lu YP, 1997, CANCER RES, V57, P1468
   Luo JL, 2005, J CLIN INVEST, V115, P2625, DOI 10.1172/JCI126322
   Marks Friedrich, 2007, V174, P37
   Mohan Royce, 2004, Angiogenesis, V7, P115, DOI 10.1007/s10456-004-1026-3
   Na HK, 2008, ARCH BIOCHEM BIOPHYS, V476, P171, DOI 10.1016/j.abb.2008.04.003
   Nakanishi C, 2005, NAT REV CANCER, V5, P297, DOI 10.1038/nrc1588
   Narayanan BA, 2006, CURR CANCER DRUG TAR, V6, P711, DOI 10.2174/156800906779010218
   Nelson SK, 2006, FREE RADICAL BIO MED, V40, P341, DOI 10.1016/j.freeradbiomed.2005.08.043
   Oberley LW, 2005, BIOMED PHARMACOTHER, V59, P143, DOI 10.1016/j.biopha.2005.03.006
   OBERLEY LW, 1984, METHOD ENZYMOL, V105, P457
   OBERLEY LW, 1979, CANCER RES, V39, P1141
   Pries R, 2006, EXPERT REV ANTICANC, V6, P1195, DOI 10.1586/14737140.6.9.1195
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Rose-John Stefan, 2007, V174, P57
   Ruckert R, 2000, BRIT J DERMATOL, V143, P1036, DOI 10.1046/j.1365-2133.2000.03784.x
   Russo A, 2005, PHYTOMEDICINE, V12, P305, DOI 10.1016/j.phymed.2003.12.008
   Schaar D, 2006, CANCER CHEMOTH PHARM, V57, P789, DOI 10.1007/s00280-005-0125-1
   Seril DN, 2003, CARCINOGENESIS, V24, P353, DOI 10.1093/carcin/24.3.353
   Sharma RA, 2005, EUR J CANCER, V41, P1955, DOI 10.1016/j.ejca.2005.05.009
   Singh RP, 2006, ENDOCR-RELAT CANCER, V13, P751, DOI 10.1677/erc.1.01126
   Singh Sarvjeet, 2006, Anti-Cancer Agents in Medicinal Chemistry, V6, P259, DOI 10.2174/187152006776930918
   Soto C, 2003, COMP BIOCHEM PHYS C, V136, P205, DOI 10.1016/S1532-0456(03)00214-X
   Stuart EC, 2006, LIFE SCI, V79, P2329, DOI 10.1016/j.lfs.2006.07.036
   Velmurugan K, 2009, FREE RADICAL BIO MED, V46, P430, DOI 10.1016/j.freeradbiomed.2008.10.050
   Wright TI, 2006, J AM ACAD DERMATOL, V54, P933, DOI 10.1016/j.jaad.2005.08.062
   Zhang XP, 2007, CLIN CANCER RES, V13, P7181, DOI 10.1158/1078-0432.CCFI-07-1133
   Zhao YF, 2001, CANCER RES, V61, P6082
   Zhao YF, 2005, CANCER RES, V65, P3745, DOI 10.1158/0008-5472.CAN-04-3835
   Zhao YF, 2001, ANTIOXID REDOX SIGN, V3, P375, DOI 10.1089/15230860152409022
   Zhao Yunfeng, 2003, Methods Mol Biol, V218, P177
   Zheng X, 2006, CLIN CANCER RES, V12, P3444, DOI 10.1158/1078-0432.CCR-05-2823
NR 56
TC 30
Z9 32
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 22
PY 2009
VL 4
IS 4
AR e5284
DI 10.1371/journal.pone.0005284
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 437VB
UT WOS:000265513900017
PM 19384424
OA DOAJ Gold, Green Published
DA 2019-07-07
ER

EF